
<?
require($_SERVER["DOCUMENT_ROOT"]."/bitrix/header.php");
$APPLICATION->SetTitle("Цифровой консультант врача");
$APPLICATION->AddChainItem('Материалы', '/');
$APPLICATION->AddChainItem('Цифровой консультант врача', '/https://abbottpro.ru/cdss/');?>
<section class="event">
  <div class="second__container text-page">
    <?$APPLICATION->IncludeComponent( "bitrix:breadcrumb", "", array(
    "START_FROM" => "0", "PATH" => "", "SITE_ID" => "-" ), false,
    Array('HIDE_ICONS' => 'Y') );?>
  </div>

  <title>Цифровой консультант врача</title>
  <link rel="stylesheet" href="./css/style.css" type="text/css" />
</section>
<!-- cdss-test -->

<link rel="stylesheet" href="./css/style.css" />
    <title>ЦИФРОВОЙ КОНСУЛЬТАНТ ВРАЧА</title>
    <script
      defer
      src="https://code.jquery.com/jquery-3.6.0.min.js"
      integrity="sha256-/xUj+3OJU5yExlq6GSYGSHk7tPXikynS7ogEvDej/m4="
      crossorigin="anonymous"
    ></script>
    <script defer src="./js/globalVariables.js"></script>

    <script defer src="./js/start.js"></script>

    <script defer src="./js/dataBase.js"></script>

    <script defer src="./js/quiz.js"></script>
    <script defer src="./js/first.js"></script>

    <script defer src="./js/repeated.js"></script>
    <script defer src="./js/control.js"></script>

    <script defer src="./js/dbInteraction.js"></script>

    <script defer src="./js/dbMedicament.js"></script>

    <script defer src="./js/interaction.js"></script>
    
    <main>
    <div class="breeading-page active-page" id="start-page">
      <section class="consult-banner">
        <img
          class="consult-banner__img"
          src="./img/consult-banner.jpg"
          alt="consult-banner"
        />
        <div class="consult-banner__container">
          <div class="consult-banner__content">
            <div class="consult-banner__content__title">
              Цифровой консультант врача
            </div>
            <div class="consult-banner__content__desc">
              Индивидуальные решения по ведению пациента на основе клинических
              рекомендаций, стандартов и международных баз знаний
            </div>
          </div>
        </div>
      </section>
      <section class="consult-info">
        <div class="consult-info__container">
          <div class="consult-info__reception">
            <div class="consult-info__reception__title">
              Гастроэзофагеальная рефлюксная болезнь (ГЭРБ)
            </div>
            <div class="consult-info__reception__desc">
              Выберите прием и нажмите кнопку “начать”, чтобы смоделировать
              клинический случай и получить экспертную консультацию по ведению
              вашего пациента
            </div>
            <div class="consult-info__reception__items">
              <div class="consult-info__reception__item">
                <div class="consult-info__reception__item__title">
                  Первичный прием
                </div>
                <div class="consult-info__reception__item__block">
                  <div class="consult-info__reception__item__list">
                    <div class="consult-info__reception__item__desc">
                      Анализ жалоб
                    </div>
                    <div class="consult-info__reception__item__desc">
                      План обследования
                    </div>
                    <div class="consult-info__reception__item__desc">
                      Предварительный диагноз
                    </div>
                    <div class="consult-info__reception__item__desc">
                      Эмпирическая терапия
                    </div>
                  </div>
                  <button
                    class="consult-info__reception__item__link"
                    data-page="1"
                    onclick="ym(90602537,'reachGoal','cdss_1st'); return true;"
                  >
                    Начать
                  </button>
                </div>
              </div>
              <div class="consult-info__reception__item">
                <div class="consult-info__reception__item__title">
                  Повторный прием
                </div>
                <div class="consult-info__reception__item__block">
                  <div class="consult-info__reception__item__list">
                    <div class="consult-info__reception__item__desc">
                      Интерпретация результатов обследования
                    </div>
                    <div class="consult-info__reception__item__desc">
                      Подтверждение диагноза
                    </div>
                    <div class="consult-info__reception__item__desc">
                      Планирование терапии
                    </div>
                  </div>
                  <button
                    class="consult-info__reception__item__link"
                    data-page="2"
                    onclick="ym(90602537,'reachGoal','cdss_2nd'); return true;"
                  >
                    Начать
                  </button>
                </div>
              </div>
              <div class="consult-info__reception__item">
                <div class="consult-info__reception__item__title">
                  Контрольный прием
                </div>
                <div class="consult-info__reception__item__block">
                  <div class="consult-info__reception__item__list">
                    <div class="consult-info__reception__item__desc">
                      Оценка эффективности терапии
                    </div>
                    <div class="consult-info__reception__item__desc">
                      Депрескрайбинг*
                    </div>
                    <div class="consult-info__reception__item__desc">
                      Преодоление рефрактерности
                    </div>
                  </div>
                  <button
                    class="consult-info__reception__item__link"
                    data-page="3"
                    onclick="ym(90602537,'reachGoal','cdss_3rd'); return true;"
                  >
                    Начать
                  </button>
                </div>
              </div>
            </div>
          </div>
          <div class="consult-info__help">
            <div class="consult-info__help__title">
              Чем поможет цифровой консультант
            </div>
            <ul class="consult-info__help__list">
              <li class="consult-info__help__list__item">
                Подбор фармакотерапии
              </li>
              <li class="consult-info__help__list__item">
                Проверка межлекарственных взаимодействий
              </li>
              <li class="consult-info__help__list__item">
                Дифференциальная диагностика
              </li>
              <li class="consult-info__help__list__item">
                Интерпретация результатов диагностики
              </li>
            </ul>
          </div>
          <div class="abbott-more-sources">
            <button class="abbott-more-sources__button btn-reset">
              <span>Ключевые источники информации</span>
              <svg
                xmlns="http://www.w3.org/2000/svg"
                width="16"
                height="17"
                viewBox="0 0 16 17"
                fill="none"
              >
                <path
                  fill-rule="evenodd"
                  clip-rule="evenodd"
                  d="M4.89164 2.73051C5.19205 2.42487 5.67909 2.42487 5.9795 2.73051L11.1077 7.94791C11.252 8.09467 11.333 8.29373 11.333 8.5013C11.333 8.70885 11.252 8.90791 11.1077 9.05469L5.9795 14.2721C5.67909 14.5777 5.19205 14.5777 4.89164 14.2721C4.59124 13.9664 4.59124 13.4709 4.89164 13.1653L9.47593 8.5013L4.89164 3.83729C4.59124 3.53166 4.59124 3.03614 4.89164 2.73051Z"
                  fill="#009CDE"
                ></path>
              </svg>
            </button>
            <div class="abbott-more-sources__content">
              <ol>

              <li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В., Дронова О.Б., Кучерявый Ю.А., Пирогов С.С., Сайфутдинов Р.Г., Успенский Ю.П., Шептулин А.А., Андреев Д.Н., Румянцева Д.Е. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. https://doi.org/10.22416/1382-4376-2020-30-4-70-97.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Сторонова О.А., Абдулхаков С.Р., Андреев Д.Н., Бордин Д.С., Валитова Э.Р., Кляритская И.Л., Кривой В.В., Кучерявый Ю.А., Лапина Т.Л., Морозов С.В., Саблин О.А., Семенихина Е.В., Успенский Ю.П., Шептулин А.А. Рекомендации Российской гастроэнтерологической ассоциации по клиническому применению манометрии высокого разрешения при заболеваниях пищевода. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):61–88. https://doi.org/10.22416/1382-4376-2020-30-3-61-88</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. Therole of esophageal testing in diagnosis and management. Gastroenterol Clin North Am1996; 25:75.</li>
<li>Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification ofgastroesophageal reflux disease: a global evidence-based consensus. Am JGastroenterol 2006; 101:1900.</li>
<li>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophagealreflux disease: a systematic review. Gut 2005; 54:710.</li>
<li>Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of uppergastrointestinal disorders in the United States: results of the US Upper GastrointestinalStudy. Clin Gastroenterol Hepatol 2005; 3:543.</li>
<li>Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.</li>
<li>Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence,severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol2004; 2:665.</li>
<li>Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to protonpump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.</li>
<li>Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophagealsphincter pressure: a manometric observation in patients reporting globus sensation.Am J Gastroenterol 2009; 104:289.</li>
<li>Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea.Ann Intern Med 1997; 126:704.</li>
<li>Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.</li>
<li>DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophagealreflux disease. Practice Parameters Committee of the American College ofGastroenterology. Arch Intern Med 1995; 155:2165.</li>
<li>Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS(Ed), WB Saunders, Philadelphia 1989. p.1147.</li>
<li>Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients withgastroesophageal reflux disease: a comparison between empirical treatment withesomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.</li>
<li>Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test toidentify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360.</li>
<li>Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pumpinhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostictest characteristics. Ann Intern Med 2004; 140:518.</li>
<li>Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability andendoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313.</li>
<li>Adanir H, Baş B, Pakoz B, et al. Endoscopic Findings of Gastro-Esophageal RefluxDisease in Elderly and Younger Age Groups. Front Med (Lausanne) 2021; 8:606205.</li>
<li>Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical andfunctional correlates and further validation of the Los Angeles classification. Gut 1999;45:172.</li>
<li>Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. ClinGastroenterol Hepatol 2007; 5:4.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationMedical Position Statement on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1383.</li>
<li>Hirano I, Richter JE, Practice Parameters Committee of the American College ofGastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</li>
<li>Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practiceguideline development. Gastroenterology 1996; 110:1982.</li>
<li>Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless andDigitrapper catheter-based pH monitoring systems for measuring esophageal acidexposure. Am J Gastroenterol 2005; 100:1466.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-refluxassociation using 4-day wireless pH recording combining 48-hour periods off and on PPItherapy. Am J Gastroenterol 2008; 103:1631.</li>
<li>Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring.J Clin Gastroenterol 2012; 46:197.</li>
<li>Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal refluxsymptoms and esophagitis with or without symptoms in the general adult Swedishpopulation: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275.</li>
<li>Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatmentof benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology1982; 82:487.</li>
<li>Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricturetreated by dilatation. Gastroenterology 1983; 85:346.</li>
<li>Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazolefor refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.</li>
<li>Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists intreating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.</li>
<li>Okwara NC, Chan WW. Sorting out the Relationship Between Esophageal andPulmonary Disease. Gastroenterol Clin North Am 2021; 50:919.</li>
<li>Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophagealreflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.</li>
<li>Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acidsuppressive therapy improves asthma outcome. Am J Med 1996; 100:395.</li>
<li>Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'refluxlaryngitis'. Gastroenterology 1991; 100:305.</li>
<li>Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease(GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoringand an experimental investigation of the role of acid and pepsin in the development oflaryngeal injury. Laryngoscope 1991; 101:1.</li>
<li>Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastricacid in patients with reflux laryngitis. Gastroenterology 1995; 109:1575.</li>
<li>Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopyin patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am JGastroenterol 2004; 99:1419.</li>
<li>Remacle M, Lawson G. Diagnosis and management of laryngopharyngeal refluxdisease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:143.</li>
<li>Gaynor EB. Gastroesophageal reflux as an etiologic factor in laryngeal complications ofintubation. Laryngoscope 1988; 98:972.</li>
<li>Cote DN, Miller RH. The association of gastroesophageal reflux and otolaryngologicdisorders. Compr Ther 1995; 21:80.</li>
<li>Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated withgastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.</li>
<li>Schroeder PL, Filler SJ, Ramirez B, et al. Dental erosion and acid reflux disease. AnnIntern Med 1995; 122:809.</li>
<li>DiBaise JK, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. AnnIntern Med 1998; 129:1078.</li>
<li>DiBaise JK, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistantsinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002; 97:843.</li>
<li>Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence inindividuals with gastroesophageal reflux: synthesis and estimates from populationstudies. Am J Gastroenterol 2011; 106:254.</li>
<li>Vaezi MF. Laryngitis and gastroesophageal reflux disease: increasing prevalence or poordiagnostic tests? Am J Gastroenterol 2004; 99:786.</li>
<li>Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous cell cancer of the head andneck. Otolaryngol Clin North Am 1985; 18:367.</li>
<li>Olsen NR. Effects of stomach acid on the larynx. Proc Am Laryngol Assoc 1983; 104:108.</li>
<li>Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma?Otolaryngol Head Neck Surg 1988; 99:370.</li>
<li>Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of thelaryngopharynx. Laryngoscope 1988; 98:1195.</li>
<li>Langevin SM, Michaud DS, Marsit CJ, et al. Gastric reflux is an independent risk factor forlaryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22:1061.</li>
<li>Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, Lagergren J. All-cause and cancer-specificmortality in GORD in a population-based cohort study (the HUNT study). Gut 2018;67:209.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationInstitute technical review on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1392.</li>
<li>Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosisand Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117:27.</li>
<li>Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control ofheartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am JGastroenterol 1999; 94:92.</li>
<li>Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acidinhibition. Gastroenterol Clin North Am 1990; 19:683.</li>
<li>Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophagealreflux disease. Gastroenterology 2001; 121:1095.</li>
<li>Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn oracid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.</li>
<li>Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy forGERD: a multi-center study in Japan. World J Gastroenterol 2011; 17:1480.</li>
<li>Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients withgastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965.</li>
<li>Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass indexand esophageal acid exposure in the extraesophageal manifestations of reflux. ClinGastroenterol Hepatol 2012; 10:874.</li>
<li>Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between uppergastrointestinal symptoms and changes in body weight in a population-based cohort.Neurogastroenterol Motil 2006; 18:987.</li>
<li>Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is notreduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.</li>
<li>Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms ofgastroesophageal reflux in women. N Engl J Med 2006; 354:2340.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction ingastroesophageal reflux. A prospective population-based cohort study: the HUNT study.Am J Gastroenterol 2013; 108:376.</li>
<li>DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines forthe diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol2005; 100:190.</li>
<li>Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle Intervention inGastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14:175.</li>
<li>Mehta RS, Song M, Staller K, Chan AT. Association Between Beverage Intake andIncidence of Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol 2020;18:2226.</li>
<li>Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathingexercise on gastroesophageal reflux disease: a randomized, controlled study. Am JGastroenterol 2012; 107:372.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation andimproved gastroesophageal reflux: a prospective population-based cohort study: theHUNT study. Am J Gastroenterol 2014; 109:171.</li>
<li>Mehta RS, Nguyen LH, Ma W, et al. Association of Diet and Lifestyle With the Risk ofGastroesophageal Reflux Disease Symptoms in US Women. JAMA Intern Med 2021;181:552.</li>
<li>Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosivegastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.</li>
<li>Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to theacid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11:1585.</li>
<li>Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodiumalginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.</li>
<li>Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented bymagnetic resonance imaging and pH-impedance monitoring: mechanistic assessmentin healthy volunteers and randomised, controlled, double-blind study in reflux patients.Aliment Pharmacol Ther 2013; 37:1093.</li>
<li>Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oralsuspension is non-inferior to omeprazole in the treatment of patients with non-erosivegastroesophageal disease. Aliment Pharmacol Ther 2013; 38:1054.</li>
<li>Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of uppergastrointestinal symptoms by an acid pocket-targeting alginate-antacid (GavisconDouble Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophagealreflux disease. Aliment Pharmacol Ther 2014; 39:595.</li>
<li>Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatmentafter 14 days of administration in healthy subjects without Helicobacter pylori infection.J Gastroenterol Hepatol 2003; 18:678.</li>
<li>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcerhealing, gastroesophageal reflux disease, and stress-related erosive syndrome.Gastroenterology 2000; 118:S9.</li>
<li>Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.</li>
<li>Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms ofgastroesophageal reflux disease and heals erosions and ulcerations. Results of amulticenter, placebo-controlled, dose-ranging study. USA Merck GastroesophagealReflux Disease Study Group. Arch Intern Med 1991; 151:2394.</li>
<li>Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal refluxdisease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol1991; 86:1735.</li>
<li>Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed onDecember 19, 2012).</li>
<li>Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is moreacceptable to patients than continuous lansoprazole 15 mg in the long-termmaintenance of endoscopy-negative gastro-oesophageal reflux patients: theCOMMAND Study. Aliment Pharmacol Ther 2004; 20:657.</li>
<li>Hunt R. Acid suppression for reflux disease: "off-the-peg" or a tailored approach? ClinGastroenterol Hepatol 2012; 10:210.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitortherapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419.</li>
<li>Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pumpinhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal refluxdisease-like symptoms and endoscopy negative reflux disease. Cochrane Database SystRev 2013; :CD002095.</li>
<li>Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worseesophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl B:66B.</li>
<li>Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptorantagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005; 11:4067.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Katzka DA, Kahrilas PJ. Advances in the diagnosis and management ofgastroesophageal reflux disease. BMJ 2020; 371:m3786.</li>
<li>Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenancetherapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci2009; 54:955.</li>
<li>Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies forreflux esophagitis. N Engl J Med 1995; 333:1106.</li>
<li>Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients withgastrooesophageal reflux disease. Gut 1992; 33:1016.</li>
<li>Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies forGastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. Decem ber 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).</li>
<li>Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention ofrelapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Gut 1994; 35:590.</li>
<li>Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of refluxesophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlledtrial. Ann Intern Med 1996; 124:859.</li>
<li>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancyand lactation. Aliment Pharmacol Ther 2020; 51:421.</li>
<li>Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet)with antacid for safety and effectiveness in reducing gastric acidity before electivecesarean section. Anesthesiology 1983; 59:86.</li>
<li>Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) inpregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.</li>
<li>Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk ofbirth defects. N Engl J Med 2010; 363:2114.</li>
<li>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophagealreflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.</li>
<li>Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. JReprod Med 2004; 49:825.</li>
<li>National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).</li>
<li>ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelinesfor endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</li>
<li>Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal refluxdisease: putative mechanisms of failure. Drugs 2007; 67:1521.</li>
<li>Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptomsrefractory to proton pump inhibitors. Gut 2012; 61:1340.</li>
<li>Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with theirprescription medications? Results of the patient unmet needs study. J Clin OutcomesManag 2000; 7:29.</li>
<li>The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.</li>
<li>Fass R. Therapeutic options for refractory gastroesophageal reflux disease. JGastroenterol Hepatol 2012; 27 Suppl 3:3.</li>
<li>El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on protonpump inhibitor therapy in primary care and community studies. Aliment PharmacolTher 2010; 32:720.</li>
<li>Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors innonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.</li>
<li>Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention andtreatment. Drugs 2003; 63:555.</li>
<li>Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.</li>
<li>Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term protonpump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.</li>
<li>Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure ingastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.</li>
<li>Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pumpinhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol 2014;109:789.</li>
<li>Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitordosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.Aliment Pharmacol Ther 2006; 23:1473.</li>
<li>Wilder-Smith C, Röhss K, Bokelund Singh S, et al. The effects of dose and timing ofesomeprazole administration on 24-h, daytime and night-time acid inhibition in healthyvolunteers. Aliment Pharmacol Ther 2010; 32:1249.</li>
<li>Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistentsymptoms despite acid suppressive therapy: a multicentre study using combinedambulatory impedance-pH monitoring. Gut 2006; 55:1398.</li>
<li>Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol2008; 6:521.</li>
<li>Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pHmonitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.</li>
<li>Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitecmonitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53:2387.</li>
<li>Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux insymptomatic GERD. Am J Gastroenterol 2001; 96:2033.</li>
<li>Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring insymptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.</li>
<li>Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in ahypersensitive esophagus might explain symptoms resistant to proton pump inhibitorsin patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2014;12:1647.</li>
<li>Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree ofduodenogastroesophageal reflux and acid reflux between patients who failed torespond and those who were successfully treated with a proton pump inhibitor oncedaily. Am J Gastroenterol 2009; 104:2005.</li>
<li>Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acidsuppressive therapy. Am J Gastroenterol 2008; 103:1090.</li>
<li>Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiatenon-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012;47:159.</li>
<li>Abdallah J, George N, Yamasaki T, et al. Most Patients With Gastroesophageal RefluxDisease Who Failed Proton Pump Inhibitor Therapy Also Have Functional EsophagealDisorders. Clin Gastroenterol Hepatol 2019; 17:1073.</li>
<li>Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology2016.</li>
<li>Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functionalheartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013;25:282.</li>
<li>Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity tobile salts in patients with functional heartburn and in healthy control subjects. Dig DisSci 2005; 50:81.</li>
<li>Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traitsof functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity toacid. Am J Gastroenterol 2006; 101:1084.</li>
<li>Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for thetreatment of refractory GERD accompanied with gastroparesis: a preliminary report. DigDis Sci 2008; 53:2621.</li>
<li>Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patientswith symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum ofvisceral sensitivity in GORD. Gut 1995; 37:7.</li>
<li>Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS andpsychological distress on outcomes and quality of life following PPI therapy in patientswith gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.</li>
<li>Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associatedwith features of psychiatric disorders and the irritable bowel syndrome. AlimentPharmacol Ther 2007; 26:443.</li>
<li>Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease andpsychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.</li>
<li>Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal refluxdisease and underdiagnosis of functional dyspepsia in a USA community.Neurogastroenterol Motil 2014; 26:1163.</li>
<li>Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive tosingle-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux,bile reflux, or both? Am J Gastroenterol 2004; 99:981.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acidbreakthrough on different regimens of omeprazole 40 mg daily. Aliment PharmacolTher 1998; 12:1235.</li>
<li>Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective aslansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophagealreflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-aprospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.</li>
<li>Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebocontrolled study of omeprazole in the treatment of patients with reflux symptoms andphysiological levels of acid reflux--the "sensitive oesophagus". Gut 1997; 40:587.</li>
<li>Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburnsymptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.</li>
<li>Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-hintragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36:627.</li>
<li>Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis ofgastro-esophageal reflux disease: Update of the Porto consensus andrecommendations from an international consensus group. Neurogastroenterol Motil2017; 29:1.</li>
<li>Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring withand without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.</li>
<li>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management ofgastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.</li>
<li>Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pHmonitoring in patients with refractory gastroesophageal reflux disease, on and offtherapy. Clin Gastroenterol Hepatol 2009; 7:743.</li>
<li>Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology2018; 154:302.</li>
<li>Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findingsin gastro-esophageal reflux disease: Conclusions from an international consensusgroup. Neurogastroenterol Motil 2017; 29.</li>
<li>Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthroughon omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.</li>
<li>Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy onnocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.</li>
<li>Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine atnight to twice daily omeprazole therapy on nocturnal acid breakthrough and acid refluxin patients with systemic sclerosis--a randomized controlled, cross-over trial. AlimentPharmacol Ther 2007; 26:1259.</li>
<li>Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinicalsignificance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545.</li>
<li>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for thecontrol of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009;:CD004275.</li>
<li>Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improvegastroesophageal reflux disease symptoms for patients on proton pump inhibitortherapy. Dis Esophagus 2005; 18:370.</li>
<li>Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophagealreflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract2014; 2014:307805.</li>
<li>Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices?Curr Opin Gastroenterol 2009; 25:352.</li>
<li>Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants inpatients with functional esophageal disorders or gastroesophageal reflux disease:a systematic review. Clin Gastroenterol Hepatol 2015; 13:251.</li>
<li>Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adultpatients with functional chest pain: a randomized, double-blind, placebo-controlled,crossover trial. Am J Gastroenterol 2010; 105:1504.</li>
<li>Park SW, Lee H, Lee HJ, et al. Low-dose amitriptyline combined with proton pumpinhibitor for functional chest pain. World J Gastroenterol 2013; 19:4958.</li>
<li>Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors forthe treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.</li>
<li>Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy ingastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20:2412.</li>
<li>Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients WithRefractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology2020; 158:2093.</li>
<li>Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the protonpump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.</li>
<li>UpToDate medical database. Approach to the initial management of patients with GERD. Graphic 116964 Version 3.0. Электронный ресурс: https://www.uptodate.com/contents/image?imageKey=GAST%2F116964, дата доступа: 14.07.2023</li>
<li>Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut. 2005;54(12):1810-1817. doi:10.1136/gut.2005.072629</li>
<li>Costa V, Pinto-Saavedra O, Hani A, Leguízamo AM, Ardila-Hani AF. Updated interpretation of Impedance–pH monitoring. Rev Colomb Gastroenterol. 2021;36(1):73-80. https://doi.org/10.22516/25007440.608</li>
<li>Hani, Albis & Leguizamo, Ana & Carvajal, Jhon & Klinger, Gabriel & Costa, Valeria. (2015). How to Perform and Interpret High-resolution Esophageal Manometry. Revista Colombiana de Gastroenterologia. 30. 74-83.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л., Хлынов И.Б., Дехнич Н.Н., Лопина О.Д., Алексеева О.П., Корочанская Н.В., Осипенко М.Ф., Павлов П.В., Пирогов С.С., Тарасова Г.Н., Успенский Ю.П., Андреев Д.Н., Румянцева Д.Е. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18. https://doi.org/10.22416/1382-4376-2020-30-6-7-18.</li>
<li>Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Can Fam Physician 2017;63:354-64 (Eng), e253-65 (Fr).</li>
<li>Cho YK. How to Interpret Esophageal Impedance pH Monitoring. J Neurogastroenterol Motil. 2010 Jul;16(3):327-30. doi: 10.5056/jnm.2010.16.3.327. Epub 2010 Jul 26. PMID: 20680174; PMCID: PMC2912128.</li>
<li>Kim GH. How to Interpret Ambulatory 24 hr Esophageal pH Monitoring. J Neurogastroenterol Motil. 2010 Apr;16(2):207-10. doi: 10.5056/jnm.2010.16.2.207. Epub 2010 Apr 27. PMID: 20535354; PMCID: PMC2879855.</li>
<li>Jehangir A, Malik Z, Parkman HP. Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterol. 2022 Mar 8;22(1):112. doi: 10.1186/s12876-022-02194-0. PMID: 35260107; PMCID: PMC8905734.</li>
<li>Yadlapati R. High-resolution esophageal manometry: interpretation in clinical practice. Curr Opin Gastroenterol. 2017 Jul;33(4):301-309. doi: 10.1097/MOG.0000000000000369. PMID: 28426462; PMCID: PMC5568812.</li>
<li>Yamasaki T, Fass R. Reflux Hypersensitivity: A New Functional Esophageal Disorder. J Neurogastroenterol Motil. 2017;23(4):495-503. doi:10.5056/jnm17097</li>
<li>Ronnie Fass, Frank Zerbib, C. Prakash Gyawali. AGA Clinical Practice Update on Functional Heartburn: Expert Review. CLINICAL PRACTICE UPDATE| VOLUME 158, ISSUE 8, P2286-2293, JUNE 2020. Published: February 01, 2020. DOI: https://doi.org/10.1053/j.gastro.2020.01.034</li>
<li>Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi: 10.14309/ajg.0000000000000731. PMID: 32773454; PMCID: PMC9896940.</li>
<li>Samo S, Qayed E. Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management? World J Gastroenterol. 2019 Jan 28;25(4):411-417. doi: 10.3748/wjg.v25.i4.411. PMID: 30700938; PMCID: PMC6350167.</li>
<li>Management of the patient with esophagogastric junction outflow obstruction (EGJOO) Shahsavari et al. Curr Opin Gastroenterol 2021, 37:397–407. DOI:10.1097/MOG.0000000000000747</li>
<li>Dhyanesh A. Patel, Rena Yadlapati, Michael F. Vaezi, Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics, Gastroenterology, Volume 162, Issue 6, 2022, Pages 1617-1634, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2021.12.289.</li>
<li>DeLay K, Krause A, Yadlapati R. Clinical Updates in Esophageal Motility Disorders Beyond Achalasia. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1789-1792.e1. doi: 10.1016/j.cgh.2021.05.041. Epub 2021 Jul 1. PMID: 34405804; PMCID: PMC8604436.</li>
<li>Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30. PMID: 24466441; PMCID: PMC3895610.</li>
<li>Чёрная А. В. Карханова А. Г., Мутовкина Н. И., Дышлюк Т. Л., Багненко С. С., Рогачев М. В., Ульянова Р. Х., Зайцев А. Н., Шевкунов Л. Н., Новиков С. Н., Шевченко Е. Ю., Брезгина Е. А. Лучевая диагностика заболеваний пищевода при злокачественных и доброкачественных изменениях: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. – Санкт-Петербург: ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России, 2021. – 144 с. ISBN 978-5-6046978-1-8</li>
<li>Государственный реестр лекарственных средств. Электронный ресурс: https://grls.rosminzdrav.ru/default.aspx, дата доступа: 14.07.2023</li>
<li>Инструкция по применению лекарственного препарата Ганатон® (итоприда гидрохлорид). РУ ЛС-002513 от 29.06.2021. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9abd2328-abcb-411e-919e-6d8ab7c238ea, дата доступа: 14.07.2023</li>
<li>Stanghellini V., Chan F., Hasler W.L. et al. Gastroduodenal Disorders Gastroenterology 2016;150:1380– 1392.</li>
<li>Касьяненко В.И., Денисов Н.Л., Васильев Ю.В. Применение итоприда при симптомах функциональной диспепсии в России: результаты проспективного открытого многоцентрового клинического исследования IV фазы. Терапевтический Архив. 2014;8:35-41.</li>
<li>Tack J. et all. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther. 2011 Jan;33(1):99-105.</li>
<li>Murray J.A. Gastroesophageal Reflux Disease. In.: Mayo Clinic Gastroenterology and Hepatology Board Review. Oxford University Press. 2015.</li>
<li>Ezzat W.F., Fawaz S.A., Fathey H. et al. Virtue of Adding Prokinetics to Proton Pump Inhibitors in the Treatment of Laryngopharyngeal Reflux Disease: Prospective Study Journal of Otolaryngology-Head & Neck Surgery. 2011;40(4):350–356/</li>
<li>Инструкция по применению лекарственного препарата Париет® (рабепразол). РУ П N011880/01 от 28.02.2022. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d7c5d813-e692-4211-a63d-2a2ac06ea1d7, дата доступа: 14.07.2023</li>
<li>Kirchheiner J., Glatt S., Fuhr U. et al. Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH // European Journal of Clinical Pharmacology, 2008, 65 (1), pp.19-31</li>
<li>Kramer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitrocorrelates. Pharmacology. 1998;56:57-70</li>
<li>Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003 Feb;48(2):322-8.</li>
<li>Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335.</li>
<li>Besancon M, Shin JM, Mercier F, et al. Biochemistry, 1993; 32:2345–2355.</li>
<li>Сереброва С.Ю. Основные фармакокинетические характеристики ингибиторов протонной помпы и эффективность их действия. Пособие для врачей. Мединфорум 2016.</li>
<li>Cefditoren [Korean product labeling]. Boryeong Pharmaceutical; November 2009.</li>
<li>Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol. 1984;18(4):535-539. [PubMed 6091711</li>
<li>Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. Adv Perit Dial. 1994;10:179-182. [PubMed 7999822</li>
<li>Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</li>
<li>Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509. [PubMed 16898956</li>
<li>Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OLCA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardio. 2008;51(3):256-260. [PubMed 18206732</li>
<li>Fontes-Carvalho R, Albuquerque A, Araugo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogre-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396-404. [PubMed 21464720</li>
<li>Frelinger 3rd AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardio. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944. [PubMed 19258584</li>
<li>Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039; author reply 1039. [PubMed 18786491</li>
<li>Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Gaglia MA Jr, Torguson R, Hanna N, et alRelation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomesAm J Cardiol2010;105(6):833-838[PubMed 20211327</li>
<li>Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964-1968. [PubMed 19731021</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997. [PubMed 19726078</li>
<li>Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26(2):e54-e57. [PubMed 20151060</li>
<li>Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917. [PubMed 20925534</li>
<li>Muthiah MD, Zheng H, Chew NWS, et al. Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. [online ahead of print] J Thromb Throbolysis. 2021. doi: 10.1007/s11239-021-02472. [PubMed 33959860</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016; Aug 10 (Epub ahead of print). [PubMed 27512080</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478</li>
<li>Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). BMC Cardiovasc Disord. 2017;17(1):3. [PubMed 28056809</li>
<li>Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939-947. [PubMed 27459657</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11): pii: e002245. [PubMed 26514161</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership: March 2021.</li>
<li>Park GJ, Bae SH, Park WS, et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017;11:1043-1053. [PubMed 28408803</li>
<li>Kamiya C, Inui N, Hakamat A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype [published online March 11, 2019]. J Pharmacol Sci. Doi: 10.1016/j.jphs.2019.03.001. [PubMed 30902567</li>
<li>Elbe A, Foerster KI, Blank A, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975-987. [PubMed 35238961</li>
<li>Erleada (apalutamide) [prescribing information. Horsham, PA: Janssen Products LP; September 2019</li>
<li>Kanebratt KP, Diczfalusy U, Backstroo T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther, 2008, 84(5):589-94. [PubMed 18650803</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; August 2018.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999-1004. [PubMed 22147077</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016</li>
<li>Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358-1365. [PubMed 25274610</li>
<li>Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81(6):1195-1196. [PubMed 26833554</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;25(7):1155-1162. [PubMed 30605231</li>
<li>Koutake Y, Taniguch J, Yasumori N, et al. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol. 2020;111(6):826-832. [PubMed 32152877]</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2012.</li>
<li>Tarceva (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; April 2014</li>
<li>van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309-1314. [PubMed 26858332</li>
<li>Veerman GDM, Hussaarts KGAM, Peric R, et al. Influence of cow's milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69-77. [PubMed 32557346</li>
<li>Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol. 2010;70(6):908-911. [PubMed 21175447</li>
<li>Du X, Liu W, Chen K, Wang Z, Li X, Yang L, Xie X. Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis. [published online ahead of print] Front Pharmacol. 2022. doi: 10.3389/fphar.2022.796538. [PubMed 35795555</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908</li>
<li>Zenke Y, Yoh K, Matsumoto S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412-418. [PubMed 26944770</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et alA multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerClin Cancer Res2010;16(11):3078-3087[PubMed 20395213</li>
<li>Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 2013;52:593-609. [PubMed 23532985</li>
<li>Truseltiq (infigratinib) [prescribing information]. Brisbane, CA: QED Therapeutics Inc; May 2021.</li>
<li>Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola®) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671-1675. [PubMed 7486898</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; June 2018</li>
<li>Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; March 2018</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022</li>
<li>Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-391. [PubMed 9357389</li>
<li>Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42(3):278-284. [PubMed 22022918</li>
<li>Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283:434-442.[PubMed 9353355</li>
<li>Zhang W, Ramamoorthy Y, Kilicarslan T, et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos. 2002;30:314-318. [PubMed 11854151]</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</li>
<li>Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1635-1643. [PubMed 23636448</li>
<li>Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. [Published online doi:10.1002/ijc.33469]. 2021. [PubMed 33428771</li>
<li>Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020;76(9):1273-1280. [PubMed 32474662</li>
<li>Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</li>
<li>Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F. Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects. Clin Pharmacokinet. 2022;61(11):1623-1639. [PubMed 36264536</li>
<li>Turalio (pexidartinib) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; August 2019.</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; August 2015</li>
<li>Juluca (dolutegravir/rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020</li>
<li>Noltec (ilaprazole) [Korean product labeling]. Ilyang Pharmaceutical Co., Ltd.; March 2020</li>
<li>K-CAB (tegoprazan) [Singapore product labeling]. Singapore: HK inno.N Corporation; January 2023.</li>
<li>Lumakras (sotorasib) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2021.</li>
<li>Filspari (sparsentan) [prescribing information]. San Diego, CA: Travere Therapeutics Inc; February 2023.</li>
<li>Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-197. [PubMed 15001970</li>
<li>Konvomep (omeprazole and sodium bicarbonate for oral suspension) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals, Inc.; August 2022.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2020</li>
<li>Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011;51(3):368-377. [PubMed 20457590</li>
<li>Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26:341346. [PubMed 16503713</li>
<li>Evotaz (atazanavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2020.</li>
<li>Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors. Clin Pharmacol Drug Dev. 2022;11(7):795-806. [PubMed 35230741</li>
<li>Rezurock (belumosudil) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals LLC; July 2021.</li>
<li>Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33(8):589-595. [PubMed 23839484</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:53-59. [PubMed 10702887</li>
<li>Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.</li>
<li>Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51. [PubMed 20642546</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90-97. [PubMed 24887634</li>
<li>Wu WT, Tsai CT, Chou YC, et al. Cardiovascular outcomes associated with clinical use of citalopram and omeprazole: a nationwide population-based cohort study. J Am Heart Assoc. 2019;8(20):e011607. [PubMed 31581860</li>
<li>Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.</li>
<li>Yokota H, Sato K, Okuda Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18(6):e433-e439. [PubMed 28579188</li>
<li>Tang W, Tomkinson H, Masson E. Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev. 2017;6(5):517-523. [PubMed 28176470</li>
<li>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res. 2019;11:8539-8546. [PubMed 31572008</li>
<li>Sedano MN, Teller JMC, Munoz CG, et al. Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON. 2018;23(3):647-653. [PubMed 30003732</li>
<li>Li J, Nickens D, Wilner K, Tan W. Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther. 202113. Epub ahead of print. [PMID: 34120312</li>
<li>Kumarakulasinghe NB, Syn N, Soon YY, et al. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget. 2016;7(51):85542-85550. [PubMed 27907909</li>
<li>Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2021.</li>
<li>Jaruratanasirikul S and Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54:159-161. [PubMed 9626921</li>
<li>Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, and Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51:453-457. [PubMed 12562722</li>
<li>Lange D, Pavao JH, Wu J, and Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Tolsura (itraconazole) [prescribing information]. Greenville NC: Mayne Pharma; December 2018</li>
<li>Lindsay J, Mudge S, and Thompson GR. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723018. [PubMed 30297369</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018</li>
<li>Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808. [PubMed 16141567]</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2017</li>
<li>Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893-1899. [PubMed 27533287</li>
<li>Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5. [PubMed 27565882]</li>
<li>Camzyos (mavacamten) [prescribing information]. Brisbane, CA: MyoKardia, Inc.; April 2022.</li>
<li>Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol.1993;33(1):82-84. [PubMed 8269594</li>
<li>Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024-1027. [PubMed 10981249</li>
<li>Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497. [PubMed 12077038</li>
<li>Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30(3):963-965. [PubMed 20393020</li>
<li>McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012;25(4):477-485. [PubMed 22550162</li>
<li>Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316-318. [PubMed 18386155</li>
<li>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Chemotherapy. 2011;57(3):225-229. [PubMed 21597286</li>
<li>Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht RDelayed elimination of methotrexate associated with co-administration of proton pump inhibitorsAnticancer Res2010;30(9):3807-3810[PubMed 20944174</li>
<li>Fang AF, Damle BD, LaBadie RR, Crownover, PH, Hewlett Jr. D, Glue, PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50. [PubMed 18154473</li>
<li>Saberi P, Ranatunga DK, Quesenberry CP, Silverberg MJ. Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011;31(3):253-261. [PubMed 21361735</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016</li>
<li>Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32(12):1462-1467. [PubMed 15448116]</li>
<li>Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50(8):960-967. [PubMed 20498287</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155-1162. [PubMed 30605231</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.</li>
<li>Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food and intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614-626. [PubMed 28430398</li>
<li>Ibrance (palbociclib) capsule [prescribing information]. New York, NY: Pfizer Inc; September 2019</li>
<li>Ibrance (palbociclib) tablet [prescribing information]. New York, NY: Pfizer Inc; November 2019</li>
<li>Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021;6(5):100231. [PubMed 34509802</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649]</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PubMed 19075045</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; November 2013</li>
<li>Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839. [PubMed 19220151</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-5510[PubMed 22890761</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott (US), LLC; April 2015</li>
<li>Kinov P, Boyanov M. Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health. 2012;4L:167-174. [PubMed 22532780</li>
<li>Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114. [PubMed 30539272</li>
<li>Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998-1004. [PubMed 21321287</li>
<li>Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161-1168. [PubMed 22890365</li>
<li>Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016-1022. [PubMed 23307040</li>
<li>Prieto-Alhambra D, Pages-Castella A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268-274. [PubMed 23761350</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Yang SD, Chen Q, Wei HK, et alBone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysisInt J Clin Exp Med2015;8(4):4899-4910[PubMed 26131063</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782</li>
<li>Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC Jr, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63(10):2070-2073. [PubMed 26415604</li>
<li>Roux C, Goldstein JL, Zhou X, et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277-284. [PubMed 21365461</li>
<li>Asaoka D, Nagahara A, Hojo M, et al. Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomed Rep. 2016;5(2):165-170. [PubMed 27446535</li>
<li>Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31(2):206-211. [PubMed 23138352</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014:607145. [PubMed 25436170]</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin Inc; July 2017</li>
<li>Prilosec (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Nexim (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016</li>
<li>Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2017.</li>
<li>Retevmo (selpercatinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; May 2020.</li>
<li>Norouzi G, AsadZade A, Salimi Y, Khoshbakht S, Pirayesh E. Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi. J Nucl Cardiol. 2022;29(4):1552-1561. [PubMed 33527332</li>
<li>Rose DS, Robinson B, Kannan S, Lee JC. Interaction between the effects of proton pump inhibitors and aspirin on gastric wall sestamibi uptake on myocardial perfusion imaging. J Nucl Cardiol. 2021;28(5):1976-1985. [PubMed 31741323</li>
<li>Qutbi M. What is this image? 2019: Image 2 result : Reduction in interfering gastric wall uptake on myocardial perfusion SPECT following a 2-week period of omeprazole withdrawal. J Nucl Cardiol. 2019;26(5):1517-1519. [PubMed 31359363</li>
<li>Singh H, Mittal BR, Sood A, et al. Association of use of proton pump inhibitors and H2 antagonists with stomach wall uptake in 99m-Tc-methoxy-isobutyl-isonitrile (MIBI) myocardial perfusion imaging. J Nucl Cardiol. 2020;27(5):1611-1619. [PubMed 31087263</li>
<li>Javadi H, Jallalat S, Semnani S, et al. The association of increased stomach wall radiotracer uptake with prolonged use of omeprazole capsules on myocardial perfusion imaging (MPI) using 99mTc-sestamibi SPECT. Nucl Med Rev Cent East Eur. 2013;16(2):91-94. [PubMed 24068640</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974</li>
<li>Cardiolyte (technetium Tc 99m sestamibi) [prescribing information]. N. Billerica, Massachusetts: Lantheus Medical Imaging; December 2019</li>
<li>Technetium Tc 99m sestamibi [product monograph]. Laval, Quebec, Canada: Curium Canada Inc; November 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2020</li>
<li>Vosevir (sofosbuvir and velpatasvir and voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2019</li>
<li>Seyen MV, Colbers A, Abbink EJ, Drenth JPH, Burger DM. Concomitant intake of coca-cola to manage the drug-drug interaction between velpatasvir and omeprazole studied in healthy volunteers. Clin Pharmacol Ther. 2019;106(5):1093-1098. [PubMed 31313296]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270</li>
<li>Evekeo (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2013.</li>
<li>Czerwinski E. Atypical subtrochanteric fractures after long-term bisphosphonate therapy. Endokrynol Pol. 2011;62(1):84-87. [PubMed 21365585</li>
<li>Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169-180. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-785. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-1998. [PubMed 19333676</li>
<li>Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-1218. [PubMed 21483462</li>
<li>Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768-776. [PubMed 21185417</li>
<li>Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131-1136. [PubMed 20872906</li>
<li>Gray SL, LaCroix AZ, Larson J, et alProton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health InitiativeArch Intern Med2010;170(9):765-771[PubMed 20458083</li>
<li>Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101. [PubMed 20353792</li>
<li>Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326. [PubMed 18695179</li>
<li>Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. [PubMed 17190895</li>
<li>Bodmer M, Meier C, Kraenzlin ME, et al. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33(10):843-852. [PubMed 20812769</li>
<li>Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903-910. [PubMed 20585937</li>
<li>Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959. [PubMed 18657011</li>
<li>Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904. [PubMed 19931262</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014;2014:607145. [PubMed 25436170</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782]</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767-773. [PubMed 27737436</li>
<li>Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257-263. [PubMed 26803708</li>
<li>Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43(4):309-315. [PubMed 10071982</li>
<li>van Doorn L, Heersche N, de Man FM, et al. Effect of the proton pump inhibitor esomeprazole on the systemic exposure of capecitabine: results of a randomized crossover trial. Clin Pharmacol Ther. 2022;111(2):455-460. [PubMed 34656072]</li>
<li>Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23(1):37-39. [PubMed 11413862</li>
<li>Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44(2):186-189. [PubMed 9278208]</li>
<li>Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2-receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183]</li>
<li>Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-353. [PubMed 22422635</li>
<li>Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23(3):317-321. [PubMed 3567046</li>
<li>Onfi (clobazam) [prescribing information]. Winchester, KY: Catalent Pharma Solutions, LLC; February 2021</li>
<li>Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999;21(6):604-608. [PubMed 10604819</li>
<li>Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589-592. [PubMed 22293514</li>
<li>Grigoleit HG, Hajdu P, Hundt HK, et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol. 1983;25(1):139-142. [PubMed 6617718]</li>
<li>Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2022.</li>
<li>Frick A, Kopitz J, and Bergemann N, “Omeprazole Reduces Clozapine Plasma Concentrations: A Case Report,” Pharmacopsychiatry, 2003, 36(3):121</li>
<li>[PubMed 12806570</li>
<li>Intensive Medicines Monitoring Programme accessed at http://www.medsafe.govt.nz/Profs/Puarticles/ClozOmep.htm May 14, 2013</li>
<li>Mookhoek EJ and Loonen AJ, “Retrospective Evaluation of the Effect of Omeprazole on Clozapine Metabolism,” Pharm World Sci, 2004, 26(3):180</li>
<li>[PubMed 15230368</li>
<li>Wagner S, Varet-Legros MG, Fabre C, et al, “Confounding Factors for Variation of Clozapine Plasma Levels: Drug Interactions With Proton Pump Inhibitor or Infectious Etiologies?” Eur J Clin Pharmacol, 2011, 67(5):533</li>
<li>[PubMed 21057941</li>
<li>Philipps RJ, Lee Demler T and Lee C, “Omeprazole-Induced Blood Dyscrasia in a Clozapine-Treated Patient,” Innov Clin Neurosci, 2012, 9(9):14</li>
<li>[PubMed 23074697]</li>
<li>Reichenspurner H, Meiser BM, Muschiol F. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transplant. 1993;12(6):987-992. [PubMed 8312324</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al. Changes of resorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc. 1994;26(5):2800-2801. [PubMed 7940881</li>
<li>Schouler L, Dumas F, Couzigou P. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86(8):1097. [PubMed 1858755</li>
<li>Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993;35(2):156-160. [PubMed 8443034</li>
<li>Castellote E, Bonet J, Lauzurica R. Does interaction between omeprazole and cyclosporin exist? Nephron. 1993;65(3):478. [PubMed 8290007</li>
<li>Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM. More about omeprazole-cyclosporine interaction. Am J Gastroenterol. 1993;88(1):154-155. [PubMed 8420264</li>
<li>Zegerid (omeprazole) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; November 2020.</li>
<li>Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057-1069. [PubMed 25929560</li>
<li>Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519. [PubMed 29105855</li>
<li>Kamiya C, Inui N, Hakamata A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361-366. [PubMed 30902567</li>
<li>Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487-494. [PubMed 15025747</li>
<li>Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141-152. [PubMed 11907488</li>
<li>Vlase L, Neag M, Popa A, Muntean D, Leucuta SE. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Curr Ther Res Clin Exp. 2010;71(6):360-368. [PubMed 24688155</li>
<li>Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653-662. [PubMed 24569517</li>
<li>Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. [PubMed 34877801</li>
<li>Inrebic (fedratinib) [prescribing information]. Summit, NJ: Celgene Corporation; August 2019</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672</li>
<li>Vfend (voriconazole) [prescribing information]New York, NY: Pfizer; January 2019</li>
<li>Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021</li>
<li>Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23(2):77-81. [PubMed 11932962</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; January 2020</li>
<li>Armas D, Holt RJ, Confer NF, Checani GC, Obaidi M, Xie Y, Brannagan M. A phase I pharmacokinetic study of cysteamine bitartrate delayed-release capsules following oral administration with orange juice, water, or omeprazole in cystinosis. Adv Ther. 2018;35(2):199-209. [PubMed 29411268]</li>
<li>Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicriob Agents Chemother. 2007;51(3):958-961. [PubMed 17210768]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Lexington, MA: Shire US Inc.; July 2019</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270]</li>
<li>Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.</li>
<li>Grahnen A, Olsson B, Johansson G, Eckernas SA. Doxycycline carrageenate-an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmcol 1994;46(2):143-146. [PubMed 8039533</li>
<li>Monodox (doxycycline monohydrate). Aqua Pharmaceuticals, LLC; Fort Lauderdale, FL: April 2017</li>
<li>Nexium (esomeprazole). AstraZeneca Pharmaceuticals LP; Wilmington DE: October 2016.</li>
<li>Grasela Jr TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615-617. [PubMed 2751276</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081</li>
<li>Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol. 1993;33(1):53-56. [PubMed 8429114]</li>
<li>Lozano R, Bibian C, Quilez RM, Gil J, Constante Y, Garcia-Arilla E. Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol. 2014;77(6):1086-1087. [PubMed 23919252</li>
<li>Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391-1400. [PubMed 23928296</li>
<li>Lexapro (escitalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Courlet P, Guidi M, Glatard A, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019;85(9):2022-2032. [PubMed 31144347</li>
<li>Escitalopram [product monograph]. Kirkland, Quebec, Canada: Accord Healthcare Inc; September 2017.</li>
<li>Marti-Masso JF, Lopez de Munain A, Lopez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother. 1992;26(3):429-430. [PubMed 1554966]</li>
<li>Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-1241. [PubMed 3932118</li>
<li>Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24(4):543-545. [PubMed 3689634</li>
<li>Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935-46. [PubMed 22612290</li>
<li>Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6):563-568. [PubMed 10613611</li>
<li>Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215-220. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al. Reduction of phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol. 1983;25(1):135-137. [PubMed 6617717</li>
<li>Bartle WK, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther. 1983;33(5):649-655. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, Jordan JE. Effect of cimetidine on phenytoin serum levels. Epilepsia. 1983;24(3):284-288. [PubMed 6851961</li>
<li>Iteogu MO, Murphy JE, Shleifer N, Davis REffect of cimetidine on single-dose phenytoin kineticsClin Pharm1983;2(4):302-304[PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology. 1985;35(4):562-565. [PubMed 3982643</li>
<li>Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. Br J Clin Pharmacol. 1989;27(1):83-87. [PubMed 2565119</li>
<li>Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effects of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 1989;30(2):225-229. [PubMed 2647472</li>
<li>Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, Remmel RP. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 1988;29(4):488-491. [PubMed 3391153</li>
<li>Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-544 (ADD 03055) in epileptic patients. Epilepsia. 1985;26(6):602-606. [PubMed 4076064</li>
<li>Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40(8):1122-1128. [PubMed 10448826</li>
<li>Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997;62(5):572-577. [PubMed 9390115</li>
<li>Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol. 1996;53(11):1191-1192. [PubMed 8912496</li>
<li>Rindone JP, Bryan G. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med. 1996;156(10):1113. [PubMed 8639000</li>
<li>Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology. 1996;46(4):1172-1173. [PubMed 8780118</li>
<li>Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother. 1998;32(12):1295-1298. [PubMed 9876809</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, Shearman DJ, Hann CS. Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed). 1981;282(6275):1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med. 1981;95(2):244-245. [PubMed 7258891</li>
<li>Phillips P, Hansky J. Phenytoin toxicity secondary to cimetidine administration. Med J Aust. 1984;141(9):602. [PubMed 6092884</li>
<li>Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12(4):329-333. [PubMed 2396305</li>
<li>Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36(4):380-382. [PubMed 12959321</li>
<li>Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol. 1992;34(1):75-78. [PubMed 1633070</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Dujic T, Cvijic S, Elezovic A, et al. Interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype. J Pers Med. [published online May 3 2021].doi:10.3390/jpm11050367] [PubMed 34063566]</li>
<li>Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474-484. [PubMed 34649118</li>
<li>Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487-5493. [PubMed 32933995</li>
<li>Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR tirals. Ann Oncol. 2020;31(4):535-531. [PubMed 32115349</li>
<li>Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016;26(9):609-615. [PubMed 27603551</li>
<li>Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacotherapy. 2022;56(4):377-386. [PubMed 34282636]</li>
<li>Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12(15):2080-2082. [PubMed 9814882</li>
<li>Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-428. [PubMed 18281734</li>
<li>Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122-129. [PubMed 27693678]</li>
<li>Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.</li>
<li>Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69(4):266-273. [PubMed 11309556</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672]</li>
<li>Sharma VR, Brannon MR, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. Southern Med J. 2004;97(9):887-889.[PubMed 15455980</li>
<li>Salovaara S, Sandberg A-S, Andlid T. Combined impact of pH and organic acids on iron uptake by caco-2 cells. J Agric Food Chem. 2003;51:7820-7824. [PubMed 14664552</li>
<li>Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Ann Rev Nutr. 2003;23:283-301. [PubMed 12626689]</li>
<li>Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42(10):4243-4246. [PubMed 21168674</li>
<li>Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061-2067. [PubMed 20671023</li>
<li>Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196-1201. [PubMed 19783713</li>
<li>Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9(7):1650-1656. [PubMed 19519820</li>
<li>Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605-611. [PubMed 19481022</li>
<li>Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46(5):1362-1365. [PubMed 24935300</li>
<li>David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit. 2012;34(3):331-336. [PubMed 22549498</li>
<li>Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30(1):46-51. [PubMed 18223462</li>
<li>Kato R, Ooi K, Ikura-Mori M, et alImpairment of mycophenolate mofetil absorption by calcium polycarbophilJ Clin Pharmacol2002;42(11):1275-1280[PubMed 12412828</li>
<li>Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518-524. [PubMed 24162246</li>
<li>Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. [PubMed 25913040</li>
<li>Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265-1272. [PubMed 21903891</li>
<li>Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120-123. [PubMed 21192310</li>
<li>van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014;72(2):86-90. [PubMed 24659591</li>
<li>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; September 2013</li>
<li>Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565-571. [PubMed 21256049</li>
<li>Sakuludomakan W, Takuathung MN, Dukaew N, Koonrungsesomboon N. Drug-drug interactions between mycophenolic acid and proton pump inhibitors: a systematic review and meta-analysis. Ther Drug Monit. 2022;44(3):384-390. [PubMed 35239287</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.</li>
<li>Mycapssa (octreotide) delayed release capsules [prescribing information]. Scotland, UK: MW Encap Ltd; June 2020.</li>
<li>Prescribing information. Adempas (riociguat). Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., October 2013.</li>
<li>Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401-1406. [PubMed 16791014</li>
<li>Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914</li>
<li>Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83(6):867-872. [PubMed 17898705</li>
<li>Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech, Inc.; September 2020</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50:1081-1084. [PubMed 12461038</li>
<li>Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacother. 2006;26(8):1060-1068. [PubMed 16863482]</li>
<li>Nexavar (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2018</li>
<li>Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. J Cancer Res Clin Oncol. 2020;146(10):2693-2697. [PubMed 32449002</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(11):3078-3087. [PubMed 20395213]</li>
<li>Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet. 2008;23:134-138. [PubMed 18445994</li>
<li>Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet. 2007;22:441-444. [PubMed 18159131</li>
<li>Moreau C, Debray D, Loriot MA, et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation. 2006;81:487-488. [PubMed 16477241</li>
<li>Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38:791-794. [PubMed 15010519</li>
<li>Homma M, Itagaki F, Yuzawa K, et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation. 2002, 73:303-304. [PubMed 11821750</li>
<li>Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821-826. [PubMed 19139162</li>
<li>Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos. 2007;28:167-175. [PubMed 17377957</li>
<li>Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56:1055-1059. [PubMed 15285851</li>
<li>Itagaki F, Homma M, Yuzawa K, et alDrug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutationTransplant Proc2002;34:2777-2778[PubMed 12431607</li>
<li>Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin a blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56:439-440. [PubMed 11009056</li>
<li>Mei T, Noguchi H, Suetsugu K, et al. Effects of concomitant administration of vonoprazan fumarate on the tacrolimus blood concentration in kidney transplant recipients. Biol Pharm Bull. 2020;43(10):1600-1603. [PubMed 32999170</li>
<li>Suzuki Y, Yoshihashi T, Takahashi K, Furuya K, Ohkohchi N, Oda T, Homma M. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. J Clin Med. 2021;10(17):3964. [PubMed 34501411</li>
<li>Pascual J, Marcen R, Orea OE, et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. Transplant Proc. 2005;37(9):3752-3753. [PubMed 16386527</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862. [PubMed 9224780</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A4 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143]</li>
<li>Mouden M, Rijkee KS, Schreuder N, Timmer JR, Jager PL. Influence of proton-pump inhibitors on stomach wall uptake of 99mTc-tetrofosmin in cadmium-zinc-telluride SPECT myocardial perfusion imaging. Nucl Med Commun. 2015;36(2):143-147. [PubMed 25356621</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974]</li>
<li>Ock M, Lee S, Kim H. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor coadministration in patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2022;47(7):1028-1035. [PubMed 35257383]</li>
<li>Aptivus (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 20202. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914]</li>
<li>Ahmad S. Omeprazole-warfarin interaction. South Med J. 1991;84(5):674-675. [PubMed 2035104</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [PubMed 1493083</li>
<li>Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-184. [PubMed 2718223</li>
<li>Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci. 2003;20(4-5):439-449. [PubMed 14659488</li>
<li>Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab. 2005;6(5):399-411. [PubMed 16248835</li>
<li>Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol. 1993;110(1):482-490. [PubMed 8220911</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit. 2008;30(3):276-281. [PubMed 18520598</li>
<li>Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011;153(3):379-385. [PubMed 21418179</li>
<li>de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LMNo effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamicsBr J Clin Pharmacol1997;44(4):399-401[PubMed 9354316</li>
<li>Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN. Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol. 1997;32(10):991-994. [PubMed 9361171</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [PubMed 15258107</li>
<li>Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780]</li>
<li>Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56 Suppl 1:56-61. [PubMed 14616415</li>
<li>Yan M, Wu ZF, Tang D, et al. The impact of PPIs on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018;108:60-64. [PubMed 30216801</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological disease. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211. [PubMed 18171251</li>
<li>Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses. 2012;55(6):483-492. [PubMed 22429709</li>
<li>Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X. Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother. 2021;65(9):e0020721. [PubMed 34152823</li>
<li>Boyd NK, Zoellner CL, Swancutt MA, et al. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001-6002. [PubMed 22890768</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer; January 2019.</li>
<li>Veerman GDM, Hurkmans DP, Paats MS, et al. Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother. 2022;155:113695. [PubMed 36126454]</li>
<li>Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol. 2004;44(6):640-645. [PubMed 15145972</li>
<li>Pylera (bismith subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</li>
<li>Tabrecta (capmatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</li>
<li>Lau YY, Gu W, Lin T, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(6):1119-1128. [PubMed 28424965</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2016.</li>
<li>Clarithromycin [prescribing information]. Bedminster, NJ: Alembic Pharmaceuticals, Inc.; February 2022</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; March 2022.</li>
<li>Michaud V, Kreutz Y, Skaar T, et al. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 2014;14(2):151-159. [PubMed 23629159</li>
<li>Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475-482. [PubMed 22318618</li>
<li>Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharmacol Drug Dev. 2016;5(4):269-277. [PubMed 27310328</li>
<li>Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2015;60(1):105-114. [PubMed 26459906</li>
<li>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29. [PubMed 25646891</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. Doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. [PubMed 18076219</li>
<li>Nader A, Mostafa NM, Kim E, Shebley M. Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. Clin Transl Sci. 2022;15(5):1269-1280. [PubMed 35137535</li>
<li>Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol. 2014;54(4):422-431. [PubMed 24165884</li>
<li>Vassiliou D, Sardh E, Harper P, et al. A drug-drug interaction study evaluating the effect of givosiran, a small interfering ribonucleic acid, on cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250-1260. [PubMed 34510420</li>
<li>Luzu (luliconazole) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; February 2017</li>
<li>Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. [PubMed 29178272</li>
<li>Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465-472. [PubMed 28155129</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Tpoxx (tecovirimat) [prescribing information]Winchester, KY: Catalent Pharma Solutions; July 2018</li>
<li>Brukinsa (zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA, Inc.; November 2019</li>
<li>Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999;47(4):454-457. [PubMed 10233213</li>
<li>Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Jaypirca (pirtobrutinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; January 2023.</li>
<li>Bolek T, Samos M, Stanciakova L, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2017;Apr 25 (Epub ahead of print). [PubMed 28452843</li>
<li>Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33(6):619-623. [PubMed 29255511</li>
<li>Stangier J, Eriksson BI, Dahl O, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563. [PubMed 15831779</li>
<li>Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59. [PubMed 18076218</li>
<li>Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175. [PubMed 21972820</li>
<li>Schnierer M, Samos M, Bolek T, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020;75(4):333-335. [PubMed 31895873</li>
<li>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. [PubMed 19717844</li>
<li>Ollier E, Hodin S, Basset T, et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29(6):604-614. [PubMed 26392328</li>
<li>O'Dea D, Whetteckey J, Ting NA prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatranCardiol Ther2016;5(2):187-201[PubMed 27709460</li>
<li>Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586-595. [PubMed 25960019</li>
<li>Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-1713, 1713a-1713b. [PubMed 23425521</li>
<li>Pradaxa (dabigatran) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; July 2020.</li>
<li>Tafinlar (dabrafenib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.</li>
<li>Drewelow B, Schaffler K, Reitmeir P, Bethke TD. Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittelforschung. 2010;60(8):483-491. [PubMed 20863004</li>
<li>Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-164. [PubMed 7648765</li>
<li>Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995;58(1):62-72. [PubMed 7628184</li>
<li>Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47(1):79-85. [PubMed 2104790</li>
<li>Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39(1):51-54. [PubMed 2276389</li>
<li>Lima DR, Santos RM, Werneck E, Andrade GN. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers. Eur J Drug Metab Pharmacokinet. 1991;16(3):161-170. [PubMed 1814733</li>
<li>Locniskar A, Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. J Clin Pharmacol. 1986;26(4):299-303. [PubMed 2871051]</li>
<li>Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569-572. [PubMed 1954072</li>
<li>Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1995;33(9):481-485. [PubMed 8520804</li>
<li>Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400-402. [PMID: 17458401</li>
<li>Le GH, Schaefer MG, Plowman BK, Morreale AP, Delattre M, Okino L, Felicio L. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors. Am J Health Syst Pharm. 2003;60(13):1343-1345. [PubMed 12901036</li>
<li>Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CBV. Omeprazole does not modulate pharmacokinetic effect of digoxin in patients with heart failure. Int J Cardiol. 2015;179:343-344. [PubMed 25464482]</li>
<li>Rozlytrek (entrectinib) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; August 2019.</li>
<li>Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508-516. [PubMed 18492125</li>
<li>Intelence (etravirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; July 2019.</li>
<li>Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose fedratinib in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(5):995-1001. [PubMed 32318809]</li>
<li>Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on the filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585-594. [PubMed 30768860</li>
<li>Jyseleca (filgotinib) [summary of product characteristics]. Mechelen, Belgium: Galapagos NV; January 2022.</li>
<li>Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;8:457-464. [PubMed 17760738</li>
<li>Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 2006;42:61-67. [PubMed 16639341</li>
<li>Kiser JJ, Lichtenstein KA, Anderson PL, et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26:511-514. [PubMed 16553510</li>
<li>Ford SL, Wire MB, Lou Y, et al. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49:467-469. [PubMed 15616339</li>
<li>Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48:791-798. [PubMed 14982766]</li>
<li>Yin O, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850. [PubMed 15608563</li>
<li>Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012;68(5):553-560. [PubMed 22189672</li>
<li>Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731. [PubMed 19299322</li>
<li>Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509. [PubMed 20186406]</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</li>
<li>Brexafemme (ibrexafungerp) [prescribing information]. Jersey City, NJ: Scynexis Inc; June 2021.</li>
<li>Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2021</li>
<li>Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386-1394. [PubMed 26054042]</li>
<li>Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185-189. [PubMed 21150767</li>
<li>Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821-829. [PubMed 27890768</li>
<li>Tran-Duy A, Connell NJ, Vanmolkot FH, et al. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med. 2019;285(2):205-214. [PubMed 30141278</li>
<li>Imai R, Higuchi T, Moriomoto M, Koyamada R, Okada S. Iron deficiency anemia due to long-term use of a proton pump inhibitor. Inter Med. 2018;57(6):899-901. [PubMed 29151538</li>
<li>Mabuchi S, Suzuki R, Sasak M, et al. Case report of severe iron deficiency anemia caused by proton pump inhibitor in an elderly patient. Geriatr Gerontol Int. 2017;662-663. [PubMed 28405975</li>
<li>Hashimoto R, Matsuda T, Chonan A. Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med. 2014;53(20):2297-2299. [PubMed 25318791</li>
<li>Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97(9):887-889. [PubMed 15455980</li>
<li>Khatib MA, Rahim O, Kania R, Molloy P. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig Dis Sci. 2002;47(11):2596-2597. [PubMed 12452401</li>
<li>Eghbali A, Khalilpour A, Taherahmadi H, Bagheri BPantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled studyTherapie2019;74(5):507-512[PubMed 30704764</li>
<li>Shalev H, Quider AA, Harosh MB, Kapelushnik J. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia. Pediatr Hematol Oncol. 2016;33(7-8):457-461. [PubMed 27960647</li>
<li>Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-1295. [PubMed 17344278</li>
<li>Tempel M, Chawla A, Messina C, Celiker MY. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol. 2013;30(3):307-310. [PubMed 24385811</li>
<li>Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-292. [PubMed 1607604</li>
<li>Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011;134(2):224-231. [PubMed 21911976</li>
<li>Sarker SA, Mahmud H, Davidsson L, et al. Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology. 2008;135(5):1534-1542. [PubMed 18775429]</li>
<li>Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34(5):317-325. [PubMed 24567279</li>
<li>Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; June 2019.</li>
<li>Koch KM, Im Y-H, Kim S-B, et al. Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients. Clin Pharmacol Drug Dev. 2013;2(4):336-341. [PubMed 27121938</li>
<li>Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015</li>
<li>Tykerb (lapatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.</li>
<li>Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</li>
<li>Adhansia XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Purdue Pharmaceuticals LP; July 2019</li>
<li>Cotempla XR ODT (methylphenidate) extended-release orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC; June 2017</li>
<li>Concerta (methylphenidate) extended-release tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2017</li>
<li>Ritalin LA (methylphenidate) extended-release capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019</li>
<li>Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Greenville, NC: Patheon Manufacturing Services LLC; June 2019</li>
<li>Jornay PM (methylphenidate) extended-release capsules [prescribing information]. Cherry Hill, NJ: Ironshore Pharmaceuticals Inc; April 2019</li>
<li>Metadate CD (methylphenidate) extended-release capsules [prescribing information]. Smyrna, GA: UCB Inc; June 2014</li>
<li>Quillichew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; March 2017</li>
<li>Quillivant XR (methylphenidate) extended-release oral suspension [prescribing information]New York, NY: Pfizer Inc; January 2017</li>
<li>Ritalin SR (methylphenidate) extended-release tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.</li>
<li>Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120-2138. [PubMed 28808886</li>
<li>Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; February 2022.</li>
<li>Ji T, Rockich K, Epstein N, et al. Evaluation of drug-drug interactions of pemigatinib in healthy participants [published online July 19, 2021]. Eur J Clin Pharmacol. doi: 10.1007/s00228-021-03184-z. [PubMed 34282472</li>
<li>Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; February 2021.</li>
<li>Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. [PubMed 18303127</li>
<li>Seiler D, Doser K, Salem I. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. Arzneimittelforschung. 2011;61(4):247-251. [PubMed 21650084</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed 25012577</li>
<li>Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906-913. [PubMed 28875498</li>
<li>Effient (prasugrel) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; December 2020.</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Yang E, Ji SC, Jang I-J, Lee S. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet. 2023;62(4):599-608. [PubMed 36897544</li>
<li>Kolawole JA, Mustapha A, Abdul-Aguye I, Ochekpe N, Taylor RB. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal. 1999;20(5):737-743. [PubMed 10701981</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole, and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. Eur J Clin Pharmacol. 1996;50(5):417-419. [PubMed 8839666]</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2020</li>
<li>Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-492. [PubMed 19143531]</li>
<li>Zhou J, Quinlan M, Glenn K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol. 2016;82(4):1022-1029. [PubMed 27277189</li>
<li>Odomzo (sonidegib) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2017.</li>
<li>Tazverik (tazemetostat) [prescribing information]. Cambridge, MA: Epizyme, Inc.; January 2020.</li>
<li>Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. [PubMed 16641395</li>
<li>Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. [PubMed 17669709</li>
<li>Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-59. [PubMed 16477543</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075</li>
<li>Abi-Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? Arq Bras Endocrinol Metabol. 2014;58(7):731-736. [PubMed 25372582</li>
<li>Ermeza (levothyroxine) solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022</li>
<li>Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. [PubMed 25259910]</li>
<li>Giri P, Gupta L, Naidu S, et al. In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, alicarb, methiocarb, motelukast and ziprasidone. Drug Metabo Lett. 2019;12(2):101-116. [PubMed 30117405</li>
<li>Egaten (triclabendazole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2019.</li>
<li>Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26-33. [PubMed 23110788]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. Doi: 10.1007/s40262-017-0591</li>
<li>[PubMed 28866861]</li>
<li>Verquvo (vericiguat) [prescribing information].Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2021.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022</li>
<li>Calquence (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2022.</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” Pharmacotherapy, 2010, 30(8):787-96. [PubMed 20653354</li>
<li>Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” Clin Cardiol, 2010, 33(3):168-71. [PubMed 20235209</li>
<li>Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” Arch Intern Med, 2010, 170(8):704-10[PubMed 20421557</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2018.</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2021.</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067]</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2019.</li>
<li>Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol. 2015;71(12):1461-1465. [PubMed 26400679</li>
<li>Bertram V, Yeo K, Anoopkumar-Dukie S, Bernaitis N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract. 2019;73(11):e13382. [PMID 31250945</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2014.</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Cojutti P, Candoni A, Forghieri, et al. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and/or with CYP inhibitors plus CYP inducers. Basic Clin Pharmacol Toxicol. 2016;118(6):474-479. [PubMed 26572687</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143</li>
<li>Scholler J, Nivoix Y, Herbrecht R, et al. Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. Int J Clin Pharm. 2011;33(6):905-908. [PubMed 22108788</li>
<li>Tsubokura M, Miura Y, Itokawa T, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol. 2011;51(10):1488-1490. [PubMed 21098688</li>
<li>Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262-3267. [PubMed 23629724</li>
<li>Dexilant (dexlansoprazole) [prescribing information]Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2018</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; October 2017</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc.; January 2019.</li>
<li>Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” Ann Pharmacother, 2003, 37(6):808-11. [PubMed 12773066</li>
<li>Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors,” Am J Cardiol, 2004, 94:1140</li>
<li>[PubMed 15518608</li>
<li>Amsden GW, Kuye O,Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” J Clin Pharmacol, 2002, 42:444</li>
<li>[PubMed 11936570</li>
<li>Lee AJ,Maddix DS, “Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin,” Ann Pharmacother, 2001, 35:26-31. [PubMed 11197581</li>
<li>Chen C, Lin J, Smolarek T, et al, “P-Glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in Mdr1a/B Knockout and Wild-Type Mice,” Drug Metab Dispos, 2007, 35:1725</li>
<li>[PubMed 17640956</li>
<li>Chen C, Mireles RJ, Campbell SD, et al, “Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors with Abcb1, Abcc2, and Oatp1b1,” Drug Metab Dispos, 2005, 33:537-46. [PubMed 15616150</li>
<li>Hochman JH, Pudvah N, Qiu J, et al, “Interactions of Human P-Glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin,” Pharm Res, 2004, 21:1686-91. [PubMed 15497697</li>
<li>Wu X, Whitfield LR,Stewart BH, “Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter,” Pharm Res, 2000, 17:209-15. [PubMed 10751037</li>
<li>Pauli-Magnus C, Rekersbrink S, Klotz U, et al, “Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein,” Naunyn Schmiedebergs Arch Pharmacol, 2001, 364:551</li>
<li>[PubMed 11770010</li>
<li>Collett A, Tanianis-Hughes J, Carlson GL, et al, “Comparison of P-Glycoprotein-Mediated Drug-Digoxin Interactions in Caco-2 with Human and Rodent Intestine: Relevance to in Vivo Prediction,” Eur J Pharm Sci, 2005, 26:386-93. [PubMed 16153812]</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Prevacid (lansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2020.</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed: 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc. 2015;4(11). [PubMed: 26514161</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed: 22464478</li>
<li>Shamliyan TA, Middleton M, Borst C. Patient-centered outcomes with concomitant use of proton pump inhibitors and other drugs. Clin Ther. 2017;39(2):404-427. [PubMed: 28189362</li>
<li>Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823. [PubMed: 20102352</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed: 25012577</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-36[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244</li>
<li>Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig. 2011;31(10):727-733. [PubMed 21877765</li>
<li>Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44(11):1223-1229. [PubMed 15496639</li>
<li>Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005;60(1):61-68. [PubMed 15963095</li>
<li>Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162-164. [PubMed 15546944]</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2014; July 28 (Epub ahead of print). [PubMed 25068772</li>
<li>Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-277. [PubMed 18615373</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi TThe role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazoleTher Drug Monit2008;30(3):276-281[PubMed 18520598</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11). pii: e002245. [PubMed 26514161</li>
<li>Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43(3):212-224. [PubMed 22564422</li>
<li>Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35(2):127-139. [PubMed 22204719</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Lu M. Report: Impact of drug combination of clopidogrel and pantoprazole in the prognosis of patients with transient ischemic attack. Pak J Pharm Sci. 2017;30(1):217-221. [PubMed 28603135</li>
<li>Choi YJ, Kim N, Jang IJ, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-511. [PubMed 28395507</li>
<li>Gu RX, Wang XZ, Li J, Deng J, Li XX, Wang JEffects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrelMil Med Res2016;3</li>
<li>[PubMed 28018669</li>
<li>Bolek T, Samos M, Simonova R, et al. Does pantoprazole affect the on-treatment platelet reactivity in patients with acute STEMI treated with ADP receptor blockers?-a pilot prospective study. Am J Ther. 2017;24(2):e162-e166. [PubMed 27415979</li>
<li>Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacol Rep. 2012;64(2):360-368. [PubMed 22661187</li>
<li>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2020</li>
<li>Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012;33(5):278-283. [PubMed 22623337]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, Dammann G, Hiemke C, Grunder G, Paulzen M. The effects of co-prescription of pantoprazole on the clozapine metabolism. Pharmacopsychiatry. 2020;53(2):65-70. [PubMed 31614374]</li>
<li>Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metabol Dispos. 2014;42(7):1174-1179. [PubMed 24764147]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. doi: 10.1007/s40262-017-0591</li>
<li>Chandelia S, Dubey NK. Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole. Indian J Crit Care Med. 2016;20(2):127-128. [PubMed 27076718</li>
<li>Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39(6):700-703. [PubMed 7654493</li>
<li>Henriksen DP, Stage TB, Hansen MR, Rasmussen L, Damkier P, Pottegard A. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. 2015;24(12):1337-1340. [PubMed 26395871</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [Pubmed1493083</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf LComparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activitiesDrug Metab Dispos2004;32(8):821-827[PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780</li>
<li>Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71(9):1059-1066. [PubMed 26071277</li>
<li>Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. [PubMed 20844485]</li>
<li>El-Bohy D, Sharkawy M, Abo-Elazm S, et al. Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney transplantation: A randomized clinical trial. Ther Apher Dial. 2020;24(5):591-598. [PubMed 31856374</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-440. [PubMed 11009056</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. Pantoprazole does not affect cyclosporin a blood concentration in kidney-transplant patients. Eur J Clin Pharmacol. 2000;55(10):733-735. [PubMed 10663451]</li>
<li>Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74(10):2187-2192. [PubMed 20736505</li>
<li>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70(3):383-392. [PubMed 20716239</li>
<li>Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. [PubMed 19108880</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-2436[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. [PubMed 16772608</li>
<li>Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735-741. [PubMed 17361128</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107]</li>
<li>Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61(3):309-314. [PubMed 16487224</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2018.</li>
<li>Liu G, Wen J, Guo D, et al. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. J Pharmacol Sci. 2016;132(4):244-248. [PubMed 27245553]</li>
<li>Hata M, Hayasaka M, Sezai A, et al, “Proton Pump Inhibitors May Increase the Risk of Delayed Bleeding Complications after Open Heart Surgery If Used Concomitantly with Warfarin,” Thorac Cardiovasc Surg, 2008, 56:274-7</li>
<li>Ahmad S, “Omeprazole-Warfarin Interaction,” South Med J, 1991, 84:674-5</li>
<li>Unge P, Svedberg LE, Nordgren A, et al, “A Study of the Interaction of Omeprazole and Warfarin in Anticoagulated Patients,” Br J Clin Pharmacol, 1992, 34:509-12</li>
<li>Sutfin T, Balmer K, Bostrom H, et al, “Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men,” Ther Drug Monit, 1989, 11:176-84</li>
<li>Zhou Q, Chan E, “Effect of Omeprazole on the Anticoagulant Activity and the Pharmacokinetics of Warfarin Enantiomers in Rats,” Eur J Pharm Sci, 2003, 20:439-49</li>
<li>Zhou Q, Zhou S, Chan E, “Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and cDNA-Expressed Cytochrome P450 Isozymes,” Curr Drug Metab, 2005, 6:399-411</li>
<li>Hermans JJ, Thijssen HH, “Human Liver Microsomal Metabolism of the Enantiomers of Warfarin and Acenocoumarol: P450 Isozyme Diversity Determines the Differences in Their Pharmacokinetics,” Br J Pharmacol, 1993, 110:482-90</li>
<li>Uno T, Sugimoto K, Sugawara K, et al, “The Role of Cytochrome P2C19 in R-Warfarin Pharmacokinetics and Its Interaction with Omeprazole,” Ther Drug Monit, 2008, 30:276-81</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” Drug Metab Dispos, 2004, 32:821-7</li>
<li>Ko J, Sukhova N, Thacker D, et al, “Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms,” Drug Metab Dispos, 1997, 25:853-862.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2016.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (Tak-390mr), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29:35-50. [PubMed 19067473</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2015;63(1):45-50. [PubMed 25068772</li>
<li>Dexilant (dexlansoprazole) [Prescribing Information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2017</li>
<li>Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, Shin JG. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos. 2005;33(2):209-213. [PubMed 15537834]</li>
<li>Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; June 2018</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2018</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30(8):787-796. [PubMed 20653354</li>
<li>Stockl KM, Le L, Zakharyan A, et alRisk of rehospitalization for patients using clopidogrel with a proton pump inhibitorArch Intern Med2010;170(8):704-710[PubMed 20421557</li>
<li>Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Mahabaleshwarkar RK, Yang Y, Datar MV, et al. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Curr Med Res Opin. 2013;29(4):315-323. [PubMed 23362935</li>
<li>Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012;32(9):809-818. [PubMed 22744772</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors - a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997. [PubMed 19726078</li>
<li>Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329. [PubMed 19933932</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population based study of drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Wei P, Zhang YG, Ling L, et al. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-2864. [PubMed 27882086</li>
<li>Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824-834. [PubMed 22364155</li>
<li>Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2CDrug Metab Dispos. 2012;40(9):1698-1711. [PubMed 22648560</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478]</li>
<li>Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2018.</li>
<li>Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc; April 2006</li>
<li>Kayexalate (sodium polystyrene sulfonate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; December 2010</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a “nonsystemic” antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Fernandez PC, Kovnat PJ. Metabolic acidosis reversed by the combination of magnesium and a cation-exchange resin. N Engl J Med. 1972;286(1):23-24. [PubMed 5006921</li>
<li>Ziessman HA. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. South Med J. 1976;69(4):497-499. [PubMed 817399</li>
<li>Madias NE, Levey AS. Metabolic alkalosis due to absorption of “nonabsorbable” antacids. Am J Med. 1983;74(1):155-158. [PubMed 6849324]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36(6):1219-1224. [PubMed 1329615</li>
<li>Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55. [PubMed 8737124</li>
<li>Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989;46(6):700-705. [PubMed 2598571</li>
<li>Shiba K, Sakamoto M, Nakazawa Y, et al. Effects of antacid on absorption and excretion of new quinolones. Drugs. 1995;49(Suppl 2):360-361. [PubMed 8549362</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):39-48. [PubMed 11352441</li>
<li>Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830-832. [PubMed 1503446</li>
<li>Lehto PL, Kivisto KTDifferent effects of products containing metal ions on the absorption of lomefloxacinClin Pharmacol Ther1994;56(5):477-482[PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35(3):302-304. [PubMed 8471407</li>
<li>Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Emrok O (levonadifloxacin) tablet [product information]. Maharashtra, India: Wockhardt Limited; April 2022.</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(suppl 1):39-48. [PubMed 11352441</li>
<li>Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy. 1999;45(6):504-511. [PubMed 10567782</li>
<li>Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther. 1998;20(6):1149-1158. [PubMed 9916608</li>
<li>Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on the absorption of DR-3355 in humans. Antimicrobial Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother. 1990;34(12):2436-2438. [PubMed 2088202</li>
<li>Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Grasela TH Jr, Schentag JJ, Sedman AJ, et alInhibition of enoxacin absorption by antacids or ranitidineAntimicrob Agents Chemother1989;33(5):615-617[PubMed 2751276</li>
<li>Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):93-97. [PubMed 9222077</li>
<li>Hoffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol. 1992;33(1):115-116. [PubMed 1540482</li>
<li>Jaehde U, Sorgel F, Stephan U, Schunak W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother. 1994;38(5):1129-1133. [PubMed 8067750</li>
<li>Maesen FP, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids. J Antimicrob Chemother. 1987;19(6):848-850. [PubMed 3475268</li>
<li>Prescribing information. Cytotec (misoprostol). New York, NY: Pfizer Inc., September 2009.</li>
<li>Quinine [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; July 2015.</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017</li>
<li>Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020-3026. [PubMed 22450971</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494</li>
<li>FDA Antiviral Drugs Advisory Committee Meeting. ISENTRESS™ (raltegravir) 400 mg For Treatment of HIV (NDA 22-145). Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf. Published September 5, 2007. Accessed online November 15, 2013.</li>
<li>Dimaval (DMPS) Hartkapseln (unithiol) [summary of product characteristics]. Berlin, Germany: Haupt Pharma Wulfing GmbH; June 2020.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc.; March 2010</li>
<li>Ruggiero M, Brunese M, Morelli S, et al. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-777. [PubMed 6895034</li>
<li>Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. Digestion. 1987;37(1):35-42. [PubMed 3609503</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: Modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;25(15):1093-1115</li>
<li>Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium. 1986;5(5-6):293-300. [PubMed 3807422</li>
<li>Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Thioctic acid tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200201478. Accessed September 1, 2014.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2013</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2020.</li>
<li>Evaluation of Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis and Clinical Implications. Guidance for Industry [Draft]. Available at: https://www.fda.gov/media/144026/download. Accessed July 22, 2021.</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; June 2019.</li>
<li>HalfLytely and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) [prescribing information]. Braintree, MA: Braintree Laboratories Inc; May 2006.</li>
<li>De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</li>
<li>Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010</li>
<li>Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015</li>
<li>Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011</li>
<li>Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc.; April 2023.</li>
<li>Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; January 2021.</li>
<li>Calcijex (calcitriol) injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; March 2012</li>
<li>Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-797. [PubMed 6895034</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;26(15):1093-1115. [PubMed 14640773</li>
<li>Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Cefdinir [prescribing information]. Parsippany, NJ: Ascend Laboratories; January 2018.</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ, Collier PS. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159-163. [PubMed 6292443</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ. In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin. J Trop Med Hyg. 1982;85(4):153-158. [PubMed 7143531</li>
<li>Iwuagwu MA, Aloko KS. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655-658. [PubMed 1359089</li>
<li>Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: sanofi-aventis US LLC; October 2018.</li>
<li>Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology. 1981;80(4):661-665. [PubMed 7202937</li>
<li>Naggar VF, Khalil SA, Gouda MW. Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans. J Pharm Sci. 1978;67(7):1029-1030. [PubMed 207854</li>
<li>Lee DA, Taylor GM, Walker JG, et al. The effect of concurrent administration of antacids on prednisolone absorption. Br J Clin Pharmacol. 1979;8(1):92-94. [PubMed 552304</li>
<li>Tanner AR, Caffin JA, Halliday JW, et al. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol. 1979;7(4):397-400. [PubMed 444359</li>
<li>Albin H, Vincon G, Demotes-Mainard F, et al. Effects of aluminum phosphate on the bioavailability of cimetidine and prednisolone. Eur J Clin Pharmacol. 1984;26(2):271-273. [PubMed 6723769]</li>
<li>Product monograph. Pradaxa (dabigatran etexilate). Burlington, Ontario: Boehringer Ingelheim Canada Ltd., February 2019</li>
<li>Prescribing information. Pradax (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.</li>
<li>Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700-709. [PubMed 19395585</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</li>
<li>Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019</li>
<li>Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2019</li>
<li>Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol. 2003;43(2):171-179. [PubMed 12616670]</li>
<li>Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016</li>
<li>Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015</li>
<li>Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764-776. [PubMed 19446149]</li>
<li>Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45-50. [PubMed 23774876</li>
<li>Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2019</li>
<li>Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2019</li>
<li>Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug-drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:1</li>
<li>[PubMed 30798679]</li>
<li>Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products LP; April 2019.</li>
<li>Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals Inc; October 2016.</li>
<li>Allegra (fexofenadine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2010.</li>
<li>Fosinopril [prescribing information]. Princeton, NJ: Sandoz Inc; May 2013</li>
<li>Apo-fosinopril (fosinopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2008.</li>
<li>Yagi T, Naito Y, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248-254. [PubMed 22240839</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008</li>
<li>Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009</li>
<li>Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490</li>
<li>Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581</li>
<li>Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976</li>
<li>McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345</li>
<li>Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282]</li>
<li>Prescribing information. Anaspaz (hyoscyamine). Lenexa, KS: B. F. Ascher &amp; Compant, Inc., 6/2010</li>
<li>Prescribing information. Hyosyne (hyoscyamine). Spring Valley, NY: Silarx Pharmaceuticals, Inc., 4/2007</li>
<li>Prescribing information. Levsin (hyoscyamine). Marietta, GA: Alaven Pharmaceutical LLC, 2/2008</li>
<li>Prescribing information. Symax SR (hyoscyamine). Ft. Worth, TX: Capellon Pharmaceuticals, LLC, 9/2012</li>
<li>Prescribing information. Oscimin-SR (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011</li>
<li>Prescribing information. Oscimin (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</li>
<li>Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr. 1991;53(1):106-111. [PubMed 1984334</li>
<li>Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol. 2002;42(10):1171-1176. [PubMed 12362933</li>
<li>Wallace KL, Curry SC, LoVecchio F, Raschke RA. Effect of magnesium hydroxide on iron absorption following simulated mild iron overdose in human subjects. Acad Emerg Med. 1998;5(10):961-965. [PubMed 9862585</li>
<li>Hall GJ, Davis AE. Inhibition of iron absorption by magnesium trisilicate. Med J Aust. 1969;2(2):95-96. [PubMed 5803866</li>
<li>Ekenved G, Halvorsen L, Solvell L. Influence of a liquid antacid on the absorption of different iron salts. Scand J Haematol Suppl. 1976;28:65-77. [PubMed 1064903</li>
<li>O'Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Rastogi SP, Padilla F, Boyd CM. Effect of aluminum hydroxide on iron absorption. J Ark Med Soc. 1976;73(3):133-134. [PubMed 134015</li>
<li>Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81(6):1068-1071. [PubMed 7286584</li>
<li>Benkhedda K, L'abbe MR, Cockel KAEffect of calcium on iron absorption in women with marginal iron statusBr J Nutr2010;103(5):742-748[PubMed 19860985</li>
<li>Minihane AM, Fairweather-Tait SJ. Effect of calcium supplementation on daily nonheme-iron absorption and long-term iron status. Am J Clin Nutr. 1998;68(1):96-102. [PubMed 9665102</li>
<li>Dawson-Hughes B, Seligson FH, Hughes VA. Effects of calcium carbonate and hydroxyapatite on zinc and iron retention in postmenopausal women. Am J Clin Nutr. 1986;44(1):83-88. [PubMed 3014855</li>
<li>Spencer BR, Guo Y, Cable RG, et al. Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. Transfusion. 2019;59(10):3146-3156. [PubMed 31318071</li>
<li>Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016;97(6):583-593. [PubMed 27155295</li>
<li>Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001;22(6):490-496. [PubMed 11426238</li>
<li>Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P. Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia/a single-centre randomized controlled isotope study. Arzneimittelforschung. 2007;57(6A):392-400. [PubMed 17691589</li>
<li>Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med. 1999;33(4):400-405. [PubMed 10092717</li>
<li>Miranda M, Olivares M, Brito A, Pizarro F. Reducing iron deficiency anemia in Bolivian school children: calcium and iron combined versus iron supplementation alone. Nutrition. 2014;30(7-8):771-775. [PubMed 24984991]</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced Oral Itraconazole Bioavailability by Antacid Suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236</li>
<li>Sporanox (itraconazole) oral suspension [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Van der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, et al. Disposition of ketoconazole, an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Ketoconazole [prescribing information]. Hoschton, GA: Aavis Pharmaceuticals, LLC; September 2021.</li>
<li>Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022.</li>
<li>Synthroid (levothyroxine sodium) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2009</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669]</li>
<li>Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020</li>
<li>Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Lialda (mesalamine) delayed-release tablets [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; December 2020</li>
<li>Delzicol (mesalamine) delayed-release capsules [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Shire USA Inc; October 2020</li>
<li>Hussain FN, Ajjan RA, Moustafa M, Weir NW, Riley SA. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Br J Clin Pharmacol. 1998;46(2):173-175. [PubMed 9723828</li>
<li>Bashiri H, Bozorgomid A. Protective effect of Asacol in combination with pantoprazole in ulcerative colitis patients who defecate Asacol tablets intactly: a clinical trial study. Clin Exp Gastroenterol. 2020;13:47-51. [PubMed 32158250</li>
<li>Urex (methenamine) [prescribing information]. Wytheville, VA: Vatring Pharmaceuticals, Inc.; December 2006.</li>
<li>Cerklewski FL, “Influence of Dietary Magnesium on Fluoride Bioavailability in the Rat,” J Nutr, 117(3):496-500. [PubMed 3572562</li>
<li>Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” Clin Pharmacol Ther, 1980, 28(4):529-35. [PubMed 7408412</li>
<li>Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002</li>
<li>Spencer H, Kramer L, Osis D, et al, “Effect of Calcium, Phosphorus, Magnesium, and Aluminum on Fluoride Metabolism in Man,” Ann N Y Acad Sci, 1980, 355:181-94. [PubMed 6940475]</li>
<li>O’Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Benjamin IB, Cortell S, Conrad ME. Bicarbonate-induced iron complexes and iron absorption. Gastroenterology. 1967;35:389</li>
<li>Coste JF, De Bari VA, Keil LB, et al. In vitro interactions of oral haematinics and antacid preparations. Curr Ther Res Clin Exp. 1977;22:205.</li>
<li>Cellcept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; December 2019</li>
<li>Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41(6):513-516. [PubMed 8799515</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. Novartis Pharmaceuticals Corporation; April 2020.</li>
<li>Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemother Pharmacol. 2013;71(1):219-226. [PubMed 23070146</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211]</li>
<li>Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulphate. Clin Pharmacol Ther. 1983;33(4):465-470. [PubMed 6831825</li>
<li>Lyle WH. Penicillamine and iron. Lancet. 1976;2(7982):420. [PubMed 73880</li>
<li>Harkness JA, Blake DR. Penicillamine nephropathy and iron. Lancet. 1982;2(8312):1368-1369. [PubMed 6129465]</li>
<li>Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12(1):26-30. [PubMed 8440814</li>
<li>Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Aton Pharma Inc; November 2015.</li>
<li>Phospha 250 Neutral (sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic and sodium phosphate, monobasic, monohydrate) [prescribing information]. Allendale, NJ: Rising Pharmaceuticals, Inc.; June 2012</li>
<li>K-Phos No. 2 (potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</li>
<li>Levofloxacin [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; May 2022</li>
<li>Lomefloxacin [product labeling]. Kolon Pharmaceutical Co., Ltd.; March 2016</li>
<li>Norfloxacin [product monograph]. Vaughan, ON, Canada: AA Pharma Inc.; June 2019</li>
<li>Ofloxacin [summary of product characteristics]. Dublin, Ireland: Gerard Laboratories; June 2022</li>
<li>Pipemidic acid [Korean product labeling]. Aprogen Pharmaceutical Co., Ltd.; January 2014</li>
<li>Ciprofloxacin [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022</li>
<li>Baxdela (delafloxacin) [product labeling]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries; April 2022</li>
<li>Moxifloxacin [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited, May 2019</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Canada: Merus Labs International, Inc.; August 2018</li>
<li>Enoxacin [Korean product labeling]. Seoul, South Korea: Crystal Life Science Co. Ltd; June 2018</li>
<li>Prulifloxacin [summary of product characteristics]. Ancona, Italy: A.C.R.A.F. S.p.A.; February 2022.</li>
<li>Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2(8501):294. [PubMed 2874321</li>
<li>Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids. Lancet. 1986;2(8497)</li>
<li>[PubMed 2873348</li>
<li>Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med. 1988;109(2):168-169. [PubMed 3382110</li>
<li>Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005;27(2):81-82. [PubMed 15999916</li>
<li>Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother. 1991;28(1):87-94. [PubMed 1663108</li>
<li>Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013</li>
<li>Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014</li>
<li>Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005</li>
<li>Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014</li>
<li>Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012</li>
<li>Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013</li>
<li>Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011</li>
<li>Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003</li>
<li>Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017</li>
<li>Pefloxacin tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199101448 Accessed October 26, 2017.</li>
<li>Edurant (rilpivirine) [prescribing information]. Raritan NJ: Tibotec Therapeutics; May 2011</li>
<li>Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</li>
<li>Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October 2013.</li>
<li>Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021;43(6):1079-1091. [PubMed 33962762</li>
<li>Evrenzo (roxadustat) [summary of product characteristics]. Woking, United Kingdom: Astellas Pharma Ltd; September 2022.</li>
<li>Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol. 1997;43(3):269-272. [PubMed 9088581</li>
<li>Sotalol [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; March 2020</li>
<li>Kahela P, Anttila M, Sundgvist H. Antacids and sotalol absorption. Acta Pharmacol Toxicol (Copenh). 1981;49(3):181-183. [PubMed 7336975]</li>
<li>Summary of product characteristics. Protelos (strontium ranelate). Gidy, France: Les Laboratoires Servier Industrie, 7/2012.</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023</li>
<li>Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. Obes Surg. 2014;24(5):741-746. [PubMed 24347350</li>
<li>Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. Obes Surg. 2018;28(8):2252-2260. [PubMed 29556889]</li>
<li>Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013</li>
<li>Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013</li>
<li>Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</li>
<li>Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet. 1962;114:9-14. [PubMed 14498173</li>
<li>Albert KS, Welch RD, DeSante KA, et al. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J Pharm Sci. 1979;68(5):586-588. [PubMed 435335</li>
<li>Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247(16):2266-2267. [PubMed 7040708</li>
<li>Demeclocycline [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; March 2017</li>
<li>Rosenblatt JE, Barrett JE, Brodie JL, et al. Comparison on in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother. 1966;6:134-141. [PubMed 4964450</li>
<li>Garty M, Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976</li>
<li>Nguyen VX, Nix DE, Gillikin S, Schentag JJEffect of oral antacid administration on the pharmacokinetics of intravenous doxycyclineAntimicrob Agents Chemother1989;33(4):434-436[PubMed 2729939</li>
<li>Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther. 1971;12(5):779-784. [PubMed 4936141</li>
<li>Nuzyra (omadacycline) [prescribing information]. Boston, MA: Paratek Pharmaceuticals, Inc.; October 2020</li>
<li>Tetralysal (lymecycline) [summary of product characteristics]. Watford, Herts, UK: Galderma (UK) Limited; June 2020</li>
<li>Seysara (sarecycline) [prescribing information]. Exton, PA: Almirall, LLC; June 2002</li>
<li>Jaffe JM, Poust RI, Feld SL, et al. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974;63(8):1256-1260. [PubMed 4852448]</li>
<li>Garty M and Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Healy DP, Dansereau RJ, Dunn AB, et al. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother. 1997;31(12):1460-1464. [PubMed 9416381</li>
<li>Khalil SA, Daabis NA, Naggar VF, et al. Effect of magnesium trisilicate and citric acid on the bioavailability of tetracycline in man. Pharmazie. 1977;32(8-9):519-522. [PubMed 201941]</li>
<li>Syprine (trientine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016</li>
<li>Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1(8273):643-647. [PubMed 6121964</li>
<li>Cuvrior (trientine) [prescribing information]. Chicago, IL: Orphalan; April 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</li>
<li>Fann WE, Davis JM, Janowsky DS, et al, “Chlorpromazine: Effects of Antacids on its Gastrointestinal Absorption,” J Clin Pharmacol, 1973, 13(10):388-90. [PubMed 4355737</li>
<li>Forrest FM, Forrest IS, and Serra MT, “Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients,” Biol Psychiatry, 1970, 2(1):53</li>
<li>[PubMed 5414905</li>
<li>Moustafa MA, Babhair SA, and Kouta HI, “Decreased Bioavailability of Some Antipsychotic Phenothiazines Due to Interactions With Absorbent Antacid and Antidiarrhoeal Mixtures,” Int J Pharm, 1987, 36:185-9.</li>
<li>Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a 'nonsystemic' antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Dad T, Garimella PS, Strom JA. Quiz: An unusual case of metabolic alkalosis in a patient with CKD. Am J Kidney Dis. 2017;69(1):A13-A16. [PubMed 28007194</li>
<li>JAMP calcium polystyrene sulfonate [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2020.</li>
<li>Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol. 1984;22(11):626-629. [PubMed 6389377]</li>
<li>Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DS, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183</li>
<li>Cefpodoxime proxetil [prescribing information]. Allendale, NJ: Rising Pharmaceuticals Inc; May 2017</li>
<li>Food and Drug Administration Center for Drug Evaluation and Research (CDER). Evaluation of gastric pH dependent drug interactions with acid-reducing agents: Study design, data analysis, and clinical implications (November 2020). Available at: https://www.fda.gov/media/144026/download.</li>
<li>Fann WE, Davis JM, Janowsky DS, Sekerke HJ, Schmidt DM. Chlorpromazine: effects of antacids on its gastrointestinal absorption. J Clin Pharmacol. 1973;12(10):388-390. [PubMed 4355737</li>
<li>Chlorpromazine [prescribing information]. Columbus, OH: American Health Packaging; October 2018</li>
<li>Perphenazine [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2016</li>
<li>Haldol (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2019</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2008.</li>
<li>Allard M, Legare N, Millaud F. A possible case of clozapine interaction with aluminum hydroxide. Schizophr Res. 2008;101(1-3):346. [PubMed 18272349</li>
<li>Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corp., March 2008</li>
<li>Prescribing information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil- Janssen Pharmaceuticals Inc., August 2008</li>
<li>Prescribing information. Seroquel (quetapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009</li>
<li>Prescribing information. Abilify (aripiprazole). Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd., August 2008.</li>
<li>Diacerein [prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198802489. Accessed October 1, 2014.</li>
<li>Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909]</li>
<li>Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis. 1974;109(1):41-47. [PubMed 4588090</li>
<li>Lin M-Y, Lin S-J, Chan L-C, Lu Y-C. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(7):806-818. [PubMed 20550762</li>
<li>Peloquin CA, Namdar R, Dodge AA, Nix DEPharmacokinetics of isoniazid under fasting conditions, with food, and with antacidsInt J Tuberc Lung Dis1999;3(8):703-710[PubMed 10460103</li>
<li>Sun H, Jin T, Wu X, Yang L, Zuo Y, Liao R. Efficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis. J Int Med Res. 2021;49(7):3000605211027736. [PubMed 34311594</li>
<li>Weber V, Abbott TEF, Ackland GL. Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. Br J Anaesth. 2021;126(3):608-621. [PubMed 33218672</li>
<li>Dong J, Gao L, Wenqing L, Xu Z, Zheng J. Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis. PLoS One. 2014;9(12):e114231. [PubMed 25460931</li>
<li>Sinatra RS, Philip BK, Naulty JS, et al. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulphate. Anesth Analg. 1985;64:1220-1222. [PubMed 2865911</li>
<li>Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular-blocking agents. Anesthesiology. 1970;32:23. [PubMed 5460601</li>
<li>Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. Anaesthesia. 1994;49:355-356. [PubMed 8179157</li>
<li>Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology. 1987;67(5):806-808. [PubMed 2890318</li>
<li>Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. Br J Anaesth. 1996;77:669-671. [PubMed 8957990</li>
<li>Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth. 1996;76(4):565-556. [PubMed 8652332</li>
<li>Yoshida A, Itoh Y, Nagaya K, et alProlonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean sectionJ Anesth2006;20(1):33-35[PubMed 16421674</li>
<li>Kwan WF, Lee C, Chen BJ. A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. J Clin Anesth. 1996;8(5):392-397. [PubMed 8832451</li>
<li>Na HS, Lee JH, Hwang, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth. 2010;104(3):344-350. [PubMed 20042475</li>
<li>Telci L, Esen F, Akcora D, et al. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Br J Anaesth. 2002;89(4):591-598. [PubMed 12393361</li>
<li>Aldrete JA, Zahler A, Aikawa JK. Prevention of succinylcholine-induced hyperkalaemia by magnesium sulfate. Can Anaesth Soc J. 1970;17(5):477-484. [PubMed 5506078</li>
<li>Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth. 1995;74(4):405-409.[PubMed 7734259</li>
<li>Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. Br J Anaesth. 2003;91(3):435-438. [PubMed 12925489</li>
<li>De Vore JS, Asrani R. Magnesium sulfate prevents succinylcholine-induced fasciculations in toxemic parturients. Anesthesiology. 1980;52(1):76-77. [PubMed 7352649</li>
<li>Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007;31(2):167-173. [PubMed 17437152</li>
<li>Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. Can J Anaesth. 2005;52(1):88-93. [PubMed 15625263</li>
<li>James MF, Cork RC, Dennett JE. Succinylcholine pretreatment with magnesium sulfate. Anesth Analg. 1986;65(4):373-376. [PubMed 3513667</li>
<li>Fei S, Xia H, Chen X, Pang D, Xu X. Magnesium sulfate reduces the rocuronium dose needed for satisfactory double lumen tube placement conditions in patients with myasthenia gravis. BMC Anesthesiol. 2019;19(1):170. [PubMed 31472669</li>
<li>Micuci AJQR, Vercosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2019;36(7):502-508. [PubMed 30985540</li>
<li>Ghodraty MR, Saif AA, Kholdebarin AR, et al. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012;26(6):858-863. [PubMed 22752440</li>
<li>Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012;29(2):95-55. [PubMed 22183158</li>
<li>Brown AF, Cobert J, Dierkes J, Kuhn CM, Grant SA. Delayed neuromuscular blockade reversal with sugammadex after vecuronium, desflurane, and magnesium administration: a case report. A A Pract. 2019;13(8):295-298. [PubMed 31283534</li>
<li>Unterbuchner C, Ziegleder R, Graf B, Metterlein T. Magnesium-induced recurarisation after reversal of rocuronium-induced neuromuscular block with sugammadex. Acta Anaesthesiol Scand. 2015;59(4):536-540. [PubMed 25582520</li>
<li>de Almeida CED, de Carvalho LR, Andrade CVC, do Nascimento Jr P, de Barros GAM, Modolo NSP. Effects of magnesium sulphate on the onset time of rocuronium at different doses: a randomized clinical trial. Braz J Anesthesiol. 2021;71(5):482-488. [PubMed 34403648</li>
<li>James MF, Schenk PA, van der Veen BW. Priming of pancuronium with magnesium. Br J Anaesth. 1991;66(2):247-249. [PubMed 1817630</li>
<li>Stacey MR, Barclay K, Asai T, et al. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Anaesthesia. 1995;50(11):933-936. [PubMed 8678246</li>
<li>Nimbex (cisatracurium) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2018</li>
<li>Quelicin (succinylcholine) [prescribing information]. Lake Forest, IL: Hospira, Inc.; August 2021</li>
<li>Atracurium [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2018</li>
<li>Pancuronium [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2019</li>
<li>Rocuronium [prescribing information]. Lehi, UT: Civica, Inc.; July 2020.</li>
<li>Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231-1235. [PubMed 18355422</li>
<li>Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.</li>
<li>Foresti V. Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Sodium polystyrene sulfonate [prescribing information]. Rahway, NJ: Sunrise Pharmaceutical, Inc.; March 2020.</li>
<li>Prograf (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; August 2009</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med. 1994;97(4):363-365. [PubMed 7942938</li>
<li>Morini E, Catalano A, Lasco A, Morabito N, Benvenga S. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. [PubMed 30919287</li>
<li>Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-486. [PubMed 21595516</li>
<li>Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med. 1992;152(1):183-184. [PubMed 1728914</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669</li>
<li>Levothyroxine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; September 2022</li>
<li>Ermeza (levothyroxine) oral solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022.</li>
<li>Regardh CG, Lundborg P, Persson BA. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Biopharm Drug Dispos. 1981;2(1):79-87. [PubMed 7236872</li>
<li>Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. Clin Pharmacol Ther. 1981;30(4):429-435. [PubMed 7285476]</li>
<li>Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 1991;31(2):164-167. [PubMed 1849152</li>
<li>Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 2003;17(3):563-577. [PubMed 14711077</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</li>
<li>Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; February 2011</li>
<li>Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998;4:941-948. [PubMed 9563888</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2016 [published October 13, 2016]. doi:10.1001/jamaoncol.2016.3358. [PubMed 27737436</li>
<li>Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104. [PubMed 11286326]</li>
<li>Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med. 1976;295(19):1034-1037. [PubMed 972657</li>
<li>Allen MD, Greenblatt DJ, Harmatz JS, Smith TW. Effect of magnesium-aluminum hydroxide and kaolin-pectin on absorption of digoxin from tablets and capsules. J Clin Pharmacol. 1981;21(1):26-30. [PubMed 7012189</li>
<li>Cooke J, Smith JA. Absence of interaction of digoxin with antacids under clinical conditions. Br Med J. 1978;2(6145):1166-1167. [PubMed 709293]</li>
<li>Radwanski E, Nomeir A, Cutler D, Affrime M, Lin CC. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double-strength liquid or with ranitidine. Am J Ther. 1998;5(2):67-72. [PubMed 10099040</li>
<li>Cedax (ceftibuten) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2015.</li>
<li>Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. Clin Pharmacol Ther. 1976;19(2):234-239. [PubMed 770046]</li>
<li>Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. Clin Pharmacol Ther. 1978;24(3):308-315. [PubMed 28870</li>
<li>Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS. Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. Clin Pharmacol Ther. 1982;31(2):180-183. [PubMed 6120059</li>
<li>Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD. Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther. 1977;22(3):329-335. [PubMed 19188</li>
<li>Tranxene (clorazepate dipotassium) [prescribing information]. Barceloneta, PR: AbbVie LTD; September 2016.</li>
<li>Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI. Diazepam absorption: effect of antacids and food. Clin Pharmacol Ther. 1978;24(5):600-609. [PubMed 699484</li>
<li>Nair SG, Gamble JA, Dundee JW, Howard PJ. The influence of three antacids on the absorption and clinical action of oral diazepam. Br J Anaesth. 1976;48(12):1175-1180. [PubMed 1023953</li>
<li>Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI. Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. J Clin Pharmacol. 1984;24(5-6):255-263. [PubMed 6747022</li>
<li>Valium (diazepam) [prescribing information]. South San Francisco, CA: Hoffman-La Roche; December 2016.</li>
<li>Yamreudeewong W, Scavone JM, Paone RP, Lewis GP. Effect of antacid coadministration on the bioavailability of erythromycin stearate. Clin Pharm. 1989;8(5):352-354. [PubMed 2743731]</li>
<li>Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333-342. [PubMed 688726]</li>
<li>Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49(1):467-469. [PubMed 15616339</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2019.</li>
<li>Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm. 1998;46(3):299-303. [PubMed 9885302]</li>
<li>Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. Drug Intell Clin Pharm. 1986;20(10):792-795. [PubMed 3769772</li>
<li>Burland WL, Darkin DW, Mills MW. Effect of antacids on absorption of cimetidine. Lancet. 1976;2(7992):965. [PubMed 62195</li>
<li>Bodemar G, Norlander B, Walan A. Diminished absorption of cimetidine caused by antacids. Lancet. 1979;1(8113):444-445. [PubMed 84296</li>
<li>Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. N Engl J Med. 1982;307(7):400-404. [PubMed 708843</li>
<li>Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29(7):670-672. [PubMed 2569486</li>
<li>Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol. 1987;24(4):551-553. [PubMed 2891370</li>
<li>Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces the bioavailability of ranitidine. Br Med J. 1982;285(6347):998-999. [PubMed 6289961</li>
<li>Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol. 1990;42(5):352-354. [PubMed 1976784</li>
<li>Donn KH, Eshelman FN, Plachetka JR, et alThe effects of antacid and propantheline on the absorption of oral ranitidinePharmacotherapy1984;4(2):89-92[PubMed 6326064</li>
<li>Sullivan TJ, Reese JH, Jauregui L, Miller K, Levine L, Bachmann KA. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. Aliment Pharmacol Ther. 1994;8(1):123-126. [PubMed 7910488]</li>
<li>Tanatril (imidapril) [summary of product characteristics]. London, UK: Mitsubishi Tanabe Pharma Europe Limited; December 2014.</li>
<li>Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663</li>
<li>Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029]</li>
<li>Kristalose (lactulose) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; July 2018</li>
<li>Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663]</li>
<li>Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</li>
<li>Livtencity (maribavir) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2021.</li>
<li>Segre EJ, Sevelius H, Varady J. Letter: Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583. [PubMed 4852768</li>
<li>Weber SS, Bankhurst AD, Mroszczak E, Ding TL. Effect of Mylanta on naproxen bioavailability. Ther Drug Monit. 1981;3(1):75-83. [PubMed 7233492</li>
<li>Naprosyn (naproxen) [prescribing information]. Apharetta, GA: Canton Laboratories, LLC.; April 2021.</li>
<li>Ismail FA, Khalafallah N, Khalil SA. Absorption of ketoprofen and bumadizone calcium on aluminum-containing antacids and its effect on ketoprofen bioavailability in man. Int J Pharm. 1987;34:189-196</li>
<li>Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6 Pt 2):33S-39S (review). [PubMed 2082311</li>
<li>Holmes GI, et al. Effects of Maalox on the bioavailability of diflunisal. Clin Pharmacol Ther. 1979;25:229</li>
<li>Verbeeck R, Tjandramaga TB, Mullie A, et al. Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol. 1979;7(5):519-522. [PubMed 314299</li>
<li>Segre EJ, Sevelium H, Varady J. Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583 (letter). [PubMed 4852768</li>
<li>Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; January 2011</li>
<li>von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone - A novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Tox. 1983;21(6):311-321. [PubMed 6688407</li>
<li>Shaker MA, Akhtar N, Minhas MU, Khan KU, Zangi MI, Munir A. Effect of an Al-Mg hydroxide antacid and food on the pharmacokinetics of dexibuprofen. Drug Res (Stuttg). 2020;70(4):158-164. [PubMed 32110819]</li>
<li>Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</li>
<li>Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. Br J Clin Pharmacol. 1978;6(2):177-179. [PubMed 678395</li>
<li>Garnett WR, Carter BL, Pellock JM. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1980;37(7):467. [PubMed 7387502</li>
<li>Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-340. [PubMed 7336470</li>
<li>McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Br J Clin Pharmacol. 1982;13(4):501-505. [PubMed 7066165</li>
<li>Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1979;36(7):436-438. [PubMed 454247</li>
<li>O'Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol. 1978;6(2):176-177. [PubMed 678394</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</li>
<li>Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115(1):12-18. [PMID 9925057</li>
<li>Gupta PR, Mehta YR, Gupta ML, Sharma TN, Jain D, Gupta RB. Rifampin-aluminium antacid interaction. J Assoc Physicians India. 1988;36(6):363-364. [PubMed 3182711</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifadin (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifamate (rifampin/isoniazid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2013</li>
<li>Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2010</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2009.</li>
<li>Itthipanichpong C, Sirivongs P, Wittayalertpunya S, Chaiyos N. The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Drug Metabol Drug Interact. 1992;10(3):213-228. [PubMed 1424642</li>
<li>Gaspari F, Vigano G, Locatelli M, Remuzzi G. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis. 1988;11(4):338-342. [PubMed 3354570</li>
<li>Shastri RA. Effect of antacids on salicylate kinetics. Int J Clin Pharmacol Ther Toxicol. 1985;23(9):480-484. [PubMed 4055159</li>
<li>Levy G, Lampman T, Kamath BL, et al. Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. N Engl J Med. 1975;293(7):323-325. [PubMed 239345</li>
<li>Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol. 1980;20(5-6 Pt 1):326-331. [PubMed 7400368</li>
<li>Macpherson CR, Milne MD, Evans BM. The excretion of salicylate. Br J Pharmacol Chemother. 1955;10(4):484-489. [PubMed 13276608</li>
<li>Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. Br J Clin Pharmacol. 1982;14(4):562-564. [PubMed 7138740</li>
<li>Feldman S, Carlstedt BC. Effect of antacid on absorption of enteric-coated aspirin. JAMA. 1974;227(6):660-661 (letter). [PubMed 4405837</li>
<li>Strickland-Hodge B, Thomas TR, Gould WA, et al. The effects of antacids on enteric-coated salicylate preparations. Rheumatol Rehabil. 1976;15(3):148-152. [PubMed 968338]</li>
<li>Kivisto KT, Neuvonen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1992;42(6):675-679. [PubMed 1623912</li>
<li>Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol. 1991;32(2):215-220. [PubMed 1931470</li>
<li>Zuccaro P, Pacifici R, Pichini S, et al. Influence of antacids on the bioavailability of glibenclamide. Drugs Exp Clin Res. 1989;15(4):165-169. [PubMed 2505996</li>
<li>Kivisto KT, Lehto P, Neuvonen PJ. The effects of different doses of sodium bicarbonate on the absorption and activity of nonmicronized glibenclamide. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):236-240. [PubMed 8390970</li>
<li>Kivisto KT, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminum hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol. 1991;40(4):383-386. [PubMed 1646724</li>
<li>Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther. 1991;49(1):39-43. [PubMed 1988239</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976]</li>
<li>Arnold LA, Spurbeck GH, Shelver WH, Henderson WM. Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm. 1979;36(8):1059-1062. [PubMed 484565</li>
<li>Reed RC, Schwartz HJ. Lack of influence of an intensive antacid regimen on theophylline bioavailability. J Pharmacokinet Biopharm. 1984;12(3):315-331. [PubMed 6502473</li>
<li>Darzentas LJ, Stewart RB, Curry SH, Yost RL. Effect of antacid on bioavailability of a sustained-release theophylline preparation. Drug Intell Clin Pharm. 1983;17(7-8):555-557. [PubMed 6872853</li>
<li>Muir JF, Peiffer G, Richard MO, et al. Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation. Eur J Clin Pharmacol. 1993;44(1):85-88. [PubMed 8436162</li>
<li>Ferrari M, Olivieri M, Romito D, Biasin C, Barozzi E, Bassetti S. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline. Riv Eur Sci Med Farmacol. 1991;13(5-6):269-274. [PubMed 1819857</li>
<li>Fernandes E, Melewicz FM. Antacids and theophylline-ranitidine interaction. Ann Intern Med. 1984;101(2):279. [PubMed 6331245</li>
<li>Myhre KI, Walstad RA. The influence of antacid on the absorption of two different sustained-release formulations of theophylline. Br J Clin Pharmacol. 1983;15(6):683-687. [PubMed 6871067</li>
<li>Shargel L, Stevens JA, Fuchs JE, Yu AB. Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. J Pharm Sci. 1981;70(6):599-602. [PubMed 7252799</li>
<li>Theophylline oral solution [prescribing information]. Congers, NY: Chartwell RX LLC; October 2022.</li>
<li>Rudzki P, Jarus-Dziedzic K, Filist M, et al. Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacol Rep. 2021;73(2):604-614 [PubMed 33686610]</li>
<li>Kroboth PD, Smith RB, Silver MR, et al. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol. 1985;19(6):839-842. [PubMed 2862896]</li>
<li>May CA, Garnett WR, Small RE, et al, “Effects of Three Antacids on the Bioavailability of Valproic Acid,” Clin Pharm, 1982, 1(3):244</li>
<li>[PubMed 6821035]</li>
<li>Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990;34(10):2032-2033. [PubMed 2291673</li>
<li>Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236]</li>
<li>Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804-808. [PubMed 14982768</li>
<li>Kraft WK, Chang PS, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020-4025. [PubMed 24798274</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2022.</li>
<li>Exjade (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2020.</li>
<li>Relyvrio (sodium phenylbutyrate and taurursodiol) [prescribing information]. Cambridge, MA: Amylyx Pharmaceuticals Inc; September 2022.</li>
<li>Weissman I, Krivoy N. Interaction of aluminum hydroxide and allopurinol in patients on chronic hemodialysis. Ann Intern Med. 1987;107(5):787. [PubMed 3662305]</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Effect of ascorbic acid on gastrointestinal aluminum absorption. Lancet. 1991;338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int. 1991;39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654</li>
<li>Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9-11. [PubMed 2913801</li>
<li>Main J, Ward MK. Potentiation of aluminum absorption by effervescent analgesic tablets in a haemodialysis patient. Br Med J. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol. 1989;31(1):40-44. [PubMed 2914409]</li>
<li>Foresti V. Intestinal obstruction due to Kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Garcia-Pardo G, Martinez-Vea A, Auguet T, et al. Intestinal obstruction complicating calcium polystyrene sulphonate therapy. Nephrol Dial Transplant. 1996;11(4):751. [PubMed 8671882</li>
<li>Hurley JK. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel. J Pediatr. 1978;92(4):592-593. [PubMed 633020</li>
<li>Calcium Resonium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., April 2006.</li>
<li>Cholbam (cholic acid) [prescribing information]. Baltimore, MD: Asklepion Pharmaceuticals LLC; March 2015.</li>
<li>Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</li>
<li>Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568-572. [PubMed 10049268</li>
<li>Myambutol (ethambutol) [prescribing information]. Langhorne, PA: STI Pharma LLC; April 2012</li>
<li>Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol. 1978;5(2):161-166. [PubMed 619949]</li>
<li>Prescribing information. Neurontin (gabapentin). New York, NY: Pfizer Inc; October 2017.</li>
<li>Mircol (mequitazine) [summary of product characteristics]. Madrid, Spain: ITF Medilab Farma, SA; July 2013.</li>
<li>Moxifloxacin [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; November 2022.</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” Lancet, 1991, 338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” Kidney Int, 1991, 39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” Am J Kid Dis, 1991, 17(6):708-11. [PubMed 2042654</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ, 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” Clin Nephrol, 1989, 31(3):123</li>
<li>[PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” Clin Nephrol, 1986, 26(3):146</li>
<li>[PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” Proc Eur Dial Transplant Assoc Eur Ren Assoc, 1985, 21:390</li>
<li>[PubMed 3991529</li>
<li>Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” Am J Physiol, 1985, 249(2 Pt 1):G209-13. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205. [PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” J Lab Clin Med, 1986, 108(2):96-102. [PubMed 3755457]</li>
<li>Moon J, Davison A, Bandy B. Vitamin D and aluminum absorption. CMAJ. 1992;147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol. 1989;31(3):123-127. [PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Clin Nephrol. 1986;26(3):146-149. [PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:390-394. [PubMed 3991529</li>
<li>Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol. 1985;249(2 Pt 1):G209-G213. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et alAbsorption, deposition and distribution of dietary aluminium in immature rats: effects of dietary vitamin D3 and food-borne chelating agentJ Environ Sci Health B1986;21(2):191-205[PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al. 1,25-dihydroxyvitamin D3 increases serum and tissue accumulation of aluminum in rats. J Lab Clin Med. 1986;108(2):96-102. [PubMed 3755457]</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Urso 250 / Urso Forte (ursodiol) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2021</li>
<li>Actigall (ursodiol) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc.; September 2002</li>
<li>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. [PubMed 30070375]</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 Alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 Alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Zemplar (paricalcitol) capsules [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Rocaltrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Zemplar (paricalcitol) injection [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>Dovonex (calcipotriene) cream [prescribing information]. Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]Greenville, NC: Mayne Pharma; May 2019</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018</li>
<li>Vitamin D (ergocalciferol) [prescribing information]. Laurelton, NY: Epic Pharma, LLC: October 2018.</li>
<li>Chenodol (chenodiol) [prescribing information]. San Diego, CA: Retrophin, Inc; June 2015.</li>
<li>Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J. 1994;87(9):894-898. [PubMed 8091252</li>
<li>Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr. 1994;48(1):71-73. [PubMed 8200332</li>
<li>Nestel AW, Meyers AM, Paiker J, Rollin HB. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients. Nephron. 1994;68(2):197-201. [PubMed 7830856</li>
<li>Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study. South Med J. 1993;86(12):1385-1388. [PubMed 8272917</li>
<li>Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs. 1991;14(10):625-629. [PubMed 1748529</li>
<li>Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; June 2019</li>
<li>Envarsus XR (tacrolimus extended-release) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Spencer H, Kramer L, Norris C, et al. Effect of aluminum hydroxide on fluoride metabolism. Clin Pharmacol Ther. 1980;28(4):529-535. [PubMed 7408412]</li>
<li>Hong CY, Hu SC, Lin SJ, Chiang BN. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Clin Pharmacol Ther Toxicol. 1985;23(5):244-246. [PubMed 4008113</li>
<li>Inderal (propranolol) tablets [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals LLC; March 2011.</li>
<li>PhosLo (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2011.</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4:345. [PubMed 3160584</li>
<li>Schentag JJ, Watson WA, Nix DE, et al. Time-dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther. 1988;43:135</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36:1219-1234. [PubMed 1329615</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulphate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36:2270-2274. [PubMed 1444308</li>
<li>Sahai J, Healey DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302-304. [PubMed 8471407</li>
<li>Frost RW, Lettieri JT, Noe A, et al. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin Pharmacol Ther. 1989;45:165</li>
<li>Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34:432-435. [PubMed 2334155</li>
<li>Kays MB, Overholser BR, Mueller BA, et alEffects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacinAm J Kidney Dis2003;42(6):1253-1259[PubMed 14655198</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014</li>
<li>Federspiel J, Bukhari MJ, Hamill MM. Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. BMJ Case Rep. 2021;14(1):e236655. [PubMed 33408101</li>
<li>Gunnarsson PO, Davidson T, Andersson SB, et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189-193. [PubMed 2338118</li>
<li>Emcyt (estramustine) [prescribing information]. New York, NY: Pharmacia and Upjohn Company; June 2007.</li>
<li>Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” Am J Clin Nutr, 2007, 85(1):6-18. [PubMed 17209171</li>
<li>Peacock M, “Calcium Metabolism in Health and Disease,” Clin J Am Soc Nephrol, 2010, 5 Suppl 1:S23-30. [PubMed 20089499</li>
<li>Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” Cochrane Database Syst Rev, 2011, (7):CD007470. [PubMed 21735411]</li>
<li>Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr. 2002;21(3):239-244. [PubMed 12074251</li>
<li>Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22. [PubMed 9554821]</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439]</li>
<li>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018. Available at https://aidsinfo.nih.gov. (Accessed 06/24/2019</li>
<li>HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. (Accessed 06/24/2019</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494]</li>
<li>Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; June 2009</li>
<li>Minocin (minocycline) [prescribing information]. Cranford, NJ: Triax Pharmaceuticals, LLC; August 2010</li>
<li>Vibramycin (doxycycline) [prescribing information]. New York, NY: Pfizer Inc; April 2007</li>
<li>Jung H, Peregrina AA, Rodriguez JM, et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos. 1997;18(5):459-463. [PubMed 9210983]</li>
<li>Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822-2825. [PubMed 10838651</li>
<li>Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11:967-971. [PubMed 11716045</li>
<li>Mazokopakis EE, Giannakopoulos TG, Starakis IK. Interaction between levothyroxine and calcium carbonate. Can Fam Physician. 2008;54(1):39. [PubMed 18208953</li>
<li>Csako G, McGriff NJ, Rotman-Pikielny P, et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35(12):1578-1583. [PubMed 11793625</li>
<li>Butner LE, Fulco PP, Feldman G. Calcium carbonate-induced hypothyroidism. Ann Intern Med. 2000;132(7):595. [PubMed 10744606</li>
<li>Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA. 1998;279(10):750. [PubMed 9508149</li>
<li>A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Diskin CJ, Stokes TJ, Dansby LM, et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol. 2007;39(2):599-602. [PubMed 17216296]</li>
<li>Salerno DM, Anderson B, Sharkey PH, et al, “Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia With and Without Calcium Pretreatment,” Ann Intern Med, 1987, 107(5):623</li>
<li>[PubMed 3662276</li>
<li>Haft JI and Habbab MA, “Treatment of Atrial Arrhythmias. Effectiveness of Verapamil When Preceded by Calcium Infusion,” Arch Intern Med, 1986, 146(6):1085</li>
<li>[PubMed 3718093</li>
<li>Schoen MD, Parker RB, Hoon TJ, et al, “Evaluation of the Pharmacokinetics and Electrocardiographic Effects of Intravenous Verapamil With Intravenous Calcium Chloride Pretreatment in Normal Subjects,” Am J Cardiol, 1991, 67(4):300</li>
<li>[PubMed 1990794</li>
<li>O’Quinn SV, et al, “Influence of Calcium on the Hemodynamic and Anti-ischemic Effects of Nifedipine Observed During Treadmill Exercise Testing,” Pharmacotherapy, 1990, 10:247 (abstract)</li>
<li>Wohns DH, Patterson JH, Clarke S, et al, “Influence of Calcium Administration on the Short-term Hemodynamic and the Anti-ischemic Effects of Nifedipine,” J Am Coll Cardiol, 1991, 18(4):1070</li>
<li>[PubMed 1894852</li>
<li>Bar-Or D and Gasiel Y, “Calcium and Calciferol Antagonize Effect of Verapamil in Atrial Fibrillation,” Br Med J, 1981, 282(6276):1585</li>
<li>[PubMed 6786574]</li>
<li>Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75(887):554-556. [PubMed 10616693</li>
<li>Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth Analg. 1972;51(2):202-205. [PubMed 5062119</li>
<li>Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA. 1978;240(6):533-534. [PubMed 671662</li>
<li>Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. Br Med J. 1978;1(6108):279-280. [PubMed 620306</li>
<li>Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507. [PubMed 5418023]</li>
<li>Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992;101(1):174-180. [PubMed 1729065]</li>
<li>Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriat Soc. 1984;32(5):405-407. [PubMed 6715769</li>
<li>Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121(5):591-594. [PubMed 497950</li>
<li>Gora ML, Seth SK, Bay WH, Visconti JA. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm. 1989;8(3):227-229. [PubMed 2706898</li>
<li>Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55-59. [PubMed 5305802</li>
<li>Rehan MA, Rashid A, Krell K, Gabutti C, Singh R. Calcium alkali thiazide syndrome: what we need to know. Cureus. 2020;12(10:e10856. [PubMed 33178509</li>
<li>Morini L, Doneli D, Santi R, et al. Severe milk-alkali syndrome in a patient with hypoparathyroidism associated with 1,25(OH)2D, hydrochlorothiazide and anthranoid laxative consumption. Eur J Case Rep Intern Med. 2017;4(10):000729. [PubMed 30755914</li>
<li>Singh A, Ashraf A. Hypercalcemic crisis induced by calcium carbonate. Clin Kidney J. 2012;5(4):288-291. [PubMed 25874082</li>
<li>Parvez B, Emuwa C, Faulkner ML, Murray JJ. Milk alkali and hydrochlorothiazide: a case report. Case Rep Med. 2011;2011:729862. [PubMed 21738535]</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>One-Alpha drops (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Dovonex (calcipotriene) [prescribing information]. Dublin, Ireland: LEO Laboratories Ltd.; March 2015</li>
<li>Rocalctrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Vectical (calcitriol) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019</li>
<li>Ergocalciferol [prescribing information]. Laurelton, NY: Epic Pharma, LLC; October 2018.</li>
<li>Flura-Drops (sodium fluoride) [prescribing information]. Lake Oswego, OR: Kirkman Laboratories Inc; September 2019.</li>
<li>Borel P, Desmarchelier C, Dumont U, et. al. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. Br J Nutr. 2016;116(12):2091-2096. [PubMed 28069089]</li>
<li>Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(suppl 1):27-32. [PubMed 11352439</li>
<li>Moxifloxacin [prescribing information]. Levittown, PA: Torrent Pharma Inc; January 2022.</li>
<li>Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016.</li>
<li>Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351-352. [PubMed 22678358</li>
<li>Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; August 2020.</li>
<li>Klein CE, Chiu YL, Cai Y, et al, “Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir,” J Clin Pharmacol, 2008, 48(5):553-62. [PubMed 18440920]</li>
<li>Wang X, Boffito M, Zhang J, et al, “Effects of the H2-Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir with or without Tenofovir in HIV-Infected Patients,” AIDS Patient Care STDS, 2011, 25(9):509-15. [PubMed 21770762</li>
<li>Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, February 2012.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; September 2018.</li>
<li>Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; October 2016</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908]</li>
<li>Saito Y, Takekuma Y, Kobayashi M, et al. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(3):381-388. [PubMed 33029650</li>
<li>Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410</li>
<li>Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004;44(8):919-927. [PubMed 15286096</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018.</li>
<li>Mchavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347</li>
<li>Ketoconazole [prescribing information]. Mason, OH: Burel Pharmaceuticals, LLC; September 2021.</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017</li>
<li>Chiu Y-L, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV infected patients. AIDS Patient Cre STDS. 2007;21(4):247-251. [PubMed 17461719</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451</li>
<li>Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985;38(6):652-655. [PubMed 2933205</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RMW. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958-966. [PubMed 17210768]</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc.; February 2020</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584]</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013</li>
<li>Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis. 2008;46(10):1627; author reply 1627</li>
<li>[PubMed 18419503</li>
<li>Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207-12. [PubMed 19858252</li>
<li>Vehreschild JJ, Muller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987-95. [PubMed 22286158</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-10[PubMed 22890761]</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; March 2022.</li>
<li>Invirase (saquinavir) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; December 2003.</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</li>
<li>Saathoff N, Lode H, Neider K, Kepperman KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Cefpodoxime [prescribing information]. Princeton, NJ: Sandoz GmbH for Sandoz Inc; February 2014.</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine After Heart Transplantation: Experimental and Clinical Results,” J Heart Lung Transplant, 1993, 12(6 Pt 1):987-92. [PubMed 8312324</li>
<li>D'Souza MJ, Pollock SH, Solomon HM, “Cyclosporine-Cimetidine Interaction,” Drug Metab Dispos, 1988, 16(1):57</li>
<li>[PubMed 2894956</li>
<li>Shaefer MS, Rossi SJ, McGuire TR, et al, “Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men,” Ann Pharmacother, 1995, 29(11):1088-91. [PubMed 8573949</li>
<li>Jadoul M and Hene RJ, “Ranitidine and the Cyclosporine Treated Recipient,” Transplantation, 1989, 48(2):359. [PubMed 2667215</li>
<li>Tsang VT, Johnston A, Heritier F, et al, “Cyclosporine Pharmacokinetics in Heart-Lung Transplant Recipients With Cystic Fibrosis Effects of Pancreatic Enzymes and Ranitidine,” Eur J Clin Pharmacol, 1994, 46(3):261</li>
<li>[PubMed 8070508</li>
<li>Jarowenko MV, Van Buren CT, Kramer WG, et al, “Ranitidine, Cimetidine, and the Cyclosporine-Treated Recipient,” Transplantation, 1986, 42(3):311</li>
<li>[PubMed 3529532]</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; February 2020</li>
<li>Doxofylline tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200101732. Accessed December 15, 2015.</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2019</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084. [PubMed 12461038]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413</li>
<li>Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2009.</li>
<li>Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med. 1987;107(2):261-262. [PubMed 3111324</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514</li>
<li>DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi Aventis US; July 2016.</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016.</li>
<li>Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol. 1984;18(2):175-181. [PubMed 6091709</li>
<li>Rocci ML Jr, Kosoglou T, Ferguson RK, Vlasses PH. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. J Pharmacol Exp Ther. 1989;248(3):923-928. [PubMed 2467982</li>
<li>Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Ther Drug Monit. 1987;9(4):378-383. [PubMed 2447687</li>
<li>Ranitidine [prescribing information]. East Winsor, NJ: Novitium Pharma LLC; September 2018.</li>
<li>O'Conner-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther. 2001;70(2):126-31. [PubMed 11503006</li>
<li>Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm. 1991;10(7):539-43. [PubMed 1860302</li>
<li>Halcion (triazolam) [prescribing information]. New York, NY: Pfizer Inc,; October 2019.</li>
<li>Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med. 1990;112(1):76-77. [PubMed 2293824</li>
<li>Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin clearance after ranitidine and cimetidine. Clin Pharmacol Ther. 1984;35(3):338-341. [PubMed 6321081</li>
<li>O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144(5):989-991. [PubMed 6324710</li>
<li>Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32(2):165-172. [PubMed 3582481</li>
<li>Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12(6):791-794. [PubMed 6122462</li>
<li>Powell JR, Donn KH. The pharmacokinetic basis for h2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95-113. [PubMed 6140286]</li>
<li>Gertz BJ, Holland SD, Kline WF, et al, “Studies of the Oral Bioavailability of Alendronate,” Clin Pharmacol Ther, 1995, 58(3):288-98. [PubMed 7554702</li>
<li>Prescribing information. Fosamax (alendronate). Whitehouse Station, NJ: Merck &amp; Co., Inc., 04/2013</li>
<li>Prescribing information. Binosto (alendronate). San Antonio, TX: Mission Pharmacal, 4/2013</li>
<li>Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” Arch Intern Med, 2011, 171(11):998-1004. [PubMed 21321287</li>
<li>Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” Endokrynol Pol, 2011, 62(1):84</li>
<li>Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” Bone, 2010, 47(2):169-80. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” Drug Saf, 2009, 32(9):775-85. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” Osteoporos Int, 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” Osteoporos Int, 2012, 23(1):277-84. [PubMed 21365461]</li>
<li>Piqray (alpelisib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; June 2022.</li>
<li>Perveen S, Gauhar S, Yousuf RI, Ali H, Zafar F, Sheikh AF. Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan. PLoS One. 2022;17(5):e0267791. [PubMed 35609024</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502]</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360</li>
<li>Diacetylmorphine (diamorphine) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc.; February 2022</li>
<li>Diamorphine [summary of product characteristics]. Middlesex, United Kingdom: Accord Healthcare Limited; May 2020.</li>
<li>Esposito R. Cimetidine and iron-deficiency anaemia. Lancet. 1977;2(8048):1132. [PubMed 73039</li>
<li>Bianchi FM, Cavassini GB, Leo P. Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):209-217. [PubMed 8100220</li>
<li>Partlow ES, Campbell NR, Chan SC, Pap KM, Granberg K, Hasinoff BB. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. Clin Pharmacol Ther. 1996;59(4):389-393. [PubMed 8612382]</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055</li>
<li>Ueno T, Miyajima Y, Landry I, Lalovic B, Schuck E. Physiologically based pharmacokinetic modeling to predict drug interaction of lemborexant with CYP3A inhibitors. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):455-466. [PubMed 33704920</li>
<li>Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int. 2005;67(3):1152-1160. [PubMed 15698457</li>
<li>Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369-376. [PubMed 10223772</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451]</li>
<li>U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360]</li>
<li>Mirapex ER (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014</li>
<li>Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33(4):495-499. [PubMed 15640376]</li>
<li>Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251-2257. [PubMed 18786302</li>
<li>Donn KH, Eshelman FN, Plachetka JR, Fabre L, Powell JR. The effects of antacid and propantheline on the absorption of oral ranitidine. Pharmacotherapy. 1984;4(2):89-92. [PubMed 6326064]</li>
<li>Machavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347]</li>
<li>Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410]</li>
<li>Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;58:663-687. [PubMed 29309257</li>
<li>Li TT, An JX, Xu JY, Tuo BG. Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver. World J Clin Cases. 2019;7(23):3915-3933. [PubMed 31832394]</li>
<li>Poudel RR, Kafle NK. Tizanidine-induced acute severe cystitis in a female taking famotidine. Clin Pharmacol. 2015;7:83-85. [PubMed 26251632</li>
<li>Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013</li>
<li>Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 1993;24(3):255-258. [PubMed 8462230</li>
<li>Bachmannn K, Sullivan TJ, Reese JH, et al. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 1995;35(5):529-535. [PubMed 7657856</li>
<li>Verdiani P, Di Carlo S, Baronti AFamotidine effects on theophylline pharmacokinetics in subjects affected by COPDComparison with cimetidine and placeboChest1988;94(4):807-810[PubMed 3168576</li>
<li>Sunlenca (lenacapavir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; November 2022.</li>
<li>Nexterone (amiodarone) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2021.</li>
<li>Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987;27(10):813-816. [PubMed 3323258</li>
<li>Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011;55(7):3091-3098. [PubMed 21518836]</li>
<li>Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; August 2019</li>
<li>Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol. 2000;49(1):64-71. [PubMed 10606839]</li>
<li>Ellence (epirubicin hydrochloride). New York, NY: Pfizer Inc.; July 2019</li>
<li>Murray LS, Jodrell DI, Morrison JG, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol). 1998;10(1):35-38. [PubMed 9543613]</li>
<li>Veozah (fezolinetant) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2023.</li>
<li>Plaquenil (hydroxychloroquine) [prescribing information]. Dublin, Ireland: Amdipharm Limited; May 2021</li>
<li>Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65(1):10-20. [PubMed 9951426</li>
<li>Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20(3):317-324. [PubMed 10831018</li>
<li>Orap (pimozide) [prescribing information]. Horsham, PA: Teva Pharmaceuticals USA; March 2014.</li>
<li>Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol. 1997;37(11):1056-1061. [PubMed 9505999</li>
<li>Serdolect (sertindole) [summary of product characteristics]. Valby, Denmark: Lundbeck AS; March 2021.</li>
<li>Volkin RL, Shadduck RK, Winkelstein A, Zeigler ZR, Selker RG. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med. 1982;142(2):243-245. [PubMed 7059252</li>
<li>Selker RG, Moore P, LoDolce D. Bone-marrow depression with cimetidine plus carmustine. N Engl J Med. 1978;299(15):834. [PubMed 692572</li>
<li>BiCNU (carmustine) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2021</li>
<li>Dorr RT, Soble MJ. H2-antagonists and carmustine. J Cancer Res Clin Oncol. 1989;115(1):41-46. [PubMed 2564000]</li>
<li>Kirch W, Janisch HD, Ohnhaus EE, van Peer A. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit. 1989;11(4):411-414. [PubMed 2741189]</li>
<li>Priskorn M, Larsen F, Segonzac A, et al. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 1997;52:241-242. [PubMed 9218934</li>
<li>Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci. 2011;32(3):507-509. [PubMed 21491099</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA, Inc; January 2019.</li>
<li>Ampyra (dalfampridine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; December 2019</li>
<li>Fampyra (fampridine) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; January 2022.</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, et al, “Cimetidine Interaction with Phenytoin,” Br Med J (Clin Res Ed), 1981, 282:1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, and Springer PK, “Decreased Clearance of Phenytoin with Cimetidine,” Ann Intern Med, 1981, 95:244. [PubMed 7258891</li>
<li>Phillips P, Hansky J, “Phenytoin Toxicity Secondary to Cimetidine Administration,” Med J Aust, 1984, 141(9):602. [PubMed 6092884</li>
<li>Neuvonen PJ, Tokola RA, Kaste M, “Cimetidine-Phenytoin Interaction: Effect on Serum Phenytoin Concentration and Antipyrine Test,” Eur J Clin Pharmacol, 1981, 21(3):215-20. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al, “Reduction of Phenytoin Clearance Caused by Cimetidine,” Eur J Clin Pharmacol, 1983, 25(1):135</li>
<li>Bartle WK, Walker SE, and Shapero I, “Dose-Dependent Effect of Cimetidine on Phenytoin Kinetics,” Clin Pharmacol Ther, 1983, 33:649-55. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, et al, “Effect of Cimetidine on Phenytoin Serum Levels,” Epilepsia, 1983, 24(3):284</li>
<li>Iteogu MO, Murphy JE, Shleifer N, et al, “Effect of Cimetidine on Single-Dose Phenytoin Kinetics,” Clin Pharm, 1983, 2:302, 304. [PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I, “Differential Effect of Cimetidine on Serum Concentrations of Carbamazepine and Phenytoin,” Neurology, 1985, 35(4):562</li>
<li>Sambol NC, Upton RA, Chremos AN, et al, “A Comparison of the Influence of Famotidine and Cimetidine on Phenytoin Elimination and Hepatic Blood Flow,” Br J Clin Pharmacol, 1989, 27(1):83</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2022</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055]</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017.</li>
<li>Zokinvy (lonafarnib) [prescribing information]. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; November 2020.</li>
<li>Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2018</li>
<li>Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545-551. [PubMed 3593625</li>
<li>Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637-645. [PubMed 18551044</li>
<li>Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471-2472. [PubMed 12882884</li>
<li>Boehm KM, Gunaga S. Cimetidine-induced lactic acidosis and acute pancreatitis. South Med J. 2010;103(8):849. [PubMed 20622719</li>
<li>Seo JH, Lee da Y, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. Intern Med. 2013;52(19):2245-2248. [PubMed 24088760</li>
<li>Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica. 2008;38(9):1203-1218. [PubMed 18686197</li>
<li>Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185-191. [PubMed 19164462</li>
<li>Sultana N, Arayne MS, Ahmed N. In vitro availability of metformin in presence of h(2) receptor antagonists. Pak J Pharm Sci. 2006;19(1):28-34. [PubMed 16632449]</li>
<li>Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther. 1991;49(1):32-38. [PubMed 1988238</li>
<li>Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2015.</li>
<li>Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol. 1988;26(3):118-121. [PubMed 2457561</li>
<li>Christian CD Jr, Meredith CG, Speeg KV Jr. Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther. 1984;36(2):221-227. [PubMed 6204803</li>
<li>Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25(3):339-345. [PubMed 6194997</li>
<li>Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982;307(17):1080. [PubMed 6181402</li>
<li>Bauer LA, Black D, Gensler A. Procainamide-cimetidine interaction in elderly male patients. J Am Geriatr Soc. 1990;38(4):467-469. [PubMed 2329253</li>
<li>Higbee MD, Wood JS, Mead RA. Procainamide-cimetidine interaction: a potential toxic interaction in the elderly. J Am Geriatr Soc. 1984;32(2):162-164. [PubMed 6693705</li>
<li>Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol. 1985;28(6):671-675. [PubMed 2866097]</li>
<li>Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol. 1986;22(3):346-350. [PubMed 3768247</li>
<li>Qualaquin (quinine sulfate) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals Industry Inc; June 2019.</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019</li>
<li>El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther. 2016;9(4):157-161. [PubMed 26684920</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499</li>
<li>Fyarro (sirolimus) protein-bound [prescribing information]. Pacific Palisades, CA: Aadi Bioscience Inc; November 2021.</li>
<li>Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19(6):494-499. [PubMed 10587283</li>
<li>Preskorn SH. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract. 2005;11(3):192-196. [PubMed 15920392</li>
<li>Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 1997;25(1):24-32. [PubMed 9027670</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2010</li>
<li>Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59(1):45-50. [PubMed 12682803</li>
<li>Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther. 2007;82(5):555-565. [PubMed 17460606</li>
<li>Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60(5):543-553. [PubMed 8941027</li>
<li>Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002;16(4):361-364. [PubMed 12503836</li>
<li>Sunvepra (asunaprevir) [product monograph]Montreal, Canada: Bristol-Myers Squibb Canada; March 2016</li>
<li>Manerix (moclobemide) [product monograph]. Mississauga, Ontario: Hoffmann-LaRoche Limited, June 2011.</li>
<li>Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78(4):400-411. [PubMed 16198659</li>
<li>Villa-Zapata L, Gomez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disporportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022;45(8):863-871. [PubMed 35834155]</li>
<li>Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2019.</li>
<li>Flind AC. Cimetidine and oral anticoagulants. Br Med J. 1978;2(6148):1367. [PubMed 719395</li>
<li>Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2(8138):317-319. [PubMed 89387</li>
<li>Kerley B, Ali M. Cimetidine potentiation of warfarin action. Can Med Assoc J. 1982;126(2):116. [PubMed 7059881</li>
<li>Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med. 1979;90(3):348-349. [PubMed 426403</li>
<li>Hetzel D, Birkett D, Miners J. Cimetidine interaction with warfarin. Lancet. 1979;2(8143):639. [PubMed 90304</li>
<li>Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol. 1986;30(5):619-623. [PubMed 3758150</li>
<li>Harenberg J, Staiger CH, de Vries JX, et al. Cimetidine does not increase the anticoagulant effect of phenprocoumon. Br J Clin Pharmacol. 1982;14(2):292-293. [PubMed 7104184</li>
<li>O’Reilly RAComparative interaction of cimetidine and ranitidine with racemic warfarin in manArch Intern Med1984;144(5):989-991[PubMed 6324710</li>
<li>Unrecognized drug interactions ith famotidine and nizatidine. Arch Intern Med. 1991;151(4):810, 814, 815. [PubMed 1672811]</li>
<li>Sonata (zaleplon) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; November 2016.</li>
<li>Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest. 1998;15(6):515-522. [PubMed 18370509</li>
<li>Zomig (zolmitriptan) [prescribing information]. Hayward, CA: Impax Laboratories Inc; September 2012.</li>
<li>Alfenta (alfentanil) [prescribing information]. Lake Forest, IL: Akorn, Inc.; October 2019.</li>
<li>Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Abernathy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46(1):35-39. [PubMed 8005185</li>
<li>Suzuki Y, Shioiri T, Muratake T, et al. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol. 2003;58(12):829-833. [PubMed 12698310</li>
<li>Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol. 2009;65(7):699-704. [PubMed 19225771</li>
<li>Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug alprazolam. Eur J Clin Pharmacol. 2006;62(7):587-588. [PubMed 16791582</li>
<li>Xanax (alprazolam) [prescribing information]. New York, NY: Pfizer Inc; March 2021.</li>
<li>Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; November 2020</li>
<li>Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53(6):475-478. [PubMed 9551707]</li>
<li>Astelin (azelastine) nasal spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals Inc.; October 2014.</li>
<li>Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987;41(5):562-570. [PubMed 2882883</li>
<li>Apo-bromazepam (bromazepam) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2016.</li>
<li>Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. Pharmacotherapy. 1985;5(1):16-19. [PubMed 3982974</li>
<li>Felodipine [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; December 2020</li>
<li>Kirch W, Ramsch K, Janisch HD, Ohnhaus EE. The influence of two histamine H2-receptor antagonists, cimetidine, and ranitidine on the plasma levels and clinical effect of nifedipine and metoprolol. Arch Toxicol Suppl. 1984;7:256-259. [PubMed 6151387</li>
<li>Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther. 1989;249(2):638-645. [PubMed 2724144</li>
<li>Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43(6):673-680. [PubMed 3378388</li>
<li>Smith SR, Kendall MJ, Lobo J, Beerahee A, Jack DB, Wilkins MR. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol. 1987;23(3):311-315. [PubMed 3567045</li>
<li>Renwick AG, Le Vie J, Challenor VF, Waller DG, Gruchy B, George CF. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol. 1987;32(4):351-355. [PubMed 3609112</li>
<li>van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DDPharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidineClin Pharmacol Ther1988;43(3):332-341[PubMed 3345623</li>
<li>Muck W, Wingender W, Seiberling M, Woelke E, Ramsch KD, Kuhlmann J. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol. 1992;42(3):325-328. [PubMed 1577052</li>
<li>Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50(4):394-403. [PubMed 1914375</li>
<li>Kirch W, Hutt HJ, Heidemann H, Ramsch K, Janisch HD, Ohnhaus EE. Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S982-S985. [PubMed 6085389</li>
<li>Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther. 1990;253(3):1042-1048. [PubMed 2359015</li>
<li>Abernethy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Loi CM, Rollins DE, Dukes GE, Peat MA. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther. 1985;37(6):654-657. [PubMed 4006365</li>
<li>Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol. 1985;19(3):385-391. [PubMed 3986090</li>
<li>Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984;36(4):551-554. [PubMed 6478741</li>
<li>Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Conjupri (levamlodipine) [prescribing information]. CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia. 1986;27(5):553-558. [PubMed 3757941</li>
<li>Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol. 1984;27(3):341-343. [PubMed 6096154</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. Epilepsia. 1985;26(2):127-130. [PubMed 3987645</li>
<li>Macphee GJ, Thompson GG, Scobie G, et al. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984;18(3):411-419. [PubMed 6487479</li>
<li>Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011;24(1):63-68. [PubMed 21190921</li>
<li>Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit. 1987;9(1):24-27. [PubMed 3107168</li>
<li>Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 1986;8(4):387-392. [PubMed 3824425</li>
<li>Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy volunteers. Phytother Res. 2015;29(5):701-706. [PubMed 25624269</li>
<li>Pisani F, Narbone MC, Fazio A, et alEffect of viloxazine on serum carbamazepine levels in epileptic patientsEpilepsia1984;25(4):482-485[PubMed 6745218</li>
<li>Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49(10):1142-1145. [PubMed 3783175</li>
<li>Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine. Ann Intern Med. 1981;94(4 pt 1):544. [PubMed 7212521</li>
<li>Garcia B, Zaborras E, Areas V, Obeso G, Jimenez I, de Juana P, Bermejo T. Interaction between isoniazid and carbamazepine potentiated by cimetidine. Ann Pharmacother. 1992;26(6):841-842. [PubMed 1611171</li>
<li>Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol. 1993:36(6):615-616. [PubMed 12959283</li>
<li>Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991:84(6):583-584. [PubMed 1792934</li>
<li>Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie. 1992:47(2):165. [PubMed 1412145</li>
<li>Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust. 1991;155(11-12):851. [PubMed 1745195</li>
<li>Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand. 1983;68(4):253-256. [PubMed 6659865</li>
<li>Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine of fluvoxamine. Ther Drug Monit. 1993:15(3):247-250. [PubMed 8333006</li>
<li>Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother. 1987;20(Suppl B):121-129. [PubMed 3429380</li>
<li>Leite SA, Leite PJ, Rocha GA, Routledge PA, Bittencourt PR. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq Neuropsiquiatr. 1994;52(2):210-215. [PubMed 7826249</li>
<li>Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018</li>
<li>Equetro (carbamazepine) extended-release capsules [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2016</li>
<li>Carbatrol (carbamazepine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc.; August 2018.</li>
<li>Desmond PV, Patwardhan RV, Schenker S, Speeg Jr KV. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med. 1980;93(2):266-268. [PubMed 7406377</li>
<li>Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg Jr KV. Lack of tolerance and rapid recovery of cimetidine - inhibited chlordiazepoxide (Librium) elimination. Gastroenterology. 1981;81(3):547-551. [PubMed 7250643</li>
<li>Nelson DC, Avant GR, Speeg Jr KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology. 1985;5(2):305-309. [PubMed 3979962</li>
<li>Cimetidine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2019.</li>
<li>Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. Eur J Clin Pharmacol. 1981;21(1):83-85. [PubMed 7333351]</li>
<li>Szymanski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52:21-22. [PubMed 1988413</li>
<li>Watras M, Taylor D. A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. Ther Adv Psychopharmacol. 2013;3(5):294-297. [PubMed 24167705]</li>
<li>Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49(1):49-63. [PubMed 10606838</li>
<li>Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18(4):311-316. [PubMed 9690697</li>
<li>Raaska K, Raitasuo V, Laitila J, Neuvonen P. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalized patients. Basic Clin Pharmacol Toxicol. 2004;94(1):13-18. [PubMed 14725610</li>
<li>Al Hadithy A, Leeffers E, Bruggeman R. Clozapine levels might be affected by excessive cola consumption. J Clin Psychopharmacol. 2012;32(5):717-719. [PubMed 22926611</li>
<li>Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol. 1994;14(4):284-285. [PubMed 7962690</li>
<li>Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52(1):21-22. [PubMed 1988413</li>
<li>Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. Psychosomatics. 2007;48(2):170-175. [PubMed 17329613</li>
<li>Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol. 2002;22(6):621-622. [PubMed 12454563</li>
<li>Schoretsanitis G, Kane JM, de Leon JAdding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature reviewJ Clin Psychopharmacol2020;40(3):308-310[PubMed 32332470</li>
<li>Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50-56. [PubMed 23104241</li>
<li>Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2017.</li>
<li>Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother. 2014;48(12):1580-1584. [PubMed 25280976</li>
<li>Cai J, Huang Z, Yang G, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.  Am J Cardiovasc Drugs. 2011;11(6):401-409. [PubMed 22149319</li>
<li>Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant. 2007;21(2):277-284. [PubMed 17425758</li>
<li>Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation. 2003;76(5):865-868. [PubMed 14501869</li>
<li>McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol. 1997;48(5):336. [PubMed 9403222</li>
<li>Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7(6):831-835. [PubMed 8793790</li>
<li>Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. [PubMed 16133554</li>
<li>Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28(1):25-29. [PubMed 16541194</li>
<li>Synercid (quinupristin/dalfopristin) [prescribing information]New York, NY: Pfizer Inc; March 2017</li>
<li>Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet. 1990;19(6):499-502. [PubMed 2292171</li>
<li>Momper JD, Yang J, Kerr J, Saunders I, Smith J, Shah MM. Interaction between cyclosporine and palbociclib in a renal transplant patient: case report and pharmacokinetic perspective. J Pharm Pract. 2020;33(6):912-914. [PubMed 31248333</li>
<li>Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24(3):297-300. [PubMed 8082935</li>
<li>Wang CH, Chou NK, Wu FL, et al. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. Transplant Proc. 2006;38(7):2032-2034. [PubMed 16979990</li>
<li>Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol. 2005;45(7):781-791. [PubMed 15951468</li>
<li>Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081]</li>
<li>Mogford N, Pallett A, George C. Erythromycin deafness and cimetidine treatment. BMJ. 1994;309(6969):1620. [PubMed 7819942]</li>
<li>Mailing D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2021.</li>
<li>Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</li>
<li>Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</li>
<li>Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984;18(3):421-430. [PubMed 6487480]</li>
<li>Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32(4):432-436. [PubMed 9562139</li>
<li>Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol. 1995;8(4):231-233. [PubMed 8561837]</li>
<li>Archambeaud-Moueroux F, Nouaille Y, Nadalon S, Treves R, Merle L. Interaction between gliclazide and cimetidine. Eur J Clin Pharmacol. 1987;31(5):631. [PubMed 3830250]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413]</li>
<li>Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022</li>
<li>Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008;14(9):2701-2709. [PubMed 18451235]</li>
<li>Kishikawa K, Namiki A, Miyashita K, Saitoh K. Effects of famotidine and cimetidine on plasma levels of epidurally administered lignocaine. Anaesthesia. 1990;45(9):719-721. [PubMed 2240530</li>
<li>Parish RC, Gotz VP, Lopez LM, Mehta JL, Curry SH. Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit. 1987;9(3):292-297. [PubMed 3672572</li>
<li>Abernathy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Jackson JE, Bentley JB, Glass SJ, Fukui T, Gandolfi AJ, Plachetka JR. Effects of histamine-2 receptor blockade on lidocaine kinetics. Clin Pharmacol Ther. 1985;37(5):544-548. [PubMed 3987178</li>
<li>Bauer LA, Edwards WA, Randolph FP, Blouin RA. Cimetidine-induced decrease in lidocaine metabolism. Am Heart J. 1984;108(2):413-415. [PubMed 6464978</li>
<li>Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S. Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther. 1984;35(5):695-701. [PubMed 6713782</li>
<li>Feely J, Wilkinson GR, McAllister CB, Wood AJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982;96(5):592-594. [PubMed 7073151</li>
<li>Powell JR, Foster J, Patterson JH, Cross R, Wargin W. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics. Clin Pharm. 1986;5(12):993-998. [PubMed 3802729</li>
<li>Berk SI, Gal P, Bauman JL, Douglas JB, McCue JD, Powell JRThe effect of oral cimetidine on total and unbound serum lidocaine concentrations in patients with suspected myocardial infarctionInt J Cardiol1987;14(1):91-94[PubMed 3804509</li>
<li>Knapp AB, Maguire W, Keren G, et al. The cimetidine-lidocaine interaction. Ann Intern Med. 1983;98(2):174-177. [PubMed 6824249</li>
<li>Patterson JH, Foster J, Powell JR, Cross R, Wargin W, Clark JL. Influence of a continuous cimetidine infusion on lidocaine plasma concentrations in patients. J Clin Pharmacol. 1985;25(8):607-609. [PubMed 4078028</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Single dose oral H2-antagonists do not affect plasma lidocaine levels in the parturient. Acta Anaesthesiol Scan. 1989;33(7):593-596. [PubMed 2683547</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Effect of intravenous cimetidine on lignocaine disposition during extradural caesarean section. Anaesthesia. 1989;44(9):739-741. [PubMed 2802120</li>
<li>Dailey PA, Hughes SC, Rosen MA, Healy K, Cheek DB, Shnider SM. Effect of cimetidine and ranitidine on lidocaine concentrations during epidural anesthesia for cesarean section. Anesthesiology. 1988;69(6):1013-1017. [PubMed 3195744</li>
<li>Lidocaine [prescribing information]. Lake Forest, IL: Hospira Inc; April 2013.</li>
<li>Co-Phenylcaine Forte (lidocaine and phenylephrine) [Singapore product labeling]. Singapore: Ziwell Medical (S) Pte Ltd.; October 2015.</li>
<li>Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. Br J Clin Pharmacol. 1984;18(6):907-914. [PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062-1065. [PubMed 3605428</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR, Hudson RJ. Ranitidine does not alter pethidine disposition in man. Br J Clin Pharmacol. 1985;20(1):55-59. [PubMed 4027136]</li>
<li>Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160-166. [PubMed 20233179</li>
<li>Urva S, Bouillaud E, Delaney R, Jappe A, Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2013;53(4):444-450. [PubMed 23426978</li>
<li>Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol. 2011;51(12):1712-1720. [PubMed 21209230</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020</li>
<li>Kiang TKL. Clinical pharmacokinetics and drug-drug interactions of elbasvir/grazoprevir. Eur J Drug Metab Pharmacokinet. 2018;43(5):509-531. [PubMed 29557529</li>
<li>Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; February 2017</li>
<li>Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56-62. [PubMed 25103957</li>
<li>Koch KM, Dees EC, Coker SA, et alThe effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancerCancer Chemother Pharmacol2017;80(6):1141-1146[PubMed 29098381</li>
<li>Vitrakvi (larotrectinib) [prescribing information]. Stamford CT: Loxo Oncology Inc; November 2018</li>
<li>Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191-202. [PubMed 24825095</li>
<li>Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 plus 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652-659. [PubMed 20881954</li>
<li>Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859-1866. [PubMed 16183781</li>
<li>Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol. 1994;46(6):551-555. [PubMed 7995324</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics; November 2019</li>
<li>Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. [PubMed 21870106</li>
<li>Qelbree (viloxazine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Tavneos (avacopan) [prescribing information]. Cincinnati, OH: ChemoCentryx, Inc.; October 2021</li>
<li>Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017</li>
<li>Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15(6):1406-1416. [PubMed 35293131</li>
<li>Vaprisol (conivaptan) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; October 2016</li>
<li>Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53(3):298-305. [PubMed 8453848</li>
<li>Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol. 1993;73(3):180</li>
<li>Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56(5):389-394. [PubMed 11009047</li>
<li>Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</li>
<li>Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126-132. [PubMed 9562227</li>
<li>Nymalize (nimodipine) oral solution [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; December 2020</li>
<li>Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; December 2015.</li>
<li>Tornizol (ornidazole) [South Korea prescribing information]. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199300808. Accessed June 3, 2022</li>
<li>Arrow ornidazole (ornidazole) [New Zealand data sheet]. Auckland, New Zealand: Teva Pharma (New Zealand) Limited; October 2018</li>
<li>Ramesh S, Kumar YS, Rao YM. Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77. [PubMed 17152348]</li>
<li>Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(Suppl 350):102-106. [PubMed 2530759]</li>
<li>Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol. 1988;28(7):649-654. [PubMed 3216031</li>
<li>Luke DR, Rocci ML Jr, Hoholick C. Inhibition of pentoxifylline clearance by cimetidine. J Pharm Sci. 1986;75(2):155-157. [PubMed 3958924]</li>
<li>Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther. 2000;67(3):222-228. [PubMed 10741624]</li>
<li>Yee T, Barakos JA, Knight RT. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med. 1999;170(2):112-115. [PubMed 10063399</li>
<li>Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis. 1994;169(3):689-691. [PubMed 8158054</li>
<li>Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother. 1997;41(6):1256-1259. [PubMed 9174180</li>
<li>Biltricide (praziquantel) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; January 2019.</li>
<li>Inderal (propranolol) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; March 2011</li>
<li>Kirch W, Spahn H, Kohler H, Ohnhaus EE, Mutschler E. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr. 1982;60(22):1401-1407. [PubMed 7176462</li>
<li>Kirch W, Spahn H, Kohler H, Mutschler E. Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine. Arch Toxicol Suppl. 1983;6:379-383. [PubMed 6578746</li>
<li>Kirch W, Kohler H, Spahn H, Mutschler E. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet. 1981;2(8245):531-532. [PubMed 6115283</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17(Suppl 1):51S-57S. [PubMed 6146340</li>
<li>Tateishi T, Ohashi K, Fujimura A, Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992;32(12):1099-1104. [PubMed 1487547</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Comparison of kinetic interactions of nadolol and propranolol with cimetidine. Am Heart J. 1984;108(4 Part 2):1084-1086. [PubMed 6148867</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Kinetic interactions of nadolol and propranolol with cimetidine. Br J Clin Pharmacol. 1984;17(4):486-487. [PubMed 6721996</li>
<li>Donn KH, Powell JR, Rogers JF, Eshelman FNThe influence of H2-receptor antagonists on steady-state concentrations of propranolol and 4-hydroxypropranololJ Clin Pharmacol1984;24(11-12):500-508[PubMed 6150946</li>
<li>Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J. 1981;282(6280)1917-1919. [PubMed 6786672</li>
<li>Reimann IW, Klotz U, Siems B, Frolich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981;12(6):785-790. [PubMed 7340880</li>
<li>Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzneimittelforschung. 1987;37(8):953-956. [PubMed 2890358</li>
<li>Asgharnejad M, Powell JR, Donn KH, Danis M. The effect of cimetidine dose timing on oral propranolol kinetics in adults. J Clin Pharmacol. 1988;28(4):339-343. [PubMed 3392231</li>
<li>Reimann IW, Klotz U, Frolich JC. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther. 1982;32(6):749-757. [PubMed 6291839</li>
<li>Donovan MA, Heagerty AM, Patel L, Castleden M, Pohl JE. Cimetidine and bioavailability of propranolol. Lancet. 1981;1(8212):164. [PubMed 6109849</li>
<li>MacKichan JJ, Boudoulas H, Schall SF. Effect of cimetidine on quinidine bioavailability. Biopharm Drug Dispos. 1989;10(1):121-125. [PubMed 2923957</li>
<li>Hardy BG, Zador IT, Golden L, Lalka D, Schentag JJ. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol. 1983;52(1):172-175. [PubMed 6858908</li>
<li>Kolb KW, Garnett WR, Small RE, Vetrovec GW, Kline BJ, Fox T. Effect of cimetidine on quinidine clearance. Ther Drug Monit. 1984;6(3):306-312. [PubMed 6506138</li>
<li>Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol. 1988;26(8):388-391. [PubMed 3220613</li>
<li>Farringer JA, McWay-Hess K, Clementi WA. Cimetidine-quinidine interaction. Clin Pharm. 1984;3(1):81-83. [PubMed 6697678</li>
<li>Polish LB, Branch RA, Fitzgerald GA. Digitoxin-quinidine interaction: potentiation during administration of cimetidine. South Med J. 1981;74(5):633-634. [PubMed 7244727</li>
<li>Quinidine sulfate [prescribing information]. Laurelton, NY: Epic Pharma LLC; July 2021.</li>
<li>Bohmer GM, Gleiter CH, Morike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol. 2011;51(4):594-602. [PubMed 20484614</li>
<li>Cui X, Huang J, Zheng X, Jiang J, Kuang Y, Hu P. Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: application for a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029-1030:60-67. [PubMed 27423044</li>
<li>Li Q, Wang Y, Liu L, Ma P, Ding L. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in healthy Chinese subjects after single and multiple oral doses. Eur J Drug Metab Pharmacokinet. 2017;42(3):371-381. [PubMed 27306372</li>
<li>Zoryve (roflumilast) cream [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2022</li>
<li>Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</li>
<li>Kim J-R, Jung JA, Kim S, Huh W, Ghim J-L, Shin J-G, Ko J-W. Effect of cilostazol on the pharmacokinetics of simvastatin in healthy subjects. Biomed Res Int. 2019;1365180. [PubMed 30729119</li>
<li>Xu CF, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 23(9):2470-2471. [PubMed 22918879</li>
<li>Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19(1):247. [PubMed 31640597</li>
<li>Poumeaud F, Fontanier A, Dion J, et al. Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report. Front Oncol. 2022;12:1026434. [PubMed 36591506</li>
<li>Huynh T, Cordato D, Yang F. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32(9-10):486-490. [PubMed 12380704</li>
<li>Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; September 2020.</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499]</li>
<li>Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001;15(2):95-99. [PubMed 11264634</li>
<li>Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit. 2005;27(5):587-591. [PubMed 16175131</li>
<li>Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc.; January 2016</li>
<li>Breslin NT, Salerno DM, Topkara VK, et al. Prior amiodarone exposure reduces tacrolimus dosing requirements in heart transplant recipients. Prog Transplant. 2019;29(2):129-134. [PubMed 30845890</li>
<li>Mavyret (glecaprevir/pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2020</li>
<li>Shapiro R, Venkataramaan R, Warty VS, et al. FK 506 interaction with danazol. Lancet. 1993;341(8856):1344-1345. [PubMed 7684106</li>
<li>Seck S, Bellantoni M, Zoccali C, Enia G. Ranolazine can markedly increase tacrolimus blood levels. NDT Plus. 2011;4(1):44-45. [PubMed 25984101</li>
<li>Patni H, Gitman M, Hazzan A, Jhaveri KD. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail. 2012;34(2):251-253. [PubMed 22263871</li>
<li>Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain EPharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant childTransplantation 2012;93(7):e29-e30[PubMed 22450597</li>
<li>Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2013;69(10):1861-1862. [PubMed 23765408</li>
<li>Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2018</li>
<li>Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2020.</li>
<li>Maeda Y, Konishi T, Omoda K, et al. Inhibition of theophylline metabolism by aciclovir. Biol Pharm Bull. 1996;19(12):1591-1595. [PubMed 8996645</li>
<li>Sato J, Nakata H, Owda E, Kikuta T, Umetsu M, Ito K. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J Clin Pharmacol. 1993;44(3):295-298. [PubMed 8491248</li>
<li>Vestal RE, Thummel KE, Musser B, Mercer GD. Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol. 1983;15(4):411-418. [PubMed 6849776</li>
<li>Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med. 1984;144(3):484-486. [PubMed 6322709</li>
<li>Cohen IA, Johnson CE, Berardi RR, Hyneck ML, Achem SR. Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit. 1985;7(4):426-434. [PubMed 4082242</li>
<li>Mulkey PM, Murphy JE, Shleifer NH. Steady-state theophylline pharmacokinetic during and after short-term cimetidine administration. Clin Pharm. 1983;2(5):439-441. [PubMed 6627870</li>
<li>Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 1989;45(5):476-486. [PubMed 2721103</li>
<li>Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982;23(2):129-134. [PubMed 7140802</li>
<li>Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski REffects of tobacco smoking and oral contraceptive use on theophylline dispositionBr J Clin Pharmacol1983;16(3):271-280[PubMed 6626419</li>
<li>Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;24(2):939-941. [PubMed 2444839</li>
<li>Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline. Pharm Weekbl Sci. 1987;11(9 suppl):S72-S75. [PubMed 3481439</li>
<li>Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986;22(6):677-683. [PubMed 3567014</li>
<li>Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest. 1987;92(4):663-669. [PubMed 3477409</li>
<li>Staib AH, Harder S, Fuhr U, Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol. 1989;27(6):289-293. [PubMed 2737798</li>
<li>Miners JO, Wing LM, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol. 1985;20(3):219-223. [PubMed 4041342</li>
<li>Lombardi TP, Bertino JS Jr, Goldberg A, Middleton E Jr, Slaughter RL. The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. J Clin Pharmacol. 1987;27(7):523-529. [PubMed 2888791</li>
<li>Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980;28(4):463-467. [PubMed 7408406</li>
<li>Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41(3):358-362. [PubMed 3816023</li>
<li>Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(suppl 2):77-83. [PubMed 8620674</li>
<li>Spinler SA, Gammaitoni A, Charland SL, Hurwitz J. Propafenone-theophylline interaction. Pharmacotherapy. 1993;13(1):68-71. [PubMed 8437970</li>
<li>Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. Clin Pharmacol Ther. 1992;51(3):353-355. [PubMed 1544292</li>
<li>Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ. Cimetidine-theophylline interaction: report of four patients. Ann Allergy. 1982;48(2):100-102. [PubMed 6121526</li>
<li>Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR. Cimetidine decreases theophylline clearance. Ann Intern Med. 1981;95(1):68-69. [PubMed 7247131</li>
<li>Lofgren RP, Gilbertson RA. Cimetidine and theophylline. Ann Intern Med. 1982;96(3):378. [PubMed 6800293</li>
<li>Mojtahedzadeh M, Sadray S, Hadjibabaie M, Fasihi M, Rezaee S. Determination of theophylline clearance after cimetidine infusion in critically ill patients. J Infus Nurs. 2003;26(4):234-238. [PubMed 12869856</li>
<li>Koren G, Chin TF, Correia J, Tesoro A, MacLeod SM. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. Clin Invest Med. 1985;8(3):222-2[PubMed 4042465</li>
<li>Theo-24 (theophylline anhydrous) [prescribing information]. Malvern, PA; Endo Pharmaceuticals Inc.; August 2017.</li>
<li>Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986;26(5):372-377. [PubMed 3700691</li>
<li>Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157-163. [PubMed 3383988</li>
<li>Adebayo GI, Coker HA. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. Eur J Clin Pharmacol. 1988;34(6):653-656. [PubMed 3169118</li>
<li>Stockley C, Keal J, Rolan P, Bochner F, Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur J Clin Pharmacol. 1986;31(2): 235-237. [PubMed 3803421</li>
<li>Dey NG, Castleden CM, Ward J, Cornhill J, McBurney A. The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol. 1983;16(4):438-440. [PubMed 6626438]</li>
<li>Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983;16(6):743-746. [PubMed 6140941</li>
<li>Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol. 1998;28(3):228-233. [PubMed 3360971</li>
<li>Pourbaix S. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Britton ML, Waller ES. Central nervous system toxicity associated with concurrent use of triazolam and cimetidine. Drug Intell Clin Pharm. 1985;19(9):666-668. [PubMed 40428607. Parker WA, MacLachlan RA. Prolonged hypnotic response to triazolam-cimetidine combination in an elderly patient. Drug Intell Clin Pharm. 1984;18(12):980-981. [PubMed 6150838]</li>
<li>Curry SH, De Vane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433. [PubMed 3912187</li>
<li>Amsterdam JD, Brunswick DJ, Potter L, et al. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology. 1984;83:373-375. [PubMed 6436867</li>
<li>Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. [PubMed 3950073</li>
<li>Sutherland DL, Remillard AJ, Haight KR, et al. The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. Eur J Clin Pharmacol. 1987;32:159-164. [PubMed 3582480</li>
<li>Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. [PubMed 379426</li>
<li>Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. [PubMed 6692646</li>
<li>Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229(3):702-705. [PubMed 6726654</li>
<li>Brown MA, Haight KR, McKay G. Cimetidine-doxepin interaction. J Clin Psychopharmacol. 1985;5:245-247. [PubMed 4019813</li>
<li>Shapiro PACimetidine-imipramine interaction: case report and commentsAm J Psychiatry1984;141:152[PubMed 6691449</li>
<li>Miller DD, Macklin M. Cimetidine-imipramine interaction: a case report. Am J Psychiatry. 1983;140:351. [PubMed 6829810</li>
<li>Miller DD, Sawyer JB, Duffy JP. Cimetidine’s effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm. 1983;17(12):904-905. [PubMed 6653407</li>
<li>Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther. 1987;42:278-282. [PubMed 3621787]</li>
<li>Urasap (urapidil) [Summary of Product Characteristics]. Frosinone, Italy: INCA-Pharm Srl; September 2012.</li>
<li>De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46(2):458-463. [PubMed 11796358</li>
<li>Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2010.</li>
<li>Desager JP, Harvengt C, Bianchetti G, Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int J Clin Pharmacol Ther Toxicol. 1993;31(11):568-571. [PubMed 7904983]</li>
<li>Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; November 2022</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Hendset M, Molden E, Enoksen TB, et al. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit. 2010;32(6):787-790. [PubMed 21068650</li>
<li>Abilify Maintena (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; January 2020</li>
<li>Abilify Asimtufii (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; April 2023.</li>
<li>Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20(1):55-64. [PubMed 15770075</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44(11):1850-1854. [PubMed 20978219</li>
<li>Qulipta (atogepant) [prescribing information]. Dublin, Ireland: Forest Laboratories Ireland Ltd; September 2021.</li>
<li>Ortikos (budesonide) extended-release capsules [prescribing information]. Sun Pharmaceutical Industries, Inc.; June 2019.</li>
<li>Buspirone [prescribing information]. Laurelton, NY: Epic Pharma LLC; May 2020</li>
<li>Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ. Lack of interaction between cimetidine and buspirone. Pharmacotherapy. 1987;7(3):72-79. [PubMed 2888096]</li>
<li>Epidiolex (cannabidiol) oral solution [prescribing information]. Carlsbad, CA: Greenwich Biosciences Inc; October 2020</li>
<li>Thai C, Tayo B, Critchley D. A phase I open-label, fixed sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(11):1279-1289. [PubMed 33951339</li>
<li>Beach CA, Mays DC, Guiler RC, Jacober CH, Gerber N. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986;39(3):265-270. [PubMed 3948467</li>
<li>Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol. 1995;48(2):161-166. [PubMed 7589032</li>
<li>Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425-428. [PubMed 4029248</li>
<li>Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther. 1999;65(3):262-274. [PubMed 10096258</li>
<li>Pegintron (peginterferon alfa-2b) [prescribing information]Whitehouse Station, NJ: Merck &amp; Co Inc; January 2019</li>
<li>Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988;35(6):651-656. [PubMed 2853056</li>
<li>Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45(3):234-240. [PubMed 2920498</li>
<li>Michaud V, Mouksassi MS, Labbe L, et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit. 2006;28(6):779-783. [PubMed 17164694</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Coreg (carvedilol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</li>
<li>Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104(12):3116-3117. [PubMed 19956146]</li>
<li>Rize (clotiazepam) [KR prescribing information]. Available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802970]. Accessed [January 30, 2023]</li>
<li>Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H. Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol. 1984;26(1):55-59. [PubMed 6143670]</li>
<li>Mitigare (colchicine) capsule [prescribing information]. Memphis, TN: Hikma Americas, Inc.; September 2014.</li>
<li>Enablex (darifenacin) [prescribing information]. Rockaway, NJ: Warner Chilcott US LLC; March 2012.</li>
<li>Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15(1):18-24. [PubMed 8451775</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997;62(2):145-156. [PubMed 9284850</li>
<li>Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008</li>
<li>Effexor (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017</li>
<li>Norvir (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2019</li>
<li>Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664-674. [PubMed 16338282</li>
<li>Orladeyo (berotralstat) [prescribing information]Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989;146(12):1611-1613. [PubMed 2486749</li>
<li>Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329-336. [PubMed 2288330</li>
<li>Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit. 1992;14(3):194-196. [PubMed 1412604</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res. 1993;13(3):167-171. [PubMed 8225700</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15(3):243-246. [PubMed 8333005]</li>
<li>Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017</li>
<li>Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70(9):1115-1122. [PubMed 25028073</li>
<li>Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacol (Berl). 1998;135(1):22-26. [PubMed 9489930</li>
<li>Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(4):747-755. [PubMed 24013574</li>
<li>Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020</li>
<li>Qelbree (viloxazine) [prescribing information]Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Saphris (asenapine) [prescribing information]. Irvine, CA: Allergan USA Inc; February 2017</li>
<li>Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64(3):257-268. [PubMed 9757149]</li>
<li>Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother Pharmacol. 1999;43(2):126-132. [PubMed 9923817]</li>
<li>Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer Inc.; June 2016</li>
<li>Cardura XL (doxazosin extended-release) [prescribing information]. New York, NY: Pfizer Inc.; February 2017.</li>
<li>Cerdelga (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2018</li>
<li>Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</li>
<li>Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14-23. [PubMed 11180034</li>
<li>Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50(3):203-208. [PubMed 8737760</li>
<li>Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. 2002;72(3):247-255. [PubMed 12235445]</li>
<li>Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77(1):17-23. [PubMed 15637527]</li>
<li>Flecainide [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals Pvt. Ltd.; September 2017</li>
<li>Tjandra-Maga TB, van Hecken A, van Melle P, Verbesselt R, de Schepper PJAltered pharmacokinetics of oral flecainide by cimetidineBr J Clin Pharmacol1986;22(1):108-110[PubMed 3741720]</li>
<li>Sullivan KM, Small RE, Rock WL, Cox SR, Willis HE. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm. 1986;5(7):586-589. [PubMed 3742949</li>
<li>Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol. 1990;30(7):660-664. [PubMed 2391398]</li>
<li>Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507. [PubMed 20573085</li>
<li>Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514]</li>
<li>Dumitras S, Sechaud R, Drollmann A, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771-779. [PubMed 24040847]</li>
<li>Zircol (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013</li>
<li>Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:31S-36S. [PubMed 11879257</li>
<li>Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-581. [PubMed 15365656]</li>
<li>Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</li>
<li>Luder PJ, Siffert B, Witassek F, et al. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31(4):443-448. [PubMed 3816925</li>
<li>Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24(3):390-392. [PubMed 3663452]</li>
<li>Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319-1321. [PubMed 15541258</li>
<li>Garimella T, Tao X, Sims K, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R D. 2018;18(1):55-65. [PubMed 29255971</li>
<li>Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130-137. [PubMed 12891223</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67-70. [PubMed 2917591</li>
<li>Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466-477. [PubMed 10824625</li>
<li>Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113-123. [PubMed 14748763</li>
<li>Thibault N, Ibrahim J, Peterschmitt MJ, et al. Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Mol Genet Metab. 2020;129(4):278-285. [PubMed 32029355</li>
<li>Lexapro (escitalopram) [prescribing information]Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28-34. [PubMed 17224709</li>
<li>Ogasawara K, LoRusso PM, Olszanski AJ, et al. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol. 2020;86(1):87-95. [PubMed 32537715</li>
<li>Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol. 1987;31(5):575-578. [PubMed 3830242</li>
<li>Laurent-Kenesi MA, Brentano-Funck C, Poirier JM, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 1993;36(6):531-538. [PubMed 12959269</li>
<li>Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24(2):213-220. [PubMed 3620296</li>
<li>Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Cho DY, Bae SH, Lee JK, et al. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica. 2015;45(3):256-263. [PubMed 25268386</li>
<li>Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2015</li>
<li>Effexor XR (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</li>
<li>Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's Disease. Biopharmaceut Drug Dispos. 1988;9(2):219-227. [PubMed 2897213</li>
<li>Loft S, Dossing M, Sonne J, Dalhof K, Bjerrum K, Poulsen HE. Lack of effect of cimetidine on the pharmacokinetics of metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol. 1988;35(1):65-68. [PubMed 3220096</li>
<li>Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. Eur J Clin Pharmacol. 1987;32(1):35-41. [PubMed 3582467</li>
<li>Gugler R, Jensen JC. Interaction between cimetidine and metronidazole. N Eng J Med 1983;309(24):1518-1519. [PubMed 6646177</li>
<li>Viaflex Plus Container (metronidazole injection) [prescribing information]. Deefield, IL: Baxter Healthcare Corporation; December 2017</li>
<li>Pearce RE, Cohen-Wolkowiez M, Sampson MR,Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013;41(9):1686-1694. [PubMed 23813797</li>
<li>Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE . Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol. 1991;41(8):1127-1134. [PubMed 2009091]</li>
<li>Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; November 2019.</li>
<li>Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the h2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 1997;43(2):201-204. [PubMed 9131955]</li>
<li>Bendayan R, Sullivan JR, Shaw C, et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol. 1990;38:165-169. [PubMed 2338114</li>
<li>Bendayan R, Kennedy G, Frecker RC, Sellers EM. Lack of effect of cimetidine on cigarette smoking. Eur J Clin Pharmacol. 1993;44(1):51-55. [PubMed 8436155]</li>
<li>Ochs HR, Greenblatt DJ, Gugler R, Muntefering G, Locniskar A, Abernethy DR. Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther. 1983;34(2):227-230. [PubMed 6872417</li>
<li>Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</li>
<li>Fine A, Churchill DN, “Potentially Lethal Interaction of Cimetidine and Morphine,” Can Med Assoc J, 1981, 124(11):1434</li>
<li>[PubMed 7237324</li>
<li>Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010</li>
<li>Gogas KR, Hough LB, Eberle NB, et al, “A Role for Histamine and H2-Receptors in Opioid Antinociception,” J Pharmacol Exp Ther, 1989, 250(2):476-84. [PubMed 2547933</li>
<li>Bluhm R, Zsigmond EK, Winnie AP, “Potentiation of Opioid Analgesia by H1 and H2 Antagonists,” Life Sci, 1982, 31(12-13):1229-32. [PubMed 6128651</li>
<li>Robertson JA, Hough LB, Bodnar RJ, “Potentiation of Opioid and Nonopioid Forms of Swim Analgesia by Cimetidine,” Pharmacol Biochem Behav, 1988, 31(1):107-12. [PubMed 2855266</li>
<li>Lam AM, Clement JL, “Effect of Cimetidine Premedication on Morphine-Induced Ventilatory Depression,” Can Anaesth Soc J, 1984, 31(1):36-43. [PubMed 6420025</li>
<li>Mojaverian P, Fedder IL, Vlasses PH, et al, “Cimetidine Does Not Alter Morphine Disposition in Man,” Br J Clin Pharmacol, 1982, 14(6):809-13. [PubMed 7150459</li>
<li>Dawson GW, Vestal RE, “Cimetidine Inhibits the In Vitro N-Demethylation of Methadone,” Res Commun Chem Pathol Pharmacol, 1984, 46(2):301</li>
<li>[PubMed 6515123</li>
<li>Guay DR, Meatherall RC, Chalmers JL, et al, “Cimetidine Alters Pethidine Disposition in Man,” Br J Clin Pharmacol, 1984, 18(6):907-14[PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, et al, “Meperidine-Induced Delirium,” Am J Psychiatry, 1987, 144(8):1062</li>
<li>Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014</li>
<li>Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005;28(2):328-334. [PubMed 15684493</li>
<li>Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull. 2004;27(5):684-690. [PubMed 15133245]</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S. [PubMed 6146340</li>
<li>Spahn H, Kirch W, Mutschler E. The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol. Br J Clin Pharmacol. 1983;15(4):500-501. [PubMed 6849789</li>
<li>Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016</li>
<li>Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992;51(4):379-387. [PubMed 1563208]</li>
<li>Pritchett EL, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol. 1988;28(7):619-624. [PubMed 3063727]</li>
<li>Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; December 2017.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53(suppl 1):31S-36S. [PubMed 11879257</li>
<li>Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; February 2018.</li>
<li>Lamisil (terbinafine hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016</li>
<li>Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219. [PubMed 9382559]</li>
<li>Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol. 1993;45(1):41-46. [PubMed 8405028]</li>
<li>Jonderko G, Jonderko K, Marcisz C, Kotulska A. Effect of cimetidine and ranitidine on absorption of [125]levothyroxine administered orally. Zhongguo Yao Li Xue Bao. 1992;13(5):391-394. [PubMed 1300037</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075]</li>
<li>Gabitril (tiagabine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2015.</li>
<li>Spiriva (tiotropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2015.</li>
<li>Conzip (tramadol) extended-release capsules [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC; March 2021.</li>
<li>Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Inc; February 2019.</li>
<li>Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):51-55. [PubMed 14616414</li>
<li>Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother. 2009;53(4):1712-1714. [PubMed 19171800</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; April 2019.</li>
<li>Wang K, Yao X, Zhang M, et al. Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):441-454. [PubMed 33687157]</li>
<li>de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55-59. [PubMed 31865063</li>
<li>Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019;10:2042098619854007. doi: 10.1177/2042098619854007. [PubMed 31258887</li>
<li>Tsai SC, Sheu SY, Chien LN, Lee HC, Yuan EJ, Yuan RY. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000-2009. [PubMed 29745438</li>
<li>Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780-1782. [PubMed 7500509</li>
<li>Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med. 1986;146(10):2070-2071. [PubMed 3767555</li>
<li>Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J. 2010;103(2):178-180. [PubMed 20065895</li>
<li>Corsini GU, Zompo MD, Cianchetti C, et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacologia. 1976;47(2):169-173. [PubMed 1273213</li>
<li>Tarsy D, Parkes JD, Marsden CD. Metoclopramide in parkinsonism. Lancet. 1975;1(7918):1244-1245. [PubMed 48872</li>
<li>Tarsy D, Parkes JD, Marsden CDMetoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesiasJ Neurol Neurosurg Psychiatry1975;38(4):331-335[PubMed 1095689</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020</li>
<li>Migramax (aspirin and metoclopramide) [summary of product characteristics]. London, United Kingdom: Zentiva Pharma UK Limited; March 2022.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; August 2017</li>
<li>Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC. 2013;13:152. [PubMed 23714238</li>
<li>Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004;44(6):661-665. [PubMed 15637848</li>
<li>Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ. 1988;297(6654):964-965. [PubMed 3142568</li>
<li>Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J. 1991;84(5):626-628. [PubMed 2035085</li>
<li>Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolid-fluoxetine and olanzapine-metoclopramide interactions: a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission. Case Rep Med. 2016;2016:7128909. [PubMed 27433163]</li>
<li>Cabergoline [prescribing information]. Peapack, NJ: Greenstrone LLC; November 2019.</li>
<li>Barnes TR, Braude WM, Hill DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2(8288):48-49. [PubMed 6123780</li>
<li>Metoclopramide [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; July 2021</li>
<li>Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000;23(Suppl):S64-S70. [PubMed 11052222</li>
<li>Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. [PubMed 19886950</li>
<li>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446]</li>
<li>Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.</li>
<li>Patterson JF. Metoclopramide therapy of MAOI orthostatic hypotension. J Clin Psychopharmacol. 1987;7(2):112-113. [PubMed 3584514]</li>
<li>Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</li>
<li>Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009</li>
<li>Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” Trends Neurosci, 2000, 23(Suppl):S64-70. [PubMed 11052222</li>
<li>Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” Aliment Pharmacol Ther, 2010, 31(1):11</li>
<li>Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” Ann Pharmacother, 2008, 42(9):1290</li>
<li>Trelstar (triptorelin) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions, LLC; December 2018</li>
<li>Trelstar (triptorelin) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc.; September 2022.</li>
<li>Prescribing information. Malarone (atovaquone and proguanil). Research Triangle Park, NC: GlaxoSmithKline, 02/2013.</li>
<li>Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos. 2006;27(6):285-289. [PubMed 16770757</li>
<li>Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-2281. [PubMed 27621638</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020.</li>
<li>Mehta D, Bradley EL Jr, Kissin I. Metoclopramide decreases thiopental hypnotic requirements. Anesth Analg. 1993;77(4):784-787. [PubMed 8214666</li>
<li>Thiopental sodium [Summary of Product Characteristics]. Berkshire, UK: Archimedes Pharma UK Limited; January 2014.</li>
<li>Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013</li>
<li>Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990;39(6):1045-1053. [PubMed 2322292]</li>
<li>Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011</li>
<li>Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015</li>
<li>Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015</li>
<li>Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.</li>
<li>Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: Ani Pharmaceuticals Inc; August 2017.</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation. 1987;43(2):211-213. [PubMed 3544377</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant patients. Transplant Proc. 1988;20(2 suppl 2):487-490. [PubMed 3284095</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017.</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932]</li>
<li>Aczone (dapsone) gel [prescribing information]. Irvine, CA: Allergan, Inc.; July 2015.</li>
<li>Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</li>
<li>Gamble JA, Gaston JH, Nair SG, Dundee JW. Some pharmacological factors influencing the absorption of diazepam following oral administration. Br J Anaesth. 1976;48(12):1181-1185. [PubMed 1023954</li>
<li>Chapman MH, Woolner DF, Begg EJ, Atkinson HC, Sharman JR. Coadministered oral metoclopramide does not enhance the rate of absorption of oral diazepam. Anaesth Intensive Care. 1988;16(2):202-205. [PubMed 3394914]</li>
<li>Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinetic. 1986;11(4):249-250. [PubMed 3582418</li>
<li>Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984;36(6):724-730. [PubMed 6499354</li>
<li>Schwartz BG. Metoclopramide and digoxin cause 22 episodes of bradyarrhythmias. Am J Med. 2010;123(6):e5</li>
<li>[PubMed 20569744</li>
<li>Johnson BG, O'Grady J, Bye C. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. Br J Clin Pharmacol. 1978;5(5):465-467. [PubMed 656287]</li>
<li>Monurol (fosfomycin) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2018.</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One. 2013;8(11):e81208. [PubMed 24278396</li>
<li>Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6(9):e23728. [PubMed 21961030</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015</li>
<li>Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488</li>
<li>Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662]</li>
<li>Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.</li>
<li>Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016</li>
<li>Synera (lidocaine and tetracaine) topical patch [prescribing information]. Souderton, PA: Galen US Inc; March 2014</li>
<li>Pliaglis (lidocaine and tetracaine) cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; November 2013</li>
<li>Citanest plain (prilocaine) [prescribing information]. York, PA: Dentsply Pharmaceutical; June 2010</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006</li>
<li>Marcaine Spinal (bupivacaine hydrochloride in dextrose injection, USP) [prescribing information]. Lake Forest, IL: Hospira, Inc.; November 2018</li>
<li>Lardieri AB, Crew PE, McCulley L, Kim IE, Waldron P, Diak IL. Cases of benzocaine-associated methemoglobinemia identified in the FDA adverse event reporting system and the literature [published online January 2, 2019]. Ann Pharmacother. doi: 10.1177/1060028018823532. [PubMed 30600685]</li>
<li>Tercan M, Efe EM, Turker G, et al. Do metoclopramide and ondansetrone alter mivacurium-induced neuromuscular blockade? - a randomised trial. Braz J Anesthesiol. 2014;64(1):35-39. [PubMed 24565386</li>
<li>El Ayass N, Hendrickx P. Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized double blind placebo-controlled study. Eur J Anaesthesiol. 2005;22(3):197-201. [PubMed 15852992</li>
<li>Motamed C, Kirov K, Combes X, Dhonneur G, Duvaldestin P. Effect of metoclopramide on mivacurium-induced neuromuscular block. Acta Anaesthesiol Scand. 2002;46(2):214-216. [PubMed 11942874</li>
<li>Skinner HJ, Girling KJ, Whitehurst A, Nathanson MH. Influence of metoclopramide on plasma cholinesterase and duration of action of mivacurium. Br J Anaesth. 1999;82(4):542-545. [PubMed 10472219</li>
<li>Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth. 1990;65(2):220-224. [PubMed 2223340</li>
<li>Kambam JR, Parris WC, Franks JJ, Sastry BV, Naukam R, Smith BE. The inhibitory effect of metoclopramide on plasma cholinesterase activity. Can J Anaesth. 1988;35(5):476-478. [PubMed 3273154]</li>
<li>Inomax (nitric oxide) [prescribing information]. Hampton, NJ: INO Therapeutics; March 2013</li>
<li>Genosyl (nitric oxide) [prescribing information]. Atlanta, GA: Vero Biotech; December 2019</li>
<li>Sinisterra S, Miravet E, Alfonso I, et al. Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic. J Pediatr. 2002;141(2):285-286. [PubMed 12183731</li>
<li>Lopez A, Bernardo B, Lopez-Herce J, et al. Methaemoglobinaemia secondary to treatment with trimethoprim and sulphamethoxazole associated with inhaled nitric oxide. Acta Paediatr. 1999;88(8):915-916. [PubMed 10503695</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006.</li>
<li>Metozolv ODT (metoclopramide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2011.</li>
<li>Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011;67(6):591-599. [PubMed 21161196</li>
<li>PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PMID: 19075045</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013.</li>
<li>Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006</li>
<li>Skold A, Cosco DL and Klein R, “Methemoglobinemia: Pathogenesis, Diagnosis, and Management,” South Med J, 2011, 104(11):757-61. [PubMed 22024786</li>
<li>Mansouri A and Lurie AA, “Concise Review: Methemoglobinemia,” Am J Hematol, 1993, 42(1):7-12. [PubMed 8416301]</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022</li>
<li>Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</li>
<li>Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced serotonin syndrome. Intern Med. 2017;56(6):737-739. [PubMed 28321081</li>
<li>Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002;36(1):67-71. [PubMed 11816261</li>
<li>Aussedat M, Lavoie A, Bussieres JF, Kleiber N. Suspected overlap between serotonin syndrome and neuroleptic malignant syndrome in a child treated with metoclopramide? J Pediatr Pharmacol Ther. 2020;25(6):552-558. [PubMed 32839660</li>
<li>Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664</li>
<li>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718</li>
<li>Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713</li>
<li>Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil. 2009;21(12):1235-1238. [PubMed 19906028]</li>
<li>Provenzani A, D'alessandro N, Polidori P. Toxic tacrolimus concentrations associated with intravenous use of metoclopramide in a lung transplant patient. Ann Pharmacother. 2019;53(5):548-549. [PubMed 30739475</li>
<li>Prescott WA Jr, Callahan PL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 2004;24(4):532-537. [PubMed 15098810</li>
<li>Wadhw NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019.</li>
<li>Prescribing information. Baltimore, MD: Cangene BioPharma, Inc., 2/2012</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</li>
<li>Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology. 1989;70(6):905-908. [PubMed 2658689</li>
<li>Turner DR, Kao YJ, Bivona C. Neuromuscular block by suxamethonium following treatment with histamine type 2 antagonists or metoclopramide. Br J Anaesth. 1989;63(3):348-350. [PubMed 2572248</li>
<li>Dell-Kuster S, Levano S, Burkhart CS, et al. Predictors of the variability in neuromuscular block duration following succinylcholine: A prospective, observational study. Eur J Anaesthesiol. 2015;32(10):687-696. [PubMed 26213905</li>
<li>Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” Br Med J, 1973, 1:587. [PubMed 4694406</li>
<li>Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” Br J Clin Pharmacol, 1981, 11:430-1P</li>
<li>Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” J Pharm Pharmacol, 2001, 53(7):1041</li>
<li>[PubMed 11480539</li>
<li>van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” Methods Find Exp Clin Pharmacol, 1990, 12(4):291</li>
<li>[PubMed 2374477</li>
<li>van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” Methods Find Exp Clin Pharmacol, 1992, 14(5):379-82. [PubMed 1513194</li>
<li>Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” Br J Clin Pharmacol, 1983, 15(4):487</li>
<li>[PubMed 6849786</li>
<li>Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” Cephalalgia, 1988, 8(3):139-47. [PubMed 31970094</li>
<li>Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” Eur J Clin Pharmacol, 1992, 42(2):235</li>
<li>[PubMed 1618258]</li>
<li>Kaukab I, Shah SNH, Kharaba ZJ, Buabeid MA, Alfoteih YA, Murtaza G. Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake. Expert Opin Metab Toxicol. 2020;16(8):735-740. [PubMed 32524862]</li>
<li>Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013;28(2):99-105. [PubMed 23221858</li>
<li>Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559</li>
<li>Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. [PubMed 18809731</li>
<li>Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018</li>
<li>Khedezla (desvenlafaxine) [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; August 2017.</li>
<li>Moffett PM, Cartwright L, Grossart EA, O’Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23(1):102-105. [PubMed 26720490</li>
<li>Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-58. [PubMed 22046106</li>
<li>Tracz K, Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br J Clin Pharmacol. 2015;79(4):669-676. [PubMed 25293524</li>
<li>Obal D, Yang D, Sessler DI. Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Mayo Clin Proc. 2014;89(1):69-80. [PubMed 24388024</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder TClinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort studyBr J Clin Pharmacol2009;67(3):347-354[PubMed 19523015</li>
<li>Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105(2):389-395. [PubMed 8306734</li>
<li>Kroll CR, Gettes LS. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol. 2002;13(9):936-938. [PubMed 12380935</li>
<li>Otsuka M, Kanamori H, Sasaki S, et al. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med. 1997;36(10):705-708. [PubMed 9372331</li>
<li>Farguhar Zanetti LA, Oliphant CM. Pentamidine-induced torsades de pointes. Ann Pharmacother. 1994;28(2):282-283. [PubMed 8173154</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</li>
<li>Matsuo J, Yamaori S. Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. [published online ahead of print] J Clin Pharm Ther. 2021. doi:10.1111/jcpt.13539. [PubMed 34664726</li>
<li>Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther. 1988;43(5):577-581. [PubMed 3365919</li>
<li>Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol. 2003;41(8):1199-1201. [PubMed 12842189</li>
<li>Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality. 1991;3(1):14-18. [PubMed 2039678</li>
<li>Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</li>
<li>Kaukab I, Shah SNH, Abrar MA, Anwer N, Murtaza G. Influence of rifampicin pre-treatment on the in vivo pharmacokinetics of metoclopramide in Pakistani healthy volunteers following concurrent oral administration. Curr Drug Metab. 2020;21(4):301-306. [PubMed 32407272]</li>
<li>Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003:31(5):631-636. [PubMed 12695352]</li>
<li>Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.</li>
<li>Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2016;37(1):15-27. [PubMed 26356245</li>
<li>Pham CP, de Feiter PW, van der Kuy PHM, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7-8):1456-1461. [PubMed 16849620</li>
<li>Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc.; March 2015.</li>
<li>Yoshizato T, Kotegawa T, Imai H, et al. Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol. 2012;68(9):1287-1294. [PubMed 22418831</li>
<li>Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411-421. [PubMed 21883386</li>
<li>Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63(6):656</li>
<li>[PubMed 18477279</li>
<li>Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179(3):172. [PubMed 12885276</li>
<li>Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron. 2002;90(2):234</li>
<li>[PubMed 11818715</li>
<li>Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009;2009. [PubMed 21931583</li>
<li>Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum Mal Osteoartic. 1992;59(4):281</li>
<li>(Article in French) [PubMed 1496277</li>
<li>Collidge TA, Razvi S, Nolan C, et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barre syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med. 2010;27(6):696-700. [PubMed 20546290</li>
<li>Kearney S, Carr AS, McConville J, McCarron MO, Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ. 2012;345:e6562. [PubMed 23047962</li>
<li>O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325</li>
<li>[PubMed 18644925</li>
<li>Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka EAcute rhabdomyolysis after atorvastatin and fusidic acid therapyAm J Med2000;109(1)</li>
<li>[PubMed 10991749</li>
<li>Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33</li>
<li>Xelenta (lefamulin) [prescribing information]. Ireland: Nabriva Therapeutics US, Inc.; August 2019.</li>
<li>Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213-1217. [PubMed 21732066</li>
<li>Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46(8):722-730. [PubMed 2665687</li>
<li>Orap (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon VRisk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugsJ Clin Psychopharmacol2017;37(5):540-545[PubMed 28817488</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2019</li>
<li>Panos G, Velissaris D, Karamouzos V, Matzaroglou C, Tylianakis M. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295-300. [PubMed 27125217</li>
<li>Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. [PubMed 20297862</li>
<li>Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355-2358. [PubMed 28475803</li>
<li>Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301-311. [PubMed 19646076</li>
<li>Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726-1734. [PubMed 16705579]</li>
<li>van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-1014. [PubMed 20925438</li>
<li>Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421-424. [PubMed 25828198</li>
<li>Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888. [PubMed 20652862</li>
<li>Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663-666. [PubMed 18589449</li>
<li>Vieira MC, Miyague NI, Van Steen K, et al. Effects of domperidone on QTc interval in infants. Acta Paediatr. 2012;101(5):494-496. [PubMed 22226330</li>
<li>Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-723. [PubMed 15690231</li>
<li>Digby G, Machaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17(2):184-188. [PubMed 20544619</li>
<li>Fais P, Vermiglio E, Laposata C, et al. A case of sudden cardiac death following Domperidone self-medication. Forensic Sci Int. 2015;254:e1-e3. [PubMed 26119456</li>
<li>Domperidone [product monograph]Toronto, Ontario, Canada: Apotex Inc; March 2015</li>
<li>Xalkori (crizotinib) [prescribing information]. New York, NY: Pfizer Inc; March 2016</li>
<li>Kisqali (ribociclib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2017</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2018</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et alDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes2013;6(4):479-487[PubMed 23716032</li>
<li>Rocha CM, Barbosa MMQT interval prolongation associated with the oral use of domperidone in an infantPediatr Cardiol2005;26(5):720-723[PubMed 15690231</li>
<li>Romero J, Baldinger SH, Goodman-Meza D, et al. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol. 2016;45(1):37-45. [PubMed 26589717</li>
<li>Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. 2012;52(4):520-529. [PubMed 21558456</li>
<li>Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk AClarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reportsTher Adv Infect Dis2013;1(4):121-138[PubMed 25165548</li>
<li>Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2017</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019</li>
<li>Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204. [PubMed 20673553</li>
<li>Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. [PubMed 16317317</li>
<li>Meyer-MassettiC, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et alThe FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med2010;5(4):E8-16[PubMed 20394022</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketin analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon VDevelopment of a risk score for QTc-prolongation: the RISQ-PATH studyInt J Clin Pharm2017;39(2):424-432[PubMed 28281228</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsaes de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Parlodel (bromocriptine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; July 2021</li>
<li>Bromocriptine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.</li>
<li>Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2019</li>
<li>Sangana R, Gu H, Chun DY, Einolf HJ. Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches. Drug Metab Dispos. 2018;46(1):26-32. [PubMed 29038231]</li>
<li>Devandla A, Yamsani SK, Yamsani MR. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers. Drug Metab Pers Ther. 2015;30(4):257-261. [PubMed 26353177]</li>
<li>Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287</li>
<li>Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E16. [PubMed 20394022</li>
<li>Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262-268. [PubMed 15231861</li>
<li>Kitagawa K, Kawada K, Morita S, et al. Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 2012;23(3):743-747. [PubMed 21690231</li>
<li>Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16(11):3019-3027. [PubMed 20501625</li>
<li>Kim H-H, An SH, Cho YH, Kim S-Y, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013;52(6):1223-1224. [PubMed 23368679</li>
<li>Chung LW, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156-157. [PubMed 18618340</li>
<li>Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. [PubMed 20529041</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJThe FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med2010;5(4):E8-E16[PubMed 20394022</li>
<li>Product monograph. Dom-Domperidone (domperidone). Montreal, Quebec, Canada: Dominion Pharmaceutical, May 2012.</li>
<li>Min JJ, Lee J, Lee H-C, Ryu H-G, Shin M, Kim HJ. A comparison of the effects of sevoflurane and desflurane on corrected QT interval prolongation in patients undergoing living donor liver transplantation: a prospective observational study. Transplant Proc. 2016;48(1):96-101. [PubMed 26915850</li>
<li>Bestas A, Hanbeyoglu O, Keles E, Bayar MK. The effect of adrenaline on desflurane-induced prolonged QTc interval: a randomized double-blind trial. Eur Rev Med Pharmacol Sci. 2013;17(11):1523-1528. [PubMed 23771541</li>
<li>Liu Y, Fu X, Gao H, Ren Y, Li H, He Y, Wang G. Effects of different concentrations of desflurane on the index of cardiac electrophysiological balance in gynecologic surgery patients. Can J Physiol Pharmacol. 2020;98(5):332-335. [PubMed 31770012</li>
<li>Aypar E, Karagoz AH, Ozer S, Celiker A, Ocal T. The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac rhythm in children. Paediatr Anaesth. 2007;17(6):563-567. [PubMed 17498019</li>
<li>Owczuk R, Wujtewicz MA, Sawicka W,Lasek J, Wujtewicz M. The influence of desflurane on QTc interval. Anesth Analg. 2005;101(2):419-422. [PubMed 16037155</li>
<li>Lindgren L, Saarnivaara L. Cardiovascular responses to enflurane induction followed by suxamethonium in children. Br J Anaesth. 1983;55(4):269-273. [PubMed 6838741</li>
<li>Lindgren L. E.C.G. changes during halothane and enflurane anaesthesia for E.N.T. surgery in children. Br J Anaesth. 1981;53(6):653-662. [PubMed 7248128</li>
<li>Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol. 2001;67(9):637-640. [PubMed 11731753</li>
<li>Kuenszberg E, Loeckinger A, Kleinsasser A, Lindner KH, Peuhringer F, Hoermann CSevoflurane progressively prolongs the QT interval in unpremedicated female adultsEur J Anaesthesiol2000;17(11):662-664[PubMed 11029563</li>
<li>Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, Lindner KH, Peuhringer F. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg. 2000;90(1):25-27. [PubMed 10624970</li>
<li>Silay E, Kati I, Tekin M, Guler N, Huseyinoglu UA, Coskuner I, Yagmur C. Comparison of the effects of desflurane and sevoflurane on the QTc interval and QT dispersion. Acta Cardiol. 2005;60(5):459-464. [PubMed 16261774</li>
<li>Thiruvenkatarajan V, Osborn KD, Van Wijk RMAW, Euler P, Sethi R, Moodie S, Biradar V. Torsade de pointes in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia. Anaesth Intensive Care. 2010;38(3):555-559. [PubMed 20514968</li>
<li>Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg. 1998;86(4):701-702. [PubMed 9539586</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E[PubMed 20394022</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 220664]</li>
<li>L’Hommedieu CS, Nicholas D, Armes DA, et al, “Potentiation of Magnesium Sulfate-Induced Neuromuscular Weakness by Gentamicin, Tobramycin, and Amikacin,” J Pediatr, 1983, 102(4):629-31. [PubMed 6834204]</li>
<li>Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994;38(2):326-329. [PubMed 7910724</li>
<li>Nix DE, Watson WA, Handy L, et al. The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin. Pharmacotherapy. 1989;9(6):377-380. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum. Antimicrob Agents Chemother. 1990;34:931-933. [PubMed 2360833</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al. Combined Use of Ciprofloxacin and Sucralfate. DICP. 1991;25:578-582. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin Levels When Receiving Sucralfate. JAMA. 1989;262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin. Antimicrob Agents Chemother. 1989;33(1):99-102. [PubMed 2712548</li>
<li>Lehto PL, Kivisto KT. Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin. Antimicrob Agents Chemother. 1994;38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al. Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers. Antimicrob Agents Chemother. 1992;36:2785-2760. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al. The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers. Eur J Clin Pharmacol. 1994;47(1):67-69. [PubMed 7988627</li>
<li>Zix JAPharmacokinetics of Sparfloxacin and Interaction With Cisapride and SucralfateAntimicrob Agents Chemother1997;41:1668-1672[PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al. The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin. Br J Clin Pharmacol. 2000;49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al. The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers. Int J Antimicrob Agents. 2000;15(4):283-289. [PubMed 10929878</li>
<li>Stass H, Schuhly U, Moller JG, et al. Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, A Novel 8-methoxyfluoroquinolone, in Healthy Volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):49-55. [PubMed 11352442</li>
<li>Lehto PL, Kivisto KT. Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate absorption. DICP. 1991;25(7-8):745-746. [PubMed 1949932</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; June 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed [March 6, 2020].</li>
<li>Furosemide tablets [prescribing information]. Somerset, NJ: Solco Healthcare US, LLC: April 2020.</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ., 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205[PubMed 3011882</li>
<li>Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed). 1983;286(6375):1379-1381. [PubMed 6404468</li>
<li>Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis. 1989;13(3):194-199. [PubMed 2919600</li>
<li>Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int. 1990;47(5):291-295. [PubMed 2257522</li>
<li>Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. Nutr Clin Pract. 1991;6(5):199-201. [PubMed 1775116</li>
<li>Spivey JM, Cummings DM, Pierson NR, “Failure of Prostatitis Treatment Secondary to Probable Ciprofloxacin-Sucralfate Drug Interaction,” Pharmacotherapy, 1996, 16(2):314</li>
<li>[PubMed 8820479</li>
<li>Nix DE, Watson WA, Handy L, et al, “The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin,” Pharmacotherapy, 1989, 9(6):377-80. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al, “Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum,” Antimicrob Agents Chemother, 1990, 34:931</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al, “Combined Use of Ciprofloxacin and Sucralfate,” DICP, 1991, 25:578-82. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, and Quintiliani R, “Ciprofloxacin Levels When Receiving Sucralfate,” JAMA, 1989, 262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al, “Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin,” Antimicrob Agents Chemother, 1989, 33(1):99-102. [PubMed 2712548</li>
<li>Lehto P and Kivisto KT, “Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin,” Antimicrob Agents Chemother, 1994, 38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al, “Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers,” Antimicrob Agents Chemother, 1992, 36:2785-60. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al, “The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers,” Eur J Clin Pharmacol, 1994, 47(1):67</li>
<li>Zix JA, “Pharmacokinetics of Sparfloxacin and Interaction With Cisapride and Sucralfate,” Antimicrob Agents Chemother, 1997, 41:1668-72. [PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al, “The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin,” Br J Clin Pharmacol, 2000, 49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al, “The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers,” Int J Antimicrob Agents, 2000, 15(4):283</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of helicobacter pylori. Chem Pharm Bull (Tokyo). 2008;56(10):1412-1416. [PubMed 18827380</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. The acidic complexation of tetracycline with sucralfate for its mucoadhesive preparation. Drug Dev Ind Pharm. 2004;30(7):715-724. [PubMed 15491049</li>
<li>Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol Suppl. 1995;210:82-844. [PubMed 8578215]</li>
<li>Urso Forte (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; June 2013</li>
<li>Sucralfate [prescribing information]. Largo, FL: VistaPharm, Inc.; February 2020</li>
<li>Dovonex (calcipotriene) cream [prescribing information]Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]. Greenville, NC: Mayne Pharma; May 2019</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845]</li>
<li>Havrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med. 1992;117(5):445-446. [PubMed 1503346</li>
<li>Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994;96(6):531-535. [PubMed 8017451</li>
<li>Khan F, Jeanniton E, Renedo M. Does sucralfate impede levothyroxine therapy? Ann Intern Med. 1993;118(4):317. [PubMed 8481187</li>
<li>Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. Ann Intern Med. 1994;121(2):152. [PubMed 8017736</li>
<li>Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2020.</li>
<li>Smart HL, Somerville KW, Williams J, Richens A, Langman MJ. The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol. 1985;20(3):238-240. [PubMed 3840029</li>
<li>Hall TG, Cuddy PG, Glass CJ, Melethil S. Effect of sucralfate on phenytoin bioavailability. Drug Intell Clin Pharm. 1986;20(7-8):607-611. [PubMed 3755676</li>
<li>Malli R, Jones WN, Rindone JP, Labadie EL. The effect of sucralfate on the steady-state serum concentrations of phenytoin. Drug Metabol Drug Interact. 1989;7(4):287-293. [PubMed 2489199</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2022.</li>
<li>Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin. Ann Intern Med. 1983;98(4):557. [PubMed 6687662</li>
<li>Braverman SE, Marino MT. Sucralfate-warfarin interaction. Drug Intell Clin Pharm. 1988;22:913. [PubMed 3234259</li>
<li>Parrish RH, Waller B, Gondalia BG. Sucralfate-warfarin interaction. Ann Pharmacother. 1992;26:1015-1016. [PubMed 1504385</li>
<li>Neuvonen PJ, Jaakkola A, Totterman J, Penttila O. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol. 1985;20(2):178-179. [PubMed 3840028</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med. 1989;86(6A):38-44. [PubMed 2735334</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med. 1987;83(3B):67-73. [PubMed 3661612</li>
<li>Caille G, du Souich P, Gervais P, Besner JG. Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharm Drug Dispos. 1987;8(2):173-183. [PubMed 3593897</li>
<li>Lafontaine D, Mailhot C, Vermeulen M, Bissonnette B, Lambert C. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm. 1990;9(10):773-777. [PubMed 2242657</li>
<li>Crysvita (burosumab-twza) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; September 2019.</li>
<li>Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010</li>
<li>Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004</li>
<li>Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010</li>
<li>Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007</li>
<li>Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010</li>
<li>Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</li>
<li>One-Alpha (alfacalcidol) oral drops [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories; July 2020</li>
<li>Rocaltrol (calcitriol) oral solution [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019.</li>
<li>Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2(1):10-32. [PubMed 3547004</li>
<li>West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975;16(2):93-98. [PubMed 1168607</li>
<li>Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut. 1969;10(9):717-722. [PubMed 4318526</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Welchol (colesevelam) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; June 2013</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010</li>
<li>Rocaltrol (calcitriol) [prescribing information. Parisppany, NJ: Validus Pharmaceuticals LLC; July 2009</li>
<li>Rayaldee (calcifediol) [prescribing information]Miami, FL: OPKO Pharmaceuticals LLC; June 2016</li>
<li>Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. Gastroenterology. 1972;62(4):642-646. [PubMed 5020877</li>
<li>Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology. 1978;74(5 pt 1):900-902. [PubMed 640344</li>
<li>Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. Dig Dis Sci. 1985;30(5):477-482. [PubMed 3987479</li>
<li>Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427-430. [PubMed 2125243</li>
<li>Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med. 1992;119(4):407-411. [PubMed 1583392</li>
<li>Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980;65(2):243-250. [PubMed 7354970]</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2011</li>
<li>Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2007</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario:LEO Pharma Inc.; March 2010.</li>
<li>Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015</li>
<li>Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36(7):647-653. [PubMed 8844448</li>
<li>Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306-313. [PubMed 10757623</li>
<li>McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-822. [PubMed 12126214]</li>
<li>Vella A, Gerber TC, Hayes DL, et al. Digoxin, hypercalcemia, and cardiac conduction. Postgrad Med J. 1999;75:554-556. [PubMed 10616693</li>
<li>Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. [PubMed 22998989</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018.</li>
<li>Formosa N, Torpiano J, Allgrove J, Dattani MT. Anticonvulsant treatment associated with intractable hypocalcaemia in a female child with hypoparathyroidism. Horm Res Paediatr. 2015;83(1):62-66. [PubMed 25227206</li>
<li>Rubinger D, Korn-Lubetzki I, Feldman S, Popovtzer MM. Delayed response to a alpha-hydroxycholecalciferol therapy in a case of hypoparathyroidism during anticonvulsant therapy. Isr J Med Sci. 1980;16(11);772-774. [PubMed 7440128</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc; August 2017.</li>
<li>Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011</li>
<li>Hepburn NC, Abdul-Aziz LA and Whiteoak R, “Danazol-Induced Hypercalcaemia in Alphacalcidol-Treated Hypoparathyroidism,” Postgrad Med J, 1989, 65(769):849-50. [PubMed 2616424]</li>
<li>Lemann J, Jr., Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28:951-958. [PubMed 3003445</li>
<li>Santos F, Smith MJ,Chan JC. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. Am J Dis Child. 1986;140:139-142. [PubMed 3753816</li>
<li>Brickman AS, Massry SG,Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms. J Clin Invest. 1972;51:945-954. [PubMed 4552338</li>
<li>Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res. 2006;38:821-826. [PubMed 17163358</li>
<li>Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12:531-535. [PubMed 2592738</li>
<li>Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250:144-153. [PubMed 11489064</li>
<li>Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34:421-424. [PubMed 3887100</li>
<li>Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33:1140-1146. [PubMed 3404813</li>
<li>Nowack R, Hofner MC, Reichel H, et alSubacute effects of thiazide administration on renal hemodynamics and calcium metabolismClin Investig1992;70:686-691[PubMed 1392446</li>
<li>Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50. [PubMed 12492451</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019.</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201-2. doi: 10.4212/cjhp.v66i3.1261. PMID: 23814291; PMCID: PMC3694945.Ы</li>
                  
              </ol>
            </div>
          </div>

          <div class="consult-info__desc">
            *Депрескрайбинг - это процесс снижения дозировки, приостановки
            приема или полной отмены лекарственного препарата с целью снижения
            полипрагмазии и улучшения результатов лечения.
          </div>
        </div>
      </section>
    </div>

    <div class="section-wrap interaction" id="interaction-page">
      <section class="section gastro-calculator-wrap">
        <div class="section__container">
          <div class="row">
            <div class="gastro-calculator-card">
              <div class="gastro-calculator-header">
                <div
                  id="interaction-header-label"
                  class="gastro-calculator-header__label"
                >
                  Шаг 1: Выбор препаратов
                </div>
                <div
                  id="interaction-header-percent"
                  class="gastro-calculator-header__percent"
                >
                  10%
                </div>
                <div
                  id="interaction-progress-bar"
                  class="gastro-calculator-header__bar progress-bar"
                >
                  <span style="width: 10%"></span>
                </div>
              </div>
              <div class="gastro-calculator-content">
                <div
                  id="interaction-slide-1"
                  class="gastro-calculator-slide is-active"
                >
                  <div class="calculator-slide calculator-slide--columns">
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap">
                        <button
                          class="btn-back-to btn-reset go-to-back"
                          data-slide=""
                        >
                          Назад
                        </button>
                      </div>
                      <div class="calculator-title">
                        проверка межлекарственных взаимодействий
                      </div>
                      <div class="calculator-text">
                        <p>
                          Укажите все лекарственные препараты (МНН), которые
                          пациент принимает в настоящее время, для проверки
                          межлекарственных взаимодействий с препаратами для
                          лечения ГЭРБ
                        </p>
                      </div>
                      <div class="fast-search">
                        <div class="fast-search__input">
                          <input
                            type="text"
                            id="interaction-fast-search-input"
                            placeholder="Начните ввод"
                          />
                        </div>
                        <div class="fast-search__dropdown">
                          <div class="search-dropdown">
                            <div id="interaction-search-output"></div>
                            <div
                              id="interaction-nothing-found"
                              class="search-dropdown__item btn-reset pointer-events-none"
                            >
                              Начните вводить...
                            </div>
                          </div>
                        </div>
                      </div>
                      <div class="calculator-bottom">
                        <div class="often-searched">
                          <div class="often-searched__label">Часто ищут:</div>
                          <div
                            id="interaction-horizontal-symptoms"
                            class="often-searched__content"
                          >
                            <button class="searched-item btn-reset add-symptom">
                              Акалабрутиниб
                            </button>
                            <button class="searched-item btn-reset add-symptom">
                              Цефдиторен
                            </button>
                            <button class="searched-item btn-reset add-symptom">
                              Цефуроксим
                            </button>
                            <button class="searched-item btn-reset add-symptom">
                              Клопидогрел
                            </button>
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap hide-on-mobile">
                        <a href="#" class="btn-back-to dummy">dummy</a>
                      </div>
                      <div class="calculator-header calculator-header-gap">
                        <div class="calculator-title">
                          Выбранные лекарственные препараты (МНН)
                        </div>
                        <button
                          class="btn-as-link btn-reset clear-all-symptoms"
                        >
                          Сбросить все
                        </button>
                      </div>
                      <div
                        id="interaction-added-symptoms"
                        class="added-symptoms"
                      ></div>
                      <div class="calculator-bottom btn-wrap btn-wrap--end">
                        <button
                          id="interaction-go"
                          class="btn btn--250 btn-reset hide go-to-next"
                          data-slide="#interaction-slide-2"
                        >
                          Продолжить
                        </button>
                      </div>
                    </div>
                  </div>
                </div>

                <div id="interaction-slide-2" class="gastro-calculator-slide">
                  <div class="calculator-slide">
                    <div class="calculator-btn-wrap btn-wrap">
                      <button
                        class="btn-back-to btn-reset go-to-back"
                        data-slide="#interaction-slide-1"
                      >
                        Назад
                      </button>
                    </div>

                    <div class="interaction__header">
                      <h1 class="interaction__title title-reset">
                        проверка межлекарственных взаимодействий
                      </h1>
                      <p class="interaction__text">
                        Проверка была проведена со следующими лекарственными
                        препаратами (МНН)
                      </p>
                      <div class="interaction-buttons"></div>
                    </div>

                    <div id="interaction-main" class="interaction-main"></div>

                    <div
                      class="repeated-content__divider repeated-content__divider_mobile"
                    ></div>

                    <div class="calculator-bottom btn-wrap btn-wrap--end">
                      <button
                        class="btn btn--250 btn--border btn-reset back-to-page-before-interaction"
                      >
                        К результатам приема
                      </button>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div class="gastro-calculator-btn-wrap">
              <div class="abbott-more-sources">
                <button class="abbott-more-sources__button btn-reset">
                  <span>Ключевые источники информации</span>
                  <svg
                    xmlns="http://www.w3.org/2000/svg"
                    width="16"
                    height="17"
                    viewBox="0 0 16 17"
                    fill="none"
                  >
                    <path
                      fill-rule="evenodd"
                      clip-rule="evenodd"
                      d="M4.89164 2.73051C5.19205 2.42487 5.67909 2.42487 5.9795 2.73051L11.1077 7.94791C11.252 8.09467 11.333 8.29373 11.333 8.5013C11.333 8.70885 11.252 8.90791 11.1077 9.05469L5.9795 14.2721C5.67909 14.5777 5.19205 14.5777 4.89164 14.2721C4.59124 13.9664 4.59124 13.4709 4.89164 13.1653L9.47593 8.5013L4.89164 3.83729C4.59124 3.53166 4.59124 3.03614 4.89164 2.73051Z"
                      fill="#009CDE"
                    ></path>
                  </svg>
                </button>
                <div class="abbott-more-sources__content">
                  <ol>
                  <li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В., Дронова О.Б., Кучерявый Ю.А., Пирогов С.С., Сайфутдинов Р.Г., Успенский Ю.П., Шептулин А.А., Андреев Д.Н., Румянцева Д.Е. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. https://doi.org/10.22416/1382-4376-2020-30-4-70-97.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Сторонова О.А., Абдулхаков С.Р., Андреев Д.Н., Бордин Д.С., Валитова Э.Р., Кляритская И.Л., Кривой В.В., Кучерявый Ю.А., Лапина Т.Л., Морозов С.В., Саблин О.А., Семенихина Е.В., Успенский Ю.П., Шептулин А.А. Рекомендации Российской гастроэнтерологической ассоциации по клиническому применению манометрии высокого разрешения при заболеваниях пищевода. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):61–88. https://doi.org/10.22416/1382-4376-2020-30-3-61-88</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. Therole of esophageal testing in diagnosis and management. Gastroenterol Clin North Am1996; 25:75.</li>
<li>Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification ofgastroesophageal reflux disease: a global evidence-based consensus. Am JGastroenterol 2006; 101:1900.</li>
<li>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophagealreflux disease: a systematic review. Gut 2005; 54:710.</li>
<li>Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of uppergastrointestinal disorders in the United States: results of the US Upper GastrointestinalStudy. Clin Gastroenterol Hepatol 2005; 3:543.</li>
<li>Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.</li>
<li>Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence,severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol2004; 2:665.</li>
<li>Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to protonpump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.</li>
<li>Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophagealsphincter pressure: a manometric observation in patients reporting globus sensation.Am J Gastroenterol 2009; 104:289.</li>
<li>Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea.Ann Intern Med 1997; 126:704.</li>
<li>Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.</li>
<li>DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophagealreflux disease. Practice Parameters Committee of the American College ofGastroenterology. Arch Intern Med 1995; 155:2165.</li>
<li>Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS(Ed), WB Saunders, Philadelphia 1989. p.1147.</li>
<li>Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients withgastroesophageal reflux disease: a comparison between empirical treatment withesomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.</li>
<li>Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test toidentify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360.</li>
<li>Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pumpinhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostictest characteristics. Ann Intern Med 2004; 140:518.</li>
<li>Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability andendoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313.</li>
<li>Adanir H, Baş B, Pakoz B, et al. Endoscopic Findings of Gastro-Esophageal RefluxDisease in Elderly and Younger Age Groups. Front Med (Lausanne) 2021; 8:606205.</li>
<li>Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical andfunctional correlates and further validation of the Los Angeles classification. Gut 1999;45:172.</li>
<li>Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. ClinGastroenterol Hepatol 2007; 5:4.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationMedical Position Statement on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1383.</li>
<li>Hirano I, Richter JE, Practice Parameters Committee of the American College ofGastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</li>
<li>Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practiceguideline development. Gastroenterology 1996; 110:1982.</li>
<li>Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless andDigitrapper catheter-based pH monitoring systems for measuring esophageal acidexposure. Am J Gastroenterol 2005; 100:1466.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-refluxassociation using 4-day wireless pH recording combining 48-hour periods off and on PPItherapy. Am J Gastroenterol 2008; 103:1631.</li>
<li>Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring.J Clin Gastroenterol 2012; 46:197.</li>
<li>Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal refluxsymptoms and esophagitis with or without symptoms in the general adult Swedishpopulation: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275.</li>
<li>Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatmentof benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology1982; 82:487.</li>
<li>Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricturetreated by dilatation. Gastroenterology 1983; 85:346.</li>
<li>Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazolefor refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.</li>
<li>Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists intreating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.</li>
<li>Okwara NC, Chan WW. Sorting out the Relationship Between Esophageal andPulmonary Disease. Gastroenterol Clin North Am 2021; 50:919.</li>
<li>Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophagealreflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.</li>
<li>Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acidsuppressive therapy improves asthma outcome. Am J Med 1996; 100:395.</li>
<li>Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'refluxlaryngitis'. Gastroenterology 1991; 100:305.</li>
<li>Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease(GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoringand an experimental investigation of the role of acid and pepsin in the development oflaryngeal injury. Laryngoscope 1991; 101:1.</li>
<li>Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastricacid in patients with reflux laryngitis. Gastroenterology 1995; 109:1575.</li>
<li>Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopyin patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am JGastroenterol 2004; 99:1419.</li>
<li>Remacle M, Lawson G. Diagnosis and management of laryngopharyngeal refluxdisease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:143.</li>
<li>Gaynor EB. Gastroesophageal reflux as an etiologic factor in laryngeal complications ofintubation. Laryngoscope 1988; 98:972.</li>
<li>Cote DN, Miller RH. The association of gastroesophageal reflux and otolaryngologicdisorders. Compr Ther 1995; 21:80.</li>
<li>Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated withgastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.</li>
<li>Schroeder PL, Filler SJ, Ramirez B, et al. Dental erosion and acid reflux disease. AnnIntern Med 1995; 122:809.</li>
<li>DiBaise JK, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. AnnIntern Med 1998; 129:1078.</li>
<li>DiBaise JK, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistantsinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002; 97:843.</li>
<li>Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence inindividuals with gastroesophageal reflux: synthesis and estimates from populationstudies. Am J Gastroenterol 2011; 106:254.</li>
<li>Vaezi MF. Laryngitis and gastroesophageal reflux disease: increasing prevalence or poordiagnostic tests? Am J Gastroenterol 2004; 99:786.</li>
<li>Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous cell cancer of the head andneck. Otolaryngol Clin North Am 1985; 18:367.</li>
<li>Olsen NR. Effects of stomach acid on the larynx. Proc Am Laryngol Assoc 1983; 104:108.</li>
<li>Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma?Otolaryngol Head Neck Surg 1988; 99:370.</li>
<li>Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of thelaryngopharynx. Laryngoscope 1988; 98:1195.</li>
<li>Langevin SM, Michaud DS, Marsit CJ, et al. Gastric reflux is an independent risk factor forlaryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22:1061.</li>
<li>Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, Lagergren J. All-cause and cancer-specificmortality in GORD in a population-based cohort study (the HUNT study). Gut 2018;67:209.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationInstitute technical review on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1392.</li>
<li>Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosisand Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117:27.</li>
<li>Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control ofheartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am JGastroenterol 1999; 94:92.</li>
<li>Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acidinhibition. Gastroenterol Clin North Am 1990; 19:683.</li>
<li>Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophagealreflux disease. Gastroenterology 2001; 121:1095.</li>
<li>Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn oracid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.</li>
<li>Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy forGERD: a multi-center study in Japan. World J Gastroenterol 2011; 17:1480.</li>
<li>Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients withgastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965.</li>
<li>Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass indexand esophageal acid exposure in the extraesophageal manifestations of reflux. ClinGastroenterol Hepatol 2012; 10:874.</li>
<li>Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between uppergastrointestinal symptoms and changes in body weight in a population-based cohort.Neurogastroenterol Motil 2006; 18:987.</li>
<li>Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is notreduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.</li>
<li>Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms ofgastroesophageal reflux in women. N Engl J Med 2006; 354:2340.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction ingastroesophageal reflux. A prospective population-based cohort study: the HUNT study.Am J Gastroenterol 2013; 108:376.</li>
<li>DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines forthe diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol2005; 100:190.</li>
<li>Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle Intervention inGastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14:175.</li>
<li>Mehta RS, Song M, Staller K, Chan AT. Association Between Beverage Intake andIncidence of Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol 2020;18:2226.</li>
<li>Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathingexercise on gastroesophageal reflux disease: a randomized, controlled study. Am JGastroenterol 2012; 107:372.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation andimproved gastroesophageal reflux: a prospective population-based cohort study: theHUNT study. Am J Gastroenterol 2014; 109:171.</li>
<li>Mehta RS, Nguyen LH, Ma W, et al. Association of Diet and Lifestyle With the Risk ofGastroesophageal Reflux Disease Symptoms in US Women. JAMA Intern Med 2021;181:552.</li>
<li>Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosivegastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.</li>
<li>Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to theacid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11:1585.</li>
<li>Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodiumalginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.</li>
<li>Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented bymagnetic resonance imaging and pH-impedance monitoring: mechanistic assessmentin healthy volunteers and randomised, controlled, double-blind study in reflux patients.Aliment Pharmacol Ther 2013; 37:1093.</li>
<li>Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oralsuspension is non-inferior to omeprazole in the treatment of patients with non-erosivegastroesophageal disease. Aliment Pharmacol Ther 2013; 38:1054.</li>
<li>Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of uppergastrointestinal symptoms by an acid pocket-targeting alginate-antacid (GavisconDouble Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophagealreflux disease. Aliment Pharmacol Ther 2014; 39:595.</li>
<li>Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatmentafter 14 days of administration in healthy subjects without Helicobacter pylori infection.J Gastroenterol Hepatol 2003; 18:678.</li>
<li>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcerhealing, gastroesophageal reflux disease, and stress-related erosive syndrome.Gastroenterology 2000; 118:S9.</li>
<li>Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.</li>
<li>Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms ofgastroesophageal reflux disease and heals erosions and ulcerations. Results of amulticenter, placebo-controlled, dose-ranging study. USA Merck GastroesophagealReflux Disease Study Group. Arch Intern Med 1991; 151:2394.</li>
<li>Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal refluxdisease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol1991; 86:1735.</li>
<li>Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed onDecember 19, 2012).</li>
<li>Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is moreacceptable to patients than continuous lansoprazole 15 mg in the long-termmaintenance of endoscopy-negative gastro-oesophageal reflux patients: theCOMMAND Study. Aliment Pharmacol Ther 2004; 20:657.</li>
<li>Hunt R. Acid suppression for reflux disease: "off-the-peg" or a tailored approach? ClinGastroenterol Hepatol 2012; 10:210.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitortherapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419.</li>
<li>Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pumpinhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal refluxdisease-like symptoms and endoscopy negative reflux disease. Cochrane Database SystRev 2013; :CD002095.</li>
<li>Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worseesophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl B:66B.</li>
<li>Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptorantagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005; 11:4067.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Katzka DA, Kahrilas PJ. Advances in the diagnosis and management ofgastroesophageal reflux disease. BMJ 2020; 371:m3786.</li>
<li>Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenancetherapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci2009; 54:955.</li>
<li>Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies forreflux esophagitis. N Engl J Med 1995; 333:1106.</li>
<li>Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients withgastrooesophageal reflux disease. Gut 1992; 33:1016.</li>
<li>Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies forGastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. Decem ber 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).</li>
<li>Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention ofrelapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Gut 1994; 35:590.</li>
<li>Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of refluxesophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlledtrial. Ann Intern Med 1996; 124:859.</li>
<li>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancyand lactation. Aliment Pharmacol Ther 2020; 51:421.</li>
<li>Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet)with antacid for safety and effectiveness in reducing gastric acidity before electivecesarean section. Anesthesiology 1983; 59:86.</li>
<li>Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) inpregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.</li>
<li>Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk ofbirth defects. N Engl J Med 2010; 363:2114.</li>
<li>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophagealreflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.</li>
<li>Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. JReprod Med 2004; 49:825.</li>
<li>National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).</li>
<li>ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelinesfor endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</li>
<li>Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal refluxdisease: putative mechanisms of failure. Drugs 2007; 67:1521.</li>
<li>Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptomsrefractory to proton pump inhibitors. Gut 2012; 61:1340.</li>
<li>Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with theirprescription medications? Results of the patient unmet needs study. J Clin OutcomesManag 2000; 7:29.</li>
<li>The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.</li>
<li>Fass R. Therapeutic options for refractory gastroesophageal reflux disease. JGastroenterol Hepatol 2012; 27 Suppl 3:3.</li>
<li>El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on protonpump inhibitor therapy in primary care and community studies. Aliment PharmacolTher 2010; 32:720.</li>
<li>Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors innonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.</li>
<li>Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention andtreatment. Drugs 2003; 63:555.</li>
<li>Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.</li>
<li>Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term protonpump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.</li>
<li>Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure ingastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.</li>
<li>Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pumpinhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol 2014;109:789.</li>
<li>Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitordosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.Aliment Pharmacol Ther 2006; 23:1473.</li>
<li>Wilder-Smith C, Röhss K, Bokelund Singh S, et al. The effects of dose and timing ofesomeprazole administration on 24-h, daytime and night-time acid inhibition in healthyvolunteers. Aliment Pharmacol Ther 2010; 32:1249.</li>
<li>Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistentsymptoms despite acid suppressive therapy: a multicentre study using combinedambulatory impedance-pH monitoring. Gut 2006; 55:1398.</li>
<li>Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol2008; 6:521.</li>
<li>Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pHmonitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.</li>
<li>Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitecmonitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53:2387.</li>
<li>Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux insymptomatic GERD. Am J Gastroenterol 2001; 96:2033.</li>
<li>Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring insymptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.</li>
<li>Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in ahypersensitive esophagus might explain symptoms resistant to proton pump inhibitorsin patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2014;12:1647.</li>
<li>Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree ofduodenogastroesophageal reflux and acid reflux between patients who failed torespond and those who were successfully treated with a proton pump inhibitor oncedaily. Am J Gastroenterol 2009; 104:2005.</li>
<li>Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acidsuppressive therapy. Am J Gastroenterol 2008; 103:1090.</li>
<li>Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiatenon-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012;47:159.</li>
<li>Abdallah J, George N, Yamasaki T, et al. Most Patients With Gastroesophageal RefluxDisease Who Failed Proton Pump Inhibitor Therapy Also Have Functional EsophagealDisorders. Clin Gastroenterol Hepatol 2019; 17:1073.</li>
<li>Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology2016.</li>
<li>Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functionalheartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013;25:282.</li>
<li>Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity tobile salts in patients with functional heartburn and in healthy control subjects. Dig DisSci 2005; 50:81.</li>
<li>Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traitsof functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity toacid. Am J Gastroenterol 2006; 101:1084.</li>
<li>Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for thetreatment of refractory GERD accompanied with gastroparesis: a preliminary report. DigDis Sci 2008; 53:2621.</li>
<li>Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patientswith symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum ofvisceral sensitivity in GORD. Gut 1995; 37:7.</li>
<li>Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS andpsychological distress on outcomes and quality of life following PPI therapy in patientswith gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.</li>
<li>Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associatedwith features of psychiatric disorders and the irritable bowel syndrome. AlimentPharmacol Ther 2007; 26:443.</li>
<li>Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease andpsychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.</li>
<li>Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal refluxdisease and underdiagnosis of functional dyspepsia in a USA community.Neurogastroenterol Motil 2014; 26:1163.</li>
<li>Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive tosingle-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux,bile reflux, or both? Am J Gastroenterol 2004; 99:981.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acidbreakthrough on different regimens of omeprazole 40 mg daily. Aliment PharmacolTher 1998; 12:1235.</li>
<li>Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective aslansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophagealreflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-aprospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.</li>
<li>Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebocontrolled study of omeprazole in the treatment of patients with reflux symptoms andphysiological levels of acid reflux--the "sensitive oesophagus". Gut 1997; 40:587.</li>
<li>Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburnsymptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.</li>
<li>Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-hintragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36:627.</li>
<li>Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis ofgastro-esophageal reflux disease: Update of the Porto consensus andrecommendations from an international consensus group. Neurogastroenterol Motil2017; 29:1.</li>
<li>Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring withand without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.</li>
<li>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management ofgastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.</li>
<li>Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pHmonitoring in patients with refractory gastroesophageal reflux disease, on and offtherapy. Clin Gastroenterol Hepatol 2009; 7:743.</li>
<li>Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology2018; 154:302.</li>
<li>Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findingsin gastro-esophageal reflux disease: Conclusions from an international consensusgroup. Neurogastroenterol Motil 2017; 29.</li>
<li>Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthroughon omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.</li>
<li>Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy onnocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.</li>
<li>Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine atnight to twice daily omeprazole therapy on nocturnal acid breakthrough and acid refluxin patients with systemic sclerosis--a randomized controlled, cross-over trial. AlimentPharmacol Ther 2007; 26:1259.</li>
<li>Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinicalsignificance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545.</li>
<li>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for thecontrol of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009;:CD004275.</li>
<li>Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improvegastroesophageal reflux disease symptoms for patients on proton pump inhibitortherapy. Dis Esophagus 2005; 18:370.</li>
<li>Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophagealreflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract2014; 2014:307805.</li>
<li>Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices?Curr Opin Gastroenterol 2009; 25:352.</li>
<li>Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants inpatients with functional esophageal disorders or gastroesophageal reflux disease:a systematic review. Clin Gastroenterol Hepatol 2015; 13:251.</li>
<li>Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adultpatients with functional chest pain: a randomized, double-blind, placebo-controlled,crossover trial. Am J Gastroenterol 2010; 105:1504.</li>
<li>Park SW, Lee H, Lee HJ, et al. Low-dose amitriptyline combined with proton pumpinhibitor for functional chest pain. World J Gastroenterol 2013; 19:4958.</li>
<li>Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors forthe treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.</li>
<li>Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy ingastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20:2412.</li>
<li>Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients WithRefractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology2020; 158:2093.</li>
<li>Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the protonpump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.</li>
<li>UpToDate medical database. Approach to the initial management of patients with GERD. Graphic 116964 Version 3.0. Электронный ресурс: https://www.uptodate.com/contents/image?imageKey=GAST%2F116964, дата доступа: 14.07.2023</li>
<li>Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut. 2005;54(12):1810-1817. doi:10.1136/gut.2005.072629</li>
<li>Costa V, Pinto-Saavedra O, Hani A, Leguízamo AM, Ardila-Hani AF. Updated interpretation of Impedance–pH monitoring. Rev Colomb Gastroenterol. 2021;36(1):73-80. https://doi.org/10.22516/25007440.608</li>
<li>Hani, Albis & Leguizamo, Ana & Carvajal, Jhon & Klinger, Gabriel & Costa, Valeria. (2015). How to Perform and Interpret High-resolution Esophageal Manometry. Revista Colombiana de Gastroenterologia. 30. 74-83.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л., Хлынов И.Б., Дехнич Н.Н., Лопина О.Д., Алексеева О.П., Корочанская Н.В., Осипенко М.Ф., Павлов П.В., Пирогов С.С., Тарасова Г.Н., Успенский Ю.П., Андреев Д.Н., Румянцева Д.Е. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18. https://doi.org/10.22416/1382-4376-2020-30-6-7-18.</li>
<li>Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Can Fam Physician 2017;63:354-64 (Eng), e253-65 (Fr).</li>
<li>Cho YK. How to Interpret Esophageal Impedance pH Monitoring. J Neurogastroenterol Motil. 2010 Jul;16(3):327-30. doi: 10.5056/jnm.2010.16.3.327. Epub 2010 Jul 26. PMID: 20680174; PMCID: PMC2912128.</li>
<li>Kim GH. How to Interpret Ambulatory 24 hr Esophageal pH Monitoring. J Neurogastroenterol Motil. 2010 Apr;16(2):207-10. doi: 10.5056/jnm.2010.16.2.207. Epub 2010 Apr 27. PMID: 20535354; PMCID: PMC2879855.</li>
<li>Jehangir A, Malik Z, Parkman HP. Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterol. 2022 Mar 8;22(1):112. doi: 10.1186/s12876-022-02194-0. PMID: 35260107; PMCID: PMC8905734.</li>
<li>Yadlapati R. High-resolution esophageal manometry: interpretation in clinical practice. Curr Opin Gastroenterol. 2017 Jul;33(4):301-309. doi: 10.1097/MOG.0000000000000369. PMID: 28426462; PMCID: PMC5568812.</li>
<li>Yamasaki T, Fass R. Reflux Hypersensitivity: A New Functional Esophageal Disorder. J Neurogastroenterol Motil. 2017;23(4):495-503. doi:10.5056/jnm17097</li>
<li>Ronnie Fass, Frank Zerbib, C. Prakash Gyawali. AGA Clinical Practice Update on Functional Heartburn: Expert Review. CLINICAL PRACTICE UPDATE| VOLUME 158, ISSUE 8, P2286-2293, JUNE 2020. Published: February 01, 2020. DOI: https://doi.org/10.1053/j.gastro.2020.01.034</li>
<li>Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi: 10.14309/ajg.0000000000000731. PMID: 32773454; PMCID: PMC9896940.</li>
<li>Samo S, Qayed E. Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management? World J Gastroenterol. 2019 Jan 28;25(4):411-417. doi: 10.3748/wjg.v25.i4.411. PMID: 30700938; PMCID: PMC6350167.</li>
<li>Management of the patient with esophagogastric junction outflow obstruction (EGJOO) Shahsavari et al. Curr Opin Gastroenterol 2021, 37:397–407. DOI:10.1097/MOG.0000000000000747</li>
<li>Dhyanesh A. Patel, Rena Yadlapati, Michael F. Vaezi, Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics, Gastroenterology, Volume 162, Issue 6, 2022, Pages 1617-1634, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2021.12.289.</li>
<li>DeLay K, Krause A, Yadlapati R. Clinical Updates in Esophageal Motility Disorders Beyond Achalasia. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1789-1792.e1. doi: 10.1016/j.cgh.2021.05.041. Epub 2021 Jul 1. PMID: 34405804; PMCID: PMC8604436.</li>
<li>Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30. PMID: 24466441; PMCID: PMC3895610.</li>
<li>Чёрная А. В. Карханова А. Г., Мутовкина Н. И., Дышлюк Т. Л., Багненко С. С., Рогачев М. В., Ульянова Р. Х., Зайцев А. Н., Шевкунов Л. Н., Новиков С. Н., Шевченко Е. Ю., Брезгина Е. А. Лучевая диагностика заболеваний пищевода при злокачественных и доброкачественных изменениях: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. – Санкт-Петербург: ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России, 2021. – 144 с. ISBN 978-5-6046978-1-8</li>
<li>Государственный реестр лекарственных средств. Электронный ресурс: https://grls.rosminzdrav.ru/default.aspx, дата доступа: 14.07.2023</li>
<li>Инструкция по применению лекарственного препарата Ганатон® (итоприда гидрохлорид). РУ ЛС-002513 от 29.06.2021. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9abd2328-abcb-411e-919e-6d8ab7c238ea, дата доступа: 14.07.2023</li>
<li>Stanghellini V., Chan F., Hasler W.L. et al. Gastroduodenal Disorders Gastroenterology 2016;150:1380– 1392.</li>
<li>Касьяненко В.И., Денисов Н.Л., Васильев Ю.В. Применение итоприда при симптомах функциональной диспепсии в России: результаты проспективного открытого многоцентрового клинического исследования IV фазы. Терапевтический Архив. 2014;8:35-41.</li>
<li>Tack J. et all. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther. 2011 Jan;33(1):99-105.</li>
<li>Murray J.A. Gastroesophageal Reflux Disease. In.: Mayo Clinic Gastroenterology and Hepatology Board Review. Oxford University Press. 2015.</li>
<li>Ezzat W.F., Fawaz S.A., Fathey H. et al. Virtue of Adding Prokinetics to Proton Pump Inhibitors in the Treatment of Laryngopharyngeal Reflux Disease: Prospective Study Journal of Otolaryngology-Head & Neck Surgery. 2011;40(4):350–356/</li>
<li>Инструкция по применению лекарственного препарата Париет® (рабепразол). РУ П N011880/01 от 28.02.2022. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d7c5d813-e692-4211-a63d-2a2ac06ea1d7, дата доступа: 14.07.2023</li>
<li>Kirchheiner J., Glatt S., Fuhr U. et al. Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH // European Journal of Clinical Pharmacology, 2008, 65 (1), pp.19-31</li>
<li>Kramer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitrocorrelates. Pharmacology. 1998;56:57-70</li>
<li>Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003 Feb;48(2):322-8.</li>
<li>Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335.</li>
<li>Besancon M, Shin JM, Mercier F, et al. Biochemistry, 1993; 32:2345–2355.</li>
<li>Сереброва С.Ю. Основные фармакокинетические характеристики ингибиторов протонной помпы и эффективность их действия. Пособие для врачей. Мединфорум 2016.</li>
<li>Cefditoren [Korean product labeling]. Boryeong Pharmaceutical; November 2009.</li>
<li>Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol. 1984;18(4):535-539. [PubMed 6091711</li>
<li>Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. Adv Perit Dial. 1994;10:179-182. [PubMed 7999822</li>
<li>Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</li>
<li>Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509. [PubMed 16898956</li>
<li>Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OLCA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardio. 2008;51(3):256-260. [PubMed 18206732</li>
<li>Fontes-Carvalho R, Albuquerque A, Araugo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogre-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396-404. [PubMed 21464720</li>
<li>Frelinger 3rd AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardio. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944. [PubMed 19258584</li>
<li>Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039; author reply 1039. [PubMed 18786491</li>
<li>Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Gaglia MA Jr, Torguson R, Hanna N, et alRelation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomesAm J Cardiol2010;105(6):833-838[PubMed 20211327</li>
<li>Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964-1968. [PubMed 19731021</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997. [PubMed 19726078</li>
<li>Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26(2):e54-e57. [PubMed 20151060</li>
<li>Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917. [PubMed 20925534</li>
<li>Muthiah MD, Zheng H, Chew NWS, et al. Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. [online ahead of print] J Thromb Throbolysis. 2021. doi: 10.1007/s11239-021-02472. [PubMed 33959860</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016; Aug 10 (Epub ahead of print). [PubMed 27512080</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478</li>
<li>Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). BMC Cardiovasc Disord. 2017;17(1):3. [PubMed 28056809</li>
<li>Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939-947. [PubMed 27459657</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11): pii: e002245. [PubMed 26514161</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership: March 2021.</li>
<li>Park GJ, Bae SH, Park WS, et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017;11:1043-1053. [PubMed 28408803</li>
<li>Kamiya C, Inui N, Hakamat A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype [published online March 11, 2019]. J Pharmacol Sci. Doi: 10.1016/j.jphs.2019.03.001. [PubMed 30902567</li>
<li>Elbe A, Foerster KI, Blank A, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975-987. [PubMed 35238961</li>
<li>Erleada (apalutamide) [prescribing information. Horsham, PA: Janssen Products LP; September 2019</li>
<li>Kanebratt KP, Diczfalusy U, Backstroo T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther, 2008, 84(5):589-94. [PubMed 18650803</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; August 2018.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999-1004. [PubMed 22147077</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016</li>
<li>Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358-1365. [PubMed 25274610</li>
<li>Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81(6):1195-1196. [PubMed 26833554</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;25(7):1155-1162. [PubMed 30605231</li>
<li>Koutake Y, Taniguch J, Yasumori N, et al. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol. 2020;111(6):826-832. [PubMed 32152877]</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2012.</li>
<li>Tarceva (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; April 2014</li>
<li>van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309-1314. [PubMed 26858332</li>
<li>Veerman GDM, Hussaarts KGAM, Peric R, et al. Influence of cow's milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69-77. [PubMed 32557346</li>
<li>Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol. 2010;70(6):908-911. [PubMed 21175447</li>
<li>Du X, Liu W, Chen K, Wang Z, Li X, Yang L, Xie X. Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis. [published online ahead of print] Front Pharmacol. 2022. doi: 10.3389/fphar.2022.796538. [PubMed 35795555</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908</li>
<li>Zenke Y, Yoh K, Matsumoto S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412-418. [PubMed 26944770</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et alA multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerClin Cancer Res2010;16(11):3078-3087[PubMed 20395213</li>
<li>Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 2013;52:593-609. [PubMed 23532985</li>
<li>Truseltiq (infigratinib) [prescribing information]. Brisbane, CA: QED Therapeutics Inc; May 2021.</li>
<li>Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola®) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671-1675. [PubMed 7486898</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; June 2018</li>
<li>Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; March 2018</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022</li>
<li>Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-391. [PubMed 9357389</li>
<li>Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42(3):278-284. [PubMed 22022918</li>
<li>Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283:434-442.[PubMed 9353355</li>
<li>Zhang W, Ramamoorthy Y, Kilicarslan T, et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos. 2002;30:314-318. [PubMed 11854151]</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</li>
<li>Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1635-1643. [PubMed 23636448</li>
<li>Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. [Published online doi:10.1002/ijc.33469]. 2021. [PubMed 33428771</li>
<li>Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020;76(9):1273-1280. [PubMed 32474662</li>
<li>Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</li>
<li>Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F. Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects. Clin Pharmacokinet. 2022;61(11):1623-1639. [PubMed 36264536</li>
<li>Turalio (pexidartinib) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; August 2019.</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; August 2015</li>
<li>Juluca (dolutegravir/rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020</li>
<li>Noltec (ilaprazole) [Korean product labeling]. Ilyang Pharmaceutical Co., Ltd.; March 2020</li>
<li>K-CAB (tegoprazan) [Singapore product labeling]. Singapore: HK inno.N Corporation; January 2023.</li>
<li>Lumakras (sotorasib) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2021.</li>
<li>Filspari (sparsentan) [prescribing information]. San Diego, CA: Travere Therapeutics Inc; February 2023.</li>
<li>Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-197. [PubMed 15001970</li>
<li>Konvomep (omeprazole and sodium bicarbonate for oral suspension) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals, Inc.; August 2022.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2020</li>
<li>Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011;51(3):368-377. [PubMed 20457590</li>
<li>Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26:341346. [PubMed 16503713</li>
<li>Evotaz (atazanavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2020.</li>
<li>Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors. Clin Pharmacol Drug Dev. 2022;11(7):795-806. [PubMed 35230741</li>
<li>Rezurock (belumosudil) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals LLC; July 2021.</li>
<li>Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33(8):589-595. [PubMed 23839484</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:53-59. [PubMed 10702887</li>
<li>Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.</li>
<li>Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51. [PubMed 20642546</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90-97. [PubMed 24887634</li>
<li>Wu WT, Tsai CT, Chou YC, et al. Cardiovascular outcomes associated with clinical use of citalopram and omeprazole: a nationwide population-based cohort study. J Am Heart Assoc. 2019;8(20):e011607. [PubMed 31581860</li>
<li>Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.</li>
<li>Yokota H, Sato K, Okuda Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18(6):e433-e439. [PubMed 28579188</li>
<li>Tang W, Tomkinson H, Masson E. Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev. 2017;6(5):517-523. [PubMed 28176470</li>
<li>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res. 2019;11:8539-8546. [PubMed 31572008</li>
<li>Sedano MN, Teller JMC, Munoz CG, et al. Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON. 2018;23(3):647-653. [PubMed 30003732</li>
<li>Li J, Nickens D, Wilner K, Tan W. Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther. 202113. Epub ahead of print. [PMID: 34120312</li>
<li>Kumarakulasinghe NB, Syn N, Soon YY, et al. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget. 2016;7(51):85542-85550. [PubMed 27907909</li>
<li>Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2021.</li>
<li>Jaruratanasirikul S and Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54:159-161. [PubMed 9626921</li>
<li>Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, and Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51:453-457. [PubMed 12562722</li>
<li>Lange D, Pavao JH, Wu J, and Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Tolsura (itraconazole) [prescribing information]. Greenville NC: Mayne Pharma; December 2018</li>
<li>Lindsay J, Mudge S, and Thompson GR. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723018. [PubMed 30297369</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018</li>
<li>Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808. [PubMed 16141567]</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2017</li>
<li>Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893-1899. [PubMed 27533287</li>
<li>Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5. [PubMed 27565882]</li>
<li>Camzyos (mavacamten) [prescribing information]. Brisbane, CA: MyoKardia, Inc.; April 2022.</li>
<li>Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol.1993;33(1):82-84. [PubMed 8269594</li>
<li>Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024-1027. [PubMed 10981249</li>
<li>Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497. [PubMed 12077038</li>
<li>Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30(3):963-965. [PubMed 20393020</li>
<li>McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012;25(4):477-485. [PubMed 22550162</li>
<li>Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316-318. [PubMed 18386155</li>
<li>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Chemotherapy. 2011;57(3):225-229. [PubMed 21597286</li>
<li>Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht RDelayed elimination of methotrexate associated with co-administration of proton pump inhibitorsAnticancer Res2010;30(9):3807-3810[PubMed 20944174</li>
<li>Fang AF, Damle BD, LaBadie RR, Crownover, PH, Hewlett Jr. D, Glue, PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50. [PubMed 18154473</li>
<li>Saberi P, Ranatunga DK, Quesenberry CP, Silverberg MJ. Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011;31(3):253-261. [PubMed 21361735</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016</li>
<li>Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32(12):1462-1467. [PubMed 15448116]</li>
<li>Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50(8):960-967. [PubMed 20498287</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155-1162. [PubMed 30605231</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.</li>
<li>Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food and intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614-626. [PubMed 28430398</li>
<li>Ibrance (palbociclib) capsule [prescribing information]. New York, NY: Pfizer Inc; September 2019</li>
<li>Ibrance (palbociclib) tablet [prescribing information]. New York, NY: Pfizer Inc; November 2019</li>
<li>Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021;6(5):100231. [PubMed 34509802</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649]</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PubMed 19075045</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; November 2013</li>
<li>Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839. [PubMed 19220151</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-5510[PubMed 22890761</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott (US), LLC; April 2015</li>
<li>Kinov P, Boyanov M. Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health. 2012;4L:167-174. [PubMed 22532780</li>
<li>Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114. [PubMed 30539272</li>
<li>Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998-1004. [PubMed 21321287</li>
<li>Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161-1168. [PubMed 22890365</li>
<li>Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016-1022. [PubMed 23307040</li>
<li>Prieto-Alhambra D, Pages-Castella A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268-274. [PubMed 23761350</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Yang SD, Chen Q, Wei HK, et alBone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysisInt J Clin Exp Med2015;8(4):4899-4910[PubMed 26131063</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782</li>
<li>Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC Jr, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63(10):2070-2073. [PubMed 26415604</li>
<li>Roux C, Goldstein JL, Zhou X, et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277-284. [PubMed 21365461</li>
<li>Asaoka D, Nagahara A, Hojo M, et al. Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomed Rep. 2016;5(2):165-170. [PubMed 27446535</li>
<li>Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31(2):206-211. [PubMed 23138352</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014:607145. [PubMed 25436170]</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin Inc; July 2017</li>
<li>Prilosec (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Nexim (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016</li>
<li>Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2017.</li>
<li>Retevmo (selpercatinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; May 2020.</li>
<li>Norouzi G, AsadZade A, Salimi Y, Khoshbakht S, Pirayesh E. Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi. J Nucl Cardiol. 2022;29(4):1552-1561. [PubMed 33527332</li>
<li>Rose DS, Robinson B, Kannan S, Lee JC. Interaction between the effects of proton pump inhibitors and aspirin on gastric wall sestamibi uptake on myocardial perfusion imaging. J Nucl Cardiol. 2021;28(5):1976-1985. [PubMed 31741323</li>
<li>Qutbi M. What is this image? 2019: Image 2 result : Reduction in interfering gastric wall uptake on myocardial perfusion SPECT following a 2-week period of omeprazole withdrawal. J Nucl Cardiol. 2019;26(5):1517-1519. [PubMed 31359363</li>
<li>Singh H, Mittal BR, Sood A, et al. Association of use of proton pump inhibitors and H2 antagonists with stomach wall uptake in 99m-Tc-methoxy-isobutyl-isonitrile (MIBI) myocardial perfusion imaging. J Nucl Cardiol. 2020;27(5):1611-1619. [PubMed 31087263</li>
<li>Javadi H, Jallalat S, Semnani S, et al. The association of increased stomach wall radiotracer uptake with prolonged use of omeprazole capsules on myocardial perfusion imaging (MPI) using 99mTc-sestamibi SPECT. Nucl Med Rev Cent East Eur. 2013;16(2):91-94. [PubMed 24068640</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974</li>
<li>Cardiolyte (technetium Tc 99m sestamibi) [prescribing information]. N. Billerica, Massachusetts: Lantheus Medical Imaging; December 2019</li>
<li>Technetium Tc 99m sestamibi [product monograph]. Laval, Quebec, Canada: Curium Canada Inc; November 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2020</li>
<li>Vosevir (sofosbuvir and velpatasvir and voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2019</li>
<li>Seyen MV, Colbers A, Abbink EJ, Drenth JPH, Burger DM. Concomitant intake of coca-cola to manage the drug-drug interaction between velpatasvir and omeprazole studied in healthy volunteers. Clin Pharmacol Ther. 2019;106(5):1093-1098. [PubMed 31313296]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270</li>
<li>Evekeo (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2013.</li>
<li>Czerwinski E. Atypical subtrochanteric fractures after long-term bisphosphonate therapy. Endokrynol Pol. 2011;62(1):84-87. [PubMed 21365585</li>
<li>Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169-180. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-785. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-1998. [PubMed 19333676</li>
<li>Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-1218. [PubMed 21483462</li>
<li>Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768-776. [PubMed 21185417</li>
<li>Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131-1136. [PubMed 20872906</li>
<li>Gray SL, LaCroix AZ, Larson J, et alProton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health InitiativeArch Intern Med2010;170(9):765-771[PubMed 20458083</li>
<li>Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101. [PubMed 20353792</li>
<li>Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326. [PubMed 18695179</li>
<li>Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. [PubMed 17190895</li>
<li>Bodmer M, Meier C, Kraenzlin ME, et al. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33(10):843-852. [PubMed 20812769</li>
<li>Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903-910. [PubMed 20585937</li>
<li>Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959. [PubMed 18657011</li>
<li>Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904. [PubMed 19931262</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014;2014:607145. [PubMed 25436170</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782]</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767-773. [PubMed 27737436</li>
<li>Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257-263. [PubMed 26803708</li>
<li>Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43(4):309-315. [PubMed 10071982</li>
<li>van Doorn L, Heersche N, de Man FM, et al. Effect of the proton pump inhibitor esomeprazole on the systemic exposure of capecitabine: results of a randomized crossover trial. Clin Pharmacol Ther. 2022;111(2):455-460. [PubMed 34656072]</li>
<li>Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23(1):37-39. [PubMed 11413862</li>
<li>Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44(2):186-189. [PubMed 9278208]</li>
<li>Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2-receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183]</li>
<li>Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-353. [PubMed 22422635</li>
<li>Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23(3):317-321. [PubMed 3567046</li>
<li>Onfi (clobazam) [prescribing information]. Winchester, KY: Catalent Pharma Solutions, LLC; February 2021</li>
<li>Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999;21(6):604-608. [PubMed 10604819</li>
<li>Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589-592. [PubMed 22293514</li>
<li>Grigoleit HG, Hajdu P, Hundt HK, et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol. 1983;25(1):139-142. [PubMed 6617718]</li>
<li>Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2022.</li>
<li>Frick A, Kopitz J, and Bergemann N, “Omeprazole Reduces Clozapine Plasma Concentrations: A Case Report,” Pharmacopsychiatry, 2003, 36(3):121</li>
<li>[PubMed 12806570</li>
<li>Intensive Medicines Monitoring Programme accessed at http://www.medsafe.govt.nz/Profs/Puarticles/ClozOmep.htm May 14, 2013</li>
<li>Mookhoek EJ and Loonen AJ, “Retrospective Evaluation of the Effect of Omeprazole on Clozapine Metabolism,” Pharm World Sci, 2004, 26(3):180</li>
<li>[PubMed 15230368</li>
<li>Wagner S, Varet-Legros MG, Fabre C, et al, “Confounding Factors for Variation of Clozapine Plasma Levels: Drug Interactions With Proton Pump Inhibitor or Infectious Etiologies?” Eur J Clin Pharmacol, 2011, 67(5):533</li>
<li>[PubMed 21057941</li>
<li>Philipps RJ, Lee Demler T and Lee C, “Omeprazole-Induced Blood Dyscrasia in a Clozapine-Treated Patient,” Innov Clin Neurosci, 2012, 9(9):14</li>
<li>[PubMed 23074697]</li>
<li>Reichenspurner H, Meiser BM, Muschiol F. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transplant. 1993;12(6):987-992. [PubMed 8312324</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al. Changes of resorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc. 1994;26(5):2800-2801. [PubMed 7940881</li>
<li>Schouler L, Dumas F, Couzigou P. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86(8):1097. [PubMed 1858755</li>
<li>Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993;35(2):156-160. [PubMed 8443034</li>
<li>Castellote E, Bonet J, Lauzurica R. Does interaction between omeprazole and cyclosporin exist? Nephron. 1993;65(3):478. [PubMed 8290007</li>
<li>Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM. More about omeprazole-cyclosporine interaction. Am J Gastroenterol. 1993;88(1):154-155. [PubMed 8420264</li>
<li>Zegerid (omeprazole) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; November 2020.</li>
<li>Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057-1069. [PubMed 25929560</li>
<li>Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519. [PubMed 29105855</li>
<li>Kamiya C, Inui N, Hakamata A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361-366. [PubMed 30902567</li>
<li>Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487-494. [PubMed 15025747</li>
<li>Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141-152. [PubMed 11907488</li>
<li>Vlase L, Neag M, Popa A, Muntean D, Leucuta SE. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Curr Ther Res Clin Exp. 2010;71(6):360-368. [PubMed 24688155</li>
<li>Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653-662. [PubMed 24569517</li>
<li>Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. [PubMed 34877801</li>
<li>Inrebic (fedratinib) [prescribing information]. Summit, NJ: Celgene Corporation; August 2019</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672</li>
<li>Vfend (voriconazole) [prescribing information]New York, NY: Pfizer; January 2019</li>
<li>Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021</li>
<li>Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23(2):77-81. [PubMed 11932962</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; January 2020</li>
<li>Armas D, Holt RJ, Confer NF, Checani GC, Obaidi M, Xie Y, Brannagan M. A phase I pharmacokinetic study of cysteamine bitartrate delayed-release capsules following oral administration with orange juice, water, or omeprazole in cystinosis. Adv Ther. 2018;35(2):199-209. [PubMed 29411268]</li>
<li>Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicriob Agents Chemother. 2007;51(3):958-961. [PubMed 17210768]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Lexington, MA: Shire US Inc.; July 2019</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270]</li>
<li>Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.</li>
<li>Grahnen A, Olsson B, Johansson G, Eckernas SA. Doxycycline carrageenate-an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmcol 1994;46(2):143-146. [PubMed 8039533</li>
<li>Monodox (doxycycline monohydrate). Aqua Pharmaceuticals, LLC; Fort Lauderdale, FL: April 2017</li>
<li>Nexium (esomeprazole). AstraZeneca Pharmaceuticals LP; Wilmington DE: October 2016.</li>
<li>Grasela Jr TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615-617. [PubMed 2751276</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081</li>
<li>Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol. 1993;33(1):53-56. [PubMed 8429114]</li>
<li>Lozano R, Bibian C, Quilez RM, Gil J, Constante Y, Garcia-Arilla E. Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol. 2014;77(6):1086-1087. [PubMed 23919252</li>
<li>Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391-1400. [PubMed 23928296</li>
<li>Lexapro (escitalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Courlet P, Guidi M, Glatard A, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019;85(9):2022-2032. [PubMed 31144347</li>
<li>Escitalopram [product monograph]. Kirkland, Quebec, Canada: Accord Healthcare Inc; September 2017.</li>
<li>Marti-Masso JF, Lopez de Munain A, Lopez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother. 1992;26(3):429-430. [PubMed 1554966]</li>
<li>Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-1241. [PubMed 3932118</li>
<li>Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24(4):543-545. [PubMed 3689634</li>
<li>Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935-46. [PubMed 22612290</li>
<li>Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6):563-568. [PubMed 10613611</li>
<li>Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215-220. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al. Reduction of phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol. 1983;25(1):135-137. [PubMed 6617717</li>
<li>Bartle WK, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther. 1983;33(5):649-655. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, Jordan JE. Effect of cimetidine on phenytoin serum levels. Epilepsia. 1983;24(3):284-288. [PubMed 6851961</li>
<li>Iteogu MO, Murphy JE, Shleifer N, Davis REffect of cimetidine on single-dose phenytoin kineticsClin Pharm1983;2(4):302-304[PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology. 1985;35(4):562-565. [PubMed 3982643</li>
<li>Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. Br J Clin Pharmacol. 1989;27(1):83-87. [PubMed 2565119</li>
<li>Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effects of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 1989;30(2):225-229. [PubMed 2647472</li>
<li>Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, Remmel RP. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 1988;29(4):488-491. [PubMed 3391153</li>
<li>Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-544 (ADD 03055) in epileptic patients. Epilepsia. 1985;26(6):602-606. [PubMed 4076064</li>
<li>Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40(8):1122-1128. [PubMed 10448826</li>
<li>Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997;62(5):572-577. [PubMed 9390115</li>
<li>Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol. 1996;53(11):1191-1192. [PubMed 8912496</li>
<li>Rindone JP, Bryan G. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med. 1996;156(10):1113. [PubMed 8639000</li>
<li>Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology. 1996;46(4):1172-1173. [PubMed 8780118</li>
<li>Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother. 1998;32(12):1295-1298. [PubMed 9876809</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, Shearman DJ, Hann CS. Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed). 1981;282(6275):1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med. 1981;95(2):244-245. [PubMed 7258891</li>
<li>Phillips P, Hansky J. Phenytoin toxicity secondary to cimetidine administration. Med J Aust. 1984;141(9):602. [PubMed 6092884</li>
<li>Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12(4):329-333. [PubMed 2396305</li>
<li>Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36(4):380-382. [PubMed 12959321</li>
<li>Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol. 1992;34(1):75-78. [PubMed 1633070</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Dujic T, Cvijic S, Elezovic A, et al. Interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype. J Pers Med. [published online May 3 2021].doi:10.3390/jpm11050367] [PubMed 34063566]</li>
<li>Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474-484. [PubMed 34649118</li>
<li>Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487-5493. [PubMed 32933995</li>
<li>Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR tirals. Ann Oncol. 2020;31(4):535-531. [PubMed 32115349</li>
<li>Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016;26(9):609-615. [PubMed 27603551</li>
<li>Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacotherapy. 2022;56(4):377-386. [PubMed 34282636]</li>
<li>Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12(15):2080-2082. [PubMed 9814882</li>
<li>Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-428. [PubMed 18281734</li>
<li>Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122-129. [PubMed 27693678]</li>
<li>Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.</li>
<li>Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69(4):266-273. [PubMed 11309556</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672]</li>
<li>Sharma VR, Brannon MR, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. Southern Med J. 2004;97(9):887-889.[PubMed 15455980</li>
<li>Salovaara S, Sandberg A-S, Andlid T. Combined impact of pH and organic acids on iron uptake by caco-2 cells. J Agric Food Chem. 2003;51:7820-7824. [PubMed 14664552</li>
<li>Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Ann Rev Nutr. 2003;23:283-301. [PubMed 12626689]</li>
<li>Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42(10):4243-4246. [PubMed 21168674</li>
<li>Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061-2067. [PubMed 20671023</li>
<li>Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196-1201. [PubMed 19783713</li>
<li>Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9(7):1650-1656. [PubMed 19519820</li>
<li>Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605-611. [PubMed 19481022</li>
<li>Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46(5):1362-1365. [PubMed 24935300</li>
<li>David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit. 2012;34(3):331-336. [PubMed 22549498</li>
<li>Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30(1):46-51. [PubMed 18223462</li>
<li>Kato R, Ooi K, Ikura-Mori M, et alImpairment of mycophenolate mofetil absorption by calcium polycarbophilJ Clin Pharmacol2002;42(11):1275-1280[PubMed 12412828</li>
<li>Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518-524. [PubMed 24162246</li>
<li>Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. [PubMed 25913040</li>
<li>Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265-1272. [PubMed 21903891</li>
<li>Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120-123. [PubMed 21192310</li>
<li>van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014;72(2):86-90. [PubMed 24659591</li>
<li>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; September 2013</li>
<li>Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565-571. [PubMed 21256049</li>
<li>Sakuludomakan W, Takuathung MN, Dukaew N, Koonrungsesomboon N. Drug-drug interactions between mycophenolic acid and proton pump inhibitors: a systematic review and meta-analysis. Ther Drug Monit. 2022;44(3):384-390. [PubMed 35239287</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.</li>
<li>Mycapssa (octreotide) delayed release capsules [prescribing information]. Scotland, UK: MW Encap Ltd; June 2020.</li>
<li>Prescribing information. Adempas (riociguat). Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., October 2013.</li>
<li>Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401-1406. [PubMed 16791014</li>
<li>Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914</li>
<li>Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83(6):867-872. [PubMed 17898705</li>
<li>Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech, Inc.; September 2020</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50:1081-1084. [PubMed 12461038</li>
<li>Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacother. 2006;26(8):1060-1068. [PubMed 16863482]</li>
<li>Nexavar (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2018</li>
<li>Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. J Cancer Res Clin Oncol. 2020;146(10):2693-2697. [PubMed 32449002</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(11):3078-3087. [PubMed 20395213]</li>
<li>Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet. 2008;23:134-138. [PubMed 18445994</li>
<li>Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet. 2007;22:441-444. [PubMed 18159131</li>
<li>Moreau C, Debray D, Loriot MA, et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation. 2006;81:487-488. [PubMed 16477241</li>
<li>Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38:791-794. [PubMed 15010519</li>
<li>Homma M, Itagaki F, Yuzawa K, et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation. 2002, 73:303-304. [PubMed 11821750</li>
<li>Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821-826. [PubMed 19139162</li>
<li>Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos. 2007;28:167-175. [PubMed 17377957</li>
<li>Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56:1055-1059. [PubMed 15285851</li>
<li>Itagaki F, Homma M, Yuzawa K, et alDrug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutationTransplant Proc2002;34:2777-2778[PubMed 12431607</li>
<li>Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin a blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56:439-440. [PubMed 11009056</li>
<li>Mei T, Noguchi H, Suetsugu K, et al. Effects of concomitant administration of vonoprazan fumarate on the tacrolimus blood concentration in kidney transplant recipients. Biol Pharm Bull. 2020;43(10):1600-1603. [PubMed 32999170</li>
<li>Suzuki Y, Yoshihashi T, Takahashi K, Furuya K, Ohkohchi N, Oda T, Homma M. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. J Clin Med. 2021;10(17):3964. [PubMed 34501411</li>
<li>Pascual J, Marcen R, Orea OE, et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. Transplant Proc. 2005;37(9):3752-3753. [PubMed 16386527</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862. [PubMed 9224780</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A4 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143]</li>
<li>Mouden M, Rijkee KS, Schreuder N, Timmer JR, Jager PL. Influence of proton-pump inhibitors on stomach wall uptake of 99mTc-tetrofosmin in cadmium-zinc-telluride SPECT myocardial perfusion imaging. Nucl Med Commun. 2015;36(2):143-147. [PubMed 25356621</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974]</li>
<li>Ock M, Lee S, Kim H. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor coadministration in patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2022;47(7):1028-1035. [PubMed 35257383]</li>
<li>Aptivus (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 20202. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914]</li>
<li>Ahmad S. Omeprazole-warfarin interaction. South Med J. 1991;84(5):674-675. [PubMed 2035104</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [PubMed 1493083</li>
<li>Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-184. [PubMed 2718223</li>
<li>Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci. 2003;20(4-5):439-449. [PubMed 14659488</li>
<li>Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab. 2005;6(5):399-411. [PubMed 16248835</li>
<li>Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol. 1993;110(1):482-490. [PubMed 8220911</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit. 2008;30(3):276-281. [PubMed 18520598</li>
<li>Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011;153(3):379-385. [PubMed 21418179</li>
<li>de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LMNo effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamicsBr J Clin Pharmacol1997;44(4):399-401[PubMed 9354316</li>
<li>Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN. Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol. 1997;32(10):991-994. [PubMed 9361171</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [PubMed 15258107</li>
<li>Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780]</li>
<li>Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56 Suppl 1:56-61. [PubMed 14616415</li>
<li>Yan M, Wu ZF, Tang D, et al. The impact of PPIs on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018;108:60-64. [PubMed 30216801</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological disease. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211. [PubMed 18171251</li>
<li>Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses. 2012;55(6):483-492. [PubMed 22429709</li>
<li>Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X. Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother. 2021;65(9):e0020721. [PubMed 34152823</li>
<li>Boyd NK, Zoellner CL, Swancutt MA, et al. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001-6002. [PubMed 22890768</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer; January 2019.</li>
<li>Veerman GDM, Hurkmans DP, Paats MS, et al. Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother. 2022;155:113695. [PubMed 36126454]</li>
<li>Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol. 2004;44(6):640-645. [PubMed 15145972</li>
<li>Pylera (bismith subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</li>
<li>Tabrecta (capmatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</li>
<li>Lau YY, Gu W, Lin T, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(6):1119-1128. [PubMed 28424965</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2016.</li>
<li>Clarithromycin [prescribing information]. Bedminster, NJ: Alembic Pharmaceuticals, Inc.; February 2022</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; March 2022.</li>
<li>Michaud V, Kreutz Y, Skaar T, et al. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 2014;14(2):151-159. [PubMed 23629159</li>
<li>Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475-482. [PubMed 22318618</li>
<li>Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharmacol Drug Dev. 2016;5(4):269-277. [PubMed 27310328</li>
<li>Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2015;60(1):105-114. [PubMed 26459906</li>
<li>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29. [PubMed 25646891</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. Doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. [PubMed 18076219</li>
<li>Nader A, Mostafa NM, Kim E, Shebley M. Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. Clin Transl Sci. 2022;15(5):1269-1280. [PubMed 35137535</li>
<li>Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol. 2014;54(4):422-431. [PubMed 24165884</li>
<li>Vassiliou D, Sardh E, Harper P, et al. A drug-drug interaction study evaluating the effect of givosiran, a small interfering ribonucleic acid, on cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250-1260. [PubMed 34510420</li>
<li>Luzu (luliconazole) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; February 2017</li>
<li>Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. [PubMed 29178272</li>
<li>Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465-472. [PubMed 28155129</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Tpoxx (tecovirimat) [prescribing information]Winchester, KY: Catalent Pharma Solutions; July 2018</li>
<li>Brukinsa (zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA, Inc.; November 2019</li>
<li>Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999;47(4):454-457. [PubMed 10233213</li>
<li>Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Jaypirca (pirtobrutinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; January 2023.</li>
<li>Bolek T, Samos M, Stanciakova L, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2017;Apr 25 (Epub ahead of print). [PubMed 28452843</li>
<li>Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33(6):619-623. [PubMed 29255511</li>
<li>Stangier J, Eriksson BI, Dahl O, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563. [PubMed 15831779</li>
<li>Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59. [PubMed 18076218</li>
<li>Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175. [PubMed 21972820</li>
<li>Schnierer M, Samos M, Bolek T, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020;75(4):333-335. [PubMed 31895873</li>
<li>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. [PubMed 19717844</li>
<li>Ollier E, Hodin S, Basset T, et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29(6):604-614. [PubMed 26392328</li>
<li>O'Dea D, Whetteckey J, Ting NA prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatranCardiol Ther2016;5(2):187-201[PubMed 27709460</li>
<li>Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586-595. [PubMed 25960019</li>
<li>Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-1713, 1713a-1713b. [PubMed 23425521</li>
<li>Pradaxa (dabigatran) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; July 2020.</li>
<li>Tafinlar (dabrafenib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.</li>
<li>Drewelow B, Schaffler K, Reitmeir P, Bethke TD. Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittelforschung. 2010;60(8):483-491. [PubMed 20863004</li>
<li>Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-164. [PubMed 7648765</li>
<li>Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995;58(1):62-72. [PubMed 7628184</li>
<li>Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47(1):79-85. [PubMed 2104790</li>
<li>Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39(1):51-54. [PubMed 2276389</li>
<li>Lima DR, Santos RM, Werneck E, Andrade GN. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers. Eur J Drug Metab Pharmacokinet. 1991;16(3):161-170. [PubMed 1814733</li>
<li>Locniskar A, Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. J Clin Pharmacol. 1986;26(4):299-303. [PubMed 2871051]</li>
<li>Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569-572. [PubMed 1954072</li>
<li>Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1995;33(9):481-485. [PubMed 8520804</li>
<li>Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400-402. [PMID: 17458401</li>
<li>Le GH, Schaefer MG, Plowman BK, Morreale AP, Delattre M, Okino L, Felicio L. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors. Am J Health Syst Pharm. 2003;60(13):1343-1345. [PubMed 12901036</li>
<li>Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CBV. Omeprazole does not modulate pharmacokinetic effect of digoxin in patients with heart failure. Int J Cardiol. 2015;179:343-344. [PubMed 25464482]</li>
<li>Rozlytrek (entrectinib) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; August 2019.</li>
<li>Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508-516. [PubMed 18492125</li>
<li>Intelence (etravirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; July 2019.</li>
<li>Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose fedratinib in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(5):995-1001. [PubMed 32318809]</li>
<li>Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on the filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585-594. [PubMed 30768860</li>
<li>Jyseleca (filgotinib) [summary of product characteristics]. Mechelen, Belgium: Galapagos NV; January 2022.</li>
<li>Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;8:457-464. [PubMed 17760738</li>
<li>Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 2006;42:61-67. [PubMed 16639341</li>
<li>Kiser JJ, Lichtenstein KA, Anderson PL, et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26:511-514. [PubMed 16553510</li>
<li>Ford SL, Wire MB, Lou Y, et al. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49:467-469. [PubMed 15616339</li>
<li>Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48:791-798. [PubMed 14982766]</li>
<li>Yin O, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850. [PubMed 15608563</li>
<li>Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012;68(5):553-560. [PubMed 22189672</li>
<li>Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731. [PubMed 19299322</li>
<li>Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509. [PubMed 20186406]</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</li>
<li>Brexafemme (ibrexafungerp) [prescribing information]. Jersey City, NJ: Scynexis Inc; June 2021.</li>
<li>Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2021</li>
<li>Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386-1394. [PubMed 26054042]</li>
<li>Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185-189. [PubMed 21150767</li>
<li>Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821-829. [PubMed 27890768</li>
<li>Tran-Duy A, Connell NJ, Vanmolkot FH, et al. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med. 2019;285(2):205-214. [PubMed 30141278</li>
<li>Imai R, Higuchi T, Moriomoto M, Koyamada R, Okada S. Iron deficiency anemia due to long-term use of a proton pump inhibitor. Inter Med. 2018;57(6):899-901. [PubMed 29151538</li>
<li>Mabuchi S, Suzuki R, Sasak M, et al. Case report of severe iron deficiency anemia caused by proton pump inhibitor in an elderly patient. Geriatr Gerontol Int. 2017;662-663. [PubMed 28405975</li>
<li>Hashimoto R, Matsuda T, Chonan A. Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med. 2014;53(20):2297-2299. [PubMed 25318791</li>
<li>Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97(9):887-889. [PubMed 15455980</li>
<li>Khatib MA, Rahim O, Kania R, Molloy P. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig Dis Sci. 2002;47(11):2596-2597. [PubMed 12452401</li>
<li>Eghbali A, Khalilpour A, Taherahmadi H, Bagheri BPantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled studyTherapie2019;74(5):507-512[PubMed 30704764</li>
<li>Shalev H, Quider AA, Harosh MB, Kapelushnik J. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia. Pediatr Hematol Oncol. 2016;33(7-8):457-461. [PubMed 27960647</li>
<li>Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-1295. [PubMed 17344278</li>
<li>Tempel M, Chawla A, Messina C, Celiker MY. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol. 2013;30(3):307-310. [PubMed 24385811</li>
<li>Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-292. [PubMed 1607604</li>
<li>Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011;134(2):224-231. [PubMed 21911976</li>
<li>Sarker SA, Mahmud H, Davidsson L, et al. Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology. 2008;135(5):1534-1542. [PubMed 18775429]</li>
<li>Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34(5):317-325. [PubMed 24567279</li>
<li>Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; June 2019.</li>
<li>Koch KM, Im Y-H, Kim S-B, et al. Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients. Clin Pharmacol Drug Dev. 2013;2(4):336-341. [PubMed 27121938</li>
<li>Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015</li>
<li>Tykerb (lapatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.</li>
<li>Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</li>
<li>Adhansia XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Purdue Pharmaceuticals LP; July 2019</li>
<li>Cotempla XR ODT (methylphenidate) extended-release orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC; June 2017</li>
<li>Concerta (methylphenidate) extended-release tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2017</li>
<li>Ritalin LA (methylphenidate) extended-release capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019</li>
<li>Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Greenville, NC: Patheon Manufacturing Services LLC; June 2019</li>
<li>Jornay PM (methylphenidate) extended-release capsules [prescribing information]. Cherry Hill, NJ: Ironshore Pharmaceuticals Inc; April 2019</li>
<li>Metadate CD (methylphenidate) extended-release capsules [prescribing information]. Smyrna, GA: UCB Inc; June 2014</li>
<li>Quillichew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; March 2017</li>
<li>Quillivant XR (methylphenidate) extended-release oral suspension [prescribing information]New York, NY: Pfizer Inc; January 2017</li>
<li>Ritalin SR (methylphenidate) extended-release tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.</li>
<li>Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120-2138. [PubMed 28808886</li>
<li>Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; February 2022.</li>
<li>Ji T, Rockich K, Epstein N, et al. Evaluation of drug-drug interactions of pemigatinib in healthy participants [published online July 19, 2021]. Eur J Clin Pharmacol. doi: 10.1007/s00228-021-03184-z. [PubMed 34282472</li>
<li>Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; February 2021.</li>
<li>Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. [PubMed 18303127</li>
<li>Seiler D, Doser K, Salem I. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. Arzneimittelforschung. 2011;61(4):247-251. [PubMed 21650084</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed 25012577</li>
<li>Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906-913. [PubMed 28875498</li>
<li>Effient (prasugrel) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; December 2020.</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Yang E, Ji SC, Jang I-J, Lee S. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet. 2023;62(4):599-608. [PubMed 36897544</li>
<li>Kolawole JA, Mustapha A, Abdul-Aguye I, Ochekpe N, Taylor RB. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal. 1999;20(5):737-743. [PubMed 10701981</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole, and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. Eur J Clin Pharmacol. 1996;50(5):417-419. [PubMed 8839666]</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2020</li>
<li>Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-492. [PubMed 19143531]</li>
<li>Zhou J, Quinlan M, Glenn K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol. 2016;82(4):1022-1029. [PubMed 27277189</li>
<li>Odomzo (sonidegib) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2017.</li>
<li>Tazverik (tazemetostat) [prescribing information]. Cambridge, MA: Epizyme, Inc.; January 2020.</li>
<li>Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. [PubMed 16641395</li>
<li>Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. [PubMed 17669709</li>
<li>Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-59. [PubMed 16477543</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075</li>
<li>Abi-Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? Arq Bras Endocrinol Metabol. 2014;58(7):731-736. [PubMed 25372582</li>
<li>Ermeza (levothyroxine) solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022</li>
<li>Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. [PubMed 25259910]</li>
<li>Giri P, Gupta L, Naidu S, et al. In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, alicarb, methiocarb, motelukast and ziprasidone. Drug Metabo Lett. 2019;12(2):101-116. [PubMed 30117405</li>
<li>Egaten (triclabendazole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2019.</li>
<li>Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26-33. [PubMed 23110788]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. Doi: 10.1007/s40262-017-0591</li>
<li>[PubMed 28866861]</li>
<li>Verquvo (vericiguat) [prescribing information].Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2021.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022</li>
<li>Calquence (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2022.</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” Pharmacotherapy, 2010, 30(8):787-96. [PubMed 20653354</li>
<li>Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” Clin Cardiol, 2010, 33(3):168-71. [PubMed 20235209</li>
<li>Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” Arch Intern Med, 2010, 170(8):704-10[PubMed 20421557</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2018.</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2021.</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067]</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2019.</li>
<li>Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol. 2015;71(12):1461-1465. [PubMed 26400679</li>
<li>Bertram V, Yeo K, Anoopkumar-Dukie S, Bernaitis N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract. 2019;73(11):e13382. [PMID 31250945</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2014.</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Cojutti P, Candoni A, Forghieri, et al. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and/or with CYP inhibitors plus CYP inducers. Basic Clin Pharmacol Toxicol. 2016;118(6):474-479. [PubMed 26572687</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143</li>
<li>Scholler J, Nivoix Y, Herbrecht R, et al. Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. Int J Clin Pharm. 2011;33(6):905-908. [PubMed 22108788</li>
<li>Tsubokura M, Miura Y, Itokawa T, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol. 2011;51(10):1488-1490. [PubMed 21098688</li>
<li>Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262-3267. [PubMed 23629724</li>
<li>Dexilant (dexlansoprazole) [prescribing information]Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2018</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; October 2017</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc.; January 2019.</li>
<li>Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” Ann Pharmacother, 2003, 37(6):808-11. [PubMed 12773066</li>
<li>Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors,” Am J Cardiol, 2004, 94:1140</li>
<li>[PubMed 15518608</li>
<li>Amsden GW, Kuye O,Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” J Clin Pharmacol, 2002, 42:444</li>
<li>[PubMed 11936570</li>
<li>Lee AJ,Maddix DS, “Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin,” Ann Pharmacother, 2001, 35:26-31. [PubMed 11197581</li>
<li>Chen C, Lin J, Smolarek T, et al, “P-Glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in Mdr1a/B Knockout and Wild-Type Mice,” Drug Metab Dispos, 2007, 35:1725</li>
<li>[PubMed 17640956</li>
<li>Chen C, Mireles RJ, Campbell SD, et al, “Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors with Abcb1, Abcc2, and Oatp1b1,” Drug Metab Dispos, 2005, 33:537-46. [PubMed 15616150</li>
<li>Hochman JH, Pudvah N, Qiu J, et al, “Interactions of Human P-Glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin,” Pharm Res, 2004, 21:1686-91. [PubMed 15497697</li>
<li>Wu X, Whitfield LR,Stewart BH, “Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter,” Pharm Res, 2000, 17:209-15. [PubMed 10751037</li>
<li>Pauli-Magnus C, Rekersbrink S, Klotz U, et al, “Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein,” Naunyn Schmiedebergs Arch Pharmacol, 2001, 364:551</li>
<li>[PubMed 11770010</li>
<li>Collett A, Tanianis-Hughes J, Carlson GL, et al, “Comparison of P-Glycoprotein-Mediated Drug-Digoxin Interactions in Caco-2 with Human and Rodent Intestine: Relevance to in Vivo Prediction,” Eur J Pharm Sci, 2005, 26:386-93. [PubMed 16153812]</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Prevacid (lansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2020.</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed: 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc. 2015;4(11). [PubMed: 26514161</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed: 22464478</li>
<li>Shamliyan TA, Middleton M, Borst C. Patient-centered outcomes with concomitant use of proton pump inhibitors and other drugs. Clin Ther. 2017;39(2):404-427. [PubMed: 28189362</li>
<li>Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823. [PubMed: 20102352</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed: 25012577</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-36[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244</li>
<li>Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig. 2011;31(10):727-733. [PubMed 21877765</li>
<li>Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44(11):1223-1229. [PubMed 15496639</li>
<li>Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005;60(1):61-68. [PubMed 15963095</li>
<li>Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162-164. [PubMed 15546944]</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2014; July 28 (Epub ahead of print). [PubMed 25068772</li>
<li>Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-277. [PubMed 18615373</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi TThe role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazoleTher Drug Monit2008;30(3):276-281[PubMed 18520598</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11). pii: e002245. [PubMed 26514161</li>
<li>Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43(3):212-224. [PubMed 22564422</li>
<li>Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35(2):127-139. [PubMed 22204719</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Lu M. Report: Impact of drug combination of clopidogrel and pantoprazole in the prognosis of patients with transient ischemic attack. Pak J Pharm Sci. 2017;30(1):217-221. [PubMed 28603135</li>
<li>Choi YJ, Kim N, Jang IJ, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-511. [PubMed 28395507</li>
<li>Gu RX, Wang XZ, Li J, Deng J, Li XX, Wang JEffects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrelMil Med Res2016;3</li>
<li>[PubMed 28018669</li>
<li>Bolek T, Samos M, Simonova R, et al. Does pantoprazole affect the on-treatment platelet reactivity in patients with acute STEMI treated with ADP receptor blockers?-a pilot prospective study. Am J Ther. 2017;24(2):e162-e166. [PubMed 27415979</li>
<li>Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacol Rep. 2012;64(2):360-368. [PubMed 22661187</li>
<li>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2020</li>
<li>Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012;33(5):278-283. [PubMed 22623337]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, Dammann G, Hiemke C, Grunder G, Paulzen M. The effects of co-prescription of pantoprazole on the clozapine metabolism. Pharmacopsychiatry. 2020;53(2):65-70. [PubMed 31614374]</li>
<li>Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metabol Dispos. 2014;42(7):1174-1179. [PubMed 24764147]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. doi: 10.1007/s40262-017-0591</li>
<li>Chandelia S, Dubey NK. Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole. Indian J Crit Care Med. 2016;20(2):127-128. [PubMed 27076718</li>
<li>Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39(6):700-703. [PubMed 7654493</li>
<li>Henriksen DP, Stage TB, Hansen MR, Rasmussen L, Damkier P, Pottegard A. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. 2015;24(12):1337-1340. [PubMed 26395871</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [Pubmed1493083</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf LComparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activitiesDrug Metab Dispos2004;32(8):821-827[PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780</li>
<li>Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71(9):1059-1066. [PubMed 26071277</li>
<li>Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. [PubMed 20844485]</li>
<li>El-Bohy D, Sharkawy M, Abo-Elazm S, et al. Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney transplantation: A randomized clinical trial. Ther Apher Dial. 2020;24(5):591-598. [PubMed 31856374</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-440. [PubMed 11009056</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. Pantoprazole does not affect cyclosporin a blood concentration in kidney-transplant patients. Eur J Clin Pharmacol. 2000;55(10):733-735. [PubMed 10663451]</li>
<li>Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74(10):2187-2192. [PubMed 20736505</li>
<li>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70(3):383-392. [PubMed 20716239</li>
<li>Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. [PubMed 19108880</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-2436[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. [PubMed 16772608</li>
<li>Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735-741. [PubMed 17361128</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107]</li>
<li>Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61(3):309-314. [PubMed 16487224</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2018.</li>
<li>Liu G, Wen J, Guo D, et al. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. J Pharmacol Sci. 2016;132(4):244-248. [PubMed 27245553]</li>
<li>Hata M, Hayasaka M, Sezai A, et al, “Proton Pump Inhibitors May Increase the Risk of Delayed Bleeding Complications after Open Heart Surgery If Used Concomitantly with Warfarin,” Thorac Cardiovasc Surg, 2008, 56:274-7</li>
<li>Ahmad S, “Omeprazole-Warfarin Interaction,” South Med J, 1991, 84:674-5</li>
<li>Unge P, Svedberg LE, Nordgren A, et al, “A Study of the Interaction of Omeprazole and Warfarin in Anticoagulated Patients,” Br J Clin Pharmacol, 1992, 34:509-12</li>
<li>Sutfin T, Balmer K, Bostrom H, et al, “Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men,” Ther Drug Monit, 1989, 11:176-84</li>
<li>Zhou Q, Chan E, “Effect of Omeprazole on the Anticoagulant Activity and the Pharmacokinetics of Warfarin Enantiomers in Rats,” Eur J Pharm Sci, 2003, 20:439-49</li>
<li>Zhou Q, Zhou S, Chan E, “Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and cDNA-Expressed Cytochrome P450 Isozymes,” Curr Drug Metab, 2005, 6:399-411</li>
<li>Hermans JJ, Thijssen HH, “Human Liver Microsomal Metabolism of the Enantiomers of Warfarin and Acenocoumarol: P450 Isozyme Diversity Determines the Differences in Their Pharmacokinetics,” Br J Pharmacol, 1993, 110:482-90</li>
<li>Uno T, Sugimoto K, Sugawara K, et al, “The Role of Cytochrome P2C19 in R-Warfarin Pharmacokinetics and Its Interaction with Omeprazole,” Ther Drug Monit, 2008, 30:276-81</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” Drug Metab Dispos, 2004, 32:821-7</li>
<li>Ko J, Sukhova N, Thacker D, et al, “Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms,” Drug Metab Dispos, 1997, 25:853-862.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2016.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (Tak-390mr), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29:35-50. [PubMed 19067473</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2015;63(1):45-50. [PubMed 25068772</li>
<li>Dexilant (dexlansoprazole) [Prescribing Information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2017</li>
<li>Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, Shin JG. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos. 2005;33(2):209-213. [PubMed 15537834]</li>
<li>Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; June 2018</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2018</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30(8):787-796. [PubMed 20653354</li>
<li>Stockl KM, Le L, Zakharyan A, et alRisk of rehospitalization for patients using clopidogrel with a proton pump inhibitorArch Intern Med2010;170(8):704-710[PubMed 20421557</li>
<li>Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Mahabaleshwarkar RK, Yang Y, Datar MV, et al. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Curr Med Res Opin. 2013;29(4):315-323. [PubMed 23362935</li>
<li>Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012;32(9):809-818. [PubMed 22744772</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors - a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997. [PubMed 19726078</li>
<li>Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329. [PubMed 19933932</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population based study of drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Wei P, Zhang YG, Ling L, et al. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-2864. [PubMed 27882086</li>
<li>Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824-834. [PubMed 22364155</li>
<li>Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2CDrug Metab Dispos. 2012;40(9):1698-1711. [PubMed 22648560</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478]</li>
<li>Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2018.</li>
<li>Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc; April 2006</li>
<li>Kayexalate (sodium polystyrene sulfonate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; December 2010</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a “nonsystemic” antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Fernandez PC, Kovnat PJ. Metabolic acidosis reversed by the combination of magnesium and a cation-exchange resin. N Engl J Med. 1972;286(1):23-24. [PubMed 5006921</li>
<li>Ziessman HA. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. South Med J. 1976;69(4):497-499. [PubMed 817399</li>
<li>Madias NE, Levey AS. Metabolic alkalosis due to absorption of “nonabsorbable” antacids. Am J Med. 1983;74(1):155-158. [PubMed 6849324]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36(6):1219-1224. [PubMed 1329615</li>
<li>Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55. [PubMed 8737124</li>
<li>Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989;46(6):700-705. [PubMed 2598571</li>
<li>Shiba K, Sakamoto M, Nakazawa Y, et al. Effects of antacid on absorption and excretion of new quinolones. Drugs. 1995;49(Suppl 2):360-361. [PubMed 8549362</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):39-48. [PubMed 11352441</li>
<li>Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830-832. [PubMed 1503446</li>
<li>Lehto PL, Kivisto KTDifferent effects of products containing metal ions on the absorption of lomefloxacinClin Pharmacol Ther1994;56(5):477-482[PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35(3):302-304. [PubMed 8471407</li>
<li>Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Emrok O (levonadifloxacin) tablet [product information]. Maharashtra, India: Wockhardt Limited; April 2022.</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(suppl 1):39-48. [PubMed 11352441</li>
<li>Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy. 1999;45(6):504-511. [PubMed 10567782</li>
<li>Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther. 1998;20(6):1149-1158. [PubMed 9916608</li>
<li>Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on the absorption of DR-3355 in humans. Antimicrobial Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother. 1990;34(12):2436-2438. [PubMed 2088202</li>
<li>Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Grasela TH Jr, Schentag JJ, Sedman AJ, et alInhibition of enoxacin absorption by antacids or ranitidineAntimicrob Agents Chemother1989;33(5):615-617[PubMed 2751276</li>
<li>Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):93-97. [PubMed 9222077</li>
<li>Hoffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol. 1992;33(1):115-116. [PubMed 1540482</li>
<li>Jaehde U, Sorgel F, Stephan U, Schunak W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother. 1994;38(5):1129-1133. [PubMed 8067750</li>
<li>Maesen FP, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids. J Antimicrob Chemother. 1987;19(6):848-850. [PubMed 3475268</li>
<li>Prescribing information. Cytotec (misoprostol). New York, NY: Pfizer Inc., September 2009.</li>
<li>Quinine [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; July 2015.</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017</li>
<li>Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020-3026. [PubMed 22450971</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494</li>
<li>FDA Antiviral Drugs Advisory Committee Meeting. ISENTRESS™ (raltegravir) 400 mg For Treatment of HIV (NDA 22-145). Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf. Published September 5, 2007. Accessed online November 15, 2013.</li>
<li>Dimaval (DMPS) Hartkapseln (unithiol) [summary of product characteristics]. Berlin, Germany: Haupt Pharma Wulfing GmbH; June 2020.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc.; March 2010</li>
<li>Ruggiero M, Brunese M, Morelli S, et al. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-777. [PubMed 6895034</li>
<li>Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. Digestion. 1987;37(1):35-42. [PubMed 3609503</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: Modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;25(15):1093-1115</li>
<li>Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium. 1986;5(5-6):293-300. [PubMed 3807422</li>
<li>Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Thioctic acid tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200201478. Accessed September 1, 2014.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2013</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2020.</li>
<li>Evaluation of Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis and Clinical Implications. Guidance for Industry [Draft]. Available at: https://www.fda.gov/media/144026/download. Accessed July 22, 2021.</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; June 2019.</li>
<li>HalfLytely and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) [prescribing information]. Braintree, MA: Braintree Laboratories Inc; May 2006.</li>
<li>De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</li>
<li>Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010</li>
<li>Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015</li>
<li>Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011</li>
<li>Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc.; April 2023.</li>
<li>Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; January 2021.</li>
<li>Calcijex (calcitriol) injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; March 2012</li>
<li>Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-797. [PubMed 6895034</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;26(15):1093-1115. [PubMed 14640773</li>
<li>Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Cefdinir [prescribing information]. Parsippany, NJ: Ascend Laboratories; January 2018.</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ, Collier PS. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159-163. [PubMed 6292443</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ. In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin. J Trop Med Hyg. 1982;85(4):153-158. [PubMed 7143531</li>
<li>Iwuagwu MA, Aloko KS. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655-658. [PubMed 1359089</li>
<li>Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: sanofi-aventis US LLC; October 2018.</li>
<li>Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology. 1981;80(4):661-665. [PubMed 7202937</li>
<li>Naggar VF, Khalil SA, Gouda MW. Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans. J Pharm Sci. 1978;67(7):1029-1030. [PubMed 207854</li>
<li>Lee DA, Taylor GM, Walker JG, et al. The effect of concurrent administration of antacids on prednisolone absorption. Br J Clin Pharmacol. 1979;8(1):92-94. [PubMed 552304</li>
<li>Tanner AR, Caffin JA, Halliday JW, et al. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol. 1979;7(4):397-400. [PubMed 444359</li>
<li>Albin H, Vincon G, Demotes-Mainard F, et al. Effects of aluminum phosphate on the bioavailability of cimetidine and prednisolone. Eur J Clin Pharmacol. 1984;26(2):271-273. [PubMed 6723769]</li>
<li>Product monograph. Pradaxa (dabigatran etexilate). Burlington, Ontario: Boehringer Ingelheim Canada Ltd., February 2019</li>
<li>Prescribing information. Pradax (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.</li>
<li>Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700-709. [PubMed 19395585</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</li>
<li>Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019</li>
<li>Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2019</li>
<li>Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol. 2003;43(2):171-179. [PubMed 12616670]</li>
<li>Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016</li>
<li>Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015</li>
<li>Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764-776. [PubMed 19446149]</li>
<li>Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45-50. [PubMed 23774876</li>
<li>Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2019</li>
<li>Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2019</li>
<li>Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug-drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:1</li>
<li>[PubMed 30798679]</li>
<li>Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products LP; April 2019.</li>
<li>Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals Inc; October 2016.</li>
<li>Allegra (fexofenadine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2010.</li>
<li>Fosinopril [prescribing information]. Princeton, NJ: Sandoz Inc; May 2013</li>
<li>Apo-fosinopril (fosinopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2008.</li>
<li>Yagi T, Naito Y, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248-254. [PubMed 22240839</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008</li>
<li>Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009</li>
<li>Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490</li>
<li>Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581</li>
<li>Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976</li>
<li>McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345</li>
<li>Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282]</li>
<li>Prescribing information. Anaspaz (hyoscyamine). Lenexa, KS: B. F. Ascher &amp; Compant, Inc., 6/2010</li>
<li>Prescribing information. Hyosyne (hyoscyamine). Spring Valley, NY: Silarx Pharmaceuticals, Inc., 4/2007</li>
<li>Prescribing information. Levsin (hyoscyamine). Marietta, GA: Alaven Pharmaceutical LLC, 2/2008</li>
<li>Prescribing information. Symax SR (hyoscyamine). Ft. Worth, TX: Capellon Pharmaceuticals, LLC, 9/2012</li>
<li>Prescribing information. Oscimin-SR (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011</li>
<li>Prescribing information. Oscimin (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</li>
<li>Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr. 1991;53(1):106-111. [PubMed 1984334</li>
<li>Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol. 2002;42(10):1171-1176. [PubMed 12362933</li>
<li>Wallace KL, Curry SC, LoVecchio F, Raschke RA. Effect of magnesium hydroxide on iron absorption following simulated mild iron overdose in human subjects. Acad Emerg Med. 1998;5(10):961-965. [PubMed 9862585</li>
<li>Hall GJ, Davis AE. Inhibition of iron absorption by magnesium trisilicate. Med J Aust. 1969;2(2):95-96. [PubMed 5803866</li>
<li>Ekenved G, Halvorsen L, Solvell L. Influence of a liquid antacid on the absorption of different iron salts. Scand J Haematol Suppl. 1976;28:65-77. [PubMed 1064903</li>
<li>O'Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Rastogi SP, Padilla F, Boyd CM. Effect of aluminum hydroxide on iron absorption. J Ark Med Soc. 1976;73(3):133-134. [PubMed 134015</li>
<li>Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81(6):1068-1071. [PubMed 7286584</li>
<li>Benkhedda K, L'abbe MR, Cockel KAEffect of calcium on iron absorption in women with marginal iron statusBr J Nutr2010;103(5):742-748[PubMed 19860985</li>
<li>Minihane AM, Fairweather-Tait SJ. Effect of calcium supplementation on daily nonheme-iron absorption and long-term iron status. Am J Clin Nutr. 1998;68(1):96-102. [PubMed 9665102</li>
<li>Dawson-Hughes B, Seligson FH, Hughes VA. Effects of calcium carbonate and hydroxyapatite on zinc and iron retention in postmenopausal women. Am J Clin Nutr. 1986;44(1):83-88. [PubMed 3014855</li>
<li>Spencer BR, Guo Y, Cable RG, et al. Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. Transfusion. 2019;59(10):3146-3156. [PubMed 31318071</li>
<li>Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016;97(6):583-593. [PubMed 27155295</li>
<li>Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001;22(6):490-496. [PubMed 11426238</li>
<li>Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P. Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia/a single-centre randomized controlled isotope study. Arzneimittelforschung. 2007;57(6A):392-400. [PubMed 17691589</li>
<li>Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med. 1999;33(4):400-405. [PubMed 10092717</li>
<li>Miranda M, Olivares M, Brito A, Pizarro F. Reducing iron deficiency anemia in Bolivian school children: calcium and iron combined versus iron supplementation alone. Nutrition. 2014;30(7-8):771-775. [PubMed 24984991]</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced Oral Itraconazole Bioavailability by Antacid Suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236</li>
<li>Sporanox (itraconazole) oral suspension [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Van der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, et al. Disposition of ketoconazole, an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Ketoconazole [prescribing information]. Hoschton, GA: Aavis Pharmaceuticals, LLC; September 2021.</li>
<li>Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022.</li>
<li>Synthroid (levothyroxine sodium) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2009</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669]</li>
<li>Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020</li>
<li>Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Lialda (mesalamine) delayed-release tablets [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; December 2020</li>
<li>Delzicol (mesalamine) delayed-release capsules [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Shire USA Inc; October 2020</li>
<li>Hussain FN, Ajjan RA, Moustafa M, Weir NW, Riley SA. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Br J Clin Pharmacol. 1998;46(2):173-175. [PubMed 9723828</li>
<li>Bashiri H, Bozorgomid A. Protective effect of Asacol in combination with pantoprazole in ulcerative colitis patients who defecate Asacol tablets intactly: a clinical trial study. Clin Exp Gastroenterol. 2020;13:47-51. [PubMed 32158250</li>
<li>Urex (methenamine) [prescribing information]. Wytheville, VA: Vatring Pharmaceuticals, Inc.; December 2006.</li>
<li>Cerklewski FL, “Influence of Dietary Magnesium on Fluoride Bioavailability in the Rat,” J Nutr, 117(3):496-500. [PubMed 3572562</li>
<li>Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” Clin Pharmacol Ther, 1980, 28(4):529-35. [PubMed 7408412</li>
<li>Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002</li>
<li>Spencer H, Kramer L, Osis D, et al, “Effect of Calcium, Phosphorus, Magnesium, and Aluminum on Fluoride Metabolism in Man,” Ann N Y Acad Sci, 1980, 355:181-94. [PubMed 6940475]</li>
<li>O’Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Benjamin IB, Cortell S, Conrad ME. Bicarbonate-induced iron complexes and iron absorption. Gastroenterology. 1967;35:389</li>
<li>Coste JF, De Bari VA, Keil LB, et al. In vitro interactions of oral haematinics and antacid preparations. Curr Ther Res Clin Exp. 1977;22:205.</li>
<li>Cellcept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; December 2019</li>
<li>Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41(6):513-516. [PubMed 8799515</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. Novartis Pharmaceuticals Corporation; April 2020.</li>
<li>Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemother Pharmacol. 2013;71(1):219-226. [PubMed 23070146</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211]</li>
<li>Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulphate. Clin Pharmacol Ther. 1983;33(4):465-470. [PubMed 6831825</li>
<li>Lyle WH. Penicillamine and iron. Lancet. 1976;2(7982):420. [PubMed 73880</li>
<li>Harkness JA, Blake DR. Penicillamine nephropathy and iron. Lancet. 1982;2(8312):1368-1369. [PubMed 6129465]</li>
<li>Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12(1):26-30. [PubMed 8440814</li>
<li>Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Aton Pharma Inc; November 2015.</li>
<li>Phospha 250 Neutral (sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic and sodium phosphate, monobasic, monohydrate) [prescribing information]. Allendale, NJ: Rising Pharmaceuticals, Inc.; June 2012</li>
<li>K-Phos No. 2 (potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</li>
<li>Levofloxacin [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; May 2022</li>
<li>Lomefloxacin [product labeling]. Kolon Pharmaceutical Co., Ltd.; March 2016</li>
<li>Norfloxacin [product monograph]. Vaughan, ON, Canada: AA Pharma Inc.; June 2019</li>
<li>Ofloxacin [summary of product characteristics]. Dublin, Ireland: Gerard Laboratories; June 2022</li>
<li>Pipemidic acid [Korean product labeling]. Aprogen Pharmaceutical Co., Ltd.; January 2014</li>
<li>Ciprofloxacin [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022</li>
<li>Baxdela (delafloxacin) [product labeling]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries; April 2022</li>
<li>Moxifloxacin [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited, May 2019</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Canada: Merus Labs International, Inc.; August 2018</li>
<li>Enoxacin [Korean product labeling]. Seoul, South Korea: Crystal Life Science Co. Ltd; June 2018</li>
<li>Prulifloxacin [summary of product characteristics]. Ancona, Italy: A.C.R.A.F. S.p.A.; February 2022.</li>
<li>Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2(8501):294. [PubMed 2874321</li>
<li>Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids. Lancet. 1986;2(8497)</li>
<li>[PubMed 2873348</li>
<li>Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med. 1988;109(2):168-169. [PubMed 3382110</li>
<li>Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005;27(2):81-82. [PubMed 15999916</li>
<li>Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother. 1991;28(1):87-94. [PubMed 1663108</li>
<li>Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013</li>
<li>Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014</li>
<li>Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005</li>
<li>Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014</li>
<li>Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012</li>
<li>Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013</li>
<li>Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011</li>
<li>Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003</li>
<li>Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017</li>
<li>Pefloxacin tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199101448 Accessed October 26, 2017.</li>
<li>Edurant (rilpivirine) [prescribing information]. Raritan NJ: Tibotec Therapeutics; May 2011</li>
<li>Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</li>
<li>Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October 2013.</li>
<li>Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021;43(6):1079-1091. [PubMed 33962762</li>
<li>Evrenzo (roxadustat) [summary of product characteristics]. Woking, United Kingdom: Astellas Pharma Ltd; September 2022.</li>
<li>Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol. 1997;43(3):269-272. [PubMed 9088581</li>
<li>Sotalol [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; March 2020</li>
<li>Kahela P, Anttila M, Sundgvist H. Antacids and sotalol absorption. Acta Pharmacol Toxicol (Copenh). 1981;49(3):181-183. [PubMed 7336975]</li>
<li>Summary of product characteristics. Protelos (strontium ranelate). Gidy, France: Les Laboratoires Servier Industrie, 7/2012.</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023</li>
<li>Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. Obes Surg. 2014;24(5):741-746. [PubMed 24347350</li>
<li>Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. Obes Surg. 2018;28(8):2252-2260. [PubMed 29556889]</li>
<li>Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013</li>
<li>Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013</li>
<li>Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</li>
<li>Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet. 1962;114:9-14. [PubMed 14498173</li>
<li>Albert KS, Welch RD, DeSante KA, et al. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J Pharm Sci. 1979;68(5):586-588. [PubMed 435335</li>
<li>Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247(16):2266-2267. [PubMed 7040708</li>
<li>Demeclocycline [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; March 2017</li>
<li>Rosenblatt JE, Barrett JE, Brodie JL, et al. Comparison on in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother. 1966;6:134-141. [PubMed 4964450</li>
<li>Garty M, Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976</li>
<li>Nguyen VX, Nix DE, Gillikin S, Schentag JJEffect of oral antacid administration on the pharmacokinetics of intravenous doxycyclineAntimicrob Agents Chemother1989;33(4):434-436[PubMed 2729939</li>
<li>Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther. 1971;12(5):779-784. [PubMed 4936141</li>
<li>Nuzyra (omadacycline) [prescribing information]. Boston, MA: Paratek Pharmaceuticals, Inc.; October 2020</li>
<li>Tetralysal (lymecycline) [summary of product characteristics]. Watford, Herts, UK: Galderma (UK) Limited; June 2020</li>
<li>Seysara (sarecycline) [prescribing information]. Exton, PA: Almirall, LLC; June 2002</li>
<li>Jaffe JM, Poust RI, Feld SL, et al. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974;63(8):1256-1260. [PubMed 4852448]</li>
<li>Garty M and Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Healy DP, Dansereau RJ, Dunn AB, et al. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother. 1997;31(12):1460-1464. [PubMed 9416381</li>
<li>Khalil SA, Daabis NA, Naggar VF, et al. Effect of magnesium trisilicate and citric acid on the bioavailability of tetracycline in man. Pharmazie. 1977;32(8-9):519-522. [PubMed 201941]</li>
<li>Syprine (trientine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016</li>
<li>Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1(8273):643-647. [PubMed 6121964</li>
<li>Cuvrior (trientine) [prescribing information]. Chicago, IL: Orphalan; April 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</li>
<li>Fann WE, Davis JM, Janowsky DS, et al, “Chlorpromazine: Effects of Antacids on its Gastrointestinal Absorption,” J Clin Pharmacol, 1973, 13(10):388-90. [PubMed 4355737</li>
<li>Forrest FM, Forrest IS, and Serra MT, “Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients,” Biol Psychiatry, 1970, 2(1):53</li>
<li>[PubMed 5414905</li>
<li>Moustafa MA, Babhair SA, and Kouta HI, “Decreased Bioavailability of Some Antipsychotic Phenothiazines Due to Interactions With Absorbent Antacid and Antidiarrhoeal Mixtures,” Int J Pharm, 1987, 36:185-9.</li>
<li>Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a 'nonsystemic' antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Dad T, Garimella PS, Strom JA. Quiz: An unusual case of metabolic alkalosis in a patient with CKD. Am J Kidney Dis. 2017;69(1):A13-A16. [PubMed 28007194</li>
<li>JAMP calcium polystyrene sulfonate [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2020.</li>
<li>Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol. 1984;22(11):626-629. [PubMed 6389377]</li>
<li>Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DS, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183</li>
<li>Cefpodoxime proxetil [prescribing information]. Allendale, NJ: Rising Pharmaceuticals Inc; May 2017</li>
<li>Food and Drug Administration Center for Drug Evaluation and Research (CDER). Evaluation of gastric pH dependent drug interactions with acid-reducing agents: Study design, data analysis, and clinical implications (November 2020). Available at: https://www.fda.gov/media/144026/download.</li>
<li>Fann WE, Davis JM, Janowsky DS, Sekerke HJ, Schmidt DM. Chlorpromazine: effects of antacids on its gastrointestinal absorption. J Clin Pharmacol. 1973;12(10):388-390. [PubMed 4355737</li>
<li>Chlorpromazine [prescribing information]. Columbus, OH: American Health Packaging; October 2018</li>
<li>Perphenazine [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2016</li>
<li>Haldol (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2019</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2008.</li>
<li>Allard M, Legare N, Millaud F. A possible case of clozapine interaction with aluminum hydroxide. Schizophr Res. 2008;101(1-3):346. [PubMed 18272349</li>
<li>Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corp., March 2008</li>
<li>Prescribing information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil- Janssen Pharmaceuticals Inc., August 2008</li>
<li>Prescribing information. Seroquel (quetapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009</li>
<li>Prescribing information. Abilify (aripiprazole). Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd., August 2008.</li>
<li>Diacerein [prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198802489. Accessed October 1, 2014.</li>
<li>Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909]</li>
<li>Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis. 1974;109(1):41-47. [PubMed 4588090</li>
<li>Lin M-Y, Lin S-J, Chan L-C, Lu Y-C. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(7):806-818. [PubMed 20550762</li>
<li>Peloquin CA, Namdar R, Dodge AA, Nix DEPharmacokinetics of isoniazid under fasting conditions, with food, and with antacidsInt J Tuberc Lung Dis1999;3(8):703-710[PubMed 10460103</li>
<li>Sun H, Jin T, Wu X, Yang L, Zuo Y, Liao R. Efficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis. J Int Med Res. 2021;49(7):3000605211027736. [PubMed 34311594</li>
<li>Weber V, Abbott TEF, Ackland GL. Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. Br J Anaesth. 2021;126(3):608-621. [PubMed 33218672</li>
<li>Dong J, Gao L, Wenqing L, Xu Z, Zheng J. Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis. PLoS One. 2014;9(12):e114231. [PubMed 25460931</li>
<li>Sinatra RS, Philip BK, Naulty JS, et al. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulphate. Anesth Analg. 1985;64:1220-1222. [PubMed 2865911</li>
<li>Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular-blocking agents. Anesthesiology. 1970;32:23. [PubMed 5460601</li>
<li>Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. Anaesthesia. 1994;49:355-356. [PubMed 8179157</li>
<li>Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology. 1987;67(5):806-808. [PubMed 2890318</li>
<li>Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. Br J Anaesth. 1996;77:669-671. [PubMed 8957990</li>
<li>Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth. 1996;76(4):565-556. [PubMed 8652332</li>
<li>Yoshida A, Itoh Y, Nagaya K, et alProlonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean sectionJ Anesth2006;20(1):33-35[PubMed 16421674</li>
<li>Kwan WF, Lee C, Chen BJ. A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. J Clin Anesth. 1996;8(5):392-397. [PubMed 8832451</li>
<li>Na HS, Lee JH, Hwang, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth. 2010;104(3):344-350. [PubMed 20042475</li>
<li>Telci L, Esen F, Akcora D, et al. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Br J Anaesth. 2002;89(4):591-598. [PubMed 12393361</li>
<li>Aldrete JA, Zahler A, Aikawa JK. Prevention of succinylcholine-induced hyperkalaemia by magnesium sulfate. Can Anaesth Soc J. 1970;17(5):477-484. [PubMed 5506078</li>
<li>Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth. 1995;74(4):405-409.[PubMed 7734259</li>
<li>Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. Br J Anaesth. 2003;91(3):435-438. [PubMed 12925489</li>
<li>De Vore JS, Asrani R. Magnesium sulfate prevents succinylcholine-induced fasciculations in toxemic parturients. Anesthesiology. 1980;52(1):76-77. [PubMed 7352649</li>
<li>Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007;31(2):167-173. [PubMed 17437152</li>
<li>Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. Can J Anaesth. 2005;52(1):88-93. [PubMed 15625263</li>
<li>James MF, Cork RC, Dennett JE. Succinylcholine pretreatment with magnesium sulfate. Anesth Analg. 1986;65(4):373-376. [PubMed 3513667</li>
<li>Fei S, Xia H, Chen X, Pang D, Xu X. Magnesium sulfate reduces the rocuronium dose needed for satisfactory double lumen tube placement conditions in patients with myasthenia gravis. BMC Anesthesiol. 2019;19(1):170. [PubMed 31472669</li>
<li>Micuci AJQR, Vercosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2019;36(7):502-508. [PubMed 30985540</li>
<li>Ghodraty MR, Saif AA, Kholdebarin AR, et al. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012;26(6):858-863. [PubMed 22752440</li>
<li>Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012;29(2):95-55. [PubMed 22183158</li>
<li>Brown AF, Cobert J, Dierkes J, Kuhn CM, Grant SA. Delayed neuromuscular blockade reversal with sugammadex after vecuronium, desflurane, and magnesium administration: a case report. A A Pract. 2019;13(8):295-298. [PubMed 31283534</li>
<li>Unterbuchner C, Ziegleder R, Graf B, Metterlein T. Magnesium-induced recurarisation after reversal of rocuronium-induced neuromuscular block with sugammadex. Acta Anaesthesiol Scand. 2015;59(4):536-540. [PubMed 25582520</li>
<li>de Almeida CED, de Carvalho LR, Andrade CVC, do Nascimento Jr P, de Barros GAM, Modolo NSP. Effects of magnesium sulphate on the onset time of rocuronium at different doses: a randomized clinical trial. Braz J Anesthesiol. 2021;71(5):482-488. [PubMed 34403648</li>
<li>James MF, Schenk PA, van der Veen BW. Priming of pancuronium with magnesium. Br J Anaesth. 1991;66(2):247-249. [PubMed 1817630</li>
<li>Stacey MR, Barclay K, Asai T, et al. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Anaesthesia. 1995;50(11):933-936. [PubMed 8678246</li>
<li>Nimbex (cisatracurium) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2018</li>
<li>Quelicin (succinylcholine) [prescribing information]. Lake Forest, IL: Hospira, Inc.; August 2021</li>
<li>Atracurium [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2018</li>
<li>Pancuronium [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2019</li>
<li>Rocuronium [prescribing information]. Lehi, UT: Civica, Inc.; July 2020.</li>
<li>Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231-1235. [PubMed 18355422</li>
<li>Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.</li>
<li>Foresti V. Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Sodium polystyrene sulfonate [prescribing information]. Rahway, NJ: Sunrise Pharmaceutical, Inc.; March 2020.</li>
<li>Prograf (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; August 2009</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med. 1994;97(4):363-365. [PubMed 7942938</li>
<li>Morini E, Catalano A, Lasco A, Morabito N, Benvenga S. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. [PubMed 30919287</li>
<li>Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-486. [PubMed 21595516</li>
<li>Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med. 1992;152(1):183-184. [PubMed 1728914</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669</li>
<li>Levothyroxine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; September 2022</li>
<li>Ermeza (levothyroxine) oral solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022.</li>
<li>Regardh CG, Lundborg P, Persson BA. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Biopharm Drug Dispos. 1981;2(1):79-87. [PubMed 7236872</li>
<li>Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. Clin Pharmacol Ther. 1981;30(4):429-435. [PubMed 7285476]</li>
<li>Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 1991;31(2):164-167. [PubMed 1849152</li>
<li>Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 2003;17(3):563-577. [PubMed 14711077</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</li>
<li>Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; February 2011</li>
<li>Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998;4:941-948. [PubMed 9563888</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2016 [published October 13, 2016]. doi:10.1001/jamaoncol.2016.3358. [PubMed 27737436</li>
<li>Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104. [PubMed 11286326]</li>
<li>Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med. 1976;295(19):1034-1037. [PubMed 972657</li>
<li>Allen MD, Greenblatt DJ, Harmatz JS, Smith TW. Effect of magnesium-aluminum hydroxide and kaolin-pectin on absorption of digoxin from tablets and capsules. J Clin Pharmacol. 1981;21(1):26-30. [PubMed 7012189</li>
<li>Cooke J, Smith JA. Absence of interaction of digoxin with antacids under clinical conditions. Br Med J. 1978;2(6145):1166-1167. [PubMed 709293]</li>
<li>Radwanski E, Nomeir A, Cutler D, Affrime M, Lin CC. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double-strength liquid or with ranitidine. Am J Ther. 1998;5(2):67-72. [PubMed 10099040</li>
<li>Cedax (ceftibuten) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2015.</li>
<li>Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. Clin Pharmacol Ther. 1976;19(2):234-239. [PubMed 770046]</li>
<li>Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. Clin Pharmacol Ther. 1978;24(3):308-315. [PubMed 28870</li>
<li>Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS. Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. Clin Pharmacol Ther. 1982;31(2):180-183. [PubMed 6120059</li>
<li>Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD. Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther. 1977;22(3):329-335. [PubMed 19188</li>
<li>Tranxene (clorazepate dipotassium) [prescribing information]. Barceloneta, PR: AbbVie LTD; September 2016.</li>
<li>Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI. Diazepam absorption: effect of antacids and food. Clin Pharmacol Ther. 1978;24(5):600-609. [PubMed 699484</li>
<li>Nair SG, Gamble JA, Dundee JW, Howard PJ. The influence of three antacids on the absorption and clinical action of oral diazepam. Br J Anaesth. 1976;48(12):1175-1180. [PubMed 1023953</li>
<li>Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI. Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. J Clin Pharmacol. 1984;24(5-6):255-263. [PubMed 6747022</li>
<li>Valium (diazepam) [prescribing information]. South San Francisco, CA: Hoffman-La Roche; December 2016.</li>
<li>Yamreudeewong W, Scavone JM, Paone RP, Lewis GP. Effect of antacid coadministration on the bioavailability of erythromycin stearate. Clin Pharm. 1989;8(5):352-354. [PubMed 2743731]</li>
<li>Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333-342. [PubMed 688726]</li>
<li>Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49(1):467-469. [PubMed 15616339</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2019.</li>
<li>Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm. 1998;46(3):299-303. [PubMed 9885302]</li>
<li>Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. Drug Intell Clin Pharm. 1986;20(10):792-795. [PubMed 3769772</li>
<li>Burland WL, Darkin DW, Mills MW. Effect of antacids on absorption of cimetidine. Lancet. 1976;2(7992):965. [PubMed 62195</li>
<li>Bodemar G, Norlander B, Walan A. Diminished absorption of cimetidine caused by antacids. Lancet. 1979;1(8113):444-445. [PubMed 84296</li>
<li>Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. N Engl J Med. 1982;307(7):400-404. [PubMed 708843</li>
<li>Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29(7):670-672. [PubMed 2569486</li>
<li>Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol. 1987;24(4):551-553. [PubMed 2891370</li>
<li>Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces the bioavailability of ranitidine. Br Med J. 1982;285(6347):998-999. [PubMed 6289961</li>
<li>Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol. 1990;42(5):352-354. [PubMed 1976784</li>
<li>Donn KH, Eshelman FN, Plachetka JR, et alThe effects of antacid and propantheline on the absorption of oral ranitidinePharmacotherapy1984;4(2):89-92[PubMed 6326064</li>
<li>Sullivan TJ, Reese JH, Jauregui L, Miller K, Levine L, Bachmann KA. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. Aliment Pharmacol Ther. 1994;8(1):123-126. [PubMed 7910488]</li>
<li>Tanatril (imidapril) [summary of product characteristics]. London, UK: Mitsubishi Tanabe Pharma Europe Limited; December 2014.</li>
<li>Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663</li>
<li>Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029]</li>
<li>Kristalose (lactulose) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; July 2018</li>
<li>Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663]</li>
<li>Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</li>
<li>Livtencity (maribavir) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2021.</li>
<li>Segre EJ, Sevelius H, Varady J. Letter: Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583. [PubMed 4852768</li>
<li>Weber SS, Bankhurst AD, Mroszczak E, Ding TL. Effect of Mylanta on naproxen bioavailability. Ther Drug Monit. 1981;3(1):75-83. [PubMed 7233492</li>
<li>Naprosyn (naproxen) [prescribing information]. Apharetta, GA: Canton Laboratories, LLC.; April 2021.</li>
<li>Ismail FA, Khalafallah N, Khalil SA. Absorption of ketoprofen and bumadizone calcium on aluminum-containing antacids and its effect on ketoprofen bioavailability in man. Int J Pharm. 1987;34:189-196</li>
<li>Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6 Pt 2):33S-39S (review). [PubMed 2082311</li>
<li>Holmes GI, et al. Effects of Maalox on the bioavailability of diflunisal. Clin Pharmacol Ther. 1979;25:229</li>
<li>Verbeeck R, Tjandramaga TB, Mullie A, et al. Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol. 1979;7(5):519-522. [PubMed 314299</li>
<li>Segre EJ, Sevelium H, Varady J. Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583 (letter). [PubMed 4852768</li>
<li>Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; January 2011</li>
<li>von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone - A novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Tox. 1983;21(6):311-321. [PubMed 6688407</li>
<li>Shaker MA, Akhtar N, Minhas MU, Khan KU, Zangi MI, Munir A. Effect of an Al-Mg hydroxide antacid and food on the pharmacokinetics of dexibuprofen. Drug Res (Stuttg). 2020;70(4):158-164. [PubMed 32110819]</li>
<li>Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</li>
<li>Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. Br J Clin Pharmacol. 1978;6(2):177-179. [PubMed 678395</li>
<li>Garnett WR, Carter BL, Pellock JM. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1980;37(7):467. [PubMed 7387502</li>
<li>Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-340. [PubMed 7336470</li>
<li>McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Br J Clin Pharmacol. 1982;13(4):501-505. [PubMed 7066165</li>
<li>Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1979;36(7):436-438. [PubMed 454247</li>
<li>O'Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol. 1978;6(2):176-177. [PubMed 678394</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</li>
<li>Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115(1):12-18. [PMID 9925057</li>
<li>Gupta PR, Mehta YR, Gupta ML, Sharma TN, Jain D, Gupta RB. Rifampin-aluminium antacid interaction. J Assoc Physicians India. 1988;36(6):363-364. [PubMed 3182711</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifadin (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifamate (rifampin/isoniazid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2013</li>
<li>Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2010</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2009.</li>
<li>Itthipanichpong C, Sirivongs P, Wittayalertpunya S, Chaiyos N. The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Drug Metabol Drug Interact. 1992;10(3):213-228. [PubMed 1424642</li>
<li>Gaspari F, Vigano G, Locatelli M, Remuzzi G. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis. 1988;11(4):338-342. [PubMed 3354570</li>
<li>Shastri RA. Effect of antacids on salicylate kinetics. Int J Clin Pharmacol Ther Toxicol. 1985;23(9):480-484. [PubMed 4055159</li>
<li>Levy G, Lampman T, Kamath BL, et al. Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. N Engl J Med. 1975;293(7):323-325. [PubMed 239345</li>
<li>Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol. 1980;20(5-6 Pt 1):326-331. [PubMed 7400368</li>
<li>Macpherson CR, Milne MD, Evans BM. The excretion of salicylate. Br J Pharmacol Chemother. 1955;10(4):484-489. [PubMed 13276608</li>
<li>Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. Br J Clin Pharmacol. 1982;14(4):562-564. [PubMed 7138740</li>
<li>Feldman S, Carlstedt BC. Effect of antacid on absorption of enteric-coated aspirin. JAMA. 1974;227(6):660-661 (letter). [PubMed 4405837</li>
<li>Strickland-Hodge B, Thomas TR, Gould WA, et al. The effects of antacids on enteric-coated salicylate preparations. Rheumatol Rehabil. 1976;15(3):148-152. [PubMed 968338]</li>
<li>Kivisto KT, Neuvonen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1992;42(6):675-679. [PubMed 1623912</li>
<li>Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol. 1991;32(2):215-220. [PubMed 1931470</li>
<li>Zuccaro P, Pacifici R, Pichini S, et al. Influence of antacids on the bioavailability of glibenclamide. Drugs Exp Clin Res. 1989;15(4):165-169. [PubMed 2505996</li>
<li>Kivisto KT, Lehto P, Neuvonen PJ. The effects of different doses of sodium bicarbonate on the absorption and activity of nonmicronized glibenclamide. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):236-240. [PubMed 8390970</li>
<li>Kivisto KT, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminum hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol. 1991;40(4):383-386. [PubMed 1646724</li>
<li>Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther. 1991;49(1):39-43. [PubMed 1988239</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976]</li>
<li>Arnold LA, Spurbeck GH, Shelver WH, Henderson WM. Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm. 1979;36(8):1059-1062. [PubMed 484565</li>
<li>Reed RC, Schwartz HJ. Lack of influence of an intensive antacid regimen on theophylline bioavailability. J Pharmacokinet Biopharm. 1984;12(3):315-331. [PubMed 6502473</li>
<li>Darzentas LJ, Stewart RB, Curry SH, Yost RL. Effect of antacid on bioavailability of a sustained-release theophylline preparation. Drug Intell Clin Pharm. 1983;17(7-8):555-557. [PubMed 6872853</li>
<li>Muir JF, Peiffer G, Richard MO, et al. Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation. Eur J Clin Pharmacol. 1993;44(1):85-88. [PubMed 8436162</li>
<li>Ferrari M, Olivieri M, Romito D, Biasin C, Barozzi E, Bassetti S. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline. Riv Eur Sci Med Farmacol. 1991;13(5-6):269-274. [PubMed 1819857</li>
<li>Fernandes E, Melewicz FM. Antacids and theophylline-ranitidine interaction. Ann Intern Med. 1984;101(2):279. [PubMed 6331245</li>
<li>Myhre KI, Walstad RA. The influence of antacid on the absorption of two different sustained-release formulations of theophylline. Br J Clin Pharmacol. 1983;15(6):683-687. [PubMed 6871067</li>
<li>Shargel L, Stevens JA, Fuchs JE, Yu AB. Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. J Pharm Sci. 1981;70(6):599-602. [PubMed 7252799</li>
<li>Theophylline oral solution [prescribing information]. Congers, NY: Chartwell RX LLC; October 2022.</li>
<li>Rudzki P, Jarus-Dziedzic K, Filist M, et al. Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacol Rep. 2021;73(2):604-614 [PubMed 33686610]</li>
<li>Kroboth PD, Smith RB, Silver MR, et al. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol. 1985;19(6):839-842. [PubMed 2862896]</li>
<li>May CA, Garnett WR, Small RE, et al, “Effects of Three Antacids on the Bioavailability of Valproic Acid,” Clin Pharm, 1982, 1(3):244</li>
<li>[PubMed 6821035]</li>
<li>Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990;34(10):2032-2033. [PubMed 2291673</li>
<li>Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236]</li>
<li>Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804-808. [PubMed 14982768</li>
<li>Kraft WK, Chang PS, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020-4025. [PubMed 24798274</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2022.</li>
<li>Exjade (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2020.</li>
<li>Relyvrio (sodium phenylbutyrate and taurursodiol) [prescribing information]. Cambridge, MA: Amylyx Pharmaceuticals Inc; September 2022.</li>
<li>Weissman I, Krivoy N. Interaction of aluminum hydroxide and allopurinol in patients on chronic hemodialysis. Ann Intern Med. 1987;107(5):787. [PubMed 3662305]</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Effect of ascorbic acid on gastrointestinal aluminum absorption. Lancet. 1991;338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int. 1991;39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654</li>
<li>Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9-11. [PubMed 2913801</li>
<li>Main J, Ward MK. Potentiation of aluminum absorption by effervescent analgesic tablets in a haemodialysis patient. Br Med J. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol. 1989;31(1):40-44. [PubMed 2914409]</li>
<li>Foresti V. Intestinal obstruction due to Kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Garcia-Pardo G, Martinez-Vea A, Auguet T, et al. Intestinal obstruction complicating calcium polystyrene sulphonate therapy. Nephrol Dial Transplant. 1996;11(4):751. [PubMed 8671882</li>
<li>Hurley JK. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel. J Pediatr. 1978;92(4):592-593. [PubMed 633020</li>
<li>Calcium Resonium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., April 2006.</li>
<li>Cholbam (cholic acid) [prescribing information]. Baltimore, MD: Asklepion Pharmaceuticals LLC; March 2015.</li>
<li>Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</li>
<li>Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568-572. [PubMed 10049268</li>
<li>Myambutol (ethambutol) [prescribing information]. Langhorne, PA: STI Pharma LLC; April 2012</li>
<li>Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol. 1978;5(2):161-166. [PubMed 619949]</li>
<li>Prescribing information. Neurontin (gabapentin). New York, NY: Pfizer Inc; October 2017.</li>
<li>Mircol (mequitazine) [summary of product characteristics]. Madrid, Spain: ITF Medilab Farma, SA; July 2013.</li>
<li>Moxifloxacin [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; November 2022.</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” Lancet, 1991, 338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” Kidney Int, 1991, 39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” Am J Kid Dis, 1991, 17(6):708-11. [PubMed 2042654</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ, 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” Clin Nephrol, 1989, 31(3):123</li>
<li>[PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” Clin Nephrol, 1986, 26(3):146</li>
<li>[PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” Proc Eur Dial Transplant Assoc Eur Ren Assoc, 1985, 21:390</li>
<li>[PubMed 3991529</li>
<li>Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” Am J Physiol, 1985, 249(2 Pt 1):G209-13. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205. [PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” J Lab Clin Med, 1986, 108(2):96-102. [PubMed 3755457]</li>
<li>Moon J, Davison A, Bandy B. Vitamin D and aluminum absorption. CMAJ. 1992;147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol. 1989;31(3):123-127. [PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Clin Nephrol. 1986;26(3):146-149. [PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:390-394. [PubMed 3991529</li>
<li>Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol. 1985;249(2 Pt 1):G209-G213. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et alAbsorption, deposition and distribution of dietary aluminium in immature rats: effects of dietary vitamin D3 and food-borne chelating agentJ Environ Sci Health B1986;21(2):191-205[PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al. 1,25-dihydroxyvitamin D3 increases serum and tissue accumulation of aluminum in rats. J Lab Clin Med. 1986;108(2):96-102. [PubMed 3755457]</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Urso 250 / Urso Forte (ursodiol) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2021</li>
<li>Actigall (ursodiol) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc.; September 2002</li>
<li>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. [PubMed 30070375]</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 Alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 Alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Zemplar (paricalcitol) capsules [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Rocaltrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Zemplar (paricalcitol) injection [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>Dovonex (calcipotriene) cream [prescribing information]. Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]Greenville, NC: Mayne Pharma; May 2019</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018</li>
<li>Vitamin D (ergocalciferol) [prescribing information]. Laurelton, NY: Epic Pharma, LLC: October 2018.</li>
<li>Chenodol (chenodiol) [prescribing information]. San Diego, CA: Retrophin, Inc; June 2015.</li>
<li>Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J. 1994;87(9):894-898. [PubMed 8091252</li>
<li>Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr. 1994;48(1):71-73. [PubMed 8200332</li>
<li>Nestel AW, Meyers AM, Paiker J, Rollin HB. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients. Nephron. 1994;68(2):197-201. [PubMed 7830856</li>
<li>Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study. South Med J. 1993;86(12):1385-1388. [PubMed 8272917</li>
<li>Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs. 1991;14(10):625-629. [PubMed 1748529</li>
<li>Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; June 2019</li>
<li>Envarsus XR (tacrolimus extended-release) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Spencer H, Kramer L, Norris C, et al. Effect of aluminum hydroxide on fluoride metabolism. Clin Pharmacol Ther. 1980;28(4):529-535. [PubMed 7408412]</li>
<li>Hong CY, Hu SC, Lin SJ, Chiang BN. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Clin Pharmacol Ther Toxicol. 1985;23(5):244-246. [PubMed 4008113</li>
<li>Inderal (propranolol) tablets [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals LLC; March 2011.</li>
<li>PhosLo (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2011.</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4:345. [PubMed 3160584</li>
<li>Schentag JJ, Watson WA, Nix DE, et al. Time-dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther. 1988;43:135</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36:1219-1234. [PubMed 1329615</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulphate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36:2270-2274. [PubMed 1444308</li>
<li>Sahai J, Healey DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302-304. [PubMed 8471407</li>
<li>Frost RW, Lettieri JT, Noe A, et al. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin Pharmacol Ther. 1989;45:165</li>
<li>Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34:432-435. [PubMed 2334155</li>
<li>Kays MB, Overholser BR, Mueller BA, et alEffects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacinAm J Kidney Dis2003;42(6):1253-1259[PubMed 14655198</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014</li>
<li>Federspiel J, Bukhari MJ, Hamill MM. Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. BMJ Case Rep. 2021;14(1):e236655. [PubMed 33408101</li>
<li>Gunnarsson PO, Davidson T, Andersson SB, et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189-193. [PubMed 2338118</li>
<li>Emcyt (estramustine) [prescribing information]. New York, NY: Pharmacia and Upjohn Company; June 2007.</li>
<li>Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” Am J Clin Nutr, 2007, 85(1):6-18. [PubMed 17209171</li>
<li>Peacock M, “Calcium Metabolism in Health and Disease,” Clin J Am Soc Nephrol, 2010, 5 Suppl 1:S23-30. [PubMed 20089499</li>
<li>Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” Cochrane Database Syst Rev, 2011, (7):CD007470. [PubMed 21735411]</li>
<li>Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr. 2002;21(3):239-244. [PubMed 12074251</li>
<li>Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22. [PubMed 9554821]</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439]</li>
<li>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018. Available at https://aidsinfo.nih.gov. (Accessed 06/24/2019</li>
<li>HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. (Accessed 06/24/2019</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494]</li>
<li>Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; June 2009</li>
<li>Minocin (minocycline) [prescribing information]. Cranford, NJ: Triax Pharmaceuticals, LLC; August 2010</li>
<li>Vibramycin (doxycycline) [prescribing information]. New York, NY: Pfizer Inc; April 2007</li>
<li>Jung H, Peregrina AA, Rodriguez JM, et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos. 1997;18(5):459-463. [PubMed 9210983]</li>
<li>Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822-2825. [PubMed 10838651</li>
<li>Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11:967-971. [PubMed 11716045</li>
<li>Mazokopakis EE, Giannakopoulos TG, Starakis IK. Interaction between levothyroxine and calcium carbonate. Can Fam Physician. 2008;54(1):39. [PubMed 18208953</li>
<li>Csako G, McGriff NJ, Rotman-Pikielny P, et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35(12):1578-1583. [PubMed 11793625</li>
<li>Butner LE, Fulco PP, Feldman G. Calcium carbonate-induced hypothyroidism. Ann Intern Med. 2000;132(7):595. [PubMed 10744606</li>
<li>Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA. 1998;279(10):750. [PubMed 9508149</li>
<li>A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Diskin CJ, Stokes TJ, Dansby LM, et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol. 2007;39(2):599-602. [PubMed 17216296]</li>
<li>Salerno DM, Anderson B, Sharkey PH, et al, “Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia With and Without Calcium Pretreatment,” Ann Intern Med, 1987, 107(5):623</li>
<li>[PubMed 3662276</li>
<li>Haft JI and Habbab MA, “Treatment of Atrial Arrhythmias. Effectiveness of Verapamil When Preceded by Calcium Infusion,” Arch Intern Med, 1986, 146(6):1085</li>
<li>[PubMed 3718093</li>
<li>Schoen MD, Parker RB, Hoon TJ, et al, “Evaluation of the Pharmacokinetics and Electrocardiographic Effects of Intravenous Verapamil With Intravenous Calcium Chloride Pretreatment in Normal Subjects,” Am J Cardiol, 1991, 67(4):300</li>
<li>[PubMed 1990794</li>
<li>O’Quinn SV, et al, “Influence of Calcium on the Hemodynamic and Anti-ischemic Effects of Nifedipine Observed During Treadmill Exercise Testing,” Pharmacotherapy, 1990, 10:247 (abstract)</li>
<li>Wohns DH, Patterson JH, Clarke S, et al, “Influence of Calcium Administration on the Short-term Hemodynamic and the Anti-ischemic Effects of Nifedipine,” J Am Coll Cardiol, 1991, 18(4):1070</li>
<li>[PubMed 1894852</li>
<li>Bar-Or D and Gasiel Y, “Calcium and Calciferol Antagonize Effect of Verapamil in Atrial Fibrillation,” Br Med J, 1981, 282(6276):1585</li>
<li>[PubMed 6786574]</li>
<li>Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75(887):554-556. [PubMed 10616693</li>
<li>Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth Analg. 1972;51(2):202-205. [PubMed 5062119</li>
<li>Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA. 1978;240(6):533-534. [PubMed 671662</li>
<li>Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. Br Med J. 1978;1(6108):279-280. [PubMed 620306</li>
<li>Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507. [PubMed 5418023]</li>
<li>Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992;101(1):174-180. [PubMed 1729065]</li>
<li>Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriat Soc. 1984;32(5):405-407. [PubMed 6715769</li>
<li>Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121(5):591-594. [PubMed 497950</li>
<li>Gora ML, Seth SK, Bay WH, Visconti JA. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm. 1989;8(3):227-229. [PubMed 2706898</li>
<li>Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55-59. [PubMed 5305802</li>
<li>Rehan MA, Rashid A, Krell K, Gabutti C, Singh R. Calcium alkali thiazide syndrome: what we need to know. Cureus. 2020;12(10:e10856. [PubMed 33178509</li>
<li>Morini L, Doneli D, Santi R, et al. Severe milk-alkali syndrome in a patient with hypoparathyroidism associated with 1,25(OH)2D, hydrochlorothiazide and anthranoid laxative consumption. Eur J Case Rep Intern Med. 2017;4(10):000729. [PubMed 30755914</li>
<li>Singh A, Ashraf A. Hypercalcemic crisis induced by calcium carbonate. Clin Kidney J. 2012;5(4):288-291. [PubMed 25874082</li>
<li>Parvez B, Emuwa C, Faulkner ML, Murray JJ. Milk alkali and hydrochlorothiazide: a case report. Case Rep Med. 2011;2011:729862. [PubMed 21738535]</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>One-Alpha drops (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Dovonex (calcipotriene) [prescribing information]. Dublin, Ireland: LEO Laboratories Ltd.; March 2015</li>
<li>Rocalctrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Vectical (calcitriol) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019</li>
<li>Ergocalciferol [prescribing information]. Laurelton, NY: Epic Pharma, LLC; October 2018.</li>
<li>Flura-Drops (sodium fluoride) [prescribing information]. Lake Oswego, OR: Kirkman Laboratories Inc; September 2019.</li>
<li>Borel P, Desmarchelier C, Dumont U, et. al. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. Br J Nutr. 2016;116(12):2091-2096. [PubMed 28069089]</li>
<li>Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(suppl 1):27-32. [PubMed 11352439</li>
<li>Moxifloxacin [prescribing information]. Levittown, PA: Torrent Pharma Inc; January 2022.</li>
<li>Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016.</li>
<li>Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351-352. [PubMed 22678358</li>
<li>Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; August 2020.</li>
<li>Klein CE, Chiu YL, Cai Y, et al, “Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir,” J Clin Pharmacol, 2008, 48(5):553-62. [PubMed 18440920]</li>
<li>Wang X, Boffito M, Zhang J, et al, “Effects of the H2-Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir with or without Tenofovir in HIV-Infected Patients,” AIDS Patient Care STDS, 2011, 25(9):509-15. [PubMed 21770762</li>
<li>Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, February 2012.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; September 2018.</li>
<li>Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; October 2016</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908]</li>
<li>Saito Y, Takekuma Y, Kobayashi M, et al. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(3):381-388. [PubMed 33029650</li>
<li>Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410</li>
<li>Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004;44(8):919-927. [PubMed 15286096</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018.</li>
<li>Mchavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347</li>
<li>Ketoconazole [prescribing information]. Mason, OH: Burel Pharmaceuticals, LLC; September 2021.</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017</li>
<li>Chiu Y-L, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV infected patients. AIDS Patient Cre STDS. 2007;21(4):247-251. [PubMed 17461719</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451</li>
<li>Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985;38(6):652-655. [PubMed 2933205</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RMW. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958-966. [PubMed 17210768]</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc.; February 2020</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584]</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013</li>
<li>Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis. 2008;46(10):1627; author reply 1627</li>
<li>[PubMed 18419503</li>
<li>Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207-12. [PubMed 19858252</li>
<li>Vehreschild JJ, Muller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987-95. [PubMed 22286158</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-10[PubMed 22890761]</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; March 2022.</li>
<li>Invirase (saquinavir) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; December 2003.</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</li>
<li>Saathoff N, Lode H, Neider K, Kepperman KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Cefpodoxime [prescribing information]. Princeton, NJ: Sandoz GmbH for Sandoz Inc; February 2014.</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine After Heart Transplantation: Experimental and Clinical Results,” J Heart Lung Transplant, 1993, 12(6 Pt 1):987-92. [PubMed 8312324</li>
<li>D'Souza MJ, Pollock SH, Solomon HM, “Cyclosporine-Cimetidine Interaction,” Drug Metab Dispos, 1988, 16(1):57</li>
<li>[PubMed 2894956</li>
<li>Shaefer MS, Rossi SJ, McGuire TR, et al, “Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men,” Ann Pharmacother, 1995, 29(11):1088-91. [PubMed 8573949</li>
<li>Jadoul M and Hene RJ, “Ranitidine and the Cyclosporine Treated Recipient,” Transplantation, 1989, 48(2):359. [PubMed 2667215</li>
<li>Tsang VT, Johnston A, Heritier F, et al, “Cyclosporine Pharmacokinetics in Heart-Lung Transplant Recipients With Cystic Fibrosis Effects of Pancreatic Enzymes and Ranitidine,” Eur J Clin Pharmacol, 1994, 46(3):261</li>
<li>[PubMed 8070508</li>
<li>Jarowenko MV, Van Buren CT, Kramer WG, et al, “Ranitidine, Cimetidine, and the Cyclosporine-Treated Recipient,” Transplantation, 1986, 42(3):311</li>
<li>[PubMed 3529532]</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; February 2020</li>
<li>Doxofylline tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200101732. Accessed December 15, 2015.</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2019</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084. [PubMed 12461038]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413</li>
<li>Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2009.</li>
<li>Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med. 1987;107(2):261-262. [PubMed 3111324</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514</li>
<li>DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi Aventis US; July 2016.</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016.</li>
<li>Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol. 1984;18(2):175-181. [PubMed 6091709</li>
<li>Rocci ML Jr, Kosoglou T, Ferguson RK, Vlasses PH. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. J Pharmacol Exp Ther. 1989;248(3):923-928. [PubMed 2467982</li>
<li>Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Ther Drug Monit. 1987;9(4):378-383. [PubMed 2447687</li>
<li>Ranitidine [prescribing information]. East Winsor, NJ: Novitium Pharma LLC; September 2018.</li>
<li>O'Conner-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther. 2001;70(2):126-31. [PubMed 11503006</li>
<li>Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm. 1991;10(7):539-43. [PubMed 1860302</li>
<li>Halcion (triazolam) [prescribing information]. New York, NY: Pfizer Inc,; October 2019.</li>
<li>Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med. 1990;112(1):76-77. [PubMed 2293824</li>
<li>Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin clearance after ranitidine and cimetidine. Clin Pharmacol Ther. 1984;35(3):338-341. [PubMed 6321081</li>
<li>O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144(5):989-991. [PubMed 6324710</li>
<li>Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32(2):165-172. [PubMed 3582481</li>
<li>Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12(6):791-794. [PubMed 6122462</li>
<li>Powell JR, Donn KH. The pharmacokinetic basis for h2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95-113. [PubMed 6140286]</li>
<li>Gertz BJ, Holland SD, Kline WF, et al, “Studies of the Oral Bioavailability of Alendronate,” Clin Pharmacol Ther, 1995, 58(3):288-98. [PubMed 7554702</li>
<li>Prescribing information. Fosamax (alendronate). Whitehouse Station, NJ: Merck &amp; Co., Inc., 04/2013</li>
<li>Prescribing information. Binosto (alendronate). San Antonio, TX: Mission Pharmacal, 4/2013</li>
<li>Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” Arch Intern Med, 2011, 171(11):998-1004. [PubMed 21321287</li>
<li>Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” Endokrynol Pol, 2011, 62(1):84</li>
<li>Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” Bone, 2010, 47(2):169-80. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” Drug Saf, 2009, 32(9):775-85. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” Osteoporos Int, 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” Osteoporos Int, 2012, 23(1):277-84. [PubMed 21365461]</li>
<li>Piqray (alpelisib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; June 2022.</li>
<li>Perveen S, Gauhar S, Yousuf RI, Ali H, Zafar F, Sheikh AF. Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan. PLoS One. 2022;17(5):e0267791. [PubMed 35609024</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502]</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360</li>
<li>Diacetylmorphine (diamorphine) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc.; February 2022</li>
<li>Diamorphine [summary of product characteristics]. Middlesex, United Kingdom: Accord Healthcare Limited; May 2020.</li>
<li>Esposito R. Cimetidine and iron-deficiency anaemia. Lancet. 1977;2(8048):1132. [PubMed 73039</li>
<li>Bianchi FM, Cavassini GB, Leo P. Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):209-217. [PubMed 8100220</li>
<li>Partlow ES, Campbell NR, Chan SC, Pap KM, Granberg K, Hasinoff BB. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. Clin Pharmacol Ther. 1996;59(4):389-393. [PubMed 8612382]</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055</li>
<li>Ueno T, Miyajima Y, Landry I, Lalovic B, Schuck E. Physiologically based pharmacokinetic modeling to predict drug interaction of lemborexant with CYP3A inhibitors. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):455-466. [PubMed 33704920</li>
<li>Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int. 2005;67(3):1152-1160. [PubMed 15698457</li>
<li>Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369-376. [PubMed 10223772</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451]</li>
<li>U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360]</li>
<li>Mirapex ER (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014</li>
<li>Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33(4):495-499. [PubMed 15640376]</li>
<li>Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251-2257. [PubMed 18786302</li>
<li>Donn KH, Eshelman FN, Plachetka JR, Fabre L, Powell JR. The effects of antacid and propantheline on the absorption of oral ranitidine. Pharmacotherapy. 1984;4(2):89-92. [PubMed 6326064]</li>
<li>Machavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347]</li>
<li>Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410]</li>
<li>Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;58:663-687. [PubMed 29309257</li>
<li>Li TT, An JX, Xu JY, Tuo BG. Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver. World J Clin Cases. 2019;7(23):3915-3933. [PubMed 31832394]</li>
<li>Poudel RR, Kafle NK. Tizanidine-induced acute severe cystitis in a female taking famotidine. Clin Pharmacol. 2015;7:83-85. [PubMed 26251632</li>
<li>Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013</li>
<li>Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 1993;24(3):255-258. [PubMed 8462230</li>
<li>Bachmannn K, Sullivan TJ, Reese JH, et al. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 1995;35(5):529-535. [PubMed 7657856</li>
<li>Verdiani P, Di Carlo S, Baronti AFamotidine effects on theophylline pharmacokinetics in subjects affected by COPDComparison with cimetidine and placeboChest1988;94(4):807-810[PubMed 3168576</li>
<li>Sunlenca (lenacapavir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; November 2022.</li>
<li>Nexterone (amiodarone) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2021.</li>
<li>Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987;27(10):813-816. [PubMed 3323258</li>
<li>Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011;55(7):3091-3098. [PubMed 21518836]</li>
<li>Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; August 2019</li>
<li>Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol. 2000;49(1):64-71. [PubMed 10606839]</li>
<li>Ellence (epirubicin hydrochloride). New York, NY: Pfizer Inc.; July 2019</li>
<li>Murray LS, Jodrell DI, Morrison JG, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol). 1998;10(1):35-38. [PubMed 9543613]</li>
<li>Veozah (fezolinetant) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2023.</li>
<li>Plaquenil (hydroxychloroquine) [prescribing information]. Dublin, Ireland: Amdipharm Limited; May 2021</li>
<li>Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65(1):10-20. [PubMed 9951426</li>
<li>Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20(3):317-324. [PubMed 10831018</li>
<li>Orap (pimozide) [prescribing information]. Horsham, PA: Teva Pharmaceuticals USA; March 2014.</li>
<li>Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol. 1997;37(11):1056-1061. [PubMed 9505999</li>
<li>Serdolect (sertindole) [summary of product characteristics]. Valby, Denmark: Lundbeck AS; March 2021.</li>
<li>Volkin RL, Shadduck RK, Winkelstein A, Zeigler ZR, Selker RG. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med. 1982;142(2):243-245. [PubMed 7059252</li>
<li>Selker RG, Moore P, LoDolce D. Bone-marrow depression with cimetidine plus carmustine. N Engl J Med. 1978;299(15):834. [PubMed 692572</li>
<li>BiCNU (carmustine) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2021</li>
<li>Dorr RT, Soble MJ. H2-antagonists and carmustine. J Cancer Res Clin Oncol. 1989;115(1):41-46. [PubMed 2564000]</li>
<li>Kirch W, Janisch HD, Ohnhaus EE, van Peer A. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit. 1989;11(4):411-414. [PubMed 2741189]</li>
<li>Priskorn M, Larsen F, Segonzac A, et al. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 1997;52:241-242. [PubMed 9218934</li>
<li>Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci. 2011;32(3):507-509. [PubMed 21491099</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA, Inc; January 2019.</li>
<li>Ampyra (dalfampridine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; December 2019</li>
<li>Fampyra (fampridine) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; January 2022.</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, et al, “Cimetidine Interaction with Phenytoin,” Br Med J (Clin Res Ed), 1981, 282:1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, and Springer PK, “Decreased Clearance of Phenytoin with Cimetidine,” Ann Intern Med, 1981, 95:244. [PubMed 7258891</li>
<li>Phillips P, Hansky J, “Phenytoin Toxicity Secondary to Cimetidine Administration,” Med J Aust, 1984, 141(9):602. [PubMed 6092884</li>
<li>Neuvonen PJ, Tokola RA, Kaste M, “Cimetidine-Phenytoin Interaction: Effect on Serum Phenytoin Concentration and Antipyrine Test,” Eur J Clin Pharmacol, 1981, 21(3):215-20. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al, “Reduction of Phenytoin Clearance Caused by Cimetidine,” Eur J Clin Pharmacol, 1983, 25(1):135</li>
<li>Bartle WK, Walker SE, and Shapero I, “Dose-Dependent Effect of Cimetidine on Phenytoin Kinetics,” Clin Pharmacol Ther, 1983, 33:649-55. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, et al, “Effect of Cimetidine on Phenytoin Serum Levels,” Epilepsia, 1983, 24(3):284</li>
<li>Iteogu MO, Murphy JE, Shleifer N, et al, “Effect of Cimetidine on Single-Dose Phenytoin Kinetics,” Clin Pharm, 1983, 2:302, 304. [PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I, “Differential Effect of Cimetidine on Serum Concentrations of Carbamazepine and Phenytoin,” Neurology, 1985, 35(4):562</li>
<li>Sambol NC, Upton RA, Chremos AN, et al, “A Comparison of the Influence of Famotidine and Cimetidine on Phenytoin Elimination and Hepatic Blood Flow,” Br J Clin Pharmacol, 1989, 27(1):83</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2022</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055]</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017.</li>
<li>Zokinvy (lonafarnib) [prescribing information]. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; November 2020.</li>
<li>Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2018</li>
<li>Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545-551. [PubMed 3593625</li>
<li>Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637-645. [PubMed 18551044</li>
<li>Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471-2472. [PubMed 12882884</li>
<li>Boehm KM, Gunaga S. Cimetidine-induced lactic acidosis and acute pancreatitis. South Med J. 2010;103(8):849. [PubMed 20622719</li>
<li>Seo JH, Lee da Y, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. Intern Med. 2013;52(19):2245-2248. [PubMed 24088760</li>
<li>Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica. 2008;38(9):1203-1218. [PubMed 18686197</li>
<li>Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185-191. [PubMed 19164462</li>
<li>Sultana N, Arayne MS, Ahmed N. In vitro availability of metformin in presence of h(2) receptor antagonists. Pak J Pharm Sci. 2006;19(1):28-34. [PubMed 16632449]</li>
<li>Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther. 1991;49(1):32-38. [PubMed 1988238</li>
<li>Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2015.</li>
<li>Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol. 1988;26(3):118-121. [PubMed 2457561</li>
<li>Christian CD Jr, Meredith CG, Speeg KV Jr. Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther. 1984;36(2):221-227. [PubMed 6204803</li>
<li>Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25(3):339-345. [PubMed 6194997</li>
<li>Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982;307(17):1080. [PubMed 6181402</li>
<li>Bauer LA, Black D, Gensler A. Procainamide-cimetidine interaction in elderly male patients. J Am Geriatr Soc. 1990;38(4):467-469. [PubMed 2329253</li>
<li>Higbee MD, Wood JS, Mead RA. Procainamide-cimetidine interaction: a potential toxic interaction in the elderly. J Am Geriatr Soc. 1984;32(2):162-164. [PubMed 6693705</li>
<li>Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol. 1985;28(6):671-675. [PubMed 2866097]</li>
<li>Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol. 1986;22(3):346-350. [PubMed 3768247</li>
<li>Qualaquin (quinine sulfate) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals Industry Inc; June 2019.</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019</li>
<li>El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther. 2016;9(4):157-161. [PubMed 26684920</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499</li>
<li>Fyarro (sirolimus) protein-bound [prescribing information]. Pacific Palisades, CA: Aadi Bioscience Inc; November 2021.</li>
<li>Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19(6):494-499. [PubMed 10587283</li>
<li>Preskorn SH. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract. 2005;11(3):192-196. [PubMed 15920392</li>
<li>Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 1997;25(1):24-32. [PubMed 9027670</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2010</li>
<li>Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59(1):45-50. [PubMed 12682803</li>
<li>Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther. 2007;82(5):555-565. [PubMed 17460606</li>
<li>Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60(5):543-553. [PubMed 8941027</li>
<li>Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002;16(4):361-364. [PubMed 12503836</li>
<li>Sunvepra (asunaprevir) [product monograph]Montreal, Canada: Bristol-Myers Squibb Canada; March 2016</li>
<li>Manerix (moclobemide) [product monograph]. Mississauga, Ontario: Hoffmann-LaRoche Limited, June 2011.</li>
<li>Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78(4):400-411. [PubMed 16198659</li>
<li>Villa-Zapata L, Gomez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disporportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022;45(8):863-871. [PubMed 35834155]</li>
<li>Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2019.</li>
<li>Flind AC. Cimetidine and oral anticoagulants. Br Med J. 1978;2(6148):1367. [PubMed 719395</li>
<li>Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2(8138):317-319. [PubMed 89387</li>
<li>Kerley B, Ali M. Cimetidine potentiation of warfarin action. Can Med Assoc J. 1982;126(2):116. [PubMed 7059881</li>
<li>Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med. 1979;90(3):348-349. [PubMed 426403</li>
<li>Hetzel D, Birkett D, Miners J. Cimetidine interaction with warfarin. Lancet. 1979;2(8143):639. [PubMed 90304</li>
<li>Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol. 1986;30(5):619-623. [PubMed 3758150</li>
<li>Harenberg J, Staiger CH, de Vries JX, et al. Cimetidine does not increase the anticoagulant effect of phenprocoumon. Br J Clin Pharmacol. 1982;14(2):292-293. [PubMed 7104184</li>
<li>O’Reilly RAComparative interaction of cimetidine and ranitidine with racemic warfarin in manArch Intern Med1984;144(5):989-991[PubMed 6324710</li>
<li>Unrecognized drug interactions ith famotidine and nizatidine. Arch Intern Med. 1991;151(4):810, 814, 815. [PubMed 1672811]</li>
<li>Sonata (zaleplon) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; November 2016.</li>
<li>Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest. 1998;15(6):515-522. [PubMed 18370509</li>
<li>Zomig (zolmitriptan) [prescribing information]. Hayward, CA: Impax Laboratories Inc; September 2012.</li>
<li>Alfenta (alfentanil) [prescribing information]. Lake Forest, IL: Akorn, Inc.; October 2019.</li>
<li>Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Abernathy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46(1):35-39. [PubMed 8005185</li>
<li>Suzuki Y, Shioiri T, Muratake T, et al. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol. 2003;58(12):829-833. [PubMed 12698310</li>
<li>Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol. 2009;65(7):699-704. [PubMed 19225771</li>
<li>Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug alprazolam. Eur J Clin Pharmacol. 2006;62(7):587-588. [PubMed 16791582</li>
<li>Xanax (alprazolam) [prescribing information]. New York, NY: Pfizer Inc; March 2021.</li>
<li>Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; November 2020</li>
<li>Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53(6):475-478. [PubMed 9551707]</li>
<li>Astelin (azelastine) nasal spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals Inc.; October 2014.</li>
<li>Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987;41(5):562-570. [PubMed 2882883</li>
<li>Apo-bromazepam (bromazepam) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2016.</li>
<li>Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. Pharmacotherapy. 1985;5(1):16-19. [PubMed 3982974</li>
<li>Felodipine [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; December 2020</li>
<li>Kirch W, Ramsch K, Janisch HD, Ohnhaus EE. The influence of two histamine H2-receptor antagonists, cimetidine, and ranitidine on the plasma levels and clinical effect of nifedipine and metoprolol. Arch Toxicol Suppl. 1984;7:256-259. [PubMed 6151387</li>
<li>Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther. 1989;249(2):638-645. [PubMed 2724144</li>
<li>Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43(6):673-680. [PubMed 3378388</li>
<li>Smith SR, Kendall MJ, Lobo J, Beerahee A, Jack DB, Wilkins MR. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol. 1987;23(3):311-315. [PubMed 3567045</li>
<li>Renwick AG, Le Vie J, Challenor VF, Waller DG, Gruchy B, George CF. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol. 1987;32(4):351-355. [PubMed 3609112</li>
<li>van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DDPharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidineClin Pharmacol Ther1988;43(3):332-341[PubMed 3345623</li>
<li>Muck W, Wingender W, Seiberling M, Woelke E, Ramsch KD, Kuhlmann J. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol. 1992;42(3):325-328. [PubMed 1577052</li>
<li>Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50(4):394-403. [PubMed 1914375</li>
<li>Kirch W, Hutt HJ, Heidemann H, Ramsch K, Janisch HD, Ohnhaus EE. Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S982-S985. [PubMed 6085389</li>
<li>Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther. 1990;253(3):1042-1048. [PubMed 2359015</li>
<li>Abernethy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Loi CM, Rollins DE, Dukes GE, Peat MA. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther. 1985;37(6):654-657. [PubMed 4006365</li>
<li>Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol. 1985;19(3):385-391. [PubMed 3986090</li>
<li>Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984;36(4):551-554. [PubMed 6478741</li>
<li>Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Conjupri (levamlodipine) [prescribing information]. CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia. 1986;27(5):553-558. [PubMed 3757941</li>
<li>Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol. 1984;27(3):341-343. [PubMed 6096154</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. Epilepsia. 1985;26(2):127-130. [PubMed 3987645</li>
<li>Macphee GJ, Thompson GG, Scobie G, et al. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984;18(3):411-419. [PubMed 6487479</li>
<li>Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011;24(1):63-68. [PubMed 21190921</li>
<li>Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit. 1987;9(1):24-27. [PubMed 3107168</li>
<li>Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 1986;8(4):387-392. [PubMed 3824425</li>
<li>Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy volunteers. Phytother Res. 2015;29(5):701-706. [PubMed 25624269</li>
<li>Pisani F, Narbone MC, Fazio A, et alEffect of viloxazine on serum carbamazepine levels in epileptic patientsEpilepsia1984;25(4):482-485[PubMed 6745218</li>
<li>Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49(10):1142-1145. [PubMed 3783175</li>
<li>Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine. Ann Intern Med. 1981;94(4 pt 1):544. [PubMed 7212521</li>
<li>Garcia B, Zaborras E, Areas V, Obeso G, Jimenez I, de Juana P, Bermejo T. Interaction between isoniazid and carbamazepine potentiated by cimetidine. Ann Pharmacother. 1992;26(6):841-842. [PubMed 1611171</li>
<li>Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol. 1993:36(6):615-616. [PubMed 12959283</li>
<li>Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991:84(6):583-584. [PubMed 1792934</li>
<li>Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie. 1992:47(2):165. [PubMed 1412145</li>
<li>Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust. 1991;155(11-12):851. [PubMed 1745195</li>
<li>Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand. 1983;68(4):253-256. [PubMed 6659865</li>
<li>Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine of fluvoxamine. Ther Drug Monit. 1993:15(3):247-250. [PubMed 8333006</li>
<li>Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother. 1987;20(Suppl B):121-129. [PubMed 3429380</li>
<li>Leite SA, Leite PJ, Rocha GA, Routledge PA, Bittencourt PR. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq Neuropsiquiatr. 1994;52(2):210-215. [PubMed 7826249</li>
<li>Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018</li>
<li>Equetro (carbamazepine) extended-release capsules [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2016</li>
<li>Carbatrol (carbamazepine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc.; August 2018.</li>
<li>Desmond PV, Patwardhan RV, Schenker S, Speeg Jr KV. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med. 1980;93(2):266-268. [PubMed 7406377</li>
<li>Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg Jr KV. Lack of tolerance and rapid recovery of cimetidine - inhibited chlordiazepoxide (Librium) elimination. Gastroenterology. 1981;81(3):547-551. [PubMed 7250643</li>
<li>Nelson DC, Avant GR, Speeg Jr KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology. 1985;5(2):305-309. [PubMed 3979962</li>
<li>Cimetidine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2019.</li>
<li>Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. Eur J Clin Pharmacol. 1981;21(1):83-85. [PubMed 7333351]</li>
<li>Szymanski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52:21-22. [PubMed 1988413</li>
<li>Watras M, Taylor D. A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. Ther Adv Psychopharmacol. 2013;3(5):294-297. [PubMed 24167705]</li>
<li>Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49(1):49-63. [PubMed 10606838</li>
<li>Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18(4):311-316. [PubMed 9690697</li>
<li>Raaska K, Raitasuo V, Laitila J, Neuvonen P. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalized patients. Basic Clin Pharmacol Toxicol. 2004;94(1):13-18. [PubMed 14725610</li>
<li>Al Hadithy A, Leeffers E, Bruggeman R. Clozapine levels might be affected by excessive cola consumption. J Clin Psychopharmacol. 2012;32(5):717-719. [PubMed 22926611</li>
<li>Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol. 1994;14(4):284-285. [PubMed 7962690</li>
<li>Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52(1):21-22. [PubMed 1988413</li>
<li>Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. Psychosomatics. 2007;48(2):170-175. [PubMed 17329613</li>
<li>Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol. 2002;22(6):621-622. [PubMed 12454563</li>
<li>Schoretsanitis G, Kane JM, de Leon JAdding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature reviewJ Clin Psychopharmacol2020;40(3):308-310[PubMed 32332470</li>
<li>Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50-56. [PubMed 23104241</li>
<li>Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2017.</li>
<li>Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother. 2014;48(12):1580-1584. [PubMed 25280976</li>
<li>Cai J, Huang Z, Yang G, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.  Am J Cardiovasc Drugs. 2011;11(6):401-409. [PubMed 22149319</li>
<li>Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant. 2007;21(2):277-284. [PubMed 17425758</li>
<li>Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation. 2003;76(5):865-868. [PubMed 14501869</li>
<li>McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol. 1997;48(5):336. [PubMed 9403222</li>
<li>Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7(6):831-835. [PubMed 8793790</li>
<li>Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. [PubMed 16133554</li>
<li>Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28(1):25-29. [PubMed 16541194</li>
<li>Synercid (quinupristin/dalfopristin) [prescribing information]New York, NY: Pfizer Inc; March 2017</li>
<li>Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet. 1990;19(6):499-502. [PubMed 2292171</li>
<li>Momper JD, Yang J, Kerr J, Saunders I, Smith J, Shah MM. Interaction between cyclosporine and palbociclib in a renal transplant patient: case report and pharmacokinetic perspective. J Pharm Pract. 2020;33(6):912-914. [PubMed 31248333</li>
<li>Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24(3):297-300. [PubMed 8082935</li>
<li>Wang CH, Chou NK, Wu FL, et al. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. Transplant Proc. 2006;38(7):2032-2034. [PubMed 16979990</li>
<li>Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol. 2005;45(7):781-791. [PubMed 15951468</li>
<li>Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081]</li>
<li>Mogford N, Pallett A, George C. Erythromycin deafness and cimetidine treatment. BMJ. 1994;309(6969):1620. [PubMed 7819942]</li>
<li>Mailing D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2021.</li>
<li>Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</li>
<li>Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</li>
<li>Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984;18(3):421-430. [PubMed 6487480]</li>
<li>Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32(4):432-436. [PubMed 9562139</li>
<li>Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol. 1995;8(4):231-233. [PubMed 8561837]</li>
<li>Archambeaud-Moueroux F, Nouaille Y, Nadalon S, Treves R, Merle L. Interaction between gliclazide and cimetidine. Eur J Clin Pharmacol. 1987;31(5):631. [PubMed 3830250]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413]</li>
<li>Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022</li>
<li>Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008;14(9):2701-2709. [PubMed 18451235]</li>
<li>Kishikawa K, Namiki A, Miyashita K, Saitoh K. Effects of famotidine and cimetidine on plasma levels of epidurally administered lignocaine. Anaesthesia. 1990;45(9):719-721. [PubMed 2240530</li>
<li>Parish RC, Gotz VP, Lopez LM, Mehta JL, Curry SH. Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit. 1987;9(3):292-297. [PubMed 3672572</li>
<li>Abernathy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Jackson JE, Bentley JB, Glass SJ, Fukui T, Gandolfi AJ, Plachetka JR. Effects of histamine-2 receptor blockade on lidocaine kinetics. Clin Pharmacol Ther. 1985;37(5):544-548. [PubMed 3987178</li>
<li>Bauer LA, Edwards WA, Randolph FP, Blouin RA. Cimetidine-induced decrease in lidocaine metabolism. Am Heart J. 1984;108(2):413-415. [PubMed 6464978</li>
<li>Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S. Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther. 1984;35(5):695-701. [PubMed 6713782</li>
<li>Feely J, Wilkinson GR, McAllister CB, Wood AJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982;96(5):592-594. [PubMed 7073151</li>
<li>Powell JR, Foster J, Patterson JH, Cross R, Wargin W. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics. Clin Pharm. 1986;5(12):993-998. [PubMed 3802729</li>
<li>Berk SI, Gal P, Bauman JL, Douglas JB, McCue JD, Powell JRThe effect of oral cimetidine on total and unbound serum lidocaine concentrations in patients with suspected myocardial infarctionInt J Cardiol1987;14(1):91-94[PubMed 3804509</li>
<li>Knapp AB, Maguire W, Keren G, et al. The cimetidine-lidocaine interaction. Ann Intern Med. 1983;98(2):174-177. [PubMed 6824249</li>
<li>Patterson JH, Foster J, Powell JR, Cross R, Wargin W, Clark JL. Influence of a continuous cimetidine infusion on lidocaine plasma concentrations in patients. J Clin Pharmacol. 1985;25(8):607-609. [PubMed 4078028</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Single dose oral H2-antagonists do not affect plasma lidocaine levels in the parturient. Acta Anaesthesiol Scan. 1989;33(7):593-596. [PubMed 2683547</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Effect of intravenous cimetidine on lignocaine disposition during extradural caesarean section. Anaesthesia. 1989;44(9):739-741. [PubMed 2802120</li>
<li>Dailey PA, Hughes SC, Rosen MA, Healy K, Cheek DB, Shnider SM. Effect of cimetidine and ranitidine on lidocaine concentrations during epidural anesthesia for cesarean section. Anesthesiology. 1988;69(6):1013-1017. [PubMed 3195744</li>
<li>Lidocaine [prescribing information]. Lake Forest, IL: Hospira Inc; April 2013.</li>
<li>Co-Phenylcaine Forte (lidocaine and phenylephrine) [Singapore product labeling]. Singapore: Ziwell Medical (S) Pte Ltd.; October 2015.</li>
<li>Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. Br J Clin Pharmacol. 1984;18(6):907-914. [PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062-1065. [PubMed 3605428</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR, Hudson RJ. Ranitidine does not alter pethidine disposition in man. Br J Clin Pharmacol. 1985;20(1):55-59. [PubMed 4027136]</li>
<li>Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160-166. [PubMed 20233179</li>
<li>Urva S, Bouillaud E, Delaney R, Jappe A, Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2013;53(4):444-450. [PubMed 23426978</li>
<li>Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol. 2011;51(12):1712-1720. [PubMed 21209230</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020</li>
<li>Kiang TKL. Clinical pharmacokinetics and drug-drug interactions of elbasvir/grazoprevir. Eur J Drug Metab Pharmacokinet. 2018;43(5):509-531. [PubMed 29557529</li>
<li>Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; February 2017</li>
<li>Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56-62. [PubMed 25103957</li>
<li>Koch KM, Dees EC, Coker SA, et alThe effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancerCancer Chemother Pharmacol2017;80(6):1141-1146[PubMed 29098381</li>
<li>Vitrakvi (larotrectinib) [prescribing information]. Stamford CT: Loxo Oncology Inc; November 2018</li>
<li>Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191-202. [PubMed 24825095</li>
<li>Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 plus 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652-659. [PubMed 20881954</li>
<li>Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859-1866. [PubMed 16183781</li>
<li>Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol. 1994;46(6):551-555. [PubMed 7995324</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics; November 2019</li>
<li>Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. [PubMed 21870106</li>
<li>Qelbree (viloxazine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Tavneos (avacopan) [prescribing information]. Cincinnati, OH: ChemoCentryx, Inc.; October 2021</li>
<li>Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017</li>
<li>Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15(6):1406-1416. [PubMed 35293131</li>
<li>Vaprisol (conivaptan) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; October 2016</li>
<li>Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53(3):298-305. [PubMed 8453848</li>
<li>Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol. 1993;73(3):180</li>
<li>Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56(5):389-394. [PubMed 11009047</li>
<li>Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</li>
<li>Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126-132. [PubMed 9562227</li>
<li>Nymalize (nimodipine) oral solution [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; December 2020</li>
<li>Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; December 2015.</li>
<li>Tornizol (ornidazole) [South Korea prescribing information]. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199300808. Accessed June 3, 2022</li>
<li>Arrow ornidazole (ornidazole) [New Zealand data sheet]. Auckland, New Zealand: Teva Pharma (New Zealand) Limited; October 2018</li>
<li>Ramesh S, Kumar YS, Rao YM. Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77. [PubMed 17152348]</li>
<li>Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(Suppl 350):102-106. [PubMed 2530759]</li>
<li>Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol. 1988;28(7):649-654. [PubMed 3216031</li>
<li>Luke DR, Rocci ML Jr, Hoholick C. Inhibition of pentoxifylline clearance by cimetidine. J Pharm Sci. 1986;75(2):155-157. [PubMed 3958924]</li>
<li>Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther. 2000;67(3):222-228. [PubMed 10741624]</li>
<li>Yee T, Barakos JA, Knight RT. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med. 1999;170(2):112-115. [PubMed 10063399</li>
<li>Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis. 1994;169(3):689-691. [PubMed 8158054</li>
<li>Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother. 1997;41(6):1256-1259. [PubMed 9174180</li>
<li>Biltricide (praziquantel) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; January 2019.</li>
<li>Inderal (propranolol) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; March 2011</li>
<li>Kirch W, Spahn H, Kohler H, Ohnhaus EE, Mutschler E. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr. 1982;60(22):1401-1407. [PubMed 7176462</li>
<li>Kirch W, Spahn H, Kohler H, Mutschler E. Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine. Arch Toxicol Suppl. 1983;6:379-383. [PubMed 6578746</li>
<li>Kirch W, Kohler H, Spahn H, Mutschler E. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet. 1981;2(8245):531-532. [PubMed 6115283</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17(Suppl 1):51S-57S. [PubMed 6146340</li>
<li>Tateishi T, Ohashi K, Fujimura A, Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992;32(12):1099-1104. [PubMed 1487547</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Comparison of kinetic interactions of nadolol and propranolol with cimetidine. Am Heart J. 1984;108(4 Part 2):1084-1086. [PubMed 6148867</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Kinetic interactions of nadolol and propranolol with cimetidine. Br J Clin Pharmacol. 1984;17(4):486-487. [PubMed 6721996</li>
<li>Donn KH, Powell JR, Rogers JF, Eshelman FNThe influence of H2-receptor antagonists on steady-state concentrations of propranolol and 4-hydroxypropranololJ Clin Pharmacol1984;24(11-12):500-508[PubMed 6150946</li>
<li>Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J. 1981;282(6280)1917-1919. [PubMed 6786672</li>
<li>Reimann IW, Klotz U, Siems B, Frolich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981;12(6):785-790. [PubMed 7340880</li>
<li>Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzneimittelforschung. 1987;37(8):953-956. [PubMed 2890358</li>
<li>Asgharnejad M, Powell JR, Donn KH, Danis M. The effect of cimetidine dose timing on oral propranolol kinetics in adults. J Clin Pharmacol. 1988;28(4):339-343. [PubMed 3392231</li>
<li>Reimann IW, Klotz U, Frolich JC. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther. 1982;32(6):749-757. [PubMed 6291839</li>
<li>Donovan MA, Heagerty AM, Patel L, Castleden M, Pohl JE. Cimetidine and bioavailability of propranolol. Lancet. 1981;1(8212):164. [PubMed 6109849</li>
<li>MacKichan JJ, Boudoulas H, Schall SF. Effect of cimetidine on quinidine bioavailability. Biopharm Drug Dispos. 1989;10(1):121-125. [PubMed 2923957</li>
<li>Hardy BG, Zador IT, Golden L, Lalka D, Schentag JJ. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol. 1983;52(1):172-175. [PubMed 6858908</li>
<li>Kolb KW, Garnett WR, Small RE, Vetrovec GW, Kline BJ, Fox T. Effect of cimetidine on quinidine clearance. Ther Drug Monit. 1984;6(3):306-312. [PubMed 6506138</li>
<li>Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol. 1988;26(8):388-391. [PubMed 3220613</li>
<li>Farringer JA, McWay-Hess K, Clementi WA. Cimetidine-quinidine interaction. Clin Pharm. 1984;3(1):81-83. [PubMed 6697678</li>
<li>Polish LB, Branch RA, Fitzgerald GA. Digitoxin-quinidine interaction: potentiation during administration of cimetidine. South Med J. 1981;74(5):633-634. [PubMed 7244727</li>
<li>Quinidine sulfate [prescribing information]. Laurelton, NY: Epic Pharma LLC; July 2021.</li>
<li>Bohmer GM, Gleiter CH, Morike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol. 2011;51(4):594-602. [PubMed 20484614</li>
<li>Cui X, Huang J, Zheng X, Jiang J, Kuang Y, Hu P. Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: application for a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029-1030:60-67. [PubMed 27423044</li>
<li>Li Q, Wang Y, Liu L, Ma P, Ding L. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in healthy Chinese subjects after single and multiple oral doses. Eur J Drug Metab Pharmacokinet. 2017;42(3):371-381. [PubMed 27306372</li>
<li>Zoryve (roflumilast) cream [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2022</li>
<li>Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</li>
<li>Kim J-R, Jung JA, Kim S, Huh W, Ghim J-L, Shin J-G, Ko J-W. Effect of cilostazol on the pharmacokinetics of simvastatin in healthy subjects. Biomed Res Int. 2019;1365180. [PubMed 30729119</li>
<li>Xu CF, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 23(9):2470-2471. [PubMed 22918879</li>
<li>Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19(1):247. [PubMed 31640597</li>
<li>Poumeaud F, Fontanier A, Dion J, et al. Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report. Front Oncol. 2022;12:1026434. [PubMed 36591506</li>
<li>Huynh T, Cordato D, Yang F. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32(9-10):486-490. [PubMed 12380704</li>
<li>Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; September 2020.</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499]</li>
<li>Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001;15(2):95-99. [PubMed 11264634</li>
<li>Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit. 2005;27(5):587-591. [PubMed 16175131</li>
<li>Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc.; January 2016</li>
<li>Breslin NT, Salerno DM, Topkara VK, et al. Prior amiodarone exposure reduces tacrolimus dosing requirements in heart transplant recipients. Prog Transplant. 2019;29(2):129-134. [PubMed 30845890</li>
<li>Mavyret (glecaprevir/pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2020</li>
<li>Shapiro R, Venkataramaan R, Warty VS, et al. FK 506 interaction with danazol. Lancet. 1993;341(8856):1344-1345. [PubMed 7684106</li>
<li>Seck S, Bellantoni M, Zoccali C, Enia G. Ranolazine can markedly increase tacrolimus blood levels. NDT Plus. 2011;4(1):44-45. [PubMed 25984101</li>
<li>Patni H, Gitman M, Hazzan A, Jhaveri KD. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail. 2012;34(2):251-253. [PubMed 22263871</li>
<li>Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain EPharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant childTransplantation 2012;93(7):e29-e30[PubMed 22450597</li>
<li>Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2013;69(10):1861-1862. [PubMed 23765408</li>
<li>Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2018</li>
<li>Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2020.</li>
<li>Maeda Y, Konishi T, Omoda K, et al. Inhibition of theophylline metabolism by aciclovir. Biol Pharm Bull. 1996;19(12):1591-1595. [PubMed 8996645</li>
<li>Sato J, Nakata H, Owda E, Kikuta T, Umetsu M, Ito K. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J Clin Pharmacol. 1993;44(3):295-298. [PubMed 8491248</li>
<li>Vestal RE, Thummel KE, Musser B, Mercer GD. Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol. 1983;15(4):411-418. [PubMed 6849776</li>
<li>Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med. 1984;144(3):484-486. [PubMed 6322709</li>
<li>Cohen IA, Johnson CE, Berardi RR, Hyneck ML, Achem SR. Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit. 1985;7(4):426-434. [PubMed 4082242</li>
<li>Mulkey PM, Murphy JE, Shleifer NH. Steady-state theophylline pharmacokinetic during and after short-term cimetidine administration. Clin Pharm. 1983;2(5):439-441. [PubMed 6627870</li>
<li>Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 1989;45(5):476-486. [PubMed 2721103</li>
<li>Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982;23(2):129-134. [PubMed 7140802</li>
<li>Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski REffects of tobacco smoking and oral contraceptive use on theophylline dispositionBr J Clin Pharmacol1983;16(3):271-280[PubMed 6626419</li>
<li>Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;24(2):939-941. [PubMed 2444839</li>
<li>Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline. Pharm Weekbl Sci. 1987;11(9 suppl):S72-S75. [PubMed 3481439</li>
<li>Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986;22(6):677-683. [PubMed 3567014</li>
<li>Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest. 1987;92(4):663-669. [PubMed 3477409</li>
<li>Staib AH, Harder S, Fuhr U, Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol. 1989;27(6):289-293. [PubMed 2737798</li>
<li>Miners JO, Wing LM, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol. 1985;20(3):219-223. [PubMed 4041342</li>
<li>Lombardi TP, Bertino JS Jr, Goldberg A, Middleton E Jr, Slaughter RL. The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. J Clin Pharmacol. 1987;27(7):523-529. [PubMed 2888791</li>
<li>Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980;28(4):463-467. [PubMed 7408406</li>
<li>Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41(3):358-362. [PubMed 3816023</li>
<li>Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(suppl 2):77-83. [PubMed 8620674</li>
<li>Spinler SA, Gammaitoni A, Charland SL, Hurwitz J. Propafenone-theophylline interaction. Pharmacotherapy. 1993;13(1):68-71. [PubMed 8437970</li>
<li>Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. Clin Pharmacol Ther. 1992;51(3):353-355. [PubMed 1544292</li>
<li>Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ. Cimetidine-theophylline interaction: report of four patients. Ann Allergy. 1982;48(2):100-102. [PubMed 6121526</li>
<li>Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR. Cimetidine decreases theophylline clearance. Ann Intern Med. 1981;95(1):68-69. [PubMed 7247131</li>
<li>Lofgren RP, Gilbertson RA. Cimetidine and theophylline. Ann Intern Med. 1982;96(3):378. [PubMed 6800293</li>
<li>Mojtahedzadeh M, Sadray S, Hadjibabaie M, Fasihi M, Rezaee S. Determination of theophylline clearance after cimetidine infusion in critically ill patients. J Infus Nurs. 2003;26(4):234-238. [PubMed 12869856</li>
<li>Koren G, Chin TF, Correia J, Tesoro A, MacLeod SM. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. Clin Invest Med. 1985;8(3):222-2[PubMed 4042465</li>
<li>Theo-24 (theophylline anhydrous) [prescribing information]. Malvern, PA; Endo Pharmaceuticals Inc.; August 2017.</li>
<li>Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986;26(5):372-377. [PubMed 3700691</li>
<li>Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157-163. [PubMed 3383988</li>
<li>Adebayo GI, Coker HA. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. Eur J Clin Pharmacol. 1988;34(6):653-656. [PubMed 3169118</li>
<li>Stockley C, Keal J, Rolan P, Bochner F, Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur J Clin Pharmacol. 1986;31(2): 235-237. [PubMed 3803421</li>
<li>Dey NG, Castleden CM, Ward J, Cornhill J, McBurney A. The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol. 1983;16(4):438-440. [PubMed 6626438]</li>
<li>Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983;16(6):743-746. [PubMed 6140941</li>
<li>Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol. 1998;28(3):228-233. [PubMed 3360971</li>
<li>Pourbaix S. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Britton ML, Waller ES. Central nervous system toxicity associated with concurrent use of triazolam and cimetidine. Drug Intell Clin Pharm. 1985;19(9):666-668. [PubMed 40428607. Parker WA, MacLachlan RA. Prolonged hypnotic response to triazolam-cimetidine combination in an elderly patient. Drug Intell Clin Pharm. 1984;18(12):980-981. [PubMed 6150838]</li>
<li>Curry SH, De Vane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433. [PubMed 3912187</li>
<li>Amsterdam JD, Brunswick DJ, Potter L, et al. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology. 1984;83:373-375. [PubMed 6436867</li>
<li>Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. [PubMed 3950073</li>
<li>Sutherland DL, Remillard AJ, Haight KR, et al. The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. Eur J Clin Pharmacol. 1987;32:159-164. [PubMed 3582480</li>
<li>Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. [PubMed 379426</li>
<li>Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. [PubMed 6692646</li>
<li>Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229(3):702-705. [PubMed 6726654</li>
<li>Brown MA, Haight KR, McKay G. Cimetidine-doxepin interaction. J Clin Psychopharmacol. 1985;5:245-247. [PubMed 4019813</li>
<li>Shapiro PACimetidine-imipramine interaction: case report and commentsAm J Psychiatry1984;141:152[PubMed 6691449</li>
<li>Miller DD, Macklin M. Cimetidine-imipramine interaction: a case report. Am J Psychiatry. 1983;140:351. [PubMed 6829810</li>
<li>Miller DD, Sawyer JB, Duffy JP. Cimetidine’s effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm. 1983;17(12):904-905. [PubMed 6653407</li>
<li>Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther. 1987;42:278-282. [PubMed 3621787]</li>
<li>Urasap (urapidil) [Summary of Product Characteristics]. Frosinone, Italy: INCA-Pharm Srl; September 2012.</li>
<li>De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46(2):458-463. [PubMed 11796358</li>
<li>Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2010.</li>
<li>Desager JP, Harvengt C, Bianchetti G, Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int J Clin Pharmacol Ther Toxicol. 1993;31(11):568-571. [PubMed 7904983]</li>
<li>Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; November 2022</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Hendset M, Molden E, Enoksen TB, et al. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit. 2010;32(6):787-790. [PubMed 21068650</li>
<li>Abilify Maintena (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; January 2020</li>
<li>Abilify Asimtufii (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; April 2023.</li>
<li>Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20(1):55-64. [PubMed 15770075</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44(11):1850-1854. [PubMed 20978219</li>
<li>Qulipta (atogepant) [prescribing information]. Dublin, Ireland: Forest Laboratories Ireland Ltd; September 2021.</li>
<li>Ortikos (budesonide) extended-release capsules [prescribing information]. Sun Pharmaceutical Industries, Inc.; June 2019.</li>
<li>Buspirone [prescribing information]. Laurelton, NY: Epic Pharma LLC; May 2020</li>
<li>Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ. Lack of interaction between cimetidine and buspirone. Pharmacotherapy. 1987;7(3):72-79. [PubMed 2888096]</li>
<li>Epidiolex (cannabidiol) oral solution [prescribing information]. Carlsbad, CA: Greenwich Biosciences Inc; October 2020</li>
<li>Thai C, Tayo B, Critchley D. A phase I open-label, fixed sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(11):1279-1289. [PubMed 33951339</li>
<li>Beach CA, Mays DC, Guiler RC, Jacober CH, Gerber N. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986;39(3):265-270. [PubMed 3948467</li>
<li>Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol. 1995;48(2):161-166. [PubMed 7589032</li>
<li>Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425-428. [PubMed 4029248</li>
<li>Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther. 1999;65(3):262-274. [PubMed 10096258</li>
<li>Pegintron (peginterferon alfa-2b) [prescribing information]Whitehouse Station, NJ: Merck &amp; Co Inc; January 2019</li>
<li>Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988;35(6):651-656. [PubMed 2853056</li>
<li>Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45(3):234-240. [PubMed 2920498</li>
<li>Michaud V, Mouksassi MS, Labbe L, et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit. 2006;28(6):779-783. [PubMed 17164694</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Coreg (carvedilol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</li>
<li>Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104(12):3116-3117. [PubMed 19956146]</li>
<li>Rize (clotiazepam) [KR prescribing information]. Available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802970]. Accessed [January 30, 2023]</li>
<li>Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H. Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol. 1984;26(1):55-59. [PubMed 6143670]</li>
<li>Mitigare (colchicine) capsule [prescribing information]. Memphis, TN: Hikma Americas, Inc.; September 2014.</li>
<li>Enablex (darifenacin) [prescribing information]. Rockaway, NJ: Warner Chilcott US LLC; March 2012.</li>
<li>Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15(1):18-24. [PubMed 8451775</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997;62(2):145-156. [PubMed 9284850</li>
<li>Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008</li>
<li>Effexor (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017</li>
<li>Norvir (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2019</li>
<li>Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664-674. [PubMed 16338282</li>
<li>Orladeyo (berotralstat) [prescribing information]Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989;146(12):1611-1613. [PubMed 2486749</li>
<li>Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329-336. [PubMed 2288330</li>
<li>Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit. 1992;14(3):194-196. [PubMed 1412604</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res. 1993;13(3):167-171. [PubMed 8225700</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15(3):243-246. [PubMed 8333005]</li>
<li>Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017</li>
<li>Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70(9):1115-1122. [PubMed 25028073</li>
<li>Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacol (Berl). 1998;135(1):22-26. [PubMed 9489930</li>
<li>Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(4):747-755. [PubMed 24013574</li>
<li>Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020</li>
<li>Qelbree (viloxazine) [prescribing information]Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Saphris (asenapine) [prescribing information]. Irvine, CA: Allergan USA Inc; February 2017</li>
<li>Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64(3):257-268. [PubMed 9757149]</li>
<li>Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother Pharmacol. 1999;43(2):126-132. [PubMed 9923817]</li>
<li>Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer Inc.; June 2016</li>
<li>Cardura XL (doxazosin extended-release) [prescribing information]. New York, NY: Pfizer Inc.; February 2017.</li>
<li>Cerdelga (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2018</li>
<li>Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</li>
<li>Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14-23. [PubMed 11180034</li>
<li>Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50(3):203-208. [PubMed 8737760</li>
<li>Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. 2002;72(3):247-255. [PubMed 12235445]</li>
<li>Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77(1):17-23. [PubMed 15637527]</li>
<li>Flecainide [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals Pvt. Ltd.; September 2017</li>
<li>Tjandra-Maga TB, van Hecken A, van Melle P, Verbesselt R, de Schepper PJAltered pharmacokinetics of oral flecainide by cimetidineBr J Clin Pharmacol1986;22(1):108-110[PubMed 3741720]</li>
<li>Sullivan KM, Small RE, Rock WL, Cox SR, Willis HE. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm. 1986;5(7):586-589. [PubMed 3742949</li>
<li>Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol. 1990;30(7):660-664. [PubMed 2391398]</li>
<li>Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507. [PubMed 20573085</li>
<li>Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514]</li>
<li>Dumitras S, Sechaud R, Drollmann A, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771-779. [PubMed 24040847]</li>
<li>Zircol (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013</li>
<li>Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:31S-36S. [PubMed 11879257</li>
<li>Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-581. [PubMed 15365656]</li>
<li>Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</li>
<li>Luder PJ, Siffert B, Witassek F, et al. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31(4):443-448. [PubMed 3816925</li>
<li>Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24(3):390-392. [PubMed 3663452]</li>
<li>Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319-1321. [PubMed 15541258</li>
<li>Garimella T, Tao X, Sims K, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R D. 2018;18(1):55-65. [PubMed 29255971</li>
<li>Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130-137. [PubMed 12891223</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67-70. [PubMed 2917591</li>
<li>Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466-477. [PubMed 10824625</li>
<li>Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113-123. [PubMed 14748763</li>
<li>Thibault N, Ibrahim J, Peterschmitt MJ, et al. Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Mol Genet Metab. 2020;129(4):278-285. [PubMed 32029355</li>
<li>Lexapro (escitalopram) [prescribing information]Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28-34. [PubMed 17224709</li>
<li>Ogasawara K, LoRusso PM, Olszanski AJ, et al. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol. 2020;86(1):87-95. [PubMed 32537715</li>
<li>Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol. 1987;31(5):575-578. [PubMed 3830242</li>
<li>Laurent-Kenesi MA, Brentano-Funck C, Poirier JM, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 1993;36(6):531-538. [PubMed 12959269</li>
<li>Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24(2):213-220. [PubMed 3620296</li>
<li>Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Cho DY, Bae SH, Lee JK, et al. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica. 2015;45(3):256-263. [PubMed 25268386</li>
<li>Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2015</li>
<li>Effexor XR (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</li>
<li>Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's Disease. Biopharmaceut Drug Dispos. 1988;9(2):219-227. [PubMed 2897213</li>
<li>Loft S, Dossing M, Sonne J, Dalhof K, Bjerrum K, Poulsen HE. Lack of effect of cimetidine on the pharmacokinetics of metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol. 1988;35(1):65-68. [PubMed 3220096</li>
<li>Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. Eur J Clin Pharmacol. 1987;32(1):35-41. [PubMed 3582467</li>
<li>Gugler R, Jensen JC. Interaction between cimetidine and metronidazole. N Eng J Med 1983;309(24):1518-1519. [PubMed 6646177</li>
<li>Viaflex Plus Container (metronidazole injection) [prescribing information]. Deefield, IL: Baxter Healthcare Corporation; December 2017</li>
<li>Pearce RE, Cohen-Wolkowiez M, Sampson MR,Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013;41(9):1686-1694. [PubMed 23813797</li>
<li>Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE . Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol. 1991;41(8):1127-1134. [PubMed 2009091]</li>
<li>Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; November 2019.</li>
<li>Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the h2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 1997;43(2):201-204. [PubMed 9131955]</li>
<li>Bendayan R, Sullivan JR, Shaw C, et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol. 1990;38:165-169. [PubMed 2338114</li>
<li>Bendayan R, Kennedy G, Frecker RC, Sellers EM. Lack of effect of cimetidine on cigarette smoking. Eur J Clin Pharmacol. 1993;44(1):51-55. [PubMed 8436155]</li>
<li>Ochs HR, Greenblatt DJ, Gugler R, Muntefering G, Locniskar A, Abernethy DR. Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther. 1983;34(2):227-230. [PubMed 6872417</li>
<li>Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</li>
<li>Fine A, Churchill DN, “Potentially Lethal Interaction of Cimetidine and Morphine,” Can Med Assoc J, 1981, 124(11):1434</li>
<li>[PubMed 7237324</li>
<li>Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010</li>
<li>Gogas KR, Hough LB, Eberle NB, et al, “A Role for Histamine and H2-Receptors in Opioid Antinociception,” J Pharmacol Exp Ther, 1989, 250(2):476-84. [PubMed 2547933</li>
<li>Bluhm R, Zsigmond EK, Winnie AP, “Potentiation of Opioid Analgesia by H1 and H2 Antagonists,” Life Sci, 1982, 31(12-13):1229-32. [PubMed 6128651</li>
<li>Robertson JA, Hough LB, Bodnar RJ, “Potentiation of Opioid and Nonopioid Forms of Swim Analgesia by Cimetidine,” Pharmacol Biochem Behav, 1988, 31(1):107-12. [PubMed 2855266</li>
<li>Lam AM, Clement JL, “Effect of Cimetidine Premedication on Morphine-Induced Ventilatory Depression,” Can Anaesth Soc J, 1984, 31(1):36-43. [PubMed 6420025</li>
<li>Mojaverian P, Fedder IL, Vlasses PH, et al, “Cimetidine Does Not Alter Morphine Disposition in Man,” Br J Clin Pharmacol, 1982, 14(6):809-13. [PubMed 7150459</li>
<li>Dawson GW, Vestal RE, “Cimetidine Inhibits the In Vitro N-Demethylation of Methadone,” Res Commun Chem Pathol Pharmacol, 1984, 46(2):301</li>
<li>[PubMed 6515123</li>
<li>Guay DR, Meatherall RC, Chalmers JL, et al, “Cimetidine Alters Pethidine Disposition in Man,” Br J Clin Pharmacol, 1984, 18(6):907-14[PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, et al, “Meperidine-Induced Delirium,” Am J Psychiatry, 1987, 144(8):1062</li>
<li>Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014</li>
<li>Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005;28(2):328-334. [PubMed 15684493</li>
<li>Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull. 2004;27(5):684-690. [PubMed 15133245]</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S. [PubMed 6146340</li>
<li>Spahn H, Kirch W, Mutschler E. The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol. Br J Clin Pharmacol. 1983;15(4):500-501. [PubMed 6849789</li>
<li>Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016</li>
<li>Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992;51(4):379-387. [PubMed 1563208]</li>
<li>Pritchett EL, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol. 1988;28(7):619-624. [PubMed 3063727]</li>
<li>Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; December 2017.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53(suppl 1):31S-36S. [PubMed 11879257</li>
<li>Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; February 2018.</li>
<li>Lamisil (terbinafine hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016</li>
<li>Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219. [PubMed 9382559]</li>
<li>Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol. 1993;45(1):41-46. [PubMed 8405028]</li>
<li>Jonderko G, Jonderko K, Marcisz C, Kotulska A. Effect of cimetidine and ranitidine on absorption of [125]levothyroxine administered orally. Zhongguo Yao Li Xue Bao. 1992;13(5):391-394. [PubMed 1300037</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075]</li>
<li>Gabitril (tiagabine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2015.</li>
<li>Spiriva (tiotropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2015.</li>
<li>Conzip (tramadol) extended-release capsules [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC; March 2021.</li>
<li>Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Inc; February 2019.</li>
<li>Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):51-55. [PubMed 14616414</li>
<li>Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother. 2009;53(4):1712-1714. [PubMed 19171800</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; April 2019.</li>
<li>Wang K, Yao X, Zhang M, et al. Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):441-454. [PubMed 33687157]</li>
<li>de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55-59. [PubMed 31865063</li>
<li>Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019;10:2042098619854007. doi: 10.1177/2042098619854007. [PubMed 31258887</li>
<li>Tsai SC, Sheu SY, Chien LN, Lee HC, Yuan EJ, Yuan RY. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000-2009. [PubMed 29745438</li>
<li>Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780-1782. [PubMed 7500509</li>
<li>Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med. 1986;146(10):2070-2071. [PubMed 3767555</li>
<li>Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J. 2010;103(2):178-180. [PubMed 20065895</li>
<li>Corsini GU, Zompo MD, Cianchetti C, et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacologia. 1976;47(2):169-173. [PubMed 1273213</li>
<li>Tarsy D, Parkes JD, Marsden CD. Metoclopramide in parkinsonism. Lancet. 1975;1(7918):1244-1245. [PubMed 48872</li>
<li>Tarsy D, Parkes JD, Marsden CDMetoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesiasJ Neurol Neurosurg Psychiatry1975;38(4):331-335[PubMed 1095689</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020</li>
<li>Migramax (aspirin and metoclopramide) [summary of product characteristics]. London, United Kingdom: Zentiva Pharma UK Limited; March 2022.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; August 2017</li>
<li>Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC. 2013;13:152. [PubMed 23714238</li>
<li>Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004;44(6):661-665. [PubMed 15637848</li>
<li>Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ. 1988;297(6654):964-965. [PubMed 3142568</li>
<li>Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J. 1991;84(5):626-628. [PubMed 2035085</li>
<li>Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolid-fluoxetine and olanzapine-metoclopramide interactions: a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission. Case Rep Med. 2016;2016:7128909. [PubMed 27433163]</li>
<li>Cabergoline [prescribing information]. Peapack, NJ: Greenstrone LLC; November 2019.</li>
<li>Barnes TR, Braude WM, Hill DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2(8288):48-49. [PubMed 6123780</li>
<li>Metoclopramide [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; July 2021</li>
<li>Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000;23(Suppl):S64-S70. [PubMed 11052222</li>
<li>Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. [PubMed 19886950</li>
<li>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446]</li>
<li>Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.</li>
<li>Patterson JF. Metoclopramide therapy of MAOI orthostatic hypotension. J Clin Psychopharmacol. 1987;7(2):112-113. [PubMed 3584514]</li>
<li>Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</li>
<li>Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009</li>
<li>Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” Trends Neurosci, 2000, 23(Suppl):S64-70. [PubMed 11052222</li>
<li>Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” Aliment Pharmacol Ther, 2010, 31(1):11</li>
<li>Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” Ann Pharmacother, 2008, 42(9):1290</li>
<li>Trelstar (triptorelin) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions, LLC; December 2018</li>
<li>Trelstar (triptorelin) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc.; September 2022.</li>
<li>Prescribing information. Malarone (atovaquone and proguanil). Research Triangle Park, NC: GlaxoSmithKline, 02/2013.</li>
<li>Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos. 2006;27(6):285-289. [PubMed 16770757</li>
<li>Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-2281. [PubMed 27621638</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020.</li>
<li>Mehta D, Bradley EL Jr, Kissin I. Metoclopramide decreases thiopental hypnotic requirements. Anesth Analg. 1993;77(4):784-787. [PubMed 8214666</li>
<li>Thiopental sodium [Summary of Product Characteristics]. Berkshire, UK: Archimedes Pharma UK Limited; January 2014.</li>
<li>Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013</li>
<li>Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990;39(6):1045-1053. [PubMed 2322292]</li>
<li>Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011</li>
<li>Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015</li>
<li>Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015</li>
<li>Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.</li>
<li>Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: Ani Pharmaceuticals Inc; August 2017.</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation. 1987;43(2):211-213. [PubMed 3544377</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant patients. Transplant Proc. 1988;20(2 suppl 2):487-490. [PubMed 3284095</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017.</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932]</li>
<li>Aczone (dapsone) gel [prescribing information]. Irvine, CA: Allergan, Inc.; July 2015.</li>
<li>Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</li>
<li>Gamble JA, Gaston JH, Nair SG, Dundee JW. Some pharmacological factors influencing the absorption of diazepam following oral administration. Br J Anaesth. 1976;48(12):1181-1185. [PubMed 1023954</li>
<li>Chapman MH, Woolner DF, Begg EJ, Atkinson HC, Sharman JR. Coadministered oral metoclopramide does not enhance the rate of absorption of oral diazepam. Anaesth Intensive Care. 1988;16(2):202-205. [PubMed 3394914]</li>
<li>Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinetic. 1986;11(4):249-250. [PubMed 3582418</li>
<li>Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984;36(6):724-730. [PubMed 6499354</li>
<li>Schwartz BG. Metoclopramide and digoxin cause 22 episodes of bradyarrhythmias. Am J Med. 2010;123(6):e5</li>
<li>[PubMed 20569744</li>
<li>Johnson BG, O'Grady J, Bye C. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. Br J Clin Pharmacol. 1978;5(5):465-467. [PubMed 656287]</li>
<li>Monurol (fosfomycin) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2018.</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One. 2013;8(11):e81208. [PubMed 24278396</li>
<li>Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6(9):e23728. [PubMed 21961030</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015</li>
<li>Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488</li>
<li>Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662]</li>
<li>Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.</li>
<li>Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016</li>
<li>Synera (lidocaine and tetracaine) topical patch [prescribing information]. Souderton, PA: Galen US Inc; March 2014</li>
<li>Pliaglis (lidocaine and tetracaine) cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; November 2013</li>
<li>Citanest plain (prilocaine) [prescribing information]. York, PA: Dentsply Pharmaceutical; June 2010</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006</li>
<li>Marcaine Spinal (bupivacaine hydrochloride in dextrose injection, USP) [prescribing information]. Lake Forest, IL: Hospira, Inc.; November 2018</li>
<li>Lardieri AB, Crew PE, McCulley L, Kim IE, Waldron P, Diak IL. Cases of benzocaine-associated methemoglobinemia identified in the FDA adverse event reporting system and the literature [published online January 2, 2019]. Ann Pharmacother. doi: 10.1177/1060028018823532. [PubMed 30600685]</li>
<li>Tercan M, Efe EM, Turker G, et al. Do metoclopramide and ondansetrone alter mivacurium-induced neuromuscular blockade? - a randomised trial. Braz J Anesthesiol. 2014;64(1):35-39. [PubMed 24565386</li>
<li>El Ayass N, Hendrickx P. Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized double blind placebo-controlled study. Eur J Anaesthesiol. 2005;22(3):197-201. [PubMed 15852992</li>
<li>Motamed C, Kirov K, Combes X, Dhonneur G, Duvaldestin P. Effect of metoclopramide on mivacurium-induced neuromuscular block. Acta Anaesthesiol Scand. 2002;46(2):214-216. [PubMed 11942874</li>
<li>Skinner HJ, Girling KJ, Whitehurst A, Nathanson MH. Influence of metoclopramide on plasma cholinesterase and duration of action of mivacurium. Br J Anaesth. 1999;82(4):542-545. [PubMed 10472219</li>
<li>Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth. 1990;65(2):220-224. [PubMed 2223340</li>
<li>Kambam JR, Parris WC, Franks JJ, Sastry BV, Naukam R, Smith BE. The inhibitory effect of metoclopramide on plasma cholinesterase activity. Can J Anaesth. 1988;35(5):476-478. [PubMed 3273154]</li>
<li>Inomax (nitric oxide) [prescribing information]. Hampton, NJ: INO Therapeutics; March 2013</li>
<li>Genosyl (nitric oxide) [prescribing information]. Atlanta, GA: Vero Biotech; December 2019</li>
<li>Sinisterra S, Miravet E, Alfonso I, et al. Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic. J Pediatr. 2002;141(2):285-286. [PubMed 12183731</li>
<li>Lopez A, Bernardo B, Lopez-Herce J, et al. Methaemoglobinaemia secondary to treatment with trimethoprim and sulphamethoxazole associated with inhaled nitric oxide. Acta Paediatr. 1999;88(8):915-916. [PubMed 10503695</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006.</li>
<li>Metozolv ODT (metoclopramide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2011.</li>
<li>Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011;67(6):591-599. [PubMed 21161196</li>
<li>PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PMID: 19075045</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013.</li>
<li>Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006</li>
<li>Skold A, Cosco DL and Klein R, “Methemoglobinemia: Pathogenesis, Diagnosis, and Management,” South Med J, 2011, 104(11):757-61. [PubMed 22024786</li>
<li>Mansouri A and Lurie AA, “Concise Review: Methemoglobinemia,” Am J Hematol, 1993, 42(1):7-12. [PubMed 8416301]</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022</li>
<li>Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</li>
<li>Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced serotonin syndrome. Intern Med. 2017;56(6):737-739. [PubMed 28321081</li>
<li>Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002;36(1):67-71. [PubMed 11816261</li>
<li>Aussedat M, Lavoie A, Bussieres JF, Kleiber N. Suspected overlap between serotonin syndrome and neuroleptic malignant syndrome in a child treated with metoclopramide? J Pediatr Pharmacol Ther. 2020;25(6):552-558. [PubMed 32839660</li>
<li>Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664</li>
<li>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718</li>
<li>Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713</li>
<li>Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil. 2009;21(12):1235-1238. [PubMed 19906028]</li>
<li>Provenzani A, D'alessandro N, Polidori P. Toxic tacrolimus concentrations associated with intravenous use of metoclopramide in a lung transplant patient. Ann Pharmacother. 2019;53(5):548-549. [PubMed 30739475</li>
<li>Prescott WA Jr, Callahan PL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 2004;24(4):532-537. [PubMed 15098810</li>
<li>Wadhw NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019.</li>
<li>Prescribing information. Baltimore, MD: Cangene BioPharma, Inc., 2/2012</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</li>
<li>Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology. 1989;70(6):905-908. [PubMed 2658689</li>
<li>Turner DR, Kao YJ, Bivona C. Neuromuscular block by suxamethonium following treatment with histamine type 2 antagonists or metoclopramide. Br J Anaesth. 1989;63(3):348-350. [PubMed 2572248</li>
<li>Dell-Kuster S, Levano S, Burkhart CS, et al. Predictors of the variability in neuromuscular block duration following succinylcholine: A prospective, observational study. Eur J Anaesthesiol. 2015;32(10):687-696. [PubMed 26213905</li>
<li>Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” Br Med J, 1973, 1:587. [PubMed 4694406</li>
<li>Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” Br J Clin Pharmacol, 1981, 11:430-1P</li>
<li>Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” J Pharm Pharmacol, 2001, 53(7):1041</li>
<li>[PubMed 11480539</li>
<li>van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” Methods Find Exp Clin Pharmacol, 1990, 12(4):291</li>
<li>[PubMed 2374477</li>
<li>van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” Methods Find Exp Clin Pharmacol, 1992, 14(5):379-82. [PubMed 1513194</li>
<li>Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” Br J Clin Pharmacol, 1983, 15(4):487</li>
<li>[PubMed 6849786</li>
<li>Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” Cephalalgia, 1988, 8(3):139-47. [PubMed 31970094</li>
<li>Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” Eur J Clin Pharmacol, 1992, 42(2):235</li>
<li>[PubMed 1618258]</li>
<li>Kaukab I, Shah SNH, Kharaba ZJ, Buabeid MA, Alfoteih YA, Murtaza G. Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake. Expert Opin Metab Toxicol. 2020;16(8):735-740. [PubMed 32524862]</li>
<li>Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013;28(2):99-105. [PubMed 23221858</li>
<li>Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559</li>
<li>Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. [PubMed 18809731</li>
<li>Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018</li>
<li>Khedezla (desvenlafaxine) [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; August 2017.</li>
<li>Moffett PM, Cartwright L, Grossart EA, O’Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23(1):102-105. [PubMed 26720490</li>
<li>Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-58. [PubMed 22046106</li>
<li>Tracz K, Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br J Clin Pharmacol. 2015;79(4):669-676. [PubMed 25293524</li>
<li>Obal D, Yang D, Sessler DI. Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Mayo Clin Proc. 2014;89(1):69-80. [PubMed 24388024</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder TClinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort studyBr J Clin Pharmacol2009;67(3):347-354[PubMed 19523015</li>
<li>Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105(2):389-395. [PubMed 8306734</li>
<li>Kroll CR, Gettes LS. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol. 2002;13(9):936-938. [PubMed 12380935</li>
<li>Otsuka M, Kanamori H, Sasaki S, et al. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med. 1997;36(10):705-708. [PubMed 9372331</li>
<li>Farguhar Zanetti LA, Oliphant CM. Pentamidine-induced torsades de pointes. Ann Pharmacother. 1994;28(2):282-283. [PubMed 8173154</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</li>
<li>Matsuo J, Yamaori S. Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. [published online ahead of print] J Clin Pharm Ther. 2021. doi:10.1111/jcpt.13539. [PubMed 34664726</li>
<li>Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther. 1988;43(5):577-581. [PubMed 3365919</li>
<li>Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol. 2003;41(8):1199-1201. [PubMed 12842189</li>
<li>Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality. 1991;3(1):14-18. [PubMed 2039678</li>
<li>Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</li>
<li>Kaukab I, Shah SNH, Abrar MA, Anwer N, Murtaza G. Influence of rifampicin pre-treatment on the in vivo pharmacokinetics of metoclopramide in Pakistani healthy volunteers following concurrent oral administration. Curr Drug Metab. 2020;21(4):301-306. [PubMed 32407272]</li>
<li>Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003:31(5):631-636. [PubMed 12695352]</li>
<li>Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.</li>
<li>Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2016;37(1):15-27. [PubMed 26356245</li>
<li>Pham CP, de Feiter PW, van der Kuy PHM, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7-8):1456-1461. [PubMed 16849620</li>
<li>Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc.; March 2015.</li>
<li>Yoshizato T, Kotegawa T, Imai H, et al. Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol. 2012;68(9):1287-1294. [PubMed 22418831</li>
<li>Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411-421. [PubMed 21883386</li>
<li>Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63(6):656</li>
<li>[PubMed 18477279</li>
<li>Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179(3):172. [PubMed 12885276</li>
<li>Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron. 2002;90(2):234</li>
<li>[PubMed 11818715</li>
<li>Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009;2009. [PubMed 21931583</li>
<li>Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum Mal Osteoartic. 1992;59(4):281</li>
<li>(Article in French) [PubMed 1496277</li>
<li>Collidge TA, Razvi S, Nolan C, et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barre syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med. 2010;27(6):696-700. [PubMed 20546290</li>
<li>Kearney S, Carr AS, McConville J, McCarron MO, Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ. 2012;345:e6562. [PubMed 23047962</li>
<li>O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325</li>
<li>[PubMed 18644925</li>
<li>Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka EAcute rhabdomyolysis after atorvastatin and fusidic acid therapyAm J Med2000;109(1)</li>
<li>[PubMed 10991749</li>
<li>Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33</li>
<li>Xelenta (lefamulin) [prescribing information]. Ireland: Nabriva Therapeutics US, Inc.; August 2019.</li>
<li>Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213-1217. [PubMed 21732066</li>
<li>Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46(8):722-730. [PubMed 2665687</li>
<li>Orap (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon VRisk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugsJ Clin Psychopharmacol2017;37(5):540-545[PubMed 28817488</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2019</li>
<li>Panos G, Velissaris D, Karamouzos V, Matzaroglou C, Tylianakis M. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295-300. [PubMed 27125217</li>
<li>Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. [PubMed 20297862</li>
<li>Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355-2358. [PubMed 28475803</li>
<li>Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301-311. [PubMed 19646076</li>
<li>Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726-1734. [PubMed 16705579]</li>
<li>van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-1014. [PubMed 20925438</li>
<li>Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421-424. [PubMed 25828198</li>
<li>Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888. [PubMed 20652862</li>
<li>Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663-666. [PubMed 18589449</li>
<li>Vieira MC, Miyague NI, Van Steen K, et al. Effects of domperidone on QTc interval in infants. Acta Paediatr. 2012;101(5):494-496. [PubMed 22226330</li>
<li>Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-723. [PubMed 15690231</li>
<li>Digby G, Machaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17(2):184-188. [PubMed 20544619</li>
<li>Fais P, Vermiglio E, Laposata C, et al. A case of sudden cardiac death following Domperidone self-medication. Forensic Sci Int. 2015;254:e1-e3. [PubMed 26119456</li>
<li>Domperidone [product monograph]Toronto, Ontario, Canada: Apotex Inc; March 2015</li>
<li>Xalkori (crizotinib) [prescribing information]. New York, NY: Pfizer Inc; March 2016</li>
<li>Kisqali (ribociclib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2017</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2018</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et alDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes2013;6(4):479-487[PubMed 23716032</li>
<li>Rocha CM, Barbosa MMQT interval prolongation associated with the oral use of domperidone in an infantPediatr Cardiol2005;26(5):720-723[PubMed 15690231</li>
<li>Romero J, Baldinger SH, Goodman-Meza D, et al. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol. 2016;45(1):37-45. [PubMed 26589717</li>
<li>Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. 2012;52(4):520-529. [PubMed 21558456</li>
<li>Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk AClarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reportsTher Adv Infect Dis2013;1(4):121-138[PubMed 25165548</li>
<li>Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2017</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019</li>
<li>Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204. [PubMed 20673553</li>
<li>Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. [PubMed 16317317</li>
<li>Meyer-MassettiC, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et alThe FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med2010;5(4):E8-16[PubMed 20394022</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketin analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon VDevelopment of a risk score for QTc-prolongation: the RISQ-PATH studyInt J Clin Pharm2017;39(2):424-432[PubMed 28281228</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsaes de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Parlodel (bromocriptine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; July 2021</li>
<li>Bromocriptine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.</li>
<li>Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2019</li>
<li>Sangana R, Gu H, Chun DY, Einolf HJ. Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches. Drug Metab Dispos. 2018;46(1):26-32. [PubMed 29038231]</li>
<li>Devandla A, Yamsani SK, Yamsani MR. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers. Drug Metab Pers Ther. 2015;30(4):257-261. [PubMed 26353177]</li>
<li>Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287</li>
<li>Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E16. [PubMed 20394022</li>
<li>Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262-268. [PubMed 15231861</li>
<li>Kitagawa K, Kawada K, Morita S, et al. Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 2012;23(3):743-747. [PubMed 21690231</li>
<li>Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16(11):3019-3027. [PubMed 20501625</li>
<li>Kim H-H, An SH, Cho YH, Kim S-Y, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013;52(6):1223-1224. [PubMed 23368679</li>
<li>Chung LW, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156-157. [PubMed 18618340</li>
<li>Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. [PubMed 20529041</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJThe FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med2010;5(4):E8-E16[PubMed 20394022</li>
<li>Product monograph. Dom-Domperidone (domperidone). Montreal, Quebec, Canada: Dominion Pharmaceutical, May 2012.</li>
<li>Min JJ, Lee J, Lee H-C, Ryu H-G, Shin M, Kim HJ. A comparison of the effects of sevoflurane and desflurane on corrected QT interval prolongation in patients undergoing living donor liver transplantation: a prospective observational study. Transplant Proc. 2016;48(1):96-101. [PubMed 26915850</li>
<li>Bestas A, Hanbeyoglu O, Keles E, Bayar MK. The effect of adrenaline on desflurane-induced prolonged QTc interval: a randomized double-blind trial. Eur Rev Med Pharmacol Sci. 2013;17(11):1523-1528. [PubMed 23771541</li>
<li>Liu Y, Fu X, Gao H, Ren Y, Li H, He Y, Wang G. Effects of different concentrations of desflurane on the index of cardiac electrophysiological balance in gynecologic surgery patients. Can J Physiol Pharmacol. 2020;98(5):332-335. [PubMed 31770012</li>
<li>Aypar E, Karagoz AH, Ozer S, Celiker A, Ocal T. The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac rhythm in children. Paediatr Anaesth. 2007;17(6):563-567. [PubMed 17498019</li>
<li>Owczuk R, Wujtewicz MA, Sawicka W,Lasek J, Wujtewicz M. The influence of desflurane on QTc interval. Anesth Analg. 2005;101(2):419-422. [PubMed 16037155</li>
<li>Lindgren L, Saarnivaara L. Cardiovascular responses to enflurane induction followed by suxamethonium in children. Br J Anaesth. 1983;55(4):269-273. [PubMed 6838741</li>
<li>Lindgren L. E.C.G. changes during halothane and enflurane anaesthesia for E.N.T. surgery in children. Br J Anaesth. 1981;53(6):653-662. [PubMed 7248128</li>
<li>Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol. 2001;67(9):637-640. [PubMed 11731753</li>
<li>Kuenszberg E, Loeckinger A, Kleinsasser A, Lindner KH, Peuhringer F, Hoermann CSevoflurane progressively prolongs the QT interval in unpremedicated female adultsEur J Anaesthesiol2000;17(11):662-664[PubMed 11029563</li>
<li>Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, Lindner KH, Peuhringer F. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg. 2000;90(1):25-27. [PubMed 10624970</li>
<li>Silay E, Kati I, Tekin M, Guler N, Huseyinoglu UA, Coskuner I, Yagmur C. Comparison of the effects of desflurane and sevoflurane on the QTc interval and QT dispersion. Acta Cardiol. 2005;60(5):459-464. [PubMed 16261774</li>
<li>Thiruvenkatarajan V, Osborn KD, Van Wijk RMAW, Euler P, Sethi R, Moodie S, Biradar V. Torsade de pointes in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia. Anaesth Intensive Care. 2010;38(3):555-559. [PubMed 20514968</li>
<li>Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg. 1998;86(4):701-702. [PubMed 9539586</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E[PubMed 20394022</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 220664]</li>
<li>L’Hommedieu CS, Nicholas D, Armes DA, et al, “Potentiation of Magnesium Sulfate-Induced Neuromuscular Weakness by Gentamicin, Tobramycin, and Amikacin,” J Pediatr, 1983, 102(4):629-31. [PubMed 6834204]</li>
<li>Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994;38(2):326-329. [PubMed 7910724</li>
<li>Nix DE, Watson WA, Handy L, et al. The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin. Pharmacotherapy. 1989;9(6):377-380. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum. Antimicrob Agents Chemother. 1990;34:931-933. [PubMed 2360833</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al. Combined Use of Ciprofloxacin and Sucralfate. DICP. 1991;25:578-582. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin Levels When Receiving Sucralfate. JAMA. 1989;262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin. Antimicrob Agents Chemother. 1989;33(1):99-102. [PubMed 2712548</li>
<li>Lehto PL, Kivisto KT. Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin. Antimicrob Agents Chemother. 1994;38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al. Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers. Antimicrob Agents Chemother. 1992;36:2785-2760. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al. The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers. Eur J Clin Pharmacol. 1994;47(1):67-69. [PubMed 7988627</li>
<li>Zix JAPharmacokinetics of Sparfloxacin and Interaction With Cisapride and SucralfateAntimicrob Agents Chemother1997;41:1668-1672[PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al. The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin. Br J Clin Pharmacol. 2000;49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al. The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers. Int J Antimicrob Agents. 2000;15(4):283-289. [PubMed 10929878</li>
<li>Stass H, Schuhly U, Moller JG, et al. Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, A Novel 8-methoxyfluoroquinolone, in Healthy Volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):49-55. [PubMed 11352442</li>
<li>Lehto PL, Kivisto KT. Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate absorption. DICP. 1991;25(7-8):745-746. [PubMed 1949932</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; June 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed [March 6, 2020].</li>
<li>Furosemide tablets [prescribing information]. Somerset, NJ: Solco Healthcare US, LLC: April 2020.</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ., 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205[PubMed 3011882</li>
<li>Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed). 1983;286(6375):1379-1381. [PubMed 6404468</li>
<li>Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis. 1989;13(3):194-199. [PubMed 2919600</li>
<li>Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int. 1990;47(5):291-295. [PubMed 2257522</li>
<li>Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. Nutr Clin Pract. 1991;6(5):199-201. [PubMed 1775116</li>
<li>Spivey JM, Cummings DM, Pierson NR, “Failure of Prostatitis Treatment Secondary to Probable Ciprofloxacin-Sucralfate Drug Interaction,” Pharmacotherapy, 1996, 16(2):314</li>
<li>[PubMed 8820479</li>
<li>Nix DE, Watson WA, Handy L, et al, “The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin,” Pharmacotherapy, 1989, 9(6):377-80. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al, “Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum,” Antimicrob Agents Chemother, 1990, 34:931</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al, “Combined Use of Ciprofloxacin and Sucralfate,” DICP, 1991, 25:578-82. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, and Quintiliani R, “Ciprofloxacin Levels When Receiving Sucralfate,” JAMA, 1989, 262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al, “Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin,” Antimicrob Agents Chemother, 1989, 33(1):99-102. [PubMed 2712548</li>
<li>Lehto P and Kivisto KT, “Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin,” Antimicrob Agents Chemother, 1994, 38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al, “Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers,” Antimicrob Agents Chemother, 1992, 36:2785-60. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al, “The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers,” Eur J Clin Pharmacol, 1994, 47(1):67</li>
<li>Zix JA, “Pharmacokinetics of Sparfloxacin and Interaction With Cisapride and Sucralfate,” Antimicrob Agents Chemother, 1997, 41:1668-72. [PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al, “The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin,” Br J Clin Pharmacol, 2000, 49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al, “The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers,” Int J Antimicrob Agents, 2000, 15(4):283</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of helicobacter pylori. Chem Pharm Bull (Tokyo). 2008;56(10):1412-1416. [PubMed 18827380</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. The acidic complexation of tetracycline with sucralfate for its mucoadhesive preparation. Drug Dev Ind Pharm. 2004;30(7):715-724. [PubMed 15491049</li>
<li>Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol Suppl. 1995;210:82-844. [PubMed 8578215]</li>
<li>Urso Forte (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; June 2013</li>
<li>Sucralfate [prescribing information]. Largo, FL: VistaPharm, Inc.; February 2020</li>
<li>Dovonex (calcipotriene) cream [prescribing information]Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]. Greenville, NC: Mayne Pharma; May 2019</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845]</li>
<li>Havrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med. 1992;117(5):445-446. [PubMed 1503346</li>
<li>Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994;96(6):531-535. [PubMed 8017451</li>
<li>Khan F, Jeanniton E, Renedo M. Does sucralfate impede levothyroxine therapy? Ann Intern Med. 1993;118(4):317. [PubMed 8481187</li>
<li>Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. Ann Intern Med. 1994;121(2):152. [PubMed 8017736</li>
<li>Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2020.</li>
<li>Smart HL, Somerville KW, Williams J, Richens A, Langman MJ. The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol. 1985;20(3):238-240. [PubMed 3840029</li>
<li>Hall TG, Cuddy PG, Glass CJ, Melethil S. Effect of sucralfate on phenytoin bioavailability. Drug Intell Clin Pharm. 1986;20(7-8):607-611. [PubMed 3755676</li>
<li>Malli R, Jones WN, Rindone JP, Labadie EL. The effect of sucralfate on the steady-state serum concentrations of phenytoin. Drug Metabol Drug Interact. 1989;7(4):287-293. [PubMed 2489199</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2022.</li>
<li>Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin. Ann Intern Med. 1983;98(4):557. [PubMed 6687662</li>
<li>Braverman SE, Marino MT. Sucralfate-warfarin interaction. Drug Intell Clin Pharm. 1988;22:913. [PubMed 3234259</li>
<li>Parrish RH, Waller B, Gondalia BG. Sucralfate-warfarin interaction. Ann Pharmacother. 1992;26:1015-1016. [PubMed 1504385</li>
<li>Neuvonen PJ, Jaakkola A, Totterman J, Penttila O. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol. 1985;20(2):178-179. [PubMed 3840028</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med. 1989;86(6A):38-44. [PubMed 2735334</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med. 1987;83(3B):67-73. [PubMed 3661612</li>
<li>Caille G, du Souich P, Gervais P, Besner JG. Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharm Drug Dispos. 1987;8(2):173-183. [PubMed 3593897</li>
<li>Lafontaine D, Mailhot C, Vermeulen M, Bissonnette B, Lambert C. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm. 1990;9(10):773-777. [PubMed 2242657</li>
<li>Crysvita (burosumab-twza) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; September 2019.</li>
<li>Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010</li>
<li>Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004</li>
<li>Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010</li>
<li>Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007</li>
<li>Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010</li>
<li>Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</li>
<li>One-Alpha (alfacalcidol) oral drops [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories; July 2020</li>
<li>Rocaltrol (calcitriol) oral solution [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019.</li>
<li>Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2(1):10-32. [PubMed 3547004</li>
<li>West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975;16(2):93-98. [PubMed 1168607</li>
<li>Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut. 1969;10(9):717-722. [PubMed 4318526</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Welchol (colesevelam) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; June 2013</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010</li>
<li>Rocaltrol (calcitriol) [prescribing information. Parisppany, NJ: Validus Pharmaceuticals LLC; July 2009</li>
<li>Rayaldee (calcifediol) [prescribing information]Miami, FL: OPKO Pharmaceuticals LLC; June 2016</li>
<li>Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. Gastroenterology. 1972;62(4):642-646. [PubMed 5020877</li>
<li>Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology. 1978;74(5 pt 1):900-902. [PubMed 640344</li>
<li>Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. Dig Dis Sci. 1985;30(5):477-482. [PubMed 3987479</li>
<li>Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427-430. [PubMed 2125243</li>
<li>Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med. 1992;119(4):407-411. [PubMed 1583392</li>
<li>Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980;65(2):243-250. [PubMed 7354970]</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2011</li>
<li>Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2007</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario:LEO Pharma Inc.; March 2010.</li>
<li>Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015</li>
<li>Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36(7):647-653. [PubMed 8844448</li>
<li>Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306-313. [PubMed 10757623</li>
<li>McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-822. [PubMed 12126214]</li>
<li>Vella A, Gerber TC, Hayes DL, et al. Digoxin, hypercalcemia, and cardiac conduction. Postgrad Med J. 1999;75:554-556. [PubMed 10616693</li>
<li>Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. [PubMed 22998989</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018.</li>
<li>Formosa N, Torpiano J, Allgrove J, Dattani MT. Anticonvulsant treatment associated with intractable hypocalcaemia in a female child with hypoparathyroidism. Horm Res Paediatr. 2015;83(1):62-66. [PubMed 25227206</li>
<li>Rubinger D, Korn-Lubetzki I, Feldman S, Popovtzer MM. Delayed response to a alpha-hydroxycholecalciferol therapy in a case of hypoparathyroidism during anticonvulsant therapy. Isr J Med Sci. 1980;16(11);772-774. [PubMed 7440128</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc; August 2017.</li>
<li>Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011</li>
<li>Hepburn NC, Abdul-Aziz LA and Whiteoak R, “Danazol-Induced Hypercalcaemia in Alphacalcidol-Treated Hypoparathyroidism,” Postgrad Med J, 1989, 65(769):849-50. [PubMed 2616424]</li>
<li>Lemann J, Jr., Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28:951-958. [PubMed 3003445</li>
<li>Santos F, Smith MJ,Chan JC. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. Am J Dis Child. 1986;140:139-142. [PubMed 3753816</li>
<li>Brickman AS, Massry SG,Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms. J Clin Invest. 1972;51:945-954. [PubMed 4552338</li>
<li>Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res. 2006;38:821-826. [PubMed 17163358</li>
<li>Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12:531-535. [PubMed 2592738</li>
<li>Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250:144-153. [PubMed 11489064</li>
<li>Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34:421-424. [PubMed 3887100</li>
<li>Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33:1140-1146. [PubMed 3404813</li>
<li>Nowack R, Hofner MC, Reichel H, et alSubacute effects of thiazide administration on renal hemodynamics and calcium metabolismClin Investig1992;70:686-691[PubMed 1392446</li>
<li>Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50. [PubMed 12492451</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019.</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201-2. doi: 10.4212/cjhp.v66i3.1261. PMID: 23814291; PMCID: PMC3694945.Ы</li>
                  </ol>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>
    </div>

    <div class="section-wrap first-test" id="first-test-page">
      <section class="section gastro-calculator-wrap">
        <div class="section__container">
          <div class="row">
            <div class="gastro-calculator-card">
              <div class="gastro-calculator-header">
                <div id="header-label" class="gastro-calculator-header__label">
                  Шаг 1: Сбор симптомов
                </div>
                <div
                  id="header-percent"
                  class="gastro-calculator-header__percent"
                >
                  33%
                </div>
                <div
                  id="progress-bar"
                  class="gastro-calculator-header__bar progress-bar"
                >
                  <span style="width: 33.3333%"></span>
                </div>
              </div>
              <div class="gastro-calculator-content">
                <div
                  id="first-slide-1"
                  class="gastro-calculator-slide is-active"
                >
                  <div class="calculator-slide calculator-slide--columns">
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap">
                        <button
                          class="btn-back-to btn-reset go-to-back"
                          data-slide="#start-page"
                        >
                          Назад
                        </button>
                      </div>
                      <div class="calculator-title">жалобы пациента</div>
                      <div class="calculator-text">
                        <p>Добавьте все симпомы, которые беспокоят пациента</p>
                      </div>
                      <div class="fast-search">
                        <div class="fast-search__input">
                          <input
                            type="text"
                            id="fast-search-input"
                            placeholder="Поиск симптомов"
                          />
                        </div>
                        <div class="fast-search__dropdown">
                          <div class="search-dropdown">
                            <div id="search-output"></div>
                            <div
                              id="nothing-found"
                              class="search-dropdown__item btn-reset pointer-events-none"
                            >
                              Начните вводить...
                            </div>
                          </div>
                        </div>
                      </div>
                      <div class="calculator-bottom">
                        <div class="often-searched">
                          <div class="often-searched__label">Часто ищут:</div>
                          <div
                            id="horizontal-symptoms"
                            class="often-searched__content"
                          ></div>
                        </div>
                      </div>
                    </div>
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap hide-on-mobile">
                        <a href="#" class="btn-back-to dummy">dummy</a>
                      </div>
                      <div class="calculator-header">
                        <div class="calculator-title">Добавленные симптомы</div>
                        <button
                          class="btn-as-link btn-reset clear-all-symptoms"
                        >
                          Сбросить все
                        </button>
                      </div>
                      <div id="added-symptoms" class="added-symptoms"></div>
                      <div class="calculator-bottom btn-wrap btn-wrap--end">
                        <button
                          id="go-to-test"
                          class="btn btn--250 btn-reset hide go-to-next"
                          data-slide="#first-slide-2"
                        >
                          Продолжить
                        </button>
                      </div>
                    </div>
                  </div>
                </div>
               
                <div id="first-slide-2" class="gastro-calculator-slide">
                  <div class="gastro-calculator-slide__header">
                    <div class="calculator-btn-wrap btn-wrap">
                      <button
                        class="btn-back-to btn-reset go-to-back"
                        data-slide="#first-slide-1"
                      >
                        Назад
                      </button>
                    </div>
                    <div class="calculator-title">ТЕСТ gerd Q</div>
                    <div class="calculator-text">
                      <p>За последнюю неделю:</p>
                    </div>
                  </div>
                  <div
                    class="calculator-slide calculator-slide--columns calculator-slide--test"
                  >
                    <div class="calculator-slide-column">
                      <div class="question-item">
                        <div class="question-item__label" data-counter="1.">
                          Как часто пациент ощущал изжогу (чувство жжения за
                          грудиной)?
                        </div>
                        <div class="question-item__buttons hide-on-mobile">
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="1"
                            data-points="0"
                          >
                            0 дней
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="1"
                            data-points="1"
                          >
                            1 день
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="1"
                            data-points="2"
                          >
                            2-3 дня
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="1"
                            data-points="3"
                          >
                            4-7 дней
                          </button>
                        </div>
                        <div class="question-item__selects show-on-mobile">
                          <div class="abbott-test-select abbott-test-select--closed">
                            <div
                              data-default="Выберите ответ"
                              class="abbott-test-select__selected"
                            >
                              <span>Выберите ответ</span>
                            </div>
                            <div class="abbott-test-select__select">
                              <div class="abbott-test-select__wrap">
                                <button
                                  data-text="0 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="1"
                                  data-points="0"
                                >
                                  <span>0 дней</span>
                                </button>
                                <button
                                  data-text="1 день"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="1"
                                  data-points="1"
                                >
                                  <span>1 день</span>
                                </button>
                                <button
                                  data-text="2-3 дня"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="1"
                                  data-points="2"
                                >
                                  <span>2-3 дня</span>
                                </button>
                                <button
                                  data-text="4-7 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="1"
                                  data-points="3"
                                >
                                  <span>4-7 дней</span>
                                </button>
                              </div>
                            </div>
                          </div>
                        </div>
                        <input type="hidden" class="question-item__input" />
                      </div>
                      <div class="question-item">
                        <div class="question-item__label" data-counter="2.">
                          Как часто пациент отмечал, что содержимое желудка
                          (жидкость либо пища) снова попадает в глотку или
                          полость рта (отрыжка)?
                        </div>
                        <div class="question-item__buttons hide-on-mobile">
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="2"
                            data-points="0"
                          >
                            0 дней
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="2"
                            data-points="1"
                          >
                            1 день
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="2"
                            data-points="2"
                          >
                            2-3 дня
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="2"
                            data-points="3"
                          >
                            4-7 дней
                          </button>
                        </div>
                        <div class="question-item__selects show-on-mobile">
                          <div class="abbott-test-select abbott-test-select--closed">
                            <div
                              data-default="Выберите ответ"
                              class="abbott-test-select__selected"
                            >
                              <span>Выберите ответ</span>
                            </div>
                            <div class="abbott-test-select__select">
                              <div class="abbott-test-select__wrap">
                                <button
                                  data-text="0 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="2"
                                  data-points="0"
                                >
                                  <span>0 дней</span>
                                </button>
                                <button
                                  data-text="1 день"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="2"
                                  data-points="1"
                                >
                                  <span>1 день</span>
                                </button>
                                <button
                                  data-text="2-3 дня"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="2"
                                  data-points="2"
                                >
                                  <span>2-3 дня</span>
                                </button>
                                <button
                                  data-text="4-7 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="2"
                                  data-points="3"
                                >
                                  <span>4-7 дней</span>
                                </button>
                              </div>
                            </div>
                          </div>
                        </div>
                        <input type="hidden" class="question-item__input" />
                      </div>
                      <div class="question-item">
                        <div class="question-item__label" data-counter="3.">
                          Как часто пациент ощущал боль в центре верхней части
                          живота?
                        </div>
                        <div class="question-item__buttons hide-on-mobile">
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="3"
                            data-points="3"
                          >
                            0 дней
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="3"
                            data-points="2"
                          >
                            1 день
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="3"
                            data-points="1"
                          >
                            2-3 дня
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="3"
                            data-points="0"
                          >
                            4-7 дней
                          </button>
                        </div>
                        <div class="question-item__selects show-on-mobile">
                          <div class="abbott-test-select abbott-test-select--closed">
                            <div
                              data-default="Выберите ответ"
                              class="abbott-test-select__selected"
                            >
                              <span>Выберите ответ</span>
                            </div>
                            <div class="abbott-test-select__select">
                              <div class="abbott-test-select__wrap">
                                <button
                                  data-text="0 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="3"
                                  data-points="3"
                                >
                                  <span>0 дней</span>
                                </button>
                                <button
                                  data-text="1 день"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="3"
                                  data-points="2"
                                >
                                  <span>1 день</span>
                                </button>
                                <button
                                  data-text="2-3 дня"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="3"
                                  data-points="1"
                                >
                                  <span>2-3 дня</span>
                                </button>
                                <button
                                  data-text="4-7 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="3"
                                  data-points="0"
                                >
                                  <span>4-7 дней</span>
                                </button>
                              </div>
                            </div>
                          </div>
                        </div>
                        <input type="hidden" class="question-item__input" />
                      </div>
                    </div>
                    <div class="calculator-slide-column">
                      <div class="question-item">
                        <div class="question-item__label" data-counter="4.">
                          Как часто пациент ощущал тошноту?
                        </div>
                        <div class="question-item__buttons hide-on-mobile">
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="4"
                            data-points="3"
                          >
                            0 дней
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="4"
                            data-points="2"
                          >
                            1 день
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="4"
                            data-points="1"
                          >
                            2-3 дня
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="4"
                            data-points="0"
                          >
                            4-7 дней
                          </button>
                        </div>
                        <div class="question-item__selects show-on-mobile">
                          <div class="abbott-test-select abbott-test-select--closed">
                            <div
                              data-default="Выберите ответ"
                              class="abbott-test-select__selected"
                            >
                              <span>Выберите ответ</span>
                            </div>
                            <div class="abbott-test-select__select">
                              <div class="abbott-test-select__wrap">
                                <button
                                  data-text="0 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="4"
                                  data-points="3"
                                >
                                  <span>0 дней</span>
                                </button>
                                <button
                                  data-text="1 день"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="4"
                                  data-points="2"
                                >
                                  <span>1 день</span>
                                </button>
                                <button
                                  data-text="2-3 дня"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="4"
                                  data-points="1"
                                >
                                  <span>2-3 дня</span>
                                </button>
                                <button
                                  data-text="4-7 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="4"
                                  data-points="0"
                                >
                                  <span>4-7 дней</span>
                                </button>
                              </div>
                            </div>
                          </div>
                        </div>
                        <input type="hidden" class="question-item__input" />
                      </div>
                      <div class="question-item">
                        <div class="question-item__label" data-counter="5.">
                          Как часто изжога и/или отрыжка мешали пациенту хорошо
                          выспаться ночью?
                        </div>
                        <div class="question-item__buttons hide-on-mobile">
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="5"
                            data-points="0"
                          >
                            0 дней
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="5"
                            data-points="1"
                          >
                            1 день
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="5"
                            data-points="2"
                          >
                            2-3 дня
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="5"
                            data-points="3"
                          >
                            4-7 дней
                          </button>
                        </div>
                        <div class="question-item__selects show-on-mobile">
                          <div class="abbott-test-select abbott-test-select--closed">
                            <div
                              data-default="Выберите ответ"
                              class="abbott-test-select__selected"
                            >
                              <span>Выберите ответ</span>
                            </div>
                            <div class="abbott-test-select__select">
                              <div class="abbott-test-select__wrap">
                                <button
                                  data-text="0 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="5"
                                  data-points="0"
                                >
                                  <span>0 дней</span>
                                </button>
                                <button
                                  data-text="1 день"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="5"
                                  data-points="1"
                                >
                                  <span>1 день</span>
                                </button>
                                <button
                                  data-text="2-3 дня"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="5"
                                  data-points="2"
                                >
                                  <span>2-3 дня</span>
                                </button>
                                <button
                                  data-text="4-7 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="5"
                                  data-points="3"
                                >
                                  <span>4-7 дней</span>
                                </button>
                              </div>
                            </div>
                          </div>
                        </div>
                        <input type="hidden" class="question-item__input" />
                      </div>
                      <div class="question-item">
                        <div class="question-item__label" data-counter="6.">
                          Как часто по поводу изжоги и/или отрыжки пациент
                          дополнительно принимал другие средства (антациды,
                          альгинаты, пищевую соду), кроме рекомендованных
                          врачом?
                        </div>
                        <div class="question-item__buttons hide-on-mobile">
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="6"
                            data-points="0"
                          >
                            0 дней
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="6"
                            data-points="1"
                          >
                            1 день
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="6"
                            data-points="2"
                          >
                            2-3 дня
                          </button>
                          <button
                            class="question-button btn-reset answer-js"
                            data-question="6"
                            data-points="3"
                          >
                            4-7 дней
                          </button>
                        </div>
                        <div class="question-item__selects show-on-mobile">
                          <div class="abbott-test-select select--closed">
                            <div
                              data-default="Выберите ответ"
                              class="abbott-test-select__selected"
                            >
                              <span>Выберите ответ</span>
                            </div>
                            <div class="abbott-test-select__select">
                              <div class="abbott-test-select__wrap">
                                <button
                                  data-text="0 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="6"
                                  data-points="0"
                                >
                                  <span>0 дней</span>
                                </button>
                                <button
                                  data-text="1 день"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="6"
                                  data-points="1"
                                >
                                  <span>1 день</span>
                                </button>
                                <button
                                  data-text="2-3 дня"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="6"
                                  data-points="2"
                                >
                                  <span>2-3 дня</span>
                                </button>
                                <button
                                  data-text="4-7 дней"
                                  class="abbott-test-select__option btn-reset answer-js"
                                  data-question="6"
                                  data-points="3"
                                >
                                  <span>4-7 дней</span>
                                </button>
                              </div>
                            </div>
                          </div>
                        </div>
                        <input type="hidden" class="question-item__input" />
                      </div>
                    </div>
                  </div>
                  <div
                    class="gastro-calculator-slide__bottom btn-wrap btn-wrap--center"
                  >
                    <button
                      id="go-to-result"
                      class="btn btn--250 btn-reset go-to-result hide"
                      onclick="ym(90602537,'reachGoal','cdss_end1'); return true;"
                    >
                      Продолжить
                    </button>
                  </div>
                </div>

                <div id="first-slide-3" class="gastro-calculator-slide">
                  <div class="calculator-slide calculator-slide--columns">
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap">
                        <button
                          class="btn-back-to btn-reset go-to-back"
                          data-slide="#first-slide-2"
                        >
                          Назад
                        </button>
                      </div>
                      <div class="calculator-title">
                        предварительный диагноз
                      </div>
                      <div class="diagnosis-probability">
                        <p>Вероятность диагноза ГЭРБ</p>
                        <div
                          id="first-slide-3-probability"
                          class="diagnosis-probability__percent"
                        >
                          ХХ%
                        </div>
                      </div>
                      <div class="calculator-section">
                        <div class="calculator-title">
                          Рекомендуемый план обследования
                        </div>
                        <div class="calculator-text">
                          <p>
                            Согласно выбранным симптомам и проведению первичного
                            обследования рекомендованный список обследований:
                          </p>
                        </div>
                        <div class="btn-wrap">
                          <div class="btn-as-link">Базовые обследования</div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">ЭГДС</div>
                            <div class="icon-card__btns">
                              <a href="/cdss/pdf/Подготовка к ЭГДС СППР.pdf" target="_blank">Памятка для пациента</a>
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-1.png" alt="" />
                          </div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Манометрия высокого разрешения
                            </div>
                            <div class="icon-card__btns">
                              <a href="/cdss/pdf/Подготовка к манометрии пищевода СППР.pdf" target="_blank">Памятка для пациента</a>
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-2.png" alt="" />
                          </div>
                        </div>
                        <div class="warning-message">
                          <p>
                            Учитывая наличие у пациента <b>дисфагии</b>,
                            проведение манометрии высокого разрешения или
                            рентгенографии пищевода и желудка с барием является
                            обязательным
                          </p>
                        </div>
                      </div>
                      <div class="calculator-section">
                        <div class="btn-wrap">
                          <div class="btn-as-link">
                            Факультативные обследования
                          </div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Суточная pH-импедансометрия
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-3.png" alt="" />
                          </div>
                        </div>
                      </div>
                      <div
                        id="first-slide-3-additional"
                        class="calculator-section"
                      >
                        <div class="btn-wrap">
                          <div class="btn-as-link">Дополнительно</div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Назначить повторный приём
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-4.png" alt="" />
                          </div>
                        </div>
                      </div>
                    </div>
                    <div
                      class="calculator-slide-column calculator-slide-column--gaps"
                    >
                      <div class="calculator-btn-wrap btn-wrap hide-on-mobile">
                        <a href="#" class="btn-back-to dummy">dummy</a>
                      </div>
                      <div class="calculator-title">Эмпирическая терапия</div>
                      <div class="calculator-text">
                        <p>
                          ИПП на выбор до получения результатов диагностических
                          исследований с последующей коррекцией терапии, но на
                          срок не более 4 недель:
                        </p>
                      </div>
                      <div class="therapy-columns">
                        <div class="therapy-item">
                          <p>Рабепразол</p>
                          <small>20 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Лансопразол</p>
                          <small>60 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Омепразол</p>
                          <small>20 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Пантопразол</p>
                          <small>40 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Эзомепразол</p>
                          <small>40 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Декслансопразол</p>
                          <small>60 мг 1 раз в день</small>
                        </div>
                      </div>
                      <div class="calculator-text">
                        <p>
                          Учитывая наличие у пациента ночных эпизодов ГЭРБ,
                          которые существенно ухудшают качество жизни,
                          <a href="/academy/preparation/pariet-20" target="_blank"> <span>рабепразол</span> </a>является оптимальным выбором,
                          т.к. он:
                        </p>
                      </div>
                      <div class="calculator-text">
                      <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                      Быстрее других ИПП купирует симтомы ГЭРБ
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                      Действует до 48 часов
                      </li>
                    </ul>

                        
                      </div>
                      <div class="warning-message">
                        <p>
                          При необходимости проведения теста на H. pylori
                          следует воздержаться от назначения/приема ИПП (в том
                          числе комбинированнных препаратов) за 2 недели до
                          теста
                        </p>
                      </div>
                      <button
                        class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                        data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                        onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                      >
                        <img src="./img/magnifier.svg" alt="лупа" />
                        проверить межлекарственные взаимодействия
                      </button>
                      <div class="calculator-bottom btn-wrap btn-wrap--end">
                        <button
                          class="btn btn--250 btn--border reload-page btn-reset"
                        >
                          Закончить прием
                        </button>
                      </div>
                    </div>
                  </div>
                </div>
                <div id="first-slide-4" class="gastro-calculator-slide">
                  <div class="calculator-slide calculator-slide--columns">
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap">
                        <button
                          class="btn-back-to btn-reset go-to-back"
                          data-slide="#first-slide-2"
                        >
                          Назад
                        </button>
                      </div>
                      <div class="calculator-title">
                        предварительный диагноз
                      </div>
                      <div class="diagnosis-probability">
                        <p>Вероятность диагноза ГЭРБ</p>
                        <div
                          id="first-slide-4-probability"
                          class="diagnosis-probability__percent"
                        >
                          ХХ%
                        </div>
                      </div>
                      <div class="calculator-section">
                        <div class="calculator-title">
                          Рекомендуемый план обследования
                        </div>
                        <div class="calculator-text">
                          <p>
                          В соответствии с наблюдаемыми у пациента симптомами и степенью их выраженности рекомендован следующий план обследований
                          </p>
                        </div>
                        <div class="btn-wrap">
                          <div class="btn-as-link">Базовые обследования</div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">ЭГДС</div>
                            <div class="icon-card__btns">
                              <a href="/cdss/pdf/Подготовка к ЭГДС СППР.pdf" target="_blank">Памятка для пациента</a>
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-1.png" alt="" />
                          </div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Манометрия высокого разрешения
                            </div>
                            <div class="icon-card__btns">
                              <a href="/cdss/pdf/Подготовка к манометрии пищевода СППР.pdf" target="_blank">Памятка для пациента</a>
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-2.png" alt="" />
                          </div>
                        </div>
                        <div class="warning-message">
                          <p>
                            Учитывая наличие у пациента <b>дисфагии</b>,
                            проведение манометрии высокого разрешения или
                            рентгенографии пищевода и желудка с барием является
                            обязательным
                          </p>
                        </div>
                      </div>
                      <div class="calculator-section">
                        <div class="btn-wrap">
                          <div class="btn-as-link">
                            Факультативные обследования
                          </div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Суточная pH-импедансометрия
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-3.png" alt="" />
                          </div>
                        </div>
                      </div>
                      <div
                        id="first-slide-4-additional"
                        class="calculator-section"
                      >
                        <div class="btn-wrap">
                          <div class="btn-as-link">Дополнительно</div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Назначить повторный приём
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-4.png" alt="" />
                          </div>
                        </div>
                      </div>
                    </div>
                    <div
                      class="calculator-slide-column calculator-slide-column--gaps"
                    >
                      <div class="calculator-btn-wrap btn-wrap hide-on-mobile">
                        <a href="#" class="btn-back-to dummy">dummy</a>
                      </div>
                      <div class="calculator-title">Эмпирическая терапия</div>
                      <div class="calculator-text">
                        <p>
                          ИПП на выбор до получения результатов диагностических
                          исследований с последующей коррекцией терапии, но на
                          срок не более 4 недель:
                        </p>
                      </div>
                      <div class="therapy-columns">
                        <div class="therapy-item">
                          <p>Рабепразол</p>
                          <small>20 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Лансопразол</p>
                          <small>60 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Омепразол</p>
                          <small>20 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Пантопразол</p>
                          <small>40 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Эзомепразол</p>
                          <small>40 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Декслансопразол</p>
                          <small>60 мг 1 раз в день</small>
                        </div>
                      </div>
                      <div class="calculator-text">
                        <p>
                          Учитывая наличие у пациента ночных эпизодов ГЭРБ,
                          которые существенно ухудшают качество жизни,
                          <a href="/academy/preparation/pariet-20" target="_blank"> <span>рабепразол</span> </a> является оптимальным выбором,
                          т.к. он:
                        </p>
                      </div>
                      <div class="calculator-text">
                      <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                      Быстрее других ИПП купирует симтомы ГЭРБ
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                      Действует до 48 часов
                      </li>
                    </ul>
                      </div>
                      <div class="warning-message">
                        <p>
                          При необходимости проведения теста на H. pylori
                          следует воздержаться от назначения/приема ИПП (в том
                          числе комбинированнных препаратов) за 2 недели до
                          теста
                        </p>
                      </div>
                      <button
                        class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                        data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                        onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                      >
                        <img src="./img/magnifier.svg" alt="лупа" />
                        проверить межлекарственные взаимодействия
                      </button>
                      <div class="calculator-bottom btn-wrap btn-wrap--end">
                        <button
                          class="btn btn--250 btn--border reload-page btn-reset"
                        >
                          Закончить прием
                        </button>
                      </div>
                    </div>
                  </div>
                </div>
                <div id="more-than-8" class="gastro-calculator-slide">
                  <div class="calculator-slide calculator-slide--columns">
                    <div class="calculator-slide-column">
                      <div class="calculator-btn-wrap btn-wrap">
                        <button
                          class="btn-back-to btn-reset go-to-back"
                          data-slide="#first-slide-2"
                        >
                          Назад
                        </button>
                      </div>
                      <div class="calculator-title">
                        предварительный диагноз
                      </div>
                      <div class="diagnosis-probability">
                        <p>Вероятность диагноза ГЭРБ</p>
                        <div
                          id="more-than-8-probability"
                          class="diagnosis-probability__percent"
                        >
                          ХХ%
                        </div>
                      </div>
                      <div class="calculator-section">
                        <div class="calculator-title">
                          Рекомендуемый план обследования
                        </div>
                        <div class="calculator-text">
                          <p>
                          В соответствии с наблюдаемыми у пациента симптомами и степенью их выраженности рекомендован следующий план обследований
                          </p>
                        </div>
                        <div class="btn-wrap">
                          <div class="btn-as-link">Базовые обследования</div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">ЭГДС</div>
                            <div class="icon-card__btns">
                              <a href="/cdss/pdf/Подготовка к ЭГДС СППР.pdf" target="_blank">Памятка для пациента</a>
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-1.png" alt="" />
                          </div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Суточная pH-импедансометрия
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-3.png" alt="" />
                          </div>
                        </div>
                        <div class="warning-message">
                          <p>
                            Учитывая наличие у пациента
                            <b>внепищеводных проявлений ГЭРБ</b>, проведение
                            pH-импедансометрии является обязательным
                          </p>
                        </div>
                      </div>
                      <div class="calculator-section">
                        <div class="btn-wrap">
                          <div class="btn-as-link">
                            Факультативные обследования
                          </div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Манометрия высокого разрешения
                            </div>
                            <div class="icon-card__btns">
                              <a href="/cdss/pdf/Подготовка к манометрии пищевода СППР.pdf" target="_blank">Памятка для пациента</a>
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-2.png" alt="" />
                          </div>
                        </div>
                      </div>
                      <div
                        id="more-than-8-additional"
                        class="calculator-section"
                      >
                        <div class="btn-wrap">
                          <div class="btn-as-link">Дополнительно</div>
                        </div>
                        <div class="icon-card">
                          <div class="icon-card__content">
                            <div class="icon-card__title">
                              Назначить повторный приём
                            </div>
                          </div>
                          <div class="icon-card__icon">
                            <img src="img/icon-card-4.png" alt="" />
                          </div>
                        </div>
                      </div>
                    </div>
                    <div
                      class="calculator-slide-column calculator-slide-column--gaps"
                    >
                      <div class="calculator-btn-wrap btn-wrap hide-on-mobile">
                        <a href="#" class="btn-back-to dummy">dummy</a>
                      </div>
                      <div class="calculator-title">Эмпирическая терапия</div>
                      <div class="calculator-text">
                        <p>
                          ИПП на выбор до получения результатов диагностических
                          исследований с последующей коррекцией терапии, но на
                          срок не более 4 недель:
                        </p>
                      </div>
                      <div class="therapy-columns">
                        <div class="therapy-item">
                          <p>Рабепразол</p>
                          <small>20 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Лансопразол</p>
                          <small>60 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Омепразол</p>
                          <small>20 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Пантопразол</p>
                          <small>40 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Эзомепразол</p>
                          <small>40 мг 1 раз в день</small>
                        </div>
                        <div class="therapy-item">
                          <p>Декслансопразол</p>
                          <small>60 мг 1 раз в день</small>
                        </div>
                      </div>
                      <div class="calculator-text">
                        <p>
                          Учитывая наличие у пациента ночных эпизодов ГЭРБ,
                          которые существенно ухудшают качество жизни,<a href="/academy/preparation/pariet-20" target="_blank">
                          <span>рабепразол</span></a> является оптимальным выбором,
                          т.к. он:
                        </p>
                      </div>
                      <div class="calculator-text">
                      <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                      Быстрее других ИПП купирует симтомы ГЭРБ
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                      Действует до 48 часов
                      </li>
                    </ul>

                  
                      </div>
                      <div class="warning-message">
                        <p>
                          При необходимости проведения теста на H. pylori
                          следует воздержаться от назначения/приема ИПП (в том
                          числе комбинированнных препаратов) за 2 недели до
                          теста
                        </p>
                      </div>
                      <div class="warning-message">
                        <p>
                          При проведении pH-импедансометрии рекомендуется
                          приостановить прием ИПП за 3-5 дней до проведения
                          процедуры
                        </p>
                      </div>
                      <button
                        class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                        data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                        onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                      >
                        <img src="./img/magnifier.svg" alt="лупа" />
                        проверить межлекарственные взаимодействия
                      </button>
                      <div class="calculator-bottom btn-wrap btn-wrap--end">
                        <button
                          class="btn btn--250 btn--border reload-page btn-reset"
                        >
                          Закончить прием
                        </button>
                      </div>
                    </div>
                  </div>
                </div>
                <div id="less-than-3" class="gastro-calculator-slide">
                  <div class="calculator-slide">
                    <div class="calculator-btn-wrap btn-wrap">
                      <button
                        class="btn-back-to btn-reset go-to-back"
                        data-slide="#first-slide-2"
                      >
                        Назад
                      </button>
                    </div>
                    <div class="calculator-title">Результаты диагностики</div>
                    <div id="less-than-3-results" class="results-wrap">
                      <div class="result-item">
                        <span>Диагноз ГЭРБ маловероятен.</span>
                        <br />Рекомендовано продолжить диагностический поиск в
                        других нозологиях
                      </div>
                    </div>
                    <div class="calculator-bottom btn-wrap btn-wrap--end">
                      <button
                        class="btn btn--250 btn--border reload-page btn-reset"
                      >
                        Закончить прием
                      </button>
                    </div>
                  </div>
                </div>
                <div id="extraesophageal" class="gastro-calculator-slide">
                  <div class="calculator-slide">
                    <div class="calculator-btn-wrap btn-wrap">
                      <button
                        class="btn-back-to btn-reset go-to-back"
                        data-slide="#first-slide-1"
                      >
                        Назад
                      </button>
                    </div>
                    <div class="calculator-title">Результаты диагностики</div>
                    <div
                      id="extraesophageal-results"
                      class="results-wrap"
                    ></div>
                    <div class="calculator-bottom btn-wrap btn-wrap--end">
                      <button
                        class="btn btn--250 btn--border reload-page btn-reset"
                      >
                        Закончить прием
                      </button>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div class="gastro-calculator-btn-wrap">
              <div class="abbott-more-sources">
                <button class="abbott-more-sources__button btn-reset">
                  <span>Ключевые источники информации</span>
                  <svg
                    xmlns="http://www.w3.org/2000/svg"
                    width="16"
                    height="17"
                    viewBox="0 0 16 17"
                    fill="none"
                  >
                    <path
                      fill-rule="evenodd"
                      clip-rule="evenodd"
                      d="M4.89164 2.73051C5.19205 2.42487 5.67909 2.42487 5.9795 2.73051L11.1077 7.94791C11.252 8.09467 11.333 8.29373 11.333 8.5013C11.333 8.70885 11.252 8.90791 11.1077 9.05469L5.9795 14.2721C5.67909 14.5777 5.19205 14.5777 4.89164 14.2721C4.59124 13.9664 4.59124 13.4709 4.89164 13.1653L9.47593 8.5013L4.89164 3.83729C4.59124 3.53166 4.59124 3.03614 4.89164 2.73051Z"
                      fill="#009CDE"
                    ></path>
                  </svg>
                </button>
                <div class="abbott-more-sources__content">
                <ol>
                <li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В., Дронова О.Б., Кучерявый Ю.А., Пирогов С.С., Сайфутдинов Р.Г., Успенский Ю.П., Шептулин А.А., Андреев Д.Н., Румянцева Д.Е. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. https://doi.org/10.22416/1382-4376-2020-30-4-70-97.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Сторонова О.А., Абдулхаков С.Р., Андреев Д.Н., Бордин Д.С., Валитова Э.Р., Кляритская И.Л., Кривой В.В., Кучерявый Ю.А., Лапина Т.Л., Морозов С.В., Саблин О.А., Семенихина Е.В., Успенский Ю.П., Шептулин А.А. Рекомендации Российской гастроэнтерологической ассоциации по клиническому применению манометрии высокого разрешения при заболеваниях пищевода. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):61–88. https://doi.org/10.22416/1382-4376-2020-30-3-61-88</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. Therole of esophageal testing in diagnosis and management. Gastroenterol Clin North Am1996; 25:75.</li>
<li>Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification ofgastroesophageal reflux disease: a global evidence-based consensus. Am JGastroenterol 2006; 101:1900.</li>
<li>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophagealreflux disease: a systematic review. Gut 2005; 54:710.</li>
<li>Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of uppergastrointestinal disorders in the United States: results of the US Upper GastrointestinalStudy. Clin Gastroenterol Hepatol 2005; 3:543.</li>
<li>Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.</li>
<li>Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence,severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol2004; 2:665.</li>
<li>Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to protonpump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.</li>
<li>Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophagealsphincter pressure: a manometric observation in patients reporting globus sensation.Am J Gastroenterol 2009; 104:289.</li>
<li>Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea.Ann Intern Med 1997; 126:704.</li>
<li>Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.</li>
<li>DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophagealreflux disease. Practice Parameters Committee of the American College ofGastroenterology. Arch Intern Med 1995; 155:2165.</li>
<li>Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS(Ed), WB Saunders, Philadelphia 1989. p.1147.</li>
<li>Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients withgastroesophageal reflux disease: a comparison between empirical treatment withesomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.</li>
<li>Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test toidentify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360.</li>
<li>Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pumpinhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostictest characteristics. Ann Intern Med 2004; 140:518.</li>
<li>Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability andendoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313.</li>
<li>Adanir H, Baş B, Pakoz B, et al. Endoscopic Findings of Gastro-Esophageal RefluxDisease in Elderly and Younger Age Groups. Front Med (Lausanne) 2021; 8:606205.</li>
<li>Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical andfunctional correlates and further validation of the Los Angeles classification. Gut 1999;45:172.</li>
<li>Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. ClinGastroenterol Hepatol 2007; 5:4.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationMedical Position Statement on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1383.</li>
<li>Hirano I, Richter JE, Practice Parameters Committee of the American College ofGastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</li>
<li>Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practiceguideline development. Gastroenterology 1996; 110:1982.</li>
<li>Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless andDigitrapper catheter-based pH monitoring systems for measuring esophageal acidexposure. Am J Gastroenterol 2005; 100:1466.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-refluxassociation using 4-day wireless pH recording combining 48-hour periods off and on PPItherapy. Am J Gastroenterol 2008; 103:1631.</li>
<li>Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring.J Clin Gastroenterol 2012; 46:197.</li>
<li>Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal refluxsymptoms and esophagitis with or without symptoms in the general adult Swedishpopulation: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275.</li>
<li>Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatmentof benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology1982; 82:487.</li>
<li>Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricturetreated by dilatation. Gastroenterology 1983; 85:346.</li>
<li>Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazolefor refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.</li>
<li>Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists intreating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.</li>
<li>Okwara NC, Chan WW. Sorting out the Relationship Between Esophageal andPulmonary Disease. Gastroenterol Clin North Am 2021; 50:919.</li>
<li>Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophagealreflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.</li>
<li>Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acidsuppressive therapy improves asthma outcome. Am J Med 1996; 100:395.</li>
<li>Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'refluxlaryngitis'. Gastroenterology 1991; 100:305.</li>
<li>Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease(GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoringand an experimental investigation of the role of acid and pepsin in the development oflaryngeal injury. Laryngoscope 1991; 101:1.</li>
<li>Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastricacid in patients with reflux laryngitis. Gastroenterology 1995; 109:1575.</li>
<li>Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopyin patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am JGastroenterol 2004; 99:1419.</li>
<li>Remacle M, Lawson G. Diagnosis and management of laryngopharyngeal refluxdisease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:143.</li>
<li>Gaynor EB. Gastroesophageal reflux as an etiologic factor in laryngeal complications ofintubation. Laryngoscope 1988; 98:972.</li>
<li>Cote DN, Miller RH. The association of gastroesophageal reflux and otolaryngologicdisorders. Compr Ther 1995; 21:80.</li>
<li>Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated withgastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.</li>
<li>Schroeder PL, Filler SJ, Ramirez B, et al. Dental erosion and acid reflux disease. AnnIntern Med 1995; 122:809.</li>
<li>DiBaise JK, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. AnnIntern Med 1998; 129:1078.</li>
<li>DiBaise JK, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistantsinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002; 97:843.</li>
<li>Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence inindividuals with gastroesophageal reflux: synthesis and estimates from populationstudies. Am J Gastroenterol 2011; 106:254.</li>
<li>Vaezi MF. Laryngitis and gastroesophageal reflux disease: increasing prevalence or poordiagnostic tests? Am J Gastroenterol 2004; 99:786.</li>
<li>Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous cell cancer of the head andneck. Otolaryngol Clin North Am 1985; 18:367.</li>
<li>Olsen NR. Effects of stomach acid on the larynx. Proc Am Laryngol Assoc 1983; 104:108.</li>
<li>Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma?Otolaryngol Head Neck Surg 1988; 99:370.</li>
<li>Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of thelaryngopharynx. Laryngoscope 1988; 98:1195.</li>
<li>Langevin SM, Michaud DS, Marsit CJ, et al. Gastric reflux is an independent risk factor forlaryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22:1061.</li>
<li>Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, Lagergren J. All-cause and cancer-specificmortality in GORD in a population-based cohort study (the HUNT study). Gut 2018;67:209.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationInstitute technical review on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1392.</li>
<li>Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosisand Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117:27.</li>
<li>Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control ofheartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am JGastroenterol 1999; 94:92.</li>
<li>Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acidinhibition. Gastroenterol Clin North Am 1990; 19:683.</li>
<li>Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophagealreflux disease. Gastroenterology 2001; 121:1095.</li>
<li>Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn oracid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.</li>
<li>Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy forGERD: a multi-center study in Japan. World J Gastroenterol 2011; 17:1480.</li>
<li>Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients withgastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965.</li>
<li>Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass indexand esophageal acid exposure in the extraesophageal manifestations of reflux. ClinGastroenterol Hepatol 2012; 10:874.</li>
<li>Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between uppergastrointestinal symptoms and changes in body weight in a population-based cohort.Neurogastroenterol Motil 2006; 18:987.</li>
<li>Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is notreduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.</li>
<li>Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms ofgastroesophageal reflux in women. N Engl J Med 2006; 354:2340.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction ingastroesophageal reflux. A prospective population-based cohort study: the HUNT study.Am J Gastroenterol 2013; 108:376.</li>
<li>DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines forthe diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol2005; 100:190.</li>
<li>Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle Intervention inGastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14:175.</li>
<li>Mehta RS, Song M, Staller K, Chan AT. Association Between Beverage Intake andIncidence of Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol 2020;18:2226.</li>
<li>Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathingexercise on gastroesophageal reflux disease: a randomized, controlled study. Am JGastroenterol 2012; 107:372.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation andimproved gastroesophageal reflux: a prospective population-based cohort study: theHUNT study. Am J Gastroenterol 2014; 109:171.</li>
<li>Mehta RS, Nguyen LH, Ma W, et al. Association of Diet and Lifestyle With the Risk ofGastroesophageal Reflux Disease Symptoms in US Women. JAMA Intern Med 2021;181:552.</li>
<li>Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosivegastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.</li>
<li>Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to theacid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11:1585.</li>
<li>Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodiumalginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.</li>
<li>Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented bymagnetic resonance imaging and pH-impedance monitoring: mechanistic assessmentin healthy volunteers and randomised, controlled, double-blind study in reflux patients.Aliment Pharmacol Ther 2013; 37:1093.</li>
<li>Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oralsuspension is non-inferior to omeprazole in the treatment of patients with non-erosivegastroesophageal disease. Aliment Pharmacol Ther 2013; 38:1054.</li>
<li>Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of uppergastrointestinal symptoms by an acid pocket-targeting alginate-antacid (GavisconDouble Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophagealreflux disease. Aliment Pharmacol Ther 2014; 39:595.</li>
<li>Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatmentafter 14 days of administration in healthy subjects without Helicobacter pylori infection.J Gastroenterol Hepatol 2003; 18:678.</li>
<li>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcerhealing, gastroesophageal reflux disease, and stress-related erosive syndrome.Gastroenterology 2000; 118:S9.</li>
<li>Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.</li>
<li>Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms ofgastroesophageal reflux disease and heals erosions and ulcerations. Results of amulticenter, placebo-controlled, dose-ranging study. USA Merck GastroesophagealReflux Disease Study Group. Arch Intern Med 1991; 151:2394.</li>
<li>Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal refluxdisease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol1991; 86:1735.</li>
<li>Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed onDecember 19, 2012).</li>
<li>Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is moreacceptable to patients than continuous lansoprazole 15 mg in the long-termmaintenance of endoscopy-negative gastro-oesophageal reflux patients: theCOMMAND Study. Aliment Pharmacol Ther 2004; 20:657.</li>
<li>Hunt R. Acid suppression for reflux disease: "off-the-peg" or a tailored approach? ClinGastroenterol Hepatol 2012; 10:210.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitortherapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419.</li>
<li>Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pumpinhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal refluxdisease-like symptoms and endoscopy negative reflux disease. Cochrane Database SystRev 2013; :CD002095.</li>
<li>Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worseesophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl B:66B.</li>
<li>Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptorantagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005; 11:4067.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Katzka DA, Kahrilas PJ. Advances in the diagnosis and management ofgastroesophageal reflux disease. BMJ 2020; 371:m3786.</li>
<li>Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenancetherapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci2009; 54:955.</li>
<li>Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies forreflux esophagitis. N Engl J Med 1995; 333:1106.</li>
<li>Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients withgastrooesophageal reflux disease. Gut 1992; 33:1016.</li>
<li>Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies forGastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. Decem ber 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).</li>
<li>Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention ofrelapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Gut 1994; 35:590.</li>
<li>Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of refluxesophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlledtrial. Ann Intern Med 1996; 124:859.</li>
<li>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancyand lactation. Aliment Pharmacol Ther 2020; 51:421.</li>
<li>Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet)with antacid for safety and effectiveness in reducing gastric acidity before electivecesarean section. Anesthesiology 1983; 59:86.</li>
<li>Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) inpregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.</li>
<li>Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk ofbirth defects. N Engl J Med 2010; 363:2114.</li>
<li>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophagealreflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.</li>
<li>Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. JReprod Med 2004; 49:825.</li>
<li>National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).</li>
<li>ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelinesfor endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</li>
<li>Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal refluxdisease: putative mechanisms of failure. Drugs 2007; 67:1521.</li>
<li>Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptomsrefractory to proton pump inhibitors. Gut 2012; 61:1340.</li>
<li>Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with theirprescription medications? Results of the patient unmet needs study. J Clin OutcomesManag 2000; 7:29.</li>
<li>The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.</li>
<li>Fass R. Therapeutic options for refractory gastroesophageal reflux disease. JGastroenterol Hepatol 2012; 27 Suppl 3:3.</li>
<li>El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on protonpump inhibitor therapy in primary care and community studies. Aliment PharmacolTher 2010; 32:720.</li>
<li>Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors innonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.</li>
<li>Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention andtreatment. Drugs 2003; 63:555.</li>
<li>Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.</li>
<li>Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term protonpump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.</li>
<li>Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure ingastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.</li>
<li>Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pumpinhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol 2014;109:789.</li>
<li>Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitordosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.Aliment Pharmacol Ther 2006; 23:1473.</li>
<li>Wilder-Smith C, Röhss K, Bokelund Singh S, et al. The effects of dose and timing ofesomeprazole administration on 24-h, daytime and night-time acid inhibition in healthyvolunteers. Aliment Pharmacol Ther 2010; 32:1249.</li>
<li>Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistentsymptoms despite acid suppressive therapy: a multicentre study using combinedambulatory impedance-pH monitoring. Gut 2006; 55:1398.</li>
<li>Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol2008; 6:521.</li>
<li>Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pHmonitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.</li>
<li>Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitecmonitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53:2387.</li>
<li>Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux insymptomatic GERD. Am J Gastroenterol 2001; 96:2033.</li>
<li>Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring insymptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.</li>
<li>Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in ahypersensitive esophagus might explain symptoms resistant to proton pump inhibitorsin patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2014;12:1647.</li>
<li>Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree ofduodenogastroesophageal reflux and acid reflux between patients who failed torespond and those who were successfully treated with a proton pump inhibitor oncedaily. Am J Gastroenterol 2009; 104:2005.</li>
<li>Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acidsuppressive therapy. Am J Gastroenterol 2008; 103:1090.</li>
<li>Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiatenon-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012;47:159.</li>
<li>Abdallah J, George N, Yamasaki T, et al. Most Patients With Gastroesophageal RefluxDisease Who Failed Proton Pump Inhibitor Therapy Also Have Functional EsophagealDisorders. Clin Gastroenterol Hepatol 2019; 17:1073.</li>
<li>Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology2016.</li>
<li>Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functionalheartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013;25:282.</li>
<li>Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity tobile salts in patients with functional heartburn and in healthy control subjects. Dig DisSci 2005; 50:81.</li>
<li>Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traitsof functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity toacid. Am J Gastroenterol 2006; 101:1084.</li>
<li>Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for thetreatment of refractory GERD accompanied with gastroparesis: a preliminary report. DigDis Sci 2008; 53:2621.</li>
<li>Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patientswith symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum ofvisceral sensitivity in GORD. Gut 1995; 37:7.</li>
<li>Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS andpsychological distress on outcomes and quality of life following PPI therapy in patientswith gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.</li>
<li>Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associatedwith features of psychiatric disorders and the irritable bowel syndrome. AlimentPharmacol Ther 2007; 26:443.</li>
<li>Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease andpsychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.</li>
<li>Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal refluxdisease and underdiagnosis of functional dyspepsia in a USA community.Neurogastroenterol Motil 2014; 26:1163.</li>
<li>Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive tosingle-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux,bile reflux, or both? Am J Gastroenterol 2004; 99:981.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acidbreakthrough on different regimens of omeprazole 40 mg daily. Aliment PharmacolTher 1998; 12:1235.</li>
<li>Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective aslansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophagealreflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-aprospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.</li>
<li>Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebocontrolled study of omeprazole in the treatment of patients with reflux symptoms andphysiological levels of acid reflux--the "sensitive oesophagus". Gut 1997; 40:587.</li>
<li>Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburnsymptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.</li>
<li>Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-hintragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36:627.</li>
<li>Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis ofgastro-esophageal reflux disease: Update of the Porto consensus andrecommendations from an international consensus group. Neurogastroenterol Motil2017; 29:1.</li>
<li>Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring withand without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.</li>
<li>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management ofgastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.</li>
<li>Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pHmonitoring in patients with refractory gastroesophageal reflux disease, on and offtherapy. Clin Gastroenterol Hepatol 2009; 7:743.</li>
<li>Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology2018; 154:302.</li>
<li>Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findingsin gastro-esophageal reflux disease: Conclusions from an international consensusgroup. Neurogastroenterol Motil 2017; 29.</li>
<li>Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthroughon omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.</li>
<li>Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy onnocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.</li>
<li>Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine atnight to twice daily omeprazole therapy on nocturnal acid breakthrough and acid refluxin patients with systemic sclerosis--a randomized controlled, cross-over trial. AlimentPharmacol Ther 2007; 26:1259.</li>
<li>Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinicalsignificance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545.</li>
<li>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for thecontrol of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009;:CD004275.</li>
<li>Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improvegastroesophageal reflux disease symptoms for patients on proton pump inhibitortherapy. Dis Esophagus 2005; 18:370.</li>
<li>Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophagealreflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract2014; 2014:307805.</li>
<li>Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices?Curr Opin Gastroenterol 2009; 25:352.</li>
<li>Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants inpatients with functional esophageal disorders or gastroesophageal reflux disease:a systematic review. Clin Gastroenterol Hepatol 2015; 13:251.</li>
<li>Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adultpatients with functional chest pain: a randomized, double-blind, placebo-controlled,crossover trial. Am J Gastroenterol 2010; 105:1504.</li>
<li>Park SW, Lee H, Lee HJ, et al. Low-dose amitriptyline combined with proton pumpinhibitor for functional chest pain. World J Gastroenterol 2013; 19:4958.</li>
<li>Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors forthe treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.</li>
<li>Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy ingastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20:2412.</li>
<li>Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients WithRefractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology2020; 158:2093.</li>
<li>Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the protonpump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.</li>
<li>UpToDate medical database. Approach to the initial management of patients with GERD. Graphic 116964 Version 3.0. Электронный ресурс: https://www.uptodate.com/contents/image?imageKey=GAST%2F116964, дата доступа: 14.07.2023</li>
<li>Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut. 2005;54(12):1810-1817. doi:10.1136/gut.2005.072629</li>
<li>Costa V, Pinto-Saavedra O, Hani A, Leguízamo AM, Ardila-Hani AF. Updated interpretation of Impedance–pH monitoring. Rev Colomb Gastroenterol. 2021;36(1):73-80. https://doi.org/10.22516/25007440.608</li>
<li>Hani, Albis & Leguizamo, Ana & Carvajal, Jhon & Klinger, Gabriel & Costa, Valeria. (2015). How to Perform and Interpret High-resolution Esophageal Manometry. Revista Colombiana de Gastroenterologia. 30. 74-83.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л., Хлынов И.Б., Дехнич Н.Н., Лопина О.Д., Алексеева О.П., Корочанская Н.В., Осипенко М.Ф., Павлов П.В., Пирогов С.С., Тарасова Г.Н., Успенский Ю.П., Андреев Д.Н., Румянцева Д.Е. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18. https://doi.org/10.22416/1382-4376-2020-30-6-7-18.</li>
<li>Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Can Fam Physician 2017;63:354-64 (Eng), e253-65 (Fr).</li>
<li>Cho YK. How to Interpret Esophageal Impedance pH Monitoring. J Neurogastroenterol Motil. 2010 Jul;16(3):327-30. doi: 10.5056/jnm.2010.16.3.327. Epub 2010 Jul 26. PMID: 20680174; PMCID: PMC2912128.</li>
<li>Kim GH. How to Interpret Ambulatory 24 hr Esophageal pH Monitoring. J Neurogastroenterol Motil. 2010 Apr;16(2):207-10. doi: 10.5056/jnm.2010.16.2.207. Epub 2010 Apr 27. PMID: 20535354; PMCID: PMC2879855.</li>
<li>Jehangir A, Malik Z, Parkman HP. Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterol. 2022 Mar 8;22(1):112. doi: 10.1186/s12876-022-02194-0. PMID: 35260107; PMCID: PMC8905734.</li>
<li>Yadlapati R. High-resolution esophageal manometry: interpretation in clinical practice. Curr Opin Gastroenterol. 2017 Jul;33(4):301-309. doi: 10.1097/MOG.0000000000000369. PMID: 28426462; PMCID: PMC5568812.</li>
<li>Yamasaki T, Fass R. Reflux Hypersensitivity: A New Functional Esophageal Disorder. J Neurogastroenterol Motil. 2017;23(4):495-503. doi:10.5056/jnm17097</li>
<li>Ronnie Fass, Frank Zerbib, C. Prakash Gyawali. AGA Clinical Practice Update on Functional Heartburn: Expert Review. CLINICAL PRACTICE UPDATE| VOLUME 158, ISSUE 8, P2286-2293, JUNE 2020. Published: February 01, 2020. DOI: https://doi.org/10.1053/j.gastro.2020.01.034</li>
<li>Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi: 10.14309/ajg.0000000000000731. PMID: 32773454; PMCID: PMC9896940.</li>
<li>Samo S, Qayed E. Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management? World J Gastroenterol. 2019 Jan 28;25(4):411-417. doi: 10.3748/wjg.v25.i4.411. PMID: 30700938; PMCID: PMC6350167.</li>
<li>Management of the patient with esophagogastric junction outflow obstruction (EGJOO) Shahsavari et al. Curr Opin Gastroenterol 2021, 37:397–407. DOI:10.1097/MOG.0000000000000747</li>
<li>Dhyanesh A. Patel, Rena Yadlapati, Michael F. Vaezi, Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics, Gastroenterology, Volume 162, Issue 6, 2022, Pages 1617-1634, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2021.12.289.</li>
<li>DeLay K, Krause A, Yadlapati R. Clinical Updates in Esophageal Motility Disorders Beyond Achalasia. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1789-1792.e1. doi: 10.1016/j.cgh.2021.05.041. Epub 2021 Jul 1. PMID: 34405804; PMCID: PMC8604436.</li>
<li>Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30. PMID: 24466441; PMCID: PMC3895610.</li>
<li>Чёрная А. В. Карханова А. Г., Мутовкина Н. И., Дышлюк Т. Л., Багненко С. С., Рогачев М. В., Ульянова Р. Х., Зайцев А. Н., Шевкунов Л. Н., Новиков С. Н., Шевченко Е. Ю., Брезгина Е. А. Лучевая диагностика заболеваний пищевода при злокачественных и доброкачественных изменениях: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. – Санкт-Петербург: ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России, 2021. – 144 с. ISBN 978-5-6046978-1-8</li>
<li>Государственный реестр лекарственных средств. Электронный ресурс: https://grls.rosminzdrav.ru/default.aspx, дата доступа: 14.07.2023</li>
<li>Инструкция по применению лекарственного препарата Ганатон® (итоприда гидрохлорид). РУ ЛС-002513 от 29.06.2021. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9abd2328-abcb-411e-919e-6d8ab7c238ea, дата доступа: 14.07.2023</li>
<li>Stanghellini V., Chan F., Hasler W.L. et al. Gastroduodenal Disorders Gastroenterology 2016;150:1380– 1392.</li>
<li>Касьяненко В.И., Денисов Н.Л., Васильев Ю.В. Применение итоприда при симптомах функциональной диспепсии в России: результаты проспективного открытого многоцентрового клинического исследования IV фазы. Терапевтический Архив. 2014;8:35-41.</li>
<li>Tack J. et all. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther. 2011 Jan;33(1):99-105.</li>
<li>Murray J.A. Gastroesophageal Reflux Disease. In.: Mayo Clinic Gastroenterology and Hepatology Board Review. Oxford University Press. 2015.</li>
<li>Ezzat W.F., Fawaz S.A., Fathey H. et al. Virtue of Adding Prokinetics to Proton Pump Inhibitors in the Treatment of Laryngopharyngeal Reflux Disease: Prospective Study Journal of Otolaryngology-Head & Neck Surgery. 2011;40(4):350–356/</li>
<li>Инструкция по применению лекарственного препарата Париет® (рабепразол). РУ П N011880/01 от 28.02.2022. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d7c5d813-e692-4211-a63d-2a2ac06ea1d7, дата доступа: 14.07.2023</li>
<li>Kirchheiner J., Glatt S., Fuhr U. et al. Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH // European Journal of Clinical Pharmacology, 2008, 65 (1), pp.19-31</li>
<li>Kramer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitrocorrelates. Pharmacology. 1998;56:57-70</li>
<li>Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003 Feb;48(2):322-8.</li>
<li>Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335.</li>
<li>Besancon M, Shin JM, Mercier F, et al. Biochemistry, 1993; 32:2345–2355.</li>
<li>Сереброва С.Ю. Основные фармакокинетические характеристики ингибиторов протонной помпы и эффективность их действия. Пособие для врачей. Мединфорум 2016.</li>
<li>Cefditoren [Korean product labeling]. Boryeong Pharmaceutical; November 2009.</li>
<li>Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol. 1984;18(4):535-539. [PubMed 6091711</li>
<li>Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. Adv Perit Dial. 1994;10:179-182. [PubMed 7999822</li>
<li>Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</li>
<li>Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509. [PubMed 16898956</li>
<li>Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OLCA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardio. 2008;51(3):256-260. [PubMed 18206732</li>
<li>Fontes-Carvalho R, Albuquerque A, Araugo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogre-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396-404. [PubMed 21464720</li>
<li>Frelinger 3rd AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardio. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944. [PubMed 19258584</li>
<li>Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039; author reply 1039. [PubMed 18786491</li>
<li>Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Gaglia MA Jr, Torguson R, Hanna N, et alRelation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomesAm J Cardiol2010;105(6):833-838[PubMed 20211327</li>
<li>Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964-1968. [PubMed 19731021</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997. [PubMed 19726078</li>
<li>Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26(2):e54-e57. [PubMed 20151060</li>
<li>Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917. [PubMed 20925534</li>
<li>Muthiah MD, Zheng H, Chew NWS, et al. Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. [online ahead of print] J Thromb Throbolysis. 2021. doi: 10.1007/s11239-021-02472. [PubMed 33959860</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016; Aug 10 (Epub ahead of print). [PubMed 27512080</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478</li>
<li>Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). BMC Cardiovasc Disord. 2017;17(1):3. [PubMed 28056809</li>
<li>Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939-947. [PubMed 27459657</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11): pii: e002245. [PubMed 26514161</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership: March 2021.</li>
<li>Park GJ, Bae SH, Park WS, et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017;11:1043-1053. [PubMed 28408803</li>
<li>Kamiya C, Inui N, Hakamat A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype [published online March 11, 2019]. J Pharmacol Sci. Doi: 10.1016/j.jphs.2019.03.001. [PubMed 30902567</li>
<li>Elbe A, Foerster KI, Blank A, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975-987. [PubMed 35238961</li>
<li>Erleada (apalutamide) [prescribing information. Horsham, PA: Janssen Products LP; September 2019</li>
<li>Kanebratt KP, Diczfalusy U, Backstroo T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther, 2008, 84(5):589-94. [PubMed 18650803</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; August 2018.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999-1004. [PubMed 22147077</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016</li>
<li>Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358-1365. [PubMed 25274610</li>
<li>Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81(6):1195-1196. [PubMed 26833554</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;25(7):1155-1162. [PubMed 30605231</li>
<li>Koutake Y, Taniguch J, Yasumori N, et al. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol. 2020;111(6):826-832. [PubMed 32152877]</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2012.</li>
<li>Tarceva (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; April 2014</li>
<li>van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309-1314. [PubMed 26858332</li>
<li>Veerman GDM, Hussaarts KGAM, Peric R, et al. Influence of cow's milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69-77. [PubMed 32557346</li>
<li>Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol. 2010;70(6):908-911. [PubMed 21175447</li>
<li>Du X, Liu W, Chen K, Wang Z, Li X, Yang L, Xie X. Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis. [published online ahead of print] Front Pharmacol. 2022. doi: 10.3389/fphar.2022.796538. [PubMed 35795555</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908</li>
<li>Zenke Y, Yoh K, Matsumoto S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412-418. [PubMed 26944770</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et alA multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerClin Cancer Res2010;16(11):3078-3087[PubMed 20395213</li>
<li>Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 2013;52:593-609. [PubMed 23532985</li>
<li>Truseltiq (infigratinib) [prescribing information]. Brisbane, CA: QED Therapeutics Inc; May 2021.</li>
<li>Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola®) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671-1675. [PubMed 7486898</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; June 2018</li>
<li>Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; March 2018</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022</li>
<li>Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-391. [PubMed 9357389</li>
<li>Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42(3):278-284. [PubMed 22022918</li>
<li>Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283:434-442.[PubMed 9353355</li>
<li>Zhang W, Ramamoorthy Y, Kilicarslan T, et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos. 2002;30:314-318. [PubMed 11854151]</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</li>
<li>Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1635-1643. [PubMed 23636448</li>
<li>Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. [Published online doi:10.1002/ijc.33469]. 2021. [PubMed 33428771</li>
<li>Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020;76(9):1273-1280. [PubMed 32474662</li>
<li>Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</li>
<li>Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F. Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects. Clin Pharmacokinet. 2022;61(11):1623-1639. [PubMed 36264536</li>
<li>Turalio (pexidartinib) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; August 2019.</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; August 2015</li>
<li>Juluca (dolutegravir/rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020</li>
<li>Noltec (ilaprazole) [Korean product labeling]. Ilyang Pharmaceutical Co., Ltd.; March 2020</li>
<li>K-CAB (tegoprazan) [Singapore product labeling]. Singapore: HK inno.N Corporation; January 2023.</li>
<li>Lumakras (sotorasib) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2021.</li>
<li>Filspari (sparsentan) [prescribing information]. San Diego, CA: Travere Therapeutics Inc; February 2023.</li>
<li>Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-197. [PubMed 15001970</li>
<li>Konvomep (omeprazole and sodium bicarbonate for oral suspension) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals, Inc.; August 2022.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2020</li>
<li>Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011;51(3):368-377. [PubMed 20457590</li>
<li>Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26:341346. [PubMed 16503713</li>
<li>Evotaz (atazanavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2020.</li>
<li>Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors. Clin Pharmacol Drug Dev. 2022;11(7):795-806. [PubMed 35230741</li>
<li>Rezurock (belumosudil) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals LLC; July 2021.</li>
<li>Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33(8):589-595. [PubMed 23839484</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:53-59. [PubMed 10702887</li>
<li>Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.</li>
<li>Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51. [PubMed 20642546</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90-97. [PubMed 24887634</li>
<li>Wu WT, Tsai CT, Chou YC, et al. Cardiovascular outcomes associated with clinical use of citalopram and omeprazole: a nationwide population-based cohort study. J Am Heart Assoc. 2019;8(20):e011607. [PubMed 31581860</li>
<li>Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.</li>
<li>Yokota H, Sato K, Okuda Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18(6):e433-e439. [PubMed 28579188</li>
<li>Tang W, Tomkinson H, Masson E. Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev. 2017;6(5):517-523. [PubMed 28176470</li>
<li>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res. 2019;11:8539-8546. [PubMed 31572008</li>
<li>Sedano MN, Teller JMC, Munoz CG, et al. Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON. 2018;23(3):647-653. [PubMed 30003732</li>
<li>Li J, Nickens D, Wilner K, Tan W. Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther. 202113. Epub ahead of print. [PMID: 34120312</li>
<li>Kumarakulasinghe NB, Syn N, Soon YY, et al. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget. 2016;7(51):85542-85550. [PubMed 27907909</li>
<li>Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2021.</li>
<li>Jaruratanasirikul S and Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54:159-161. [PubMed 9626921</li>
<li>Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, and Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51:453-457. [PubMed 12562722</li>
<li>Lange D, Pavao JH, Wu J, and Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Tolsura (itraconazole) [prescribing information]. Greenville NC: Mayne Pharma; December 2018</li>
<li>Lindsay J, Mudge S, and Thompson GR. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723018. [PubMed 30297369</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018</li>
<li>Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808. [PubMed 16141567]</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2017</li>
<li>Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893-1899. [PubMed 27533287</li>
<li>Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5. [PubMed 27565882]</li>
<li>Camzyos (mavacamten) [prescribing information]. Brisbane, CA: MyoKardia, Inc.; April 2022.</li>
<li>Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol.1993;33(1):82-84. [PubMed 8269594</li>
<li>Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024-1027. [PubMed 10981249</li>
<li>Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497. [PubMed 12077038</li>
<li>Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30(3):963-965. [PubMed 20393020</li>
<li>McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012;25(4):477-485. [PubMed 22550162</li>
<li>Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316-318. [PubMed 18386155</li>
<li>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Chemotherapy. 2011;57(3):225-229. [PubMed 21597286</li>
<li>Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht RDelayed elimination of methotrexate associated with co-administration of proton pump inhibitorsAnticancer Res2010;30(9):3807-3810[PubMed 20944174</li>
<li>Fang AF, Damle BD, LaBadie RR, Crownover, PH, Hewlett Jr. D, Glue, PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50. [PubMed 18154473</li>
<li>Saberi P, Ranatunga DK, Quesenberry CP, Silverberg MJ. Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011;31(3):253-261. [PubMed 21361735</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016</li>
<li>Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32(12):1462-1467. [PubMed 15448116]</li>
<li>Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50(8):960-967. [PubMed 20498287</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155-1162. [PubMed 30605231</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.</li>
<li>Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food and intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614-626. [PubMed 28430398</li>
<li>Ibrance (palbociclib) capsule [prescribing information]. New York, NY: Pfizer Inc; September 2019</li>
<li>Ibrance (palbociclib) tablet [prescribing information]. New York, NY: Pfizer Inc; November 2019</li>
<li>Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021;6(5):100231. [PubMed 34509802</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649]</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PubMed 19075045</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; November 2013</li>
<li>Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839. [PubMed 19220151</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-5510[PubMed 22890761</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott (US), LLC; April 2015</li>
<li>Kinov P, Boyanov M. Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health. 2012;4L:167-174. [PubMed 22532780</li>
<li>Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114. [PubMed 30539272</li>
<li>Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998-1004. [PubMed 21321287</li>
<li>Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161-1168. [PubMed 22890365</li>
<li>Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016-1022. [PubMed 23307040</li>
<li>Prieto-Alhambra D, Pages-Castella A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268-274. [PubMed 23761350</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Yang SD, Chen Q, Wei HK, et alBone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysisInt J Clin Exp Med2015;8(4):4899-4910[PubMed 26131063</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782</li>
<li>Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC Jr, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63(10):2070-2073. [PubMed 26415604</li>
<li>Roux C, Goldstein JL, Zhou X, et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277-284. [PubMed 21365461</li>
<li>Asaoka D, Nagahara A, Hojo M, et al. Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomed Rep. 2016;5(2):165-170. [PubMed 27446535</li>
<li>Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31(2):206-211. [PubMed 23138352</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014:607145. [PubMed 25436170]</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin Inc; July 2017</li>
<li>Prilosec (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Nexim (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016</li>
<li>Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2017.</li>
<li>Retevmo (selpercatinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; May 2020.</li>
<li>Norouzi G, AsadZade A, Salimi Y, Khoshbakht S, Pirayesh E. Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi. J Nucl Cardiol. 2022;29(4):1552-1561. [PubMed 33527332</li>
<li>Rose DS, Robinson B, Kannan S, Lee JC. Interaction between the effects of proton pump inhibitors and aspirin on gastric wall sestamibi uptake on myocardial perfusion imaging. J Nucl Cardiol. 2021;28(5):1976-1985. [PubMed 31741323</li>
<li>Qutbi M. What is this image? 2019: Image 2 result : Reduction in interfering gastric wall uptake on myocardial perfusion SPECT following a 2-week period of omeprazole withdrawal. J Nucl Cardiol. 2019;26(5):1517-1519. [PubMed 31359363</li>
<li>Singh H, Mittal BR, Sood A, et al. Association of use of proton pump inhibitors and H2 antagonists with stomach wall uptake in 99m-Tc-methoxy-isobutyl-isonitrile (MIBI) myocardial perfusion imaging. J Nucl Cardiol. 2020;27(5):1611-1619. [PubMed 31087263</li>
<li>Javadi H, Jallalat S, Semnani S, et al. The association of increased stomach wall radiotracer uptake with prolonged use of omeprazole capsules on myocardial perfusion imaging (MPI) using 99mTc-sestamibi SPECT. Nucl Med Rev Cent East Eur. 2013;16(2):91-94. [PubMed 24068640</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974</li>
<li>Cardiolyte (technetium Tc 99m sestamibi) [prescribing information]. N. Billerica, Massachusetts: Lantheus Medical Imaging; December 2019</li>
<li>Technetium Tc 99m sestamibi [product monograph]. Laval, Quebec, Canada: Curium Canada Inc; November 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2020</li>
<li>Vosevir (sofosbuvir and velpatasvir and voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2019</li>
<li>Seyen MV, Colbers A, Abbink EJ, Drenth JPH, Burger DM. Concomitant intake of coca-cola to manage the drug-drug interaction between velpatasvir and omeprazole studied in healthy volunteers. Clin Pharmacol Ther. 2019;106(5):1093-1098. [PubMed 31313296]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270</li>
<li>Evekeo (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2013.</li>
<li>Czerwinski E. Atypical subtrochanteric fractures after long-term bisphosphonate therapy. Endokrynol Pol. 2011;62(1):84-87. [PubMed 21365585</li>
<li>Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169-180. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-785. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-1998. [PubMed 19333676</li>
<li>Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-1218. [PubMed 21483462</li>
<li>Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768-776. [PubMed 21185417</li>
<li>Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131-1136. [PubMed 20872906</li>
<li>Gray SL, LaCroix AZ, Larson J, et alProton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health InitiativeArch Intern Med2010;170(9):765-771[PubMed 20458083</li>
<li>Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101. [PubMed 20353792</li>
<li>Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326. [PubMed 18695179</li>
<li>Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. [PubMed 17190895</li>
<li>Bodmer M, Meier C, Kraenzlin ME, et al. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33(10):843-852. [PubMed 20812769</li>
<li>Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903-910. [PubMed 20585937</li>
<li>Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959. [PubMed 18657011</li>
<li>Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904. [PubMed 19931262</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014;2014:607145. [PubMed 25436170</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782]</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767-773. [PubMed 27737436</li>
<li>Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257-263. [PubMed 26803708</li>
<li>Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43(4):309-315. [PubMed 10071982</li>
<li>van Doorn L, Heersche N, de Man FM, et al. Effect of the proton pump inhibitor esomeprazole on the systemic exposure of capecitabine: results of a randomized crossover trial. Clin Pharmacol Ther. 2022;111(2):455-460. [PubMed 34656072]</li>
<li>Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23(1):37-39. [PubMed 11413862</li>
<li>Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44(2):186-189. [PubMed 9278208]</li>
<li>Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2-receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183]</li>
<li>Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-353. [PubMed 22422635</li>
<li>Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23(3):317-321. [PubMed 3567046</li>
<li>Onfi (clobazam) [prescribing information]. Winchester, KY: Catalent Pharma Solutions, LLC; February 2021</li>
<li>Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999;21(6):604-608. [PubMed 10604819</li>
<li>Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589-592. [PubMed 22293514</li>
<li>Grigoleit HG, Hajdu P, Hundt HK, et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol. 1983;25(1):139-142. [PubMed 6617718]</li>
<li>Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2022.</li>
<li>Frick A, Kopitz J, and Bergemann N, “Omeprazole Reduces Clozapine Plasma Concentrations: A Case Report,” Pharmacopsychiatry, 2003, 36(3):121</li>
<li>[PubMed 12806570</li>
<li>Intensive Medicines Monitoring Programme accessed at http://www.medsafe.govt.nz/Profs/Puarticles/ClozOmep.htm May 14, 2013</li>
<li>Mookhoek EJ and Loonen AJ, “Retrospective Evaluation of the Effect of Omeprazole on Clozapine Metabolism,” Pharm World Sci, 2004, 26(3):180</li>
<li>[PubMed 15230368</li>
<li>Wagner S, Varet-Legros MG, Fabre C, et al, “Confounding Factors for Variation of Clozapine Plasma Levels: Drug Interactions With Proton Pump Inhibitor or Infectious Etiologies?” Eur J Clin Pharmacol, 2011, 67(5):533</li>
<li>[PubMed 21057941</li>
<li>Philipps RJ, Lee Demler T and Lee C, “Omeprazole-Induced Blood Dyscrasia in a Clozapine-Treated Patient,” Innov Clin Neurosci, 2012, 9(9):14</li>
<li>[PubMed 23074697]</li>
<li>Reichenspurner H, Meiser BM, Muschiol F. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transplant. 1993;12(6):987-992. [PubMed 8312324</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al. Changes of resorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc. 1994;26(5):2800-2801. [PubMed 7940881</li>
<li>Schouler L, Dumas F, Couzigou P. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86(8):1097. [PubMed 1858755</li>
<li>Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993;35(2):156-160. [PubMed 8443034</li>
<li>Castellote E, Bonet J, Lauzurica R. Does interaction between omeprazole and cyclosporin exist? Nephron. 1993;65(3):478. [PubMed 8290007</li>
<li>Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM. More about omeprazole-cyclosporine interaction. Am J Gastroenterol. 1993;88(1):154-155. [PubMed 8420264</li>
<li>Zegerid (omeprazole) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; November 2020.</li>
<li>Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057-1069. [PubMed 25929560</li>
<li>Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519. [PubMed 29105855</li>
<li>Kamiya C, Inui N, Hakamata A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361-366. [PubMed 30902567</li>
<li>Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487-494. [PubMed 15025747</li>
<li>Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141-152. [PubMed 11907488</li>
<li>Vlase L, Neag M, Popa A, Muntean D, Leucuta SE. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Curr Ther Res Clin Exp. 2010;71(6):360-368. [PubMed 24688155</li>
<li>Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653-662. [PubMed 24569517</li>
<li>Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. [PubMed 34877801</li>
<li>Inrebic (fedratinib) [prescribing information]. Summit, NJ: Celgene Corporation; August 2019</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672</li>
<li>Vfend (voriconazole) [prescribing information]New York, NY: Pfizer; January 2019</li>
<li>Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021</li>
<li>Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23(2):77-81. [PubMed 11932962</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; January 2020</li>
<li>Armas D, Holt RJ, Confer NF, Checani GC, Obaidi M, Xie Y, Brannagan M. A phase I pharmacokinetic study of cysteamine bitartrate delayed-release capsules following oral administration with orange juice, water, or omeprazole in cystinosis. Adv Ther. 2018;35(2):199-209. [PubMed 29411268]</li>
<li>Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicriob Agents Chemother. 2007;51(3):958-961. [PubMed 17210768]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Lexington, MA: Shire US Inc.; July 2019</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270]</li>
<li>Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.</li>
<li>Grahnen A, Olsson B, Johansson G, Eckernas SA. Doxycycline carrageenate-an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmcol 1994;46(2):143-146. [PubMed 8039533</li>
<li>Monodox (doxycycline monohydrate). Aqua Pharmaceuticals, LLC; Fort Lauderdale, FL: April 2017</li>
<li>Nexium (esomeprazole). AstraZeneca Pharmaceuticals LP; Wilmington DE: October 2016.</li>
<li>Grasela Jr TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615-617. [PubMed 2751276</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081</li>
<li>Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol. 1993;33(1):53-56. [PubMed 8429114]</li>
<li>Lozano R, Bibian C, Quilez RM, Gil J, Constante Y, Garcia-Arilla E. Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol. 2014;77(6):1086-1087. [PubMed 23919252</li>
<li>Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391-1400. [PubMed 23928296</li>
<li>Lexapro (escitalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Courlet P, Guidi M, Glatard A, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019;85(9):2022-2032. [PubMed 31144347</li>
<li>Escitalopram [product monograph]. Kirkland, Quebec, Canada: Accord Healthcare Inc; September 2017.</li>
<li>Marti-Masso JF, Lopez de Munain A, Lopez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother. 1992;26(3):429-430. [PubMed 1554966]</li>
<li>Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-1241. [PubMed 3932118</li>
<li>Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24(4):543-545. [PubMed 3689634</li>
<li>Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935-46. [PubMed 22612290</li>
<li>Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6):563-568. [PubMed 10613611</li>
<li>Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215-220. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al. Reduction of phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol. 1983;25(1):135-137. [PubMed 6617717</li>
<li>Bartle WK, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther. 1983;33(5):649-655. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, Jordan JE. Effect of cimetidine on phenytoin serum levels. Epilepsia. 1983;24(3):284-288. [PubMed 6851961</li>
<li>Iteogu MO, Murphy JE, Shleifer N, Davis REffect of cimetidine on single-dose phenytoin kineticsClin Pharm1983;2(4):302-304[PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology. 1985;35(4):562-565. [PubMed 3982643</li>
<li>Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. Br J Clin Pharmacol. 1989;27(1):83-87. [PubMed 2565119</li>
<li>Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effects of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 1989;30(2):225-229. [PubMed 2647472</li>
<li>Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, Remmel RP. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 1988;29(4):488-491. [PubMed 3391153</li>
<li>Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-544 (ADD 03055) in epileptic patients. Epilepsia. 1985;26(6):602-606. [PubMed 4076064</li>
<li>Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40(8):1122-1128. [PubMed 10448826</li>
<li>Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997;62(5):572-577. [PubMed 9390115</li>
<li>Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol. 1996;53(11):1191-1192. [PubMed 8912496</li>
<li>Rindone JP, Bryan G. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med. 1996;156(10):1113. [PubMed 8639000</li>
<li>Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology. 1996;46(4):1172-1173. [PubMed 8780118</li>
<li>Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother. 1998;32(12):1295-1298. [PubMed 9876809</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, Shearman DJ, Hann CS. Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed). 1981;282(6275):1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med. 1981;95(2):244-245. [PubMed 7258891</li>
<li>Phillips P, Hansky J. Phenytoin toxicity secondary to cimetidine administration. Med J Aust. 1984;141(9):602. [PubMed 6092884</li>
<li>Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12(4):329-333. [PubMed 2396305</li>
<li>Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36(4):380-382. [PubMed 12959321</li>
<li>Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol. 1992;34(1):75-78. [PubMed 1633070</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Dujic T, Cvijic S, Elezovic A, et al. Interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype. J Pers Med. [published online May 3 2021].doi:10.3390/jpm11050367] [PubMed 34063566]</li>
<li>Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474-484. [PubMed 34649118</li>
<li>Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487-5493. [PubMed 32933995</li>
<li>Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR tirals. Ann Oncol. 2020;31(4):535-531. [PubMed 32115349</li>
<li>Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016;26(9):609-615. [PubMed 27603551</li>
<li>Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacotherapy. 2022;56(4):377-386. [PubMed 34282636]</li>
<li>Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12(15):2080-2082. [PubMed 9814882</li>
<li>Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-428. [PubMed 18281734</li>
<li>Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122-129. [PubMed 27693678]</li>
<li>Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.</li>
<li>Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69(4):266-273. [PubMed 11309556</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672]</li>
<li>Sharma VR, Brannon MR, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. Southern Med J. 2004;97(9):887-889.[PubMed 15455980</li>
<li>Salovaara S, Sandberg A-S, Andlid T. Combined impact of pH and organic acids on iron uptake by caco-2 cells. J Agric Food Chem. 2003;51:7820-7824. [PubMed 14664552</li>
<li>Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Ann Rev Nutr. 2003;23:283-301. [PubMed 12626689]</li>
<li>Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42(10):4243-4246. [PubMed 21168674</li>
<li>Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061-2067. [PubMed 20671023</li>
<li>Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196-1201. [PubMed 19783713</li>
<li>Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9(7):1650-1656. [PubMed 19519820</li>
<li>Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605-611. [PubMed 19481022</li>
<li>Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46(5):1362-1365. [PubMed 24935300</li>
<li>David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit. 2012;34(3):331-336. [PubMed 22549498</li>
<li>Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30(1):46-51. [PubMed 18223462</li>
<li>Kato R, Ooi K, Ikura-Mori M, et alImpairment of mycophenolate mofetil absorption by calcium polycarbophilJ Clin Pharmacol2002;42(11):1275-1280[PubMed 12412828</li>
<li>Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518-524. [PubMed 24162246</li>
<li>Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. [PubMed 25913040</li>
<li>Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265-1272. [PubMed 21903891</li>
<li>Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120-123. [PubMed 21192310</li>
<li>van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014;72(2):86-90. [PubMed 24659591</li>
<li>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; September 2013</li>
<li>Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565-571. [PubMed 21256049</li>
<li>Sakuludomakan W, Takuathung MN, Dukaew N, Koonrungsesomboon N. Drug-drug interactions between mycophenolic acid and proton pump inhibitors: a systematic review and meta-analysis. Ther Drug Monit. 2022;44(3):384-390. [PubMed 35239287</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.</li>
<li>Mycapssa (octreotide) delayed release capsules [prescribing information]. Scotland, UK: MW Encap Ltd; June 2020.</li>
<li>Prescribing information. Adempas (riociguat). Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., October 2013.</li>
<li>Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401-1406. [PubMed 16791014</li>
<li>Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914</li>
<li>Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83(6):867-872. [PubMed 17898705</li>
<li>Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech, Inc.; September 2020</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50:1081-1084. [PubMed 12461038</li>
<li>Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacother. 2006;26(8):1060-1068. [PubMed 16863482]</li>
<li>Nexavar (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2018</li>
<li>Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. J Cancer Res Clin Oncol. 2020;146(10):2693-2697. [PubMed 32449002</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(11):3078-3087. [PubMed 20395213]</li>
<li>Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet. 2008;23:134-138. [PubMed 18445994</li>
<li>Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet. 2007;22:441-444. [PubMed 18159131</li>
<li>Moreau C, Debray D, Loriot MA, et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation. 2006;81:487-488. [PubMed 16477241</li>
<li>Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38:791-794. [PubMed 15010519</li>
<li>Homma M, Itagaki F, Yuzawa K, et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation. 2002, 73:303-304. [PubMed 11821750</li>
<li>Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821-826. [PubMed 19139162</li>
<li>Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos. 2007;28:167-175. [PubMed 17377957</li>
<li>Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56:1055-1059. [PubMed 15285851</li>
<li>Itagaki F, Homma M, Yuzawa K, et alDrug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutationTransplant Proc2002;34:2777-2778[PubMed 12431607</li>
<li>Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin a blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56:439-440. [PubMed 11009056</li>
<li>Mei T, Noguchi H, Suetsugu K, et al. Effects of concomitant administration of vonoprazan fumarate on the tacrolimus blood concentration in kidney transplant recipients. Biol Pharm Bull. 2020;43(10):1600-1603. [PubMed 32999170</li>
<li>Suzuki Y, Yoshihashi T, Takahashi K, Furuya K, Ohkohchi N, Oda T, Homma M. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. J Clin Med. 2021;10(17):3964. [PubMed 34501411</li>
<li>Pascual J, Marcen R, Orea OE, et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. Transplant Proc. 2005;37(9):3752-3753. [PubMed 16386527</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862. [PubMed 9224780</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A4 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143]</li>
<li>Mouden M, Rijkee KS, Schreuder N, Timmer JR, Jager PL. Influence of proton-pump inhibitors on stomach wall uptake of 99mTc-tetrofosmin in cadmium-zinc-telluride SPECT myocardial perfusion imaging. Nucl Med Commun. 2015;36(2):143-147. [PubMed 25356621</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974]</li>
<li>Ock M, Lee S, Kim H. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor coadministration in patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2022;47(7):1028-1035. [PubMed 35257383]</li>
<li>Aptivus (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 20202. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914]</li>
<li>Ahmad S. Omeprazole-warfarin interaction. South Med J. 1991;84(5):674-675. [PubMed 2035104</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [PubMed 1493083</li>
<li>Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-184. [PubMed 2718223</li>
<li>Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci. 2003;20(4-5):439-449. [PubMed 14659488</li>
<li>Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab. 2005;6(5):399-411. [PubMed 16248835</li>
<li>Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol. 1993;110(1):482-490. [PubMed 8220911</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit. 2008;30(3):276-281. [PubMed 18520598</li>
<li>Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011;153(3):379-385. [PubMed 21418179</li>
<li>de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LMNo effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamicsBr J Clin Pharmacol1997;44(4):399-401[PubMed 9354316</li>
<li>Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN. Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol. 1997;32(10):991-994. [PubMed 9361171</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [PubMed 15258107</li>
<li>Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780]</li>
<li>Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56 Suppl 1:56-61. [PubMed 14616415</li>
<li>Yan M, Wu ZF, Tang D, et al. The impact of PPIs on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018;108:60-64. [PubMed 30216801</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological disease. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211. [PubMed 18171251</li>
<li>Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses. 2012;55(6):483-492. [PubMed 22429709</li>
<li>Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X. Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother. 2021;65(9):e0020721. [PubMed 34152823</li>
<li>Boyd NK, Zoellner CL, Swancutt MA, et al. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001-6002. [PubMed 22890768</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer; January 2019.</li>
<li>Veerman GDM, Hurkmans DP, Paats MS, et al. Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother. 2022;155:113695. [PubMed 36126454]</li>
<li>Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol. 2004;44(6):640-645. [PubMed 15145972</li>
<li>Pylera (bismith subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</li>
<li>Tabrecta (capmatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</li>
<li>Lau YY, Gu W, Lin T, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(6):1119-1128. [PubMed 28424965</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2016.</li>
<li>Clarithromycin [prescribing information]. Bedminster, NJ: Alembic Pharmaceuticals, Inc.; February 2022</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; March 2022.</li>
<li>Michaud V, Kreutz Y, Skaar T, et al. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 2014;14(2):151-159. [PubMed 23629159</li>
<li>Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475-482. [PubMed 22318618</li>
<li>Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharmacol Drug Dev. 2016;5(4):269-277. [PubMed 27310328</li>
<li>Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2015;60(1):105-114. [PubMed 26459906</li>
<li>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29. [PubMed 25646891</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. Doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. [PubMed 18076219</li>
<li>Nader A, Mostafa NM, Kim E, Shebley M. Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. Clin Transl Sci. 2022;15(5):1269-1280. [PubMed 35137535</li>
<li>Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol. 2014;54(4):422-431. [PubMed 24165884</li>
<li>Vassiliou D, Sardh E, Harper P, et al. A drug-drug interaction study evaluating the effect of givosiran, a small interfering ribonucleic acid, on cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250-1260. [PubMed 34510420</li>
<li>Luzu (luliconazole) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; February 2017</li>
<li>Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. [PubMed 29178272</li>
<li>Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465-472. [PubMed 28155129</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Tpoxx (tecovirimat) [prescribing information]Winchester, KY: Catalent Pharma Solutions; July 2018</li>
<li>Brukinsa (zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA, Inc.; November 2019</li>
<li>Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999;47(4):454-457. [PubMed 10233213</li>
<li>Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Jaypirca (pirtobrutinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; January 2023.</li>
<li>Bolek T, Samos M, Stanciakova L, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2017;Apr 25 (Epub ahead of print). [PubMed 28452843</li>
<li>Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33(6):619-623. [PubMed 29255511</li>
<li>Stangier J, Eriksson BI, Dahl O, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563. [PubMed 15831779</li>
<li>Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59. [PubMed 18076218</li>
<li>Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175. [PubMed 21972820</li>
<li>Schnierer M, Samos M, Bolek T, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020;75(4):333-335. [PubMed 31895873</li>
<li>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. [PubMed 19717844</li>
<li>Ollier E, Hodin S, Basset T, et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29(6):604-614. [PubMed 26392328</li>
<li>O'Dea D, Whetteckey J, Ting NA prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatranCardiol Ther2016;5(2):187-201[PubMed 27709460</li>
<li>Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586-595. [PubMed 25960019</li>
<li>Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-1713, 1713a-1713b. [PubMed 23425521</li>
<li>Pradaxa (dabigatran) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; July 2020.</li>
<li>Tafinlar (dabrafenib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.</li>
<li>Drewelow B, Schaffler K, Reitmeir P, Bethke TD. Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittelforschung. 2010;60(8):483-491. [PubMed 20863004</li>
<li>Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-164. [PubMed 7648765</li>
<li>Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995;58(1):62-72. [PubMed 7628184</li>
<li>Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47(1):79-85. [PubMed 2104790</li>
<li>Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39(1):51-54. [PubMed 2276389</li>
<li>Lima DR, Santos RM, Werneck E, Andrade GN. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers. Eur J Drug Metab Pharmacokinet. 1991;16(3):161-170. [PubMed 1814733</li>
<li>Locniskar A, Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. J Clin Pharmacol. 1986;26(4):299-303. [PubMed 2871051]</li>
<li>Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569-572. [PubMed 1954072</li>
<li>Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1995;33(9):481-485. [PubMed 8520804</li>
<li>Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400-402. [PMID: 17458401</li>
<li>Le GH, Schaefer MG, Plowman BK, Morreale AP, Delattre M, Okino L, Felicio L. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors. Am J Health Syst Pharm. 2003;60(13):1343-1345. [PubMed 12901036</li>
<li>Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CBV. Omeprazole does not modulate pharmacokinetic effect of digoxin in patients with heart failure. Int J Cardiol. 2015;179:343-344. [PubMed 25464482]</li>
<li>Rozlytrek (entrectinib) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; August 2019.</li>
<li>Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508-516. [PubMed 18492125</li>
<li>Intelence (etravirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; July 2019.</li>
<li>Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose fedratinib in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(5):995-1001. [PubMed 32318809]</li>
<li>Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on the filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585-594. [PubMed 30768860</li>
<li>Jyseleca (filgotinib) [summary of product characteristics]. Mechelen, Belgium: Galapagos NV; January 2022.</li>
<li>Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;8:457-464. [PubMed 17760738</li>
<li>Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 2006;42:61-67. [PubMed 16639341</li>
<li>Kiser JJ, Lichtenstein KA, Anderson PL, et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26:511-514. [PubMed 16553510</li>
<li>Ford SL, Wire MB, Lou Y, et al. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49:467-469. [PubMed 15616339</li>
<li>Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48:791-798. [PubMed 14982766]</li>
<li>Yin O, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850. [PubMed 15608563</li>
<li>Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012;68(5):553-560. [PubMed 22189672</li>
<li>Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731. [PubMed 19299322</li>
<li>Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509. [PubMed 20186406]</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</li>
<li>Brexafemme (ibrexafungerp) [prescribing information]. Jersey City, NJ: Scynexis Inc; June 2021.</li>
<li>Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2021</li>
<li>Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386-1394. [PubMed 26054042]</li>
<li>Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185-189. [PubMed 21150767</li>
<li>Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821-829. [PubMed 27890768</li>
<li>Tran-Duy A, Connell NJ, Vanmolkot FH, et al. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med. 2019;285(2):205-214. [PubMed 30141278</li>
<li>Imai R, Higuchi T, Moriomoto M, Koyamada R, Okada S. Iron deficiency anemia due to long-term use of a proton pump inhibitor. Inter Med. 2018;57(6):899-901. [PubMed 29151538</li>
<li>Mabuchi S, Suzuki R, Sasak M, et al. Case report of severe iron deficiency anemia caused by proton pump inhibitor in an elderly patient. Geriatr Gerontol Int. 2017;662-663. [PubMed 28405975</li>
<li>Hashimoto R, Matsuda T, Chonan A. Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med. 2014;53(20):2297-2299. [PubMed 25318791</li>
<li>Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97(9):887-889. [PubMed 15455980</li>
<li>Khatib MA, Rahim O, Kania R, Molloy P. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig Dis Sci. 2002;47(11):2596-2597. [PubMed 12452401</li>
<li>Eghbali A, Khalilpour A, Taherahmadi H, Bagheri BPantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled studyTherapie2019;74(5):507-512[PubMed 30704764</li>
<li>Shalev H, Quider AA, Harosh MB, Kapelushnik J. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia. Pediatr Hematol Oncol. 2016;33(7-8):457-461. [PubMed 27960647</li>
<li>Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-1295. [PubMed 17344278</li>
<li>Tempel M, Chawla A, Messina C, Celiker MY. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol. 2013;30(3):307-310. [PubMed 24385811</li>
<li>Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-292. [PubMed 1607604</li>
<li>Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011;134(2):224-231. [PubMed 21911976</li>
<li>Sarker SA, Mahmud H, Davidsson L, et al. Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology. 2008;135(5):1534-1542. [PubMed 18775429]</li>
<li>Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34(5):317-325. [PubMed 24567279</li>
<li>Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; June 2019.</li>
<li>Koch KM, Im Y-H, Kim S-B, et al. Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients. Clin Pharmacol Drug Dev. 2013;2(4):336-341. [PubMed 27121938</li>
<li>Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015</li>
<li>Tykerb (lapatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.</li>
<li>Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</li>
<li>Adhansia XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Purdue Pharmaceuticals LP; July 2019</li>
<li>Cotempla XR ODT (methylphenidate) extended-release orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC; June 2017</li>
<li>Concerta (methylphenidate) extended-release tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2017</li>
<li>Ritalin LA (methylphenidate) extended-release capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019</li>
<li>Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Greenville, NC: Patheon Manufacturing Services LLC; June 2019</li>
<li>Jornay PM (methylphenidate) extended-release capsules [prescribing information]. Cherry Hill, NJ: Ironshore Pharmaceuticals Inc; April 2019</li>
<li>Metadate CD (methylphenidate) extended-release capsules [prescribing information]. Smyrna, GA: UCB Inc; June 2014</li>
<li>Quillichew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; March 2017</li>
<li>Quillivant XR (methylphenidate) extended-release oral suspension [prescribing information]New York, NY: Pfizer Inc; January 2017</li>
<li>Ritalin SR (methylphenidate) extended-release tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.</li>
<li>Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120-2138. [PubMed 28808886</li>
<li>Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; February 2022.</li>
<li>Ji T, Rockich K, Epstein N, et al. Evaluation of drug-drug interactions of pemigatinib in healthy participants [published online July 19, 2021]. Eur J Clin Pharmacol. doi: 10.1007/s00228-021-03184-z. [PubMed 34282472</li>
<li>Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; February 2021.</li>
<li>Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. [PubMed 18303127</li>
<li>Seiler D, Doser K, Salem I. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. Arzneimittelforschung. 2011;61(4):247-251. [PubMed 21650084</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed 25012577</li>
<li>Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906-913. [PubMed 28875498</li>
<li>Effient (prasugrel) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; December 2020.</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Yang E, Ji SC, Jang I-J, Lee S. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet. 2023;62(4):599-608. [PubMed 36897544</li>
<li>Kolawole JA, Mustapha A, Abdul-Aguye I, Ochekpe N, Taylor RB. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal. 1999;20(5):737-743. [PubMed 10701981</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole, and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. Eur J Clin Pharmacol. 1996;50(5):417-419. [PubMed 8839666]</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2020</li>
<li>Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-492. [PubMed 19143531]</li>
<li>Zhou J, Quinlan M, Glenn K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol. 2016;82(4):1022-1029. [PubMed 27277189</li>
<li>Odomzo (sonidegib) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2017.</li>
<li>Tazverik (tazemetostat) [prescribing information]. Cambridge, MA: Epizyme, Inc.; January 2020.</li>
<li>Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. [PubMed 16641395</li>
<li>Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. [PubMed 17669709</li>
<li>Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-59. [PubMed 16477543</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075</li>
<li>Abi-Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? Arq Bras Endocrinol Metabol. 2014;58(7):731-736. [PubMed 25372582</li>
<li>Ermeza (levothyroxine) solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022</li>
<li>Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. [PubMed 25259910]</li>
<li>Giri P, Gupta L, Naidu S, et al. In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, alicarb, methiocarb, motelukast and ziprasidone. Drug Metabo Lett. 2019;12(2):101-116. [PubMed 30117405</li>
<li>Egaten (triclabendazole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2019.</li>
<li>Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26-33. [PubMed 23110788]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. Doi: 10.1007/s40262-017-0591</li>
<li>[PubMed 28866861]</li>
<li>Verquvo (vericiguat) [prescribing information].Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2021.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022</li>
<li>Calquence (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2022.</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” Pharmacotherapy, 2010, 30(8):787-96. [PubMed 20653354</li>
<li>Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” Clin Cardiol, 2010, 33(3):168-71. [PubMed 20235209</li>
<li>Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” Arch Intern Med, 2010, 170(8):704-10[PubMed 20421557</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2018.</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2021.</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067]</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2019.</li>
<li>Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol. 2015;71(12):1461-1465. [PubMed 26400679</li>
<li>Bertram V, Yeo K, Anoopkumar-Dukie S, Bernaitis N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract. 2019;73(11):e13382. [PMID 31250945</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2014.</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Cojutti P, Candoni A, Forghieri, et al. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and/or with CYP inhibitors plus CYP inducers. Basic Clin Pharmacol Toxicol. 2016;118(6):474-479. [PubMed 26572687</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143</li>
<li>Scholler J, Nivoix Y, Herbrecht R, et al. Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. Int J Clin Pharm. 2011;33(6):905-908. [PubMed 22108788</li>
<li>Tsubokura M, Miura Y, Itokawa T, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol. 2011;51(10):1488-1490. [PubMed 21098688</li>
<li>Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262-3267. [PubMed 23629724</li>
<li>Dexilant (dexlansoprazole) [prescribing information]Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2018</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; October 2017</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc.; January 2019.</li>
<li>Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” Ann Pharmacother, 2003, 37(6):808-11. [PubMed 12773066</li>
<li>Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors,” Am J Cardiol, 2004, 94:1140</li>
<li>[PubMed 15518608</li>
<li>Amsden GW, Kuye O,Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” J Clin Pharmacol, 2002, 42:444</li>
<li>[PubMed 11936570</li>
<li>Lee AJ,Maddix DS, “Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin,” Ann Pharmacother, 2001, 35:26-31. [PubMed 11197581</li>
<li>Chen C, Lin J, Smolarek T, et al, “P-Glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in Mdr1a/B Knockout and Wild-Type Mice,” Drug Metab Dispos, 2007, 35:1725</li>
<li>[PubMed 17640956</li>
<li>Chen C, Mireles RJ, Campbell SD, et al, “Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors with Abcb1, Abcc2, and Oatp1b1,” Drug Metab Dispos, 2005, 33:537-46. [PubMed 15616150</li>
<li>Hochman JH, Pudvah N, Qiu J, et al, “Interactions of Human P-Glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin,” Pharm Res, 2004, 21:1686-91. [PubMed 15497697</li>
<li>Wu X, Whitfield LR,Stewart BH, “Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter,” Pharm Res, 2000, 17:209-15. [PubMed 10751037</li>
<li>Pauli-Magnus C, Rekersbrink S, Klotz U, et al, “Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein,” Naunyn Schmiedebergs Arch Pharmacol, 2001, 364:551</li>
<li>[PubMed 11770010</li>
<li>Collett A, Tanianis-Hughes J, Carlson GL, et al, “Comparison of P-Glycoprotein-Mediated Drug-Digoxin Interactions in Caco-2 with Human and Rodent Intestine: Relevance to in Vivo Prediction,” Eur J Pharm Sci, 2005, 26:386-93. [PubMed 16153812]</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Prevacid (lansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2020.</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed: 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc. 2015;4(11). [PubMed: 26514161</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed: 22464478</li>
<li>Shamliyan TA, Middleton M, Borst C. Patient-centered outcomes with concomitant use of proton pump inhibitors and other drugs. Clin Ther. 2017;39(2):404-427. [PubMed: 28189362</li>
<li>Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823. [PubMed: 20102352</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed: 25012577</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-36[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244</li>
<li>Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig. 2011;31(10):727-733. [PubMed 21877765</li>
<li>Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44(11):1223-1229. [PubMed 15496639</li>
<li>Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005;60(1):61-68. [PubMed 15963095</li>
<li>Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162-164. [PubMed 15546944]</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2014; July 28 (Epub ahead of print). [PubMed 25068772</li>
<li>Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-277. [PubMed 18615373</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi TThe role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazoleTher Drug Monit2008;30(3):276-281[PubMed 18520598</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11). pii: e002245. [PubMed 26514161</li>
<li>Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43(3):212-224. [PubMed 22564422</li>
<li>Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35(2):127-139. [PubMed 22204719</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Lu M. Report: Impact of drug combination of clopidogrel and pantoprazole in the prognosis of patients with transient ischemic attack. Pak J Pharm Sci. 2017;30(1):217-221. [PubMed 28603135</li>
<li>Choi YJ, Kim N, Jang IJ, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-511. [PubMed 28395507</li>
<li>Gu RX, Wang XZ, Li J, Deng J, Li XX, Wang JEffects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrelMil Med Res2016;3</li>
<li>[PubMed 28018669</li>
<li>Bolek T, Samos M, Simonova R, et al. Does pantoprazole affect the on-treatment platelet reactivity in patients with acute STEMI treated with ADP receptor blockers?-a pilot prospective study. Am J Ther. 2017;24(2):e162-e166. [PubMed 27415979</li>
<li>Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacol Rep. 2012;64(2):360-368. [PubMed 22661187</li>
<li>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2020</li>
<li>Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012;33(5):278-283. [PubMed 22623337]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, Dammann G, Hiemke C, Grunder G, Paulzen M. The effects of co-prescription of pantoprazole on the clozapine metabolism. Pharmacopsychiatry. 2020;53(2):65-70. [PubMed 31614374]</li>
<li>Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metabol Dispos. 2014;42(7):1174-1179. [PubMed 24764147]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. doi: 10.1007/s40262-017-0591</li>
<li>Chandelia S, Dubey NK. Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole. Indian J Crit Care Med. 2016;20(2):127-128. [PubMed 27076718</li>
<li>Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39(6):700-703. [PubMed 7654493</li>
<li>Henriksen DP, Stage TB, Hansen MR, Rasmussen L, Damkier P, Pottegard A. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. 2015;24(12):1337-1340. [PubMed 26395871</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [Pubmed1493083</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf LComparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activitiesDrug Metab Dispos2004;32(8):821-827[PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780</li>
<li>Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71(9):1059-1066. [PubMed 26071277</li>
<li>Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. [PubMed 20844485]</li>
<li>El-Bohy D, Sharkawy M, Abo-Elazm S, et al. Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney transplantation: A randomized clinical trial. Ther Apher Dial. 2020;24(5):591-598. [PubMed 31856374</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-440. [PubMed 11009056</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. Pantoprazole does not affect cyclosporin a blood concentration in kidney-transplant patients. Eur J Clin Pharmacol. 2000;55(10):733-735. [PubMed 10663451]</li>
<li>Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74(10):2187-2192. [PubMed 20736505</li>
<li>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70(3):383-392. [PubMed 20716239</li>
<li>Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. [PubMed 19108880</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-2436[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. [PubMed 16772608</li>
<li>Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735-741. [PubMed 17361128</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107]</li>
<li>Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61(3):309-314. [PubMed 16487224</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2018.</li>
<li>Liu G, Wen J, Guo D, et al. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. J Pharmacol Sci. 2016;132(4):244-248. [PubMed 27245553]</li>
<li>Hata M, Hayasaka M, Sezai A, et al, “Proton Pump Inhibitors May Increase the Risk of Delayed Bleeding Complications after Open Heart Surgery If Used Concomitantly with Warfarin,” Thorac Cardiovasc Surg, 2008, 56:274-7</li>
<li>Ahmad S, “Omeprazole-Warfarin Interaction,” South Med J, 1991, 84:674-5</li>
<li>Unge P, Svedberg LE, Nordgren A, et al, “A Study of the Interaction of Omeprazole and Warfarin in Anticoagulated Patients,” Br J Clin Pharmacol, 1992, 34:509-12</li>
<li>Sutfin T, Balmer K, Bostrom H, et al, “Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men,” Ther Drug Monit, 1989, 11:176-84</li>
<li>Zhou Q, Chan E, “Effect of Omeprazole on the Anticoagulant Activity and the Pharmacokinetics of Warfarin Enantiomers in Rats,” Eur J Pharm Sci, 2003, 20:439-49</li>
<li>Zhou Q, Zhou S, Chan E, “Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and cDNA-Expressed Cytochrome P450 Isozymes,” Curr Drug Metab, 2005, 6:399-411</li>
<li>Hermans JJ, Thijssen HH, “Human Liver Microsomal Metabolism of the Enantiomers of Warfarin and Acenocoumarol: P450 Isozyme Diversity Determines the Differences in Their Pharmacokinetics,” Br J Pharmacol, 1993, 110:482-90</li>
<li>Uno T, Sugimoto K, Sugawara K, et al, “The Role of Cytochrome P2C19 in R-Warfarin Pharmacokinetics and Its Interaction with Omeprazole,” Ther Drug Monit, 2008, 30:276-81</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” Drug Metab Dispos, 2004, 32:821-7</li>
<li>Ko J, Sukhova N, Thacker D, et al, “Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms,” Drug Metab Dispos, 1997, 25:853-862.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2016.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (Tak-390mr), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29:35-50. [PubMed 19067473</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2015;63(1):45-50. [PubMed 25068772</li>
<li>Dexilant (dexlansoprazole) [Prescribing Information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2017</li>
<li>Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, Shin JG. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos. 2005;33(2):209-213. [PubMed 15537834]</li>
<li>Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; June 2018</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2018</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30(8):787-796. [PubMed 20653354</li>
<li>Stockl KM, Le L, Zakharyan A, et alRisk of rehospitalization for patients using clopidogrel with a proton pump inhibitorArch Intern Med2010;170(8):704-710[PubMed 20421557</li>
<li>Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Mahabaleshwarkar RK, Yang Y, Datar MV, et al. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Curr Med Res Opin. 2013;29(4):315-323. [PubMed 23362935</li>
<li>Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012;32(9):809-818. [PubMed 22744772</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors - a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997. [PubMed 19726078</li>
<li>Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329. [PubMed 19933932</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population based study of drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Wei P, Zhang YG, Ling L, et al. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-2864. [PubMed 27882086</li>
<li>Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824-834. [PubMed 22364155</li>
<li>Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2CDrug Metab Dispos. 2012;40(9):1698-1711. [PubMed 22648560</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478]</li>
<li>Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2018.</li>
<li>Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc; April 2006</li>
<li>Kayexalate (sodium polystyrene sulfonate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; December 2010</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a “nonsystemic” antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Fernandez PC, Kovnat PJ. Metabolic acidosis reversed by the combination of magnesium and a cation-exchange resin. N Engl J Med. 1972;286(1):23-24. [PubMed 5006921</li>
<li>Ziessman HA. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. South Med J. 1976;69(4):497-499. [PubMed 817399</li>
<li>Madias NE, Levey AS. Metabolic alkalosis due to absorption of “nonabsorbable” antacids. Am J Med. 1983;74(1):155-158. [PubMed 6849324]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36(6):1219-1224. [PubMed 1329615</li>
<li>Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55. [PubMed 8737124</li>
<li>Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989;46(6):700-705. [PubMed 2598571</li>
<li>Shiba K, Sakamoto M, Nakazawa Y, et al. Effects of antacid on absorption and excretion of new quinolones. Drugs. 1995;49(Suppl 2):360-361. [PubMed 8549362</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):39-48. [PubMed 11352441</li>
<li>Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830-832. [PubMed 1503446</li>
<li>Lehto PL, Kivisto KTDifferent effects of products containing metal ions on the absorption of lomefloxacinClin Pharmacol Ther1994;56(5):477-482[PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35(3):302-304. [PubMed 8471407</li>
<li>Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Emrok O (levonadifloxacin) tablet [product information]. Maharashtra, India: Wockhardt Limited; April 2022.</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(suppl 1):39-48. [PubMed 11352441</li>
<li>Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy. 1999;45(6):504-511. [PubMed 10567782</li>
<li>Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther. 1998;20(6):1149-1158. [PubMed 9916608</li>
<li>Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on the absorption of DR-3355 in humans. Antimicrobial Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother. 1990;34(12):2436-2438. [PubMed 2088202</li>
<li>Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Grasela TH Jr, Schentag JJ, Sedman AJ, et alInhibition of enoxacin absorption by antacids or ranitidineAntimicrob Agents Chemother1989;33(5):615-617[PubMed 2751276</li>
<li>Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):93-97. [PubMed 9222077</li>
<li>Hoffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol. 1992;33(1):115-116. [PubMed 1540482</li>
<li>Jaehde U, Sorgel F, Stephan U, Schunak W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother. 1994;38(5):1129-1133. [PubMed 8067750</li>
<li>Maesen FP, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids. J Antimicrob Chemother. 1987;19(6):848-850. [PubMed 3475268</li>
<li>Prescribing information. Cytotec (misoprostol). New York, NY: Pfizer Inc., September 2009.</li>
<li>Quinine [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; July 2015.</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017</li>
<li>Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020-3026. [PubMed 22450971</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494</li>
<li>FDA Antiviral Drugs Advisory Committee Meeting. ISENTRESS™ (raltegravir) 400 mg For Treatment of HIV (NDA 22-145). Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf. Published September 5, 2007. Accessed online November 15, 2013.</li>
<li>Dimaval (DMPS) Hartkapseln (unithiol) [summary of product characteristics]. Berlin, Germany: Haupt Pharma Wulfing GmbH; June 2020.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc.; March 2010</li>
<li>Ruggiero M, Brunese M, Morelli S, et al. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-777. [PubMed 6895034</li>
<li>Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. Digestion. 1987;37(1):35-42. [PubMed 3609503</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: Modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;25(15):1093-1115</li>
<li>Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium. 1986;5(5-6):293-300. [PubMed 3807422</li>
<li>Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Thioctic acid tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200201478. Accessed September 1, 2014.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2013</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2020.</li>
<li>Evaluation of Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis and Clinical Implications. Guidance for Industry [Draft]. Available at: https://www.fda.gov/media/144026/download. Accessed July 22, 2021.</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; June 2019.</li>
<li>HalfLytely and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) [prescribing information]. Braintree, MA: Braintree Laboratories Inc; May 2006.</li>
<li>De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</li>
<li>Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010</li>
<li>Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015</li>
<li>Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011</li>
<li>Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc.; April 2023.</li>
<li>Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; January 2021.</li>
<li>Calcijex (calcitriol) injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; March 2012</li>
<li>Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-797. [PubMed 6895034</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;26(15):1093-1115. [PubMed 14640773</li>
<li>Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Cefdinir [prescribing information]. Parsippany, NJ: Ascend Laboratories; January 2018.</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ, Collier PS. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159-163. [PubMed 6292443</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ. In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin. J Trop Med Hyg. 1982;85(4):153-158. [PubMed 7143531</li>
<li>Iwuagwu MA, Aloko KS. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655-658. [PubMed 1359089</li>
<li>Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: sanofi-aventis US LLC; October 2018.</li>
<li>Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology. 1981;80(4):661-665. [PubMed 7202937</li>
<li>Naggar VF, Khalil SA, Gouda MW. Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans. J Pharm Sci. 1978;67(7):1029-1030. [PubMed 207854</li>
<li>Lee DA, Taylor GM, Walker JG, et al. The effect of concurrent administration of antacids on prednisolone absorption. Br J Clin Pharmacol. 1979;8(1):92-94. [PubMed 552304</li>
<li>Tanner AR, Caffin JA, Halliday JW, et al. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol. 1979;7(4):397-400. [PubMed 444359</li>
<li>Albin H, Vincon G, Demotes-Mainard F, et al. Effects of aluminum phosphate on the bioavailability of cimetidine and prednisolone. Eur J Clin Pharmacol. 1984;26(2):271-273. [PubMed 6723769]</li>
<li>Product monograph. Pradaxa (dabigatran etexilate). Burlington, Ontario: Boehringer Ingelheim Canada Ltd., February 2019</li>
<li>Prescribing information. Pradax (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.</li>
<li>Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700-709. [PubMed 19395585</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</li>
<li>Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019</li>
<li>Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2019</li>
<li>Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol. 2003;43(2):171-179. [PubMed 12616670]</li>
<li>Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016</li>
<li>Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015</li>
<li>Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764-776. [PubMed 19446149]</li>
<li>Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45-50. [PubMed 23774876</li>
<li>Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2019</li>
<li>Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2019</li>
<li>Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug-drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:1</li>
<li>[PubMed 30798679]</li>
<li>Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products LP; April 2019.</li>
<li>Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals Inc; October 2016.</li>
<li>Allegra (fexofenadine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2010.</li>
<li>Fosinopril [prescribing information]. Princeton, NJ: Sandoz Inc; May 2013</li>
<li>Apo-fosinopril (fosinopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2008.</li>
<li>Yagi T, Naito Y, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248-254. [PubMed 22240839</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008</li>
<li>Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009</li>
<li>Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490</li>
<li>Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581</li>
<li>Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976</li>
<li>McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345</li>
<li>Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282]</li>
<li>Prescribing information. Anaspaz (hyoscyamine). Lenexa, KS: B. F. Ascher &amp; Compant, Inc., 6/2010</li>
<li>Prescribing information. Hyosyne (hyoscyamine). Spring Valley, NY: Silarx Pharmaceuticals, Inc., 4/2007</li>
<li>Prescribing information. Levsin (hyoscyamine). Marietta, GA: Alaven Pharmaceutical LLC, 2/2008</li>
<li>Prescribing information. Symax SR (hyoscyamine). Ft. Worth, TX: Capellon Pharmaceuticals, LLC, 9/2012</li>
<li>Prescribing information. Oscimin-SR (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011</li>
<li>Prescribing information. Oscimin (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</li>
<li>Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr. 1991;53(1):106-111. [PubMed 1984334</li>
<li>Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol. 2002;42(10):1171-1176. [PubMed 12362933</li>
<li>Wallace KL, Curry SC, LoVecchio F, Raschke RA. Effect of magnesium hydroxide on iron absorption following simulated mild iron overdose in human subjects. Acad Emerg Med. 1998;5(10):961-965. [PubMed 9862585</li>
<li>Hall GJ, Davis AE. Inhibition of iron absorption by magnesium trisilicate. Med J Aust. 1969;2(2):95-96. [PubMed 5803866</li>
<li>Ekenved G, Halvorsen L, Solvell L. Influence of a liquid antacid on the absorption of different iron salts. Scand J Haematol Suppl. 1976;28:65-77. [PubMed 1064903</li>
<li>O'Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Rastogi SP, Padilla F, Boyd CM. Effect of aluminum hydroxide on iron absorption. J Ark Med Soc. 1976;73(3):133-134. [PubMed 134015</li>
<li>Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81(6):1068-1071. [PubMed 7286584</li>
<li>Benkhedda K, L'abbe MR, Cockel KAEffect of calcium on iron absorption in women with marginal iron statusBr J Nutr2010;103(5):742-748[PubMed 19860985</li>
<li>Minihane AM, Fairweather-Tait SJ. Effect of calcium supplementation on daily nonheme-iron absorption and long-term iron status. Am J Clin Nutr. 1998;68(1):96-102. [PubMed 9665102</li>
<li>Dawson-Hughes B, Seligson FH, Hughes VA. Effects of calcium carbonate and hydroxyapatite on zinc and iron retention in postmenopausal women. Am J Clin Nutr. 1986;44(1):83-88. [PubMed 3014855</li>
<li>Spencer BR, Guo Y, Cable RG, et al. Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. Transfusion. 2019;59(10):3146-3156. [PubMed 31318071</li>
<li>Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016;97(6):583-593. [PubMed 27155295</li>
<li>Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001;22(6):490-496. [PubMed 11426238</li>
<li>Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P. Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia/a single-centre randomized controlled isotope study. Arzneimittelforschung. 2007;57(6A):392-400. [PubMed 17691589</li>
<li>Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med. 1999;33(4):400-405. [PubMed 10092717</li>
<li>Miranda M, Olivares M, Brito A, Pizarro F. Reducing iron deficiency anemia in Bolivian school children: calcium and iron combined versus iron supplementation alone. Nutrition. 2014;30(7-8):771-775. [PubMed 24984991]</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced Oral Itraconazole Bioavailability by Antacid Suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236</li>
<li>Sporanox (itraconazole) oral suspension [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Van der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, et al. Disposition of ketoconazole, an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Ketoconazole [prescribing information]. Hoschton, GA: Aavis Pharmaceuticals, LLC; September 2021.</li>
<li>Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022.</li>
<li>Synthroid (levothyroxine sodium) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2009</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669]</li>
<li>Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020</li>
<li>Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Lialda (mesalamine) delayed-release tablets [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; December 2020</li>
<li>Delzicol (mesalamine) delayed-release capsules [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Shire USA Inc; October 2020</li>
<li>Hussain FN, Ajjan RA, Moustafa M, Weir NW, Riley SA. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Br J Clin Pharmacol. 1998;46(2):173-175. [PubMed 9723828</li>
<li>Bashiri H, Bozorgomid A. Protective effect of Asacol in combination with pantoprazole in ulcerative colitis patients who defecate Asacol tablets intactly: a clinical trial study. Clin Exp Gastroenterol. 2020;13:47-51. [PubMed 32158250</li>
<li>Urex (methenamine) [prescribing information]. Wytheville, VA: Vatring Pharmaceuticals, Inc.; December 2006.</li>
<li>Cerklewski FL, “Influence of Dietary Magnesium on Fluoride Bioavailability in the Rat,” J Nutr, 117(3):496-500. [PubMed 3572562</li>
<li>Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” Clin Pharmacol Ther, 1980, 28(4):529-35. [PubMed 7408412</li>
<li>Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002</li>
<li>Spencer H, Kramer L, Osis D, et al, “Effect of Calcium, Phosphorus, Magnesium, and Aluminum on Fluoride Metabolism in Man,” Ann N Y Acad Sci, 1980, 355:181-94. [PubMed 6940475]</li>
<li>O’Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Benjamin IB, Cortell S, Conrad ME. Bicarbonate-induced iron complexes and iron absorption. Gastroenterology. 1967;35:389</li>
<li>Coste JF, De Bari VA, Keil LB, et al. In vitro interactions of oral haematinics and antacid preparations. Curr Ther Res Clin Exp. 1977;22:205.</li>
<li>Cellcept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; December 2019</li>
<li>Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41(6):513-516. [PubMed 8799515</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. Novartis Pharmaceuticals Corporation; April 2020.</li>
<li>Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemother Pharmacol. 2013;71(1):219-226. [PubMed 23070146</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211]</li>
<li>Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulphate. Clin Pharmacol Ther. 1983;33(4):465-470. [PubMed 6831825</li>
<li>Lyle WH. Penicillamine and iron. Lancet. 1976;2(7982):420. [PubMed 73880</li>
<li>Harkness JA, Blake DR. Penicillamine nephropathy and iron. Lancet. 1982;2(8312):1368-1369. [PubMed 6129465]</li>
<li>Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12(1):26-30. [PubMed 8440814</li>
<li>Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Aton Pharma Inc; November 2015.</li>
<li>Phospha 250 Neutral (sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic and sodium phosphate, monobasic, monohydrate) [prescribing information]. Allendale, NJ: Rising Pharmaceuticals, Inc.; June 2012</li>
<li>K-Phos No. 2 (potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</li>
<li>Levofloxacin [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; May 2022</li>
<li>Lomefloxacin [product labeling]. Kolon Pharmaceutical Co., Ltd.; March 2016</li>
<li>Norfloxacin [product monograph]. Vaughan, ON, Canada: AA Pharma Inc.; June 2019</li>
<li>Ofloxacin [summary of product characteristics]. Dublin, Ireland: Gerard Laboratories; June 2022</li>
<li>Pipemidic acid [Korean product labeling]. Aprogen Pharmaceutical Co., Ltd.; January 2014</li>
<li>Ciprofloxacin [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022</li>
<li>Baxdela (delafloxacin) [product labeling]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries; April 2022</li>
<li>Moxifloxacin [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited, May 2019</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Canada: Merus Labs International, Inc.; August 2018</li>
<li>Enoxacin [Korean product labeling]. Seoul, South Korea: Crystal Life Science Co. Ltd; June 2018</li>
<li>Prulifloxacin [summary of product characteristics]. Ancona, Italy: A.C.R.A.F. S.p.A.; February 2022.</li>
<li>Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2(8501):294. [PubMed 2874321</li>
<li>Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids. Lancet. 1986;2(8497)</li>
<li>[PubMed 2873348</li>
<li>Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med. 1988;109(2):168-169. [PubMed 3382110</li>
<li>Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005;27(2):81-82. [PubMed 15999916</li>
<li>Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother. 1991;28(1):87-94. [PubMed 1663108</li>
<li>Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013</li>
<li>Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014</li>
<li>Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005</li>
<li>Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014</li>
<li>Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012</li>
<li>Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013</li>
<li>Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011</li>
<li>Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003</li>
<li>Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017</li>
<li>Pefloxacin tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199101448 Accessed October 26, 2017.</li>
<li>Edurant (rilpivirine) [prescribing information]. Raritan NJ: Tibotec Therapeutics; May 2011</li>
<li>Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</li>
<li>Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October 2013.</li>
<li>Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021;43(6):1079-1091. [PubMed 33962762</li>
<li>Evrenzo (roxadustat) [summary of product characteristics]. Woking, United Kingdom: Astellas Pharma Ltd; September 2022.</li>
<li>Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol. 1997;43(3):269-272. [PubMed 9088581</li>
<li>Sotalol [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; March 2020</li>
<li>Kahela P, Anttila M, Sundgvist H. Antacids and sotalol absorption. Acta Pharmacol Toxicol (Copenh). 1981;49(3):181-183. [PubMed 7336975]</li>
<li>Summary of product characteristics. Protelos (strontium ranelate). Gidy, France: Les Laboratoires Servier Industrie, 7/2012.</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023</li>
<li>Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. Obes Surg. 2014;24(5):741-746. [PubMed 24347350</li>
<li>Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. Obes Surg. 2018;28(8):2252-2260. [PubMed 29556889]</li>
<li>Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013</li>
<li>Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013</li>
<li>Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</li>
<li>Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet. 1962;114:9-14. [PubMed 14498173</li>
<li>Albert KS, Welch RD, DeSante KA, et al. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J Pharm Sci. 1979;68(5):586-588. [PubMed 435335</li>
<li>Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247(16):2266-2267. [PubMed 7040708</li>
<li>Demeclocycline [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; March 2017</li>
<li>Rosenblatt JE, Barrett JE, Brodie JL, et al. Comparison on in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother. 1966;6:134-141. [PubMed 4964450</li>
<li>Garty M, Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976</li>
<li>Nguyen VX, Nix DE, Gillikin S, Schentag JJEffect of oral antacid administration on the pharmacokinetics of intravenous doxycyclineAntimicrob Agents Chemother1989;33(4):434-436[PubMed 2729939</li>
<li>Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther. 1971;12(5):779-784. [PubMed 4936141</li>
<li>Nuzyra (omadacycline) [prescribing information]. Boston, MA: Paratek Pharmaceuticals, Inc.; October 2020</li>
<li>Tetralysal (lymecycline) [summary of product characteristics]. Watford, Herts, UK: Galderma (UK) Limited; June 2020</li>
<li>Seysara (sarecycline) [prescribing information]. Exton, PA: Almirall, LLC; June 2002</li>
<li>Jaffe JM, Poust RI, Feld SL, et al. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974;63(8):1256-1260. [PubMed 4852448]</li>
<li>Garty M and Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Healy DP, Dansereau RJ, Dunn AB, et al. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother. 1997;31(12):1460-1464. [PubMed 9416381</li>
<li>Khalil SA, Daabis NA, Naggar VF, et al. Effect of magnesium trisilicate and citric acid on the bioavailability of tetracycline in man. Pharmazie. 1977;32(8-9):519-522. [PubMed 201941]</li>
<li>Syprine (trientine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016</li>
<li>Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1(8273):643-647. [PubMed 6121964</li>
<li>Cuvrior (trientine) [prescribing information]. Chicago, IL: Orphalan; April 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</li>
<li>Fann WE, Davis JM, Janowsky DS, et al, “Chlorpromazine: Effects of Antacids on its Gastrointestinal Absorption,” J Clin Pharmacol, 1973, 13(10):388-90. [PubMed 4355737</li>
<li>Forrest FM, Forrest IS, and Serra MT, “Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients,” Biol Psychiatry, 1970, 2(1):53</li>
<li>[PubMed 5414905</li>
<li>Moustafa MA, Babhair SA, and Kouta HI, “Decreased Bioavailability of Some Antipsychotic Phenothiazines Due to Interactions With Absorbent Antacid and Antidiarrhoeal Mixtures,” Int J Pharm, 1987, 36:185-9.</li>
<li>Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a 'nonsystemic' antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Dad T, Garimella PS, Strom JA. Quiz: An unusual case of metabolic alkalosis in a patient with CKD. Am J Kidney Dis. 2017;69(1):A13-A16. [PubMed 28007194</li>
<li>JAMP calcium polystyrene sulfonate [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2020.</li>
<li>Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol. 1984;22(11):626-629. [PubMed 6389377]</li>
<li>Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DS, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183</li>
<li>Cefpodoxime proxetil [prescribing information]. Allendale, NJ: Rising Pharmaceuticals Inc; May 2017</li>
<li>Food and Drug Administration Center for Drug Evaluation and Research (CDER). Evaluation of gastric pH dependent drug interactions with acid-reducing agents: Study design, data analysis, and clinical implications (November 2020). Available at: https://www.fda.gov/media/144026/download.</li>
<li>Fann WE, Davis JM, Janowsky DS, Sekerke HJ, Schmidt DM. Chlorpromazine: effects of antacids on its gastrointestinal absorption. J Clin Pharmacol. 1973;12(10):388-390. [PubMed 4355737</li>
<li>Chlorpromazine [prescribing information]. Columbus, OH: American Health Packaging; October 2018</li>
<li>Perphenazine [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2016</li>
<li>Haldol (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2019</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2008.</li>
<li>Allard M, Legare N, Millaud F. A possible case of clozapine interaction with aluminum hydroxide. Schizophr Res. 2008;101(1-3):346. [PubMed 18272349</li>
<li>Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corp., March 2008</li>
<li>Prescribing information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil- Janssen Pharmaceuticals Inc., August 2008</li>
<li>Prescribing information. Seroquel (quetapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009</li>
<li>Prescribing information. Abilify (aripiprazole). Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd., August 2008.</li>
<li>Diacerein [prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198802489. Accessed October 1, 2014.</li>
<li>Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909]</li>
<li>Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis. 1974;109(1):41-47. [PubMed 4588090</li>
<li>Lin M-Y, Lin S-J, Chan L-C, Lu Y-C. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(7):806-818. [PubMed 20550762</li>
<li>Peloquin CA, Namdar R, Dodge AA, Nix DEPharmacokinetics of isoniazid under fasting conditions, with food, and with antacidsInt J Tuberc Lung Dis1999;3(8):703-710[PubMed 10460103</li>
<li>Sun H, Jin T, Wu X, Yang L, Zuo Y, Liao R. Efficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis. J Int Med Res. 2021;49(7):3000605211027736. [PubMed 34311594</li>
<li>Weber V, Abbott TEF, Ackland GL. Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. Br J Anaesth. 2021;126(3):608-621. [PubMed 33218672</li>
<li>Dong J, Gao L, Wenqing L, Xu Z, Zheng J. Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis. PLoS One. 2014;9(12):e114231. [PubMed 25460931</li>
<li>Sinatra RS, Philip BK, Naulty JS, et al. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulphate. Anesth Analg. 1985;64:1220-1222. [PubMed 2865911</li>
<li>Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular-blocking agents. Anesthesiology. 1970;32:23. [PubMed 5460601</li>
<li>Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. Anaesthesia. 1994;49:355-356. [PubMed 8179157</li>
<li>Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology. 1987;67(5):806-808. [PubMed 2890318</li>
<li>Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. Br J Anaesth. 1996;77:669-671. [PubMed 8957990</li>
<li>Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth. 1996;76(4):565-556. [PubMed 8652332</li>
<li>Yoshida A, Itoh Y, Nagaya K, et alProlonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean sectionJ Anesth2006;20(1):33-35[PubMed 16421674</li>
<li>Kwan WF, Lee C, Chen BJ. A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. J Clin Anesth. 1996;8(5):392-397. [PubMed 8832451</li>
<li>Na HS, Lee JH, Hwang, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth. 2010;104(3):344-350. [PubMed 20042475</li>
<li>Telci L, Esen F, Akcora D, et al. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Br J Anaesth. 2002;89(4):591-598. [PubMed 12393361</li>
<li>Aldrete JA, Zahler A, Aikawa JK. Prevention of succinylcholine-induced hyperkalaemia by magnesium sulfate. Can Anaesth Soc J. 1970;17(5):477-484. [PubMed 5506078</li>
<li>Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth. 1995;74(4):405-409.[PubMed 7734259</li>
<li>Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. Br J Anaesth. 2003;91(3):435-438. [PubMed 12925489</li>
<li>De Vore JS, Asrani R. Magnesium sulfate prevents succinylcholine-induced fasciculations in toxemic parturients. Anesthesiology. 1980;52(1):76-77. [PubMed 7352649</li>
<li>Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007;31(2):167-173. [PubMed 17437152</li>
<li>Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. Can J Anaesth. 2005;52(1):88-93. [PubMed 15625263</li>
<li>James MF, Cork RC, Dennett JE. Succinylcholine pretreatment with magnesium sulfate. Anesth Analg. 1986;65(4):373-376. [PubMed 3513667</li>
<li>Fei S, Xia H, Chen X, Pang D, Xu X. Magnesium sulfate reduces the rocuronium dose needed for satisfactory double lumen tube placement conditions in patients with myasthenia gravis. BMC Anesthesiol. 2019;19(1):170. [PubMed 31472669</li>
<li>Micuci AJQR, Vercosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2019;36(7):502-508. [PubMed 30985540</li>
<li>Ghodraty MR, Saif AA, Kholdebarin AR, et al. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012;26(6):858-863. [PubMed 22752440</li>
<li>Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012;29(2):95-55. [PubMed 22183158</li>
<li>Brown AF, Cobert J, Dierkes J, Kuhn CM, Grant SA. Delayed neuromuscular blockade reversal with sugammadex after vecuronium, desflurane, and magnesium administration: a case report. A A Pract. 2019;13(8):295-298. [PubMed 31283534</li>
<li>Unterbuchner C, Ziegleder R, Graf B, Metterlein T. Magnesium-induced recurarisation after reversal of rocuronium-induced neuromuscular block with sugammadex. Acta Anaesthesiol Scand. 2015;59(4):536-540. [PubMed 25582520</li>
<li>de Almeida CED, de Carvalho LR, Andrade CVC, do Nascimento Jr P, de Barros GAM, Modolo NSP. Effects of magnesium sulphate on the onset time of rocuronium at different doses: a randomized clinical trial. Braz J Anesthesiol. 2021;71(5):482-488. [PubMed 34403648</li>
<li>James MF, Schenk PA, van der Veen BW. Priming of pancuronium with magnesium. Br J Anaesth. 1991;66(2):247-249. [PubMed 1817630</li>
<li>Stacey MR, Barclay K, Asai T, et al. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Anaesthesia. 1995;50(11):933-936. [PubMed 8678246</li>
<li>Nimbex (cisatracurium) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2018</li>
<li>Quelicin (succinylcholine) [prescribing information]. Lake Forest, IL: Hospira, Inc.; August 2021</li>
<li>Atracurium [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2018</li>
<li>Pancuronium [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2019</li>
<li>Rocuronium [prescribing information]. Lehi, UT: Civica, Inc.; July 2020.</li>
<li>Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231-1235. [PubMed 18355422</li>
<li>Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.</li>
<li>Foresti V. Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Sodium polystyrene sulfonate [prescribing information]. Rahway, NJ: Sunrise Pharmaceutical, Inc.; March 2020.</li>
<li>Prograf (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; August 2009</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med. 1994;97(4):363-365. [PubMed 7942938</li>
<li>Morini E, Catalano A, Lasco A, Morabito N, Benvenga S. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. [PubMed 30919287</li>
<li>Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-486. [PubMed 21595516</li>
<li>Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med. 1992;152(1):183-184. [PubMed 1728914</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669</li>
<li>Levothyroxine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; September 2022</li>
<li>Ermeza (levothyroxine) oral solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022.</li>
<li>Regardh CG, Lundborg P, Persson BA. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Biopharm Drug Dispos. 1981;2(1):79-87. [PubMed 7236872</li>
<li>Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. Clin Pharmacol Ther. 1981;30(4):429-435. [PubMed 7285476]</li>
<li>Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 1991;31(2):164-167. [PubMed 1849152</li>
<li>Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 2003;17(3):563-577. [PubMed 14711077</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</li>
<li>Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; February 2011</li>
<li>Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998;4:941-948. [PubMed 9563888</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2016 [published October 13, 2016]. doi:10.1001/jamaoncol.2016.3358. [PubMed 27737436</li>
<li>Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104. [PubMed 11286326]</li>
<li>Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med. 1976;295(19):1034-1037. [PubMed 972657</li>
<li>Allen MD, Greenblatt DJ, Harmatz JS, Smith TW. Effect of magnesium-aluminum hydroxide and kaolin-pectin on absorption of digoxin from tablets and capsules. J Clin Pharmacol. 1981;21(1):26-30. [PubMed 7012189</li>
<li>Cooke J, Smith JA. Absence of interaction of digoxin with antacids under clinical conditions. Br Med J. 1978;2(6145):1166-1167. [PubMed 709293]</li>
<li>Radwanski E, Nomeir A, Cutler D, Affrime M, Lin CC. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double-strength liquid or with ranitidine. Am J Ther. 1998;5(2):67-72. [PubMed 10099040</li>
<li>Cedax (ceftibuten) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2015.</li>
<li>Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. Clin Pharmacol Ther. 1976;19(2):234-239. [PubMed 770046]</li>
<li>Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. Clin Pharmacol Ther. 1978;24(3):308-315. [PubMed 28870</li>
<li>Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS. Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. Clin Pharmacol Ther. 1982;31(2):180-183. [PubMed 6120059</li>
<li>Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD. Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther. 1977;22(3):329-335. [PubMed 19188</li>
<li>Tranxene (clorazepate dipotassium) [prescribing information]. Barceloneta, PR: AbbVie LTD; September 2016.</li>
<li>Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI. Diazepam absorption: effect of antacids and food. Clin Pharmacol Ther. 1978;24(5):600-609. [PubMed 699484</li>
<li>Nair SG, Gamble JA, Dundee JW, Howard PJ. The influence of three antacids on the absorption and clinical action of oral diazepam. Br J Anaesth. 1976;48(12):1175-1180. [PubMed 1023953</li>
<li>Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI. Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. J Clin Pharmacol. 1984;24(5-6):255-263. [PubMed 6747022</li>
<li>Valium (diazepam) [prescribing information]. South San Francisco, CA: Hoffman-La Roche; December 2016.</li>
<li>Yamreudeewong W, Scavone JM, Paone RP, Lewis GP. Effect of antacid coadministration on the bioavailability of erythromycin stearate. Clin Pharm. 1989;8(5):352-354. [PubMed 2743731]</li>
<li>Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333-342. [PubMed 688726]</li>
<li>Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49(1):467-469. [PubMed 15616339</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2019.</li>
<li>Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm. 1998;46(3):299-303. [PubMed 9885302]</li>
<li>Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. Drug Intell Clin Pharm. 1986;20(10):792-795. [PubMed 3769772</li>
<li>Burland WL, Darkin DW, Mills MW. Effect of antacids on absorption of cimetidine. Lancet. 1976;2(7992):965. [PubMed 62195</li>
<li>Bodemar G, Norlander B, Walan A. Diminished absorption of cimetidine caused by antacids. Lancet. 1979;1(8113):444-445. [PubMed 84296</li>
<li>Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. N Engl J Med. 1982;307(7):400-404. [PubMed 708843</li>
<li>Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29(7):670-672. [PubMed 2569486</li>
<li>Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol. 1987;24(4):551-553. [PubMed 2891370</li>
<li>Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces the bioavailability of ranitidine. Br Med J. 1982;285(6347):998-999. [PubMed 6289961</li>
<li>Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol. 1990;42(5):352-354. [PubMed 1976784</li>
<li>Donn KH, Eshelman FN, Plachetka JR, et alThe effects of antacid and propantheline on the absorption of oral ranitidinePharmacotherapy1984;4(2):89-92[PubMed 6326064</li>
<li>Sullivan TJ, Reese JH, Jauregui L, Miller K, Levine L, Bachmann KA. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. Aliment Pharmacol Ther. 1994;8(1):123-126. [PubMed 7910488]</li>
<li>Tanatril (imidapril) [summary of product characteristics]. London, UK: Mitsubishi Tanabe Pharma Europe Limited; December 2014.</li>
<li>Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663</li>
<li>Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029]</li>
<li>Kristalose (lactulose) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; July 2018</li>
<li>Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663]</li>
<li>Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</li>
<li>Livtencity (maribavir) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2021.</li>
<li>Segre EJ, Sevelius H, Varady J. Letter: Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583. [PubMed 4852768</li>
<li>Weber SS, Bankhurst AD, Mroszczak E, Ding TL. Effect of Mylanta on naproxen bioavailability. Ther Drug Monit. 1981;3(1):75-83. [PubMed 7233492</li>
<li>Naprosyn (naproxen) [prescribing information]. Apharetta, GA: Canton Laboratories, LLC.; April 2021.</li>
<li>Ismail FA, Khalafallah N, Khalil SA. Absorption of ketoprofen and bumadizone calcium on aluminum-containing antacids and its effect on ketoprofen bioavailability in man. Int J Pharm. 1987;34:189-196</li>
<li>Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6 Pt 2):33S-39S (review). [PubMed 2082311</li>
<li>Holmes GI, et al. Effects of Maalox on the bioavailability of diflunisal. Clin Pharmacol Ther. 1979;25:229</li>
<li>Verbeeck R, Tjandramaga TB, Mullie A, et al. Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol. 1979;7(5):519-522. [PubMed 314299</li>
<li>Segre EJ, Sevelium H, Varady J. Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583 (letter). [PubMed 4852768</li>
<li>Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; January 2011</li>
<li>von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone - A novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Tox. 1983;21(6):311-321. [PubMed 6688407</li>
<li>Shaker MA, Akhtar N, Minhas MU, Khan KU, Zangi MI, Munir A. Effect of an Al-Mg hydroxide antacid and food on the pharmacokinetics of dexibuprofen. Drug Res (Stuttg). 2020;70(4):158-164. [PubMed 32110819]</li>
<li>Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</li>
<li>Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. Br J Clin Pharmacol. 1978;6(2):177-179. [PubMed 678395</li>
<li>Garnett WR, Carter BL, Pellock JM. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1980;37(7):467. [PubMed 7387502</li>
<li>Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-340. [PubMed 7336470</li>
<li>McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Br J Clin Pharmacol. 1982;13(4):501-505. [PubMed 7066165</li>
<li>Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1979;36(7):436-438. [PubMed 454247</li>
<li>O'Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol. 1978;6(2):176-177. [PubMed 678394</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</li>
<li>Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115(1):12-18. [PMID 9925057</li>
<li>Gupta PR, Mehta YR, Gupta ML, Sharma TN, Jain D, Gupta RB. Rifampin-aluminium antacid interaction. J Assoc Physicians India. 1988;36(6):363-364. [PubMed 3182711</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifadin (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifamate (rifampin/isoniazid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2013</li>
<li>Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2010</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2009.</li>
<li>Itthipanichpong C, Sirivongs P, Wittayalertpunya S, Chaiyos N. The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Drug Metabol Drug Interact. 1992;10(3):213-228. [PubMed 1424642</li>
<li>Gaspari F, Vigano G, Locatelli M, Remuzzi G. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis. 1988;11(4):338-342. [PubMed 3354570</li>
<li>Shastri RA. Effect of antacids on salicylate kinetics. Int J Clin Pharmacol Ther Toxicol. 1985;23(9):480-484. [PubMed 4055159</li>
<li>Levy G, Lampman T, Kamath BL, et al. Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. N Engl J Med. 1975;293(7):323-325. [PubMed 239345</li>
<li>Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol. 1980;20(5-6 Pt 1):326-331. [PubMed 7400368</li>
<li>Macpherson CR, Milne MD, Evans BM. The excretion of salicylate. Br J Pharmacol Chemother. 1955;10(4):484-489. [PubMed 13276608</li>
<li>Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. Br J Clin Pharmacol. 1982;14(4):562-564. [PubMed 7138740</li>
<li>Feldman S, Carlstedt BC. Effect of antacid on absorption of enteric-coated aspirin. JAMA. 1974;227(6):660-661 (letter). [PubMed 4405837</li>
<li>Strickland-Hodge B, Thomas TR, Gould WA, et al. The effects of antacids on enteric-coated salicylate preparations. Rheumatol Rehabil. 1976;15(3):148-152. [PubMed 968338]</li>
<li>Kivisto KT, Neuvonen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1992;42(6):675-679. [PubMed 1623912</li>
<li>Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol. 1991;32(2):215-220. [PubMed 1931470</li>
<li>Zuccaro P, Pacifici R, Pichini S, et al. Influence of antacids on the bioavailability of glibenclamide. Drugs Exp Clin Res. 1989;15(4):165-169. [PubMed 2505996</li>
<li>Kivisto KT, Lehto P, Neuvonen PJ. The effects of different doses of sodium bicarbonate on the absorption and activity of nonmicronized glibenclamide. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):236-240. [PubMed 8390970</li>
<li>Kivisto KT, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminum hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol. 1991;40(4):383-386. [PubMed 1646724</li>
<li>Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther. 1991;49(1):39-43. [PubMed 1988239</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976]</li>
<li>Arnold LA, Spurbeck GH, Shelver WH, Henderson WM. Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm. 1979;36(8):1059-1062. [PubMed 484565</li>
<li>Reed RC, Schwartz HJ. Lack of influence of an intensive antacid regimen on theophylline bioavailability. J Pharmacokinet Biopharm. 1984;12(3):315-331. [PubMed 6502473</li>
<li>Darzentas LJ, Stewart RB, Curry SH, Yost RL. Effect of antacid on bioavailability of a sustained-release theophylline preparation. Drug Intell Clin Pharm. 1983;17(7-8):555-557. [PubMed 6872853</li>
<li>Muir JF, Peiffer G, Richard MO, et al. Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation. Eur J Clin Pharmacol. 1993;44(1):85-88. [PubMed 8436162</li>
<li>Ferrari M, Olivieri M, Romito D, Biasin C, Barozzi E, Bassetti S. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline. Riv Eur Sci Med Farmacol. 1991;13(5-6):269-274. [PubMed 1819857</li>
<li>Fernandes E, Melewicz FM. Antacids and theophylline-ranitidine interaction. Ann Intern Med. 1984;101(2):279. [PubMed 6331245</li>
<li>Myhre KI, Walstad RA. The influence of antacid on the absorption of two different sustained-release formulations of theophylline. Br J Clin Pharmacol. 1983;15(6):683-687. [PubMed 6871067</li>
<li>Shargel L, Stevens JA, Fuchs JE, Yu AB. Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. J Pharm Sci. 1981;70(6):599-602. [PubMed 7252799</li>
<li>Theophylline oral solution [prescribing information]. Congers, NY: Chartwell RX LLC; October 2022.</li>
<li>Rudzki P, Jarus-Dziedzic K, Filist M, et al. Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacol Rep. 2021;73(2):604-614 [PubMed 33686610]</li>
<li>Kroboth PD, Smith RB, Silver MR, et al. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol. 1985;19(6):839-842. [PubMed 2862896]</li>
<li>May CA, Garnett WR, Small RE, et al, “Effects of Three Antacids on the Bioavailability of Valproic Acid,” Clin Pharm, 1982, 1(3):244</li>
<li>[PubMed 6821035]</li>
<li>Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990;34(10):2032-2033. [PubMed 2291673</li>
<li>Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236]</li>
<li>Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804-808. [PubMed 14982768</li>
<li>Kraft WK, Chang PS, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020-4025. [PubMed 24798274</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2022.</li>
<li>Exjade (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2020.</li>
<li>Relyvrio (sodium phenylbutyrate and taurursodiol) [prescribing information]. Cambridge, MA: Amylyx Pharmaceuticals Inc; September 2022.</li>
<li>Weissman I, Krivoy N. Interaction of aluminum hydroxide and allopurinol in patients on chronic hemodialysis. Ann Intern Med. 1987;107(5):787. [PubMed 3662305]</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Effect of ascorbic acid on gastrointestinal aluminum absorption. Lancet. 1991;338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int. 1991;39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654</li>
<li>Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9-11. [PubMed 2913801</li>
<li>Main J, Ward MK. Potentiation of aluminum absorption by effervescent analgesic tablets in a haemodialysis patient. Br Med J. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol. 1989;31(1):40-44. [PubMed 2914409]</li>
<li>Foresti V. Intestinal obstruction due to Kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Garcia-Pardo G, Martinez-Vea A, Auguet T, et al. Intestinal obstruction complicating calcium polystyrene sulphonate therapy. Nephrol Dial Transplant. 1996;11(4):751. [PubMed 8671882</li>
<li>Hurley JK. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel. J Pediatr. 1978;92(4):592-593. [PubMed 633020</li>
<li>Calcium Resonium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., April 2006.</li>
<li>Cholbam (cholic acid) [prescribing information]. Baltimore, MD: Asklepion Pharmaceuticals LLC; March 2015.</li>
<li>Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</li>
<li>Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568-572. [PubMed 10049268</li>
<li>Myambutol (ethambutol) [prescribing information]. Langhorne, PA: STI Pharma LLC; April 2012</li>
<li>Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol. 1978;5(2):161-166. [PubMed 619949]</li>
<li>Prescribing information. Neurontin (gabapentin). New York, NY: Pfizer Inc; October 2017.</li>
<li>Mircol (mequitazine) [summary of product characteristics]. Madrid, Spain: ITF Medilab Farma, SA; July 2013.</li>
<li>Moxifloxacin [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; November 2022.</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” Lancet, 1991, 338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” Kidney Int, 1991, 39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” Am J Kid Dis, 1991, 17(6):708-11. [PubMed 2042654</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ, 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” Clin Nephrol, 1989, 31(3):123</li>
<li>[PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” Clin Nephrol, 1986, 26(3):146</li>
<li>[PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” Proc Eur Dial Transplant Assoc Eur Ren Assoc, 1985, 21:390</li>
<li>[PubMed 3991529</li>
<li>Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” Am J Physiol, 1985, 249(2 Pt 1):G209-13. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205. [PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” J Lab Clin Med, 1986, 108(2):96-102. [PubMed 3755457]</li>
<li>Moon J, Davison A, Bandy B. Vitamin D and aluminum absorption. CMAJ. 1992;147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol. 1989;31(3):123-127. [PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Clin Nephrol. 1986;26(3):146-149. [PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:390-394. [PubMed 3991529</li>
<li>Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol. 1985;249(2 Pt 1):G209-G213. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et alAbsorption, deposition and distribution of dietary aluminium in immature rats: effects of dietary vitamin D3 and food-borne chelating agentJ Environ Sci Health B1986;21(2):191-205[PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al. 1,25-dihydroxyvitamin D3 increases serum and tissue accumulation of aluminum in rats. J Lab Clin Med. 1986;108(2):96-102. [PubMed 3755457]</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Urso 250 / Urso Forte (ursodiol) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2021</li>
<li>Actigall (ursodiol) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc.; September 2002</li>
<li>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. [PubMed 30070375]</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 Alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 Alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Zemplar (paricalcitol) capsules [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Rocaltrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Zemplar (paricalcitol) injection [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>Dovonex (calcipotriene) cream [prescribing information]. Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]Greenville, NC: Mayne Pharma; May 2019</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018</li>
<li>Vitamin D (ergocalciferol) [prescribing information]. Laurelton, NY: Epic Pharma, LLC: October 2018.</li>
<li>Chenodol (chenodiol) [prescribing information]. San Diego, CA: Retrophin, Inc; June 2015.</li>
<li>Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J. 1994;87(9):894-898. [PubMed 8091252</li>
<li>Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr. 1994;48(1):71-73. [PubMed 8200332</li>
<li>Nestel AW, Meyers AM, Paiker J, Rollin HB. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients. Nephron. 1994;68(2):197-201. [PubMed 7830856</li>
<li>Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study. South Med J. 1993;86(12):1385-1388. [PubMed 8272917</li>
<li>Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs. 1991;14(10):625-629. [PubMed 1748529</li>
<li>Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; June 2019</li>
<li>Envarsus XR (tacrolimus extended-release) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Spencer H, Kramer L, Norris C, et al. Effect of aluminum hydroxide on fluoride metabolism. Clin Pharmacol Ther. 1980;28(4):529-535. [PubMed 7408412]</li>
<li>Hong CY, Hu SC, Lin SJ, Chiang BN. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Clin Pharmacol Ther Toxicol. 1985;23(5):244-246. [PubMed 4008113</li>
<li>Inderal (propranolol) tablets [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals LLC; March 2011.</li>
<li>PhosLo (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2011.</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4:345. [PubMed 3160584</li>
<li>Schentag JJ, Watson WA, Nix DE, et al. Time-dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther. 1988;43:135</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36:1219-1234. [PubMed 1329615</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulphate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36:2270-2274. [PubMed 1444308</li>
<li>Sahai J, Healey DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302-304. [PubMed 8471407</li>
<li>Frost RW, Lettieri JT, Noe A, et al. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin Pharmacol Ther. 1989;45:165</li>
<li>Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34:432-435. [PubMed 2334155</li>
<li>Kays MB, Overholser BR, Mueller BA, et alEffects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacinAm J Kidney Dis2003;42(6):1253-1259[PubMed 14655198</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014</li>
<li>Federspiel J, Bukhari MJ, Hamill MM. Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. BMJ Case Rep. 2021;14(1):e236655. [PubMed 33408101</li>
<li>Gunnarsson PO, Davidson T, Andersson SB, et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189-193. [PubMed 2338118</li>
<li>Emcyt (estramustine) [prescribing information]. New York, NY: Pharmacia and Upjohn Company; June 2007.</li>
<li>Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” Am J Clin Nutr, 2007, 85(1):6-18. [PubMed 17209171</li>
<li>Peacock M, “Calcium Metabolism in Health and Disease,” Clin J Am Soc Nephrol, 2010, 5 Suppl 1:S23-30. [PubMed 20089499</li>
<li>Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” Cochrane Database Syst Rev, 2011, (7):CD007470. [PubMed 21735411]</li>
<li>Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr. 2002;21(3):239-244. [PubMed 12074251</li>
<li>Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22. [PubMed 9554821]</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439]</li>
<li>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018. Available at https://aidsinfo.nih.gov. (Accessed 06/24/2019</li>
<li>HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. (Accessed 06/24/2019</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494]</li>
<li>Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; June 2009</li>
<li>Minocin (minocycline) [prescribing information]. Cranford, NJ: Triax Pharmaceuticals, LLC; August 2010</li>
<li>Vibramycin (doxycycline) [prescribing information]. New York, NY: Pfizer Inc; April 2007</li>
<li>Jung H, Peregrina AA, Rodriguez JM, et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos. 1997;18(5):459-463. [PubMed 9210983]</li>
<li>Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822-2825. [PubMed 10838651</li>
<li>Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11:967-971. [PubMed 11716045</li>
<li>Mazokopakis EE, Giannakopoulos TG, Starakis IK. Interaction between levothyroxine and calcium carbonate. Can Fam Physician. 2008;54(1):39. [PubMed 18208953</li>
<li>Csako G, McGriff NJ, Rotman-Pikielny P, et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35(12):1578-1583. [PubMed 11793625</li>
<li>Butner LE, Fulco PP, Feldman G. Calcium carbonate-induced hypothyroidism. Ann Intern Med. 2000;132(7):595. [PubMed 10744606</li>
<li>Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA. 1998;279(10):750. [PubMed 9508149</li>
<li>A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Diskin CJ, Stokes TJ, Dansby LM, et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol. 2007;39(2):599-602. [PubMed 17216296]</li>
<li>Salerno DM, Anderson B, Sharkey PH, et al, “Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia With and Without Calcium Pretreatment,” Ann Intern Med, 1987, 107(5):623</li>
<li>[PubMed 3662276</li>
<li>Haft JI and Habbab MA, “Treatment of Atrial Arrhythmias. Effectiveness of Verapamil When Preceded by Calcium Infusion,” Arch Intern Med, 1986, 146(6):1085</li>
<li>[PubMed 3718093</li>
<li>Schoen MD, Parker RB, Hoon TJ, et al, “Evaluation of the Pharmacokinetics and Electrocardiographic Effects of Intravenous Verapamil With Intravenous Calcium Chloride Pretreatment in Normal Subjects,” Am J Cardiol, 1991, 67(4):300</li>
<li>[PubMed 1990794</li>
<li>O’Quinn SV, et al, “Influence of Calcium on the Hemodynamic and Anti-ischemic Effects of Nifedipine Observed During Treadmill Exercise Testing,” Pharmacotherapy, 1990, 10:247 (abstract)</li>
<li>Wohns DH, Patterson JH, Clarke S, et al, “Influence of Calcium Administration on the Short-term Hemodynamic and the Anti-ischemic Effects of Nifedipine,” J Am Coll Cardiol, 1991, 18(4):1070</li>
<li>[PubMed 1894852</li>
<li>Bar-Or D and Gasiel Y, “Calcium and Calciferol Antagonize Effect of Verapamil in Atrial Fibrillation,” Br Med J, 1981, 282(6276):1585</li>
<li>[PubMed 6786574]</li>
<li>Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75(887):554-556. [PubMed 10616693</li>
<li>Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth Analg. 1972;51(2):202-205. [PubMed 5062119</li>
<li>Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA. 1978;240(6):533-534. [PubMed 671662</li>
<li>Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. Br Med J. 1978;1(6108):279-280. [PubMed 620306</li>
<li>Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507. [PubMed 5418023]</li>
<li>Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992;101(1):174-180. [PubMed 1729065]</li>
<li>Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriat Soc. 1984;32(5):405-407. [PubMed 6715769</li>
<li>Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121(5):591-594. [PubMed 497950</li>
<li>Gora ML, Seth SK, Bay WH, Visconti JA. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm. 1989;8(3):227-229. [PubMed 2706898</li>
<li>Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55-59. [PubMed 5305802</li>
<li>Rehan MA, Rashid A, Krell K, Gabutti C, Singh R. Calcium alkali thiazide syndrome: what we need to know. Cureus. 2020;12(10:e10856. [PubMed 33178509</li>
<li>Morini L, Doneli D, Santi R, et al. Severe milk-alkali syndrome in a patient with hypoparathyroidism associated with 1,25(OH)2D, hydrochlorothiazide and anthranoid laxative consumption. Eur J Case Rep Intern Med. 2017;4(10):000729. [PubMed 30755914</li>
<li>Singh A, Ashraf A. Hypercalcemic crisis induced by calcium carbonate. Clin Kidney J. 2012;5(4):288-291. [PubMed 25874082</li>
<li>Parvez B, Emuwa C, Faulkner ML, Murray JJ. Milk alkali and hydrochlorothiazide: a case report. Case Rep Med. 2011;2011:729862. [PubMed 21738535]</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>One-Alpha drops (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Dovonex (calcipotriene) [prescribing information]. Dublin, Ireland: LEO Laboratories Ltd.; March 2015</li>
<li>Rocalctrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Vectical (calcitriol) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019</li>
<li>Ergocalciferol [prescribing information]. Laurelton, NY: Epic Pharma, LLC; October 2018.</li>
<li>Flura-Drops (sodium fluoride) [prescribing information]. Lake Oswego, OR: Kirkman Laboratories Inc; September 2019.</li>
<li>Borel P, Desmarchelier C, Dumont U, et. al. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. Br J Nutr. 2016;116(12):2091-2096. [PubMed 28069089]</li>
<li>Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(suppl 1):27-32. [PubMed 11352439</li>
<li>Moxifloxacin [prescribing information]. Levittown, PA: Torrent Pharma Inc; January 2022.</li>
<li>Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016.</li>
<li>Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351-352. [PubMed 22678358</li>
<li>Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; August 2020.</li>
<li>Klein CE, Chiu YL, Cai Y, et al, “Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir,” J Clin Pharmacol, 2008, 48(5):553-62. [PubMed 18440920]</li>
<li>Wang X, Boffito M, Zhang J, et al, “Effects of the H2-Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir with or without Tenofovir in HIV-Infected Patients,” AIDS Patient Care STDS, 2011, 25(9):509-15. [PubMed 21770762</li>
<li>Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, February 2012.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; September 2018.</li>
<li>Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; October 2016</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908]</li>
<li>Saito Y, Takekuma Y, Kobayashi M, et al. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(3):381-388. [PubMed 33029650</li>
<li>Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410</li>
<li>Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004;44(8):919-927. [PubMed 15286096</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018.</li>
<li>Mchavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347</li>
<li>Ketoconazole [prescribing information]. Mason, OH: Burel Pharmaceuticals, LLC; September 2021.</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017</li>
<li>Chiu Y-L, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV infected patients. AIDS Patient Cre STDS. 2007;21(4):247-251. [PubMed 17461719</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451</li>
<li>Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985;38(6):652-655. [PubMed 2933205</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RMW. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958-966. [PubMed 17210768]</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc.; February 2020</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584]</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013</li>
<li>Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis. 2008;46(10):1627; author reply 1627</li>
<li>[PubMed 18419503</li>
<li>Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207-12. [PubMed 19858252</li>
<li>Vehreschild JJ, Muller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987-95. [PubMed 22286158</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-10[PubMed 22890761]</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; March 2022.</li>
<li>Invirase (saquinavir) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; December 2003.</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</li>
<li>Saathoff N, Lode H, Neider K, Kepperman KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Cefpodoxime [prescribing information]. Princeton, NJ: Sandoz GmbH for Sandoz Inc; February 2014.</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine After Heart Transplantation: Experimental and Clinical Results,” J Heart Lung Transplant, 1993, 12(6 Pt 1):987-92. [PubMed 8312324</li>
<li>D'Souza MJ, Pollock SH, Solomon HM, “Cyclosporine-Cimetidine Interaction,” Drug Metab Dispos, 1988, 16(1):57</li>
<li>[PubMed 2894956</li>
<li>Shaefer MS, Rossi SJ, McGuire TR, et al, “Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men,” Ann Pharmacother, 1995, 29(11):1088-91. [PubMed 8573949</li>
<li>Jadoul M and Hene RJ, “Ranitidine and the Cyclosporine Treated Recipient,” Transplantation, 1989, 48(2):359. [PubMed 2667215</li>
<li>Tsang VT, Johnston A, Heritier F, et al, “Cyclosporine Pharmacokinetics in Heart-Lung Transplant Recipients With Cystic Fibrosis Effects of Pancreatic Enzymes and Ranitidine,” Eur J Clin Pharmacol, 1994, 46(3):261</li>
<li>[PubMed 8070508</li>
<li>Jarowenko MV, Van Buren CT, Kramer WG, et al, “Ranitidine, Cimetidine, and the Cyclosporine-Treated Recipient,” Transplantation, 1986, 42(3):311</li>
<li>[PubMed 3529532]</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; February 2020</li>
<li>Doxofylline tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200101732. Accessed December 15, 2015.</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2019</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084. [PubMed 12461038]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413</li>
<li>Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2009.</li>
<li>Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med. 1987;107(2):261-262. [PubMed 3111324</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514</li>
<li>DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi Aventis US; July 2016.</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016.</li>
<li>Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol. 1984;18(2):175-181. [PubMed 6091709</li>
<li>Rocci ML Jr, Kosoglou T, Ferguson RK, Vlasses PH. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. J Pharmacol Exp Ther. 1989;248(3):923-928. [PubMed 2467982</li>
<li>Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Ther Drug Monit. 1987;9(4):378-383. [PubMed 2447687</li>
<li>Ranitidine [prescribing information]. East Winsor, NJ: Novitium Pharma LLC; September 2018.</li>
<li>O'Conner-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther. 2001;70(2):126-31. [PubMed 11503006</li>
<li>Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm. 1991;10(7):539-43. [PubMed 1860302</li>
<li>Halcion (triazolam) [prescribing information]. New York, NY: Pfizer Inc,; October 2019.</li>
<li>Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med. 1990;112(1):76-77. [PubMed 2293824</li>
<li>Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin clearance after ranitidine and cimetidine. Clin Pharmacol Ther. 1984;35(3):338-341. [PubMed 6321081</li>
<li>O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144(5):989-991. [PubMed 6324710</li>
<li>Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32(2):165-172. [PubMed 3582481</li>
<li>Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12(6):791-794. [PubMed 6122462</li>
<li>Powell JR, Donn KH. The pharmacokinetic basis for h2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95-113. [PubMed 6140286]</li>
<li>Gertz BJ, Holland SD, Kline WF, et al, “Studies of the Oral Bioavailability of Alendronate,” Clin Pharmacol Ther, 1995, 58(3):288-98. [PubMed 7554702</li>
<li>Prescribing information. Fosamax (alendronate). Whitehouse Station, NJ: Merck &amp; Co., Inc., 04/2013</li>
<li>Prescribing information. Binosto (alendronate). San Antonio, TX: Mission Pharmacal, 4/2013</li>
<li>Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” Arch Intern Med, 2011, 171(11):998-1004. [PubMed 21321287</li>
<li>Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” Endokrynol Pol, 2011, 62(1):84</li>
<li>Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” Bone, 2010, 47(2):169-80. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” Drug Saf, 2009, 32(9):775-85. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” Osteoporos Int, 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” Osteoporos Int, 2012, 23(1):277-84. [PubMed 21365461]</li>
<li>Piqray (alpelisib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; June 2022.</li>
<li>Perveen S, Gauhar S, Yousuf RI, Ali H, Zafar F, Sheikh AF. Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan. PLoS One. 2022;17(5):e0267791. [PubMed 35609024</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502]</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360</li>
<li>Diacetylmorphine (diamorphine) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc.; February 2022</li>
<li>Diamorphine [summary of product characteristics]. Middlesex, United Kingdom: Accord Healthcare Limited; May 2020.</li>
<li>Esposito R. Cimetidine and iron-deficiency anaemia. Lancet. 1977;2(8048):1132. [PubMed 73039</li>
<li>Bianchi FM, Cavassini GB, Leo P. Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):209-217. [PubMed 8100220</li>
<li>Partlow ES, Campbell NR, Chan SC, Pap KM, Granberg K, Hasinoff BB. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. Clin Pharmacol Ther. 1996;59(4):389-393. [PubMed 8612382]</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055</li>
<li>Ueno T, Miyajima Y, Landry I, Lalovic B, Schuck E. Physiologically based pharmacokinetic modeling to predict drug interaction of lemborexant with CYP3A inhibitors. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):455-466. [PubMed 33704920</li>
<li>Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int. 2005;67(3):1152-1160. [PubMed 15698457</li>
<li>Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369-376. [PubMed 10223772</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451]</li>
<li>U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360]</li>
<li>Mirapex ER (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014</li>
<li>Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33(4):495-499. [PubMed 15640376]</li>
<li>Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251-2257. [PubMed 18786302</li>
<li>Donn KH, Eshelman FN, Plachetka JR, Fabre L, Powell JR. The effects of antacid and propantheline on the absorption of oral ranitidine. Pharmacotherapy. 1984;4(2):89-92. [PubMed 6326064]</li>
<li>Machavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347]</li>
<li>Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410]</li>
<li>Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;58:663-687. [PubMed 29309257</li>
<li>Li TT, An JX, Xu JY, Tuo BG. Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver. World J Clin Cases. 2019;7(23):3915-3933. [PubMed 31832394]</li>
<li>Poudel RR, Kafle NK. Tizanidine-induced acute severe cystitis in a female taking famotidine. Clin Pharmacol. 2015;7:83-85. [PubMed 26251632</li>
<li>Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013</li>
<li>Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 1993;24(3):255-258. [PubMed 8462230</li>
<li>Bachmannn K, Sullivan TJ, Reese JH, et al. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 1995;35(5):529-535. [PubMed 7657856</li>
<li>Verdiani P, Di Carlo S, Baronti AFamotidine effects on theophylline pharmacokinetics in subjects affected by COPDComparison with cimetidine and placeboChest1988;94(4):807-810[PubMed 3168576</li>
<li>Sunlenca (lenacapavir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; November 2022.</li>
<li>Nexterone (amiodarone) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2021.</li>
<li>Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987;27(10):813-816. [PubMed 3323258</li>
<li>Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011;55(7):3091-3098. [PubMed 21518836]</li>
<li>Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; August 2019</li>
<li>Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol. 2000;49(1):64-71. [PubMed 10606839]</li>
<li>Ellence (epirubicin hydrochloride). New York, NY: Pfizer Inc.; July 2019</li>
<li>Murray LS, Jodrell DI, Morrison JG, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol). 1998;10(1):35-38. [PubMed 9543613]</li>
<li>Veozah (fezolinetant) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2023.</li>
<li>Plaquenil (hydroxychloroquine) [prescribing information]. Dublin, Ireland: Amdipharm Limited; May 2021</li>
<li>Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65(1):10-20. [PubMed 9951426</li>
<li>Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20(3):317-324. [PubMed 10831018</li>
<li>Orap (pimozide) [prescribing information]. Horsham, PA: Teva Pharmaceuticals USA; March 2014.</li>
<li>Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol. 1997;37(11):1056-1061. [PubMed 9505999</li>
<li>Serdolect (sertindole) [summary of product characteristics]. Valby, Denmark: Lundbeck AS; March 2021.</li>
<li>Volkin RL, Shadduck RK, Winkelstein A, Zeigler ZR, Selker RG. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med. 1982;142(2):243-245. [PubMed 7059252</li>
<li>Selker RG, Moore P, LoDolce D. Bone-marrow depression with cimetidine plus carmustine. N Engl J Med. 1978;299(15):834. [PubMed 692572</li>
<li>BiCNU (carmustine) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2021</li>
<li>Dorr RT, Soble MJ. H2-antagonists and carmustine. J Cancer Res Clin Oncol. 1989;115(1):41-46. [PubMed 2564000]</li>
<li>Kirch W, Janisch HD, Ohnhaus EE, van Peer A. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit. 1989;11(4):411-414. [PubMed 2741189]</li>
<li>Priskorn M, Larsen F, Segonzac A, et al. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 1997;52:241-242. [PubMed 9218934</li>
<li>Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci. 2011;32(3):507-509. [PubMed 21491099</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA, Inc; January 2019.</li>
<li>Ampyra (dalfampridine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; December 2019</li>
<li>Fampyra (fampridine) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; January 2022.</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, et al, “Cimetidine Interaction with Phenytoin,” Br Med J (Clin Res Ed), 1981, 282:1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, and Springer PK, “Decreased Clearance of Phenytoin with Cimetidine,” Ann Intern Med, 1981, 95:244. [PubMed 7258891</li>
<li>Phillips P, Hansky J, “Phenytoin Toxicity Secondary to Cimetidine Administration,” Med J Aust, 1984, 141(9):602. [PubMed 6092884</li>
<li>Neuvonen PJ, Tokola RA, Kaste M, “Cimetidine-Phenytoin Interaction: Effect on Serum Phenytoin Concentration and Antipyrine Test,” Eur J Clin Pharmacol, 1981, 21(3):215-20. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al, “Reduction of Phenytoin Clearance Caused by Cimetidine,” Eur J Clin Pharmacol, 1983, 25(1):135</li>
<li>Bartle WK, Walker SE, and Shapero I, “Dose-Dependent Effect of Cimetidine on Phenytoin Kinetics,” Clin Pharmacol Ther, 1983, 33:649-55. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, et al, “Effect of Cimetidine on Phenytoin Serum Levels,” Epilepsia, 1983, 24(3):284</li>
<li>Iteogu MO, Murphy JE, Shleifer N, et al, “Effect of Cimetidine on Single-Dose Phenytoin Kinetics,” Clin Pharm, 1983, 2:302, 304. [PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I, “Differential Effect of Cimetidine on Serum Concentrations of Carbamazepine and Phenytoin,” Neurology, 1985, 35(4):562</li>
<li>Sambol NC, Upton RA, Chremos AN, et al, “A Comparison of the Influence of Famotidine and Cimetidine on Phenytoin Elimination and Hepatic Blood Flow,” Br J Clin Pharmacol, 1989, 27(1):83</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2022</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055]</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017.</li>
<li>Zokinvy (lonafarnib) [prescribing information]. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; November 2020.</li>
<li>Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2018</li>
<li>Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545-551. [PubMed 3593625</li>
<li>Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637-645. [PubMed 18551044</li>
<li>Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471-2472. [PubMed 12882884</li>
<li>Boehm KM, Gunaga S. Cimetidine-induced lactic acidosis and acute pancreatitis. South Med J. 2010;103(8):849. [PubMed 20622719</li>
<li>Seo JH, Lee da Y, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. Intern Med. 2013;52(19):2245-2248. [PubMed 24088760</li>
<li>Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica. 2008;38(9):1203-1218. [PubMed 18686197</li>
<li>Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185-191. [PubMed 19164462</li>
<li>Sultana N, Arayne MS, Ahmed N. In vitro availability of metformin in presence of h(2) receptor antagonists. Pak J Pharm Sci. 2006;19(1):28-34. [PubMed 16632449]</li>
<li>Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther. 1991;49(1):32-38. [PubMed 1988238</li>
<li>Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2015.</li>
<li>Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol. 1988;26(3):118-121. [PubMed 2457561</li>
<li>Christian CD Jr, Meredith CG, Speeg KV Jr. Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther. 1984;36(2):221-227. [PubMed 6204803</li>
<li>Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25(3):339-345. [PubMed 6194997</li>
<li>Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982;307(17):1080. [PubMed 6181402</li>
<li>Bauer LA, Black D, Gensler A. Procainamide-cimetidine interaction in elderly male patients. J Am Geriatr Soc. 1990;38(4):467-469. [PubMed 2329253</li>
<li>Higbee MD, Wood JS, Mead RA. Procainamide-cimetidine interaction: a potential toxic interaction in the elderly. J Am Geriatr Soc. 1984;32(2):162-164. [PubMed 6693705</li>
<li>Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol. 1985;28(6):671-675. [PubMed 2866097]</li>
<li>Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol. 1986;22(3):346-350. [PubMed 3768247</li>
<li>Qualaquin (quinine sulfate) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals Industry Inc; June 2019.</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019</li>
<li>El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther. 2016;9(4):157-161. [PubMed 26684920</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499</li>
<li>Fyarro (sirolimus) protein-bound [prescribing information]. Pacific Palisades, CA: Aadi Bioscience Inc; November 2021.</li>
<li>Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19(6):494-499. [PubMed 10587283</li>
<li>Preskorn SH. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract. 2005;11(3):192-196. [PubMed 15920392</li>
<li>Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 1997;25(1):24-32. [PubMed 9027670</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2010</li>
<li>Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59(1):45-50. [PubMed 12682803</li>
<li>Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther. 2007;82(5):555-565. [PubMed 17460606</li>
<li>Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60(5):543-553. [PubMed 8941027</li>
<li>Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002;16(4):361-364. [PubMed 12503836</li>
<li>Sunvepra (asunaprevir) [product monograph]Montreal, Canada: Bristol-Myers Squibb Canada; March 2016</li>
<li>Manerix (moclobemide) [product monograph]. Mississauga, Ontario: Hoffmann-LaRoche Limited, June 2011.</li>
<li>Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78(4):400-411. [PubMed 16198659</li>
<li>Villa-Zapata L, Gomez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disporportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022;45(8):863-871. [PubMed 35834155]</li>
<li>Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2019.</li>
<li>Flind AC. Cimetidine and oral anticoagulants. Br Med J. 1978;2(6148):1367. [PubMed 719395</li>
<li>Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2(8138):317-319. [PubMed 89387</li>
<li>Kerley B, Ali M. Cimetidine potentiation of warfarin action. Can Med Assoc J. 1982;126(2):116. [PubMed 7059881</li>
<li>Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med. 1979;90(3):348-349. [PubMed 426403</li>
<li>Hetzel D, Birkett D, Miners J. Cimetidine interaction with warfarin. Lancet. 1979;2(8143):639. [PubMed 90304</li>
<li>Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol. 1986;30(5):619-623. [PubMed 3758150</li>
<li>Harenberg J, Staiger CH, de Vries JX, et al. Cimetidine does not increase the anticoagulant effect of phenprocoumon. Br J Clin Pharmacol. 1982;14(2):292-293. [PubMed 7104184</li>
<li>O’Reilly RAComparative interaction of cimetidine and ranitidine with racemic warfarin in manArch Intern Med1984;144(5):989-991[PubMed 6324710</li>
<li>Unrecognized drug interactions ith famotidine and nizatidine. Arch Intern Med. 1991;151(4):810, 814, 815. [PubMed 1672811]</li>
<li>Sonata (zaleplon) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; November 2016.</li>
<li>Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest. 1998;15(6):515-522. [PubMed 18370509</li>
<li>Zomig (zolmitriptan) [prescribing information]. Hayward, CA: Impax Laboratories Inc; September 2012.</li>
<li>Alfenta (alfentanil) [prescribing information]. Lake Forest, IL: Akorn, Inc.; October 2019.</li>
<li>Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Abernathy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46(1):35-39. [PubMed 8005185</li>
<li>Suzuki Y, Shioiri T, Muratake T, et al. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol. 2003;58(12):829-833. [PubMed 12698310</li>
<li>Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol. 2009;65(7):699-704. [PubMed 19225771</li>
<li>Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug alprazolam. Eur J Clin Pharmacol. 2006;62(7):587-588. [PubMed 16791582</li>
<li>Xanax (alprazolam) [prescribing information]. New York, NY: Pfizer Inc; March 2021.</li>
<li>Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; November 2020</li>
<li>Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53(6):475-478. [PubMed 9551707]</li>
<li>Astelin (azelastine) nasal spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals Inc.; October 2014.</li>
<li>Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987;41(5):562-570. [PubMed 2882883</li>
<li>Apo-bromazepam (bromazepam) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2016.</li>
<li>Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. Pharmacotherapy. 1985;5(1):16-19. [PubMed 3982974</li>
<li>Felodipine [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; December 2020</li>
<li>Kirch W, Ramsch K, Janisch HD, Ohnhaus EE. The influence of two histamine H2-receptor antagonists, cimetidine, and ranitidine on the plasma levels and clinical effect of nifedipine and metoprolol. Arch Toxicol Suppl. 1984;7:256-259. [PubMed 6151387</li>
<li>Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther. 1989;249(2):638-645. [PubMed 2724144</li>
<li>Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43(6):673-680. [PubMed 3378388</li>
<li>Smith SR, Kendall MJ, Lobo J, Beerahee A, Jack DB, Wilkins MR. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol. 1987;23(3):311-315. [PubMed 3567045</li>
<li>Renwick AG, Le Vie J, Challenor VF, Waller DG, Gruchy B, George CF. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol. 1987;32(4):351-355. [PubMed 3609112</li>
<li>van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DDPharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidineClin Pharmacol Ther1988;43(3):332-341[PubMed 3345623</li>
<li>Muck W, Wingender W, Seiberling M, Woelke E, Ramsch KD, Kuhlmann J. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol. 1992;42(3):325-328. [PubMed 1577052</li>
<li>Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50(4):394-403. [PubMed 1914375</li>
<li>Kirch W, Hutt HJ, Heidemann H, Ramsch K, Janisch HD, Ohnhaus EE. Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S982-S985. [PubMed 6085389</li>
<li>Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther. 1990;253(3):1042-1048. [PubMed 2359015</li>
<li>Abernethy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Loi CM, Rollins DE, Dukes GE, Peat MA. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther. 1985;37(6):654-657. [PubMed 4006365</li>
<li>Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol. 1985;19(3):385-391. [PubMed 3986090</li>
<li>Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984;36(4):551-554. [PubMed 6478741</li>
<li>Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Conjupri (levamlodipine) [prescribing information]. CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia. 1986;27(5):553-558. [PubMed 3757941</li>
<li>Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol. 1984;27(3):341-343. [PubMed 6096154</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. Epilepsia. 1985;26(2):127-130. [PubMed 3987645</li>
<li>Macphee GJ, Thompson GG, Scobie G, et al. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984;18(3):411-419. [PubMed 6487479</li>
<li>Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011;24(1):63-68. [PubMed 21190921</li>
<li>Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit. 1987;9(1):24-27. [PubMed 3107168</li>
<li>Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 1986;8(4):387-392. [PubMed 3824425</li>
<li>Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy volunteers. Phytother Res. 2015;29(5):701-706. [PubMed 25624269</li>
<li>Pisani F, Narbone MC, Fazio A, et alEffect of viloxazine on serum carbamazepine levels in epileptic patientsEpilepsia1984;25(4):482-485[PubMed 6745218</li>
<li>Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49(10):1142-1145. [PubMed 3783175</li>
<li>Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine. Ann Intern Med. 1981;94(4 pt 1):544. [PubMed 7212521</li>
<li>Garcia B, Zaborras E, Areas V, Obeso G, Jimenez I, de Juana P, Bermejo T. Interaction between isoniazid and carbamazepine potentiated by cimetidine. Ann Pharmacother. 1992;26(6):841-842. [PubMed 1611171</li>
<li>Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol. 1993:36(6):615-616. [PubMed 12959283</li>
<li>Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991:84(6):583-584. [PubMed 1792934</li>
<li>Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie. 1992:47(2):165. [PubMed 1412145</li>
<li>Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust. 1991;155(11-12):851. [PubMed 1745195</li>
<li>Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand. 1983;68(4):253-256. [PubMed 6659865</li>
<li>Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine of fluvoxamine. Ther Drug Monit. 1993:15(3):247-250. [PubMed 8333006</li>
<li>Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother. 1987;20(Suppl B):121-129. [PubMed 3429380</li>
<li>Leite SA, Leite PJ, Rocha GA, Routledge PA, Bittencourt PR. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq Neuropsiquiatr. 1994;52(2):210-215. [PubMed 7826249</li>
<li>Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018</li>
<li>Equetro (carbamazepine) extended-release capsules [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2016</li>
<li>Carbatrol (carbamazepine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc.; August 2018.</li>
<li>Desmond PV, Patwardhan RV, Schenker S, Speeg Jr KV. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med. 1980;93(2):266-268. [PubMed 7406377</li>
<li>Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg Jr KV. Lack of tolerance and rapid recovery of cimetidine - inhibited chlordiazepoxide (Librium) elimination. Gastroenterology. 1981;81(3):547-551. [PubMed 7250643</li>
<li>Nelson DC, Avant GR, Speeg Jr KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology. 1985;5(2):305-309. [PubMed 3979962</li>
<li>Cimetidine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2019.</li>
<li>Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. Eur J Clin Pharmacol. 1981;21(1):83-85. [PubMed 7333351]</li>
<li>Szymanski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52:21-22. [PubMed 1988413</li>
<li>Watras M, Taylor D. A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. Ther Adv Psychopharmacol. 2013;3(5):294-297. [PubMed 24167705]</li>
<li>Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49(1):49-63. [PubMed 10606838</li>
<li>Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18(4):311-316. [PubMed 9690697</li>
<li>Raaska K, Raitasuo V, Laitila J, Neuvonen P. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalized patients. Basic Clin Pharmacol Toxicol. 2004;94(1):13-18. [PubMed 14725610</li>
<li>Al Hadithy A, Leeffers E, Bruggeman R. Clozapine levels might be affected by excessive cola consumption. J Clin Psychopharmacol. 2012;32(5):717-719. [PubMed 22926611</li>
<li>Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol. 1994;14(4):284-285. [PubMed 7962690</li>
<li>Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52(1):21-22. [PubMed 1988413</li>
<li>Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. Psychosomatics. 2007;48(2):170-175. [PubMed 17329613</li>
<li>Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol. 2002;22(6):621-622. [PubMed 12454563</li>
<li>Schoretsanitis G, Kane JM, de Leon JAdding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature reviewJ Clin Psychopharmacol2020;40(3):308-310[PubMed 32332470</li>
<li>Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50-56. [PubMed 23104241</li>
<li>Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2017.</li>
<li>Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother. 2014;48(12):1580-1584. [PubMed 25280976</li>
<li>Cai J, Huang Z, Yang G, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.  Am J Cardiovasc Drugs. 2011;11(6):401-409. [PubMed 22149319</li>
<li>Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant. 2007;21(2):277-284. [PubMed 17425758</li>
<li>Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation. 2003;76(5):865-868. [PubMed 14501869</li>
<li>McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol. 1997;48(5):336. [PubMed 9403222</li>
<li>Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7(6):831-835. [PubMed 8793790</li>
<li>Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. [PubMed 16133554</li>
<li>Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28(1):25-29. [PubMed 16541194</li>
<li>Synercid (quinupristin/dalfopristin) [prescribing information]New York, NY: Pfizer Inc; March 2017</li>
<li>Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet. 1990;19(6):499-502. [PubMed 2292171</li>
<li>Momper JD, Yang J, Kerr J, Saunders I, Smith J, Shah MM. Interaction between cyclosporine and palbociclib in a renal transplant patient: case report and pharmacokinetic perspective. J Pharm Pract. 2020;33(6):912-914. [PubMed 31248333</li>
<li>Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24(3):297-300. [PubMed 8082935</li>
<li>Wang CH, Chou NK, Wu FL, et al. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. Transplant Proc. 2006;38(7):2032-2034. [PubMed 16979990</li>
<li>Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol. 2005;45(7):781-791. [PubMed 15951468</li>
<li>Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081]</li>
<li>Mogford N, Pallett A, George C. Erythromycin deafness and cimetidine treatment. BMJ. 1994;309(6969):1620. [PubMed 7819942]</li>
<li>Mailing D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2021.</li>
<li>Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</li>
<li>Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</li>
<li>Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984;18(3):421-430. [PubMed 6487480]</li>
<li>Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32(4):432-436. [PubMed 9562139</li>
<li>Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol. 1995;8(4):231-233. [PubMed 8561837]</li>
<li>Archambeaud-Moueroux F, Nouaille Y, Nadalon S, Treves R, Merle L. Interaction between gliclazide and cimetidine. Eur J Clin Pharmacol. 1987;31(5):631. [PubMed 3830250]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413]</li>
<li>Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022</li>
<li>Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008;14(9):2701-2709. [PubMed 18451235]</li>
<li>Kishikawa K, Namiki A, Miyashita K, Saitoh K. Effects of famotidine and cimetidine on plasma levels of epidurally administered lignocaine. Anaesthesia. 1990;45(9):719-721. [PubMed 2240530</li>
<li>Parish RC, Gotz VP, Lopez LM, Mehta JL, Curry SH. Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit. 1987;9(3):292-297. [PubMed 3672572</li>
<li>Abernathy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Jackson JE, Bentley JB, Glass SJ, Fukui T, Gandolfi AJ, Plachetka JR. Effects of histamine-2 receptor blockade on lidocaine kinetics. Clin Pharmacol Ther. 1985;37(5):544-548. [PubMed 3987178</li>
<li>Bauer LA, Edwards WA, Randolph FP, Blouin RA. Cimetidine-induced decrease in lidocaine metabolism. Am Heart J. 1984;108(2):413-415. [PubMed 6464978</li>
<li>Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S. Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther. 1984;35(5):695-701. [PubMed 6713782</li>
<li>Feely J, Wilkinson GR, McAllister CB, Wood AJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982;96(5):592-594. [PubMed 7073151</li>
<li>Powell JR, Foster J, Patterson JH, Cross R, Wargin W. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics. Clin Pharm. 1986;5(12):993-998. [PubMed 3802729</li>
<li>Berk SI, Gal P, Bauman JL, Douglas JB, McCue JD, Powell JRThe effect of oral cimetidine on total and unbound serum lidocaine concentrations in patients with suspected myocardial infarctionInt J Cardiol1987;14(1):91-94[PubMed 3804509</li>
<li>Knapp AB, Maguire W, Keren G, et al. The cimetidine-lidocaine interaction. Ann Intern Med. 1983;98(2):174-177. [PubMed 6824249</li>
<li>Patterson JH, Foster J, Powell JR, Cross R, Wargin W, Clark JL. Influence of a continuous cimetidine infusion on lidocaine plasma concentrations in patients. J Clin Pharmacol. 1985;25(8):607-609. [PubMed 4078028</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Single dose oral H2-antagonists do not affect plasma lidocaine levels in the parturient. Acta Anaesthesiol Scan. 1989;33(7):593-596. [PubMed 2683547</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Effect of intravenous cimetidine on lignocaine disposition during extradural caesarean section. Anaesthesia. 1989;44(9):739-741. [PubMed 2802120</li>
<li>Dailey PA, Hughes SC, Rosen MA, Healy K, Cheek DB, Shnider SM. Effect of cimetidine and ranitidine on lidocaine concentrations during epidural anesthesia for cesarean section. Anesthesiology. 1988;69(6):1013-1017. [PubMed 3195744</li>
<li>Lidocaine [prescribing information]. Lake Forest, IL: Hospira Inc; April 2013.</li>
<li>Co-Phenylcaine Forte (lidocaine and phenylephrine) [Singapore product labeling]. Singapore: Ziwell Medical (S) Pte Ltd.; October 2015.</li>
<li>Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. Br J Clin Pharmacol. 1984;18(6):907-914. [PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062-1065. [PubMed 3605428</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR, Hudson RJ. Ranitidine does not alter pethidine disposition in man. Br J Clin Pharmacol. 1985;20(1):55-59. [PubMed 4027136]</li>
<li>Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160-166. [PubMed 20233179</li>
<li>Urva S, Bouillaud E, Delaney R, Jappe A, Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2013;53(4):444-450. [PubMed 23426978</li>
<li>Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol. 2011;51(12):1712-1720. [PubMed 21209230</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020</li>
<li>Kiang TKL. Clinical pharmacokinetics and drug-drug interactions of elbasvir/grazoprevir. Eur J Drug Metab Pharmacokinet. 2018;43(5):509-531. [PubMed 29557529</li>
<li>Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; February 2017</li>
<li>Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56-62. [PubMed 25103957</li>
<li>Koch KM, Dees EC, Coker SA, et alThe effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancerCancer Chemother Pharmacol2017;80(6):1141-1146[PubMed 29098381</li>
<li>Vitrakvi (larotrectinib) [prescribing information]. Stamford CT: Loxo Oncology Inc; November 2018</li>
<li>Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191-202. [PubMed 24825095</li>
<li>Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 plus 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652-659. [PubMed 20881954</li>
<li>Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859-1866. [PubMed 16183781</li>
<li>Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol. 1994;46(6):551-555. [PubMed 7995324</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics; November 2019</li>
<li>Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. [PubMed 21870106</li>
<li>Qelbree (viloxazine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Tavneos (avacopan) [prescribing information]. Cincinnati, OH: ChemoCentryx, Inc.; October 2021</li>
<li>Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017</li>
<li>Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15(6):1406-1416. [PubMed 35293131</li>
<li>Vaprisol (conivaptan) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; October 2016</li>
<li>Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53(3):298-305. [PubMed 8453848</li>
<li>Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol. 1993;73(3):180</li>
<li>Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56(5):389-394. [PubMed 11009047</li>
<li>Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</li>
<li>Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126-132. [PubMed 9562227</li>
<li>Nymalize (nimodipine) oral solution [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; December 2020</li>
<li>Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; December 2015.</li>
<li>Tornizol (ornidazole) [South Korea prescribing information]. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199300808. Accessed June 3, 2022</li>
<li>Arrow ornidazole (ornidazole) [New Zealand data sheet]. Auckland, New Zealand: Teva Pharma (New Zealand) Limited; October 2018</li>
<li>Ramesh S, Kumar YS, Rao YM. Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77. [PubMed 17152348]</li>
<li>Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(Suppl 350):102-106. [PubMed 2530759]</li>
<li>Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol. 1988;28(7):649-654. [PubMed 3216031</li>
<li>Luke DR, Rocci ML Jr, Hoholick C. Inhibition of pentoxifylline clearance by cimetidine. J Pharm Sci. 1986;75(2):155-157. [PubMed 3958924]</li>
<li>Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther. 2000;67(3):222-228. [PubMed 10741624]</li>
<li>Yee T, Barakos JA, Knight RT. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med. 1999;170(2):112-115. [PubMed 10063399</li>
<li>Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis. 1994;169(3):689-691. [PubMed 8158054</li>
<li>Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother. 1997;41(6):1256-1259. [PubMed 9174180</li>
<li>Biltricide (praziquantel) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; January 2019.</li>
<li>Inderal (propranolol) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; March 2011</li>
<li>Kirch W, Spahn H, Kohler H, Ohnhaus EE, Mutschler E. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr. 1982;60(22):1401-1407. [PubMed 7176462</li>
<li>Kirch W, Spahn H, Kohler H, Mutschler E. Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine. Arch Toxicol Suppl. 1983;6:379-383. [PubMed 6578746</li>
<li>Kirch W, Kohler H, Spahn H, Mutschler E. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet. 1981;2(8245):531-532. [PubMed 6115283</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17(Suppl 1):51S-57S. [PubMed 6146340</li>
<li>Tateishi T, Ohashi K, Fujimura A, Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992;32(12):1099-1104. [PubMed 1487547</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Comparison of kinetic interactions of nadolol and propranolol with cimetidine. Am Heart J. 1984;108(4 Part 2):1084-1086. [PubMed 6148867</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Kinetic interactions of nadolol and propranolol with cimetidine. Br J Clin Pharmacol. 1984;17(4):486-487. [PubMed 6721996</li>
<li>Donn KH, Powell JR, Rogers JF, Eshelman FNThe influence of H2-receptor antagonists on steady-state concentrations of propranolol and 4-hydroxypropranololJ Clin Pharmacol1984;24(11-12):500-508[PubMed 6150946</li>
<li>Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J. 1981;282(6280)1917-1919. [PubMed 6786672</li>
<li>Reimann IW, Klotz U, Siems B, Frolich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981;12(6):785-790. [PubMed 7340880</li>
<li>Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzneimittelforschung. 1987;37(8):953-956. [PubMed 2890358</li>
<li>Asgharnejad M, Powell JR, Donn KH, Danis M. The effect of cimetidine dose timing on oral propranolol kinetics in adults. J Clin Pharmacol. 1988;28(4):339-343. [PubMed 3392231</li>
<li>Reimann IW, Klotz U, Frolich JC. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther. 1982;32(6):749-757. [PubMed 6291839</li>
<li>Donovan MA, Heagerty AM, Patel L, Castleden M, Pohl JE. Cimetidine and bioavailability of propranolol. Lancet. 1981;1(8212):164. [PubMed 6109849</li>
<li>MacKichan JJ, Boudoulas H, Schall SF. Effect of cimetidine on quinidine bioavailability. Biopharm Drug Dispos. 1989;10(1):121-125. [PubMed 2923957</li>
<li>Hardy BG, Zador IT, Golden L, Lalka D, Schentag JJ. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol. 1983;52(1):172-175. [PubMed 6858908</li>
<li>Kolb KW, Garnett WR, Small RE, Vetrovec GW, Kline BJ, Fox T. Effect of cimetidine on quinidine clearance. Ther Drug Monit. 1984;6(3):306-312. [PubMed 6506138</li>
<li>Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol. 1988;26(8):388-391. [PubMed 3220613</li>
<li>Farringer JA, McWay-Hess K, Clementi WA. Cimetidine-quinidine interaction. Clin Pharm. 1984;3(1):81-83. [PubMed 6697678</li>
<li>Polish LB, Branch RA, Fitzgerald GA. Digitoxin-quinidine interaction: potentiation during administration of cimetidine. South Med J. 1981;74(5):633-634. [PubMed 7244727</li>
<li>Quinidine sulfate [prescribing information]. Laurelton, NY: Epic Pharma LLC; July 2021.</li>
<li>Bohmer GM, Gleiter CH, Morike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol. 2011;51(4):594-602. [PubMed 20484614</li>
<li>Cui X, Huang J, Zheng X, Jiang J, Kuang Y, Hu P. Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: application for a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029-1030:60-67. [PubMed 27423044</li>
<li>Li Q, Wang Y, Liu L, Ma P, Ding L. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in healthy Chinese subjects after single and multiple oral doses. Eur J Drug Metab Pharmacokinet. 2017;42(3):371-381. [PubMed 27306372</li>
<li>Zoryve (roflumilast) cream [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2022</li>
<li>Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</li>
<li>Kim J-R, Jung JA, Kim S, Huh W, Ghim J-L, Shin J-G, Ko J-W. Effect of cilostazol on the pharmacokinetics of simvastatin in healthy subjects. Biomed Res Int. 2019;1365180. [PubMed 30729119</li>
<li>Xu CF, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 23(9):2470-2471. [PubMed 22918879</li>
<li>Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19(1):247. [PubMed 31640597</li>
<li>Poumeaud F, Fontanier A, Dion J, et al. Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report. Front Oncol. 2022;12:1026434. [PubMed 36591506</li>
<li>Huynh T, Cordato D, Yang F. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32(9-10):486-490. [PubMed 12380704</li>
<li>Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; September 2020.</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499]</li>
<li>Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001;15(2):95-99. [PubMed 11264634</li>
<li>Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit. 2005;27(5):587-591. [PubMed 16175131</li>
<li>Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc.; January 2016</li>
<li>Breslin NT, Salerno DM, Topkara VK, et al. Prior amiodarone exposure reduces tacrolimus dosing requirements in heart transplant recipients. Prog Transplant. 2019;29(2):129-134. [PubMed 30845890</li>
<li>Mavyret (glecaprevir/pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2020</li>
<li>Shapiro R, Venkataramaan R, Warty VS, et al. FK 506 interaction with danazol. Lancet. 1993;341(8856):1344-1345. [PubMed 7684106</li>
<li>Seck S, Bellantoni M, Zoccali C, Enia G. Ranolazine can markedly increase tacrolimus blood levels. NDT Plus. 2011;4(1):44-45. [PubMed 25984101</li>
<li>Patni H, Gitman M, Hazzan A, Jhaveri KD. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail. 2012;34(2):251-253. [PubMed 22263871</li>
<li>Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain EPharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant childTransplantation 2012;93(7):e29-e30[PubMed 22450597</li>
<li>Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2013;69(10):1861-1862. [PubMed 23765408</li>
<li>Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2018</li>
<li>Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2020.</li>
<li>Maeda Y, Konishi T, Omoda K, et al. Inhibition of theophylline metabolism by aciclovir. Biol Pharm Bull. 1996;19(12):1591-1595. [PubMed 8996645</li>
<li>Sato J, Nakata H, Owda E, Kikuta T, Umetsu M, Ito K. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J Clin Pharmacol. 1993;44(3):295-298. [PubMed 8491248</li>
<li>Vestal RE, Thummel KE, Musser B, Mercer GD. Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol. 1983;15(4):411-418. [PubMed 6849776</li>
<li>Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med. 1984;144(3):484-486. [PubMed 6322709</li>
<li>Cohen IA, Johnson CE, Berardi RR, Hyneck ML, Achem SR. Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit. 1985;7(4):426-434. [PubMed 4082242</li>
<li>Mulkey PM, Murphy JE, Shleifer NH. Steady-state theophylline pharmacokinetic during and after short-term cimetidine administration. Clin Pharm. 1983;2(5):439-441. [PubMed 6627870</li>
<li>Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 1989;45(5):476-486. [PubMed 2721103</li>
<li>Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982;23(2):129-134. [PubMed 7140802</li>
<li>Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski REffects of tobacco smoking and oral contraceptive use on theophylline dispositionBr J Clin Pharmacol1983;16(3):271-280[PubMed 6626419</li>
<li>Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;24(2):939-941. [PubMed 2444839</li>
<li>Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline. Pharm Weekbl Sci. 1987;11(9 suppl):S72-S75. [PubMed 3481439</li>
<li>Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986;22(6):677-683. [PubMed 3567014</li>
<li>Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest. 1987;92(4):663-669. [PubMed 3477409</li>
<li>Staib AH, Harder S, Fuhr U, Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol. 1989;27(6):289-293. [PubMed 2737798</li>
<li>Miners JO, Wing LM, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol. 1985;20(3):219-223. [PubMed 4041342</li>
<li>Lombardi TP, Bertino JS Jr, Goldberg A, Middleton E Jr, Slaughter RL. The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. J Clin Pharmacol. 1987;27(7):523-529. [PubMed 2888791</li>
<li>Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980;28(4):463-467. [PubMed 7408406</li>
<li>Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41(3):358-362. [PubMed 3816023</li>
<li>Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(suppl 2):77-83. [PubMed 8620674</li>
<li>Spinler SA, Gammaitoni A, Charland SL, Hurwitz J. Propafenone-theophylline interaction. Pharmacotherapy. 1993;13(1):68-71. [PubMed 8437970</li>
<li>Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. Clin Pharmacol Ther. 1992;51(3):353-355. [PubMed 1544292</li>
<li>Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ. Cimetidine-theophylline interaction: report of four patients. Ann Allergy. 1982;48(2):100-102. [PubMed 6121526</li>
<li>Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR. Cimetidine decreases theophylline clearance. Ann Intern Med. 1981;95(1):68-69. [PubMed 7247131</li>
<li>Lofgren RP, Gilbertson RA. Cimetidine and theophylline. Ann Intern Med. 1982;96(3):378. [PubMed 6800293</li>
<li>Mojtahedzadeh M, Sadray S, Hadjibabaie M, Fasihi M, Rezaee S. Determination of theophylline clearance after cimetidine infusion in critically ill patients. J Infus Nurs. 2003;26(4):234-238. [PubMed 12869856</li>
<li>Koren G, Chin TF, Correia J, Tesoro A, MacLeod SM. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. Clin Invest Med. 1985;8(3):222-2[PubMed 4042465</li>
<li>Theo-24 (theophylline anhydrous) [prescribing information]. Malvern, PA; Endo Pharmaceuticals Inc.; August 2017.</li>
<li>Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986;26(5):372-377. [PubMed 3700691</li>
<li>Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157-163. [PubMed 3383988</li>
<li>Adebayo GI, Coker HA. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. Eur J Clin Pharmacol. 1988;34(6):653-656. [PubMed 3169118</li>
<li>Stockley C, Keal J, Rolan P, Bochner F, Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur J Clin Pharmacol. 1986;31(2): 235-237. [PubMed 3803421</li>
<li>Dey NG, Castleden CM, Ward J, Cornhill J, McBurney A. The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol. 1983;16(4):438-440. [PubMed 6626438]</li>
<li>Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983;16(6):743-746. [PubMed 6140941</li>
<li>Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol. 1998;28(3):228-233. [PubMed 3360971</li>
<li>Pourbaix S. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Britton ML, Waller ES. Central nervous system toxicity associated with concurrent use of triazolam and cimetidine. Drug Intell Clin Pharm. 1985;19(9):666-668. [PubMed 40428607. Parker WA, MacLachlan RA. Prolonged hypnotic response to triazolam-cimetidine combination in an elderly patient. Drug Intell Clin Pharm. 1984;18(12):980-981. [PubMed 6150838]</li>
<li>Curry SH, De Vane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433. [PubMed 3912187</li>
<li>Amsterdam JD, Brunswick DJ, Potter L, et al. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology. 1984;83:373-375. [PubMed 6436867</li>
<li>Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. [PubMed 3950073</li>
<li>Sutherland DL, Remillard AJ, Haight KR, et al. The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. Eur J Clin Pharmacol. 1987;32:159-164. [PubMed 3582480</li>
<li>Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. [PubMed 379426</li>
<li>Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. [PubMed 6692646</li>
<li>Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229(3):702-705. [PubMed 6726654</li>
<li>Brown MA, Haight KR, McKay G. Cimetidine-doxepin interaction. J Clin Psychopharmacol. 1985;5:245-247. [PubMed 4019813</li>
<li>Shapiro PACimetidine-imipramine interaction: case report and commentsAm J Psychiatry1984;141:152[PubMed 6691449</li>
<li>Miller DD, Macklin M. Cimetidine-imipramine interaction: a case report. Am J Psychiatry. 1983;140:351. [PubMed 6829810</li>
<li>Miller DD, Sawyer JB, Duffy JP. Cimetidine’s effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm. 1983;17(12):904-905. [PubMed 6653407</li>
<li>Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther. 1987;42:278-282. [PubMed 3621787]</li>
<li>Urasap (urapidil) [Summary of Product Characteristics]. Frosinone, Italy: INCA-Pharm Srl; September 2012.</li>
<li>De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46(2):458-463. [PubMed 11796358</li>
<li>Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2010.</li>
<li>Desager JP, Harvengt C, Bianchetti G, Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int J Clin Pharmacol Ther Toxicol. 1993;31(11):568-571. [PubMed 7904983]</li>
<li>Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; November 2022</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Hendset M, Molden E, Enoksen TB, et al. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit. 2010;32(6):787-790. [PubMed 21068650</li>
<li>Abilify Maintena (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; January 2020</li>
<li>Abilify Asimtufii (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; April 2023.</li>
<li>Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20(1):55-64. [PubMed 15770075</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44(11):1850-1854. [PubMed 20978219</li>
<li>Qulipta (atogepant) [prescribing information]. Dublin, Ireland: Forest Laboratories Ireland Ltd; September 2021.</li>
<li>Ortikos (budesonide) extended-release capsules [prescribing information]. Sun Pharmaceutical Industries, Inc.; June 2019.</li>
<li>Buspirone [prescribing information]. Laurelton, NY: Epic Pharma LLC; May 2020</li>
<li>Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ. Lack of interaction between cimetidine and buspirone. Pharmacotherapy. 1987;7(3):72-79. [PubMed 2888096]</li>
<li>Epidiolex (cannabidiol) oral solution [prescribing information]. Carlsbad, CA: Greenwich Biosciences Inc; October 2020</li>
<li>Thai C, Tayo B, Critchley D. A phase I open-label, fixed sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(11):1279-1289. [PubMed 33951339</li>
<li>Beach CA, Mays DC, Guiler RC, Jacober CH, Gerber N. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986;39(3):265-270. [PubMed 3948467</li>
<li>Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol. 1995;48(2):161-166. [PubMed 7589032</li>
<li>Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425-428. [PubMed 4029248</li>
<li>Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther. 1999;65(3):262-274. [PubMed 10096258</li>
<li>Pegintron (peginterferon alfa-2b) [prescribing information]Whitehouse Station, NJ: Merck &amp; Co Inc; January 2019</li>
<li>Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988;35(6):651-656. [PubMed 2853056</li>
<li>Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45(3):234-240. [PubMed 2920498</li>
<li>Michaud V, Mouksassi MS, Labbe L, et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit. 2006;28(6):779-783. [PubMed 17164694</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Coreg (carvedilol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</li>
<li>Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104(12):3116-3117. [PubMed 19956146]</li>
<li>Rize (clotiazepam) [KR prescribing information]. Available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802970]. Accessed [January 30, 2023]</li>
<li>Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H. Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol. 1984;26(1):55-59. [PubMed 6143670]</li>
<li>Mitigare (colchicine) capsule [prescribing information]. Memphis, TN: Hikma Americas, Inc.; September 2014.</li>
<li>Enablex (darifenacin) [prescribing information]. Rockaway, NJ: Warner Chilcott US LLC; March 2012.</li>
<li>Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15(1):18-24. [PubMed 8451775</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997;62(2):145-156. [PubMed 9284850</li>
<li>Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008</li>
<li>Effexor (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017</li>
<li>Norvir (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2019</li>
<li>Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664-674. [PubMed 16338282</li>
<li>Orladeyo (berotralstat) [prescribing information]Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989;146(12):1611-1613. [PubMed 2486749</li>
<li>Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329-336. [PubMed 2288330</li>
<li>Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit. 1992;14(3):194-196. [PubMed 1412604</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res. 1993;13(3):167-171. [PubMed 8225700</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15(3):243-246. [PubMed 8333005]</li>
<li>Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017</li>
<li>Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70(9):1115-1122. [PubMed 25028073</li>
<li>Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacol (Berl). 1998;135(1):22-26. [PubMed 9489930</li>
<li>Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(4):747-755. [PubMed 24013574</li>
<li>Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020</li>
<li>Qelbree (viloxazine) [prescribing information]Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Saphris (asenapine) [prescribing information]. Irvine, CA: Allergan USA Inc; February 2017</li>
<li>Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64(3):257-268. [PubMed 9757149]</li>
<li>Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother Pharmacol. 1999;43(2):126-132. [PubMed 9923817]</li>
<li>Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer Inc.; June 2016</li>
<li>Cardura XL (doxazosin extended-release) [prescribing information]. New York, NY: Pfizer Inc.; February 2017.</li>
<li>Cerdelga (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2018</li>
<li>Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</li>
<li>Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14-23. [PubMed 11180034</li>
<li>Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50(3):203-208. [PubMed 8737760</li>
<li>Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. 2002;72(3):247-255. [PubMed 12235445]</li>
<li>Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77(1):17-23. [PubMed 15637527]</li>
<li>Flecainide [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals Pvt. Ltd.; September 2017</li>
<li>Tjandra-Maga TB, van Hecken A, van Melle P, Verbesselt R, de Schepper PJAltered pharmacokinetics of oral flecainide by cimetidineBr J Clin Pharmacol1986;22(1):108-110[PubMed 3741720]</li>
<li>Sullivan KM, Small RE, Rock WL, Cox SR, Willis HE. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm. 1986;5(7):586-589. [PubMed 3742949</li>
<li>Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol. 1990;30(7):660-664. [PubMed 2391398]</li>
<li>Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507. [PubMed 20573085</li>
<li>Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514]</li>
<li>Dumitras S, Sechaud R, Drollmann A, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771-779. [PubMed 24040847]</li>
<li>Zircol (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013</li>
<li>Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:31S-36S. [PubMed 11879257</li>
<li>Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-581. [PubMed 15365656]</li>
<li>Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</li>
<li>Luder PJ, Siffert B, Witassek F, et al. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31(4):443-448. [PubMed 3816925</li>
<li>Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24(3):390-392. [PubMed 3663452]</li>
<li>Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319-1321. [PubMed 15541258</li>
<li>Garimella T, Tao X, Sims K, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R D. 2018;18(1):55-65. [PubMed 29255971</li>
<li>Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130-137. [PubMed 12891223</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67-70. [PubMed 2917591</li>
<li>Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466-477. [PubMed 10824625</li>
<li>Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113-123. [PubMed 14748763</li>
<li>Thibault N, Ibrahim J, Peterschmitt MJ, et al. Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Mol Genet Metab. 2020;129(4):278-285. [PubMed 32029355</li>
<li>Lexapro (escitalopram) [prescribing information]Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28-34. [PubMed 17224709</li>
<li>Ogasawara K, LoRusso PM, Olszanski AJ, et al. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol. 2020;86(1):87-95. [PubMed 32537715</li>
<li>Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol. 1987;31(5):575-578. [PubMed 3830242</li>
<li>Laurent-Kenesi MA, Brentano-Funck C, Poirier JM, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 1993;36(6):531-538. [PubMed 12959269</li>
<li>Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24(2):213-220. [PubMed 3620296</li>
<li>Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Cho DY, Bae SH, Lee JK, et al. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica. 2015;45(3):256-263. [PubMed 25268386</li>
<li>Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2015</li>
<li>Effexor XR (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</li>
<li>Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's Disease. Biopharmaceut Drug Dispos. 1988;9(2):219-227. [PubMed 2897213</li>
<li>Loft S, Dossing M, Sonne J, Dalhof K, Bjerrum K, Poulsen HE. Lack of effect of cimetidine on the pharmacokinetics of metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol. 1988;35(1):65-68. [PubMed 3220096</li>
<li>Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. Eur J Clin Pharmacol. 1987;32(1):35-41. [PubMed 3582467</li>
<li>Gugler R, Jensen JC. Interaction between cimetidine and metronidazole. N Eng J Med 1983;309(24):1518-1519. [PubMed 6646177</li>
<li>Viaflex Plus Container (metronidazole injection) [prescribing information]. Deefield, IL: Baxter Healthcare Corporation; December 2017</li>
<li>Pearce RE, Cohen-Wolkowiez M, Sampson MR,Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013;41(9):1686-1694. [PubMed 23813797</li>
<li>Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE . Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol. 1991;41(8):1127-1134. [PubMed 2009091]</li>
<li>Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; November 2019.</li>
<li>Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the h2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 1997;43(2):201-204. [PubMed 9131955]</li>
<li>Bendayan R, Sullivan JR, Shaw C, et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol. 1990;38:165-169. [PubMed 2338114</li>
<li>Bendayan R, Kennedy G, Frecker RC, Sellers EM. Lack of effect of cimetidine on cigarette smoking. Eur J Clin Pharmacol. 1993;44(1):51-55. [PubMed 8436155]</li>
<li>Ochs HR, Greenblatt DJ, Gugler R, Muntefering G, Locniskar A, Abernethy DR. Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther. 1983;34(2):227-230. [PubMed 6872417</li>
<li>Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</li>
<li>Fine A, Churchill DN, “Potentially Lethal Interaction of Cimetidine and Morphine,” Can Med Assoc J, 1981, 124(11):1434</li>
<li>[PubMed 7237324</li>
<li>Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010</li>
<li>Gogas KR, Hough LB, Eberle NB, et al, “A Role for Histamine and H2-Receptors in Opioid Antinociception,” J Pharmacol Exp Ther, 1989, 250(2):476-84. [PubMed 2547933</li>
<li>Bluhm R, Zsigmond EK, Winnie AP, “Potentiation of Opioid Analgesia by H1 and H2 Antagonists,” Life Sci, 1982, 31(12-13):1229-32. [PubMed 6128651</li>
<li>Robertson JA, Hough LB, Bodnar RJ, “Potentiation of Opioid and Nonopioid Forms of Swim Analgesia by Cimetidine,” Pharmacol Biochem Behav, 1988, 31(1):107-12. [PubMed 2855266</li>
<li>Lam AM, Clement JL, “Effect of Cimetidine Premedication on Morphine-Induced Ventilatory Depression,” Can Anaesth Soc J, 1984, 31(1):36-43. [PubMed 6420025</li>
<li>Mojaverian P, Fedder IL, Vlasses PH, et al, “Cimetidine Does Not Alter Morphine Disposition in Man,” Br J Clin Pharmacol, 1982, 14(6):809-13. [PubMed 7150459</li>
<li>Dawson GW, Vestal RE, “Cimetidine Inhibits the In Vitro N-Demethylation of Methadone,” Res Commun Chem Pathol Pharmacol, 1984, 46(2):301</li>
<li>[PubMed 6515123</li>
<li>Guay DR, Meatherall RC, Chalmers JL, et al, “Cimetidine Alters Pethidine Disposition in Man,” Br J Clin Pharmacol, 1984, 18(6):907-14[PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, et al, “Meperidine-Induced Delirium,” Am J Psychiatry, 1987, 144(8):1062</li>
<li>Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014</li>
<li>Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005;28(2):328-334. [PubMed 15684493</li>
<li>Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull. 2004;27(5):684-690. [PubMed 15133245]</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S. [PubMed 6146340</li>
<li>Spahn H, Kirch W, Mutschler E. The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol. Br J Clin Pharmacol. 1983;15(4):500-501. [PubMed 6849789</li>
<li>Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016</li>
<li>Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992;51(4):379-387. [PubMed 1563208]</li>
<li>Pritchett EL, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol. 1988;28(7):619-624. [PubMed 3063727]</li>
<li>Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; December 2017.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53(suppl 1):31S-36S. [PubMed 11879257</li>
<li>Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; February 2018.</li>
<li>Lamisil (terbinafine hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016</li>
<li>Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219. [PubMed 9382559]</li>
<li>Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol. 1993;45(1):41-46. [PubMed 8405028]</li>
<li>Jonderko G, Jonderko K, Marcisz C, Kotulska A. Effect of cimetidine and ranitidine on absorption of [125]levothyroxine administered orally. Zhongguo Yao Li Xue Bao. 1992;13(5):391-394. [PubMed 1300037</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075]</li>
<li>Gabitril (tiagabine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2015.</li>
<li>Spiriva (tiotropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2015.</li>
<li>Conzip (tramadol) extended-release capsules [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC; March 2021.</li>
<li>Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Inc; February 2019.</li>
<li>Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):51-55. [PubMed 14616414</li>
<li>Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother. 2009;53(4):1712-1714. [PubMed 19171800</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; April 2019.</li>
<li>Wang K, Yao X, Zhang M, et al. Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):441-454. [PubMed 33687157]</li>
<li>de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55-59. [PubMed 31865063</li>
<li>Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019;10:2042098619854007. doi: 10.1177/2042098619854007. [PubMed 31258887</li>
<li>Tsai SC, Sheu SY, Chien LN, Lee HC, Yuan EJ, Yuan RY. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000-2009. [PubMed 29745438</li>
<li>Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780-1782. [PubMed 7500509</li>
<li>Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med. 1986;146(10):2070-2071. [PubMed 3767555</li>
<li>Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J. 2010;103(2):178-180. [PubMed 20065895</li>
<li>Corsini GU, Zompo MD, Cianchetti C, et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacologia. 1976;47(2):169-173. [PubMed 1273213</li>
<li>Tarsy D, Parkes JD, Marsden CD. Metoclopramide in parkinsonism. Lancet. 1975;1(7918):1244-1245. [PubMed 48872</li>
<li>Tarsy D, Parkes JD, Marsden CDMetoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesiasJ Neurol Neurosurg Psychiatry1975;38(4):331-335[PubMed 1095689</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020</li>
<li>Migramax (aspirin and metoclopramide) [summary of product characteristics]. London, United Kingdom: Zentiva Pharma UK Limited; March 2022.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; August 2017</li>
<li>Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC. 2013;13:152. [PubMed 23714238</li>
<li>Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004;44(6):661-665. [PubMed 15637848</li>
<li>Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ. 1988;297(6654):964-965. [PubMed 3142568</li>
<li>Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J. 1991;84(5):626-628. [PubMed 2035085</li>
<li>Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolid-fluoxetine and olanzapine-metoclopramide interactions: a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission. Case Rep Med. 2016;2016:7128909. [PubMed 27433163]</li>
<li>Cabergoline [prescribing information]. Peapack, NJ: Greenstrone LLC; November 2019.</li>
<li>Barnes TR, Braude WM, Hill DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2(8288):48-49. [PubMed 6123780</li>
<li>Metoclopramide [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; July 2021</li>
<li>Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000;23(Suppl):S64-S70. [PubMed 11052222</li>
<li>Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. [PubMed 19886950</li>
<li>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446]</li>
<li>Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.</li>
<li>Patterson JF. Metoclopramide therapy of MAOI orthostatic hypotension. J Clin Psychopharmacol. 1987;7(2):112-113. [PubMed 3584514]</li>
<li>Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</li>
<li>Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009</li>
<li>Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” Trends Neurosci, 2000, 23(Suppl):S64-70. [PubMed 11052222</li>
<li>Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” Aliment Pharmacol Ther, 2010, 31(1):11</li>
<li>Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” Ann Pharmacother, 2008, 42(9):1290</li>
<li>Trelstar (triptorelin) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions, LLC; December 2018</li>
<li>Trelstar (triptorelin) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc.; September 2022.</li>
<li>Prescribing information. Malarone (atovaquone and proguanil). Research Triangle Park, NC: GlaxoSmithKline, 02/2013.</li>
<li>Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos. 2006;27(6):285-289. [PubMed 16770757</li>
<li>Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-2281. [PubMed 27621638</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020.</li>
<li>Mehta D, Bradley EL Jr, Kissin I. Metoclopramide decreases thiopental hypnotic requirements. Anesth Analg. 1993;77(4):784-787. [PubMed 8214666</li>
<li>Thiopental sodium [Summary of Product Characteristics]. Berkshire, UK: Archimedes Pharma UK Limited; January 2014.</li>
<li>Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013</li>
<li>Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990;39(6):1045-1053. [PubMed 2322292]</li>
<li>Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011</li>
<li>Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015</li>
<li>Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015</li>
<li>Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.</li>
<li>Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: Ani Pharmaceuticals Inc; August 2017.</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation. 1987;43(2):211-213. [PubMed 3544377</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant patients. Transplant Proc. 1988;20(2 suppl 2):487-490. [PubMed 3284095</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017.</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932]</li>
<li>Aczone (dapsone) gel [prescribing information]. Irvine, CA: Allergan, Inc.; July 2015.</li>
<li>Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</li>
<li>Gamble JA, Gaston JH, Nair SG, Dundee JW. Some pharmacological factors influencing the absorption of diazepam following oral administration. Br J Anaesth. 1976;48(12):1181-1185. [PubMed 1023954</li>
<li>Chapman MH, Woolner DF, Begg EJ, Atkinson HC, Sharman JR. Coadministered oral metoclopramide does not enhance the rate of absorption of oral diazepam. Anaesth Intensive Care. 1988;16(2):202-205. [PubMed 3394914]</li>
<li>Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinetic. 1986;11(4):249-250. [PubMed 3582418</li>
<li>Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984;36(6):724-730. [PubMed 6499354</li>
<li>Schwartz BG. Metoclopramide and digoxin cause 22 episodes of bradyarrhythmias. Am J Med. 2010;123(6):e5</li>
<li>[PubMed 20569744</li>
<li>Johnson BG, O'Grady J, Bye C. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. Br J Clin Pharmacol. 1978;5(5):465-467. [PubMed 656287]</li>
<li>Monurol (fosfomycin) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2018.</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One. 2013;8(11):e81208. [PubMed 24278396</li>
<li>Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6(9):e23728. [PubMed 21961030</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015</li>
<li>Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488</li>
<li>Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662]</li>
<li>Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.</li>
<li>Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016</li>
<li>Synera (lidocaine and tetracaine) topical patch [prescribing information]. Souderton, PA: Galen US Inc; March 2014</li>
<li>Pliaglis (lidocaine and tetracaine) cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; November 2013</li>
<li>Citanest plain (prilocaine) [prescribing information]. York, PA: Dentsply Pharmaceutical; June 2010</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006</li>
<li>Marcaine Spinal (bupivacaine hydrochloride in dextrose injection, USP) [prescribing information]. Lake Forest, IL: Hospira, Inc.; November 2018</li>
<li>Lardieri AB, Crew PE, McCulley L, Kim IE, Waldron P, Diak IL. Cases of benzocaine-associated methemoglobinemia identified in the FDA adverse event reporting system and the literature [published online January 2, 2019]. Ann Pharmacother. doi: 10.1177/1060028018823532. [PubMed 30600685]</li>
<li>Tercan M, Efe EM, Turker G, et al. Do metoclopramide and ondansetrone alter mivacurium-induced neuromuscular blockade? - a randomised trial. Braz J Anesthesiol. 2014;64(1):35-39. [PubMed 24565386</li>
<li>El Ayass N, Hendrickx P. Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized double blind placebo-controlled study. Eur J Anaesthesiol. 2005;22(3):197-201. [PubMed 15852992</li>
<li>Motamed C, Kirov K, Combes X, Dhonneur G, Duvaldestin P. Effect of metoclopramide on mivacurium-induced neuromuscular block. Acta Anaesthesiol Scand. 2002;46(2):214-216. [PubMed 11942874</li>
<li>Skinner HJ, Girling KJ, Whitehurst A, Nathanson MH. Influence of metoclopramide on plasma cholinesterase and duration of action of mivacurium. Br J Anaesth. 1999;82(4):542-545. [PubMed 10472219</li>
<li>Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth. 1990;65(2):220-224. [PubMed 2223340</li>
<li>Kambam JR, Parris WC, Franks JJ, Sastry BV, Naukam R, Smith BE. The inhibitory effect of metoclopramide on plasma cholinesterase activity. Can J Anaesth. 1988;35(5):476-478. [PubMed 3273154]</li>
<li>Inomax (nitric oxide) [prescribing information]. Hampton, NJ: INO Therapeutics; March 2013</li>
<li>Genosyl (nitric oxide) [prescribing information]. Atlanta, GA: Vero Biotech; December 2019</li>
<li>Sinisterra S, Miravet E, Alfonso I, et al. Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic. J Pediatr. 2002;141(2):285-286. [PubMed 12183731</li>
<li>Lopez A, Bernardo B, Lopez-Herce J, et al. Methaemoglobinaemia secondary to treatment with trimethoprim and sulphamethoxazole associated with inhaled nitric oxide. Acta Paediatr. 1999;88(8):915-916. [PubMed 10503695</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006.</li>
<li>Metozolv ODT (metoclopramide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2011.</li>
<li>Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011;67(6):591-599. [PubMed 21161196</li>
<li>PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PMID: 19075045</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013.</li>
<li>Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006</li>
<li>Skold A, Cosco DL and Klein R, “Methemoglobinemia: Pathogenesis, Diagnosis, and Management,” South Med J, 2011, 104(11):757-61. [PubMed 22024786</li>
<li>Mansouri A and Lurie AA, “Concise Review: Methemoglobinemia,” Am J Hematol, 1993, 42(1):7-12. [PubMed 8416301]</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022</li>
<li>Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</li>
<li>Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced serotonin syndrome. Intern Med. 2017;56(6):737-739. [PubMed 28321081</li>
<li>Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002;36(1):67-71. [PubMed 11816261</li>
<li>Aussedat M, Lavoie A, Bussieres JF, Kleiber N. Suspected overlap between serotonin syndrome and neuroleptic malignant syndrome in a child treated with metoclopramide? J Pediatr Pharmacol Ther. 2020;25(6):552-558. [PubMed 32839660</li>
<li>Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664</li>
<li>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718</li>
<li>Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713</li>
<li>Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil. 2009;21(12):1235-1238. [PubMed 19906028]</li>
<li>Provenzani A, D'alessandro N, Polidori P. Toxic tacrolimus concentrations associated with intravenous use of metoclopramide in a lung transplant patient. Ann Pharmacother. 2019;53(5):548-549. [PubMed 30739475</li>
<li>Prescott WA Jr, Callahan PL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 2004;24(4):532-537. [PubMed 15098810</li>
<li>Wadhw NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019.</li>
<li>Prescribing information. Baltimore, MD: Cangene BioPharma, Inc., 2/2012</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</li>
<li>Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology. 1989;70(6):905-908. [PubMed 2658689</li>
<li>Turner DR, Kao YJ, Bivona C. Neuromuscular block by suxamethonium following treatment with histamine type 2 antagonists or metoclopramide. Br J Anaesth. 1989;63(3):348-350. [PubMed 2572248</li>
<li>Dell-Kuster S, Levano S, Burkhart CS, et al. Predictors of the variability in neuromuscular block duration following succinylcholine: A prospective, observational study. Eur J Anaesthesiol. 2015;32(10):687-696. [PubMed 26213905</li>
<li>Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” Br Med J, 1973, 1:587. [PubMed 4694406</li>
<li>Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” Br J Clin Pharmacol, 1981, 11:430-1P</li>
<li>Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” J Pharm Pharmacol, 2001, 53(7):1041</li>
<li>[PubMed 11480539</li>
<li>van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” Methods Find Exp Clin Pharmacol, 1990, 12(4):291</li>
<li>[PubMed 2374477</li>
<li>van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” Methods Find Exp Clin Pharmacol, 1992, 14(5):379-82. [PubMed 1513194</li>
<li>Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” Br J Clin Pharmacol, 1983, 15(4):487</li>
<li>[PubMed 6849786</li>
<li>Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” Cephalalgia, 1988, 8(3):139-47. [PubMed 31970094</li>
<li>Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” Eur J Clin Pharmacol, 1992, 42(2):235</li>
<li>[PubMed 1618258]</li>
<li>Kaukab I, Shah SNH, Kharaba ZJ, Buabeid MA, Alfoteih YA, Murtaza G. Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake. Expert Opin Metab Toxicol. 2020;16(8):735-740. [PubMed 32524862]</li>
<li>Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013;28(2):99-105. [PubMed 23221858</li>
<li>Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559</li>
<li>Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. [PubMed 18809731</li>
<li>Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018</li>
<li>Khedezla (desvenlafaxine) [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; August 2017.</li>
<li>Moffett PM, Cartwright L, Grossart EA, O’Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23(1):102-105. [PubMed 26720490</li>
<li>Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-58. [PubMed 22046106</li>
<li>Tracz K, Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br J Clin Pharmacol. 2015;79(4):669-676. [PubMed 25293524</li>
<li>Obal D, Yang D, Sessler DI. Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Mayo Clin Proc. 2014;89(1):69-80. [PubMed 24388024</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder TClinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort studyBr J Clin Pharmacol2009;67(3):347-354[PubMed 19523015</li>
<li>Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105(2):389-395. [PubMed 8306734</li>
<li>Kroll CR, Gettes LS. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol. 2002;13(9):936-938. [PubMed 12380935</li>
<li>Otsuka M, Kanamori H, Sasaki S, et al. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med. 1997;36(10):705-708. [PubMed 9372331</li>
<li>Farguhar Zanetti LA, Oliphant CM. Pentamidine-induced torsades de pointes. Ann Pharmacother. 1994;28(2):282-283. [PubMed 8173154</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</li>
<li>Matsuo J, Yamaori S. Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. [published online ahead of print] J Clin Pharm Ther. 2021. doi:10.1111/jcpt.13539. [PubMed 34664726</li>
<li>Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther. 1988;43(5):577-581. [PubMed 3365919</li>
<li>Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol. 2003;41(8):1199-1201. [PubMed 12842189</li>
<li>Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality. 1991;3(1):14-18. [PubMed 2039678</li>
<li>Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</li>
<li>Kaukab I, Shah SNH, Abrar MA, Anwer N, Murtaza G. Influence of rifampicin pre-treatment on the in vivo pharmacokinetics of metoclopramide in Pakistani healthy volunteers following concurrent oral administration. Curr Drug Metab. 2020;21(4):301-306. [PubMed 32407272]</li>
<li>Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003:31(5):631-636. [PubMed 12695352]</li>
<li>Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.</li>
<li>Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2016;37(1):15-27. [PubMed 26356245</li>
<li>Pham CP, de Feiter PW, van der Kuy PHM, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7-8):1456-1461. [PubMed 16849620</li>
<li>Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc.; March 2015.</li>
<li>Yoshizato T, Kotegawa T, Imai H, et al. Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol. 2012;68(9):1287-1294. [PubMed 22418831</li>
<li>Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411-421. [PubMed 21883386</li>
<li>Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63(6):656</li>
<li>[PubMed 18477279</li>
<li>Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179(3):172. [PubMed 12885276</li>
<li>Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron. 2002;90(2):234</li>
<li>[PubMed 11818715</li>
<li>Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009;2009. [PubMed 21931583</li>
<li>Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum Mal Osteoartic. 1992;59(4):281</li>
<li>(Article in French) [PubMed 1496277</li>
<li>Collidge TA, Razvi S, Nolan C, et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barre syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med. 2010;27(6):696-700. [PubMed 20546290</li>
<li>Kearney S, Carr AS, McConville J, McCarron MO, Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ. 2012;345:e6562. [PubMed 23047962</li>
<li>O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325</li>
<li>[PubMed 18644925</li>
<li>Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka EAcute rhabdomyolysis after atorvastatin and fusidic acid therapyAm J Med2000;109(1)</li>
<li>[PubMed 10991749</li>
<li>Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33</li>
<li>Xelenta (lefamulin) [prescribing information]. Ireland: Nabriva Therapeutics US, Inc.; August 2019.</li>
<li>Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213-1217. [PubMed 21732066</li>
<li>Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46(8):722-730. [PubMed 2665687</li>
<li>Orap (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon VRisk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugsJ Clin Psychopharmacol2017;37(5):540-545[PubMed 28817488</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2019</li>
<li>Panos G, Velissaris D, Karamouzos V, Matzaroglou C, Tylianakis M. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295-300. [PubMed 27125217</li>
<li>Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. [PubMed 20297862</li>
<li>Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355-2358. [PubMed 28475803</li>
<li>Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301-311. [PubMed 19646076</li>
<li>Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726-1734. [PubMed 16705579]</li>
<li>van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-1014. [PubMed 20925438</li>
<li>Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421-424. [PubMed 25828198</li>
<li>Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888. [PubMed 20652862</li>
<li>Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663-666. [PubMed 18589449</li>
<li>Vieira MC, Miyague NI, Van Steen K, et al. Effects of domperidone on QTc interval in infants. Acta Paediatr. 2012;101(5):494-496. [PubMed 22226330</li>
<li>Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-723. [PubMed 15690231</li>
<li>Digby G, Machaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17(2):184-188. [PubMed 20544619</li>
<li>Fais P, Vermiglio E, Laposata C, et al. A case of sudden cardiac death following Domperidone self-medication. Forensic Sci Int. 2015;254:e1-e3. [PubMed 26119456</li>
<li>Domperidone [product monograph]Toronto, Ontario, Canada: Apotex Inc; March 2015</li>
<li>Xalkori (crizotinib) [prescribing information]. New York, NY: Pfizer Inc; March 2016</li>
<li>Kisqali (ribociclib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2017</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2018</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et alDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes2013;6(4):479-487[PubMed 23716032</li>
<li>Rocha CM, Barbosa MMQT interval prolongation associated with the oral use of domperidone in an infantPediatr Cardiol2005;26(5):720-723[PubMed 15690231</li>
<li>Romero J, Baldinger SH, Goodman-Meza D, et al. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol. 2016;45(1):37-45. [PubMed 26589717</li>
<li>Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. 2012;52(4):520-529. [PubMed 21558456</li>
<li>Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk AClarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reportsTher Adv Infect Dis2013;1(4):121-138[PubMed 25165548</li>
<li>Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2017</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019</li>
<li>Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204. [PubMed 20673553</li>
<li>Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. [PubMed 16317317</li>
<li>Meyer-MassettiC, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et alThe FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med2010;5(4):E8-16[PubMed 20394022</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketin analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon VDevelopment of a risk score for QTc-prolongation: the RISQ-PATH studyInt J Clin Pharm2017;39(2):424-432[PubMed 28281228</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsaes de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Parlodel (bromocriptine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; July 2021</li>
<li>Bromocriptine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.</li>
<li>Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2019</li>
<li>Sangana R, Gu H, Chun DY, Einolf HJ. Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches. Drug Metab Dispos. 2018;46(1):26-32. [PubMed 29038231]</li>
<li>Devandla A, Yamsani SK, Yamsani MR. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers. Drug Metab Pers Ther. 2015;30(4):257-261. [PubMed 26353177]</li>
<li>Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287</li>
<li>Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E16. [PubMed 20394022</li>
<li>Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262-268. [PubMed 15231861</li>
<li>Kitagawa K, Kawada K, Morita S, et al. Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 2012;23(3):743-747. [PubMed 21690231</li>
<li>Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16(11):3019-3027. [PubMed 20501625</li>
<li>Kim H-H, An SH, Cho YH, Kim S-Y, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013;52(6):1223-1224. [PubMed 23368679</li>
<li>Chung LW, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156-157. [PubMed 18618340</li>
<li>Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. [PubMed 20529041</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJThe FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med2010;5(4):E8-E16[PubMed 20394022</li>
<li>Product monograph. Dom-Domperidone (domperidone). Montreal, Quebec, Canada: Dominion Pharmaceutical, May 2012.</li>
<li>Min JJ, Lee J, Lee H-C, Ryu H-G, Shin M, Kim HJ. A comparison of the effects of sevoflurane and desflurane on corrected QT interval prolongation in patients undergoing living donor liver transplantation: a prospective observational study. Transplant Proc. 2016;48(1):96-101. [PubMed 26915850</li>
<li>Bestas A, Hanbeyoglu O, Keles E, Bayar MK. The effect of adrenaline on desflurane-induced prolonged QTc interval: a randomized double-blind trial. Eur Rev Med Pharmacol Sci. 2013;17(11):1523-1528. [PubMed 23771541</li>
<li>Liu Y, Fu X, Gao H, Ren Y, Li H, He Y, Wang G. Effects of different concentrations of desflurane on the index of cardiac electrophysiological balance in gynecologic surgery patients. Can J Physiol Pharmacol. 2020;98(5):332-335. [PubMed 31770012</li>
<li>Aypar E, Karagoz AH, Ozer S, Celiker A, Ocal T. The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac rhythm in children. Paediatr Anaesth. 2007;17(6):563-567. [PubMed 17498019</li>
<li>Owczuk R, Wujtewicz MA, Sawicka W,Lasek J, Wujtewicz M. The influence of desflurane on QTc interval. Anesth Analg. 2005;101(2):419-422. [PubMed 16037155</li>
<li>Lindgren L, Saarnivaara L. Cardiovascular responses to enflurane induction followed by suxamethonium in children. Br J Anaesth. 1983;55(4):269-273. [PubMed 6838741</li>
<li>Lindgren L. E.C.G. changes during halothane and enflurane anaesthesia for E.N.T. surgery in children. Br J Anaesth. 1981;53(6):653-662. [PubMed 7248128</li>
<li>Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol. 2001;67(9):637-640. [PubMed 11731753</li>
<li>Kuenszberg E, Loeckinger A, Kleinsasser A, Lindner KH, Peuhringer F, Hoermann CSevoflurane progressively prolongs the QT interval in unpremedicated female adultsEur J Anaesthesiol2000;17(11):662-664[PubMed 11029563</li>
<li>Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, Lindner KH, Peuhringer F. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg. 2000;90(1):25-27. [PubMed 10624970</li>
<li>Silay E, Kati I, Tekin M, Guler N, Huseyinoglu UA, Coskuner I, Yagmur C. Comparison of the effects of desflurane and sevoflurane on the QTc interval and QT dispersion. Acta Cardiol. 2005;60(5):459-464. [PubMed 16261774</li>
<li>Thiruvenkatarajan V, Osborn KD, Van Wijk RMAW, Euler P, Sethi R, Moodie S, Biradar V. Torsade de pointes in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia. Anaesth Intensive Care. 2010;38(3):555-559. [PubMed 20514968</li>
<li>Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg. 1998;86(4):701-702. [PubMed 9539586</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E[PubMed 20394022</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 220664]</li>
<li>L’Hommedieu CS, Nicholas D, Armes DA, et al, “Potentiation of Magnesium Sulfate-Induced Neuromuscular Weakness by Gentamicin, Tobramycin, and Amikacin,” J Pediatr, 1983, 102(4):629-31. [PubMed 6834204]</li>
<li>Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994;38(2):326-329. [PubMed 7910724</li>
<li>Nix DE, Watson WA, Handy L, et al. The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin. Pharmacotherapy. 1989;9(6):377-380. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum. Antimicrob Agents Chemother. 1990;34:931-933. [PubMed 2360833</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al. Combined Use of Ciprofloxacin and Sucralfate. DICP. 1991;25:578-582. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin Levels When Receiving Sucralfate. JAMA. 1989;262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin. Antimicrob Agents Chemother. 1989;33(1):99-102. [PubMed 2712548</li>
<li>Lehto PL, Kivisto KT. Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin. Antimicrob Agents Chemother. 1994;38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al. Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers. Antimicrob Agents Chemother. 1992;36:2785-2760. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al. The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers. Eur J Clin Pharmacol. 1994;47(1):67-69. [PubMed 7988627</li>
<li>Zix JAPharmacokinetics of Sparfloxacin and Interaction With Cisapride and SucralfateAntimicrob Agents Chemother1997;41:1668-1672[PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al. The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin. Br J Clin Pharmacol. 2000;49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al. The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers. Int J Antimicrob Agents. 2000;15(4):283-289. [PubMed 10929878</li>
<li>Stass H, Schuhly U, Moller JG, et al. Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, A Novel 8-methoxyfluoroquinolone, in Healthy Volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):49-55. [PubMed 11352442</li>
<li>Lehto PL, Kivisto KT. Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate absorption. DICP. 1991;25(7-8):745-746. [PubMed 1949932</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; June 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed [March 6, 2020].</li>
<li>Furosemide tablets [prescribing information]. Somerset, NJ: Solco Healthcare US, LLC: April 2020.</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ., 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205[PubMed 3011882</li>
<li>Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed). 1983;286(6375):1379-1381. [PubMed 6404468</li>
<li>Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis. 1989;13(3):194-199. [PubMed 2919600</li>
<li>Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int. 1990;47(5):291-295. [PubMed 2257522</li>
<li>Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. Nutr Clin Pract. 1991;6(5):199-201. [PubMed 1775116</li>
<li>Spivey JM, Cummings DM, Pierson NR, “Failure of Prostatitis Treatment Secondary to Probable Ciprofloxacin-Sucralfate Drug Interaction,” Pharmacotherapy, 1996, 16(2):314</li>
<li>[PubMed 8820479</li>
<li>Nix DE, Watson WA, Handy L, et al, “The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin,” Pharmacotherapy, 1989, 9(6):377-80. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al, “Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum,” Antimicrob Agents Chemother, 1990, 34:931</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al, “Combined Use of Ciprofloxacin and Sucralfate,” DICP, 1991, 25:578-82. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, and Quintiliani R, “Ciprofloxacin Levels When Receiving Sucralfate,” JAMA, 1989, 262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al, “Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin,” Antimicrob Agents Chemother, 1989, 33(1):99-102. [PubMed 2712548</li>
<li>Lehto P and Kivisto KT, “Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin,” Antimicrob Agents Chemother, 1994, 38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al, “Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers,” Antimicrob Agents Chemother, 1992, 36:2785-60. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al, “The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers,” Eur J Clin Pharmacol, 1994, 47(1):67</li>
<li>Zix JA, “Pharmacokinetics of Sparfloxacin and Interaction With Cisapride and Sucralfate,” Antimicrob Agents Chemother, 1997, 41:1668-72. [PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al, “The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin,” Br J Clin Pharmacol, 2000, 49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al, “The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers,” Int J Antimicrob Agents, 2000, 15(4):283</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of helicobacter pylori. Chem Pharm Bull (Tokyo). 2008;56(10):1412-1416. [PubMed 18827380</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. The acidic complexation of tetracycline with sucralfate for its mucoadhesive preparation. Drug Dev Ind Pharm. 2004;30(7):715-724. [PubMed 15491049</li>
<li>Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol Suppl. 1995;210:82-844. [PubMed 8578215]</li>
<li>Urso Forte (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; June 2013</li>
<li>Sucralfate [prescribing information]. Largo, FL: VistaPharm, Inc.; February 2020</li>
<li>Dovonex (calcipotriene) cream [prescribing information]Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]. Greenville, NC: Mayne Pharma; May 2019</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845]</li>
<li>Havrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med. 1992;117(5):445-446. [PubMed 1503346</li>
<li>Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994;96(6):531-535. [PubMed 8017451</li>
<li>Khan F, Jeanniton E, Renedo M. Does sucralfate impede levothyroxine therapy? Ann Intern Med. 1993;118(4):317. [PubMed 8481187</li>
<li>Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. Ann Intern Med. 1994;121(2):152. [PubMed 8017736</li>
<li>Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2020.</li>
<li>Smart HL, Somerville KW, Williams J, Richens A, Langman MJ. The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol. 1985;20(3):238-240. [PubMed 3840029</li>
<li>Hall TG, Cuddy PG, Glass CJ, Melethil S. Effect of sucralfate on phenytoin bioavailability. Drug Intell Clin Pharm. 1986;20(7-8):607-611. [PubMed 3755676</li>
<li>Malli R, Jones WN, Rindone JP, Labadie EL. The effect of sucralfate on the steady-state serum concentrations of phenytoin. Drug Metabol Drug Interact. 1989;7(4):287-293. [PubMed 2489199</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2022.</li>
<li>Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin. Ann Intern Med. 1983;98(4):557. [PubMed 6687662</li>
<li>Braverman SE, Marino MT. Sucralfate-warfarin interaction. Drug Intell Clin Pharm. 1988;22:913. [PubMed 3234259</li>
<li>Parrish RH, Waller B, Gondalia BG. Sucralfate-warfarin interaction. Ann Pharmacother. 1992;26:1015-1016. [PubMed 1504385</li>
<li>Neuvonen PJ, Jaakkola A, Totterman J, Penttila O. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol. 1985;20(2):178-179. [PubMed 3840028</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med. 1989;86(6A):38-44. [PubMed 2735334</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med. 1987;83(3B):67-73. [PubMed 3661612</li>
<li>Caille G, du Souich P, Gervais P, Besner JG. Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharm Drug Dispos. 1987;8(2):173-183. [PubMed 3593897</li>
<li>Lafontaine D, Mailhot C, Vermeulen M, Bissonnette B, Lambert C. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm. 1990;9(10):773-777. [PubMed 2242657</li>
<li>Crysvita (burosumab-twza) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; September 2019.</li>
<li>Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010</li>
<li>Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004</li>
<li>Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010</li>
<li>Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007</li>
<li>Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010</li>
<li>Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</li>
<li>One-Alpha (alfacalcidol) oral drops [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories; July 2020</li>
<li>Rocaltrol (calcitriol) oral solution [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019.</li>
<li>Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2(1):10-32. [PubMed 3547004</li>
<li>West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975;16(2):93-98. [PubMed 1168607</li>
<li>Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut. 1969;10(9):717-722. [PubMed 4318526</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Welchol (colesevelam) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; June 2013</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010</li>
<li>Rocaltrol (calcitriol) [prescribing information. Parisppany, NJ: Validus Pharmaceuticals LLC; July 2009</li>
<li>Rayaldee (calcifediol) [prescribing information]Miami, FL: OPKO Pharmaceuticals LLC; June 2016</li>
<li>Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. Gastroenterology. 1972;62(4):642-646. [PubMed 5020877</li>
<li>Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology. 1978;74(5 pt 1):900-902. [PubMed 640344</li>
<li>Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. Dig Dis Sci. 1985;30(5):477-482. [PubMed 3987479</li>
<li>Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427-430. [PubMed 2125243</li>
<li>Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med. 1992;119(4):407-411. [PubMed 1583392</li>
<li>Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980;65(2):243-250. [PubMed 7354970]</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2011</li>
<li>Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2007</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario:LEO Pharma Inc.; March 2010.</li>
<li>Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015</li>
<li>Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36(7):647-653. [PubMed 8844448</li>
<li>Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306-313. [PubMed 10757623</li>
<li>McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-822. [PubMed 12126214]</li>
<li>Vella A, Gerber TC, Hayes DL, et al. Digoxin, hypercalcemia, and cardiac conduction. Postgrad Med J. 1999;75:554-556. [PubMed 10616693</li>
<li>Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. [PubMed 22998989</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018.</li>
<li>Formosa N, Torpiano J, Allgrove J, Dattani MT. Anticonvulsant treatment associated with intractable hypocalcaemia in a female child with hypoparathyroidism. Horm Res Paediatr. 2015;83(1):62-66. [PubMed 25227206</li>
<li>Rubinger D, Korn-Lubetzki I, Feldman S, Popovtzer MM. Delayed response to a alpha-hydroxycholecalciferol therapy in a case of hypoparathyroidism during anticonvulsant therapy. Isr J Med Sci. 1980;16(11);772-774. [PubMed 7440128</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc; August 2017.</li>
<li>Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011</li>
<li>Hepburn NC, Abdul-Aziz LA and Whiteoak R, “Danazol-Induced Hypercalcaemia in Alphacalcidol-Treated Hypoparathyroidism,” Postgrad Med J, 1989, 65(769):849-50. [PubMed 2616424]</li>
<li>Lemann J, Jr., Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28:951-958. [PubMed 3003445</li>
<li>Santos F, Smith MJ,Chan JC. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. Am J Dis Child. 1986;140:139-142. [PubMed 3753816</li>
<li>Brickman AS, Massry SG,Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms. J Clin Invest. 1972;51:945-954. [PubMed 4552338</li>
<li>Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res. 2006;38:821-826. [PubMed 17163358</li>
<li>Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12:531-535. [PubMed 2592738</li>
<li>Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250:144-153. [PubMed 11489064</li>
<li>Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34:421-424. [PubMed 3887100</li>
<li>Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33:1140-1146. [PubMed 3404813</li>
<li>Nowack R, Hofner MC, Reichel H, et alSubacute effects of thiazide administration on renal hemodynamics and calcium metabolismClin Investig1992;70:686-691[PubMed 1392446</li>
<li>Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50. [PubMed 12492451</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019.</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201-2. doi: 10.4212/cjhp.v66i3.1261. PMID: 23814291; PMCID: PMC3694945.Ы</li>
              </ol>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>
    </div>

    <div class="repeated" id="repeated-test-page">
      <section class="repeated__section">
        <div class="repeated__container">
          <div class="repeated__card">
            <div class="repeated-header">
              <div class="repeated-header__top">
                <div id="repeated-header-label" class="repeated-header__label">
                  Шаг 1: Уточняющие вопросы
                </div>
                <div
                  id="repeated-header-percent"
                  class="repeated-header__percent"
                >
                  30%
                </div>
                <div
                  id="repeated-header-progress-bar"
                  class="repeated-header__bar repeated-bar"
                >
                  <span style="width: 30%" class="repeated-bar__span"></span>
                </div>
              </div>
              <button class="repeated-header__back-btn btn-reset">Назад</button>
            </div>

            <div class="repeated-content">
              <div
                id="slide-1"
                class="repeated-content__slide repeated-content__slide--active"
              >
                <div class="repeated-content__header">
                  <h1 class="repeated-content__title title-reset">
                    обследование
                  </h1>
                  <h2 class="repeated-content__subtitle title-reset">
                    Какие исследования были проведены пациенту?
                  </h2>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-list list-reset">
                    <li class="repeated-list__item">
                      <input
                        class="repeated-list__checkbox repeated-list__checkbox_slide-1"
                        type="checkbox"
                        id="checkbox-1"
                        name="checkbox-1"
                        value="1"
                      />
                      <label for="checkbox-1" class="repeated-list__label"
                        >ЭГДС</label
                      >
                    </li>
                    <li class="repeated-list__item">
                      <input
                        class="repeated-list__checkbox repeated-list__checkbox_slide-1"
                        type="checkbox"
                        id="checkbox-2"
                        name="checkbox-2"
                        value="2"
                      />
                      <label for="checkbox-2" class="repeated-list__label"
                        >pH-импедансометрия</label
                      >
                    </li>
                    <li class="repeated-list__item">
                      <input
                        class="repeated-list__checkbox repeated-list__checkbox_slide-1"
                        type="checkbox"
                        id="checkbox-3"
                        name="checkbox-3"
                        value="3"
                      />
                      <label for="checkbox-3" class="repeated-list__label"
                        >Манометрия высокого разрешения</label
                      >
                    </li>
                    <li class="repeated-list__item">
                      <input
                        class="repeated-list__checkbox repeated-list__checkbox_slide-1"
                        type="checkbox"
                        id="checkbox-4"
                        name="checkbox-4"
                        value="4"
                      />
                      <label for="checkbox-4" class="repeated-list__label"
                        >Рентгеноскопия пищевода и желудка с сульфатом
                        бария</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-2" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">ЭГДС</h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    В ходе ЭГДС выявлены признаки повреждения слизистой оболочки
                    пищевода?
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-2-1"
                        name="repeated-buttons-slide-2"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-2-1"
                        class="repeated-buttons__label"
                        >Да</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-2-2"
                        name="repeated-buttons-slide-2"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-2-2"
                        class="repeated-buttons__label"
                        >Нет</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-3" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    pH-импедансометрия
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Процент времени, в течение которого
                    pH&nbsp;был&nbsp;&lt;&nbsp;4
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-3-1"
                        name="repeated-buttons-slide-3"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-3-1"
                        class="repeated-buttons__label"
                        >Менее 4%</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-3-2"
                        name="repeated-buttons-slide-3"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-3-2"
                        class="repeated-buttons__label"
                        >От 4% до 6%</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-3-3"
                        name="repeated-buttons-slide-3"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-3-3"
                        class="repeated-buttons__label"
                        >Более 6%</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-4" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    pH-импедансометрия
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Индекс симптома (ИС) &gt; 50% ?
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-4-1"
                        name="repeated-buttons-slide-4"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-4-1"
                        class="repeated-buttons__label"
                        >Да</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-4-2"
                        name="repeated-buttons-slide-4"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-4-2"
                        class="repeated-buttons__label"
                        >Нет</label
                      >
                    </li>
                  </ul>
                </div>
                <div class="repeated-tab">
                  <button class="repeated-tab__header btn-reset">
                    Рассчитать индекс симптома
                  </button>
                  <div class="repeated-tab__content">
                    <h3 class="repeated-tab__title title-reset">
                      Расчет Индекса симптома (ИС):
                    </h3>
                    <div class="repeated-tab__field">
                      <label
                        for="repeated-tab-input-1"
                        class="repeated-tab__label"
                      >
                        Введите количество рефлюксов, которые сопровождались
                        снижением pH&nbsp;менее 4,0&nbsp;в&nbsp;ходе
                        pH-импедансометрии:
                      </label>
                      <div class="repeated-tab__block">
                        <input
                          id="repeated-tab-input-1"
                          type="number"
                          class="repeated-tab__input input-reset"
                          placeholder="0"
                          name="symptom-index-x"
                        />
                        <span class="repeated-tab__span">X</span>
                      </div>
                    </div>
                    <div class="repeated-tab__field">
                      <label
                        for="repeated-tab-input-2"
                        class="repeated-tab__label"
                      >
                        Введите количество эпизодов ГЭРБ, которые возникали
                        у&nbsp;пациента в&nbsp;течение всего времени проведения
                        исследования:</label
                      >
                      <div class="repeated-tab__block">
                        <input
                          id="repeated-tab-input-2"
                          type="number"
                          class="repeated-tab__input input-reset"
                          placeholder="0"
                          name="symptom-index-y"
                        />
                        <span class="repeated-tab__span">Y</span>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

              <div id="slide-5" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Рентгеноскопия пищевода и желудка с сульфатом бария
                  </h2>
                </div>
                <div class="repeated-content__main">
                  <div class="repeated-symptoms">
                    <button
                      class="repeated-symptoms__btn btn-reset"
                      type="button"
                      name="repeated-symptoms-slide-5-1"
                    >
                      <ul class="repeated-symptoms__list">
                        <li class="repeated-symptoms__item">
                          Наличие уровня жидкости и воздуха в пустом пищеводе
                        </li>
                        <li class="repeated-symptoms__item">
                          Отсутствие газового пузыря желудка
                        </li>
                        <li class="repeated-symptoms__item">
                          Отсутствие первичной перистальтики
                        </li>
                        <li class="repeated-symptoms__item">
                          Третичные сокращения пищевода
                        </li>
                      </ul>
                      <ul class="repeated-symptoms__list">
                        <li class="repeated-symptoms__item">
                          Медленное опорожнение пищевода
                        </li>
                        <li class="repeated-symptoms__item">
                          Может наблюдаться расширение просвета пищевода и его
                          S-образная деформация
                        </li>
                        <li class="repeated-symptoms__item">
                          Сужение на уровне пищеводно-желудочного перехода
                          (симптом птичьего клюва)
                        </li>
                      </ul>
                    </button>
                    <button
                      class="repeated-symptoms__btn btn-reset"
                      type="button"
                      name="repeated-symptoms-slide-5-2"
                    >
                      <ul
                        class="repeated-symptoms__list repeated-symptoms__list_alone"
                      >
                        <li class="repeated-symptoms__item">
                          Периодически возникающие нескоординированные
                          спастические сокращения пищевода
                        </li>
                        <li class="repeated-symptoms__item">
                          Нормальный тонус нижнего пищеводного сфинктера
                          сохранен, раскрывается рефлекторно во время глотания
                        </li>
                        <li class="repeated-symptoms__item">
                          Могут наблюдаться деформации в виде «четок»,
                          «штопора», псевдодивертикулов
                        </li>
                      </ul>
                    </button>
                    <button
                      class="repeated-symptoms__btn btn-reset"
                      type="button"
                      name="repeated-symptoms-slide-5-3"
                    >
                      <ul
                        class="repeated-symptoms__list repeated-symptoms__list_alone"
                      >
                        <li class="repeated-symptoms__item">
                          Желудочные складки обнаруживаются в проекции
                          пищеводного отверстия диафрагмы
                        </li>
                        <li class="repeated-symptoms__item">
                          Грыжевая часть желудка образует выпячивание округлой
                          формы, которое широко сообщается с поддиафрагмальной
                          частью желудка
                        </li>
                        <li class="repeated-symptoms__item">
                          Косвенные признаки грыж ПОД: малый размер газового
                          пузыря и искривление наддиафрагмального отдела
                          пищевода
                        </li>
                      </ul>
                    </button>
                  </div>
                </div>
              </div>

              <div id="slide-6" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    pH-импедансометрия
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Количество эпизодов рефлюкса в течение исследования?
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-6-1"
                        name="repeated-buttons-slide-6"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-6-1"
                        class="repeated-buttons__label"
                        >&lt; 80</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-6-2"
                        name="repeated-buttons-slide-6"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-6-2"
                        class="repeated-buttons__label"
                        >&gt; 80</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-7" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Манометрия высокого разрешения
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Значение суммарного давления расслабления (IRP)
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-7-1"
                        name="repeated-buttons-slide-7"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-7-1"
                        class="repeated-buttons__label"
                        >&gt;15 мм рт.ст.</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-7-2"
                        name="repeated-buttons-slide-7"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-7-2"
                        class="repeated-buttons__label"
                      >
                        &lt; 15 мм рт.ст.</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-8" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Манометрия высокого разрешения
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Оценка перистальтической активности
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-8-1"
                        name="repeated-buttons-slide-8"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-8-1"
                        class="repeated-buttons__label"
                        >Перистальтика отсутствует</label
                      >
                    </li>
                    <li
                      class="repeated-buttons__item repeated-buttons__item_big"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-8-2"
                        name="repeated-buttons-slide-8"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-8-2"
                        class="repeated-buttons__label"
                      >
                        Перистальтика снижена или в норме</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-9" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Манометрия высокого разрешения
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Оценка перистальтической активности
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li
                      class="repeated-buttons__item repeated-buttons__item_full-width"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-9-1"
                        name="repeated-buttons-slide-9"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-9-1"
                        class="repeated-buttons__label"
                        >Отсутствие сокращений пищевода в 100% глотков
                        (перистальтика отсутствует) (ИСДС &lt; 100 мм рт.
                        ст.)</label
                      >
                    </li>
                    <li
                      class="repeated-buttons__item repeated-buttons__item_full-width"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-9-2"
                        name="repeated-buttons-slide-9"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-9-2"
                        class="repeated-buttons__label"
                        >Время латентного периода дистального сегмента пищевода
                        (DL) &lt; 4,5 сек, может сопровождаться незавершенным
                        транзитом болюса</label
                      >
                    </li>
                    <li
                      class="repeated-buttons__item repeated-buttons__item_full-width"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-9-3"
                        name="repeated-buttons-slide-9"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-9-3"
                        class="repeated-buttons__label"
                        >Интегральная сократимость дистального сегмента пищевода
                        (DCI) &gt; 8000 мм рт. ст. х с х см в 20% и более
                        глотков</label
                      >
                    </li>
                    <li
                      class="repeated-buttons__item repeated-buttons__item_full-width"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-9-4"
                        name="repeated-buttons-slide-9"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-9-4"
                        class="repeated-buttons__label"
                        >Неэффективные сокращения пищевода в ≥ 70% глотков с
                        ИСДС &lt; 450 мм рт. ст. х с х см или 50% глотков
                        отсутствуют</label
                      >
                    </li>
                    <li
                      class="repeated-buttons__item repeated-buttons__item_full-width"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-9-5"
                        name="repeated-buttons-slide-9"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-9-5"
                        class="repeated-buttons__label"
                        >Увеличение длины разрыва сокращения стенки пищевода
                        (фрагментированное сокращение) &gt; 5 см в ≥ 50% глотков
                        с ИСДС &gt; 450 мм рт. ст. х с х см</label
                      >
                    </li>
                    <li
                      class="repeated-buttons__item repeated-buttons__item_full-width"
                    >
                      <input
                        type="radio"
                        id="repeated-buttons-slide-9-6"
                        name="repeated-buttons-slide-9"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-9-6"
                        class="repeated-buttons__label"
                        >Перистальтика в норме</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-10" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Для оценки полной клинической картины заболевания и
                    постановки правильного диагноза пациенту рекомендуется
                    проведение ЭГДС
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Хотите оценить результаты проведенных исследований?
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <ul class="repeated-buttons list-reset">
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-10-1"
                        name="repeated-buttons-slide-10"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-10-1"
                        class="repeated-buttons__label"
                        >Да</label
                      >
                    </li>
                    <li class="repeated-buttons__item">
                      <input
                        type="radio"
                        id="repeated-buttons-slide-10-2"
                        name="repeated-buttons-slide-10"
                        class="repeated-buttons__input"
                      />
                      <label
                        for="repeated-buttons-slide-10-2"
                        class="repeated-buttons__label"
                        >Нет</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-11" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    повреждения слизистой оболочки пищевода
                  </h2>
                </div>
                <div class="repeated-content__main">
                  <div class="repeated-content__question">
                    <h3 class="repeated-content__subtitle title-reset">
                      Обнаружены стриктуры пищевода?
                    </h3>
                    <ul class="repeated-buttons list-reset">
                      <li class="repeated-buttons__item">
                        <input
                          type="radio"
                          id="repeated-buttons-slide-11-1"
                          name="repeated-buttons-slide-11/1"
                          class="repeated-buttons__input"
                        />
                        <label
                          for="repeated-buttons-slide-11-1"
                          class="repeated-buttons__label"
                          >Да</label
                        >
                      </li>
                      <li class="repeated-buttons__item">
                        <input
                          type="radio"
                          id="repeated-buttons-slide-11-2"
                          name="repeated-buttons-slide-11/1"
                          class="repeated-buttons__input"
                        />
                        <label
                          for="repeated-buttons-slide-11-2"
                          class="repeated-buttons__label"
                          >Нет</label
                        >
                      </li>
                    </ul>
                    <div class="repeated-content__dangerous">
                      Рассмотреть возможность оперативного лечения
                    </div>
                  </div>
                  <div class="repeated-content__question">
                    <h3 class="repeated-content__subtitle title-reset">
                      Обнаружены признаки аденокарциномы пищевода?
                    </h3>
                    <ul class="repeated-buttons list-reset">
                      <li class="repeated-buttons__item">
                        <input
                          type="radio"
                          id="repeated-buttons-slide-11-3"
                          name="repeated-buttons-slide-11/2"
                          class="repeated-buttons__input"
                        />
                        <label
                          for="repeated-buttons-slide-11-3"
                          class="repeated-buttons__label"
                          >Да</label
                        >
                      </li>
                      <li class="repeated-buttons__item">
                        <input
                          type="radio"
                          id="repeated-buttons-slide-11-4"
                          name="repeated-buttons-slide-11/2"
                          class="repeated-buttons__input"
                        />
                        <label
                          for="repeated-buttons-slide-11-4"
                          class="repeated-buttons__label"
                          >Нет</label
                        >
                      </li>
                    </ul>
                    <div class="repeated-content__dangerous">
                      Необходима консультация онколога
                    </div>
                  </div>
                  <div class="repeated-content__question">
                    <h3 class="repeated-content__subtitle title-reset">
                      Обнаружены признаки пищевода Барретта?
                    </h3>
                    <ul class="repeated-buttons list-reset">
                      <li class="repeated-buttons__item">
                        <input
                          type="radio"
                          id="repeated-buttons-slide-11-5"
                          name="repeated-buttons-slide-11/3"
                          class="repeated-buttons__input"
                        />
                        <label
                          for="repeated-buttons-slide-11-5"
                          class="repeated-buttons__label"
                          >Да</label
                        >
                      </li>
                      <li class="repeated-buttons__item">
                        <input
                          type="radio"
                          id="repeated-buttons-slide-11-6"
                          name="repeated-buttons-slide-11/3"
                          class="repeated-buttons__input"
                        />
                        <label
                          for="repeated-buttons-slide-11-6"
                          class="repeated-buttons__label"
                          >Нет</label
                        >
                      </li>
                    </ul>
                  </div>
                </div>
              </div>

              <div id="slide-12" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    повреждения слизистой оболочки пищевода
                  </h2>
                  <h3 class="repeated-content__subtitle title-reset">
                    Участки повреждения слизистой оболочки:
                  </h3>
                </div>
                <div class="repeated-content__main">
                  <div class="repeated-plots">
                    <div class="repeated-plots__wrapper">
                      <button
                        class="repeated-plots__btn btn-reset"
                        type="button"
                        onclick="ym(90602537,'reachGoal','cdss_end2'); return true;"
                      >
                        <strong>Размером до 5 мм</strong>, расположены на
                        вершине складок (не затрагивают ткани внутри
                        складки).<br /><br />
                        Эрозивный эзофагит степени А, согласно Лос-Анджелесской
                        классификации.
                      </button>
                      <button
                        class="repeated-plots__btn btn-reset"
                        type="button"
                        onclick="ym(90602537,'reachGoal','cdss_end2'); return true;"
                      >
                        <strong>Размером более 5 мм</strong>, расположены на
                        вершине складок (не затрагивают ткани внутри
                        складки).<br /><br />
                        Эрозивный эзофагит степени В, согласно Лос-Анджелесской
                        классификации.
                      </button>
                    </div>
                    <div class="repeated-plots__wrapper">
                      <button
                        class="repeated-plots__btn btn-reset"
                        type="button"
                        onclick="ym(90602537,'reachGoal','cdss_end2'); return true;"
                      >
                        Затрагивает ткани между двумя и более складками, но
                        вовлекает <strong>менее 75%</strong> окружности
                        пищевода.<br /><br />
                        Эрозивный эзофагит степени С, согласно Лос-Анджелесской
                        классификации.
                      </button>
                      <button
                        class="repeated-plots__btn btn-reset"
                        type="button"
                        onclick="ym(90602537,'reachGoal','cdss_end2'); return true;"
                      >
                        Вовлекает <strong>более 75%</strong> окружности
                        пищевода.<br /><br />
                        Эрозивный эзофагит степени D, согласно Лос-Анджелесской
                        классификации.
                      </button>
                    </div>
                  </div>
                  <ul class="repeated-list list-reset">
                    <li class="repeated-list__item">
                      <input
                        class="repeated-list__checkbox repeated-list__checkbox_slide-12"
                        type="checkbox"
                        id="slide-12-checkbox-1"
                        name="slide-12-checkbox-1"
                        value="1"
                      />
                      <label
                        for="slide-12-checkbox-1"
                        class="repeated-list__label"
                        >Есть признаки грыжи пищеводного отверстия
                        диафрагмы</label
                      >
                    </li>
                    <li class="repeated-list__item">
                      <input
                        class="repeated-list__checkbox repeated-list__checkbox_slide-12"
                        type="checkbox"
                        id="slide-12-checkbox-2"
                        name="slide-12-checkbox-2"
                        value="2"
                      />
                      <label
                        for="slide-12-checkbox-2"
                        class="repeated-list__label"
                        >Пациента беспокоят ночные симптомы</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-in-work" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">В работе!</h2>
                </div>
              </div>

              <div
                id="result-gerd-grade-a-esophagitis"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">диагноз</h2>
                  </div>

                  <div class="repeated-diagnosis repeated-diagnosis_row">
                    <span class="repeated-diagnosis__text">ГЭРБ</span>
                    <span
                      class="repeated-diagnosis__text repeated-diagnosis__text_grade"
                      >ЭЗОФАГИТ СТЕПЕНИ А</span
                    >
                  </div>

                  <div class="repeated-content__hernia">
                    <h2 class="repeated-content__title title-reset">
                      Дополнительные обследования
                    </h2>
                    <p class="repeated-content__text">
                      Согласно выбранным симптомам и проведению первичного
                      обследования рекомендованный список дополнительных
                      обследований:
                    </p>
                    <div class="repeated-recommendations">
                      <div class="repeated-recommendations__item">
                        <div class="repeated-recommendations__info">
                          <h3
                            class="repeated-recommendations__title title-reset"
                          >
                            Рентгеноскопия пищевода и желудка с сульфатом бария
                          </h3>
                          <a
                            href="/cdss/pdf/Подготовка к рентгеноскопии СППР.pdf"
                            target="_blank"
                            class="repeated-recommendations__memo"
                            >Памятка для пациента</a
                          >
                        </div>
                        <img
                          src="./img/icon-card-14.png"
                          class="repeated-recommendations__icon"
                          alt=""
                        />
                      </div>
                    </div>
                    <div class="repeated-content__divider"></div>
                  </div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Обсудите риск прогрессирования болезни и развитие таких
                        осложнений, как пищевод Барретта, стриктуры и АКП.
                      </p>
                    </div>
                  </div>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Дополнительно
                  </h3>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Назначить повторный прием после проведения терапии
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Назначение на 4 недели:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пантопразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в сутки
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик (по показаниям):
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                          <div class="repeated-recommendations__desc">
                            50 мг 3 раза в сутки
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                          <div class="repeated-recommendations__desc">
                            0,5–1 г 4 раза в сутки или по 1 г утром и вечером;
                            <br />
                            максимальная суточная доза — 8 г
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                          <div class="repeated-recommendations__desc">
                            по одному пакетику-саше 3 раза в день после приема
                            пищи и перед сном
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_night"
                    >
                      Учитывая наличие у пациента
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >ночных эпизодов ГЭРБ</span
                      >, при выборе препарата из класса ИПП рекомендуется
                      отдавать предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      > </a>, т.к. у препарата есть:
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_not-night"
                    >
                      При выборе препарата из класса ИПП рекомендуется отдавать
                      предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      > </a>, т.к. у препарата есть:
                    </p>
                  </div>

                  <div class="repeated-recommendations">
                    <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                        Уникальный цитопротективный эффект за счет секреции
                        слизи муцинов
                      </li>
                      <li class="repeated-recommendations__elem">
                        Минимальный риск межлекарственного взаимодействия
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                        Действие до 48 часов
                      </li>
                    </ul>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Рекомендуется добавление
                      <a href="/academy/preparation/ganaton" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >итоприда гидрохлорида</span
                      ></a>
                      для устранения моторных нарушений.
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >Итоприда гидрохлорид</span
                      >
                      доказано нормализует тонус НПС, улучшает ПРНПС и
                      антродуоденальную координацию, снижая количество эпизодов
                      рефлюкса.
                    </p>
                  </div>

                  <button
                    class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                    data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                    onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                  >
                    <img src="./img/magnifier.svg" alt="лупа" />
                    проверить межлекарственные взаимодействия
                  </button>

                  <div
                    class="repeated-content__divider repeated-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-gerd-grade-b-esophagitis"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">диагноз</h2>
                  </div>

                  <div class="repeated-diagnosis repeated-diagnosis_row">
                    <span class="repeated-diagnosis__text">ГЭРБ</span>
                    <span
                      class="repeated-diagnosis__text repeated-diagnosis__text_grade"
                      >ЭЗОФАГИТ СТЕПЕНИ b</span
                    >
                  </div>

                  <div class="repeated-content__hernia">
                    <h2 class="repeated-content__title title-reset">
                      Дополнительные обследования
                    </h2>
                    <p class="repeated-content__text">
                      Согласно выбранным симптомам и проведению первичного
                      обследования рекомендованный список дополнительных
                      обследований:
                    </p>
                    <div class="repeated-recommendations">
                      <div class="repeated-recommendations__item">
                        <div class="repeated-recommendations__info">
                          <h3
                            class="repeated-recommendations__title title-reset"
                          >
                            Рентгеноскопия пищевода и желудка с сульфатом бария
                          </h3>
                          <a
                            href="/cdss/pdf/Подготовка к рентгеноскопии СППР.pdf"
                            target="_blank"
                            class="repeated-recommendations__memo"
                            >Памятка для пациента</a
                          >
                        </div>
                        <img
                          src="./img/icon-card-14.png"
                          class="repeated-recommendations__icon"
                          alt=""
                        />
                      </div>
                    </div>
                    <div class="repeated-content__divider"></div>
                  </div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Обсудите риск прогрессирования болезни и развитие таких
                        осложнений, как пищевод Барретта, стриктуры и АКП.
                      </p>
                    </div>
                  </div>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Дополнительно
                  </h3>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Назначить повторный прием после проведения терапии
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      ЛЕКАРСТВЕННАЯ ТЕрапия:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП на выбор на срок 4-8 недель:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пантопразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в сутки
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                          <div class="repeated-recommendations__desc">
                            50 мг 3 раза в сутки
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                          <div class="repeated-recommendations__desc">
                            0,5–1 г 4 раза в сутки или по 1 г утром и вечером;
                            <br />
                            максимальная суточная доза — 8 г
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                          <div class="repeated-recommendations__desc">
                            по одному пакетику-саше 3 раза в день после приема
                            пищи и перед сном
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Учитывая степень повреждения слизистой оболочки пищевода,
                      рекомендовано увеличить длительность проводимой терапии на
                      срок до 8 недель.
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_night"
                    >
                      Учитывая наличие у пациента
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >ночных эпизодов ГЭРБ</span
                      >, при выборе препарата из класса ИПП рекомендуется
                      отдавать предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      ></a>, т.к. у препарата есть:
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_not-night"
                    >
                      При выборе препарата из класса ИПП рекомендуется отдавать
                      предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      > </a>, т.к. у препарата есть:
                    </p>
                  </div>

                  <div class="repeated-recommendations">
                    <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                        Купирование симптомов ГЭРБ быстрее других ИПП
                      </li>
                      <li class="repeated-recommendations__elem">
                        Уникальный цитопротективный эффект за счет секреции
                        слизи муцинов
                      </li>
                      <li class="repeated-recommendations__elem">
                        Минимальный риск межлекарственного взаимодействия
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                        Действие до 48 часов
                      </li>
                    </ul>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Рекомендуется добавление
                      <a href="/academy/preparation/ganaton" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >итоприда гидрохлорида</span
                      ></a>
                      для устранения моторных нарушений.
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >Итоприда гидрохлорид</span
                      >
                      доказано нормализует тонус НПС, улучшает ПРНПС и
                      антродуоденальную координацию, снижая количество эпизодов
                      рефлюкса.
                    </p>
                  </div>

                  <button
                    class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                    data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                    onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                  >
                    <img src="./img/magnifier.svg" alt="лупа" />
                    проверить межлекарственные взаимодействия
                  </button>

                  <div
                    class="repeated-content__divider repeated-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-gerd-grade-c-esophagitis"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">диагноз</h2>
                  </div>

                  <div class="repeated-diagnosis repeated-diagnosis_row">
                    <span class="repeated-diagnosis__text">ГЭРБ</span>
                    <span
                      class="repeated-diagnosis__text repeated-diagnosis__text_grade"
                      >ЭЗОФАГИТ СТЕПЕНИ c</span
                    >
                  </div>

                  <div class="repeated-content__hernia">
                    <h2 class="repeated-content__title title-reset">
                      Дополнительные обследования
                    </h2>
                    <p class="repeated-content__text">
                      Согласно выбранным симптомам и проведению первичного
                      обследования рекомендованный список дополнительных
                      обследований:
                    </p>
                    <div class="repeated-recommendations">
                      <div class="repeated-recommendations__item">
                        <div class="repeated-recommendations__info">
                          <h3
                            class="repeated-recommendations__title title-reset"
                          >
                            Рентгеноскопия пищевода и желудка с сульфатом бария
                          </h3>
                          <a
                            href="/cdss/pdf/Подготовка к рентгеноскопии СППР.pdf"
                            target="_blank"
                            class="repeated-recommendations__memo"
                            >Памятка для пациента</a
                          >
                        </div>
                        <img
                          src="./img/icon-card-14.png"
                          class="repeated-recommendations__icon"
                          alt=""
                        />
                      </div>
                    </div>
                    <div class="repeated-content__divider"></div>
                  </div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Обсудите риск прогрессирования болезни и развитие таких
                        осложнений, как пищевод Барретта, стриктуры и АКП.
                      </p>
                    </div>
                  </div>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Дополнительно
                  </h3>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Назначить повторный прием после проведения терапии
                          через 8 недель после начала терапии
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      ЛЕКАРСТВЕННАЯ ТЕрапия:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП на выбор на срок 4-8 недель:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пантопразол
                          <div class="repeated-recommendations__desc">
                            80 мг 1 раз в сутки
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                          <div class="repeated-recommendations__desc">
                            50 мг 3 раза в сутки
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                          <div class="repeated-recommendations__desc">
                            0,5–1 г 4 раза в сутки или по 1 г утром и вечером;
                            <br />
                            максимальная суточная доза — 8 г
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                          <div class="repeated-recommendations__desc">
                            по одному пакетику-саше 3 раза в день после приема
                            пищи и перед сном
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Учитывая степень повреждения слизистой оболочки пищевода,
                      рекомендовано увеличить длительность проводимой терапии на
                      срок до 8 недель.
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_night"
                    >
                      Учитывая наличие у пациента
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >ночных эпизодов ГЭРБ</span
                      >, при выборе препарата из класса ИПП рекомендуется
                      отдавать предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"> <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      ></a>, т.к. у препарата есть:
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_not-night"
                    >
                      При выборе препарата из класса ИПП рекомендуется отдавать
                      предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      > </a>, т.к. у препарата есть:
                    </p>
                  </div>

                  <div class="repeated-recommendations">
                    <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                        Купирование симптомов ГЭРБ быстрее других ИПП
                      </li>
                      <li class="repeated-recommendations__elem">
                        Уникальный цитопротективный эффект за счет секреции
                        слизи муцинов
                      </li>
                      <li class="repeated-recommendations__elem">
                        Минимальный риск межлекарственного взаимодействия
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                        Действие до 48 часов
                      </li>
                    </ul>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Рекомендуется добавление
                      <a href="/academy/preparation/ganaton" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >итоприда гидрохлорида</span
                      ></a>
                      для устранения моторных нарушений.
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >Итоприда гидрохлорид</span
                      >
                      доказано нормализует тонус НПС, снижая количество эпизодов
                      рефлюкса.
                    </p>
                  </div>

                  <button
                    class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                    data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                    onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                  >
                    <img src="./img/magnifier.svg" alt="лупа" />
                    проверить межлекарственные взаимодействия
                  </button>

                  <div
                    class="repeated-content__divider repeated-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-gerd-grade-d-esophagitis"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">диагноз</h2>
                  </div>

                  <div class="repeated-diagnosis repeated-diagnosis_row">
                    <span class="repeated-diagnosis__text">ГЭРБ</span>
                    <span
                      class="repeated-diagnosis__text repeated-diagnosis__text_grade"
                      >ЭЗОФАГИТ СТЕПЕНИ d</span
                    >
                  </div>

                  <div class="repeated-content__hernia">
                    <h2 class="repeated-content__title title-reset">
                      Дополнительные обследования
                    </h2>
                    <p class="repeated-content__text">
                      Согласно выбранным симптомам и проведению первичного
                      обследования рекомендованный список дополнительных
                      обследований:
                    </p>
                    <div class="repeated-recommendations">
                      <div class="repeated-recommendations__item">
                        <div class="repeated-recommendations__info">
                          <h3
                            class="repeated-recommendations__title title-reset"
                          >
                            Рентгеноскопия пищевода и желудка с сульфатом бария
                          </h3>
                          <a
                            href="/cdss/pdf/Подготовка к рентгеноскопии СППР.pdf"
                            target="_blank"
                            class="repeated-recommendations__memo"
                            >Памятка для пациента</a
                          >
                        </div>
                        <img
                          src="./img/icon-card-14.png"
                          class="repeated-recommendations__icon"
                          alt=""
                        />
                      </div>
                    </div>
                    <div class="repeated-content__divider"></div>
                  </div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Обсудите риск прогрессирования болезни и развитие таких
                        осложнений, как пищевод Барретта, стриктуры и АКП.
                      </p>
                    </div>
                  </div>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Дополнительно
                  </h3>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Назначить контрольный прием через 8 недель после
                          начала терапии
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      ЛЕКАРСТВЕННАЯ ТЕрапия:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП на выбор на срок 4-8 недель:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пантопразол
                          <div class="repeated-recommendations__desc">
                            80 мг 1 раз в сутки
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                          <div class="repeated-recommendations__desc">
                            50 мг 3 раза в сутки
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                          <div class="repeated-recommendations__desc">
                            0,5–1 г 4 раза в сутки или по 1 г утром и вечером;
                            <br />
                            максимальная суточная доза — 8 г
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                          <div class="repeated-recommendations__desc">
                            по одному пакетику-саше 3 раза в день после приема
                            пищи и перед сном
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Учитывая крайне высокую степень повреждения слизистой
                      оболочки пищевода, рекомендуется проведение терапии сроком
                      на 8 недель и более.
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_night"
                    >
                      Учитывая наличие у пациента
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >ночных эпизодов ГЭРБ</span
                      >, при выборе препарата из класса ИПП рекомендуется
                      отдавать предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      ></a>, т.к. у препарата есть:
                    </p>
                    <p
                      class="repeated-recommendations__text repeated-recommendations__text_not-night"
                    >
                      При выборе препарата из класса ИПП рекомендуется отдавать
                      предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      ></a>, т.к. у препарата есть:
                    </p>
                  </div>

                  <div class="repeated-recommendations">
                    <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                        Купирование симптомов ГЭРБ быстрее других ИПП
                      </li>
                      <li class="repeated-recommendations__elem">
                        Уникальный цитопротективный эффект за счет секреции
                        слизи муцинов
                      </li>
                      <li class="repeated-recommendations__elem">
                        Минимальный риск межлекарственного взаимодействия
                      </li>
                      <li
                        class="repeated-recommendations__elem repeated-recommendations__elem_strong"
                      >
                        Действие до 48 часов
                      </li>
                    </ul>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Рекомендуется добавление
                      <a href="/academy/preparation/ganaton" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >итоприда гидрохлорида</span
                      ></a>
                      для устранения моторных нарушений.
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >Итоприда гидрохлорид</span
                      >
                      доказано нормализует тонус НПС, снижая количество эпизодов
                      рефлюкса.
                    </p>
                  </div>

                  <button
                    class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                    data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Пантопразол,Декслансопразол,Итоприд,Сукральфат"
                    onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                  >
                    <img src="./img/magnifier.svg" alt="лупа" />
                    проверить межлекарственные взаимодействия
                  </button>

                  <div
                    class="repeated-content__divider repeated-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-complicated-gerd-barrett-esophagus"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Результаты диагностики
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span
                    class="repeated-diagnosis__text repeated-diagnosis__text_important"
                    >Диагноз</span
                  >
                  <span class="repeated-diagnosis__text"
                    >Осложненная ГЭРБ, пищевод Барретта</span
                  >
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Подробно ознакомиться с клиническими рекомендациями РГА
                        по лечению пищевода Барретта можно по ссылке:
                      </h3>
                      <a
                        href="https://www.gastro.ru/userfiles/R_Barret_14.pdf"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div id="result-gerd-needs-egds" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text">ГЭРБ</span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Дополнительные обследования
                  </h2>
                  <p class="repeated-recommendations__text">
                    Для подтверждения диагноза, определения степени эзофагита и
                    назначения лекарственной терапии
                  </p>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        ЭГДС
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-1.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div id="result-required-egds" class="repeated-content__slide">
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Для оценки полной клинической картины заболевания и
                    постановки корректного диагноза пациенту рекомендуется
                    проведение ЭГДС.
                  </h2>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-hypersensitive-esophagus"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Гиперсенситивный пищевод</span
                  >
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Медикаментозное
                      </h3>
                      <p class="repeated-recommendations__text">
                        ИПП только у пациентов, у которых ИС &gt;50%
                      </p>
                      <a
                        href="https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2816%2900178-5"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Модификация пищевого поведения и образа жизни
                      </h3>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Дополнительно
                      </h3>
                      <p class="repeated-recommendations__text">
                        Консультация врача-психиатра
                      </p>
                    </div>
                    <img
                      src="./img/icon-card-5.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-esophageal-botility-disorders-or-functional-heartburn"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Результаты диагностики
                  </h2>
                </div>
                <div class="repeated-diagnosis repeated-diagnosis_alone">
                  <span
                    class="repeated-diagnosis__text repeated-diagnosis__text_important"
                    >Вероятный диагноз: нарушения моторики пищевода или
                    функциональная изжога.</span
                  >
                  <span class="repeated-diagnosis__text"
                    >Для подтверждения диагноза рекомендуется проведение
                    манометрии высокого разрешения.</span
                  >
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-esophageal-botility-disorders-or-functional-heartburn-2"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Нарушения моторики пищевода или функциональная изжога</span
                  >
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Дополнительные обследования
                  </h2>
                  <p class="repeated-recommendations__text">
                    Для подтверждения диагноза рекомендуется проведение
                    дополнительного исследования
                  </p>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Манометрия высокого разрешения
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-2.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-achalasia-esophagus"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Ахалазия пищевода
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Изменение образа жизни и пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Тщательное пережевывание пищи
                        </li>
                        <li class="repeated-recommendations__elem">
                          Контроль позиции тела при приеме пищи
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Пероральная медикаментозная терапия в дооперационном
                        периоде или при наличии противопоказаний к операции
                      </h3>
                      <a
                        href="https://www.gastro.ru/userfiles/R_AhalKard_2016.pdf"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Пневматическая дилатация
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-8.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Миотомия по Геллеру
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пероральная эндоскопическая миотомия и др.
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-achalasia-esophagus-2"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Ахалазия пищевода
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Пероральная медикаментозная терапия
                      </h3>
                      <a
                        href="https://www.gastro.ru/userfiles/R_AhalKard_2016.pdf"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Пневматическая дилатация
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-8.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Миотомия по Геллеру
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пероральная эндоскопическая миотомия и др.
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-diffuse-esophageal-spasm"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Диффузный спазм пищевода (эзофагоспазм)
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Изменение образа жизни и пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Тщательное пережевывание пищи
                        </li>
                        <li class="repeated-recommendations__elem">
                          Контроль позиции тела при приеме пищи
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Медикаментозная терапия
                      </h3>
                      <a
                        href="https://www.gastro.ru/userfiles/R_AhalKard_2016.pdf"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Дополнительно
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Консультация врача-невролога
                        </li>
                        <li class="repeated-recommendations__elem">
                          Консультация врача-психотерапевта/психиатра
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-5.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <p class="repeated-recommendations__text">
                        Пероральная эндоскопическая миотомия и др.
                      </p>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-hernia-esophageal-orifice-diaphragm"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Грыжа пищеводного отверстия диафрагмы (ГПОД)
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Изменение образа жизни и пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Тщательное пережевывание пищи
                        </li>
                        <li class="repeated-recommendations__elem">
                          Контроль позиции тела при приеме пищи
                        </li>
                        <li class="repeated-recommendations__elem">
                          Исключение газированных напитков и т.д.
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Медикаментозная терапия
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          ИПП на выбор
                          <div class="repeated-recommendations__wrapper">
                            <ul
                              class="repeated-recommendations__list repeated-recommendations__list_inner"
                            >
                              <li class="repeated-recommendations__elem">
                                Рабепразол
                                <div class="repeated-recommendations__desc">
                                  20 мг 1 раз в день
                                </div>
                              </li>
                              <li class="repeated-recommendations__elem">
                                Омепразол
                                <div class="repeated-recommendations__desc">
                                  20 мг 1 раз в день
                                </div>
                              </li>
                              <li class="repeated-recommendations__elem">
                                Эзомепразол
                                <div class="repeated-recommendations__desc">
                                  40 мг 1 раз в день
                                </div>
                              </li>
                            </ul>
                            <ul
                              class="repeated-recommendations__list repeated-recommendations__list_inner"
                            >
                              <li class="repeated-recommendations__elem">
                                Лансопразол
                                <div class="repeated-recommendations__desc">
                                  60 мг 1 раз в день
                                </div>
                              </li>
                              <li class="repeated-recommendations__elem">
                                Пантопразол
                                <div class="repeated-recommendations__desc">
                                  20 мг 1 раз в день
                                </div>
                              </li>
                              <li class="repeated-recommendations__elem">
                                Декслансопразол
                                <div class="repeated-recommendations__desc">
                                  60 мг 1 раз в день
                                </div>
                              </li>
                            </ul>
                          </div>
                        </li>
                        <li
                          class="repeated-recommendations__elem repeated-recommendations__elem_inner-ul"
                        >
                          Прокинетик
                          <div class="repeated-recommendations__wrapper">
                            <ul
                              class="repeated-recommendations__list repeated-recommendations__list_inner"
                            >
                              <li class="repeated-recommendations__elem">
                                Итоприда гидрохлорид
                                <div class="repeated-recommendations__desc">
                                  50 мг 3 раза в сутки
                                </div>
                              </li>
                            </ul>
                          </div>
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <p class="repeated-recommendations__text">
                        Фундопликация
                      </p>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-study-ambiguous-conduct-egds"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Результаты диагностики
                  </h2>
                </div>
                <div class="repeated-diagnosis repeated-diagnosis_alone">
                  <span
                    class="repeated-diagnosis__text repeated-diagnosis__text_important"
                    >Результаты исследования неоднозначны.</span
                  >
                  <span class="repeated-diagnosis__text"
                    >Для постановки диагноза необходимо проведение ЭГДС и
                    комплексное рассмотрение картины на ЭГДС, количество
                    эпизодов рефлюкса и % времени pH &lt; 4</span
                  >
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-reflux-esophagitis"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      ВЕРОЯТНЫЙ диагноз
                    </h2>
                  </div>

                  <div class="repeated-diagnosis">
                    <span class="repeated-diagnosis__text"
                      >Рефлюкс-эзофагит</span
                    >
                  </div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Дополнительно
                  </h3>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Назначить повторный прием после проведения терапии
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Назначение на 4 недели:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пантопразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик (по показаниям):
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                          <div class="repeated-recommendations__desc">
                            50 мг 3 раза в сутки
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                          <div class="repeated-recommendations__desc">
                            0,5–1 г 4 раза в сутки или по 1 г утром и вечером;
                            <br />
                            максимальная суточная доза — 8 г
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                          <div class="repeated-recommendations__desc">
                            по одному пакетику-саше 3 раза в день после приема
                            пищи и перед сном
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      При выборе препарата из класса ИПП рекомендуется отдавать
                      предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      ></a>, т.к. у препарата есть:
                    </p>
                  </div>

                  <div class="repeated-recommendations">
                    <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                        Уникальный цитопротективный эффект за счет секреции
                        слизи муцинов
                      </li>
                      <li class="repeated-recommendations__elem">
                        Минимальный риск межлекарственного взаимодействия
                      </li>
                    </ul>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Рекомендуется добавление
                      <a href="/academy/preparation/ganaton" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >итоприда гидрохлорида</span
                      ></a>
                      для устранения моторных нарушений.
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >Итоприда гидрохлорид</span
                      >
                      доказано нормализует тонус НПС, улучшает ПРНПС и
                      антродуоденальную координацию, снижая количество эпизодов
                      рефлюкса.
                    </p>
                  </div>

                  <button
                    class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                    data-medicine="Рабепразол,Омепразол,Эзомепразол,Лансопразол,Декслансопразол,Итоприд,Сукральфат"
                    onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                  >
                    <img src="./img/magnifier.svg" alt="лупа" />
                    проверить межлекарственные взаимодействия
                  </button>

                  <div
                    class="repeated-content__divider repeated-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-gerd-confirmed"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">диагноз</h2>
                  </div>

                  <div class="repeated-diagnosis">
                    <span class="repeated-diagnosis__text"
                      >ГЭРБ подтвержден</span
                    >
                  </div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Дополнительно
                  </h3>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Назначить повторный прием после проведения терапии
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Назначение на 4 недели:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик (по показаниям):
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                          <div class="repeated-recommendations__desc">
                            50 мг 3 раза в сутки
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                          <div class="repeated-recommendations__desc">
                            0,5–1 г 4 раза в сутки или по 1 г утром и вечером;
                            <br />
                            максимальная суточная доза — 8 г
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                          <div class="repeated-recommendations__desc">
                            по одному пакетику-саше 3 раза в день после приема
                            пищи и перед сном
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      При выборе препарата из класса ИПП рекомендуется отдавать
                      предпочтение оригинальному
                      <a href="/academy/preparation/pariet-20" target="_blank"> <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >рабепразолу</span
                      ></a>, т.к. у препарата есть:
                    </p>
                  </div>

                  <div class="repeated-recommendations">
                    <ul class="repeated-recommendations__list">
                      <li class="repeated-recommendations__elem">
                        Максимальный в классе ИПП потенциал кислотосупрессии
                      </li>
                      <li class="repeated-recommendations__elem">
                        Уникальный цитопротективный эффект за счет секреции
                        слизи муцинов
                      </li>
                      <li class="repeated-recommendations__elem">
                        Минимальный риск межлекарственного взаимодействия
                      </li>
                    </ul>
                  </div>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Рекомендуется добавление
                      <a href="/academy/preparation/ganaton" target="_blank"><span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >итоприда гидрохлорида</span
                      ></a>
                      для устранения моторных нарушений.
                      <span
                        class="repeated-recommendations__span repeated-recommendations__span_blue"
                        >Итоприда гидрохлорид</span
                      >
                      доказано нормализует тонус НПС, улучшает ПРНПС и
                      антродуоденальную координацию, снижая количество эпизодов
                      рефлюкса.
                    </p>
                  </div>

                  <button
                    class="repeated-content__link repeated-content__link_testing btn-reset check-interaction-btn"
                    onclick="ym(90602537,'reachGoal','cdss_comparison'); return true;"
                  >
                    <img src="./img/magnifier.svg" alt="лупа" />
                    проверить межлекарственные взаимодействия
                  </button>

                  <div
                    class="repeated-content__divider repeated-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-nerd-func-heartburn-hypersensitive-esophagus"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Вероятный диагноз
                    </h2>
                  </div>

                  <div class="repeated-diagnosis">
                    <span class="repeated-diagnosis__text"
                      >НЭРБ, функциональная изжога, гиперсенситивный
                      пищевод</span
                    >
                  </div>

                  <h3 class="repeated-content__title title-reset">
                    Дополнительные обследования
                  </h3>

                  <div class="repeated-recommendations">
                    <p class="repeated-recommendations__text">
                      Для подтверждения диагноза рекомендуется проведение
                      дополнительных исследований:
                    </p>
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Суточная pH-импедансометрия
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-3.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>

                  <div class="repeated-content__divider"></div>

                  <h3 class="repeated-content__attention title-reset">
                    Обратить внимание
                  </h3>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Обсудите риск прогрессирования болезни и развитие таких
                        осложнений, как пищевод Барретта, стриктуры и АКП.
                      </p>
                    </div>
                  </div>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Разъясните важность соблюдения схемы приема препаратов и
                        модификации образа жизни.
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="repeated-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Назначение на 4 недели:
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      ИПП
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Рабепразол
                          <div class="repeated-recommendations__desc">
                            20мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Омепразол
                          <div class="repeated-recommendations__desc">
                            20 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Эзомепразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Лансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пантопразол
                          <div class="repeated-recommendations__desc">
                            40 мг 1 раз в сутки
                          </div>
                        </li>
                        <li class="repeated-recommendations__elem">
                          Декслансопразол
                          <div class="repeated-recommendations__desc">
                            60 мг 1 раз в день
                          </div>
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Прокинетик (по показаниям):
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Итоприда гидрохлорид
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Эзофагопротекторы:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Сукральфат
                        </li>
                        <li class="repeated-recommendations__elem">
                          Альфазокс
                        </li>
                      </ul>
                    </div>
                  </div>

                  <div class="repeated-recommendations">
                    <h3 class="repeated-recommendations__title title-reset">
                      Антациды с или без алгината натрия:
                    </h3>
                    <h3 class="repeated-recommendations__subtitle title-reset">
                      Монопрепараты:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Алюминия гидроксид
                        </li>
                        <li class="repeated-recommendations__elem">
                          Магния гидроксид
                        </li>
                      </ul>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Кальция карбонат
                        </li>
                        <li class="repeated-recommendations__elem">
                          Натрия бикарбонат
                        </li>
                      </ul>
                    </div>
                    <h3 class="repeated-recommendations__subtitle title-reset">
                      Комбинированные препараты:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Магния гидроксид и алюминия гидроксид
                        </li>
                        <li class="repeated-recommendations__elem">
                          Алюминия гидроксид, магния карбонат и магния гидроксид
                        </li>
                        <li class="repeated-recommendations__elem">
                          Кальция карбонат и магния карбонат
                        </li>
                        <li class="repeated-recommendations__elem">
                          Алюминия гидроксид и магния карбонат
                        </li>
                      </ul>
                    </div>
                    <h3 class="repeated-recommendations__subtitle title-reset">
                      Препараты, содержащие алгинат натрия:
                    </h3>
                    <div
                      class="repeated-recommendations__wrapper repeated-recommendations__wrapper_mb0 repeated-recommendations__wrapper_flex-sb"
                    >
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Кальция карбонат, Калия бикарбонат, Натрия
                          гидрокарбонат, Натрия алгинат
                        </li>
                      </ul>
                    </div>
                  </div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_full-width"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-violation-patency-esophageal-gastric-junction"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>

                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text">
                    Нарушение проходимости пищеводно-желудочного перехода (ПЖП)
                  </span>
                </div>

                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Дилатационная терапия с/без постановки стента
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Стандартная
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пневматическая
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-8.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Миотомия по Геллеру
                        </li>
                        <li class="repeated-recommendations__elem">
                          Пероральная эндоскопическая миотомия и др.
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Медикаментозная терапия
                      </h3>
                      <p class="repeated-recommendations__text">
                        Назначение системных лекарственных препаратов
                        неэффективно,
                        <span
                          class="repeated-recommendations__span repeated-recommendations__span_black"
                          >но ИПП могут облегчать симптомы</span
                        >
                      </p>
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-violation-motor-fucntion-thoracic-esophagus-lack-peristalsis"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Нарушение двигательной функции грудного отдела пищевода,
                    отсутствие перистальтики
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Направление пациента на визит в профильный центр
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-5.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Модификация пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Отдавать предпочтение нетвердой или размягченной пище
                        </li>
                        <li class="repeated-recommendations__elem">
                          Тщательно пережевывать пищу
                        </li>
                        <li class="repeated-recommendations__elem">
                          Запивать еду достаточным количеством жидкости
                        </li>
                        <li class="repeated-recommendations__elem">
                          Не переедать и прекратить последний прием пищи за 4
                          часа до сна
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-11.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-distal-esophagospasm"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Дистальный эзофагоспазм
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Изменение образа жизни и пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Тщательное пережевывание пищи
                        </li>
                        <li class="repeated-recommendations__elem">
                          Контроль позиции тела при приеме пищи
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Медикаментозная терапия
                      </h3>
                      <a
                        href="https://www.gastro.ru/userfiles/R_AhalKard_2016.pdf"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <p class="repeated-recommendations__text">
                        Пероральная эндоскопическая миотомия и др.
                      </p>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>

                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-hypercontractile-esophagus"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Гиперконтрактильный пищевод
                  </span>
                </div>
                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Изменение образа жизни и пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Тщательное пережевывание пищи
                        </li>
                        <li class="repeated-recommendations__elem">
                          Контроль позиции тела при приеме пищи
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Медикаментозная терапия
                      </h3>
                      <a
                        href="https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2816%2900178-5"
                        target="_blank"
                        class="repeated-recommendations__link"
                        >Подробнее</a
                      >
                    </div>
                    <img
                      src="./img/icon-card-6.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Хирургическое лечение
                      </h3>
                      <p class="repeated-recommendations__text">
                        Пероральная эндоскопическая миотомия и др.
                      </p>
                    </div>
                    <img
                      src="./img/icon-card-9.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>

                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-ineffective-peristalsis"
                class="repeated-content__slide"
              >
                <div class="repeated-content__header">
                  <h2 class="repeated-content__title title-reset">
                    Вероятный диагноз
                  </h2>
                </div>
                <div class="repeated-diagnosis">
                  <span class="repeated-diagnosis__text"
                    >Неэффективная перистальтика
                  </span>
                </div>

                <div
                  class="repeated-recommendations repeated-content__recommendations"
                >
                  <h2 class="repeated-content__title title-reset">
                    Возможные рекомендации
                  </h2>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Направление пациента на визит в профильный центр
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-5.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Исключение факторов ослабления перистальтики
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-1.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Проведение комплексного обследования с целью исключения
                        заболеваний, проявляющихся ослаблением перистальтики
                      </h3>
                    </div>
                    <img
                      src="./img/icon-card-12.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>

                  <div class="repeated-recommendations__item">
                    <div class="repeated-recommendations__info">
                      <h3 class="repeated-recommendations__title title-reset">
                        Модификация пищевого поведения
                      </h3>
                      <ul class="repeated-recommendations__list">
                        <li class="repeated-recommendations__elem">
                          Отдавать предпочтение нетвердой или размягченной пище
                        </li>
                        <li class="repeated-recommendations__elem">
                          Тщательно пережевывать пищу
                        </li>
                        <li class="repeated-recommendations__elem">
                          Запивать еду достаточным количеством жидкости
                        </li>
                        <li class="repeated-recommendations__elem">
                          Не переедать и прекратить последний прием пищи за 4
                          часа до сна
                        </li>
                      </ul>
                    </div>
                    <img
                      src="./img/icon-card-7.png"
                      class="repeated-recommendations__icon"
                      alt=""
                    />
                  </div>
                </div>

                <a
                  href="/cdss/"
                  class="repeated-content__link repeated-content__link_end"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-functional-heartburn"
                class="repeated-content__slide repeated-content__slide--columns"
              >
                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Вероятный диагноз
                    </h2>
                  </div>

                  <div class="repeated-diagnosis">
                    <span class="repeated-diagnosis__text"
                      >Функциональная изжога</span
                    >
                  </div>

                  <div class="repeated-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="repeated-warning__icon"
                      alt=""
                    />
                    <div class="repeated-warning__info">
                      <p class="repeated-warning__text">
                        Для подтверждения диагноза необходимо исключить такие
                        состояния, как: эозинофильный эзофагит, срыгивание
                        (руминация)
                      </p>
                    </div>
                  </div>
                </div>

                <div class="repeated-content__column">
                  <div class="repeated-content__header">
                    <h2 class="repeated-content__title title-reset">
                      Возможные Рекомендации
                    </h2>
                  </div>

                  <div class="repeated-recommendations">
                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Модификация пищевого поведения и образа жизни
                        </h3>
                        <ul class="repeated-recommendations__list">
                          <li class="repeated-recommendations__elem">
                            Нормализация сна
                          </li>
                          <li class="repeated-recommendations__elem">
                            Снижение уровня стресса
                          </li>
                        </ul>
                      </div>
                      <img
                        src="./img/icon-card-7.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>

                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Медикаментозная терапия
                        </h3>
                        <a
                          href="https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2816%2900178-5"
                          target="_blank"
                          class="repeated-recommendations__link"
                          >Подробнее</a
                        >
                      </div>
                      <img
                        src="./img/icon-card-6.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>

                    <div class="repeated-recommendations__item">
                      <div class="repeated-recommendations__info">
                        <h3 class="repeated-recommendations__title title-reset">
                          Алтеранативная медицина (в редких случаях)
                        </h3>
                        <p class="repeated-recommendations__text">
                          Акупунктура
                        </p>
                      </div>
                      <img
                        src="./img/icon-card-13.png"
                        class="repeated-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>

                  <a
                    href="/cdss/"
                    class="repeated-content__link repeated-content__link_end repeated-content__link_full-width"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>
            </div>

            <div class="repeated-footer">
              <button class="repeated-footer__btn btn-reset">Продолжить</button>
            </div>
          </div>

          <div class="abbott-more-sources">
            <button class="abbott-more-sources__button btn-reset">
              <span>Ключевые источники информации</span>
              <svg
                xmlns="http://www.w3.org/2000/svg"
                width="16"
                height="17"
                viewBox="0 0 16 17"
                fill="none"
              >
                <path
                  fill-rule="evenodd"
                  clip-rule="evenodd"
                  d="M4.89164 2.73051C5.19205 2.42487 5.67909 2.42487 5.9795 2.73051L11.1077 7.94791C11.252 8.09467 11.333 8.29373 11.333 8.5013C11.333 8.70885 11.252 8.90791 11.1077 9.05469L5.9795 14.2721C5.67909 14.5777 5.19205 14.5777 4.89164 14.2721C4.59124 13.9664 4.59124 13.4709 4.89164 13.1653L9.47593 8.5013L4.89164 3.83729C4.59124 3.53166 4.59124 3.03614 4.89164 2.73051Z"
                  fill="#009CDE"
                ></path>
              </svg>
            </button>
            <div class="abbott-more-sources__content">
              <ol>
              <li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В., Дронова О.Б., Кучерявый Ю.А., Пирогов С.С., Сайфутдинов Р.Г., Успенский Ю.П., Шептулин А.А., Андреев Д.Н., Румянцева Д.Е. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. https://doi.org/10.22416/1382-4376-2020-30-4-70-97.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Сторонова О.А., Абдулхаков С.Р., Андреев Д.Н., Бордин Д.С., Валитова Э.Р., Кляритская И.Л., Кривой В.В., Кучерявый Ю.А., Лапина Т.Л., Морозов С.В., Саблин О.А., Семенихина Е.В., Успенский Ю.П., Шептулин А.А. Рекомендации Российской гастроэнтерологической ассоциации по клиническому применению манометрии высокого разрешения при заболеваниях пищевода. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):61–88. https://doi.org/10.22416/1382-4376-2020-30-3-61-88</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. Therole of esophageal testing in diagnosis and management. Gastroenterol Clin North Am1996; 25:75.</li>
<li>Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification ofgastroesophageal reflux disease: a global evidence-based consensus. Am JGastroenterol 2006; 101:1900.</li>
<li>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophagealreflux disease: a systematic review. Gut 2005; 54:710.</li>
<li>Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of uppergastrointestinal disorders in the United States: results of the US Upper GastrointestinalStudy. Clin Gastroenterol Hepatol 2005; 3:543.</li>
<li>Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.</li>
<li>Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence,severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol2004; 2:665.</li>
<li>Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to protonpump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.</li>
<li>Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophagealsphincter pressure: a manometric observation in patients reporting globus sensation.Am J Gastroenterol 2009; 104:289.</li>
<li>Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea.Ann Intern Med 1997; 126:704.</li>
<li>Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.</li>
<li>DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophagealreflux disease. Practice Parameters Committee of the American College ofGastroenterology. Arch Intern Med 1995; 155:2165.</li>
<li>Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS(Ed), WB Saunders, Philadelphia 1989. p.1147.</li>
<li>Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients withgastroesophageal reflux disease: a comparison between empirical treatment withesomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.</li>
<li>Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test toidentify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360.</li>
<li>Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pumpinhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostictest characteristics. Ann Intern Med 2004; 140:518.</li>
<li>Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability andendoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313.</li>
<li>Adanir H, Baş B, Pakoz B, et al. Endoscopic Findings of Gastro-Esophageal RefluxDisease in Elderly and Younger Age Groups. Front Med (Lausanne) 2021; 8:606205.</li>
<li>Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical andfunctional correlates and further validation of the Los Angeles classification. Gut 1999;45:172.</li>
<li>Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. ClinGastroenterol Hepatol 2007; 5:4.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationMedical Position Statement on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1383.</li>
<li>Hirano I, Richter JE, Practice Parameters Committee of the American College ofGastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</li>
<li>Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practiceguideline development. Gastroenterology 1996; 110:1982.</li>
<li>Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless andDigitrapper catheter-based pH monitoring systems for measuring esophageal acidexposure. Am J Gastroenterol 2005; 100:1466.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-refluxassociation using 4-day wireless pH recording combining 48-hour periods off and on PPItherapy. Am J Gastroenterol 2008; 103:1631.</li>
<li>Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring.J Clin Gastroenterol 2012; 46:197.</li>
<li>Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal refluxsymptoms and esophagitis with or without symptoms in the general adult Swedishpopulation: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275.</li>
<li>Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatmentof benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology1982; 82:487.</li>
<li>Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricturetreated by dilatation. Gastroenterology 1983; 85:346.</li>
<li>Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazolefor refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.</li>
<li>Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists intreating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.</li>
<li>Okwara NC, Chan WW. Sorting out the Relationship Between Esophageal andPulmonary Disease. Gastroenterol Clin North Am 2021; 50:919.</li>
<li>Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophagealreflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.</li>
<li>Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acidsuppressive therapy improves asthma outcome. Am J Med 1996; 100:395.</li>
<li>Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'refluxlaryngitis'. Gastroenterology 1991; 100:305.</li>
<li>Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease(GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoringand an experimental investigation of the role of acid and pepsin in the development oflaryngeal injury. Laryngoscope 1991; 101:1.</li>
<li>Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastricacid in patients with reflux laryngitis. Gastroenterology 1995; 109:1575.</li>
<li>Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopyin patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am JGastroenterol 2004; 99:1419.</li>
<li>Remacle M, Lawson G. Diagnosis and management of laryngopharyngeal refluxdisease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:143.</li>
<li>Gaynor EB. Gastroesophageal reflux as an etiologic factor in laryngeal complications ofintubation. Laryngoscope 1988; 98:972.</li>
<li>Cote DN, Miller RH. The association of gastroesophageal reflux and otolaryngologicdisorders. Compr Ther 1995; 21:80.</li>
<li>Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated withgastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.</li>
<li>Schroeder PL, Filler SJ, Ramirez B, et al. Dental erosion and acid reflux disease. AnnIntern Med 1995; 122:809.</li>
<li>DiBaise JK, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. AnnIntern Med 1998; 129:1078.</li>
<li>DiBaise JK, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistantsinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002; 97:843.</li>
<li>Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence inindividuals with gastroesophageal reflux: synthesis and estimates from populationstudies. Am J Gastroenterol 2011; 106:254.</li>
<li>Vaezi MF. Laryngitis and gastroesophageal reflux disease: increasing prevalence or poordiagnostic tests? Am J Gastroenterol 2004; 99:786.</li>
<li>Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous cell cancer of the head andneck. Otolaryngol Clin North Am 1985; 18:367.</li>
<li>Olsen NR. Effects of stomach acid on the larynx. Proc Am Laryngol Assoc 1983; 104:108.</li>
<li>Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma?Otolaryngol Head Neck Surg 1988; 99:370.</li>
<li>Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of thelaryngopharynx. Laryngoscope 1988; 98:1195.</li>
<li>Langevin SM, Michaud DS, Marsit CJ, et al. Gastric reflux is an independent risk factor forlaryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22:1061.</li>
<li>Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, Lagergren J. All-cause and cancer-specificmortality in GORD in a population-based cohort study (the HUNT study). Gut 2018;67:209.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationInstitute technical review on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1392.</li>
<li>Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosisand Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117:27.</li>
<li>Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control ofheartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am JGastroenterol 1999; 94:92.</li>
<li>Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acidinhibition. Gastroenterol Clin North Am 1990; 19:683.</li>
<li>Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophagealreflux disease. Gastroenterology 2001; 121:1095.</li>
<li>Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn oracid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.</li>
<li>Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy forGERD: a multi-center study in Japan. World J Gastroenterol 2011; 17:1480.</li>
<li>Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients withgastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965.</li>
<li>Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass indexand esophageal acid exposure in the extraesophageal manifestations of reflux. ClinGastroenterol Hepatol 2012; 10:874.</li>
<li>Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between uppergastrointestinal symptoms and changes in body weight in a population-based cohort.Neurogastroenterol Motil 2006; 18:987.</li>
<li>Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is notreduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.</li>
<li>Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms ofgastroesophageal reflux in women. N Engl J Med 2006; 354:2340.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction ingastroesophageal reflux. A prospective population-based cohort study: the HUNT study.Am J Gastroenterol 2013; 108:376.</li>
<li>DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines forthe diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol2005; 100:190.</li>
<li>Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle Intervention inGastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14:175.</li>
<li>Mehta RS, Song M, Staller K, Chan AT. Association Between Beverage Intake andIncidence of Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol 2020;18:2226.</li>
<li>Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathingexercise on gastroesophageal reflux disease: a randomized, controlled study. Am JGastroenterol 2012; 107:372.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation andimproved gastroesophageal reflux: a prospective population-based cohort study: theHUNT study. Am J Gastroenterol 2014; 109:171.</li>
<li>Mehta RS, Nguyen LH, Ma W, et al. Association of Diet and Lifestyle With the Risk ofGastroesophageal Reflux Disease Symptoms in US Women. JAMA Intern Med 2021;181:552.</li>
<li>Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosivegastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.</li>
<li>Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to theacid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11:1585.</li>
<li>Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodiumalginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.</li>
<li>Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented bymagnetic resonance imaging and pH-impedance monitoring: mechanistic assessmentin healthy volunteers and randomised, controlled, double-blind study in reflux patients.Aliment Pharmacol Ther 2013; 37:1093.</li>
<li>Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oralsuspension is non-inferior to omeprazole in the treatment of patients with non-erosivegastroesophageal disease. Aliment Pharmacol Ther 2013; 38:1054.</li>
<li>Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of uppergastrointestinal symptoms by an acid pocket-targeting alginate-antacid (GavisconDouble Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophagealreflux disease. Aliment Pharmacol Ther 2014; 39:595.</li>
<li>Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatmentafter 14 days of administration in healthy subjects without Helicobacter pylori infection.J Gastroenterol Hepatol 2003; 18:678.</li>
<li>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcerhealing, gastroesophageal reflux disease, and stress-related erosive syndrome.Gastroenterology 2000; 118:S9.</li>
<li>Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.</li>
<li>Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms ofgastroesophageal reflux disease and heals erosions and ulcerations. Results of amulticenter, placebo-controlled, dose-ranging study. USA Merck GastroesophagealReflux Disease Study Group. Arch Intern Med 1991; 151:2394.</li>
<li>Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal refluxdisease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol1991; 86:1735.</li>
<li>Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed onDecember 19, 2012).</li>
<li>Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is moreacceptable to patients than continuous lansoprazole 15 mg in the long-termmaintenance of endoscopy-negative gastro-oesophageal reflux patients: theCOMMAND Study. Aliment Pharmacol Ther 2004; 20:657.</li>
<li>Hunt R. Acid suppression for reflux disease: "off-the-peg" or a tailored approach? ClinGastroenterol Hepatol 2012; 10:210.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitortherapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419.</li>
<li>Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pumpinhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal refluxdisease-like symptoms and endoscopy negative reflux disease. Cochrane Database SystRev 2013; :CD002095.</li>
<li>Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worseesophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl B:66B.</li>
<li>Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptorantagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005; 11:4067.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Katzka DA, Kahrilas PJ. Advances in the diagnosis and management ofgastroesophageal reflux disease. BMJ 2020; 371:m3786.</li>
<li>Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenancetherapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci2009; 54:955.</li>
<li>Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies forreflux esophagitis. N Engl J Med 1995; 333:1106.</li>
<li>Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients withgastrooesophageal reflux disease. Gut 1992; 33:1016.</li>
<li>Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies forGastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. Decem ber 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).</li>
<li>Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention ofrelapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Gut 1994; 35:590.</li>
<li>Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of refluxesophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlledtrial. Ann Intern Med 1996; 124:859.</li>
<li>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancyand lactation. Aliment Pharmacol Ther 2020; 51:421.</li>
<li>Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet)with antacid for safety and effectiveness in reducing gastric acidity before electivecesarean section. Anesthesiology 1983; 59:86.</li>
<li>Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) inpregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.</li>
<li>Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk ofbirth defects. N Engl J Med 2010; 363:2114.</li>
<li>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophagealreflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.</li>
<li>Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. JReprod Med 2004; 49:825.</li>
<li>National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).</li>
<li>ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelinesfor endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</li>
<li>Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal refluxdisease: putative mechanisms of failure. Drugs 2007; 67:1521.</li>
<li>Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptomsrefractory to proton pump inhibitors. Gut 2012; 61:1340.</li>
<li>Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with theirprescription medications? Results of the patient unmet needs study. J Clin OutcomesManag 2000; 7:29.</li>
<li>The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.</li>
<li>Fass R. Therapeutic options for refractory gastroesophageal reflux disease. JGastroenterol Hepatol 2012; 27 Suppl 3:3.</li>
<li>El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on protonpump inhibitor therapy in primary care and community studies. Aliment PharmacolTher 2010; 32:720.</li>
<li>Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors innonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.</li>
<li>Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention andtreatment. Drugs 2003; 63:555.</li>
<li>Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.</li>
<li>Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term protonpump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.</li>
<li>Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure ingastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.</li>
<li>Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pumpinhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol 2014;109:789.</li>
<li>Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitordosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.Aliment Pharmacol Ther 2006; 23:1473.</li>
<li>Wilder-Smith C, Röhss K, Bokelund Singh S, et al. The effects of dose and timing ofesomeprazole administration on 24-h, daytime and night-time acid inhibition in healthyvolunteers. Aliment Pharmacol Ther 2010; 32:1249.</li>
<li>Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistentsymptoms despite acid suppressive therapy: a multicentre study using combinedambulatory impedance-pH monitoring. Gut 2006; 55:1398.</li>
<li>Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol2008; 6:521.</li>
<li>Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pHmonitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.</li>
<li>Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitecmonitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53:2387.</li>
<li>Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux insymptomatic GERD. Am J Gastroenterol 2001; 96:2033.</li>
<li>Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring insymptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.</li>
<li>Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in ahypersensitive esophagus might explain symptoms resistant to proton pump inhibitorsin patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2014;12:1647.</li>
<li>Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree ofduodenogastroesophageal reflux and acid reflux between patients who failed torespond and those who were successfully treated with a proton pump inhibitor oncedaily. Am J Gastroenterol 2009; 104:2005.</li>
<li>Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acidsuppressive therapy. Am J Gastroenterol 2008; 103:1090.</li>
<li>Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiatenon-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012;47:159.</li>
<li>Abdallah J, George N, Yamasaki T, et al. Most Patients With Gastroesophageal RefluxDisease Who Failed Proton Pump Inhibitor Therapy Also Have Functional EsophagealDisorders. Clin Gastroenterol Hepatol 2019; 17:1073.</li>
<li>Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology2016.</li>
<li>Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functionalheartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013;25:282.</li>
<li>Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity tobile salts in patients with functional heartburn and in healthy control subjects. Dig DisSci 2005; 50:81.</li>
<li>Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traitsof functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity toacid. Am J Gastroenterol 2006; 101:1084.</li>
<li>Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for thetreatment of refractory GERD accompanied with gastroparesis: a preliminary report. DigDis Sci 2008; 53:2621.</li>
<li>Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patientswith symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum ofvisceral sensitivity in GORD. Gut 1995; 37:7.</li>
<li>Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS andpsychological distress on outcomes and quality of life following PPI therapy in patientswith gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.</li>
<li>Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associatedwith features of psychiatric disorders and the irritable bowel syndrome. AlimentPharmacol Ther 2007; 26:443.</li>
<li>Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease andpsychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.</li>
<li>Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal refluxdisease and underdiagnosis of functional dyspepsia in a USA community.Neurogastroenterol Motil 2014; 26:1163.</li>
<li>Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive tosingle-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux,bile reflux, or both? Am J Gastroenterol 2004; 99:981.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acidbreakthrough on different regimens of omeprazole 40 mg daily. Aliment PharmacolTher 1998; 12:1235.</li>
<li>Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective aslansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophagealreflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-aprospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.</li>
<li>Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebocontrolled study of omeprazole in the treatment of patients with reflux symptoms andphysiological levels of acid reflux--the "sensitive oesophagus". Gut 1997; 40:587.</li>
<li>Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburnsymptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.</li>
<li>Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-hintragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36:627.</li>
<li>Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis ofgastro-esophageal reflux disease: Update of the Porto consensus andrecommendations from an international consensus group. Neurogastroenterol Motil2017; 29:1.</li>
<li>Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring withand without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.</li>
<li>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management ofgastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.</li>
<li>Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pHmonitoring in patients with refractory gastroesophageal reflux disease, on and offtherapy. Clin Gastroenterol Hepatol 2009; 7:743.</li>
<li>Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology2018; 154:302.</li>
<li>Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findingsin gastro-esophageal reflux disease: Conclusions from an international consensusgroup. Neurogastroenterol Motil 2017; 29.</li>
<li>Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthroughon omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.</li>
<li>Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy onnocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.</li>
<li>Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine atnight to twice daily omeprazole therapy on nocturnal acid breakthrough and acid refluxin patients with systemic sclerosis--a randomized controlled, cross-over trial. AlimentPharmacol Ther 2007; 26:1259.</li>
<li>Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinicalsignificance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545.</li>
<li>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for thecontrol of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009;:CD004275.</li>
<li>Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improvegastroesophageal reflux disease symptoms for patients on proton pump inhibitortherapy. Dis Esophagus 2005; 18:370.</li>
<li>Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophagealreflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract2014; 2014:307805.</li>
<li>Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices?Curr Opin Gastroenterol 2009; 25:352.</li>
<li>Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants inpatients with functional esophageal disorders or gastroesophageal reflux disease:a systematic review. Clin Gastroenterol Hepatol 2015; 13:251.</li>
<li>Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adultpatients with functional chest pain: a randomized, double-blind, placebo-controlled,crossover trial. Am J Gastroenterol 2010; 105:1504.</li>
<li>Park SW, Lee H, Lee HJ, et al. Low-dose amitriptyline combined with proton pumpinhibitor for functional chest pain. World J Gastroenterol 2013; 19:4958.</li>
<li>Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors forthe treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.</li>
<li>Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy ingastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20:2412.</li>
<li>Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients WithRefractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology2020; 158:2093.</li>
<li>Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the protonpump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.</li>
<li>UpToDate medical database. Approach to the initial management of patients with GERD. Graphic 116964 Version 3.0. Электронный ресурс: https://www.uptodate.com/contents/image?imageKey=GAST%2F116964, дата доступа: 14.07.2023</li>
<li>Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut. 2005;54(12):1810-1817. doi:10.1136/gut.2005.072629</li>
<li>Costa V, Pinto-Saavedra O, Hani A, Leguízamo AM, Ardila-Hani AF. Updated interpretation of Impedance–pH monitoring. Rev Colomb Gastroenterol. 2021;36(1):73-80. https://doi.org/10.22516/25007440.608</li>
<li>Hani, Albis & Leguizamo, Ana & Carvajal, Jhon & Klinger, Gabriel & Costa, Valeria. (2015). How to Perform and Interpret High-resolution Esophageal Manometry. Revista Colombiana de Gastroenterologia. 30. 74-83.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л., Хлынов И.Б., Дехнич Н.Н., Лопина О.Д., Алексеева О.П., Корочанская Н.В., Осипенко М.Ф., Павлов П.В., Пирогов С.С., Тарасова Г.Н., Успенский Ю.П., Андреев Д.Н., Румянцева Д.Е. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18. https://doi.org/10.22416/1382-4376-2020-30-6-7-18.</li>
<li>Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Can Fam Physician 2017;63:354-64 (Eng), e253-65 (Fr).</li>
<li>Cho YK. How to Interpret Esophageal Impedance pH Monitoring. J Neurogastroenterol Motil. 2010 Jul;16(3):327-30. doi: 10.5056/jnm.2010.16.3.327. Epub 2010 Jul 26. PMID: 20680174; PMCID: PMC2912128.</li>
<li>Kim GH. How to Interpret Ambulatory 24 hr Esophageal pH Monitoring. J Neurogastroenterol Motil. 2010 Apr;16(2):207-10. doi: 10.5056/jnm.2010.16.2.207. Epub 2010 Apr 27. PMID: 20535354; PMCID: PMC2879855.</li>
<li>Jehangir A, Malik Z, Parkman HP. Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterol. 2022 Mar 8;22(1):112. doi: 10.1186/s12876-022-02194-0. PMID: 35260107; PMCID: PMC8905734.</li>
<li>Yadlapati R. High-resolution esophageal manometry: interpretation in clinical practice. Curr Opin Gastroenterol. 2017 Jul;33(4):301-309. doi: 10.1097/MOG.0000000000000369. PMID: 28426462; PMCID: PMC5568812.</li>
<li>Yamasaki T, Fass R. Reflux Hypersensitivity: A New Functional Esophageal Disorder. J Neurogastroenterol Motil. 2017;23(4):495-503. doi:10.5056/jnm17097</li>
<li>Ronnie Fass, Frank Zerbib, C. Prakash Gyawali. AGA Clinical Practice Update on Functional Heartburn: Expert Review. CLINICAL PRACTICE UPDATE| VOLUME 158, ISSUE 8, P2286-2293, JUNE 2020. Published: February 01, 2020. DOI: https://doi.org/10.1053/j.gastro.2020.01.034</li>
<li>Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi: 10.14309/ajg.0000000000000731. PMID: 32773454; PMCID: PMC9896940.</li>
<li>Samo S, Qayed E. Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management? World J Gastroenterol. 2019 Jan 28;25(4):411-417. doi: 10.3748/wjg.v25.i4.411. PMID: 30700938; PMCID: PMC6350167.</li>
<li>Management of the patient with esophagogastric junction outflow obstruction (EGJOO) Shahsavari et al. Curr Opin Gastroenterol 2021, 37:397–407. DOI:10.1097/MOG.0000000000000747</li>
<li>Dhyanesh A. Patel, Rena Yadlapati, Michael F. Vaezi, Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics, Gastroenterology, Volume 162, Issue 6, 2022, Pages 1617-1634, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2021.12.289.</li>
<li>DeLay K, Krause A, Yadlapati R. Clinical Updates in Esophageal Motility Disorders Beyond Achalasia. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1789-1792.e1. doi: 10.1016/j.cgh.2021.05.041. Epub 2021 Jul 1. PMID: 34405804; PMCID: PMC8604436.</li>
<li>Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30. PMID: 24466441; PMCID: PMC3895610.</li>
<li>Чёрная А. В. Карханова А. Г., Мутовкина Н. И., Дышлюк Т. Л., Багненко С. С., Рогачев М. В., Ульянова Р. Х., Зайцев А. Н., Шевкунов Л. Н., Новиков С. Н., Шевченко Е. Ю., Брезгина Е. А. Лучевая диагностика заболеваний пищевода при злокачественных и доброкачественных изменениях: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. – Санкт-Петербург: ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России, 2021. – 144 с. ISBN 978-5-6046978-1-8</li>
<li>Государственный реестр лекарственных средств. Электронный ресурс: https://grls.rosminzdrav.ru/default.aspx, дата доступа: 14.07.2023</li>
<li>Инструкция по применению лекарственного препарата Ганатон® (итоприда гидрохлорид). РУ ЛС-002513 от 29.06.2021. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9abd2328-abcb-411e-919e-6d8ab7c238ea, дата доступа: 14.07.2023</li>
<li>Stanghellini V., Chan F., Hasler W.L. et al. Gastroduodenal Disorders Gastroenterology 2016;150:1380– 1392.</li>
<li>Касьяненко В.И., Денисов Н.Л., Васильев Ю.В. Применение итоприда при симптомах функциональной диспепсии в России: результаты проспективного открытого многоцентрового клинического исследования IV фазы. Терапевтический Архив. 2014;8:35-41.</li>
<li>Tack J. et all. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther. 2011 Jan;33(1):99-105.</li>
<li>Murray J.A. Gastroesophageal Reflux Disease. In.: Mayo Clinic Gastroenterology and Hepatology Board Review. Oxford University Press. 2015.</li>
<li>Ezzat W.F., Fawaz S.A., Fathey H. et al. Virtue of Adding Prokinetics to Proton Pump Inhibitors in the Treatment of Laryngopharyngeal Reflux Disease: Prospective Study Journal of Otolaryngology-Head & Neck Surgery. 2011;40(4):350–356/</li>
<li>Инструкция по применению лекарственного препарата Париет® (рабепразол). РУ П N011880/01 от 28.02.2022. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d7c5d813-e692-4211-a63d-2a2ac06ea1d7, дата доступа: 14.07.2023</li>
<li>Kirchheiner J., Glatt S., Fuhr U. et al. Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH // European Journal of Clinical Pharmacology, 2008, 65 (1), pp.19-31</li>
<li>Kramer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitrocorrelates. Pharmacology. 1998;56:57-70</li>
<li>Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003 Feb;48(2):322-8.</li>
<li>Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335.</li>
<li>Besancon M, Shin JM, Mercier F, et al. Biochemistry, 1993; 32:2345–2355.</li>
<li>Сереброва С.Ю. Основные фармакокинетические характеристики ингибиторов протонной помпы и эффективность их действия. Пособие для врачей. Мединфорум 2016.</li>
<li>Cefditoren [Korean product labeling]. Boryeong Pharmaceutical; November 2009.</li>
<li>Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol. 1984;18(4):535-539. [PubMed 6091711</li>
<li>Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. Adv Perit Dial. 1994;10:179-182. [PubMed 7999822</li>
<li>Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</li>
<li>Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509. [PubMed 16898956</li>
<li>Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OLCA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardio. 2008;51(3):256-260. [PubMed 18206732</li>
<li>Fontes-Carvalho R, Albuquerque A, Araugo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogre-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396-404. [PubMed 21464720</li>
<li>Frelinger 3rd AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardio. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944. [PubMed 19258584</li>
<li>Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039; author reply 1039. [PubMed 18786491</li>
<li>Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Gaglia MA Jr, Torguson R, Hanna N, et alRelation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomesAm J Cardiol2010;105(6):833-838[PubMed 20211327</li>
<li>Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964-1968. [PubMed 19731021</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997. [PubMed 19726078</li>
<li>Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26(2):e54-e57. [PubMed 20151060</li>
<li>Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917. [PubMed 20925534</li>
<li>Muthiah MD, Zheng H, Chew NWS, et al. Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. [online ahead of print] J Thromb Throbolysis. 2021. doi: 10.1007/s11239-021-02472. [PubMed 33959860</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016; Aug 10 (Epub ahead of print). [PubMed 27512080</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478</li>
<li>Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). BMC Cardiovasc Disord. 2017;17(1):3. [PubMed 28056809</li>
<li>Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939-947. [PubMed 27459657</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11): pii: e002245. [PubMed 26514161</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership: March 2021.</li>
<li>Park GJ, Bae SH, Park WS, et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017;11:1043-1053. [PubMed 28408803</li>
<li>Kamiya C, Inui N, Hakamat A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype [published online March 11, 2019]. J Pharmacol Sci. Doi: 10.1016/j.jphs.2019.03.001. [PubMed 30902567</li>
<li>Elbe A, Foerster KI, Blank A, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975-987. [PubMed 35238961</li>
<li>Erleada (apalutamide) [prescribing information. Horsham, PA: Janssen Products LP; September 2019</li>
<li>Kanebratt KP, Diczfalusy U, Backstroo T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther, 2008, 84(5):589-94. [PubMed 18650803</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; August 2018.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999-1004. [PubMed 22147077</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016</li>
<li>Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358-1365. [PubMed 25274610</li>
<li>Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81(6):1195-1196. [PubMed 26833554</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;25(7):1155-1162. [PubMed 30605231</li>
<li>Koutake Y, Taniguch J, Yasumori N, et al. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol. 2020;111(6):826-832. [PubMed 32152877]</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2012.</li>
<li>Tarceva (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; April 2014</li>
<li>van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309-1314. [PubMed 26858332</li>
<li>Veerman GDM, Hussaarts KGAM, Peric R, et al. Influence of cow's milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69-77. [PubMed 32557346</li>
<li>Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol. 2010;70(6):908-911. [PubMed 21175447</li>
<li>Du X, Liu W, Chen K, Wang Z, Li X, Yang L, Xie X. Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis. [published online ahead of print] Front Pharmacol. 2022. doi: 10.3389/fphar.2022.796538. [PubMed 35795555</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908</li>
<li>Zenke Y, Yoh K, Matsumoto S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412-418. [PubMed 26944770</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et alA multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerClin Cancer Res2010;16(11):3078-3087[PubMed 20395213</li>
<li>Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 2013;52:593-609. [PubMed 23532985</li>
<li>Truseltiq (infigratinib) [prescribing information]. Brisbane, CA: QED Therapeutics Inc; May 2021.</li>
<li>Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola®) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671-1675. [PubMed 7486898</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; June 2018</li>
<li>Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; March 2018</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022</li>
<li>Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-391. [PubMed 9357389</li>
<li>Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42(3):278-284. [PubMed 22022918</li>
<li>Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283:434-442.[PubMed 9353355</li>
<li>Zhang W, Ramamoorthy Y, Kilicarslan T, et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos. 2002;30:314-318. [PubMed 11854151]</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</li>
<li>Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1635-1643. [PubMed 23636448</li>
<li>Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. [Published online doi:10.1002/ijc.33469]. 2021. [PubMed 33428771</li>
<li>Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020;76(9):1273-1280. [PubMed 32474662</li>
<li>Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</li>
<li>Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F. Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects. Clin Pharmacokinet. 2022;61(11):1623-1639. [PubMed 36264536</li>
<li>Turalio (pexidartinib) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; August 2019.</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; August 2015</li>
<li>Juluca (dolutegravir/rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020</li>
<li>Noltec (ilaprazole) [Korean product labeling]. Ilyang Pharmaceutical Co., Ltd.; March 2020</li>
<li>K-CAB (tegoprazan) [Singapore product labeling]. Singapore: HK inno.N Corporation; January 2023.</li>
<li>Lumakras (sotorasib) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2021.</li>
<li>Filspari (sparsentan) [prescribing information]. San Diego, CA: Travere Therapeutics Inc; February 2023.</li>
<li>Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-197. [PubMed 15001970</li>
<li>Konvomep (omeprazole and sodium bicarbonate for oral suspension) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals, Inc.; August 2022.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2020</li>
<li>Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011;51(3):368-377. [PubMed 20457590</li>
<li>Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26:341346. [PubMed 16503713</li>
<li>Evotaz (atazanavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2020.</li>
<li>Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors. Clin Pharmacol Drug Dev. 2022;11(7):795-806. [PubMed 35230741</li>
<li>Rezurock (belumosudil) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals LLC; July 2021.</li>
<li>Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33(8):589-595. [PubMed 23839484</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:53-59. [PubMed 10702887</li>
<li>Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.</li>
<li>Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51. [PubMed 20642546</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90-97. [PubMed 24887634</li>
<li>Wu WT, Tsai CT, Chou YC, et al. Cardiovascular outcomes associated with clinical use of citalopram and omeprazole: a nationwide population-based cohort study. J Am Heart Assoc. 2019;8(20):e011607. [PubMed 31581860</li>
<li>Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.</li>
<li>Yokota H, Sato K, Okuda Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18(6):e433-e439. [PubMed 28579188</li>
<li>Tang W, Tomkinson H, Masson E. Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev. 2017;6(5):517-523. [PubMed 28176470</li>
<li>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res. 2019;11:8539-8546. [PubMed 31572008</li>
<li>Sedano MN, Teller JMC, Munoz CG, et al. Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON. 2018;23(3):647-653. [PubMed 30003732</li>
<li>Li J, Nickens D, Wilner K, Tan W. Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther. 202113. Epub ahead of print. [PMID: 34120312</li>
<li>Kumarakulasinghe NB, Syn N, Soon YY, et al. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget. 2016;7(51):85542-85550. [PubMed 27907909</li>
<li>Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2021.</li>
<li>Jaruratanasirikul S and Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54:159-161. [PubMed 9626921</li>
<li>Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, and Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51:453-457. [PubMed 12562722</li>
<li>Lange D, Pavao JH, Wu J, and Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Tolsura (itraconazole) [prescribing information]. Greenville NC: Mayne Pharma; December 2018</li>
<li>Lindsay J, Mudge S, and Thompson GR. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723018. [PubMed 30297369</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018</li>
<li>Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808. [PubMed 16141567]</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2017</li>
<li>Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893-1899. [PubMed 27533287</li>
<li>Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5. [PubMed 27565882]</li>
<li>Camzyos (mavacamten) [prescribing information]. Brisbane, CA: MyoKardia, Inc.; April 2022.</li>
<li>Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol.1993;33(1):82-84. [PubMed 8269594</li>
<li>Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024-1027. [PubMed 10981249</li>
<li>Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497. [PubMed 12077038</li>
<li>Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30(3):963-965. [PubMed 20393020</li>
<li>McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012;25(4):477-485. [PubMed 22550162</li>
<li>Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316-318. [PubMed 18386155</li>
<li>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Chemotherapy. 2011;57(3):225-229. [PubMed 21597286</li>
<li>Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht RDelayed elimination of methotrexate associated with co-administration of proton pump inhibitorsAnticancer Res2010;30(9):3807-3810[PubMed 20944174</li>
<li>Fang AF, Damle BD, LaBadie RR, Crownover, PH, Hewlett Jr. D, Glue, PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50. [PubMed 18154473</li>
<li>Saberi P, Ranatunga DK, Quesenberry CP, Silverberg MJ. Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011;31(3):253-261. [PubMed 21361735</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016</li>
<li>Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32(12):1462-1467. [PubMed 15448116]</li>
<li>Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50(8):960-967. [PubMed 20498287</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155-1162. [PubMed 30605231</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.</li>
<li>Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food and intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614-626. [PubMed 28430398</li>
<li>Ibrance (palbociclib) capsule [prescribing information]. New York, NY: Pfizer Inc; September 2019</li>
<li>Ibrance (palbociclib) tablet [prescribing information]. New York, NY: Pfizer Inc; November 2019</li>
<li>Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021;6(5):100231. [PubMed 34509802</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649]</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PubMed 19075045</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; November 2013</li>
<li>Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839. [PubMed 19220151</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-5510[PubMed 22890761</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott (US), LLC; April 2015</li>
<li>Kinov P, Boyanov M. Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health. 2012;4L:167-174. [PubMed 22532780</li>
<li>Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114. [PubMed 30539272</li>
<li>Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998-1004. [PubMed 21321287</li>
<li>Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161-1168. [PubMed 22890365</li>
<li>Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016-1022. [PubMed 23307040</li>
<li>Prieto-Alhambra D, Pages-Castella A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268-274. [PubMed 23761350</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Yang SD, Chen Q, Wei HK, et alBone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysisInt J Clin Exp Med2015;8(4):4899-4910[PubMed 26131063</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782</li>
<li>Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC Jr, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63(10):2070-2073. [PubMed 26415604</li>
<li>Roux C, Goldstein JL, Zhou X, et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277-284. [PubMed 21365461</li>
<li>Asaoka D, Nagahara A, Hojo M, et al. Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomed Rep. 2016;5(2):165-170. [PubMed 27446535</li>
<li>Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31(2):206-211. [PubMed 23138352</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014:607145. [PubMed 25436170]</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin Inc; July 2017</li>
<li>Prilosec (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Nexim (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016</li>
<li>Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2017.</li>
<li>Retevmo (selpercatinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; May 2020.</li>
<li>Norouzi G, AsadZade A, Salimi Y, Khoshbakht S, Pirayesh E. Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi. J Nucl Cardiol. 2022;29(4):1552-1561. [PubMed 33527332</li>
<li>Rose DS, Robinson B, Kannan S, Lee JC. Interaction between the effects of proton pump inhibitors and aspirin on gastric wall sestamibi uptake on myocardial perfusion imaging. J Nucl Cardiol. 2021;28(5):1976-1985. [PubMed 31741323</li>
<li>Qutbi M. What is this image? 2019: Image 2 result : Reduction in interfering gastric wall uptake on myocardial perfusion SPECT following a 2-week period of omeprazole withdrawal. J Nucl Cardiol. 2019;26(5):1517-1519. [PubMed 31359363</li>
<li>Singh H, Mittal BR, Sood A, et al. Association of use of proton pump inhibitors and H2 antagonists with stomach wall uptake in 99m-Tc-methoxy-isobutyl-isonitrile (MIBI) myocardial perfusion imaging. J Nucl Cardiol. 2020;27(5):1611-1619. [PubMed 31087263</li>
<li>Javadi H, Jallalat S, Semnani S, et al. The association of increased stomach wall radiotracer uptake with prolonged use of omeprazole capsules on myocardial perfusion imaging (MPI) using 99mTc-sestamibi SPECT. Nucl Med Rev Cent East Eur. 2013;16(2):91-94. [PubMed 24068640</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974</li>
<li>Cardiolyte (technetium Tc 99m sestamibi) [prescribing information]. N. Billerica, Massachusetts: Lantheus Medical Imaging; December 2019</li>
<li>Technetium Tc 99m sestamibi [product monograph]. Laval, Quebec, Canada: Curium Canada Inc; November 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2020</li>
<li>Vosevir (sofosbuvir and velpatasvir and voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2019</li>
<li>Seyen MV, Colbers A, Abbink EJ, Drenth JPH, Burger DM. Concomitant intake of coca-cola to manage the drug-drug interaction between velpatasvir and omeprazole studied in healthy volunteers. Clin Pharmacol Ther. 2019;106(5):1093-1098. [PubMed 31313296]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270</li>
<li>Evekeo (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2013.</li>
<li>Czerwinski E. Atypical subtrochanteric fractures after long-term bisphosphonate therapy. Endokrynol Pol. 2011;62(1):84-87. [PubMed 21365585</li>
<li>Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169-180. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-785. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-1998. [PubMed 19333676</li>
<li>Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-1218. [PubMed 21483462</li>
<li>Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768-776. [PubMed 21185417</li>
<li>Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131-1136. [PubMed 20872906</li>
<li>Gray SL, LaCroix AZ, Larson J, et alProton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health InitiativeArch Intern Med2010;170(9):765-771[PubMed 20458083</li>
<li>Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101. [PubMed 20353792</li>
<li>Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326. [PubMed 18695179</li>
<li>Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. [PubMed 17190895</li>
<li>Bodmer M, Meier C, Kraenzlin ME, et al. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33(10):843-852. [PubMed 20812769</li>
<li>Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903-910. [PubMed 20585937</li>
<li>Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959. [PubMed 18657011</li>
<li>Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904. [PubMed 19931262</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014;2014:607145. [PubMed 25436170</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782]</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767-773. [PubMed 27737436</li>
<li>Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257-263. [PubMed 26803708</li>
<li>Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43(4):309-315. [PubMed 10071982</li>
<li>van Doorn L, Heersche N, de Man FM, et al. Effect of the proton pump inhibitor esomeprazole on the systemic exposure of capecitabine: results of a randomized crossover trial. Clin Pharmacol Ther. 2022;111(2):455-460. [PubMed 34656072]</li>
<li>Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23(1):37-39. [PubMed 11413862</li>
<li>Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44(2):186-189. [PubMed 9278208]</li>
<li>Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2-receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183]</li>
<li>Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-353. [PubMed 22422635</li>
<li>Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23(3):317-321. [PubMed 3567046</li>
<li>Onfi (clobazam) [prescribing information]. Winchester, KY: Catalent Pharma Solutions, LLC; February 2021</li>
<li>Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999;21(6):604-608. [PubMed 10604819</li>
<li>Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589-592. [PubMed 22293514</li>
<li>Grigoleit HG, Hajdu P, Hundt HK, et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol. 1983;25(1):139-142. [PubMed 6617718]</li>
<li>Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2022.</li>
<li>Frick A, Kopitz J, and Bergemann N, “Omeprazole Reduces Clozapine Plasma Concentrations: A Case Report,” Pharmacopsychiatry, 2003, 36(3):121</li>
<li>[PubMed 12806570</li>
<li>Intensive Medicines Monitoring Programme accessed at http://www.medsafe.govt.nz/Profs/Puarticles/ClozOmep.htm May 14, 2013</li>
<li>Mookhoek EJ and Loonen AJ, “Retrospective Evaluation of the Effect of Omeprazole on Clozapine Metabolism,” Pharm World Sci, 2004, 26(3):180</li>
<li>[PubMed 15230368</li>
<li>Wagner S, Varet-Legros MG, Fabre C, et al, “Confounding Factors for Variation of Clozapine Plasma Levels: Drug Interactions With Proton Pump Inhibitor or Infectious Etiologies?” Eur J Clin Pharmacol, 2011, 67(5):533</li>
<li>[PubMed 21057941</li>
<li>Philipps RJ, Lee Demler T and Lee C, “Omeprazole-Induced Blood Dyscrasia in a Clozapine-Treated Patient,” Innov Clin Neurosci, 2012, 9(9):14</li>
<li>[PubMed 23074697]</li>
<li>Reichenspurner H, Meiser BM, Muschiol F. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transplant. 1993;12(6):987-992. [PubMed 8312324</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al. Changes of resorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc. 1994;26(5):2800-2801. [PubMed 7940881</li>
<li>Schouler L, Dumas F, Couzigou P. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86(8):1097. [PubMed 1858755</li>
<li>Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993;35(2):156-160. [PubMed 8443034</li>
<li>Castellote E, Bonet J, Lauzurica R. Does interaction between omeprazole and cyclosporin exist? Nephron. 1993;65(3):478. [PubMed 8290007</li>
<li>Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM. More about omeprazole-cyclosporine interaction. Am J Gastroenterol. 1993;88(1):154-155. [PubMed 8420264</li>
<li>Zegerid (omeprazole) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; November 2020.</li>
<li>Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057-1069. [PubMed 25929560</li>
<li>Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519. [PubMed 29105855</li>
<li>Kamiya C, Inui N, Hakamata A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361-366. [PubMed 30902567</li>
<li>Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487-494. [PubMed 15025747</li>
<li>Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141-152. [PubMed 11907488</li>
<li>Vlase L, Neag M, Popa A, Muntean D, Leucuta SE. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Curr Ther Res Clin Exp. 2010;71(6):360-368. [PubMed 24688155</li>
<li>Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653-662. [PubMed 24569517</li>
<li>Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. [PubMed 34877801</li>
<li>Inrebic (fedratinib) [prescribing information]. Summit, NJ: Celgene Corporation; August 2019</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672</li>
<li>Vfend (voriconazole) [prescribing information]New York, NY: Pfizer; January 2019</li>
<li>Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021</li>
<li>Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23(2):77-81. [PubMed 11932962</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; January 2020</li>
<li>Armas D, Holt RJ, Confer NF, Checani GC, Obaidi M, Xie Y, Brannagan M. A phase I pharmacokinetic study of cysteamine bitartrate delayed-release capsules following oral administration with orange juice, water, or omeprazole in cystinosis. Adv Ther. 2018;35(2):199-209. [PubMed 29411268]</li>
<li>Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicriob Agents Chemother. 2007;51(3):958-961. [PubMed 17210768]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Lexington, MA: Shire US Inc.; July 2019</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270]</li>
<li>Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.</li>
<li>Grahnen A, Olsson B, Johansson G, Eckernas SA. Doxycycline carrageenate-an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmcol 1994;46(2):143-146. [PubMed 8039533</li>
<li>Monodox (doxycycline monohydrate). Aqua Pharmaceuticals, LLC; Fort Lauderdale, FL: April 2017</li>
<li>Nexium (esomeprazole). AstraZeneca Pharmaceuticals LP; Wilmington DE: October 2016.</li>
<li>Grasela Jr TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615-617. [PubMed 2751276</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081</li>
<li>Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol. 1993;33(1):53-56. [PubMed 8429114]</li>
<li>Lozano R, Bibian C, Quilez RM, Gil J, Constante Y, Garcia-Arilla E. Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol. 2014;77(6):1086-1087. [PubMed 23919252</li>
<li>Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391-1400. [PubMed 23928296</li>
<li>Lexapro (escitalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Courlet P, Guidi M, Glatard A, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019;85(9):2022-2032. [PubMed 31144347</li>
<li>Escitalopram [product monograph]. Kirkland, Quebec, Canada: Accord Healthcare Inc; September 2017.</li>
<li>Marti-Masso JF, Lopez de Munain A, Lopez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother. 1992;26(3):429-430. [PubMed 1554966]</li>
<li>Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-1241. [PubMed 3932118</li>
<li>Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24(4):543-545. [PubMed 3689634</li>
<li>Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935-46. [PubMed 22612290</li>
<li>Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6):563-568. [PubMed 10613611</li>
<li>Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215-220. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al. Reduction of phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol. 1983;25(1):135-137. [PubMed 6617717</li>
<li>Bartle WK, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther. 1983;33(5):649-655. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, Jordan JE. Effect of cimetidine on phenytoin serum levels. Epilepsia. 1983;24(3):284-288. [PubMed 6851961</li>
<li>Iteogu MO, Murphy JE, Shleifer N, Davis REffect of cimetidine on single-dose phenytoin kineticsClin Pharm1983;2(4):302-304[PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology. 1985;35(4):562-565. [PubMed 3982643</li>
<li>Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. Br J Clin Pharmacol. 1989;27(1):83-87. [PubMed 2565119</li>
<li>Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effects of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 1989;30(2):225-229. [PubMed 2647472</li>
<li>Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, Remmel RP. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 1988;29(4):488-491. [PubMed 3391153</li>
<li>Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-544 (ADD 03055) in epileptic patients. Epilepsia. 1985;26(6):602-606. [PubMed 4076064</li>
<li>Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40(8):1122-1128. [PubMed 10448826</li>
<li>Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997;62(5):572-577. [PubMed 9390115</li>
<li>Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol. 1996;53(11):1191-1192. [PubMed 8912496</li>
<li>Rindone JP, Bryan G. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med. 1996;156(10):1113. [PubMed 8639000</li>
<li>Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology. 1996;46(4):1172-1173. [PubMed 8780118</li>
<li>Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother. 1998;32(12):1295-1298. [PubMed 9876809</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, Shearman DJ, Hann CS. Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed). 1981;282(6275):1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med. 1981;95(2):244-245. [PubMed 7258891</li>
<li>Phillips P, Hansky J. Phenytoin toxicity secondary to cimetidine administration. Med J Aust. 1984;141(9):602. [PubMed 6092884</li>
<li>Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12(4):329-333. [PubMed 2396305</li>
<li>Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36(4):380-382. [PubMed 12959321</li>
<li>Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol. 1992;34(1):75-78. [PubMed 1633070</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Dujic T, Cvijic S, Elezovic A, et al. Interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype. J Pers Med. [published online May 3 2021].doi:10.3390/jpm11050367] [PubMed 34063566]</li>
<li>Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474-484. [PubMed 34649118</li>
<li>Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487-5493. [PubMed 32933995</li>
<li>Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR tirals. Ann Oncol. 2020;31(4):535-531. [PubMed 32115349</li>
<li>Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016;26(9):609-615. [PubMed 27603551</li>
<li>Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacotherapy. 2022;56(4):377-386. [PubMed 34282636]</li>
<li>Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12(15):2080-2082. [PubMed 9814882</li>
<li>Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-428. [PubMed 18281734</li>
<li>Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122-129. [PubMed 27693678]</li>
<li>Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.</li>
<li>Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69(4):266-273. [PubMed 11309556</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672]</li>
<li>Sharma VR, Brannon MR, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. Southern Med J. 2004;97(9):887-889.[PubMed 15455980</li>
<li>Salovaara S, Sandberg A-S, Andlid T. Combined impact of pH and organic acids on iron uptake by caco-2 cells. J Agric Food Chem. 2003;51:7820-7824. [PubMed 14664552</li>
<li>Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Ann Rev Nutr. 2003;23:283-301. [PubMed 12626689]</li>
<li>Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42(10):4243-4246. [PubMed 21168674</li>
<li>Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061-2067. [PubMed 20671023</li>
<li>Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196-1201. [PubMed 19783713</li>
<li>Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9(7):1650-1656. [PubMed 19519820</li>
<li>Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605-611. [PubMed 19481022</li>
<li>Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46(5):1362-1365. [PubMed 24935300</li>
<li>David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit. 2012;34(3):331-336. [PubMed 22549498</li>
<li>Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30(1):46-51. [PubMed 18223462</li>
<li>Kato R, Ooi K, Ikura-Mori M, et alImpairment of mycophenolate mofetil absorption by calcium polycarbophilJ Clin Pharmacol2002;42(11):1275-1280[PubMed 12412828</li>
<li>Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518-524. [PubMed 24162246</li>
<li>Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. [PubMed 25913040</li>
<li>Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265-1272. [PubMed 21903891</li>
<li>Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120-123. [PubMed 21192310</li>
<li>van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014;72(2):86-90. [PubMed 24659591</li>
<li>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; September 2013</li>
<li>Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565-571. [PubMed 21256049</li>
<li>Sakuludomakan W, Takuathung MN, Dukaew N, Koonrungsesomboon N. Drug-drug interactions between mycophenolic acid and proton pump inhibitors: a systematic review and meta-analysis. Ther Drug Monit. 2022;44(3):384-390. [PubMed 35239287</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.</li>
<li>Mycapssa (octreotide) delayed release capsules [prescribing information]. Scotland, UK: MW Encap Ltd; June 2020.</li>
<li>Prescribing information. Adempas (riociguat). Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., October 2013.</li>
<li>Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401-1406. [PubMed 16791014</li>
<li>Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914</li>
<li>Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83(6):867-872. [PubMed 17898705</li>
<li>Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech, Inc.; September 2020</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50:1081-1084. [PubMed 12461038</li>
<li>Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacother. 2006;26(8):1060-1068. [PubMed 16863482]</li>
<li>Nexavar (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2018</li>
<li>Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. J Cancer Res Clin Oncol. 2020;146(10):2693-2697. [PubMed 32449002</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(11):3078-3087. [PubMed 20395213]</li>
<li>Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet. 2008;23:134-138. [PubMed 18445994</li>
<li>Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet. 2007;22:441-444. [PubMed 18159131</li>
<li>Moreau C, Debray D, Loriot MA, et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation. 2006;81:487-488. [PubMed 16477241</li>
<li>Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38:791-794. [PubMed 15010519</li>
<li>Homma M, Itagaki F, Yuzawa K, et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation. 2002, 73:303-304. [PubMed 11821750</li>
<li>Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821-826. [PubMed 19139162</li>
<li>Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos. 2007;28:167-175. [PubMed 17377957</li>
<li>Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56:1055-1059. [PubMed 15285851</li>
<li>Itagaki F, Homma M, Yuzawa K, et alDrug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutationTransplant Proc2002;34:2777-2778[PubMed 12431607</li>
<li>Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin a blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56:439-440. [PubMed 11009056</li>
<li>Mei T, Noguchi H, Suetsugu K, et al. Effects of concomitant administration of vonoprazan fumarate on the tacrolimus blood concentration in kidney transplant recipients. Biol Pharm Bull. 2020;43(10):1600-1603. [PubMed 32999170</li>
<li>Suzuki Y, Yoshihashi T, Takahashi K, Furuya K, Ohkohchi N, Oda T, Homma M. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. J Clin Med. 2021;10(17):3964. [PubMed 34501411</li>
<li>Pascual J, Marcen R, Orea OE, et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. Transplant Proc. 2005;37(9):3752-3753. [PubMed 16386527</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862. [PubMed 9224780</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A4 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143]</li>
<li>Mouden M, Rijkee KS, Schreuder N, Timmer JR, Jager PL. Influence of proton-pump inhibitors on stomach wall uptake of 99mTc-tetrofosmin in cadmium-zinc-telluride SPECT myocardial perfusion imaging. Nucl Med Commun. 2015;36(2):143-147. [PubMed 25356621</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974]</li>
<li>Ock M, Lee S, Kim H. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor coadministration in patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2022;47(7):1028-1035. [PubMed 35257383]</li>
<li>Aptivus (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 20202. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914]</li>
<li>Ahmad S. Omeprazole-warfarin interaction. South Med J. 1991;84(5):674-675. [PubMed 2035104</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [PubMed 1493083</li>
<li>Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-184. [PubMed 2718223</li>
<li>Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci. 2003;20(4-5):439-449. [PubMed 14659488</li>
<li>Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab. 2005;6(5):399-411. [PubMed 16248835</li>
<li>Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol. 1993;110(1):482-490. [PubMed 8220911</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit. 2008;30(3):276-281. [PubMed 18520598</li>
<li>Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011;153(3):379-385. [PubMed 21418179</li>
<li>de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LMNo effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamicsBr J Clin Pharmacol1997;44(4):399-401[PubMed 9354316</li>
<li>Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN. Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol. 1997;32(10):991-994. [PubMed 9361171</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [PubMed 15258107</li>
<li>Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780]</li>
<li>Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56 Suppl 1:56-61. [PubMed 14616415</li>
<li>Yan M, Wu ZF, Tang D, et al. The impact of PPIs on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018;108:60-64. [PubMed 30216801</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological disease. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211. [PubMed 18171251</li>
<li>Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses. 2012;55(6):483-492. [PubMed 22429709</li>
<li>Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X. Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother. 2021;65(9):e0020721. [PubMed 34152823</li>
<li>Boyd NK, Zoellner CL, Swancutt MA, et al. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001-6002. [PubMed 22890768</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer; January 2019.</li>
<li>Veerman GDM, Hurkmans DP, Paats MS, et al. Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother. 2022;155:113695. [PubMed 36126454]</li>
<li>Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol. 2004;44(6):640-645. [PubMed 15145972</li>
<li>Pylera (bismith subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</li>
<li>Tabrecta (capmatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</li>
<li>Lau YY, Gu W, Lin T, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(6):1119-1128. [PubMed 28424965</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2016.</li>
<li>Clarithromycin [prescribing information]. Bedminster, NJ: Alembic Pharmaceuticals, Inc.; February 2022</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; March 2022.</li>
<li>Michaud V, Kreutz Y, Skaar T, et al. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 2014;14(2):151-159. [PubMed 23629159</li>
<li>Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475-482. [PubMed 22318618</li>
<li>Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharmacol Drug Dev. 2016;5(4):269-277. [PubMed 27310328</li>
<li>Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2015;60(1):105-114. [PubMed 26459906</li>
<li>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29. [PubMed 25646891</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. Doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. [PubMed 18076219</li>
<li>Nader A, Mostafa NM, Kim E, Shebley M. Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. Clin Transl Sci. 2022;15(5):1269-1280. [PubMed 35137535</li>
<li>Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol. 2014;54(4):422-431. [PubMed 24165884</li>
<li>Vassiliou D, Sardh E, Harper P, et al. A drug-drug interaction study evaluating the effect of givosiran, a small interfering ribonucleic acid, on cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250-1260. [PubMed 34510420</li>
<li>Luzu (luliconazole) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; February 2017</li>
<li>Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. [PubMed 29178272</li>
<li>Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465-472. [PubMed 28155129</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Tpoxx (tecovirimat) [prescribing information]Winchester, KY: Catalent Pharma Solutions; July 2018</li>
<li>Brukinsa (zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA, Inc.; November 2019</li>
<li>Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999;47(4):454-457. [PubMed 10233213</li>
<li>Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Jaypirca (pirtobrutinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; January 2023.</li>
<li>Bolek T, Samos M, Stanciakova L, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2017;Apr 25 (Epub ahead of print). [PubMed 28452843</li>
<li>Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33(6):619-623. [PubMed 29255511</li>
<li>Stangier J, Eriksson BI, Dahl O, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563. [PubMed 15831779</li>
<li>Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59. [PubMed 18076218</li>
<li>Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175. [PubMed 21972820</li>
<li>Schnierer M, Samos M, Bolek T, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020;75(4):333-335. [PubMed 31895873</li>
<li>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. [PubMed 19717844</li>
<li>Ollier E, Hodin S, Basset T, et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29(6):604-614. [PubMed 26392328</li>
<li>O'Dea D, Whetteckey J, Ting NA prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatranCardiol Ther2016;5(2):187-201[PubMed 27709460</li>
<li>Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586-595. [PubMed 25960019</li>
<li>Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-1713, 1713a-1713b. [PubMed 23425521</li>
<li>Pradaxa (dabigatran) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; July 2020.</li>
<li>Tafinlar (dabrafenib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.</li>
<li>Drewelow B, Schaffler K, Reitmeir P, Bethke TD. Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittelforschung. 2010;60(8):483-491. [PubMed 20863004</li>
<li>Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-164. [PubMed 7648765</li>
<li>Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995;58(1):62-72. [PubMed 7628184</li>
<li>Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47(1):79-85. [PubMed 2104790</li>
<li>Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39(1):51-54. [PubMed 2276389</li>
<li>Lima DR, Santos RM, Werneck E, Andrade GN. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers. Eur J Drug Metab Pharmacokinet. 1991;16(3):161-170. [PubMed 1814733</li>
<li>Locniskar A, Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. J Clin Pharmacol. 1986;26(4):299-303. [PubMed 2871051]</li>
<li>Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569-572. [PubMed 1954072</li>
<li>Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1995;33(9):481-485. [PubMed 8520804</li>
<li>Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400-402. [PMID: 17458401</li>
<li>Le GH, Schaefer MG, Plowman BK, Morreale AP, Delattre M, Okino L, Felicio L. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors. Am J Health Syst Pharm. 2003;60(13):1343-1345. [PubMed 12901036</li>
<li>Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CBV. Omeprazole does not modulate pharmacokinetic effect of digoxin in patients with heart failure. Int J Cardiol. 2015;179:343-344. [PubMed 25464482]</li>
<li>Rozlytrek (entrectinib) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; August 2019.</li>
<li>Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508-516. [PubMed 18492125</li>
<li>Intelence (etravirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; July 2019.</li>
<li>Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose fedratinib in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(5):995-1001. [PubMed 32318809]</li>
<li>Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on the filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585-594. [PubMed 30768860</li>
<li>Jyseleca (filgotinib) [summary of product characteristics]. Mechelen, Belgium: Galapagos NV; January 2022.</li>
<li>Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;8:457-464. [PubMed 17760738</li>
<li>Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 2006;42:61-67. [PubMed 16639341</li>
<li>Kiser JJ, Lichtenstein KA, Anderson PL, et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26:511-514. [PubMed 16553510</li>
<li>Ford SL, Wire MB, Lou Y, et al. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49:467-469. [PubMed 15616339</li>
<li>Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48:791-798. [PubMed 14982766]</li>
<li>Yin O, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850. [PubMed 15608563</li>
<li>Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012;68(5):553-560. [PubMed 22189672</li>
<li>Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731. [PubMed 19299322</li>
<li>Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509. [PubMed 20186406]</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</li>
<li>Brexafemme (ibrexafungerp) [prescribing information]. Jersey City, NJ: Scynexis Inc; June 2021.</li>
<li>Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2021</li>
<li>Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386-1394. [PubMed 26054042]</li>
<li>Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185-189. [PubMed 21150767</li>
<li>Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821-829. [PubMed 27890768</li>
<li>Tran-Duy A, Connell NJ, Vanmolkot FH, et al. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med. 2019;285(2):205-214. [PubMed 30141278</li>
<li>Imai R, Higuchi T, Moriomoto M, Koyamada R, Okada S. Iron deficiency anemia due to long-term use of a proton pump inhibitor. Inter Med. 2018;57(6):899-901. [PubMed 29151538</li>
<li>Mabuchi S, Suzuki R, Sasak M, et al. Case report of severe iron deficiency anemia caused by proton pump inhibitor in an elderly patient. Geriatr Gerontol Int. 2017;662-663. [PubMed 28405975</li>
<li>Hashimoto R, Matsuda T, Chonan A. Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med. 2014;53(20):2297-2299. [PubMed 25318791</li>
<li>Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97(9):887-889. [PubMed 15455980</li>
<li>Khatib MA, Rahim O, Kania R, Molloy P. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig Dis Sci. 2002;47(11):2596-2597. [PubMed 12452401</li>
<li>Eghbali A, Khalilpour A, Taherahmadi H, Bagheri BPantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled studyTherapie2019;74(5):507-512[PubMed 30704764</li>
<li>Shalev H, Quider AA, Harosh MB, Kapelushnik J. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia. Pediatr Hematol Oncol. 2016;33(7-8):457-461. [PubMed 27960647</li>
<li>Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-1295. [PubMed 17344278</li>
<li>Tempel M, Chawla A, Messina C, Celiker MY. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol. 2013;30(3):307-310. [PubMed 24385811</li>
<li>Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-292. [PubMed 1607604</li>
<li>Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011;134(2):224-231. [PubMed 21911976</li>
<li>Sarker SA, Mahmud H, Davidsson L, et al. Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology. 2008;135(5):1534-1542. [PubMed 18775429]</li>
<li>Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34(5):317-325. [PubMed 24567279</li>
<li>Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; June 2019.</li>
<li>Koch KM, Im Y-H, Kim S-B, et al. Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients. Clin Pharmacol Drug Dev. 2013;2(4):336-341. [PubMed 27121938</li>
<li>Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015</li>
<li>Tykerb (lapatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.</li>
<li>Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</li>
<li>Adhansia XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Purdue Pharmaceuticals LP; July 2019</li>
<li>Cotempla XR ODT (methylphenidate) extended-release orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC; June 2017</li>
<li>Concerta (methylphenidate) extended-release tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2017</li>
<li>Ritalin LA (methylphenidate) extended-release capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019</li>
<li>Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Greenville, NC: Patheon Manufacturing Services LLC; June 2019</li>
<li>Jornay PM (methylphenidate) extended-release capsules [prescribing information]. Cherry Hill, NJ: Ironshore Pharmaceuticals Inc; April 2019</li>
<li>Metadate CD (methylphenidate) extended-release capsules [prescribing information]. Smyrna, GA: UCB Inc; June 2014</li>
<li>Quillichew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; March 2017</li>
<li>Quillivant XR (methylphenidate) extended-release oral suspension [prescribing information]New York, NY: Pfizer Inc; January 2017</li>
<li>Ritalin SR (methylphenidate) extended-release tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.</li>
<li>Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120-2138. [PubMed 28808886</li>
<li>Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; February 2022.</li>
<li>Ji T, Rockich K, Epstein N, et al. Evaluation of drug-drug interactions of pemigatinib in healthy participants [published online July 19, 2021]. Eur J Clin Pharmacol. doi: 10.1007/s00228-021-03184-z. [PubMed 34282472</li>
<li>Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; February 2021.</li>
<li>Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. [PubMed 18303127</li>
<li>Seiler D, Doser K, Salem I. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. Arzneimittelforschung. 2011;61(4):247-251. [PubMed 21650084</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed 25012577</li>
<li>Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906-913. [PubMed 28875498</li>
<li>Effient (prasugrel) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; December 2020.</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Yang E, Ji SC, Jang I-J, Lee S. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet. 2023;62(4):599-608. [PubMed 36897544</li>
<li>Kolawole JA, Mustapha A, Abdul-Aguye I, Ochekpe N, Taylor RB. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal. 1999;20(5):737-743. [PubMed 10701981</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole, and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. Eur J Clin Pharmacol. 1996;50(5):417-419. [PubMed 8839666]</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2020</li>
<li>Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-492. [PubMed 19143531]</li>
<li>Zhou J, Quinlan M, Glenn K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol. 2016;82(4):1022-1029. [PubMed 27277189</li>
<li>Odomzo (sonidegib) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2017.</li>
<li>Tazverik (tazemetostat) [prescribing information]. Cambridge, MA: Epizyme, Inc.; January 2020.</li>
<li>Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. [PubMed 16641395</li>
<li>Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. [PubMed 17669709</li>
<li>Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-59. [PubMed 16477543</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075</li>
<li>Abi-Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? Arq Bras Endocrinol Metabol. 2014;58(7):731-736. [PubMed 25372582</li>
<li>Ermeza (levothyroxine) solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022</li>
<li>Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. [PubMed 25259910]</li>
<li>Giri P, Gupta L, Naidu S, et al. In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, alicarb, methiocarb, motelukast and ziprasidone. Drug Metabo Lett. 2019;12(2):101-116. [PubMed 30117405</li>
<li>Egaten (triclabendazole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2019.</li>
<li>Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26-33. [PubMed 23110788]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. Doi: 10.1007/s40262-017-0591</li>
<li>[PubMed 28866861]</li>
<li>Verquvo (vericiguat) [prescribing information].Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2021.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022</li>
<li>Calquence (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2022.</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” Pharmacotherapy, 2010, 30(8):787-96. [PubMed 20653354</li>
<li>Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” Clin Cardiol, 2010, 33(3):168-71. [PubMed 20235209</li>
<li>Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” Arch Intern Med, 2010, 170(8):704-10[PubMed 20421557</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2018.</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2021.</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067]</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2019.</li>
<li>Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol. 2015;71(12):1461-1465. [PubMed 26400679</li>
<li>Bertram V, Yeo K, Anoopkumar-Dukie S, Bernaitis N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract. 2019;73(11):e13382. [PMID 31250945</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2014.</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Cojutti P, Candoni A, Forghieri, et al. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and/or with CYP inhibitors plus CYP inducers. Basic Clin Pharmacol Toxicol. 2016;118(6):474-479. [PubMed 26572687</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143</li>
<li>Scholler J, Nivoix Y, Herbrecht R, et al. Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. Int J Clin Pharm. 2011;33(6):905-908. [PubMed 22108788</li>
<li>Tsubokura M, Miura Y, Itokawa T, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol. 2011;51(10):1488-1490. [PubMed 21098688</li>
<li>Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262-3267. [PubMed 23629724</li>
<li>Dexilant (dexlansoprazole) [prescribing information]Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2018</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; October 2017</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc.; January 2019.</li>
<li>Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” Ann Pharmacother, 2003, 37(6):808-11. [PubMed 12773066</li>
<li>Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors,” Am J Cardiol, 2004, 94:1140</li>
<li>[PubMed 15518608</li>
<li>Amsden GW, Kuye O,Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” J Clin Pharmacol, 2002, 42:444</li>
<li>[PubMed 11936570</li>
<li>Lee AJ,Maddix DS, “Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin,” Ann Pharmacother, 2001, 35:26-31. [PubMed 11197581</li>
<li>Chen C, Lin J, Smolarek T, et al, “P-Glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in Mdr1a/B Knockout and Wild-Type Mice,” Drug Metab Dispos, 2007, 35:1725</li>
<li>[PubMed 17640956</li>
<li>Chen C, Mireles RJ, Campbell SD, et al, “Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors with Abcb1, Abcc2, and Oatp1b1,” Drug Metab Dispos, 2005, 33:537-46. [PubMed 15616150</li>
<li>Hochman JH, Pudvah N, Qiu J, et al, “Interactions of Human P-Glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin,” Pharm Res, 2004, 21:1686-91. [PubMed 15497697</li>
<li>Wu X, Whitfield LR,Stewart BH, “Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter,” Pharm Res, 2000, 17:209-15. [PubMed 10751037</li>
<li>Pauli-Magnus C, Rekersbrink S, Klotz U, et al, “Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein,” Naunyn Schmiedebergs Arch Pharmacol, 2001, 364:551</li>
<li>[PubMed 11770010</li>
<li>Collett A, Tanianis-Hughes J, Carlson GL, et al, “Comparison of P-Glycoprotein-Mediated Drug-Digoxin Interactions in Caco-2 with Human and Rodent Intestine: Relevance to in Vivo Prediction,” Eur J Pharm Sci, 2005, 26:386-93. [PubMed 16153812]</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Prevacid (lansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2020.</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed: 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc. 2015;4(11). [PubMed: 26514161</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed: 22464478</li>
<li>Shamliyan TA, Middleton M, Borst C. Patient-centered outcomes with concomitant use of proton pump inhibitors and other drugs. Clin Ther. 2017;39(2):404-427. [PubMed: 28189362</li>
<li>Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823. [PubMed: 20102352</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed: 25012577</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-36[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244</li>
<li>Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig. 2011;31(10):727-733. [PubMed 21877765</li>
<li>Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44(11):1223-1229. [PubMed 15496639</li>
<li>Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005;60(1):61-68. [PubMed 15963095</li>
<li>Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162-164. [PubMed 15546944]</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2014; July 28 (Epub ahead of print). [PubMed 25068772</li>
<li>Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-277. [PubMed 18615373</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi TThe role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazoleTher Drug Monit2008;30(3):276-281[PubMed 18520598</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11). pii: e002245. [PubMed 26514161</li>
<li>Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43(3):212-224. [PubMed 22564422</li>
<li>Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35(2):127-139. [PubMed 22204719</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Lu M. Report: Impact of drug combination of clopidogrel and pantoprazole in the prognosis of patients with transient ischemic attack. Pak J Pharm Sci. 2017;30(1):217-221. [PubMed 28603135</li>
<li>Choi YJ, Kim N, Jang IJ, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-511. [PubMed 28395507</li>
<li>Gu RX, Wang XZ, Li J, Deng J, Li XX, Wang JEffects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrelMil Med Res2016;3</li>
<li>[PubMed 28018669</li>
<li>Bolek T, Samos M, Simonova R, et al. Does pantoprazole affect the on-treatment platelet reactivity in patients with acute STEMI treated with ADP receptor blockers?-a pilot prospective study. Am J Ther. 2017;24(2):e162-e166. [PubMed 27415979</li>
<li>Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacol Rep. 2012;64(2):360-368. [PubMed 22661187</li>
<li>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2020</li>
<li>Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012;33(5):278-283. [PubMed 22623337]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, Dammann G, Hiemke C, Grunder G, Paulzen M. The effects of co-prescription of pantoprazole on the clozapine metabolism. Pharmacopsychiatry. 2020;53(2):65-70. [PubMed 31614374]</li>
<li>Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metabol Dispos. 2014;42(7):1174-1179. [PubMed 24764147]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. doi: 10.1007/s40262-017-0591</li>
<li>Chandelia S, Dubey NK. Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole. Indian J Crit Care Med. 2016;20(2):127-128. [PubMed 27076718</li>
<li>Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39(6):700-703. [PubMed 7654493</li>
<li>Henriksen DP, Stage TB, Hansen MR, Rasmussen L, Damkier P, Pottegard A. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. 2015;24(12):1337-1340. [PubMed 26395871</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [Pubmed1493083</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf LComparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activitiesDrug Metab Dispos2004;32(8):821-827[PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780</li>
<li>Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71(9):1059-1066. [PubMed 26071277</li>
<li>Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. [PubMed 20844485]</li>
<li>El-Bohy D, Sharkawy M, Abo-Elazm S, et al. Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney transplantation: A randomized clinical trial. Ther Apher Dial. 2020;24(5):591-598. [PubMed 31856374</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-440. [PubMed 11009056</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. Pantoprazole does not affect cyclosporin a blood concentration in kidney-transplant patients. Eur J Clin Pharmacol. 2000;55(10):733-735. [PubMed 10663451]</li>
<li>Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74(10):2187-2192. [PubMed 20736505</li>
<li>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70(3):383-392. [PubMed 20716239</li>
<li>Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. [PubMed 19108880</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-2436[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. [PubMed 16772608</li>
<li>Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735-741. [PubMed 17361128</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107]</li>
<li>Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61(3):309-314. [PubMed 16487224</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2018.</li>
<li>Liu G, Wen J, Guo D, et al. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. J Pharmacol Sci. 2016;132(4):244-248. [PubMed 27245553]</li>
<li>Hata M, Hayasaka M, Sezai A, et al, “Proton Pump Inhibitors May Increase the Risk of Delayed Bleeding Complications after Open Heart Surgery If Used Concomitantly with Warfarin,” Thorac Cardiovasc Surg, 2008, 56:274-7</li>
<li>Ahmad S, “Omeprazole-Warfarin Interaction,” South Med J, 1991, 84:674-5</li>
<li>Unge P, Svedberg LE, Nordgren A, et al, “A Study of the Interaction of Omeprazole and Warfarin in Anticoagulated Patients,” Br J Clin Pharmacol, 1992, 34:509-12</li>
<li>Sutfin T, Balmer K, Bostrom H, et al, “Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men,” Ther Drug Monit, 1989, 11:176-84</li>
<li>Zhou Q, Chan E, “Effect of Omeprazole on the Anticoagulant Activity and the Pharmacokinetics of Warfarin Enantiomers in Rats,” Eur J Pharm Sci, 2003, 20:439-49</li>
<li>Zhou Q, Zhou S, Chan E, “Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and cDNA-Expressed Cytochrome P450 Isozymes,” Curr Drug Metab, 2005, 6:399-411</li>
<li>Hermans JJ, Thijssen HH, “Human Liver Microsomal Metabolism of the Enantiomers of Warfarin and Acenocoumarol: P450 Isozyme Diversity Determines the Differences in Their Pharmacokinetics,” Br J Pharmacol, 1993, 110:482-90</li>
<li>Uno T, Sugimoto K, Sugawara K, et al, “The Role of Cytochrome P2C19 in R-Warfarin Pharmacokinetics and Its Interaction with Omeprazole,” Ther Drug Monit, 2008, 30:276-81</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” Drug Metab Dispos, 2004, 32:821-7</li>
<li>Ko J, Sukhova N, Thacker D, et al, “Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms,” Drug Metab Dispos, 1997, 25:853-862.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2016.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (Tak-390mr), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29:35-50. [PubMed 19067473</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2015;63(1):45-50. [PubMed 25068772</li>
<li>Dexilant (dexlansoprazole) [Prescribing Information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2017</li>
<li>Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, Shin JG. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos. 2005;33(2):209-213. [PubMed 15537834]</li>
<li>Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; June 2018</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2018</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30(8):787-796. [PubMed 20653354</li>
<li>Stockl KM, Le L, Zakharyan A, et alRisk of rehospitalization for patients using clopidogrel with a proton pump inhibitorArch Intern Med2010;170(8):704-710[PubMed 20421557</li>
<li>Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Mahabaleshwarkar RK, Yang Y, Datar MV, et al. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Curr Med Res Opin. 2013;29(4):315-323. [PubMed 23362935</li>
<li>Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012;32(9):809-818. [PubMed 22744772</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors - a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997. [PubMed 19726078</li>
<li>Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329. [PubMed 19933932</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population based study of drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Wei P, Zhang YG, Ling L, et al. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-2864. [PubMed 27882086</li>
<li>Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824-834. [PubMed 22364155</li>
<li>Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2CDrug Metab Dispos. 2012;40(9):1698-1711. [PubMed 22648560</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478]</li>
<li>Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2018.</li>
<li>Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc; April 2006</li>
<li>Kayexalate (sodium polystyrene sulfonate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; December 2010</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a “nonsystemic” antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Fernandez PC, Kovnat PJ. Metabolic acidosis reversed by the combination of magnesium and a cation-exchange resin. N Engl J Med. 1972;286(1):23-24. [PubMed 5006921</li>
<li>Ziessman HA. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. South Med J. 1976;69(4):497-499. [PubMed 817399</li>
<li>Madias NE, Levey AS. Metabolic alkalosis due to absorption of “nonabsorbable” antacids. Am J Med. 1983;74(1):155-158. [PubMed 6849324]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36(6):1219-1224. [PubMed 1329615</li>
<li>Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55. [PubMed 8737124</li>
<li>Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989;46(6):700-705. [PubMed 2598571</li>
<li>Shiba K, Sakamoto M, Nakazawa Y, et al. Effects of antacid on absorption and excretion of new quinolones. Drugs. 1995;49(Suppl 2):360-361. [PubMed 8549362</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):39-48. [PubMed 11352441</li>
<li>Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830-832. [PubMed 1503446</li>
<li>Lehto PL, Kivisto KTDifferent effects of products containing metal ions on the absorption of lomefloxacinClin Pharmacol Ther1994;56(5):477-482[PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35(3):302-304. [PubMed 8471407</li>
<li>Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Emrok O (levonadifloxacin) tablet [product information]. Maharashtra, India: Wockhardt Limited; April 2022.</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(suppl 1):39-48. [PubMed 11352441</li>
<li>Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy. 1999;45(6):504-511. [PubMed 10567782</li>
<li>Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther. 1998;20(6):1149-1158. [PubMed 9916608</li>
<li>Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on the absorption of DR-3355 in humans. Antimicrobial Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother. 1990;34(12):2436-2438. [PubMed 2088202</li>
<li>Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Grasela TH Jr, Schentag JJ, Sedman AJ, et alInhibition of enoxacin absorption by antacids or ranitidineAntimicrob Agents Chemother1989;33(5):615-617[PubMed 2751276</li>
<li>Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):93-97. [PubMed 9222077</li>
<li>Hoffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol. 1992;33(1):115-116. [PubMed 1540482</li>
<li>Jaehde U, Sorgel F, Stephan U, Schunak W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother. 1994;38(5):1129-1133. [PubMed 8067750</li>
<li>Maesen FP, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids. J Antimicrob Chemother. 1987;19(6):848-850. [PubMed 3475268</li>
<li>Prescribing information. Cytotec (misoprostol). New York, NY: Pfizer Inc., September 2009.</li>
<li>Quinine [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; July 2015.</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017</li>
<li>Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020-3026. [PubMed 22450971</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494</li>
<li>FDA Antiviral Drugs Advisory Committee Meeting. ISENTRESS™ (raltegravir) 400 mg For Treatment of HIV (NDA 22-145). Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf. Published September 5, 2007. Accessed online November 15, 2013.</li>
<li>Dimaval (DMPS) Hartkapseln (unithiol) [summary of product characteristics]. Berlin, Germany: Haupt Pharma Wulfing GmbH; June 2020.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc.; March 2010</li>
<li>Ruggiero M, Brunese M, Morelli S, et al. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-777. [PubMed 6895034</li>
<li>Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. Digestion. 1987;37(1):35-42. [PubMed 3609503</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: Modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;25(15):1093-1115</li>
<li>Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium. 1986;5(5-6):293-300. [PubMed 3807422</li>
<li>Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Thioctic acid tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200201478. Accessed September 1, 2014.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2013</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2020.</li>
<li>Evaluation of Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis and Clinical Implications. Guidance for Industry [Draft]. Available at: https://www.fda.gov/media/144026/download. Accessed July 22, 2021.</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; June 2019.</li>
<li>HalfLytely and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) [prescribing information]. Braintree, MA: Braintree Laboratories Inc; May 2006.</li>
<li>De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</li>
<li>Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010</li>
<li>Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015</li>
<li>Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011</li>
<li>Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc.; April 2023.</li>
<li>Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; January 2021.</li>
<li>Calcijex (calcitriol) injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; March 2012</li>
<li>Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-797. [PubMed 6895034</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;26(15):1093-1115. [PubMed 14640773</li>
<li>Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Cefdinir [prescribing information]. Parsippany, NJ: Ascend Laboratories; January 2018.</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ, Collier PS. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159-163. [PubMed 6292443</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ. In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin. J Trop Med Hyg. 1982;85(4):153-158. [PubMed 7143531</li>
<li>Iwuagwu MA, Aloko KS. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655-658. [PubMed 1359089</li>
<li>Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: sanofi-aventis US LLC; October 2018.</li>
<li>Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology. 1981;80(4):661-665. [PubMed 7202937</li>
<li>Naggar VF, Khalil SA, Gouda MW. Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans. J Pharm Sci. 1978;67(7):1029-1030. [PubMed 207854</li>
<li>Lee DA, Taylor GM, Walker JG, et al. The effect of concurrent administration of antacids on prednisolone absorption. Br J Clin Pharmacol. 1979;8(1):92-94. [PubMed 552304</li>
<li>Tanner AR, Caffin JA, Halliday JW, et al. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol. 1979;7(4):397-400. [PubMed 444359</li>
<li>Albin H, Vincon G, Demotes-Mainard F, et al. Effects of aluminum phosphate on the bioavailability of cimetidine and prednisolone. Eur J Clin Pharmacol. 1984;26(2):271-273. [PubMed 6723769]</li>
<li>Product monograph. Pradaxa (dabigatran etexilate). Burlington, Ontario: Boehringer Ingelheim Canada Ltd., February 2019</li>
<li>Prescribing information. Pradax (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.</li>
<li>Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700-709. [PubMed 19395585</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</li>
<li>Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019</li>
<li>Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2019</li>
<li>Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol. 2003;43(2):171-179. [PubMed 12616670]</li>
<li>Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016</li>
<li>Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015</li>
<li>Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764-776. [PubMed 19446149]</li>
<li>Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45-50. [PubMed 23774876</li>
<li>Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2019</li>
<li>Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2019</li>
<li>Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug-drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:1</li>
<li>[PubMed 30798679]</li>
<li>Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products LP; April 2019.</li>
<li>Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals Inc; October 2016.</li>
<li>Allegra (fexofenadine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2010.</li>
<li>Fosinopril [prescribing information]. Princeton, NJ: Sandoz Inc; May 2013</li>
<li>Apo-fosinopril (fosinopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2008.</li>
<li>Yagi T, Naito Y, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248-254. [PubMed 22240839</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008</li>
<li>Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009</li>
<li>Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490</li>
<li>Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581</li>
<li>Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976</li>
<li>McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345</li>
<li>Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282]</li>
<li>Prescribing information. Anaspaz (hyoscyamine). Lenexa, KS: B. F. Ascher &amp; Compant, Inc., 6/2010</li>
<li>Prescribing information. Hyosyne (hyoscyamine). Spring Valley, NY: Silarx Pharmaceuticals, Inc., 4/2007</li>
<li>Prescribing information. Levsin (hyoscyamine). Marietta, GA: Alaven Pharmaceutical LLC, 2/2008</li>
<li>Prescribing information. Symax SR (hyoscyamine). Ft. Worth, TX: Capellon Pharmaceuticals, LLC, 9/2012</li>
<li>Prescribing information. Oscimin-SR (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011</li>
<li>Prescribing information. Oscimin (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</li>
<li>Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr. 1991;53(1):106-111. [PubMed 1984334</li>
<li>Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol. 2002;42(10):1171-1176. [PubMed 12362933</li>
<li>Wallace KL, Curry SC, LoVecchio F, Raschke RA. Effect of magnesium hydroxide on iron absorption following simulated mild iron overdose in human subjects. Acad Emerg Med. 1998;5(10):961-965. [PubMed 9862585</li>
<li>Hall GJ, Davis AE. Inhibition of iron absorption by magnesium trisilicate. Med J Aust. 1969;2(2):95-96. [PubMed 5803866</li>
<li>Ekenved G, Halvorsen L, Solvell L. Influence of a liquid antacid on the absorption of different iron salts. Scand J Haematol Suppl. 1976;28:65-77. [PubMed 1064903</li>
<li>O'Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Rastogi SP, Padilla F, Boyd CM. Effect of aluminum hydroxide on iron absorption. J Ark Med Soc. 1976;73(3):133-134. [PubMed 134015</li>
<li>Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81(6):1068-1071. [PubMed 7286584</li>
<li>Benkhedda K, L'abbe MR, Cockel KAEffect of calcium on iron absorption in women with marginal iron statusBr J Nutr2010;103(5):742-748[PubMed 19860985</li>
<li>Minihane AM, Fairweather-Tait SJ. Effect of calcium supplementation on daily nonheme-iron absorption and long-term iron status. Am J Clin Nutr. 1998;68(1):96-102. [PubMed 9665102</li>
<li>Dawson-Hughes B, Seligson FH, Hughes VA. Effects of calcium carbonate and hydroxyapatite on zinc and iron retention in postmenopausal women. Am J Clin Nutr. 1986;44(1):83-88. [PubMed 3014855</li>
<li>Spencer BR, Guo Y, Cable RG, et al. Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. Transfusion. 2019;59(10):3146-3156. [PubMed 31318071</li>
<li>Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016;97(6):583-593. [PubMed 27155295</li>
<li>Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001;22(6):490-496. [PubMed 11426238</li>
<li>Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P. Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia/a single-centre randomized controlled isotope study. Arzneimittelforschung. 2007;57(6A):392-400. [PubMed 17691589</li>
<li>Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med. 1999;33(4):400-405. [PubMed 10092717</li>
<li>Miranda M, Olivares M, Brito A, Pizarro F. Reducing iron deficiency anemia in Bolivian school children: calcium and iron combined versus iron supplementation alone. Nutrition. 2014;30(7-8):771-775. [PubMed 24984991]</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced Oral Itraconazole Bioavailability by Antacid Suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236</li>
<li>Sporanox (itraconazole) oral suspension [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Van der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, et al. Disposition of ketoconazole, an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Ketoconazole [prescribing information]. Hoschton, GA: Aavis Pharmaceuticals, LLC; September 2021.</li>
<li>Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022.</li>
<li>Synthroid (levothyroxine sodium) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2009</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669]</li>
<li>Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020</li>
<li>Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Lialda (mesalamine) delayed-release tablets [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; December 2020</li>
<li>Delzicol (mesalamine) delayed-release capsules [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Shire USA Inc; October 2020</li>
<li>Hussain FN, Ajjan RA, Moustafa M, Weir NW, Riley SA. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Br J Clin Pharmacol. 1998;46(2):173-175. [PubMed 9723828</li>
<li>Bashiri H, Bozorgomid A. Protective effect of Asacol in combination with pantoprazole in ulcerative colitis patients who defecate Asacol tablets intactly: a clinical trial study. Clin Exp Gastroenterol. 2020;13:47-51. [PubMed 32158250</li>
<li>Urex (methenamine) [prescribing information]. Wytheville, VA: Vatring Pharmaceuticals, Inc.; December 2006.</li>
<li>Cerklewski FL, “Influence of Dietary Magnesium on Fluoride Bioavailability in the Rat,” J Nutr, 117(3):496-500. [PubMed 3572562</li>
<li>Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” Clin Pharmacol Ther, 1980, 28(4):529-35. [PubMed 7408412</li>
<li>Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002</li>
<li>Spencer H, Kramer L, Osis D, et al, “Effect of Calcium, Phosphorus, Magnesium, and Aluminum on Fluoride Metabolism in Man,” Ann N Y Acad Sci, 1980, 355:181-94. [PubMed 6940475]</li>
<li>O’Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Benjamin IB, Cortell S, Conrad ME. Bicarbonate-induced iron complexes and iron absorption. Gastroenterology. 1967;35:389</li>
<li>Coste JF, De Bari VA, Keil LB, et al. In vitro interactions of oral haematinics and antacid preparations. Curr Ther Res Clin Exp. 1977;22:205.</li>
<li>Cellcept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; December 2019</li>
<li>Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41(6):513-516. [PubMed 8799515</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. Novartis Pharmaceuticals Corporation; April 2020.</li>
<li>Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemother Pharmacol. 2013;71(1):219-226. [PubMed 23070146</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211]</li>
<li>Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulphate. Clin Pharmacol Ther. 1983;33(4):465-470. [PubMed 6831825</li>
<li>Lyle WH. Penicillamine and iron. Lancet. 1976;2(7982):420. [PubMed 73880</li>
<li>Harkness JA, Blake DR. Penicillamine nephropathy and iron. Lancet. 1982;2(8312):1368-1369. [PubMed 6129465]</li>
<li>Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12(1):26-30. [PubMed 8440814</li>
<li>Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Aton Pharma Inc; November 2015.</li>
<li>Phospha 250 Neutral (sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic and sodium phosphate, monobasic, monohydrate) [prescribing information]. Allendale, NJ: Rising Pharmaceuticals, Inc.; June 2012</li>
<li>K-Phos No. 2 (potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</li>
<li>Levofloxacin [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; May 2022</li>
<li>Lomefloxacin [product labeling]. Kolon Pharmaceutical Co., Ltd.; March 2016</li>
<li>Norfloxacin [product monograph]. Vaughan, ON, Canada: AA Pharma Inc.; June 2019</li>
<li>Ofloxacin [summary of product characteristics]. Dublin, Ireland: Gerard Laboratories; June 2022</li>
<li>Pipemidic acid [Korean product labeling]. Aprogen Pharmaceutical Co., Ltd.; January 2014</li>
<li>Ciprofloxacin [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022</li>
<li>Baxdela (delafloxacin) [product labeling]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries; April 2022</li>
<li>Moxifloxacin [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited, May 2019</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Canada: Merus Labs International, Inc.; August 2018</li>
<li>Enoxacin [Korean product labeling]. Seoul, South Korea: Crystal Life Science Co. Ltd; June 2018</li>
<li>Prulifloxacin [summary of product characteristics]. Ancona, Italy: A.C.R.A.F. S.p.A.; February 2022.</li>
<li>Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2(8501):294. [PubMed 2874321</li>
<li>Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids. Lancet. 1986;2(8497)</li>
<li>[PubMed 2873348</li>
<li>Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med. 1988;109(2):168-169. [PubMed 3382110</li>
<li>Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005;27(2):81-82. [PubMed 15999916</li>
<li>Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother. 1991;28(1):87-94. [PubMed 1663108</li>
<li>Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013</li>
<li>Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014</li>
<li>Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005</li>
<li>Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014</li>
<li>Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012</li>
<li>Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013</li>
<li>Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011</li>
<li>Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003</li>
<li>Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017</li>
<li>Pefloxacin tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199101448 Accessed October 26, 2017.</li>
<li>Edurant (rilpivirine) [prescribing information]. Raritan NJ: Tibotec Therapeutics; May 2011</li>
<li>Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</li>
<li>Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October 2013.</li>
<li>Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021;43(6):1079-1091. [PubMed 33962762</li>
<li>Evrenzo (roxadustat) [summary of product characteristics]. Woking, United Kingdom: Astellas Pharma Ltd; September 2022.</li>
<li>Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol. 1997;43(3):269-272. [PubMed 9088581</li>
<li>Sotalol [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; March 2020</li>
<li>Kahela P, Anttila M, Sundgvist H. Antacids and sotalol absorption. Acta Pharmacol Toxicol (Copenh). 1981;49(3):181-183. [PubMed 7336975]</li>
<li>Summary of product characteristics. Protelos (strontium ranelate). Gidy, France: Les Laboratoires Servier Industrie, 7/2012.</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023</li>
<li>Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. Obes Surg. 2014;24(5):741-746. [PubMed 24347350</li>
<li>Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. Obes Surg. 2018;28(8):2252-2260. [PubMed 29556889]</li>
<li>Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013</li>
<li>Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013</li>
<li>Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</li>
<li>Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet. 1962;114:9-14. [PubMed 14498173</li>
<li>Albert KS, Welch RD, DeSante KA, et al. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J Pharm Sci. 1979;68(5):586-588. [PubMed 435335</li>
<li>Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247(16):2266-2267. [PubMed 7040708</li>
<li>Demeclocycline [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; March 2017</li>
<li>Rosenblatt JE, Barrett JE, Brodie JL, et al. Comparison on in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother. 1966;6:134-141. [PubMed 4964450</li>
<li>Garty M, Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976</li>
<li>Nguyen VX, Nix DE, Gillikin S, Schentag JJEffect of oral antacid administration on the pharmacokinetics of intravenous doxycyclineAntimicrob Agents Chemother1989;33(4):434-436[PubMed 2729939</li>
<li>Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther. 1971;12(5):779-784. [PubMed 4936141</li>
<li>Nuzyra (omadacycline) [prescribing information]. Boston, MA: Paratek Pharmaceuticals, Inc.; October 2020</li>
<li>Tetralysal (lymecycline) [summary of product characteristics]. Watford, Herts, UK: Galderma (UK) Limited; June 2020</li>
<li>Seysara (sarecycline) [prescribing information]. Exton, PA: Almirall, LLC; June 2002</li>
<li>Jaffe JM, Poust RI, Feld SL, et al. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974;63(8):1256-1260. [PubMed 4852448]</li>
<li>Garty M and Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Healy DP, Dansereau RJ, Dunn AB, et al. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother. 1997;31(12):1460-1464. [PubMed 9416381</li>
<li>Khalil SA, Daabis NA, Naggar VF, et al. Effect of magnesium trisilicate and citric acid on the bioavailability of tetracycline in man. Pharmazie. 1977;32(8-9):519-522. [PubMed 201941]</li>
<li>Syprine (trientine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016</li>
<li>Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1(8273):643-647. [PubMed 6121964</li>
<li>Cuvrior (trientine) [prescribing information]. Chicago, IL: Orphalan; April 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</li>
<li>Fann WE, Davis JM, Janowsky DS, et al, “Chlorpromazine: Effects of Antacids on its Gastrointestinal Absorption,” J Clin Pharmacol, 1973, 13(10):388-90. [PubMed 4355737</li>
<li>Forrest FM, Forrest IS, and Serra MT, “Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients,” Biol Psychiatry, 1970, 2(1):53</li>
<li>[PubMed 5414905</li>
<li>Moustafa MA, Babhair SA, and Kouta HI, “Decreased Bioavailability of Some Antipsychotic Phenothiazines Due to Interactions With Absorbent Antacid and Antidiarrhoeal Mixtures,” Int J Pharm, 1987, 36:185-9.</li>
<li>Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a 'nonsystemic' antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Dad T, Garimella PS, Strom JA. Quiz: An unusual case of metabolic alkalosis in a patient with CKD. Am J Kidney Dis. 2017;69(1):A13-A16. [PubMed 28007194</li>
<li>JAMP calcium polystyrene sulfonate [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2020.</li>
<li>Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol. 1984;22(11):626-629. [PubMed 6389377]</li>
<li>Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DS, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183</li>
<li>Cefpodoxime proxetil [prescribing information]. Allendale, NJ: Rising Pharmaceuticals Inc; May 2017</li>
<li>Food and Drug Administration Center for Drug Evaluation and Research (CDER). Evaluation of gastric pH dependent drug interactions with acid-reducing agents: Study design, data analysis, and clinical implications (November 2020). Available at: https://www.fda.gov/media/144026/download.</li>
<li>Fann WE, Davis JM, Janowsky DS, Sekerke HJ, Schmidt DM. Chlorpromazine: effects of antacids on its gastrointestinal absorption. J Clin Pharmacol. 1973;12(10):388-390. [PubMed 4355737</li>
<li>Chlorpromazine [prescribing information]. Columbus, OH: American Health Packaging; October 2018</li>
<li>Perphenazine [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2016</li>
<li>Haldol (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2019</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2008.</li>
<li>Allard M, Legare N, Millaud F. A possible case of clozapine interaction with aluminum hydroxide. Schizophr Res. 2008;101(1-3):346. [PubMed 18272349</li>
<li>Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corp., March 2008</li>
<li>Prescribing information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil- Janssen Pharmaceuticals Inc., August 2008</li>
<li>Prescribing information. Seroquel (quetapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009</li>
<li>Prescribing information. Abilify (aripiprazole). Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd., August 2008.</li>
<li>Diacerein [prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198802489. Accessed October 1, 2014.</li>
<li>Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909]</li>
<li>Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis. 1974;109(1):41-47. [PubMed 4588090</li>
<li>Lin M-Y, Lin S-J, Chan L-C, Lu Y-C. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(7):806-818. [PubMed 20550762</li>
<li>Peloquin CA, Namdar R, Dodge AA, Nix DEPharmacokinetics of isoniazid under fasting conditions, with food, and with antacidsInt J Tuberc Lung Dis1999;3(8):703-710[PubMed 10460103</li>
<li>Sun H, Jin T, Wu X, Yang L, Zuo Y, Liao R. Efficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis. J Int Med Res. 2021;49(7):3000605211027736. [PubMed 34311594</li>
<li>Weber V, Abbott TEF, Ackland GL. Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. Br J Anaesth. 2021;126(3):608-621. [PubMed 33218672</li>
<li>Dong J, Gao L, Wenqing L, Xu Z, Zheng J. Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis. PLoS One. 2014;9(12):e114231. [PubMed 25460931</li>
<li>Sinatra RS, Philip BK, Naulty JS, et al. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulphate. Anesth Analg. 1985;64:1220-1222. [PubMed 2865911</li>
<li>Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular-blocking agents. Anesthesiology. 1970;32:23. [PubMed 5460601</li>
<li>Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. Anaesthesia. 1994;49:355-356. [PubMed 8179157</li>
<li>Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology. 1987;67(5):806-808. [PubMed 2890318</li>
<li>Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. Br J Anaesth. 1996;77:669-671. [PubMed 8957990</li>
<li>Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth. 1996;76(4):565-556. [PubMed 8652332</li>
<li>Yoshida A, Itoh Y, Nagaya K, et alProlonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean sectionJ Anesth2006;20(1):33-35[PubMed 16421674</li>
<li>Kwan WF, Lee C, Chen BJ. A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. J Clin Anesth. 1996;8(5):392-397. [PubMed 8832451</li>
<li>Na HS, Lee JH, Hwang, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth. 2010;104(3):344-350. [PubMed 20042475</li>
<li>Telci L, Esen F, Akcora D, et al. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Br J Anaesth. 2002;89(4):591-598. [PubMed 12393361</li>
<li>Aldrete JA, Zahler A, Aikawa JK. Prevention of succinylcholine-induced hyperkalaemia by magnesium sulfate. Can Anaesth Soc J. 1970;17(5):477-484. [PubMed 5506078</li>
<li>Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth. 1995;74(4):405-409.[PubMed 7734259</li>
<li>Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. Br J Anaesth. 2003;91(3):435-438. [PubMed 12925489</li>
<li>De Vore JS, Asrani R. Magnesium sulfate prevents succinylcholine-induced fasciculations in toxemic parturients. Anesthesiology. 1980;52(1):76-77. [PubMed 7352649</li>
<li>Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007;31(2):167-173. [PubMed 17437152</li>
<li>Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. Can J Anaesth. 2005;52(1):88-93. [PubMed 15625263</li>
<li>James MF, Cork RC, Dennett JE. Succinylcholine pretreatment with magnesium sulfate. Anesth Analg. 1986;65(4):373-376. [PubMed 3513667</li>
<li>Fei S, Xia H, Chen X, Pang D, Xu X. Magnesium sulfate reduces the rocuronium dose needed for satisfactory double lumen tube placement conditions in patients with myasthenia gravis. BMC Anesthesiol. 2019;19(1):170. [PubMed 31472669</li>
<li>Micuci AJQR, Vercosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2019;36(7):502-508. [PubMed 30985540</li>
<li>Ghodraty MR, Saif AA, Kholdebarin AR, et al. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012;26(6):858-863. [PubMed 22752440</li>
<li>Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012;29(2):95-55. [PubMed 22183158</li>
<li>Brown AF, Cobert J, Dierkes J, Kuhn CM, Grant SA. Delayed neuromuscular blockade reversal with sugammadex after vecuronium, desflurane, and magnesium administration: a case report. A A Pract. 2019;13(8):295-298. [PubMed 31283534</li>
<li>Unterbuchner C, Ziegleder R, Graf B, Metterlein T. Magnesium-induced recurarisation after reversal of rocuronium-induced neuromuscular block with sugammadex. Acta Anaesthesiol Scand. 2015;59(4):536-540. [PubMed 25582520</li>
<li>de Almeida CED, de Carvalho LR, Andrade CVC, do Nascimento Jr P, de Barros GAM, Modolo NSP. Effects of magnesium sulphate on the onset time of rocuronium at different doses: a randomized clinical trial. Braz J Anesthesiol. 2021;71(5):482-488. [PubMed 34403648</li>
<li>James MF, Schenk PA, van der Veen BW. Priming of pancuronium with magnesium. Br J Anaesth. 1991;66(2):247-249. [PubMed 1817630</li>
<li>Stacey MR, Barclay K, Asai T, et al. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Anaesthesia. 1995;50(11):933-936. [PubMed 8678246</li>
<li>Nimbex (cisatracurium) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2018</li>
<li>Quelicin (succinylcholine) [prescribing information]. Lake Forest, IL: Hospira, Inc.; August 2021</li>
<li>Atracurium [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2018</li>
<li>Pancuronium [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2019</li>
<li>Rocuronium [prescribing information]. Lehi, UT: Civica, Inc.; July 2020.</li>
<li>Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231-1235. [PubMed 18355422</li>
<li>Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.</li>
<li>Foresti V. Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Sodium polystyrene sulfonate [prescribing information]. Rahway, NJ: Sunrise Pharmaceutical, Inc.; March 2020.</li>
<li>Prograf (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; August 2009</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med. 1994;97(4):363-365. [PubMed 7942938</li>
<li>Morini E, Catalano A, Lasco A, Morabito N, Benvenga S. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. [PubMed 30919287</li>
<li>Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-486. [PubMed 21595516</li>
<li>Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med. 1992;152(1):183-184. [PubMed 1728914</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669</li>
<li>Levothyroxine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; September 2022</li>
<li>Ermeza (levothyroxine) oral solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022.</li>
<li>Regardh CG, Lundborg P, Persson BA. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Biopharm Drug Dispos. 1981;2(1):79-87. [PubMed 7236872</li>
<li>Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. Clin Pharmacol Ther. 1981;30(4):429-435. [PubMed 7285476]</li>
<li>Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 1991;31(2):164-167. [PubMed 1849152</li>
<li>Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 2003;17(3):563-577. [PubMed 14711077</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</li>
<li>Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; February 2011</li>
<li>Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998;4:941-948. [PubMed 9563888</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2016 [published October 13, 2016]. doi:10.1001/jamaoncol.2016.3358. [PubMed 27737436</li>
<li>Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104. [PubMed 11286326]</li>
<li>Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med. 1976;295(19):1034-1037. [PubMed 972657</li>
<li>Allen MD, Greenblatt DJ, Harmatz JS, Smith TW. Effect of magnesium-aluminum hydroxide and kaolin-pectin on absorption of digoxin from tablets and capsules. J Clin Pharmacol. 1981;21(1):26-30. [PubMed 7012189</li>
<li>Cooke J, Smith JA. Absence of interaction of digoxin with antacids under clinical conditions. Br Med J. 1978;2(6145):1166-1167. [PubMed 709293]</li>
<li>Radwanski E, Nomeir A, Cutler D, Affrime M, Lin CC. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double-strength liquid or with ranitidine. Am J Ther. 1998;5(2):67-72. [PubMed 10099040</li>
<li>Cedax (ceftibuten) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2015.</li>
<li>Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. Clin Pharmacol Ther. 1976;19(2):234-239. [PubMed 770046]</li>
<li>Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. Clin Pharmacol Ther. 1978;24(3):308-315. [PubMed 28870</li>
<li>Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS. Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. Clin Pharmacol Ther. 1982;31(2):180-183. [PubMed 6120059</li>
<li>Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD. Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther. 1977;22(3):329-335. [PubMed 19188</li>
<li>Tranxene (clorazepate dipotassium) [prescribing information]. Barceloneta, PR: AbbVie LTD; September 2016.</li>
<li>Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI. Diazepam absorption: effect of antacids and food. Clin Pharmacol Ther. 1978;24(5):600-609. [PubMed 699484</li>
<li>Nair SG, Gamble JA, Dundee JW, Howard PJ. The influence of three antacids on the absorption and clinical action of oral diazepam. Br J Anaesth. 1976;48(12):1175-1180. [PubMed 1023953</li>
<li>Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI. Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. J Clin Pharmacol. 1984;24(5-6):255-263. [PubMed 6747022</li>
<li>Valium (diazepam) [prescribing information]. South San Francisco, CA: Hoffman-La Roche; December 2016.</li>
<li>Yamreudeewong W, Scavone JM, Paone RP, Lewis GP. Effect of antacid coadministration on the bioavailability of erythromycin stearate. Clin Pharm. 1989;8(5):352-354. [PubMed 2743731]</li>
<li>Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333-342. [PubMed 688726]</li>
<li>Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49(1):467-469. [PubMed 15616339</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2019.</li>
<li>Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm. 1998;46(3):299-303. [PubMed 9885302]</li>
<li>Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. Drug Intell Clin Pharm. 1986;20(10):792-795. [PubMed 3769772</li>
<li>Burland WL, Darkin DW, Mills MW. Effect of antacids on absorption of cimetidine. Lancet. 1976;2(7992):965. [PubMed 62195</li>
<li>Bodemar G, Norlander B, Walan A. Diminished absorption of cimetidine caused by antacids. Lancet. 1979;1(8113):444-445. [PubMed 84296</li>
<li>Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. N Engl J Med. 1982;307(7):400-404. [PubMed 708843</li>
<li>Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29(7):670-672. [PubMed 2569486</li>
<li>Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol. 1987;24(4):551-553. [PubMed 2891370</li>
<li>Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces the bioavailability of ranitidine. Br Med J. 1982;285(6347):998-999. [PubMed 6289961</li>
<li>Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol. 1990;42(5):352-354. [PubMed 1976784</li>
<li>Donn KH, Eshelman FN, Plachetka JR, et alThe effects of antacid and propantheline on the absorption of oral ranitidinePharmacotherapy1984;4(2):89-92[PubMed 6326064</li>
<li>Sullivan TJ, Reese JH, Jauregui L, Miller K, Levine L, Bachmann KA. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. Aliment Pharmacol Ther. 1994;8(1):123-126. [PubMed 7910488]</li>
<li>Tanatril (imidapril) [summary of product characteristics]. London, UK: Mitsubishi Tanabe Pharma Europe Limited; December 2014.</li>
<li>Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663</li>
<li>Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029]</li>
<li>Kristalose (lactulose) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; July 2018</li>
<li>Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663]</li>
<li>Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</li>
<li>Livtencity (maribavir) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2021.</li>
<li>Segre EJ, Sevelius H, Varady J. Letter: Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583. [PubMed 4852768</li>
<li>Weber SS, Bankhurst AD, Mroszczak E, Ding TL. Effect of Mylanta on naproxen bioavailability. Ther Drug Monit. 1981;3(1):75-83. [PubMed 7233492</li>
<li>Naprosyn (naproxen) [prescribing information]. Apharetta, GA: Canton Laboratories, LLC.; April 2021.</li>
<li>Ismail FA, Khalafallah N, Khalil SA. Absorption of ketoprofen and bumadizone calcium on aluminum-containing antacids and its effect on ketoprofen bioavailability in man. Int J Pharm. 1987;34:189-196</li>
<li>Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6 Pt 2):33S-39S (review). [PubMed 2082311</li>
<li>Holmes GI, et al. Effects of Maalox on the bioavailability of diflunisal. Clin Pharmacol Ther. 1979;25:229</li>
<li>Verbeeck R, Tjandramaga TB, Mullie A, et al. Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol. 1979;7(5):519-522. [PubMed 314299</li>
<li>Segre EJ, Sevelium H, Varady J. Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583 (letter). [PubMed 4852768</li>
<li>Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; January 2011</li>
<li>von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone - A novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Tox. 1983;21(6):311-321. [PubMed 6688407</li>
<li>Shaker MA, Akhtar N, Minhas MU, Khan KU, Zangi MI, Munir A. Effect of an Al-Mg hydroxide antacid and food on the pharmacokinetics of dexibuprofen. Drug Res (Stuttg). 2020;70(4):158-164. [PubMed 32110819]</li>
<li>Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</li>
<li>Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. Br J Clin Pharmacol. 1978;6(2):177-179. [PubMed 678395</li>
<li>Garnett WR, Carter BL, Pellock JM. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1980;37(7):467. [PubMed 7387502</li>
<li>Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-340. [PubMed 7336470</li>
<li>McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Br J Clin Pharmacol. 1982;13(4):501-505. [PubMed 7066165</li>
<li>Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1979;36(7):436-438. [PubMed 454247</li>
<li>O'Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol. 1978;6(2):176-177. [PubMed 678394</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</li>
<li>Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115(1):12-18. [PMID 9925057</li>
<li>Gupta PR, Mehta YR, Gupta ML, Sharma TN, Jain D, Gupta RB. Rifampin-aluminium antacid interaction. J Assoc Physicians India. 1988;36(6):363-364. [PubMed 3182711</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifadin (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifamate (rifampin/isoniazid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2013</li>
<li>Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2010</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2009.</li>
<li>Itthipanichpong C, Sirivongs P, Wittayalertpunya S, Chaiyos N. The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Drug Metabol Drug Interact. 1992;10(3):213-228. [PubMed 1424642</li>
<li>Gaspari F, Vigano G, Locatelli M, Remuzzi G. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis. 1988;11(4):338-342. [PubMed 3354570</li>
<li>Shastri RA. Effect of antacids on salicylate kinetics. Int J Clin Pharmacol Ther Toxicol. 1985;23(9):480-484. [PubMed 4055159</li>
<li>Levy G, Lampman T, Kamath BL, et al. Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. N Engl J Med. 1975;293(7):323-325. [PubMed 239345</li>
<li>Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol. 1980;20(5-6 Pt 1):326-331. [PubMed 7400368</li>
<li>Macpherson CR, Milne MD, Evans BM. The excretion of salicylate. Br J Pharmacol Chemother. 1955;10(4):484-489. [PubMed 13276608</li>
<li>Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. Br J Clin Pharmacol. 1982;14(4):562-564. [PubMed 7138740</li>
<li>Feldman S, Carlstedt BC. Effect of antacid on absorption of enteric-coated aspirin. JAMA. 1974;227(6):660-661 (letter). [PubMed 4405837</li>
<li>Strickland-Hodge B, Thomas TR, Gould WA, et al. The effects of antacids on enteric-coated salicylate preparations. Rheumatol Rehabil. 1976;15(3):148-152. [PubMed 968338]</li>
<li>Kivisto KT, Neuvonen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1992;42(6):675-679. [PubMed 1623912</li>
<li>Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol. 1991;32(2):215-220. [PubMed 1931470</li>
<li>Zuccaro P, Pacifici R, Pichini S, et al. Influence of antacids on the bioavailability of glibenclamide. Drugs Exp Clin Res. 1989;15(4):165-169. [PubMed 2505996</li>
<li>Kivisto KT, Lehto P, Neuvonen PJ. The effects of different doses of sodium bicarbonate on the absorption and activity of nonmicronized glibenclamide. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):236-240. [PubMed 8390970</li>
<li>Kivisto KT, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminum hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol. 1991;40(4):383-386. [PubMed 1646724</li>
<li>Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther. 1991;49(1):39-43. [PubMed 1988239</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976]</li>
<li>Arnold LA, Spurbeck GH, Shelver WH, Henderson WM. Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm. 1979;36(8):1059-1062. [PubMed 484565</li>
<li>Reed RC, Schwartz HJ. Lack of influence of an intensive antacid regimen on theophylline bioavailability. J Pharmacokinet Biopharm. 1984;12(3):315-331. [PubMed 6502473</li>
<li>Darzentas LJ, Stewart RB, Curry SH, Yost RL. Effect of antacid on bioavailability of a sustained-release theophylline preparation. Drug Intell Clin Pharm. 1983;17(7-8):555-557. [PubMed 6872853</li>
<li>Muir JF, Peiffer G, Richard MO, et al. Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation. Eur J Clin Pharmacol. 1993;44(1):85-88. [PubMed 8436162</li>
<li>Ferrari M, Olivieri M, Romito D, Biasin C, Barozzi E, Bassetti S. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline. Riv Eur Sci Med Farmacol. 1991;13(5-6):269-274. [PubMed 1819857</li>
<li>Fernandes E, Melewicz FM. Antacids and theophylline-ranitidine interaction. Ann Intern Med. 1984;101(2):279. [PubMed 6331245</li>
<li>Myhre KI, Walstad RA. The influence of antacid on the absorption of two different sustained-release formulations of theophylline. Br J Clin Pharmacol. 1983;15(6):683-687. [PubMed 6871067</li>
<li>Shargel L, Stevens JA, Fuchs JE, Yu AB. Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. J Pharm Sci. 1981;70(6):599-602. [PubMed 7252799</li>
<li>Theophylline oral solution [prescribing information]. Congers, NY: Chartwell RX LLC; October 2022.</li>
<li>Rudzki P, Jarus-Dziedzic K, Filist M, et al. Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacol Rep. 2021;73(2):604-614 [PubMed 33686610]</li>
<li>Kroboth PD, Smith RB, Silver MR, et al. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol. 1985;19(6):839-842. [PubMed 2862896]</li>
<li>May CA, Garnett WR, Small RE, et al, “Effects of Three Antacids on the Bioavailability of Valproic Acid,” Clin Pharm, 1982, 1(3):244</li>
<li>[PubMed 6821035]</li>
<li>Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990;34(10):2032-2033. [PubMed 2291673</li>
<li>Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236]</li>
<li>Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804-808. [PubMed 14982768</li>
<li>Kraft WK, Chang PS, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020-4025. [PubMed 24798274</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2022.</li>
<li>Exjade (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2020.</li>
<li>Relyvrio (sodium phenylbutyrate and taurursodiol) [prescribing information]. Cambridge, MA: Amylyx Pharmaceuticals Inc; September 2022.</li>
<li>Weissman I, Krivoy N. Interaction of aluminum hydroxide and allopurinol in patients on chronic hemodialysis. Ann Intern Med. 1987;107(5):787. [PubMed 3662305]</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Effect of ascorbic acid on gastrointestinal aluminum absorption. Lancet. 1991;338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int. 1991;39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654</li>
<li>Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9-11. [PubMed 2913801</li>
<li>Main J, Ward MK. Potentiation of aluminum absorption by effervescent analgesic tablets in a haemodialysis patient. Br Med J. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol. 1989;31(1):40-44. [PubMed 2914409]</li>
<li>Foresti V. Intestinal obstruction due to Kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Garcia-Pardo G, Martinez-Vea A, Auguet T, et al. Intestinal obstruction complicating calcium polystyrene sulphonate therapy. Nephrol Dial Transplant. 1996;11(4):751. [PubMed 8671882</li>
<li>Hurley JK. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel. J Pediatr. 1978;92(4):592-593. [PubMed 633020</li>
<li>Calcium Resonium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., April 2006.</li>
<li>Cholbam (cholic acid) [prescribing information]. Baltimore, MD: Asklepion Pharmaceuticals LLC; March 2015.</li>
<li>Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</li>
<li>Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568-572. [PubMed 10049268</li>
<li>Myambutol (ethambutol) [prescribing information]. Langhorne, PA: STI Pharma LLC; April 2012</li>
<li>Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol. 1978;5(2):161-166. [PubMed 619949]</li>
<li>Prescribing information. Neurontin (gabapentin). New York, NY: Pfizer Inc; October 2017.</li>
<li>Mircol (mequitazine) [summary of product characteristics]. Madrid, Spain: ITF Medilab Farma, SA; July 2013.</li>
<li>Moxifloxacin [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; November 2022.</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” Lancet, 1991, 338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” Kidney Int, 1991, 39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” Am J Kid Dis, 1991, 17(6):708-11. [PubMed 2042654</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ, 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” Clin Nephrol, 1989, 31(3):123</li>
<li>[PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” Clin Nephrol, 1986, 26(3):146</li>
<li>[PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” Proc Eur Dial Transplant Assoc Eur Ren Assoc, 1985, 21:390</li>
<li>[PubMed 3991529</li>
<li>Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” Am J Physiol, 1985, 249(2 Pt 1):G209-13. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205. [PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” J Lab Clin Med, 1986, 108(2):96-102. [PubMed 3755457]</li>
<li>Moon J, Davison A, Bandy B. Vitamin D and aluminum absorption. CMAJ. 1992;147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol. 1989;31(3):123-127. [PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Clin Nephrol. 1986;26(3):146-149. [PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:390-394. [PubMed 3991529</li>
<li>Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol. 1985;249(2 Pt 1):G209-G213. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et alAbsorption, deposition and distribution of dietary aluminium in immature rats: effects of dietary vitamin D3 and food-borne chelating agentJ Environ Sci Health B1986;21(2):191-205[PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al. 1,25-dihydroxyvitamin D3 increases serum and tissue accumulation of aluminum in rats. J Lab Clin Med. 1986;108(2):96-102. [PubMed 3755457]</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Urso 250 / Urso Forte (ursodiol) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2021</li>
<li>Actigall (ursodiol) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc.; September 2002</li>
<li>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. [PubMed 30070375]</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 Alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 Alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Zemplar (paricalcitol) capsules [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Rocaltrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Zemplar (paricalcitol) injection [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>Dovonex (calcipotriene) cream [prescribing information]. Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]Greenville, NC: Mayne Pharma; May 2019</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018</li>
<li>Vitamin D (ergocalciferol) [prescribing information]. Laurelton, NY: Epic Pharma, LLC: October 2018.</li>
<li>Chenodol (chenodiol) [prescribing information]. San Diego, CA: Retrophin, Inc; June 2015.</li>
<li>Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J. 1994;87(9):894-898. [PubMed 8091252</li>
<li>Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr. 1994;48(1):71-73. [PubMed 8200332</li>
<li>Nestel AW, Meyers AM, Paiker J, Rollin HB. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients. Nephron. 1994;68(2):197-201. [PubMed 7830856</li>
<li>Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study. South Med J. 1993;86(12):1385-1388. [PubMed 8272917</li>
<li>Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs. 1991;14(10):625-629. [PubMed 1748529</li>
<li>Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; June 2019</li>
<li>Envarsus XR (tacrolimus extended-release) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Spencer H, Kramer L, Norris C, et al. Effect of aluminum hydroxide on fluoride metabolism. Clin Pharmacol Ther. 1980;28(4):529-535. [PubMed 7408412]</li>
<li>Hong CY, Hu SC, Lin SJ, Chiang BN. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Clin Pharmacol Ther Toxicol. 1985;23(5):244-246. [PubMed 4008113</li>
<li>Inderal (propranolol) tablets [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals LLC; March 2011.</li>
<li>PhosLo (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2011.</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4:345. [PubMed 3160584</li>
<li>Schentag JJ, Watson WA, Nix DE, et al. Time-dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther. 1988;43:135</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36:1219-1234. [PubMed 1329615</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulphate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36:2270-2274. [PubMed 1444308</li>
<li>Sahai J, Healey DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302-304. [PubMed 8471407</li>
<li>Frost RW, Lettieri JT, Noe A, et al. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin Pharmacol Ther. 1989;45:165</li>
<li>Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34:432-435. [PubMed 2334155</li>
<li>Kays MB, Overholser BR, Mueller BA, et alEffects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacinAm J Kidney Dis2003;42(6):1253-1259[PubMed 14655198</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014</li>
<li>Federspiel J, Bukhari MJ, Hamill MM. Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. BMJ Case Rep. 2021;14(1):e236655. [PubMed 33408101</li>
<li>Gunnarsson PO, Davidson T, Andersson SB, et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189-193. [PubMed 2338118</li>
<li>Emcyt (estramustine) [prescribing information]. New York, NY: Pharmacia and Upjohn Company; June 2007.</li>
<li>Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” Am J Clin Nutr, 2007, 85(1):6-18. [PubMed 17209171</li>
<li>Peacock M, “Calcium Metabolism in Health and Disease,” Clin J Am Soc Nephrol, 2010, 5 Suppl 1:S23-30. [PubMed 20089499</li>
<li>Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” Cochrane Database Syst Rev, 2011, (7):CD007470. [PubMed 21735411]</li>
<li>Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr. 2002;21(3):239-244. [PubMed 12074251</li>
<li>Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22. [PubMed 9554821]</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439]</li>
<li>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018. Available at https://aidsinfo.nih.gov. (Accessed 06/24/2019</li>
<li>HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. (Accessed 06/24/2019</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494]</li>
<li>Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; June 2009</li>
<li>Minocin (minocycline) [prescribing information]. Cranford, NJ: Triax Pharmaceuticals, LLC; August 2010</li>
<li>Vibramycin (doxycycline) [prescribing information]. New York, NY: Pfizer Inc; April 2007</li>
<li>Jung H, Peregrina AA, Rodriguez JM, et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos. 1997;18(5):459-463. [PubMed 9210983]</li>
<li>Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822-2825. [PubMed 10838651</li>
<li>Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11:967-971. [PubMed 11716045</li>
<li>Mazokopakis EE, Giannakopoulos TG, Starakis IK. Interaction between levothyroxine and calcium carbonate. Can Fam Physician. 2008;54(1):39. [PubMed 18208953</li>
<li>Csako G, McGriff NJ, Rotman-Pikielny P, et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35(12):1578-1583. [PubMed 11793625</li>
<li>Butner LE, Fulco PP, Feldman G. Calcium carbonate-induced hypothyroidism. Ann Intern Med. 2000;132(7):595. [PubMed 10744606</li>
<li>Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA. 1998;279(10):750. [PubMed 9508149</li>
<li>A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Diskin CJ, Stokes TJ, Dansby LM, et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol. 2007;39(2):599-602. [PubMed 17216296]</li>
<li>Salerno DM, Anderson B, Sharkey PH, et al, “Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia With and Without Calcium Pretreatment,” Ann Intern Med, 1987, 107(5):623</li>
<li>[PubMed 3662276</li>
<li>Haft JI and Habbab MA, “Treatment of Atrial Arrhythmias. Effectiveness of Verapamil When Preceded by Calcium Infusion,” Arch Intern Med, 1986, 146(6):1085</li>
<li>[PubMed 3718093</li>
<li>Schoen MD, Parker RB, Hoon TJ, et al, “Evaluation of the Pharmacokinetics and Electrocardiographic Effects of Intravenous Verapamil With Intravenous Calcium Chloride Pretreatment in Normal Subjects,” Am J Cardiol, 1991, 67(4):300</li>
<li>[PubMed 1990794</li>
<li>O’Quinn SV, et al, “Influence of Calcium on the Hemodynamic and Anti-ischemic Effects of Nifedipine Observed During Treadmill Exercise Testing,” Pharmacotherapy, 1990, 10:247 (abstract)</li>
<li>Wohns DH, Patterson JH, Clarke S, et al, “Influence of Calcium Administration on the Short-term Hemodynamic and the Anti-ischemic Effects of Nifedipine,” J Am Coll Cardiol, 1991, 18(4):1070</li>
<li>[PubMed 1894852</li>
<li>Bar-Or D and Gasiel Y, “Calcium and Calciferol Antagonize Effect of Verapamil in Atrial Fibrillation,” Br Med J, 1981, 282(6276):1585</li>
<li>[PubMed 6786574]</li>
<li>Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75(887):554-556. [PubMed 10616693</li>
<li>Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth Analg. 1972;51(2):202-205. [PubMed 5062119</li>
<li>Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA. 1978;240(6):533-534. [PubMed 671662</li>
<li>Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. Br Med J. 1978;1(6108):279-280. [PubMed 620306</li>
<li>Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507. [PubMed 5418023]</li>
<li>Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992;101(1):174-180. [PubMed 1729065]</li>
<li>Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriat Soc. 1984;32(5):405-407. [PubMed 6715769</li>
<li>Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121(5):591-594. [PubMed 497950</li>
<li>Gora ML, Seth SK, Bay WH, Visconti JA. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm. 1989;8(3):227-229. [PubMed 2706898</li>
<li>Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55-59. [PubMed 5305802</li>
<li>Rehan MA, Rashid A, Krell K, Gabutti C, Singh R. Calcium alkali thiazide syndrome: what we need to know. Cureus. 2020;12(10:e10856. [PubMed 33178509</li>
<li>Morini L, Doneli D, Santi R, et al. Severe milk-alkali syndrome in a patient with hypoparathyroidism associated with 1,25(OH)2D, hydrochlorothiazide and anthranoid laxative consumption. Eur J Case Rep Intern Med. 2017;4(10):000729. [PubMed 30755914</li>
<li>Singh A, Ashraf A. Hypercalcemic crisis induced by calcium carbonate. Clin Kidney J. 2012;5(4):288-291. [PubMed 25874082</li>
<li>Parvez B, Emuwa C, Faulkner ML, Murray JJ. Milk alkali and hydrochlorothiazide: a case report. Case Rep Med. 2011;2011:729862. [PubMed 21738535]</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>One-Alpha drops (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Dovonex (calcipotriene) [prescribing information]. Dublin, Ireland: LEO Laboratories Ltd.; March 2015</li>
<li>Rocalctrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Vectical (calcitriol) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019</li>
<li>Ergocalciferol [prescribing information]. Laurelton, NY: Epic Pharma, LLC; October 2018.</li>
<li>Flura-Drops (sodium fluoride) [prescribing information]. Lake Oswego, OR: Kirkman Laboratories Inc; September 2019.</li>
<li>Borel P, Desmarchelier C, Dumont U, et. al. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. Br J Nutr. 2016;116(12):2091-2096. [PubMed 28069089]</li>
<li>Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(suppl 1):27-32. [PubMed 11352439</li>
<li>Moxifloxacin [prescribing information]. Levittown, PA: Torrent Pharma Inc; January 2022.</li>
<li>Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016.</li>
<li>Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351-352. [PubMed 22678358</li>
<li>Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; August 2020.</li>
<li>Klein CE, Chiu YL, Cai Y, et al, “Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir,” J Clin Pharmacol, 2008, 48(5):553-62. [PubMed 18440920]</li>
<li>Wang X, Boffito M, Zhang J, et al, “Effects of the H2-Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir with or without Tenofovir in HIV-Infected Patients,” AIDS Patient Care STDS, 2011, 25(9):509-15. [PubMed 21770762</li>
<li>Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, February 2012.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; September 2018.</li>
<li>Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; October 2016</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908]</li>
<li>Saito Y, Takekuma Y, Kobayashi M, et al. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(3):381-388. [PubMed 33029650</li>
<li>Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410</li>
<li>Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004;44(8):919-927. [PubMed 15286096</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018.</li>
<li>Mchavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347</li>
<li>Ketoconazole [prescribing information]. Mason, OH: Burel Pharmaceuticals, LLC; September 2021.</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017</li>
<li>Chiu Y-L, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV infected patients. AIDS Patient Cre STDS. 2007;21(4):247-251. [PubMed 17461719</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451</li>
<li>Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985;38(6):652-655. [PubMed 2933205</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RMW. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958-966. [PubMed 17210768]</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc.; February 2020</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584]</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013</li>
<li>Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis. 2008;46(10):1627; author reply 1627</li>
<li>[PubMed 18419503</li>
<li>Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207-12. [PubMed 19858252</li>
<li>Vehreschild JJ, Muller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987-95. [PubMed 22286158</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-10[PubMed 22890761]</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; March 2022.</li>
<li>Invirase (saquinavir) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; December 2003.</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</li>
<li>Saathoff N, Lode H, Neider K, Kepperman KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Cefpodoxime [prescribing information]. Princeton, NJ: Sandoz GmbH for Sandoz Inc; February 2014.</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine After Heart Transplantation: Experimental and Clinical Results,” J Heart Lung Transplant, 1993, 12(6 Pt 1):987-92. [PubMed 8312324</li>
<li>D'Souza MJ, Pollock SH, Solomon HM, “Cyclosporine-Cimetidine Interaction,” Drug Metab Dispos, 1988, 16(1):57</li>
<li>[PubMed 2894956</li>
<li>Shaefer MS, Rossi SJ, McGuire TR, et al, “Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men,” Ann Pharmacother, 1995, 29(11):1088-91. [PubMed 8573949</li>
<li>Jadoul M and Hene RJ, “Ranitidine and the Cyclosporine Treated Recipient,” Transplantation, 1989, 48(2):359. [PubMed 2667215</li>
<li>Tsang VT, Johnston A, Heritier F, et al, “Cyclosporine Pharmacokinetics in Heart-Lung Transplant Recipients With Cystic Fibrosis Effects of Pancreatic Enzymes and Ranitidine,” Eur J Clin Pharmacol, 1994, 46(3):261</li>
<li>[PubMed 8070508</li>
<li>Jarowenko MV, Van Buren CT, Kramer WG, et al, “Ranitidine, Cimetidine, and the Cyclosporine-Treated Recipient,” Transplantation, 1986, 42(3):311</li>
<li>[PubMed 3529532]</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; February 2020</li>
<li>Doxofylline tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200101732. Accessed December 15, 2015.</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2019</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084. [PubMed 12461038]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413</li>
<li>Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2009.</li>
<li>Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med. 1987;107(2):261-262. [PubMed 3111324</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514</li>
<li>DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi Aventis US; July 2016.</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016.</li>
<li>Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol. 1984;18(2):175-181. [PubMed 6091709</li>
<li>Rocci ML Jr, Kosoglou T, Ferguson RK, Vlasses PH. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. J Pharmacol Exp Ther. 1989;248(3):923-928. [PubMed 2467982</li>
<li>Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Ther Drug Monit. 1987;9(4):378-383. [PubMed 2447687</li>
<li>Ranitidine [prescribing information]. East Winsor, NJ: Novitium Pharma LLC; September 2018.</li>
<li>O'Conner-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther. 2001;70(2):126-31. [PubMed 11503006</li>
<li>Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm. 1991;10(7):539-43. [PubMed 1860302</li>
<li>Halcion (triazolam) [prescribing information]. New York, NY: Pfizer Inc,; October 2019.</li>
<li>Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med. 1990;112(1):76-77. [PubMed 2293824</li>
<li>Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin clearance after ranitidine and cimetidine. Clin Pharmacol Ther. 1984;35(3):338-341. [PubMed 6321081</li>
<li>O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144(5):989-991. [PubMed 6324710</li>
<li>Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32(2):165-172. [PubMed 3582481</li>
<li>Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12(6):791-794. [PubMed 6122462</li>
<li>Powell JR, Donn KH. The pharmacokinetic basis for h2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95-113. [PubMed 6140286]</li>
<li>Gertz BJ, Holland SD, Kline WF, et al, “Studies of the Oral Bioavailability of Alendronate,” Clin Pharmacol Ther, 1995, 58(3):288-98. [PubMed 7554702</li>
<li>Prescribing information. Fosamax (alendronate). Whitehouse Station, NJ: Merck &amp; Co., Inc., 04/2013</li>
<li>Prescribing information. Binosto (alendronate). San Antonio, TX: Mission Pharmacal, 4/2013</li>
<li>Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” Arch Intern Med, 2011, 171(11):998-1004. [PubMed 21321287</li>
<li>Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” Endokrynol Pol, 2011, 62(1):84</li>
<li>Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” Bone, 2010, 47(2):169-80. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” Drug Saf, 2009, 32(9):775-85. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” Osteoporos Int, 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” Osteoporos Int, 2012, 23(1):277-84. [PubMed 21365461]</li>
<li>Piqray (alpelisib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; June 2022.</li>
<li>Perveen S, Gauhar S, Yousuf RI, Ali H, Zafar F, Sheikh AF. Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan. PLoS One. 2022;17(5):e0267791. [PubMed 35609024</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502]</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360</li>
<li>Diacetylmorphine (diamorphine) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc.; February 2022</li>
<li>Diamorphine [summary of product characteristics]. Middlesex, United Kingdom: Accord Healthcare Limited; May 2020.</li>
<li>Esposito R. Cimetidine and iron-deficiency anaemia. Lancet. 1977;2(8048):1132. [PubMed 73039</li>
<li>Bianchi FM, Cavassini GB, Leo P. Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):209-217. [PubMed 8100220</li>
<li>Partlow ES, Campbell NR, Chan SC, Pap KM, Granberg K, Hasinoff BB. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. Clin Pharmacol Ther. 1996;59(4):389-393. [PubMed 8612382]</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055</li>
<li>Ueno T, Miyajima Y, Landry I, Lalovic B, Schuck E. Physiologically based pharmacokinetic modeling to predict drug interaction of lemborexant with CYP3A inhibitors. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):455-466. [PubMed 33704920</li>
<li>Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int. 2005;67(3):1152-1160. [PubMed 15698457</li>
<li>Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369-376. [PubMed 10223772</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451]</li>
<li>U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360]</li>
<li>Mirapex ER (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014</li>
<li>Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33(4):495-499. [PubMed 15640376]</li>
<li>Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251-2257. [PubMed 18786302</li>
<li>Donn KH, Eshelman FN, Plachetka JR, Fabre L, Powell JR. The effects of antacid and propantheline on the absorption of oral ranitidine. Pharmacotherapy. 1984;4(2):89-92. [PubMed 6326064]</li>
<li>Machavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347]</li>
<li>Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410]</li>
<li>Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;58:663-687. [PubMed 29309257</li>
<li>Li TT, An JX, Xu JY, Tuo BG. Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver. World J Clin Cases. 2019;7(23):3915-3933. [PubMed 31832394]</li>
<li>Poudel RR, Kafle NK. Tizanidine-induced acute severe cystitis in a female taking famotidine. Clin Pharmacol. 2015;7:83-85. [PubMed 26251632</li>
<li>Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013</li>
<li>Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 1993;24(3):255-258. [PubMed 8462230</li>
<li>Bachmannn K, Sullivan TJ, Reese JH, et al. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 1995;35(5):529-535. [PubMed 7657856</li>
<li>Verdiani P, Di Carlo S, Baronti AFamotidine effects on theophylline pharmacokinetics in subjects affected by COPDComparison with cimetidine and placeboChest1988;94(4):807-810[PubMed 3168576</li>
<li>Sunlenca (lenacapavir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; November 2022.</li>
<li>Nexterone (amiodarone) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2021.</li>
<li>Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987;27(10):813-816. [PubMed 3323258</li>
<li>Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011;55(7):3091-3098. [PubMed 21518836]</li>
<li>Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; August 2019</li>
<li>Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol. 2000;49(1):64-71. [PubMed 10606839]</li>
<li>Ellence (epirubicin hydrochloride). New York, NY: Pfizer Inc.; July 2019</li>
<li>Murray LS, Jodrell DI, Morrison JG, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol). 1998;10(1):35-38. [PubMed 9543613]</li>
<li>Veozah (fezolinetant) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2023.</li>
<li>Plaquenil (hydroxychloroquine) [prescribing information]. Dublin, Ireland: Amdipharm Limited; May 2021</li>
<li>Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65(1):10-20. [PubMed 9951426</li>
<li>Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20(3):317-324. [PubMed 10831018</li>
<li>Orap (pimozide) [prescribing information]. Horsham, PA: Teva Pharmaceuticals USA; March 2014.</li>
<li>Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol. 1997;37(11):1056-1061. [PubMed 9505999</li>
<li>Serdolect (sertindole) [summary of product characteristics]. Valby, Denmark: Lundbeck AS; March 2021.</li>
<li>Volkin RL, Shadduck RK, Winkelstein A, Zeigler ZR, Selker RG. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med. 1982;142(2):243-245. [PubMed 7059252</li>
<li>Selker RG, Moore P, LoDolce D. Bone-marrow depression with cimetidine plus carmustine. N Engl J Med. 1978;299(15):834. [PubMed 692572</li>
<li>BiCNU (carmustine) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2021</li>
<li>Dorr RT, Soble MJ. H2-antagonists and carmustine. J Cancer Res Clin Oncol. 1989;115(1):41-46. [PubMed 2564000]</li>
<li>Kirch W, Janisch HD, Ohnhaus EE, van Peer A. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit. 1989;11(4):411-414. [PubMed 2741189]</li>
<li>Priskorn M, Larsen F, Segonzac A, et al. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 1997;52:241-242. [PubMed 9218934</li>
<li>Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci. 2011;32(3):507-509. [PubMed 21491099</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA, Inc; January 2019.</li>
<li>Ampyra (dalfampridine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; December 2019</li>
<li>Fampyra (fampridine) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; January 2022.</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, et al, “Cimetidine Interaction with Phenytoin,” Br Med J (Clin Res Ed), 1981, 282:1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, and Springer PK, “Decreased Clearance of Phenytoin with Cimetidine,” Ann Intern Med, 1981, 95:244. [PubMed 7258891</li>
<li>Phillips P, Hansky J, “Phenytoin Toxicity Secondary to Cimetidine Administration,” Med J Aust, 1984, 141(9):602. [PubMed 6092884</li>
<li>Neuvonen PJ, Tokola RA, Kaste M, “Cimetidine-Phenytoin Interaction: Effect on Serum Phenytoin Concentration and Antipyrine Test,” Eur J Clin Pharmacol, 1981, 21(3):215-20. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al, “Reduction of Phenytoin Clearance Caused by Cimetidine,” Eur J Clin Pharmacol, 1983, 25(1):135</li>
<li>Bartle WK, Walker SE, and Shapero I, “Dose-Dependent Effect of Cimetidine on Phenytoin Kinetics,” Clin Pharmacol Ther, 1983, 33:649-55. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, et al, “Effect of Cimetidine on Phenytoin Serum Levels,” Epilepsia, 1983, 24(3):284</li>
<li>Iteogu MO, Murphy JE, Shleifer N, et al, “Effect of Cimetidine on Single-Dose Phenytoin Kinetics,” Clin Pharm, 1983, 2:302, 304. [PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I, “Differential Effect of Cimetidine on Serum Concentrations of Carbamazepine and Phenytoin,” Neurology, 1985, 35(4):562</li>
<li>Sambol NC, Upton RA, Chremos AN, et al, “A Comparison of the Influence of Famotidine and Cimetidine on Phenytoin Elimination and Hepatic Blood Flow,” Br J Clin Pharmacol, 1989, 27(1):83</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2022</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055]</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017.</li>
<li>Zokinvy (lonafarnib) [prescribing information]. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; November 2020.</li>
<li>Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2018</li>
<li>Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545-551. [PubMed 3593625</li>
<li>Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637-645. [PubMed 18551044</li>
<li>Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471-2472. [PubMed 12882884</li>
<li>Boehm KM, Gunaga S. Cimetidine-induced lactic acidosis and acute pancreatitis. South Med J. 2010;103(8):849. [PubMed 20622719</li>
<li>Seo JH, Lee da Y, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. Intern Med. 2013;52(19):2245-2248. [PubMed 24088760</li>
<li>Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica. 2008;38(9):1203-1218. [PubMed 18686197</li>
<li>Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185-191. [PubMed 19164462</li>
<li>Sultana N, Arayne MS, Ahmed N. In vitro availability of metformin in presence of h(2) receptor antagonists. Pak J Pharm Sci. 2006;19(1):28-34. [PubMed 16632449]</li>
<li>Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther. 1991;49(1):32-38. [PubMed 1988238</li>
<li>Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2015.</li>
<li>Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol. 1988;26(3):118-121. [PubMed 2457561</li>
<li>Christian CD Jr, Meredith CG, Speeg KV Jr. Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther. 1984;36(2):221-227. [PubMed 6204803</li>
<li>Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25(3):339-345. [PubMed 6194997</li>
<li>Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982;307(17):1080. [PubMed 6181402</li>
<li>Bauer LA, Black D, Gensler A. Procainamide-cimetidine interaction in elderly male patients. J Am Geriatr Soc. 1990;38(4):467-469. [PubMed 2329253</li>
<li>Higbee MD, Wood JS, Mead RA. Procainamide-cimetidine interaction: a potential toxic interaction in the elderly. J Am Geriatr Soc. 1984;32(2):162-164. [PubMed 6693705</li>
<li>Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol. 1985;28(6):671-675. [PubMed 2866097]</li>
<li>Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol. 1986;22(3):346-350. [PubMed 3768247</li>
<li>Qualaquin (quinine sulfate) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals Industry Inc; June 2019.</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019</li>
<li>El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther. 2016;9(4):157-161. [PubMed 26684920</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499</li>
<li>Fyarro (sirolimus) protein-bound [prescribing information]. Pacific Palisades, CA: Aadi Bioscience Inc; November 2021.</li>
<li>Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19(6):494-499. [PubMed 10587283</li>
<li>Preskorn SH. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract. 2005;11(3):192-196. [PubMed 15920392</li>
<li>Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 1997;25(1):24-32. [PubMed 9027670</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2010</li>
<li>Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59(1):45-50. [PubMed 12682803</li>
<li>Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther. 2007;82(5):555-565. [PubMed 17460606</li>
<li>Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60(5):543-553. [PubMed 8941027</li>
<li>Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002;16(4):361-364. [PubMed 12503836</li>
<li>Sunvepra (asunaprevir) [product monograph]Montreal, Canada: Bristol-Myers Squibb Canada; March 2016</li>
<li>Manerix (moclobemide) [product monograph]. Mississauga, Ontario: Hoffmann-LaRoche Limited, June 2011.</li>
<li>Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78(4):400-411. [PubMed 16198659</li>
<li>Villa-Zapata L, Gomez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disporportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022;45(8):863-871. [PubMed 35834155]</li>
<li>Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2019.</li>
<li>Flind AC. Cimetidine and oral anticoagulants. Br Med J. 1978;2(6148):1367. [PubMed 719395</li>
<li>Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2(8138):317-319. [PubMed 89387</li>
<li>Kerley B, Ali M. Cimetidine potentiation of warfarin action. Can Med Assoc J. 1982;126(2):116. [PubMed 7059881</li>
<li>Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med. 1979;90(3):348-349. [PubMed 426403</li>
<li>Hetzel D, Birkett D, Miners J. Cimetidine interaction with warfarin. Lancet. 1979;2(8143):639. [PubMed 90304</li>
<li>Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol. 1986;30(5):619-623. [PubMed 3758150</li>
<li>Harenberg J, Staiger CH, de Vries JX, et al. Cimetidine does not increase the anticoagulant effect of phenprocoumon. Br J Clin Pharmacol. 1982;14(2):292-293. [PubMed 7104184</li>
<li>O’Reilly RAComparative interaction of cimetidine and ranitidine with racemic warfarin in manArch Intern Med1984;144(5):989-991[PubMed 6324710</li>
<li>Unrecognized drug interactions ith famotidine and nizatidine. Arch Intern Med. 1991;151(4):810, 814, 815. [PubMed 1672811]</li>
<li>Sonata (zaleplon) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; November 2016.</li>
<li>Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest. 1998;15(6):515-522. [PubMed 18370509</li>
<li>Zomig (zolmitriptan) [prescribing information]. Hayward, CA: Impax Laboratories Inc; September 2012.</li>
<li>Alfenta (alfentanil) [prescribing information]. Lake Forest, IL: Akorn, Inc.; October 2019.</li>
<li>Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Abernathy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46(1):35-39. [PubMed 8005185</li>
<li>Suzuki Y, Shioiri T, Muratake T, et al. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol. 2003;58(12):829-833. [PubMed 12698310</li>
<li>Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol. 2009;65(7):699-704. [PubMed 19225771</li>
<li>Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug alprazolam. Eur J Clin Pharmacol. 2006;62(7):587-588. [PubMed 16791582</li>
<li>Xanax (alprazolam) [prescribing information]. New York, NY: Pfizer Inc; March 2021.</li>
<li>Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; November 2020</li>
<li>Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53(6):475-478. [PubMed 9551707]</li>
<li>Astelin (azelastine) nasal spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals Inc.; October 2014.</li>
<li>Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987;41(5):562-570. [PubMed 2882883</li>
<li>Apo-bromazepam (bromazepam) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2016.</li>
<li>Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. Pharmacotherapy. 1985;5(1):16-19. [PubMed 3982974</li>
<li>Felodipine [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; December 2020</li>
<li>Kirch W, Ramsch K, Janisch HD, Ohnhaus EE. The influence of two histamine H2-receptor antagonists, cimetidine, and ranitidine on the plasma levels and clinical effect of nifedipine and metoprolol. Arch Toxicol Suppl. 1984;7:256-259. [PubMed 6151387</li>
<li>Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther. 1989;249(2):638-645. [PubMed 2724144</li>
<li>Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43(6):673-680. [PubMed 3378388</li>
<li>Smith SR, Kendall MJ, Lobo J, Beerahee A, Jack DB, Wilkins MR. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol. 1987;23(3):311-315. [PubMed 3567045</li>
<li>Renwick AG, Le Vie J, Challenor VF, Waller DG, Gruchy B, George CF. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol. 1987;32(4):351-355. [PubMed 3609112</li>
<li>van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DDPharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidineClin Pharmacol Ther1988;43(3):332-341[PubMed 3345623</li>
<li>Muck W, Wingender W, Seiberling M, Woelke E, Ramsch KD, Kuhlmann J. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol. 1992;42(3):325-328. [PubMed 1577052</li>
<li>Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50(4):394-403. [PubMed 1914375</li>
<li>Kirch W, Hutt HJ, Heidemann H, Ramsch K, Janisch HD, Ohnhaus EE. Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S982-S985. [PubMed 6085389</li>
<li>Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther. 1990;253(3):1042-1048. [PubMed 2359015</li>
<li>Abernethy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Loi CM, Rollins DE, Dukes GE, Peat MA. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther. 1985;37(6):654-657. [PubMed 4006365</li>
<li>Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol. 1985;19(3):385-391. [PubMed 3986090</li>
<li>Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984;36(4):551-554. [PubMed 6478741</li>
<li>Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Conjupri (levamlodipine) [prescribing information]. CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia. 1986;27(5):553-558. [PubMed 3757941</li>
<li>Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol. 1984;27(3):341-343. [PubMed 6096154</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. Epilepsia. 1985;26(2):127-130. [PubMed 3987645</li>
<li>Macphee GJ, Thompson GG, Scobie G, et al. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984;18(3):411-419. [PubMed 6487479</li>
<li>Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011;24(1):63-68. [PubMed 21190921</li>
<li>Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit. 1987;9(1):24-27. [PubMed 3107168</li>
<li>Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 1986;8(4):387-392. [PubMed 3824425</li>
<li>Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy volunteers. Phytother Res. 2015;29(5):701-706. [PubMed 25624269</li>
<li>Pisani F, Narbone MC, Fazio A, et alEffect of viloxazine on serum carbamazepine levels in epileptic patientsEpilepsia1984;25(4):482-485[PubMed 6745218</li>
<li>Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49(10):1142-1145. [PubMed 3783175</li>
<li>Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine. Ann Intern Med. 1981;94(4 pt 1):544. [PubMed 7212521</li>
<li>Garcia B, Zaborras E, Areas V, Obeso G, Jimenez I, de Juana P, Bermejo T. Interaction between isoniazid and carbamazepine potentiated by cimetidine. Ann Pharmacother. 1992;26(6):841-842. [PubMed 1611171</li>
<li>Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol. 1993:36(6):615-616. [PubMed 12959283</li>
<li>Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991:84(6):583-584. [PubMed 1792934</li>
<li>Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie. 1992:47(2):165. [PubMed 1412145</li>
<li>Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust. 1991;155(11-12):851. [PubMed 1745195</li>
<li>Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand. 1983;68(4):253-256. [PubMed 6659865</li>
<li>Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine of fluvoxamine. Ther Drug Monit. 1993:15(3):247-250. [PubMed 8333006</li>
<li>Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother. 1987;20(Suppl B):121-129. [PubMed 3429380</li>
<li>Leite SA, Leite PJ, Rocha GA, Routledge PA, Bittencourt PR. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq Neuropsiquiatr. 1994;52(2):210-215. [PubMed 7826249</li>
<li>Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018</li>
<li>Equetro (carbamazepine) extended-release capsules [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2016</li>
<li>Carbatrol (carbamazepine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc.; August 2018.</li>
<li>Desmond PV, Patwardhan RV, Schenker S, Speeg Jr KV. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med. 1980;93(2):266-268. [PubMed 7406377</li>
<li>Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg Jr KV. Lack of tolerance and rapid recovery of cimetidine - inhibited chlordiazepoxide (Librium) elimination. Gastroenterology. 1981;81(3):547-551. [PubMed 7250643</li>
<li>Nelson DC, Avant GR, Speeg Jr KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology. 1985;5(2):305-309. [PubMed 3979962</li>
<li>Cimetidine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2019.</li>
<li>Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. Eur J Clin Pharmacol. 1981;21(1):83-85. [PubMed 7333351]</li>
<li>Szymanski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52:21-22. [PubMed 1988413</li>
<li>Watras M, Taylor D. A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. Ther Adv Psychopharmacol. 2013;3(5):294-297. [PubMed 24167705]</li>
<li>Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49(1):49-63. [PubMed 10606838</li>
<li>Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18(4):311-316. [PubMed 9690697</li>
<li>Raaska K, Raitasuo V, Laitila J, Neuvonen P. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalized patients. Basic Clin Pharmacol Toxicol. 2004;94(1):13-18. [PubMed 14725610</li>
<li>Al Hadithy A, Leeffers E, Bruggeman R. Clozapine levels might be affected by excessive cola consumption. J Clin Psychopharmacol. 2012;32(5):717-719. [PubMed 22926611</li>
<li>Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol. 1994;14(4):284-285. [PubMed 7962690</li>
<li>Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52(1):21-22. [PubMed 1988413</li>
<li>Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. Psychosomatics. 2007;48(2):170-175. [PubMed 17329613</li>
<li>Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol. 2002;22(6):621-622. [PubMed 12454563</li>
<li>Schoretsanitis G, Kane JM, de Leon JAdding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature reviewJ Clin Psychopharmacol2020;40(3):308-310[PubMed 32332470</li>
<li>Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50-56. [PubMed 23104241</li>
<li>Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2017.</li>
<li>Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother. 2014;48(12):1580-1584. [PubMed 25280976</li>
<li>Cai J, Huang Z, Yang G, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.  Am J Cardiovasc Drugs. 2011;11(6):401-409. [PubMed 22149319</li>
<li>Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant. 2007;21(2):277-284. [PubMed 17425758</li>
<li>Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation. 2003;76(5):865-868. [PubMed 14501869</li>
<li>McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol. 1997;48(5):336. [PubMed 9403222</li>
<li>Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7(6):831-835. [PubMed 8793790</li>
<li>Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. [PubMed 16133554</li>
<li>Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28(1):25-29. [PubMed 16541194</li>
<li>Synercid (quinupristin/dalfopristin) [prescribing information]New York, NY: Pfizer Inc; March 2017</li>
<li>Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet. 1990;19(6):499-502. [PubMed 2292171</li>
<li>Momper JD, Yang J, Kerr J, Saunders I, Smith J, Shah MM. Interaction between cyclosporine and palbociclib in a renal transplant patient: case report and pharmacokinetic perspective. J Pharm Pract. 2020;33(6):912-914. [PubMed 31248333</li>
<li>Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24(3):297-300. [PubMed 8082935</li>
<li>Wang CH, Chou NK, Wu FL, et al. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. Transplant Proc. 2006;38(7):2032-2034. [PubMed 16979990</li>
<li>Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol. 2005;45(7):781-791. [PubMed 15951468</li>
<li>Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081]</li>
<li>Mogford N, Pallett A, George C. Erythromycin deafness and cimetidine treatment. BMJ. 1994;309(6969):1620. [PubMed 7819942]</li>
<li>Mailing D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2021.</li>
<li>Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</li>
<li>Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</li>
<li>Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984;18(3):421-430. [PubMed 6487480]</li>
<li>Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32(4):432-436. [PubMed 9562139</li>
<li>Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol. 1995;8(4):231-233. [PubMed 8561837]</li>
<li>Archambeaud-Moueroux F, Nouaille Y, Nadalon S, Treves R, Merle L. Interaction between gliclazide and cimetidine. Eur J Clin Pharmacol. 1987;31(5):631. [PubMed 3830250]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413]</li>
<li>Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022</li>
<li>Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008;14(9):2701-2709. [PubMed 18451235]</li>
<li>Kishikawa K, Namiki A, Miyashita K, Saitoh K. Effects of famotidine and cimetidine on plasma levels of epidurally administered lignocaine. Anaesthesia. 1990;45(9):719-721. [PubMed 2240530</li>
<li>Parish RC, Gotz VP, Lopez LM, Mehta JL, Curry SH. Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit. 1987;9(3):292-297. [PubMed 3672572</li>
<li>Abernathy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Jackson JE, Bentley JB, Glass SJ, Fukui T, Gandolfi AJ, Plachetka JR. Effects of histamine-2 receptor blockade on lidocaine kinetics. Clin Pharmacol Ther. 1985;37(5):544-548. [PubMed 3987178</li>
<li>Bauer LA, Edwards WA, Randolph FP, Blouin RA. Cimetidine-induced decrease in lidocaine metabolism. Am Heart J. 1984;108(2):413-415. [PubMed 6464978</li>
<li>Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S. Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther. 1984;35(5):695-701. [PubMed 6713782</li>
<li>Feely J, Wilkinson GR, McAllister CB, Wood AJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982;96(5):592-594. [PubMed 7073151</li>
<li>Powell JR, Foster J, Patterson JH, Cross R, Wargin W. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics. Clin Pharm. 1986;5(12):993-998. [PubMed 3802729</li>
<li>Berk SI, Gal P, Bauman JL, Douglas JB, McCue JD, Powell JRThe effect of oral cimetidine on total and unbound serum lidocaine concentrations in patients with suspected myocardial infarctionInt J Cardiol1987;14(1):91-94[PubMed 3804509</li>
<li>Knapp AB, Maguire W, Keren G, et al. The cimetidine-lidocaine interaction. Ann Intern Med. 1983;98(2):174-177. [PubMed 6824249</li>
<li>Patterson JH, Foster J, Powell JR, Cross R, Wargin W, Clark JL. Influence of a continuous cimetidine infusion on lidocaine plasma concentrations in patients. J Clin Pharmacol. 1985;25(8):607-609. [PubMed 4078028</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Single dose oral H2-antagonists do not affect plasma lidocaine levels in the parturient. Acta Anaesthesiol Scan. 1989;33(7):593-596. [PubMed 2683547</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Effect of intravenous cimetidine on lignocaine disposition during extradural caesarean section. Anaesthesia. 1989;44(9):739-741. [PubMed 2802120</li>
<li>Dailey PA, Hughes SC, Rosen MA, Healy K, Cheek DB, Shnider SM. Effect of cimetidine and ranitidine on lidocaine concentrations during epidural anesthesia for cesarean section. Anesthesiology. 1988;69(6):1013-1017. [PubMed 3195744</li>
<li>Lidocaine [prescribing information]. Lake Forest, IL: Hospira Inc; April 2013.</li>
<li>Co-Phenylcaine Forte (lidocaine and phenylephrine) [Singapore product labeling]. Singapore: Ziwell Medical (S) Pte Ltd.; October 2015.</li>
<li>Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. Br J Clin Pharmacol. 1984;18(6):907-914. [PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062-1065. [PubMed 3605428</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR, Hudson RJ. Ranitidine does not alter pethidine disposition in man. Br J Clin Pharmacol. 1985;20(1):55-59. [PubMed 4027136]</li>
<li>Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160-166. [PubMed 20233179</li>
<li>Urva S, Bouillaud E, Delaney R, Jappe A, Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2013;53(4):444-450. [PubMed 23426978</li>
<li>Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol. 2011;51(12):1712-1720. [PubMed 21209230</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020</li>
<li>Kiang TKL. Clinical pharmacokinetics and drug-drug interactions of elbasvir/grazoprevir. Eur J Drug Metab Pharmacokinet. 2018;43(5):509-531. [PubMed 29557529</li>
<li>Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; February 2017</li>
<li>Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56-62. [PubMed 25103957</li>
<li>Koch KM, Dees EC, Coker SA, et alThe effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancerCancer Chemother Pharmacol2017;80(6):1141-1146[PubMed 29098381</li>
<li>Vitrakvi (larotrectinib) [prescribing information]. Stamford CT: Loxo Oncology Inc; November 2018</li>
<li>Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191-202. [PubMed 24825095</li>
<li>Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 plus 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652-659. [PubMed 20881954</li>
<li>Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859-1866. [PubMed 16183781</li>
<li>Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol. 1994;46(6):551-555. [PubMed 7995324</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics; November 2019</li>
<li>Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. [PubMed 21870106</li>
<li>Qelbree (viloxazine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Tavneos (avacopan) [prescribing information]. Cincinnati, OH: ChemoCentryx, Inc.; October 2021</li>
<li>Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017</li>
<li>Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15(6):1406-1416. [PubMed 35293131</li>
<li>Vaprisol (conivaptan) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; October 2016</li>
<li>Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53(3):298-305. [PubMed 8453848</li>
<li>Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol. 1993;73(3):180</li>
<li>Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56(5):389-394. [PubMed 11009047</li>
<li>Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</li>
<li>Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126-132. [PubMed 9562227</li>
<li>Nymalize (nimodipine) oral solution [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; December 2020</li>
<li>Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; December 2015.</li>
<li>Tornizol (ornidazole) [South Korea prescribing information]. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199300808. Accessed June 3, 2022</li>
<li>Arrow ornidazole (ornidazole) [New Zealand data sheet]. Auckland, New Zealand: Teva Pharma (New Zealand) Limited; October 2018</li>
<li>Ramesh S, Kumar YS, Rao YM. Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77. [PubMed 17152348]</li>
<li>Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(Suppl 350):102-106. [PubMed 2530759]</li>
<li>Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol. 1988;28(7):649-654. [PubMed 3216031</li>
<li>Luke DR, Rocci ML Jr, Hoholick C. Inhibition of pentoxifylline clearance by cimetidine. J Pharm Sci. 1986;75(2):155-157. [PubMed 3958924]</li>
<li>Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther. 2000;67(3):222-228. [PubMed 10741624]</li>
<li>Yee T, Barakos JA, Knight RT. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med. 1999;170(2):112-115. [PubMed 10063399</li>
<li>Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis. 1994;169(3):689-691. [PubMed 8158054</li>
<li>Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother. 1997;41(6):1256-1259. [PubMed 9174180</li>
<li>Biltricide (praziquantel) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; January 2019.</li>
<li>Inderal (propranolol) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; March 2011</li>
<li>Kirch W, Spahn H, Kohler H, Ohnhaus EE, Mutschler E. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr. 1982;60(22):1401-1407. [PubMed 7176462</li>
<li>Kirch W, Spahn H, Kohler H, Mutschler E. Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine. Arch Toxicol Suppl. 1983;6:379-383. [PubMed 6578746</li>
<li>Kirch W, Kohler H, Spahn H, Mutschler E. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet. 1981;2(8245):531-532. [PubMed 6115283</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17(Suppl 1):51S-57S. [PubMed 6146340</li>
<li>Tateishi T, Ohashi K, Fujimura A, Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992;32(12):1099-1104. [PubMed 1487547</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Comparison of kinetic interactions of nadolol and propranolol with cimetidine. Am Heart J. 1984;108(4 Part 2):1084-1086. [PubMed 6148867</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Kinetic interactions of nadolol and propranolol with cimetidine. Br J Clin Pharmacol. 1984;17(4):486-487. [PubMed 6721996</li>
<li>Donn KH, Powell JR, Rogers JF, Eshelman FNThe influence of H2-receptor antagonists on steady-state concentrations of propranolol and 4-hydroxypropranololJ Clin Pharmacol1984;24(11-12):500-508[PubMed 6150946</li>
<li>Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J. 1981;282(6280)1917-1919. [PubMed 6786672</li>
<li>Reimann IW, Klotz U, Siems B, Frolich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981;12(6):785-790. [PubMed 7340880</li>
<li>Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzneimittelforschung. 1987;37(8):953-956. [PubMed 2890358</li>
<li>Asgharnejad M, Powell JR, Donn KH, Danis M. The effect of cimetidine dose timing on oral propranolol kinetics in adults. J Clin Pharmacol. 1988;28(4):339-343. [PubMed 3392231</li>
<li>Reimann IW, Klotz U, Frolich JC. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther. 1982;32(6):749-757. [PubMed 6291839</li>
<li>Donovan MA, Heagerty AM, Patel L, Castleden M, Pohl JE. Cimetidine and bioavailability of propranolol. Lancet. 1981;1(8212):164. [PubMed 6109849</li>
<li>MacKichan JJ, Boudoulas H, Schall SF. Effect of cimetidine on quinidine bioavailability. Biopharm Drug Dispos. 1989;10(1):121-125. [PubMed 2923957</li>
<li>Hardy BG, Zador IT, Golden L, Lalka D, Schentag JJ. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol. 1983;52(1):172-175. [PubMed 6858908</li>
<li>Kolb KW, Garnett WR, Small RE, Vetrovec GW, Kline BJ, Fox T. Effect of cimetidine on quinidine clearance. Ther Drug Monit. 1984;6(3):306-312. [PubMed 6506138</li>
<li>Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol. 1988;26(8):388-391. [PubMed 3220613</li>
<li>Farringer JA, McWay-Hess K, Clementi WA. Cimetidine-quinidine interaction. Clin Pharm. 1984;3(1):81-83. [PubMed 6697678</li>
<li>Polish LB, Branch RA, Fitzgerald GA. Digitoxin-quinidine interaction: potentiation during administration of cimetidine. South Med J. 1981;74(5):633-634. [PubMed 7244727</li>
<li>Quinidine sulfate [prescribing information]. Laurelton, NY: Epic Pharma LLC; July 2021.</li>
<li>Bohmer GM, Gleiter CH, Morike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol. 2011;51(4):594-602. [PubMed 20484614</li>
<li>Cui X, Huang J, Zheng X, Jiang J, Kuang Y, Hu P. Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: application for a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029-1030:60-67. [PubMed 27423044</li>
<li>Li Q, Wang Y, Liu L, Ma P, Ding L. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in healthy Chinese subjects after single and multiple oral doses. Eur J Drug Metab Pharmacokinet. 2017;42(3):371-381. [PubMed 27306372</li>
<li>Zoryve (roflumilast) cream [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2022</li>
<li>Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</li>
<li>Kim J-R, Jung JA, Kim S, Huh W, Ghim J-L, Shin J-G, Ko J-W. Effect of cilostazol on the pharmacokinetics of simvastatin in healthy subjects. Biomed Res Int. 2019;1365180. [PubMed 30729119</li>
<li>Xu CF, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 23(9):2470-2471. [PubMed 22918879</li>
<li>Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19(1):247. [PubMed 31640597</li>
<li>Poumeaud F, Fontanier A, Dion J, et al. Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report. Front Oncol. 2022;12:1026434. [PubMed 36591506</li>
<li>Huynh T, Cordato D, Yang F. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32(9-10):486-490. [PubMed 12380704</li>
<li>Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; September 2020.</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499]</li>
<li>Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001;15(2):95-99. [PubMed 11264634</li>
<li>Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit. 2005;27(5):587-591. [PubMed 16175131</li>
<li>Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc.; January 2016</li>
<li>Breslin NT, Salerno DM, Topkara VK, et al. Prior amiodarone exposure reduces tacrolimus dosing requirements in heart transplant recipients. Prog Transplant. 2019;29(2):129-134. [PubMed 30845890</li>
<li>Mavyret (glecaprevir/pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2020</li>
<li>Shapiro R, Venkataramaan R, Warty VS, et al. FK 506 interaction with danazol. Lancet. 1993;341(8856):1344-1345. [PubMed 7684106</li>
<li>Seck S, Bellantoni M, Zoccali C, Enia G. Ranolazine can markedly increase tacrolimus blood levels. NDT Plus. 2011;4(1):44-45. [PubMed 25984101</li>
<li>Patni H, Gitman M, Hazzan A, Jhaveri KD. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail. 2012;34(2):251-253. [PubMed 22263871</li>
<li>Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain EPharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant childTransplantation 2012;93(7):e29-e30[PubMed 22450597</li>
<li>Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2013;69(10):1861-1862. [PubMed 23765408</li>
<li>Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2018</li>
<li>Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2020.</li>
<li>Maeda Y, Konishi T, Omoda K, et al. Inhibition of theophylline metabolism by aciclovir. Biol Pharm Bull. 1996;19(12):1591-1595. [PubMed 8996645</li>
<li>Sato J, Nakata H, Owda E, Kikuta T, Umetsu M, Ito K. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J Clin Pharmacol. 1993;44(3):295-298. [PubMed 8491248</li>
<li>Vestal RE, Thummel KE, Musser B, Mercer GD. Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol. 1983;15(4):411-418. [PubMed 6849776</li>
<li>Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med. 1984;144(3):484-486. [PubMed 6322709</li>
<li>Cohen IA, Johnson CE, Berardi RR, Hyneck ML, Achem SR. Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit. 1985;7(4):426-434. [PubMed 4082242</li>
<li>Mulkey PM, Murphy JE, Shleifer NH. Steady-state theophylline pharmacokinetic during and after short-term cimetidine administration. Clin Pharm. 1983;2(5):439-441. [PubMed 6627870</li>
<li>Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 1989;45(5):476-486. [PubMed 2721103</li>
<li>Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982;23(2):129-134. [PubMed 7140802</li>
<li>Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski REffects of tobacco smoking and oral contraceptive use on theophylline dispositionBr J Clin Pharmacol1983;16(3):271-280[PubMed 6626419</li>
<li>Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;24(2):939-941. [PubMed 2444839</li>
<li>Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline. Pharm Weekbl Sci. 1987;11(9 suppl):S72-S75. [PubMed 3481439</li>
<li>Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986;22(6):677-683. [PubMed 3567014</li>
<li>Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest. 1987;92(4):663-669. [PubMed 3477409</li>
<li>Staib AH, Harder S, Fuhr U, Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol. 1989;27(6):289-293. [PubMed 2737798</li>
<li>Miners JO, Wing LM, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol. 1985;20(3):219-223. [PubMed 4041342</li>
<li>Lombardi TP, Bertino JS Jr, Goldberg A, Middleton E Jr, Slaughter RL. The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. J Clin Pharmacol. 1987;27(7):523-529. [PubMed 2888791</li>
<li>Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980;28(4):463-467. [PubMed 7408406</li>
<li>Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41(3):358-362. [PubMed 3816023</li>
<li>Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(suppl 2):77-83. [PubMed 8620674</li>
<li>Spinler SA, Gammaitoni A, Charland SL, Hurwitz J. Propafenone-theophylline interaction. Pharmacotherapy. 1993;13(1):68-71. [PubMed 8437970</li>
<li>Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. Clin Pharmacol Ther. 1992;51(3):353-355. [PubMed 1544292</li>
<li>Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ. Cimetidine-theophylline interaction: report of four patients. Ann Allergy. 1982;48(2):100-102. [PubMed 6121526</li>
<li>Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR. Cimetidine decreases theophylline clearance. Ann Intern Med. 1981;95(1):68-69. [PubMed 7247131</li>
<li>Lofgren RP, Gilbertson RA. Cimetidine and theophylline. Ann Intern Med. 1982;96(3):378. [PubMed 6800293</li>
<li>Mojtahedzadeh M, Sadray S, Hadjibabaie M, Fasihi M, Rezaee S. Determination of theophylline clearance after cimetidine infusion in critically ill patients. J Infus Nurs. 2003;26(4):234-238. [PubMed 12869856</li>
<li>Koren G, Chin TF, Correia J, Tesoro A, MacLeod SM. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. Clin Invest Med. 1985;8(3):222-2[PubMed 4042465</li>
<li>Theo-24 (theophylline anhydrous) [prescribing information]. Malvern, PA; Endo Pharmaceuticals Inc.; August 2017.</li>
<li>Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986;26(5):372-377. [PubMed 3700691</li>
<li>Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157-163. [PubMed 3383988</li>
<li>Adebayo GI, Coker HA. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. Eur J Clin Pharmacol. 1988;34(6):653-656. [PubMed 3169118</li>
<li>Stockley C, Keal J, Rolan P, Bochner F, Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur J Clin Pharmacol. 1986;31(2): 235-237. [PubMed 3803421</li>
<li>Dey NG, Castleden CM, Ward J, Cornhill J, McBurney A. The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol. 1983;16(4):438-440. [PubMed 6626438]</li>
<li>Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983;16(6):743-746. [PubMed 6140941</li>
<li>Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol. 1998;28(3):228-233. [PubMed 3360971</li>
<li>Pourbaix S. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Britton ML, Waller ES. Central nervous system toxicity associated with concurrent use of triazolam and cimetidine. Drug Intell Clin Pharm. 1985;19(9):666-668. [PubMed 40428607. Parker WA, MacLachlan RA. Prolonged hypnotic response to triazolam-cimetidine combination in an elderly patient. Drug Intell Clin Pharm. 1984;18(12):980-981. [PubMed 6150838]</li>
<li>Curry SH, De Vane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433. [PubMed 3912187</li>
<li>Amsterdam JD, Brunswick DJ, Potter L, et al. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology. 1984;83:373-375. [PubMed 6436867</li>
<li>Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. [PubMed 3950073</li>
<li>Sutherland DL, Remillard AJ, Haight KR, et al. The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. Eur J Clin Pharmacol. 1987;32:159-164. [PubMed 3582480</li>
<li>Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. [PubMed 379426</li>
<li>Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. [PubMed 6692646</li>
<li>Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229(3):702-705. [PubMed 6726654</li>
<li>Brown MA, Haight KR, McKay G. Cimetidine-doxepin interaction. J Clin Psychopharmacol. 1985;5:245-247. [PubMed 4019813</li>
<li>Shapiro PACimetidine-imipramine interaction: case report and commentsAm J Psychiatry1984;141:152[PubMed 6691449</li>
<li>Miller DD, Macklin M. Cimetidine-imipramine interaction: a case report. Am J Psychiatry. 1983;140:351. [PubMed 6829810</li>
<li>Miller DD, Sawyer JB, Duffy JP. Cimetidine’s effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm. 1983;17(12):904-905. [PubMed 6653407</li>
<li>Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther. 1987;42:278-282. [PubMed 3621787]</li>
<li>Urasap (urapidil) [Summary of Product Characteristics]. Frosinone, Italy: INCA-Pharm Srl; September 2012.</li>
<li>De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46(2):458-463. [PubMed 11796358</li>
<li>Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2010.</li>
<li>Desager JP, Harvengt C, Bianchetti G, Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int J Clin Pharmacol Ther Toxicol. 1993;31(11):568-571. [PubMed 7904983]</li>
<li>Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; November 2022</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Hendset M, Molden E, Enoksen TB, et al. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit. 2010;32(6):787-790. [PubMed 21068650</li>
<li>Abilify Maintena (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; January 2020</li>
<li>Abilify Asimtufii (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; April 2023.</li>
<li>Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20(1):55-64. [PubMed 15770075</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44(11):1850-1854. [PubMed 20978219</li>
<li>Qulipta (atogepant) [prescribing information]. Dublin, Ireland: Forest Laboratories Ireland Ltd; September 2021.</li>
<li>Ortikos (budesonide) extended-release capsules [prescribing information]. Sun Pharmaceutical Industries, Inc.; June 2019.</li>
<li>Buspirone [prescribing information]. Laurelton, NY: Epic Pharma LLC; May 2020</li>
<li>Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ. Lack of interaction between cimetidine and buspirone. Pharmacotherapy. 1987;7(3):72-79. [PubMed 2888096]</li>
<li>Epidiolex (cannabidiol) oral solution [prescribing information]. Carlsbad, CA: Greenwich Biosciences Inc; October 2020</li>
<li>Thai C, Tayo B, Critchley D. A phase I open-label, fixed sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(11):1279-1289. [PubMed 33951339</li>
<li>Beach CA, Mays DC, Guiler RC, Jacober CH, Gerber N. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986;39(3):265-270. [PubMed 3948467</li>
<li>Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol. 1995;48(2):161-166. [PubMed 7589032</li>
<li>Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425-428. [PubMed 4029248</li>
<li>Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther. 1999;65(3):262-274. [PubMed 10096258</li>
<li>Pegintron (peginterferon alfa-2b) [prescribing information]Whitehouse Station, NJ: Merck &amp; Co Inc; January 2019</li>
<li>Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988;35(6):651-656. [PubMed 2853056</li>
<li>Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45(3):234-240. [PubMed 2920498</li>
<li>Michaud V, Mouksassi MS, Labbe L, et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit. 2006;28(6):779-783. [PubMed 17164694</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Coreg (carvedilol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</li>
<li>Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104(12):3116-3117. [PubMed 19956146]</li>
<li>Rize (clotiazepam) [KR prescribing information]. Available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802970]. Accessed [January 30, 2023]</li>
<li>Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H. Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol. 1984;26(1):55-59. [PubMed 6143670]</li>
<li>Mitigare (colchicine) capsule [prescribing information]. Memphis, TN: Hikma Americas, Inc.; September 2014.</li>
<li>Enablex (darifenacin) [prescribing information]. Rockaway, NJ: Warner Chilcott US LLC; March 2012.</li>
<li>Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15(1):18-24. [PubMed 8451775</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997;62(2):145-156. [PubMed 9284850</li>
<li>Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008</li>
<li>Effexor (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017</li>
<li>Norvir (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2019</li>
<li>Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664-674. [PubMed 16338282</li>
<li>Orladeyo (berotralstat) [prescribing information]Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989;146(12):1611-1613. [PubMed 2486749</li>
<li>Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329-336. [PubMed 2288330</li>
<li>Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit. 1992;14(3):194-196. [PubMed 1412604</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res. 1993;13(3):167-171. [PubMed 8225700</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15(3):243-246. [PubMed 8333005]</li>
<li>Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017</li>
<li>Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70(9):1115-1122. [PubMed 25028073</li>
<li>Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacol (Berl). 1998;135(1):22-26. [PubMed 9489930</li>
<li>Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(4):747-755. [PubMed 24013574</li>
<li>Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020</li>
<li>Qelbree (viloxazine) [prescribing information]Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Saphris (asenapine) [prescribing information]. Irvine, CA: Allergan USA Inc; February 2017</li>
<li>Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64(3):257-268. [PubMed 9757149]</li>
<li>Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother Pharmacol. 1999;43(2):126-132. [PubMed 9923817]</li>
<li>Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer Inc.; June 2016</li>
<li>Cardura XL (doxazosin extended-release) [prescribing information]. New York, NY: Pfizer Inc.; February 2017.</li>
<li>Cerdelga (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2018</li>
<li>Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</li>
<li>Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14-23. [PubMed 11180034</li>
<li>Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50(3):203-208. [PubMed 8737760</li>
<li>Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. 2002;72(3):247-255. [PubMed 12235445]</li>
<li>Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77(1):17-23. [PubMed 15637527]</li>
<li>Flecainide [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals Pvt. Ltd.; September 2017</li>
<li>Tjandra-Maga TB, van Hecken A, van Melle P, Verbesselt R, de Schepper PJAltered pharmacokinetics of oral flecainide by cimetidineBr J Clin Pharmacol1986;22(1):108-110[PubMed 3741720]</li>
<li>Sullivan KM, Small RE, Rock WL, Cox SR, Willis HE. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm. 1986;5(7):586-589. [PubMed 3742949</li>
<li>Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol. 1990;30(7):660-664. [PubMed 2391398]</li>
<li>Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507. [PubMed 20573085</li>
<li>Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514]</li>
<li>Dumitras S, Sechaud R, Drollmann A, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771-779. [PubMed 24040847]</li>
<li>Zircol (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013</li>
<li>Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:31S-36S. [PubMed 11879257</li>
<li>Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-581. [PubMed 15365656]</li>
<li>Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</li>
<li>Luder PJ, Siffert B, Witassek F, et al. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31(4):443-448. [PubMed 3816925</li>
<li>Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24(3):390-392. [PubMed 3663452]</li>
<li>Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319-1321. [PubMed 15541258</li>
<li>Garimella T, Tao X, Sims K, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R D. 2018;18(1):55-65. [PubMed 29255971</li>
<li>Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130-137. [PubMed 12891223</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67-70. [PubMed 2917591</li>
<li>Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466-477. [PubMed 10824625</li>
<li>Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113-123. [PubMed 14748763</li>
<li>Thibault N, Ibrahim J, Peterschmitt MJ, et al. Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Mol Genet Metab. 2020;129(4):278-285. [PubMed 32029355</li>
<li>Lexapro (escitalopram) [prescribing information]Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28-34. [PubMed 17224709</li>
<li>Ogasawara K, LoRusso PM, Olszanski AJ, et al. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol. 2020;86(1):87-95. [PubMed 32537715</li>
<li>Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol. 1987;31(5):575-578. [PubMed 3830242</li>
<li>Laurent-Kenesi MA, Brentano-Funck C, Poirier JM, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 1993;36(6):531-538. [PubMed 12959269</li>
<li>Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24(2):213-220. [PubMed 3620296</li>
<li>Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Cho DY, Bae SH, Lee JK, et al. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica. 2015;45(3):256-263. [PubMed 25268386</li>
<li>Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2015</li>
<li>Effexor XR (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</li>
<li>Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's Disease. Biopharmaceut Drug Dispos. 1988;9(2):219-227. [PubMed 2897213</li>
<li>Loft S, Dossing M, Sonne J, Dalhof K, Bjerrum K, Poulsen HE. Lack of effect of cimetidine on the pharmacokinetics of metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol. 1988;35(1):65-68. [PubMed 3220096</li>
<li>Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. Eur J Clin Pharmacol. 1987;32(1):35-41. [PubMed 3582467</li>
<li>Gugler R, Jensen JC. Interaction between cimetidine and metronidazole. N Eng J Med 1983;309(24):1518-1519. [PubMed 6646177</li>
<li>Viaflex Plus Container (metronidazole injection) [prescribing information]. Deefield, IL: Baxter Healthcare Corporation; December 2017</li>
<li>Pearce RE, Cohen-Wolkowiez M, Sampson MR,Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013;41(9):1686-1694. [PubMed 23813797</li>
<li>Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE . Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol. 1991;41(8):1127-1134. [PubMed 2009091]</li>
<li>Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; November 2019.</li>
<li>Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the h2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 1997;43(2):201-204. [PubMed 9131955]</li>
<li>Bendayan R, Sullivan JR, Shaw C, et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol. 1990;38:165-169. [PubMed 2338114</li>
<li>Bendayan R, Kennedy G, Frecker RC, Sellers EM. Lack of effect of cimetidine on cigarette smoking. Eur J Clin Pharmacol. 1993;44(1):51-55. [PubMed 8436155]</li>
<li>Ochs HR, Greenblatt DJ, Gugler R, Muntefering G, Locniskar A, Abernethy DR. Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther. 1983;34(2):227-230. [PubMed 6872417</li>
<li>Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</li>
<li>Fine A, Churchill DN, “Potentially Lethal Interaction of Cimetidine and Morphine,” Can Med Assoc J, 1981, 124(11):1434</li>
<li>[PubMed 7237324</li>
<li>Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010</li>
<li>Gogas KR, Hough LB, Eberle NB, et al, “A Role for Histamine and H2-Receptors in Opioid Antinociception,” J Pharmacol Exp Ther, 1989, 250(2):476-84. [PubMed 2547933</li>
<li>Bluhm R, Zsigmond EK, Winnie AP, “Potentiation of Opioid Analgesia by H1 and H2 Antagonists,” Life Sci, 1982, 31(12-13):1229-32. [PubMed 6128651</li>
<li>Robertson JA, Hough LB, Bodnar RJ, “Potentiation of Opioid and Nonopioid Forms of Swim Analgesia by Cimetidine,” Pharmacol Biochem Behav, 1988, 31(1):107-12. [PubMed 2855266</li>
<li>Lam AM, Clement JL, “Effect of Cimetidine Premedication on Morphine-Induced Ventilatory Depression,” Can Anaesth Soc J, 1984, 31(1):36-43. [PubMed 6420025</li>
<li>Mojaverian P, Fedder IL, Vlasses PH, et al, “Cimetidine Does Not Alter Morphine Disposition in Man,” Br J Clin Pharmacol, 1982, 14(6):809-13. [PubMed 7150459</li>
<li>Dawson GW, Vestal RE, “Cimetidine Inhibits the In Vitro N-Demethylation of Methadone,” Res Commun Chem Pathol Pharmacol, 1984, 46(2):301</li>
<li>[PubMed 6515123</li>
<li>Guay DR, Meatherall RC, Chalmers JL, et al, “Cimetidine Alters Pethidine Disposition in Man,” Br J Clin Pharmacol, 1984, 18(6):907-14[PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, et al, “Meperidine-Induced Delirium,” Am J Psychiatry, 1987, 144(8):1062</li>
<li>Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014</li>
<li>Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005;28(2):328-334. [PubMed 15684493</li>
<li>Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull. 2004;27(5):684-690. [PubMed 15133245]</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S. [PubMed 6146340</li>
<li>Spahn H, Kirch W, Mutschler E. The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol. Br J Clin Pharmacol. 1983;15(4):500-501. [PubMed 6849789</li>
<li>Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016</li>
<li>Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992;51(4):379-387. [PubMed 1563208]</li>
<li>Pritchett EL, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol. 1988;28(7):619-624. [PubMed 3063727]</li>
<li>Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; December 2017.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53(suppl 1):31S-36S. [PubMed 11879257</li>
<li>Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; February 2018.</li>
<li>Lamisil (terbinafine hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016</li>
<li>Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219. [PubMed 9382559]</li>
<li>Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol. 1993;45(1):41-46. [PubMed 8405028]</li>
<li>Jonderko G, Jonderko K, Marcisz C, Kotulska A. Effect of cimetidine and ranitidine on absorption of [125]levothyroxine administered orally. Zhongguo Yao Li Xue Bao. 1992;13(5):391-394. [PubMed 1300037</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075]</li>
<li>Gabitril (tiagabine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2015.</li>
<li>Spiriva (tiotropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2015.</li>
<li>Conzip (tramadol) extended-release capsules [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC; March 2021.</li>
<li>Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Inc; February 2019.</li>
<li>Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):51-55. [PubMed 14616414</li>
<li>Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother. 2009;53(4):1712-1714. [PubMed 19171800</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; April 2019.</li>
<li>Wang K, Yao X, Zhang M, et al. Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):441-454. [PubMed 33687157]</li>
<li>de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55-59. [PubMed 31865063</li>
<li>Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019;10:2042098619854007. doi: 10.1177/2042098619854007. [PubMed 31258887</li>
<li>Tsai SC, Sheu SY, Chien LN, Lee HC, Yuan EJ, Yuan RY. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000-2009. [PubMed 29745438</li>
<li>Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780-1782. [PubMed 7500509</li>
<li>Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med. 1986;146(10):2070-2071. [PubMed 3767555</li>
<li>Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J. 2010;103(2):178-180. [PubMed 20065895</li>
<li>Corsini GU, Zompo MD, Cianchetti C, et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacologia. 1976;47(2):169-173. [PubMed 1273213</li>
<li>Tarsy D, Parkes JD, Marsden CD. Metoclopramide in parkinsonism. Lancet. 1975;1(7918):1244-1245. [PubMed 48872</li>
<li>Tarsy D, Parkes JD, Marsden CDMetoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesiasJ Neurol Neurosurg Psychiatry1975;38(4):331-335[PubMed 1095689</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020</li>
<li>Migramax (aspirin and metoclopramide) [summary of product characteristics]. London, United Kingdom: Zentiva Pharma UK Limited; March 2022.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; August 2017</li>
<li>Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC. 2013;13:152. [PubMed 23714238</li>
<li>Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004;44(6):661-665. [PubMed 15637848</li>
<li>Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ. 1988;297(6654):964-965. [PubMed 3142568</li>
<li>Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J. 1991;84(5):626-628. [PubMed 2035085</li>
<li>Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolid-fluoxetine and olanzapine-metoclopramide interactions: a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission. Case Rep Med. 2016;2016:7128909. [PubMed 27433163]</li>
<li>Cabergoline [prescribing information]. Peapack, NJ: Greenstrone LLC; November 2019.</li>
<li>Barnes TR, Braude WM, Hill DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2(8288):48-49. [PubMed 6123780</li>
<li>Metoclopramide [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; July 2021</li>
<li>Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000;23(Suppl):S64-S70. [PubMed 11052222</li>
<li>Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. [PubMed 19886950</li>
<li>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446]</li>
<li>Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.</li>
<li>Patterson JF. Metoclopramide therapy of MAOI orthostatic hypotension. J Clin Psychopharmacol. 1987;7(2):112-113. [PubMed 3584514]</li>
<li>Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</li>
<li>Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009</li>
<li>Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” Trends Neurosci, 2000, 23(Suppl):S64-70. [PubMed 11052222</li>
<li>Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” Aliment Pharmacol Ther, 2010, 31(1):11</li>
<li>Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” Ann Pharmacother, 2008, 42(9):1290</li>
<li>Trelstar (triptorelin) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions, LLC; December 2018</li>
<li>Trelstar (triptorelin) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc.; September 2022.</li>
<li>Prescribing information. Malarone (atovaquone and proguanil). Research Triangle Park, NC: GlaxoSmithKline, 02/2013.</li>
<li>Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos. 2006;27(6):285-289. [PubMed 16770757</li>
<li>Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-2281. [PubMed 27621638</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020.</li>
<li>Mehta D, Bradley EL Jr, Kissin I. Metoclopramide decreases thiopental hypnotic requirements. Anesth Analg. 1993;77(4):784-787. [PubMed 8214666</li>
<li>Thiopental sodium [Summary of Product Characteristics]. Berkshire, UK: Archimedes Pharma UK Limited; January 2014.</li>
<li>Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013</li>
<li>Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990;39(6):1045-1053. [PubMed 2322292]</li>
<li>Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011</li>
<li>Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015</li>
<li>Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015</li>
<li>Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.</li>
<li>Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: Ani Pharmaceuticals Inc; August 2017.</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation. 1987;43(2):211-213. [PubMed 3544377</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant patients. Transplant Proc. 1988;20(2 suppl 2):487-490. [PubMed 3284095</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017.</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932]</li>
<li>Aczone (dapsone) gel [prescribing information]. Irvine, CA: Allergan, Inc.; July 2015.</li>
<li>Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</li>
<li>Gamble JA, Gaston JH, Nair SG, Dundee JW. Some pharmacological factors influencing the absorption of diazepam following oral administration. Br J Anaesth. 1976;48(12):1181-1185. [PubMed 1023954</li>
<li>Chapman MH, Woolner DF, Begg EJ, Atkinson HC, Sharman JR. Coadministered oral metoclopramide does not enhance the rate of absorption of oral diazepam. Anaesth Intensive Care. 1988;16(2):202-205. [PubMed 3394914]</li>
<li>Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinetic. 1986;11(4):249-250. [PubMed 3582418</li>
<li>Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984;36(6):724-730. [PubMed 6499354</li>
<li>Schwartz BG. Metoclopramide and digoxin cause 22 episodes of bradyarrhythmias. Am J Med. 2010;123(6):e5</li>
<li>[PubMed 20569744</li>
<li>Johnson BG, O'Grady J, Bye C. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. Br J Clin Pharmacol. 1978;5(5):465-467. [PubMed 656287]</li>
<li>Monurol (fosfomycin) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2018.</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One. 2013;8(11):e81208. [PubMed 24278396</li>
<li>Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6(9):e23728. [PubMed 21961030</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015</li>
<li>Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488</li>
<li>Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662]</li>
<li>Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.</li>
<li>Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016</li>
<li>Synera (lidocaine and tetracaine) topical patch [prescribing information]. Souderton, PA: Galen US Inc; March 2014</li>
<li>Pliaglis (lidocaine and tetracaine) cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; November 2013</li>
<li>Citanest plain (prilocaine) [prescribing information]. York, PA: Dentsply Pharmaceutical; June 2010</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006</li>
<li>Marcaine Spinal (bupivacaine hydrochloride in dextrose injection, USP) [prescribing information]. Lake Forest, IL: Hospira, Inc.; November 2018</li>
<li>Lardieri AB, Crew PE, McCulley L, Kim IE, Waldron P, Diak IL. Cases of benzocaine-associated methemoglobinemia identified in the FDA adverse event reporting system and the literature [published online January 2, 2019]. Ann Pharmacother. doi: 10.1177/1060028018823532. [PubMed 30600685]</li>
<li>Tercan M, Efe EM, Turker G, et al. Do metoclopramide and ondansetrone alter mivacurium-induced neuromuscular blockade? - a randomised trial. Braz J Anesthesiol. 2014;64(1):35-39. [PubMed 24565386</li>
<li>El Ayass N, Hendrickx P. Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized double blind placebo-controlled study. Eur J Anaesthesiol. 2005;22(3):197-201. [PubMed 15852992</li>
<li>Motamed C, Kirov K, Combes X, Dhonneur G, Duvaldestin P. Effect of metoclopramide on mivacurium-induced neuromuscular block. Acta Anaesthesiol Scand. 2002;46(2):214-216. [PubMed 11942874</li>
<li>Skinner HJ, Girling KJ, Whitehurst A, Nathanson MH. Influence of metoclopramide on plasma cholinesterase and duration of action of mivacurium. Br J Anaesth. 1999;82(4):542-545. [PubMed 10472219</li>
<li>Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth. 1990;65(2):220-224. [PubMed 2223340</li>
<li>Kambam JR, Parris WC, Franks JJ, Sastry BV, Naukam R, Smith BE. The inhibitory effect of metoclopramide on plasma cholinesterase activity. Can J Anaesth. 1988;35(5):476-478. [PubMed 3273154]</li>
<li>Inomax (nitric oxide) [prescribing information]. Hampton, NJ: INO Therapeutics; March 2013</li>
<li>Genosyl (nitric oxide) [prescribing information]. Atlanta, GA: Vero Biotech; December 2019</li>
<li>Sinisterra S, Miravet E, Alfonso I, et al. Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic. J Pediatr. 2002;141(2):285-286. [PubMed 12183731</li>
<li>Lopez A, Bernardo B, Lopez-Herce J, et al. Methaemoglobinaemia secondary to treatment with trimethoprim and sulphamethoxazole associated with inhaled nitric oxide. Acta Paediatr. 1999;88(8):915-916. [PubMed 10503695</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006.</li>
<li>Metozolv ODT (metoclopramide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2011.</li>
<li>Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011;67(6):591-599. [PubMed 21161196</li>
<li>PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PMID: 19075045</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013.</li>
<li>Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006</li>
<li>Skold A, Cosco DL and Klein R, “Methemoglobinemia: Pathogenesis, Diagnosis, and Management,” South Med J, 2011, 104(11):757-61. [PubMed 22024786</li>
<li>Mansouri A and Lurie AA, “Concise Review: Methemoglobinemia,” Am J Hematol, 1993, 42(1):7-12. [PubMed 8416301]</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022</li>
<li>Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</li>
<li>Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced serotonin syndrome. Intern Med. 2017;56(6):737-739. [PubMed 28321081</li>
<li>Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002;36(1):67-71. [PubMed 11816261</li>
<li>Aussedat M, Lavoie A, Bussieres JF, Kleiber N. Suspected overlap between serotonin syndrome and neuroleptic malignant syndrome in a child treated with metoclopramide? J Pediatr Pharmacol Ther. 2020;25(6):552-558. [PubMed 32839660</li>
<li>Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664</li>
<li>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718</li>
<li>Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713</li>
<li>Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil. 2009;21(12):1235-1238. [PubMed 19906028]</li>
<li>Provenzani A, D'alessandro N, Polidori P. Toxic tacrolimus concentrations associated with intravenous use of metoclopramide in a lung transplant patient. Ann Pharmacother. 2019;53(5):548-549. [PubMed 30739475</li>
<li>Prescott WA Jr, Callahan PL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 2004;24(4):532-537. [PubMed 15098810</li>
<li>Wadhw NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019.</li>
<li>Prescribing information. Baltimore, MD: Cangene BioPharma, Inc., 2/2012</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</li>
<li>Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology. 1989;70(6):905-908. [PubMed 2658689</li>
<li>Turner DR, Kao YJ, Bivona C. Neuromuscular block by suxamethonium following treatment with histamine type 2 antagonists or metoclopramide. Br J Anaesth. 1989;63(3):348-350. [PubMed 2572248</li>
<li>Dell-Kuster S, Levano S, Burkhart CS, et al. Predictors of the variability in neuromuscular block duration following succinylcholine: A prospective, observational study. Eur J Anaesthesiol. 2015;32(10):687-696. [PubMed 26213905</li>
<li>Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” Br Med J, 1973, 1:587. [PubMed 4694406</li>
<li>Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” Br J Clin Pharmacol, 1981, 11:430-1P</li>
<li>Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” J Pharm Pharmacol, 2001, 53(7):1041</li>
<li>[PubMed 11480539</li>
<li>van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” Methods Find Exp Clin Pharmacol, 1990, 12(4):291</li>
<li>[PubMed 2374477</li>
<li>van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” Methods Find Exp Clin Pharmacol, 1992, 14(5):379-82. [PubMed 1513194</li>
<li>Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” Br J Clin Pharmacol, 1983, 15(4):487</li>
<li>[PubMed 6849786</li>
<li>Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” Cephalalgia, 1988, 8(3):139-47. [PubMed 31970094</li>
<li>Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” Eur J Clin Pharmacol, 1992, 42(2):235</li>
<li>[PubMed 1618258]</li>
<li>Kaukab I, Shah SNH, Kharaba ZJ, Buabeid MA, Alfoteih YA, Murtaza G. Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake. Expert Opin Metab Toxicol. 2020;16(8):735-740. [PubMed 32524862]</li>
<li>Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013;28(2):99-105. [PubMed 23221858</li>
<li>Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559</li>
<li>Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. [PubMed 18809731</li>
<li>Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018</li>
<li>Khedezla (desvenlafaxine) [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; August 2017.</li>
<li>Moffett PM, Cartwright L, Grossart EA, O’Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23(1):102-105. [PubMed 26720490</li>
<li>Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-58. [PubMed 22046106</li>
<li>Tracz K, Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br J Clin Pharmacol. 2015;79(4):669-676. [PubMed 25293524</li>
<li>Obal D, Yang D, Sessler DI. Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Mayo Clin Proc. 2014;89(1):69-80. [PubMed 24388024</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder TClinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort studyBr J Clin Pharmacol2009;67(3):347-354[PubMed 19523015</li>
<li>Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105(2):389-395. [PubMed 8306734</li>
<li>Kroll CR, Gettes LS. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol. 2002;13(9):936-938. [PubMed 12380935</li>
<li>Otsuka M, Kanamori H, Sasaki S, et al. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med. 1997;36(10):705-708. [PubMed 9372331</li>
<li>Farguhar Zanetti LA, Oliphant CM. Pentamidine-induced torsades de pointes. Ann Pharmacother. 1994;28(2):282-283. [PubMed 8173154</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</li>
<li>Matsuo J, Yamaori S. Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. [published online ahead of print] J Clin Pharm Ther. 2021. doi:10.1111/jcpt.13539. [PubMed 34664726</li>
<li>Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther. 1988;43(5):577-581. [PubMed 3365919</li>
<li>Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol. 2003;41(8):1199-1201. [PubMed 12842189</li>
<li>Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality. 1991;3(1):14-18. [PubMed 2039678</li>
<li>Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</li>
<li>Kaukab I, Shah SNH, Abrar MA, Anwer N, Murtaza G. Influence of rifampicin pre-treatment on the in vivo pharmacokinetics of metoclopramide in Pakistani healthy volunteers following concurrent oral administration. Curr Drug Metab. 2020;21(4):301-306. [PubMed 32407272]</li>
<li>Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003:31(5):631-636. [PubMed 12695352]</li>
<li>Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.</li>
<li>Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2016;37(1):15-27. [PubMed 26356245</li>
<li>Pham CP, de Feiter PW, van der Kuy PHM, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7-8):1456-1461. [PubMed 16849620</li>
<li>Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc.; March 2015.</li>
<li>Yoshizato T, Kotegawa T, Imai H, et al. Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol. 2012;68(9):1287-1294. [PubMed 22418831</li>
<li>Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411-421. [PubMed 21883386</li>
<li>Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63(6):656</li>
<li>[PubMed 18477279</li>
<li>Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179(3):172. [PubMed 12885276</li>
<li>Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron. 2002;90(2):234</li>
<li>[PubMed 11818715</li>
<li>Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009;2009. [PubMed 21931583</li>
<li>Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum Mal Osteoartic. 1992;59(4):281</li>
<li>(Article in French) [PubMed 1496277</li>
<li>Collidge TA, Razvi S, Nolan C, et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barre syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med. 2010;27(6):696-700. [PubMed 20546290</li>
<li>Kearney S, Carr AS, McConville J, McCarron MO, Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ. 2012;345:e6562. [PubMed 23047962</li>
<li>O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325</li>
<li>[PubMed 18644925</li>
<li>Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka EAcute rhabdomyolysis after atorvastatin and fusidic acid therapyAm J Med2000;109(1)</li>
<li>[PubMed 10991749</li>
<li>Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33</li>
<li>Xelenta (lefamulin) [prescribing information]. Ireland: Nabriva Therapeutics US, Inc.; August 2019.</li>
<li>Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213-1217. [PubMed 21732066</li>
<li>Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46(8):722-730. [PubMed 2665687</li>
<li>Orap (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon VRisk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugsJ Clin Psychopharmacol2017;37(5):540-545[PubMed 28817488</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2019</li>
<li>Panos G, Velissaris D, Karamouzos V, Matzaroglou C, Tylianakis M. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295-300. [PubMed 27125217</li>
<li>Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. [PubMed 20297862</li>
<li>Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355-2358. [PubMed 28475803</li>
<li>Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301-311. [PubMed 19646076</li>
<li>Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726-1734. [PubMed 16705579]</li>
<li>van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-1014. [PubMed 20925438</li>
<li>Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421-424. [PubMed 25828198</li>
<li>Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888. [PubMed 20652862</li>
<li>Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663-666. [PubMed 18589449</li>
<li>Vieira MC, Miyague NI, Van Steen K, et al. Effects of domperidone on QTc interval in infants. Acta Paediatr. 2012;101(5):494-496. [PubMed 22226330</li>
<li>Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-723. [PubMed 15690231</li>
<li>Digby G, Machaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17(2):184-188. [PubMed 20544619</li>
<li>Fais P, Vermiglio E, Laposata C, et al. A case of sudden cardiac death following Domperidone self-medication. Forensic Sci Int. 2015;254:e1-e3. [PubMed 26119456</li>
<li>Domperidone [product monograph]Toronto, Ontario, Canada: Apotex Inc; March 2015</li>
<li>Xalkori (crizotinib) [prescribing information]. New York, NY: Pfizer Inc; March 2016</li>
<li>Kisqali (ribociclib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2017</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2018</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et alDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes2013;6(4):479-487[PubMed 23716032</li>
<li>Rocha CM, Barbosa MMQT interval prolongation associated with the oral use of domperidone in an infantPediatr Cardiol2005;26(5):720-723[PubMed 15690231</li>
<li>Romero J, Baldinger SH, Goodman-Meza D, et al. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol. 2016;45(1):37-45. [PubMed 26589717</li>
<li>Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. 2012;52(4):520-529. [PubMed 21558456</li>
<li>Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk AClarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reportsTher Adv Infect Dis2013;1(4):121-138[PubMed 25165548</li>
<li>Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2017</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019</li>
<li>Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204. [PubMed 20673553</li>
<li>Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. [PubMed 16317317</li>
<li>Meyer-MassettiC, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et alThe FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med2010;5(4):E8-16[PubMed 20394022</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketin analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon VDevelopment of a risk score for QTc-prolongation: the RISQ-PATH studyInt J Clin Pharm2017;39(2):424-432[PubMed 28281228</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsaes de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Parlodel (bromocriptine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; July 2021</li>
<li>Bromocriptine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.</li>
<li>Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2019</li>
<li>Sangana R, Gu H, Chun DY, Einolf HJ. Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches. Drug Metab Dispos. 2018;46(1):26-32. [PubMed 29038231]</li>
<li>Devandla A, Yamsani SK, Yamsani MR. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers. Drug Metab Pers Ther. 2015;30(4):257-261. [PubMed 26353177]</li>
<li>Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287</li>
<li>Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E16. [PubMed 20394022</li>
<li>Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262-268. [PubMed 15231861</li>
<li>Kitagawa K, Kawada K, Morita S, et al. Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 2012;23(3):743-747. [PubMed 21690231</li>
<li>Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16(11):3019-3027. [PubMed 20501625</li>
<li>Kim H-H, An SH, Cho YH, Kim S-Y, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013;52(6):1223-1224. [PubMed 23368679</li>
<li>Chung LW, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156-157. [PubMed 18618340</li>
<li>Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. [PubMed 20529041</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJThe FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med2010;5(4):E8-E16[PubMed 20394022</li>
<li>Product monograph. Dom-Domperidone (domperidone). Montreal, Quebec, Canada: Dominion Pharmaceutical, May 2012.</li>
<li>Min JJ, Lee J, Lee H-C, Ryu H-G, Shin M, Kim HJ. A comparison of the effects of sevoflurane and desflurane on corrected QT interval prolongation in patients undergoing living donor liver transplantation: a prospective observational study. Transplant Proc. 2016;48(1):96-101. [PubMed 26915850</li>
<li>Bestas A, Hanbeyoglu O, Keles E, Bayar MK. The effect of adrenaline on desflurane-induced prolonged QTc interval: a randomized double-blind trial. Eur Rev Med Pharmacol Sci. 2013;17(11):1523-1528. [PubMed 23771541</li>
<li>Liu Y, Fu X, Gao H, Ren Y, Li H, He Y, Wang G. Effects of different concentrations of desflurane on the index of cardiac electrophysiological balance in gynecologic surgery patients. Can J Physiol Pharmacol. 2020;98(5):332-335. [PubMed 31770012</li>
<li>Aypar E, Karagoz AH, Ozer S, Celiker A, Ocal T. The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac rhythm in children. Paediatr Anaesth. 2007;17(6):563-567. [PubMed 17498019</li>
<li>Owczuk R, Wujtewicz MA, Sawicka W,Lasek J, Wujtewicz M. The influence of desflurane on QTc interval. Anesth Analg. 2005;101(2):419-422. [PubMed 16037155</li>
<li>Lindgren L, Saarnivaara L. Cardiovascular responses to enflurane induction followed by suxamethonium in children. Br J Anaesth. 1983;55(4):269-273. [PubMed 6838741</li>
<li>Lindgren L. E.C.G. changes during halothane and enflurane anaesthesia for E.N.T. surgery in children. Br J Anaesth. 1981;53(6):653-662. [PubMed 7248128</li>
<li>Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol. 2001;67(9):637-640. [PubMed 11731753</li>
<li>Kuenszberg E, Loeckinger A, Kleinsasser A, Lindner KH, Peuhringer F, Hoermann CSevoflurane progressively prolongs the QT interval in unpremedicated female adultsEur J Anaesthesiol2000;17(11):662-664[PubMed 11029563</li>
<li>Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, Lindner KH, Peuhringer F. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg. 2000;90(1):25-27. [PubMed 10624970</li>
<li>Silay E, Kati I, Tekin M, Guler N, Huseyinoglu UA, Coskuner I, Yagmur C. Comparison of the effects of desflurane and sevoflurane on the QTc interval and QT dispersion. Acta Cardiol. 2005;60(5):459-464. [PubMed 16261774</li>
<li>Thiruvenkatarajan V, Osborn KD, Van Wijk RMAW, Euler P, Sethi R, Moodie S, Biradar V. Torsade de pointes in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia. Anaesth Intensive Care. 2010;38(3):555-559. [PubMed 20514968</li>
<li>Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg. 1998;86(4):701-702. [PubMed 9539586</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E[PubMed 20394022</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 220664]</li>
<li>L’Hommedieu CS, Nicholas D, Armes DA, et al, “Potentiation of Magnesium Sulfate-Induced Neuromuscular Weakness by Gentamicin, Tobramycin, and Amikacin,” J Pediatr, 1983, 102(4):629-31. [PubMed 6834204]</li>
<li>Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994;38(2):326-329. [PubMed 7910724</li>
<li>Nix DE, Watson WA, Handy L, et al. The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin. Pharmacotherapy. 1989;9(6):377-380. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum. Antimicrob Agents Chemother. 1990;34:931-933. [PubMed 2360833</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al. Combined Use of Ciprofloxacin and Sucralfate. DICP. 1991;25:578-582. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin Levels When Receiving Sucralfate. JAMA. 1989;262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin. Antimicrob Agents Chemother. 1989;33(1):99-102. [PubMed 2712548</li>
<li>Lehto PL, Kivisto KT. Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin. Antimicrob Agents Chemother. 1994;38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al. Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers. Antimicrob Agents Chemother. 1992;36:2785-2760. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al. The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers. Eur J Clin Pharmacol. 1994;47(1):67-69. [PubMed 7988627</li>
<li>Zix JAPharmacokinetics of Sparfloxacin and Interaction With Cisapride and SucralfateAntimicrob Agents Chemother1997;41:1668-1672[PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al. The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin. Br J Clin Pharmacol. 2000;49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al. The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers. Int J Antimicrob Agents. 2000;15(4):283-289. [PubMed 10929878</li>
<li>Stass H, Schuhly U, Moller JG, et al. Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, A Novel 8-methoxyfluoroquinolone, in Healthy Volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):49-55. [PubMed 11352442</li>
<li>Lehto PL, Kivisto KT. Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate absorption. DICP. 1991;25(7-8):745-746. [PubMed 1949932</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; June 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed [March 6, 2020].</li>
<li>Furosemide tablets [prescribing information]. Somerset, NJ: Solco Healthcare US, LLC: April 2020.</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ., 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205[PubMed 3011882</li>
<li>Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed). 1983;286(6375):1379-1381. [PubMed 6404468</li>
<li>Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis. 1989;13(3):194-199. [PubMed 2919600</li>
<li>Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int. 1990;47(5):291-295. [PubMed 2257522</li>
<li>Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. Nutr Clin Pract. 1991;6(5):199-201. [PubMed 1775116</li>
<li>Spivey JM, Cummings DM, Pierson NR, “Failure of Prostatitis Treatment Secondary to Probable Ciprofloxacin-Sucralfate Drug Interaction,” Pharmacotherapy, 1996, 16(2):314</li>
<li>[PubMed 8820479</li>
<li>Nix DE, Watson WA, Handy L, et al, “The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin,” Pharmacotherapy, 1989, 9(6):377-80. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al, “Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum,” Antimicrob Agents Chemother, 1990, 34:931</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al, “Combined Use of Ciprofloxacin and Sucralfate,” DICP, 1991, 25:578-82. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, and Quintiliani R, “Ciprofloxacin Levels When Receiving Sucralfate,” JAMA, 1989, 262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al, “Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin,” Antimicrob Agents Chemother, 1989, 33(1):99-102. [PubMed 2712548</li>
<li>Lehto P and Kivisto KT, “Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin,” Antimicrob Agents Chemother, 1994, 38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al, “Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers,” Antimicrob Agents Chemother, 1992, 36:2785-60. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al, “The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers,” Eur J Clin Pharmacol, 1994, 47(1):67</li>
<li>Zix JA, “Pharmacokinetics of Sparfloxacin and Interaction With Cisapride and Sucralfate,” Antimicrob Agents Chemother, 1997, 41:1668-72. [PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al, “The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin,” Br J Clin Pharmacol, 2000, 49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al, “The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers,” Int J Antimicrob Agents, 2000, 15(4):283</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of helicobacter pylori. Chem Pharm Bull (Tokyo). 2008;56(10):1412-1416. [PubMed 18827380</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. The acidic complexation of tetracycline with sucralfate for its mucoadhesive preparation. Drug Dev Ind Pharm. 2004;30(7):715-724. [PubMed 15491049</li>
<li>Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol Suppl. 1995;210:82-844. [PubMed 8578215]</li>
<li>Urso Forte (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; June 2013</li>
<li>Sucralfate [prescribing information]. Largo, FL: VistaPharm, Inc.; February 2020</li>
<li>Dovonex (calcipotriene) cream [prescribing information]Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]. Greenville, NC: Mayne Pharma; May 2019</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845]</li>
<li>Havrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med. 1992;117(5):445-446. [PubMed 1503346</li>
<li>Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994;96(6):531-535. [PubMed 8017451</li>
<li>Khan F, Jeanniton E, Renedo M. Does sucralfate impede levothyroxine therapy? Ann Intern Med. 1993;118(4):317. [PubMed 8481187</li>
<li>Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. Ann Intern Med. 1994;121(2):152. [PubMed 8017736</li>
<li>Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2020.</li>
<li>Smart HL, Somerville KW, Williams J, Richens A, Langman MJ. The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol. 1985;20(3):238-240. [PubMed 3840029</li>
<li>Hall TG, Cuddy PG, Glass CJ, Melethil S. Effect of sucralfate on phenytoin bioavailability. Drug Intell Clin Pharm. 1986;20(7-8):607-611. [PubMed 3755676</li>
<li>Malli R, Jones WN, Rindone JP, Labadie EL. The effect of sucralfate on the steady-state serum concentrations of phenytoin. Drug Metabol Drug Interact. 1989;7(4):287-293. [PubMed 2489199</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2022.</li>
<li>Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin. Ann Intern Med. 1983;98(4):557. [PubMed 6687662</li>
<li>Braverman SE, Marino MT. Sucralfate-warfarin interaction. Drug Intell Clin Pharm. 1988;22:913. [PubMed 3234259</li>
<li>Parrish RH, Waller B, Gondalia BG. Sucralfate-warfarin interaction. Ann Pharmacother. 1992;26:1015-1016. [PubMed 1504385</li>
<li>Neuvonen PJ, Jaakkola A, Totterman J, Penttila O. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol. 1985;20(2):178-179. [PubMed 3840028</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med. 1989;86(6A):38-44. [PubMed 2735334</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med. 1987;83(3B):67-73. [PubMed 3661612</li>
<li>Caille G, du Souich P, Gervais P, Besner JG. Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharm Drug Dispos. 1987;8(2):173-183. [PubMed 3593897</li>
<li>Lafontaine D, Mailhot C, Vermeulen M, Bissonnette B, Lambert C. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm. 1990;9(10):773-777. [PubMed 2242657</li>
<li>Crysvita (burosumab-twza) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; September 2019.</li>
<li>Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010</li>
<li>Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004</li>
<li>Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010</li>
<li>Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007</li>
<li>Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010</li>
<li>Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</li>
<li>One-Alpha (alfacalcidol) oral drops [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories; July 2020</li>
<li>Rocaltrol (calcitriol) oral solution [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019.</li>
<li>Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2(1):10-32. [PubMed 3547004</li>
<li>West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975;16(2):93-98. [PubMed 1168607</li>
<li>Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut. 1969;10(9):717-722. [PubMed 4318526</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Welchol (colesevelam) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; June 2013</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010</li>
<li>Rocaltrol (calcitriol) [prescribing information. Parisppany, NJ: Validus Pharmaceuticals LLC; July 2009</li>
<li>Rayaldee (calcifediol) [prescribing information]Miami, FL: OPKO Pharmaceuticals LLC; June 2016</li>
<li>Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. Gastroenterology. 1972;62(4):642-646. [PubMed 5020877</li>
<li>Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology. 1978;74(5 pt 1):900-902. [PubMed 640344</li>
<li>Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. Dig Dis Sci. 1985;30(5):477-482. [PubMed 3987479</li>
<li>Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427-430. [PubMed 2125243</li>
<li>Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med. 1992;119(4):407-411. [PubMed 1583392</li>
<li>Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980;65(2):243-250. [PubMed 7354970]</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2011</li>
<li>Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2007</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario:LEO Pharma Inc.; March 2010.</li>
<li>Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015</li>
<li>Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36(7):647-653. [PubMed 8844448</li>
<li>Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306-313. [PubMed 10757623</li>
<li>McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-822. [PubMed 12126214]</li>
<li>Vella A, Gerber TC, Hayes DL, et al. Digoxin, hypercalcemia, and cardiac conduction. Postgrad Med J. 1999;75:554-556. [PubMed 10616693</li>
<li>Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. [PubMed 22998989</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018.</li>
<li>Formosa N, Torpiano J, Allgrove J, Dattani MT. Anticonvulsant treatment associated with intractable hypocalcaemia in a female child with hypoparathyroidism. Horm Res Paediatr. 2015;83(1):62-66. [PubMed 25227206</li>
<li>Rubinger D, Korn-Lubetzki I, Feldman S, Popovtzer MM. Delayed response to a alpha-hydroxycholecalciferol therapy in a case of hypoparathyroidism during anticonvulsant therapy. Isr J Med Sci. 1980;16(11);772-774. [PubMed 7440128</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc; August 2017.</li>
<li>Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011</li>
<li>Hepburn NC, Abdul-Aziz LA and Whiteoak R, “Danazol-Induced Hypercalcaemia in Alphacalcidol-Treated Hypoparathyroidism,” Postgrad Med J, 1989, 65(769):849-50. [PubMed 2616424]</li>
<li>Lemann J, Jr., Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28:951-958. [PubMed 3003445</li>
<li>Santos F, Smith MJ,Chan JC. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. Am J Dis Child. 1986;140:139-142. [PubMed 3753816</li>
<li>Brickman AS, Massry SG,Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms. J Clin Invest. 1972;51:945-954. [PubMed 4552338</li>
<li>Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res. 2006;38:821-826. [PubMed 17163358</li>
<li>Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12:531-535. [PubMed 2592738</li>
<li>Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250:144-153. [PubMed 11489064</li>
<li>Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34:421-424. [PubMed 3887100</li>
<li>Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33:1140-1146. [PubMed 3404813</li>
<li>Nowack R, Hofner MC, Reichel H, et alSubacute effects of thiazide administration on renal hemodynamics and calcium metabolismClin Investig1992;70:686-691[PubMed 1392446</li>
<li>Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50. [PubMed 12492451</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019.</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201-2. doi: 10.4212/cjhp.v66i3.1261. PMID: 23814291; PMCID: PMC3694945.Ы</li>
              </ol>
            </div>
          </div>
        </div>
      </section>
    </div>

    <div class="controle-test" id="controle-test-page">
      <section class="controle-test__section">
        <div class="controle-test__container">
          <div class="controle-test__card">
            <div class="controle-test-header">
              <div class="controle-test-header__top">
                <div
                  id="controle-test-header-label"
                  class="controle-test-header__label"
                >
                  Шаг 1: Уточняющие вопросы
                </div>
                <div
                  id="controle-test-header-percent"
                  class="controle-test-header__percent"
                >
                  30%
                </div>
                <div
                  id="controle-test-header-progress-bar"
                  class="controle-test-header__bar controle-test-bar"
                >
                  <span
                    style="width: 30%"
                    class="controle-test-bar__span"
                  ></span>
                </div>
              </div>
              <button class="controle-test-header__back-btn btn-reset">
                Назад
              </button>
            </div>

            <div class="controle-test-content">
              <div
                id="controle-slide-1"
                class="controle-test-content__slide controle-test-content__slide--active"
              >
                <div class="controle-test-content__header">
                  <h2 class="controle-test-content__title title-reset">
                    контроль терапии
                  </h2>
                  <h3 class="controle-test-content__subtitle title-reset">
                    Есть ли у пациента результаты контрольного исследования
                    ЭГДС?
                  </h3>
                </div>
                <div class="controle-test-content__main">
                  <ul class="controle-test-buttons list-reset">
                    <li class="controle-test-buttons__item">
                      <input
                        type="radio"
                        id="controle-test-buttons-slide-1-1"
                        name="controle-test-buttons-slide-1"
                        class="controle-test-buttons__input"
                      />
                      <label
                        for="controle-test-buttons-slide-1-1"
                        class="controle-test-buttons__label"
                        >Да</label
                      >
                    </li>
                    <li class="controle-test-buttons__item">
                      <input
                        type="radio"
                        id="controle-test-buttons-slide-1-2"
                        name="controle-test-buttons-slide-1"
                        class="controle-test-buttons__input"
                      />
                      <label
                        for="controle-test-buttons-slide-1-2"
                        class="controle-test-buttons__label"
                        >Нет</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="controle-slide-2" class="controle-test-content__slide">
                <div class="controle-test-content__header">
                  <h2 class="controle-test-content__title title-reset">
                    контроль терапии
                  </h2>
                  <h3 class="controle-test-content__subtitle title-reset">
                    Выраженное улучшение состояния на повторной ЭГДС
                  </h3>
                </div>
                <div class="controle-test-content__main">
                  <ul class="controle-test-buttons list-reset">
                    <li class="controle-test-buttons__item">
                      <input
                        type="radio"
                        id="controle-test-buttons-slide-2-1"
                        name="controle-test-buttons-slide-2"
                        class="controle-test-buttons__input"
                      />
                      <label
                        for="controle-test-buttons-slide-2-1"
                        class="controle-test-buttons__label"
                        >Да</label
                      >
                    </li>
                    <li class="controle-test-buttons__item">
                      <input
                        type="radio"
                        id="controle-test-buttons-slide-2-2"
                        name="controle-test-buttons-slide-2"
                        class="controle-test-buttons__input"
                      />
                      <label
                        for="controle-test-buttons-slide-2-2"
                        class="controle-test-buttons__label"
                        >Нет</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="controle-slide-3" class="controle-test-content__slide">
                <div class="controle-test-content__header">
                  <h2 class="controle-test-content__title title-reset">
                    контроль терапии
                  </h2>
                  <h3 class="controle-test-content__subtitle title-reset">
                    Длительность ранее проведенной терапии составляла менее 8-ми
                    недель?
                  </h3>
                </div>
                <div class="controle-test-content__main">
                  <ul class="controle-test-buttons list-reset">
                    <li class="controle-test-buttons__item">
                      <input
                        type="radio"
                        id="controle-test-buttons-slide-3-1"
                        name="controle-test-buttons-slide-3"
                        class="controle-test-buttons__input"
                      />
                      <label
                        for="controle-test-buttons-slide-3-1"
                        class="controle-test-buttons__label"
                        >Да</label
                      >
                    </li>
                    <li class="controle-test-buttons__item">
                      <input
                        type="radio"
                        id="controle-test-buttons-slide-3-2"
                        name="controle-test-buttons-slide-3"
                        class="controle-test-buttons__input"
                      />
                      <label
                        for="controle-test-buttons-slide-3-2"
                        class="controle-test-buttons__label"
                        >Нет</label
                      >
                    </li>
                  </ul>
                </div>
              </div>

              <div id="slide-gerbq-test" class="controle-test-content__slide">
                <div class="controle-test-content__header">
                  <h2 class="controle-test-content__title title-reset">
                    ТЕСТ gerd Q
                  </h2>
                </div>
                <p
                  class="controle-test-content__text controle-test-content__text_test"
                >
                  За последнюю неделю:
                </p>

                <div
                  class="calculator-slide calculator-slide--columns calculator-slide--test"
                >
                  <div class="calculator-slide-column">
                    <div class="question-item">
                      <div class="question-item__label" data-counter="1.">
                        Как часто пациент ощущал изжогу (чувство жжения за
                        грудиной)?
                      </div>

                      <div class="question-item__buttons hide-on-mobile">
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="1"
                          data-points="0"
                        >
                          0 дней
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="1"
                          data-points="1"
                        >
                          1 день
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="1"
                          data-points="2"
                        >
                          2-3 дня
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="1"
                          data-points="3"
                        >
                          4-7 дней
                        </button>
                      </div>

                      <div class="question-item__selects show-on-mobile">
                        <div class="abbott-test-select abbott-test-select--closed">
                          <div
                            data-default="Выберите ответ"
                            class="abbott-test-select__selected"
                          >
                            <span>Выберите ответ</span>
                          </div>
                          <div class="abbott-test-select__select">
                            <div class="abbott-test-select__wrap">
                              <button
                                data-text="0 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="1"
                                data-points="0"
                              >
                                <span>0 дней</span>
                              </button>
                              <button
                                data-text="1 день"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="1"
                                data-points="1"
                              >
                                <span>1 день</span>
                              </button>
                              <button
                                data-text="2-3 дня"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="1"
                                data-points="2"
                              >
                                <span>2-3 дня</span>
                              </button>
                              <button
                                data-text="4-7 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="1"
                                data-points="3"
                              >
                                <span>4-7 дней</span>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                      <input type="hidden" class="question-item__input" />
                    </div>

                    <div class="question-item">
                      <div class="question-item__label" data-counter="2.">
                        Как часто пациент отмечал, что содержимое желудка
                        (жидкость либо пища) снова попадает в глотку или полость
                        рта (отрыжка)?
                      </div>
                      <div class="question-item__buttons hide-on-mobile">
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="2"
                          data-points="0"
                        >
                          0 дней
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="2"
                          data-points="1"
                        >
                          1 день
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="2"
                          data-points="2"
                        >
                          2-3 дня
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="2"
                          data-points="3"
                        >
                          4-7 дней
                        </button>
                      </div>
                      <div class="question-item__selects show-on-mobile">
                        <div class="abbott-test-select abbott-test-select--closed">
                          <div
                            data-default="Выберите ответ"
                            class="abbott-test-select__selected"
                          >
                            <span>Выберите ответ</span>
                          </div>
                          <div class="abbott-test-select__select">
                            <div class="abbott-test-select__wrap">
                              <button
                                data-text="0 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="2"
                                data-points="0"
                              >
                                <span>0 дней</span>
                              </button>
                              <button
                                data-text="1 день"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="2"
                                data-points="1"
                              >
                                <span>1 день</span>
                              </button>
                              <button
                                data-text="2-3 дня"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="2"
                                data-points="2"
                              >
                                <span>2-3 дня</span>
                              </button>
                              <button
                                data-text="4-7 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="2"
                                data-points="3"
                              >
                                <span>4-7 дней</span>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                      <input type="hidden" class="question-item__input" />
                    </div>

                    <div class="question-item">
                      <div class="question-item__label" data-counter="3.">
                        Как часто пациент ощущал боль в центре верхней части
                        живота?
                      </div>
                      <div class="question-item__buttons hide-on-mobile">
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="3"
                          data-points="0"
                        >
                          0 дней
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="3"
                          data-points="1"
                        >
                          1 день
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="3"
                          data-points="1"
                        >
                          2-3 дня
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="3"
                          data-points="1"
                        >
                          4-7 дней
                        </button>
                      </div>
                      <div class="question-item__selects show-on-mobile">
                        <div class="abbott-test-select abbott-test-select--closed">
                          <div
                            data-default="Выберите ответ"
                            class="abbott-test-select__selected"
                          >
                            <span>Выберите ответ</span>
                          </div>
                          <div class="abbott-test-select__select">
                            <div class="abbott-test-select__wrap">
                              <button
                                data-text="0 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="3"
                                data-points="0"
                              >
                                <span>0 дней</span>
                              </button>
                              <button
                                data-text="1 день"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="3"
                                data-points="1"
                              >
                                <span>1 день</span>
                              </button>
                              <button
                                data-text="2-3 дня"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="3"
                                data-points="1"
                              >
                                <span>2-3 дня</span>
                              </button>
                              <button
                                data-text="4-7 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="3"
                                data-points="1"
                              >
                                <span>4-7 дней</span>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                      <input type="hidden" class="question-item__input" />
                    </div>
                  </div>

                  <div class="calculator-slide-column">
                    <div class="question-item">
                      <div class="question-item__label" data-counter="4.">
                        Как часто пациент ощущал тошноту?
                      </div>
                      <div class="question-item__buttons hide-on-mobile">
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="4"
                          data-points="0"
                        >
                          0 дней
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="4"
                          data-points="1"
                        >
                          1 день
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="4"
                          data-points="1"
                        >
                          2-3 дня
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="4"
                          data-points="1"
                        >
                          4-7 дней
                        </button>
                      </div>
                      <div class="question-item__selects show-on-mobile">
                        <div class="abbott-test-select abbott-test-select--closed">
                          <div
                            data-default="Выберите ответ"
                            class="abbott-test-select__selected"
                          >
                            <span>Выберите ответ</span>
                          </div>
                          <div class="abbott-test-select__select">
                            <div class="abbott-test-select__wrap">
                              <button
                                data-text="0 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="4"
                                data-points="0"
                              >
                                <span>0 дней</span>
                              </button>
                              <button
                                data-text="1 день"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="4"
                                data-points="1"
                              >
                                <span>1 день</span>
                              </button>
                              <button
                                data-text="2-3 дня"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="4"
                                data-points="1"
                              >
                                <span>2-3 дня</span>
                              </button>
                              <button
                                data-text="4-7 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="4"
                                data-points="1"
                              >
                                <span>4-7 дней</span>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                      <input type="hidden" class="question-item__input" />
                    </div>

                    <div class="question-item">
                      <div class="question-item__label" data-counter="5.">
                        Как часто изжога и/или отрыжка мешали пациенту хорошо
                        выспаться ночью?
                      </div>
                      <div class="question-item__buttons hide-on-mobile">
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="5"
                          data-points="0"
                        >
                          0 дней
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="5"
                          data-points="1"
                        >
                          1 день
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="5"
                          data-points="2"
                        >
                          2-3 дня
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="5"
                          data-points="3"
                        >
                          4-7 дней
                        </button>
                      </div>
                      <div class="question-item__selects show-on-mobile">
                        <div class="abbott-test-select abbott-test-select--closed">
                          <div
                            data-default="Выберите ответ"
                            class="abbott-test-select__selected"
                          >
                            <span>Выберите ответ</span>
                          </div>
                          <div class="abbott-test-select__select">
                            <div class="abbott-test-select__wrap">
                              <button
                                data-text="0 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="5"
                                data-points="0"
                              >
                                <span>0 дней</span>
                              </button>
                              <button
                                data-text="1 день"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="5"
                                data-points="1"
                              >
                                <span>1 день</span>
                              </button>
                              <button
                                data-text="2-3 дня"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="5"
                                data-points="2"
                              >
                                <span>2-3 дня</span>
                              </button>
                              <button
                                data-text="4-7 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="5"
                                data-points="3"
                              >
                                <span>4-7 дней</span>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                      <input type="hidden" class="question-item__input" />
                    </div>

                    <div class="question-item">
                      <div class="question-item__label" data-counter="6.">
                        Как часто по поводу изжоги и/или отрыжки пациент
                        дополнительно принимал другие средства (антациды,
                        альгинаты, пищевую соду), кроме рекомендованных врачом?
                      </div>
                      <div class="question-item__buttons hide-on-mobile">
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="6"
                          data-points="0"
                        >
                          0 дней
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="6"
                          data-points="1"
                        >
                          1 день
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="6"
                          data-points="2"
                        >
                          2-3 дня
                        </button>
                        <button
                          class="question-button btn-reset answer-js"
                          data-question="6"
                          data-points="3"
                        >
                          4-7 дней
                        </button>
                      </div>
                      <div class="question-item__selects show-on-mobile">
                        <div class="abbott-test-select select--closed">
                          <div
                            data-default="Выберите ответ"
                            class="abbott-test-select__selected"
                          >
                            <span>Выберите ответ</span>
                          </div>
                          <div class="abbott-test-select__select">
                            <div class="abbott-test-select__wrap">
                              <button
                                data-text="0 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="6"
                                data-points="0"
                              >
                                <span>0 дней</span>
                              </button>
                              <button
                                data-text="1 день"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="6"
                                data-points="1"
                              >
                                <span>1 день</span>
                              </button>
                              <button
                                data-text="2-3 дня"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="6"
                                data-points="2"
                              >
                                <span>2-3 дня</span>
                              </button>
                              <button
                                data-text="4-7 дней"
                                class="abbott-test-select__option btn-reset answer-js"
                                data-question="6"
                                data-points="3"
                              >
                                <span>4-7 дней</span>
                              </button>
                            </div>
                          </div>
                        </div>
                      </div>
                      <input type="hidden" class="question-item__input" />
                    </div>
                  </div>
                </div>
              </div>

              <div
                id="result-continue-course"
                class="controle-test-content__slide"
              >
                <div class="controle-test-content__header">
                  <h2 class="controle-test-content__title title-reset">
                    Результаты лечения
                  </h2>
                </div>
                <div class="controle-test-content__main">
                  <div
                    class="controle-test-diagnosis controle-test-diagnosis_alone"
                  >
                    <span class="controle-test-diagnosis__text"
                      >Рекомендуется продолжение курса ранее проводимой терапии
                      до общего срока в 8 недель</span
                    >
                  </div>
                </div>
                <a
                  href="/cdss/"
                  class="controle-test-content__link controle-test-content__link_end controle-test-content__link_white"
                >
                  Закончить прием
                </a>
              </div>

              <div
                id="result-gerd-refractory-current"
                class="controle-test-content__slide controle-test-content__slide--columns"
              >
                <div class="controle-test-content__column">
                  <div class="controle-test-content__header">
                    <h2 class="controle-test-content__title title-reset">
                      Вероятный диагноз
                    </h2>
                  </div>

                  <div
                    class="controle-test-diagnosis controle-test-diagnosis_row"
                  >
                    <span class="controle-test-diagnosis__text">ГЭРБ</span>
                    <span
                      class="controle-test-diagnosis__text controle-test-diagnosis__text_grade"
                      >рефрактерное течение</span
                    >
                  </div>

                  <div class="controle-test-recommendations">
                    <p class="controle-test-recommendations__text">
                      Последовательность действий по преодолению рефрактерности
                      в лечении ГЭРБ может включать в себя, но не ограничиваться
                      следующими рекомендациями:
                    </p>
                    <ol class="controle-test-recommendations__list">
                      <li class="controle-test-recommendations__elem">
                        Обсудить с пациентом и удостовериться в том, что все
                        ранее данные рекомендации по приему лекарственных
                        препаратов и изменению образа жизни соблюдались и
                        выполнялись
                      </li>
                      <li class="controle-test-recommendations__elem">
                        Рассмотреть вопрос о повторном проведении ЭГДС для
                        исключения осложнений ГЭРБ (пищевод Барретта, наличие
                        стриктур пищевода) и онкологических заболеваний (АКП)
                      </li>
                      <li class="controle-test-recommendations__elem">
                        Назначение пациенту другого ИПП или перевод его на схему
                        приема дважды в день (утром и вечером) на срок до 2
                        месяцев
                      </li>
                    </ol>
                  </div>
                </div>

                <div
                  class="controle-test-content__column controle-test-content__column_border-left"
                >
                  <div class="controle-test-content__header">
                    <h2 class="controle-test-content__title title-reset">
                      Терапия
                    </h2>
                  </div>

                  <div class="controle-test-recommendations">
                    <p class="controle-test-recommendations__text">
                      <span class="controle-test-recommendations__span">
                        В случае, если в медицинском учреждении имеется
                        необходимое оборудование, рекомендуется повторное
                        проведение pH-импедансометрии с ИПП и проверка
                        эффективности ИПП.
                      </span>
                    </p>
                    <p class="controle-test-recommendations__text">
                      Возможные находки на pH-импедансометрии включают в себя:
                    </p>
                    <ol
                      class="controle-test-recommendations__list controle-test-recommendations__list_outer"
                    >
                      <li class="controle-test-recommendations__elem">
                        Отсутствие выраженных нарушений.
                        <p class="controle-test-recommendations__text">
                          В этом случае пациенту рекомендуется консультация
                          психиатра и возможное назначение препаратов,
                          купирующих болевой синдром и жжение
                        </p>
                      </li>
                      <li class="controle-test-recommendations__elem">
                        Наличие кислотных рефлюксов, несмотря на проводимую
                        терапию ИПП.
                        <p class="controle-test-recommendations__text">
                          В этом случае рекомендуется еще раз удостовериться в
                          правильном приеме пациентом назначенного лечения ИПП.
                          Если все рекомендации выполняются верно, можно
                          рассмотреть возможность:
                        </p>
                        <ul
                          class="controle-test-recommendations__list controle-test-recommendations__list_inner"
                        >
                          <li class="controle-test-recommendations__elem">
                            замены принимаемого препарата в рамках группы ИПП
                          </li>
                          <li class="controle-test-recommendations__elem">
                            добавления к проводимой ИПП-терапии приема
                            блокаторов H2-гистаминовых рецепторов на ночь
                          </li>
                          <li class="controle-test-recommendations__elem">
                            хирургического лечения*
                          </li>
                          <li class="controle-test-recommendations__elem">
                            эндоскопического лечения (метод Стретта или
                            трансоральная фундопликация)
                          </li>
                        </ul>
                      </li>
                      <li class="controle-test-recommendations__elem">
                        Наличие слабокислых рефлюксов.
                        <p class="controle-test-recommendations__text">
                          В этом случае можно рассмотреть возможность
                          назначения:
                        </p>
                        <ul
                          class="controle-test-recommendations__list controle-test-recommendations__list_inner"
                        >
                          <li class="controle-test-recommendations__elem">
                            препаратов, снижающих количество преходящего
                            расслабления НПС (итоприда гидрохлорид)
                          </li>
                          <li class="controle-test-recommendations__elem">
                            препаратов урсодезоксихолиевой кислоты (УДХК)
                          </li>
                          <li class="controle-test-recommendations__elem">
                            препаратов, купирующих болевой синдром
                          </li>
                          <li class="controle-test-recommendations__elem">
                            хирургического лечения*
                          </li>
                          <li class="controle-test-recommendations__elem">
                            эндоскопического лечения (метод Стретта или
                            трансоральная фундопликация)
                          </li>
                        </ul>
                      </li>
                    </ol>
                    <p class="controle-test-recommendations__text">
                      <span class="controle-test-recommendations__span">
                        В случае, если в медицинском учреждении ОТСУТСТВУЕТ
                        необходимое для проведения pH-импедансометрии
                        оборудование,
                      </span>
                      пациенту можно рекомендовать следующие опции терапии:
                    </p>
                    <ul class="controle-test-recommendations__list">
                      <li class="controle-test-recommendations__elem">
                        Назначение итоприда гидрохлорида, если не назначался
                        ранее
                      </li>
                      <li class="controle-test-recommendations__elem">
                        У пациентов, основной жалобой которых является изжога,
                        можно рассмотреть добавление к проводимой ИПП-терапии
                        приема блокаторов H2-гистаминовых рецепторов на ночь (с
                        перерывами между курсами, чтобы избежать развития
                        тахифилаксии)
                      </li>
                      <li class="controle-test-recommendations__elem">
                        В случае, если это не оказывает должного эффекта, можно
                        рассмотреть назначение пациенту препаратов, купирующих
                        болевой синдром
                      </li>
                    </ul>
                    <p
                      class="controle-test-recommendations__text controle-test-recommendations__text_explanaton"
                    >
                      *Хирургическое лечение не показано пациентам, у которых
                      наблюдается абсолютное отсутствие ответа на ранее
                      проводимую терапию ИПП
                    </p>
                  </div>

                  <button
                    class="controle-test-content__link controle-test-content__link_end controle-test-content__link_full-width btn-reset additional-research-click"
                  >
                    Результаты дополнительных исследований
                  </button>

                  <div
                    class="controle-test-content__divider controle-test-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="controle-test-content__link controle-test-content__link_end controle-test-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-recommended-cancel-therapy"
                class="controle-test-content__slide controle-test-content__slide--columns"
              >
                <div
                  class="controle-test-content__column controle-test-content__column_border-right"
                >
                  <div class="controle-test-content__header">
                    <h2 class="controle-test-content__title title-reset">
                      Результаты лечения
                    </h2>
                  </div>

                  <div
                    class="controle-test-diagnosis controle-test-diagnosis_mb20"
                  >
                    <span class="controle-test-diagnosis__text"
                      >Лечение проведено эффективно, рекомендуется отменить
                      ранее назначенную терапию</span
                    >
                  </div>

                  <div class="controle-test-content__hernia">
                    <div class="controle-test-warning__info">
                      <p class="controle-test-warning__text">
                        Для устойчивой ремиссии пациенту необходимо пожизненно
                        придерживаться советов по модификации образа жизни
                      </p>
                      <a
                        href="/cdss/pdf/Модификация образа жизни.pdf"
                        target="_blank"
                        class="controle-test-warning__link"
                        >Памятка для пациента</a
                      >
                    </div>
                  </div>
                </div>

                <div class="controle-test-content__column">
                  <div class="controle-test-content__header">
                    <h2 class="controle-test-content__title title-reset">
                      Прочее:
                    </h2>
                  </div>

                  <button
                    class="controle-test-content__link controle-test-content__link_end controle-test-content__link_full-width btn-reset additional-research-click"
                  >
                    Результаты дополнительных исследований
                  </button>

                  <div
                    class="controle-test-content__divider controle-test-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="controle-test-content__link controle-test-content__link_end controle-test-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>

              <div
                id="result-recommended-correction-therapy"
                class="controle-test-content__slide controle-test-content__slide--columns"
              >
                <div
                  class="controle-test-content__column controle-test-content__column_border-right"
                >
                  <div class="controle-test-content__header">
                    <h2 class="controle-test-content__title title-reset">
                      Результаты лечения
                    </h2>
                  </div>

                  <div
                    class="controle-test-diagnosis controle-test-diagnosis_mb20"
                  >
                    <span class="controle-test-diagnosis__text"
                      >Рекомендуется коррекция терапии</span
                    >
                  </div>

                  <h2 class="controle-test-content__title title-reset">
                    Фармакотерапия
                  </h2>

                  <div class="controle-test-recommendations">
                    <div class="controle-test-recommendations__item">
                      <div class="controle-test-recommendations__info">
                        <h3
                          class="controle-test-recommendations__title title-reset"
                        >
                          Рассмотреть возможность снижения дозы ИПП до 1/2
                          суточной дозы или перехода на режим приема ИПП «по
                          требованию»
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-6.png"
                        class="controle-test-recommendations__icon"
                        alt=""
                      />
                    </div>

                    <div class="controle-test-recommendations__item">
                      <div class="controle-test-recommendations__info">
                        <h3
                          class="controle-test-recommendations__title title-reset"
                        >
                          Купирование возникающих эпизодов ГЭРБ с помощью
                          антацидов или алгинат-содержащих препаратов
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-15.png"
                        class="controle-test-recommendations__icon"
                        alt=""
                      />
                    </div>

                    <div class="controle-test-recommendations__item">
                      <div class="controle-test-recommendations__info">
                        <h3
                          class="controle-test-recommendations__title title-reset"
                        >
                          Мониторинг в течение 4-12 недель
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-10.png"
                        class="controle-test-recommendations__icon"
                        alt=""
                      />
                    </div>

                    <div class="controle-test-recommendations__item">
                      <div class="controle-test-recommendations__info">
                        <h3
                          class="controle-test-recommendations__title title-reset"
                        >
                          Придерживаться рекомендаций по изменению образа жизни
                          и пищевого поведения
                        </h3>
                      </div>
                      <img
                        src="./img/icon-card-7.png"
                        class="controle-test-recommendations__icon"
                        alt=""
                      />
                    </div>
                  </div>
                </div>

                <div class="controle-test-content__column">
                  <div class="controle-test-warning__info">
                    <p class="controle-test-warning__text">
                      Для устойчивой ремиссии пациенту необходимо пожизненно
                      придерживаться советов по модификации образа жизни
                    </p>
                    <a
                      href="/cdss/pdf/Модификация образа жизни.pdf"
                      target="_blank"
                      class="controle-test-warning__link"
                      >Памятка для пациента</a
                    >
                  </div>

                  <div class="controle-test-warning">
                    <img
                      src="./img/warning-message.svg"
                      class="controle-test-warning__icon"
                      alt=""
                    />
                    <div class="controle-test-warning__info">
                      <p class="controle-test-warning__text">
                        Если эпизоды ГЭРБ повторяются
                        <span class="controle-test-recommendations__span"
                          >3-7 дней подряд и влияют на повседневную
                          активность,</span
                        >
                        рекомендуется возврат к ранее назначенной схеме терапии
                      </p>
                    </div>
                  </div>

                  <button
                    class="controle-test-content__link controle-test-content__link_end controle-test-content__link_full-width btn-reset additional-research-click"
                  >
                    Результаты дополнительных исследований
                  </button>

                  <div
                    class="controle-test-content__divider controle-test-content__divider_mobile"
                  ></div>

                  <a
                    href="/cdss/"
                    class="controle-test-content__link controle-test-content__link_end controle-test-content__link_white"
                  >
                    Закончить прием
                  </a>
                </div>
              </div>
            </div>

            <div class="controle-test-footer">
              <button class="controle-test-footer__btn btn-reset">
                Продолжить
              </button>
            </div>
          </div>

          <div class="controle-test__sources">
            <div class="abbott-more-sources">
              <button class="abbott-more-sources__button btn-reset">
                <span>Ключевые источники информации</span>
                <svg
                  xmlns="http://www.w3.org/2000/svg"
                  width="16"
                  height="17"
                  viewBox="0 0 16 17"
                  fill="none"
                >
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M4.89164 2.73051C5.19205 2.42487 5.67909 2.42487 5.9795 2.73051L11.1077 7.94791C11.252 8.09467 11.333 8.29373 11.333 8.5013C11.333 8.70885 11.252 8.90791 11.1077 9.05469L5.9795 14.2721C5.67909 14.5777 5.19205 14.5777 4.89164 14.2721C4.59124 13.9664 4.59124 13.4709 4.89164 13.1653L9.47593 8.5013L4.89164 3.83729C4.59124 3.53166 4.59124 3.03614 4.89164 2.73051Z"
                    fill="#009CDE"
                  ></path>
                </svg>
              </button>
              <div class="abbott-more-sources__content">
                <ol>
                <li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В., Дронова О.Б., Кучерявый Ю.А., Пирогов С.С., Сайфутдинов Р.Г., Успенский Ю.П., Шептулин А.А., Андреев Д.Н., Румянцева Д.Е. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. https://doi.org/10.22416/1382-4376-2020-30-4-70-97.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Сторонова О.А., Абдулхаков С.Р., Андреев Д.Н., Бордин Д.С., Валитова Э.Р., Кляритская И.Л., Кривой В.В., Кучерявый Ю.А., Лапина Т.Л., Морозов С.В., Саблин О.А., Семенихина Е.В., Успенский Ю.П., Шептулин А.А. Рекомендации Российской гастроэнтерологической ассоциации по клиническому применению манометрии высокого разрешения при заболеваниях пищевода. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(3):61–88. https://doi.org/10.22416/1382-4376-2020-30-3-61-88</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. Therole of esophageal testing in diagnosis and management. Gastroenterol Clin North Am1996; 25:75.</li>
<li>Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification ofgastroesophageal reflux disease: a global evidence-based consensus. Am JGastroenterol 2006; 101:1900.</li>
<li>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophagealreflux disease: a systematic review. Gut 2005; 54:710.</li>
<li>Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of uppergastrointestinal disorders in the United States: results of the US Upper GastrointestinalStudy. Clin Gastroenterol Hepatol 2005; 3:543.</li>
<li>Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.</li>
<li>Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence,severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol2004; 2:665.</li>
<li>Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to protonpump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.</li>
<li>Kwiatek MA, Mirza F, Kahrilas PJ, Pandolfino JE. Hyperdynamic upper esophagealsphincter pressure: a manometric observation in patients reporting globus sensation.Am J Gastroenterol 2009; 104:289.</li>
<li>Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea.Ann Intern Med 1997; 126:704.</li>
<li>Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.</li>
<li>DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophagealreflux disease. Practice Parameters Committee of the American College ofGastroenterology. Arch Intern Med 1995; 155:2165.</li>
<li>Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS(Ed), WB Saunders, Philadelphia 1989. p.1147.</li>
<li>Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients withgastroesophageal reflux disease: a comparison between empirical treatment withesomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.</li>
<li>Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test toidentify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360.</li>
<li>Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pumpinhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostictest characteristics. Ann Intern Med 2004; 140:518.</li>
<li>Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability andendoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313.</li>
<li>Adanir H, Baş B, Pakoz B, et al. Endoscopic Findings of Gastro-Esophageal RefluxDisease in Elderly and Younger Age Groups. Front Med (Lausanne) 2021; 8:606205.</li>
<li>Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical andfunctional correlates and further validation of the Los Angeles classification. Gut 1999;45:172.</li>
<li>Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. ClinGastroenterol Hepatol 2007; 5:4.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationMedical Position Statement on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1383.</li>
<li>Hirano I, Richter JE, Practice Parameters Committee of the American College ofGastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.</li>
<li>Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practiceguideline development. Gastroenterology 1996; 110:1982.</li>
<li>Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless andDigitrapper catheter-based pH monitoring systems for measuring esophageal acidexposure. Am J Gastroenterol 2005; 100:1466.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-refluxassociation using 4-day wireless pH recording combining 48-hour periods off and on PPItherapy. Am J Gastroenterol 2008; 103:1631.</li>
<li>Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring.J Clin Gastroenterol 2012; 46:197.</li>
<li>Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal refluxsymptoms and esophagitis with or without symptoms in the general adult Swedishpopulation: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275.</li>
<li>Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatmentof benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology1982; 82:487.</li>
<li>Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricturetreated by dilatation. Gastroenterology 1983; 85:346.</li>
<li>Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazolefor refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.</li>
<li>Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists intreating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.</li>
<li>Okwara NC, Chan WW. Sorting out the Relationship Between Esophageal andPulmonary Disease. Gastroenterol Clin North Am 2021; 50:919.</li>
<li>Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophagealreflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.</li>
<li>Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acidsuppressive therapy improves asthma outcome. Am J Med 1996; 100:395.</li>
<li>Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'refluxlaryngitis'. Gastroenterology 1991; 100:305.</li>
<li>Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease(GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoringand an experimental investigation of the role of acid and pepsin in the development oflaryngeal injury. Laryngoscope 1991; 101:1.</li>
<li>Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastricacid in patients with reflux laryngitis. Gastroenterology 1995; 109:1575.</li>
<li>Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopyin patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am JGastroenterol 2004; 99:1419.</li>
<li>Remacle M, Lawson G. Diagnosis and management of laryngopharyngeal refluxdisease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:143.</li>
<li>Gaynor EB. Gastroesophageal reflux as an etiologic factor in laryngeal complications ofintubation. Laryngoscope 1988; 98:972.</li>
<li>Cote DN, Miller RH. The association of gastroesophageal reflux and otolaryngologicdisorders. Compr Ther 1995; 21:80.</li>
<li>Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated withgastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.</li>
<li>Schroeder PL, Filler SJ, Ramirez B, et al. Dental erosion and acid reflux disease. AnnIntern Med 1995; 122:809.</li>
<li>DiBaise JK, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. AnnIntern Med 1998; 129:1078.</li>
<li>DiBaise JK, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistantsinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002; 97:843.</li>
<li>Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence inindividuals with gastroesophageal reflux: synthesis and estimates from populationstudies. Am J Gastroenterol 2011; 106:254.</li>
<li>Vaezi MF. Laryngitis and gastroesophageal reflux disease: increasing prevalence or poordiagnostic tests? Am J Gastroenterol 2004; 99:786.</li>
<li>Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous cell cancer of the head andneck. Otolaryngol Clin North Am 1985; 18:367.</li>
<li>Olsen NR. Effects of stomach acid on the larynx. Proc Am Laryngol Assoc 1983; 104:108.</li>
<li>Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma?Otolaryngol Head Neck Surg 1988; 99:370.</li>
<li>Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of thelaryngopharynx. Laryngoscope 1988; 98:1195.</li>
<li>Langevin SM, Michaud DS, Marsit CJ, et al. Gastric reflux is an independent risk factor forlaryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22:1061.</li>
<li>Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, Lagergren J. All-cause and cancer-specificmortality in GORD in a population-based cohort study (the HUNT study). Gut 2018;67:209.</li>
<li>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological AssociationInstitute technical review on the management of gastroesophageal reflux disease.Gastroenterology 2008; 135:1392.</li>
<li>Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosisand Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117:27.</li>
<li>Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control ofheartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am JGastroenterol 1999; 94:92.</li>
<li>Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acidinhibition. Gastroenterol Clin North Am 1990; 19:683.</li>
<li>Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophagealreflux disease. Gastroenterology 2001; 121:1095.</li>
<li>Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn oracid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.</li>
<li>Tsuzuki T, Okada H, Kawahara Y, et al. Proton pump inhibitor step-down therapy forGERD: a multi-center study in Japan. World J Gastroenterol 2011; 17:1480.</li>
<li>Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients withgastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965.</li>
<li>Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass indexand esophageal acid exposure in the extraesophageal manifestations of reflux. ClinGastroenterol Hepatol 2012; 10:874.</li>
<li>Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between uppergastrointestinal symptoms and changes in body weight in a population-based cohort.Neurogastroenterol Motil 2006; 18:987.</li>
<li>Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is notreduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.</li>
<li>Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms ofgastroesophageal reflux in women. N Engl J Med 2006; 354:2340.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction ingastroesophageal reflux. A prospective population-based cohort study: the HUNT study.Am J Gastroenterol 2013; 108:376.</li>
<li>DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines forthe diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol2005; 100:190.</li>
<li>Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle Intervention inGastroesophageal Reflux Disease. Clin Gastroenterol Hepatol 2016; 14:175.</li>
<li>Mehta RS, Song M, Staller K, Chan AT. Association Between Beverage Intake andIncidence of Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol 2020;18:2226.</li>
<li>Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathingexercise on gastroesophageal reflux disease: a randomized, controlled study. Am JGastroenterol 2012; 107:372.</li>
<li>Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Tobacco smoking cessation andimproved gastroesophageal reflux: a prospective population-based cohort study: theHUNT study. Am J Gastroenterol 2014; 109:171.</li>
<li>Mehta RS, Nguyen LH, Ma W, et al. Association of Diet and Lifestyle With the Risk ofGastroesophageal Reflux Disease Symptoms in US Women. JAMA Intern Med 2021;181:552.</li>
<li>Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosivegastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441.</li>
<li>Rohof WO, Bennink RJ, Smout AJ, et al. An alginate-antacid formulation localizes to theacid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11:1585.</li>
<li>Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodiumalginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998; 12:159.</li>
<li>Sweis R, Kaufman E, Anggiansah A, et al. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented bymagnetic resonance imaging and pH-impedance monitoring: mechanistic assessmentin healthy volunteers and randomised, controlled, double-blind study in reflux patients.Aliment Pharmacol Ther 2013; 37:1093.</li>
<li>Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oralsuspension is non-inferior to omeprazole in the treatment of patients with non-erosivegastroesophageal disease. Aliment Pharmacol Ther 2013; 38:1054.</li>
<li>Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of uppergastrointestinal symptoms by an acid pocket-targeting alginate-antacid (GavisconDouble Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophagealreflux disease. Aliment Pharmacol Ther 2014; 39:595.</li>
<li>Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatmentafter 14 days of administration in healthy subjects without Helicobacter pylori infection.J Gastroenterol Hepatol 2003; 18:678.</li>
<li>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcerhealing, gastroesophageal reflux disease, and stress-related erosive syndrome.Gastroenterology 2000; 118:S9.</li>
<li>Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.</li>
<li>Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms ofgastroesophageal reflux disease and heals erosions and ulcerations. Results of amulticenter, placebo-controlled, dose-ranging study. USA Merck GastroesophagealReflux Disease Study Group. Arch Intern Med 1991; 151:2394.</li>
<li>Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastroesophageal refluxdisease: a 12-week, multicenter, randomized, double-blind study. Am J Gastroenterol1991; 86:1735.</li>
<li>Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf (Accessed onDecember 19, 2012).</li>
<li>Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is moreacceptable to patients than continuous lansoprazole 15 mg in the long-termmaintenance of endoscopy-negative gastro-oesophageal reflux patients: theCOMMAND Study. Aliment Pharmacol Ther 2004; 20:657.</li>
<li>Hunt R. Acid suppression for reflux disease: "off-the-peg" or a tailored approach? ClinGastroenterol Hepatol 2012; 10:210.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitortherapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419.</li>
<li>Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pumpinhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal refluxdisease-like symptoms and endoscopy negative reflux disease. Cochrane Database SystRev 2013; :CD002095.</li>
<li>Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worseesophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl B:66B.</li>
<li>Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptorantagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005; 11:4067.</li>
<li>Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides ProtonPump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: AClinical Trial. Gastroenterology 2021; 160:174.</li>
<li>Katzka DA, Kahrilas PJ. Advances in the diagnosis and management ofgastroesophageal reflux disease. BMJ 2020; 371:m3786.</li>
<li>Peura DA, Freston JW, Haber MM, et al. Lansoprazole for long-term maintenancetherapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci2009; 54:955.</li>
<li>Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies forreflux esophagitis. N Engl J Med 1995; 333:1106.</li>
<li>Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients withgastrooesophageal reflux disease. Gut 1992; 33:1016.</li>
<li>Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies forGastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. Decem ber 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).</li>
<li>Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention ofrelapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Gut 1994; 35:590.</li>
<li>Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of refluxesophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlledtrial. Ann Intern Med 1996; 124:859.</li>
<li>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancyand lactation. Aliment Pharmacol Ther 2020; 51:421.</li>
<li>Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet)with antacid for safety and effectiveness in reducing gastric acidity before electivecesarean section. Anesthesiology 1983; 59:86.</li>
<li>Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) inpregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.</li>
<li>Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk ofbirth defects. N Engl J Med 2010; 363:2114.</li>
<li>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophagealreflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.</li>
<li>Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. JReprod Med 2004; 49:825.</li>
<li>National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).</li>
<li>ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelinesfor endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</li>
<li>Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal refluxdisease: putative mechanisms of failure. Drugs 2007; 67:1521.</li>
<li>Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptomsrefractory to proton pump inhibitors. Gut 2012; 61:1340.</li>
<li>Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with theirprescription medications? Results of the patient unmet needs study. J Clin OutcomesManag 2000; 7:29.</li>
<li>The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.</li>
<li>Fass R. Therapeutic options for refractory gastroesophageal reflux disease. JGastroenterol Hepatol 2012; 27 Suppl 3:3.</li>
<li>El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on protonpump inhibitor therapy in primary care and community studies. Aliment PharmacolTher 2010; 32:720.</li>
<li>Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors innonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.</li>
<li>Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention andtreatment. Drugs 2003; 63:555.</li>
<li>Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.</li>
<li>Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term protonpump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.</li>
<li>Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure ingastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.</li>
<li>Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pumpinhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol 2014;109:789.</li>
<li>Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitordosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.Aliment Pharmacol Ther 2006; 23:1473.</li>
<li>Wilder-Smith C, Röhss K, Bokelund Singh S, et al. The effects of dose and timing ofesomeprazole administration on 24-h, daytime and night-time acid inhibition in healthyvolunteers. Aliment Pharmacol Ther 2010; 32:1249.</li>
<li>Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistentsymptoms despite acid suppressive therapy: a multicentre study using combinedambulatory impedance-pH monitoring. Gut 2006; 55:1398.</li>
<li>Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol2008; 6:521.</li>
<li>Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pHmonitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.</li>
<li>Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitecmonitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53:2387.</li>
<li>Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux insymptomatic GERD. Am J Gastroenterol 2001; 96:2033.</li>
<li>Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring insymptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.</li>
<li>Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in ahypersensitive esophagus might explain symptoms resistant to proton pump inhibitorsin patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2014;12:1647.</li>
<li>Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree ofduodenogastroesophageal reflux and acid reflux between patients who failed torespond and those who were successfully treated with a proton pump inhibitor oncedaily. Am J Gastroenterol 2009; 104:2005.</li>
<li>Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acidsuppressive therapy. Am J Gastroenterol 2008; 103:1090.</li>
<li>Savarino E, Zentilin P, Tutuian R, et al. Impedance-pH reflux patterns can differentiatenon-erosive reflux disease from functional heartburn patients. J Gastroenterol 2012;47:159.</li>
<li>Abdallah J, George N, Yamasaki T, et al. Most Patients With Gastroesophageal RefluxDisease Who Failed Proton Pump Inhibitor Therapy Also Have Functional EsophagealDisorders. Clin Gastroenterol Hepatol 2019; 17:1073.</li>
<li>Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology2016.</li>
<li>Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functionalheartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013;25:282.</li>
<li>Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity tobile salts in patients with functional heartburn and in healthy control subjects. Dig DisSci 2005; 50:81.</li>
<li>Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traitsof functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity toacid. Am J Gastroenterol 2006; 101:1084.</li>
<li>Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for thetreatment of refractory GERD accompanied with gastroparesis: a preliminary report. DigDis Sci 2008; 53:2621.</li>
<li>Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patientswith symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum ofvisceral sensitivity in GORD. Gut 1995; 37:7.</li>
<li>Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS andpsychological distress on outcomes and quality of life following PPI therapy in patientswith gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.</li>
<li>Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associatedwith features of psychiatric disorders and the irritable bowel syndrome. AlimentPharmacol Ther 2007; 26:443.</li>
<li>Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease andpsychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.</li>
<li>Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal refluxdisease and underdiagnosis of functional dyspepsia in a USA community.Neurogastroenterol Motil 2014; 26:1163.</li>
<li>Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive tosingle-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux,bile reflux, or both? Am J Gastroenterol 2004; 99:981.</li>
<li>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief ingrade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798.</li>
<li>Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acidbreakthrough on different regimens of omeprazole 40 mg daily. Aliment PharmacolTher 1998; 12:1235.</li>
<li>Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective aslansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophagealreflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-aprospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.</li>
<li>Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebocontrolled study of omeprazole in the treatment of patients with reflux symptoms andphysiological levels of acid reflux--the "sensitive oesophagus". Gut 1997; 40:587.</li>
<li>Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburnsymptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.</li>
<li>Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-hintragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 2012; 36:627.</li>
<li>Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis ofgastro-esophageal reflux disease: Update of the Porto consensus andrecommendations from an international consensus group. Neurogastroenterol Motil2017; 29:1.</li>
<li>Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring withand without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.</li>
<li>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management ofgastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.</li>
<li>Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pHmonitoring in patients with refractory gastroesophageal reflux disease, on and offtherapy. Clin Gastroenterol Hepatol 2009; 7:743.</li>
<li>Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology2018; 154:302.</li>
<li>Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findingsin gastro-esophageal reflux disease: Conclusions from an international consensusgroup. Neurogastroenterol Motil 2017; 29.</li>
<li>Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthroughon omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.</li>
<li>Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy onnocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.</li>
<li>Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine atnight to twice daily omeprazole therapy on nocturnal acid breakthrough and acid refluxin patients with systemic sclerosis--a randomized controlled, cross-over trial. AlimentPharmacol Ther 2007; 26:1259.</li>
<li>Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinicalsignificance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545.</li>
<li>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for thecontrol of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009;:CD004275.</li>
<li>Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improvegastroesophageal reflux disease symptoms for patients on proton pump inhibitortherapy. Dis Esophagus 2005; 18:370.</li>
<li>Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophagealreflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract2014; 2014:307805.</li>
<li>Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices?Curr Opin Gastroenterol 2009; 25:352.</li>
<li>Weijenborg PW, de Schepper HS, Smout AJ, Bredenoord AJ. Effects of antidepressants inpatients with functional esophageal disorders or gastroesophageal reflux disease:a systematic review. Clin Gastroenterol Hepatol 2015; 13:251.</li>
<li>Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adultpatients with functional chest pain: a randomized, double-blind, placebo-controlled,crossover trial. Am J Gastroenterol 2010; 105:1504.</li>
<li>Park SW, Lee H, Lee HJ, et al. Low-dose amitriptyline combined with proton pumpinhibitor for functional chest pain. World J Gastroenterol 2013; 19:4958.</li>
<li>Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors forthe treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.</li>
<li>Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy ingastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20:2412.</li>
<li>Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients WithRefractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology2020; 158:2093.</li>
<li>Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the protonpump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.</li>
<li>UpToDate medical database. Approach to the initial management of patients with GERD. Graphic 116964 Version 3.0. Электронный ресурс: https://www.uptodate.com/contents/image?imageKey=GAST%2F116964, дата доступа: 14.07.2023</li>
<li>Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut. 2005;54(12):1810-1817. doi:10.1136/gut.2005.072629</li>
<li>Costa V, Pinto-Saavedra O, Hani A, Leguízamo AM, Ardila-Hani AF. Updated interpretation of Impedance–pH monitoring. Rev Colomb Gastroenterol. 2021;36(1):73-80. https://doi.org/10.22516/25007440.608</li>
<li>Hani, Albis & Leguizamo, Ana & Carvajal, Jhon & Klinger, Gabriel & Costa, Valeria. (2015). How to Perform and Interpret High-resolution Esophageal Manometry. Revista Colombiana de Gastroenterologia. 30. 74-83.</li>
<li>Ивашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л., Хлынов И.Б., Дехнич Н.Н., Лопина О.Д., Алексеева О.П., Корочанская Н.В., Осипенко М.Ф., Павлов П.В., Пирогов С.С., Тарасова Г.Н., Успенский Ю.П., Андреев Д.Н., Румянцева Д.Е. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18. https://doi.org/10.22416/1382-4376-2020-30-6-7-18.</li>
<li>Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Can Fam Physician 2017;63:354-64 (Eng), e253-65 (Fr).</li>
<li>Cho YK. How to Interpret Esophageal Impedance pH Monitoring. J Neurogastroenterol Motil. 2010 Jul;16(3):327-30. doi: 10.5056/jnm.2010.16.3.327. Epub 2010 Jul 26. PMID: 20680174; PMCID: PMC2912128.</li>
<li>Kim GH. How to Interpret Ambulatory 24 hr Esophageal pH Monitoring. J Neurogastroenterol Motil. 2010 Apr;16(2):207-10. doi: 10.5056/jnm.2010.16.2.207. Epub 2010 Apr 27. PMID: 20535354; PMCID: PMC2879855.</li>
<li>Jehangir A, Malik Z, Parkman HP. Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterol. 2022 Mar 8;22(1):112. doi: 10.1186/s12876-022-02194-0. PMID: 35260107; PMCID: PMC8905734.</li>
<li>Yadlapati R. High-resolution esophageal manometry: interpretation in clinical practice. Curr Opin Gastroenterol. 2017 Jul;33(4):301-309. doi: 10.1097/MOG.0000000000000369. PMID: 28426462; PMCID: PMC5568812.</li>
<li>Yamasaki T, Fass R. Reflux Hypersensitivity: A New Functional Esophageal Disorder. J Neurogastroenterol Motil. 2017;23(4):495-503. doi:10.5056/jnm17097</li>
<li>Ronnie Fass, Frank Zerbib, C. Prakash Gyawali. AGA Clinical Practice Update on Functional Heartburn: Expert Review. CLINICAL PRACTICE UPDATE| VOLUME 158, ISSUE 8, P2286-2293, JUNE 2020. Published: February 01, 2020. DOI: https://doi.org/10.1053/j.gastro.2020.01.034</li>
<li>Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol. 2020 Sep;115(9):1393-1411. doi: 10.14309/ajg.0000000000000731. PMID: 32773454; PMCID: PMC9896940.</li>
<li>Samo S, Qayed E. Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management? World J Gastroenterol. 2019 Jan 28;25(4):411-417. doi: 10.3748/wjg.v25.i4.411. PMID: 30700938; PMCID: PMC6350167.</li>
<li>Management of the patient with esophagogastric junction outflow obstruction (EGJOO) Shahsavari et al. Curr Opin Gastroenterol 2021, 37:397–407. DOI:10.1097/MOG.0000000000000747</li>
<li>Dhyanesh A. Patel, Rena Yadlapati, Michael F. Vaezi, Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics, Gastroenterology, Volume 162, Issue 6, 2022, Pages 1617-1634, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2021.12.289.</li>
<li>DeLay K, Krause A, Yadlapati R. Clinical Updates in Esophageal Motility Disorders Beyond Achalasia. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1789-1792.e1. doi: 10.1016/j.cgh.2021.05.041. Epub 2021 Jul 1. PMID: 34405804; PMCID: PMC8604436.</li>
<li>Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014 Jan;20(1):6-16. doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30. PMID: 24466441; PMCID: PMC3895610.</li>
<li>Чёрная А. В. Карханова А. Г., Мутовкина Н. И., Дышлюк Т. Л., Багненко С. С., Рогачев М. В., Ульянова Р. Х., Зайцев А. Н., Шевкунов Л. Н., Новиков С. Н., Шевченко Е. Ю., Брезгина Е. А. Лучевая диагностика заболеваний пищевода при злокачественных и доброкачественных изменениях: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. – Санкт-Петербург: ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России, 2021. – 144 с. ISBN 978-5-6046978-1-8</li>
<li>Государственный реестр лекарственных средств. Электронный ресурс: https://grls.rosminzdrav.ru/default.aspx, дата доступа: 14.07.2023</li>
<li>Инструкция по применению лекарственного препарата Ганатон® (итоприда гидрохлорид). РУ ЛС-002513 от 29.06.2021. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9abd2328-abcb-411e-919e-6d8ab7c238ea, дата доступа: 14.07.2023</li>
<li>Stanghellini V., Chan F., Hasler W.L. et al. Gastroduodenal Disorders Gastroenterology 2016;150:1380– 1392.</li>
<li>Касьяненко В.И., Денисов Н.Л., Васильев Ю.В. Применение итоприда при симптомах функциональной диспепсии в России: результаты проспективного открытого многоцентрового клинического исследования IV фазы. Терапевтический Архив. 2014;8:35-41.</li>
<li>Tack J. et all. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther. 2011 Jan;33(1):99-105.</li>
<li>Murray J.A. Gastroesophageal Reflux Disease. In.: Mayo Clinic Gastroenterology and Hepatology Board Review. Oxford University Press. 2015.</li>
<li>Ezzat W.F., Fawaz S.A., Fathey H. et al. Virtue of Adding Prokinetics to Proton Pump Inhibitors in the Treatment of Laryngopharyngeal Reflux Disease: Prospective Study Journal of Otolaryngology-Head & Neck Surgery. 2011;40(4):350–356/</li>
<li>Инструкция по применению лекарственного препарата Париет® (рабепразол). РУ П N011880/01 от 28.02.2022. Электронный ресурс: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d7c5d813-e692-4211-a63d-2a2ac06ea1d7, дата доступа: 14.07.2023</li>
<li>Kirchheiner J., Glatt S., Fuhr U. et al. Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH // European Journal of Clinical Pharmacology, 2008, 65 (1), pp.19-31</li>
<li>Kramer W, Kruger U, Huber R et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitrocorrelates. Pharmacology. 1998;56:57-70</li>
<li>Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003 Feb;48(2):322-8.</li>
<li>Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335.</li>
<li>Besancon M, Shin JM, Mercier F, et al. Biochemistry, 1993; 32:2345–2355.</li>
<li>Сереброва С.Ю. Основные фармакокинетические характеристики ингибиторов протонной помпы и эффективность их действия. Пособие для врачей. Мединфорум 2016.</li>
<li>Cefditoren [Korean product labeling]. Boryeong Pharmaceutical; November 2009.</li>
<li>Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol. 1984;18(4):535-539. [PubMed 6091711</li>
<li>Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. Adv Perit Dial. 1994;10:179-182. [PubMed 7999822</li>
<li>Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</li>
<li>Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509. [PubMed 16898956</li>
<li>Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OLCA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardio. 2008;51(3):256-260. [PubMed 18206732</li>
<li>Fontes-Carvalho R, Albuquerque A, Araugo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogre-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396-404. [PubMed 21464720</li>
<li>Frelinger 3rd AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardio. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944. [PubMed 19258584</li>
<li>Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039; author reply 1039. [PubMed 18786491</li>
<li>Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Gaglia MA Jr, Torguson R, Hanna N, et alRelation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomesAm J Cardiol2010;105(6):833-838[PubMed 20211327</li>
<li>Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964-1968. [PubMed 19731021</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997. [PubMed 19726078</li>
<li>Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26(2):e54-e57. [PubMed 20151060</li>
<li>Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917. [PubMed 20925534</li>
<li>Muthiah MD, Zheng H, Chew NWS, et al. Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. [online ahead of print] J Thromb Throbolysis. 2021. doi: 10.1007/s11239-021-02472. [PubMed 33959860</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2016; Aug 10 (Epub ahead of print). [PubMed 27512080</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478</li>
<li>Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). BMC Cardiovasc Disord. 2017;17(1):3. [PubMed 28056809</li>
<li>Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J Manag Care Spec Pharm. 2016;22(8):939-947. [PubMed 27459657</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11): pii: e002245. [PubMed 26514161</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership: March 2021.</li>
<li>Park GJ, Bae SH, Park WS, et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther. 2017;11:1043-1053. [PubMed 28408803</li>
<li>Kamiya C, Inui N, Hakamat A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype [published online March 11, 2019]. J Pharmacol Sci. Doi: 10.1016/j.jphs.2019.03.001. [PubMed 30902567</li>
<li>Elbe A, Foerster KI, Blank A, et al. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol. 2022;78(6):975-987. [PubMed 35238961</li>
<li>Erleada (apalutamide) [prescribing information. Horsham, PA: Janssen Products LP; September 2019</li>
<li>Kanebratt KP, Diczfalusy U, Backstroo T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther, 2008, 84(5):589-94. [PubMed 18650803</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; August 2018.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999-1004. [PubMed 22147077</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016</li>
<li>Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358-1365. [PubMed 25274610</li>
<li>Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81(6):1195-1196. [PubMed 26833554</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;25(7):1155-1162. [PubMed 30605231</li>
<li>Koutake Y, Taniguch J, Yasumori N, et al. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol. 2020;111(6):826-832. [PubMed 32152877]</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2012.</li>
<li>Tarceva (erlotinib) [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; April 2014</li>
<li>van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309-1314. [PubMed 26858332</li>
<li>Veerman GDM, Hussaarts KGAM, Peric R, et al. Influence of cow's milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69-77. [PubMed 32557346</li>
<li>Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol. 2010;70(6):908-911. [PubMed 21175447</li>
<li>Du X, Liu W, Chen K, Wang Z, Li X, Yang L, Xie X. Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis. [published online ahead of print] Front Pharmacol. 2022. doi: 10.3389/fphar.2022.796538. [PubMed 35795555</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908</li>
<li>Zenke Y, Yoh K, Matsumoto S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412-418. [PubMed 26944770</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et alA multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerClin Cancer Res2010;16(11):3078-3087[PubMed 20395213</li>
<li>Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 2013;52:593-609. [PubMed 23532985</li>
<li>Truseltiq (infigratinib) [prescribing information]. Brisbane, CA: QED Therapeutics Inc; May 2021.</li>
<li>Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola®) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671-1675. [PubMed 7486898</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; June 2018</li>
<li>Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; March 2018</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022</li>
<li>Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-391. [PubMed 9357389</li>
<li>Seo KA, Lee SJ, Kim KB, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42(3):278-284. [PubMed 22022918</li>
<li>Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283:434-442.[PubMed 9353355</li>
<li>Zhang W, Ramamoorthy Y, Kilicarslan T, et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos. 2002;30:314-318. [PubMed 11854151]</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology Inc; July 2017.</li>
<li>Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(6):1635-1643. [PubMed 23636448</li>
<li>Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. [Published online doi:10.1002/ijc.33469]. 2021. [PubMed 33428771</li>
<li>Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020;76(9):1273-1280. [PubMed 32474662</li>
<li>Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</li>
<li>Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F. Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects. Clin Pharmacokinet. 2022;61(11):1623-1639. [PubMed 36264536</li>
<li>Turalio (pexidartinib) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; August 2019.</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; August 2015</li>
<li>Juluca (dolutegravir/rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020</li>
<li>Noltec (ilaprazole) [Korean product labeling]. Ilyang Pharmaceutical Co., Ltd.; March 2020</li>
<li>K-CAB (tegoprazan) [Singapore product labeling]. Singapore: HK inno.N Corporation; January 2023.</li>
<li>Lumakras (sotorasib) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2021.</li>
<li>Filspari (sparsentan) [prescribing information]. San Diego, CA: Travere Therapeutics Inc; February 2023.</li>
<li>Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-197. [PubMed 15001970</li>
<li>Konvomep (omeprazole and sodium bicarbonate for oral suspension) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals, Inc.; August 2022.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2020</li>
<li>Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011;51(3):368-377. [PubMed 20457590</li>
<li>Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26:341346. [PubMed 16503713</li>
<li>Evotaz (atazanavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2020.</li>
<li>Schueller O, Willson A, Singh N, Lohmer L, Alabanza A, Patel J. A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors. Clin Pharmacol Drug Dev. 2022;11(7):795-806. [PubMed 35230741</li>
<li>Rezurock (belumosudil) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals LLC; July 2021.</li>
<li>Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33(8):589-595. [PubMed 23839484</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:53-59. [PubMed 10702887</li>
<li>Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.</li>
<li>Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51. [PubMed 20642546</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90-97. [PubMed 24887634</li>
<li>Wu WT, Tsai CT, Chou YC, et al. Cardiovascular outcomes associated with clinical use of citalopram and omeprazole: a nationwide population-based cohort study. J Am Heart Assoc. 2019;8(20):e011607. [PubMed 31581860</li>
<li>Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.</li>
<li>Yokota H, Sato K, Okuda Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18(6):e433-e439. [PubMed 28579188</li>
<li>Tang W, Tomkinson H, Masson E. Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev. 2017;6(5):517-523. [PubMed 28176470</li>
<li>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res. 2019;11:8539-8546. [PubMed 31572008</li>
<li>Sedano MN, Teller JMC, Munoz CG, et al. Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON. 2018;23(3):647-653. [PubMed 30003732</li>
<li>Li J, Nickens D, Wilner K, Tan W. Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther. 202113. Epub ahead of print. [PMID: 34120312</li>
<li>Kumarakulasinghe NB, Syn N, Soon YY, et al. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget. 2016;7(51):85542-85550. [PubMed 27907909</li>
<li>Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2021.</li>
<li>Jaruratanasirikul S and Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54:159-161. [PubMed 9626921</li>
<li>Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, and Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51:453-457. [PubMed 12562722</li>
<li>Lange D, Pavao JH, Wu J, and Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Tolsura (itraconazole) [prescribing information]. Greenville NC: Mayne Pharma; December 2018</li>
<li>Lindsay J, Mudge S, and Thompson GR. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723018. [PubMed 30297369</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018</li>
<li>Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808. [PubMed 16141567]</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2017</li>
<li>Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893-1899. [PubMed 27533287</li>
<li>Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5. [PubMed 27565882]</li>
<li>Camzyos (mavacamten) [prescribing information]. Brisbane, CA: MyoKardia, Inc.; April 2022.</li>
<li>Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol.1993;33(1):82-84. [PubMed 8269594</li>
<li>Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024-1027. [PubMed 10981249</li>
<li>Troger U, Stotzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497. [PubMed 12077038</li>
<li>Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 2010;30(3):963-965. [PubMed 20393020</li>
<li>McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012;25(4):477-485. [PubMed 22550162</li>
<li>Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316-318. [PubMed 18386155</li>
<li>Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed? Chemotherapy. 2011;57(3):225-229. [PubMed 21597286</li>
<li>Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht RDelayed elimination of methotrexate associated with co-administration of proton pump inhibitorsAnticancer Res2010;30(9):3807-3810[PubMed 20944174</li>
<li>Fang AF, Damle BD, LaBadie RR, Crownover, PH, Hewlett Jr. D, Glue, PW. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50. [PubMed 18154473</li>
<li>Saberi P, Ranatunga DK, Quesenberry CP, Silverberg MJ. Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011;31(3):253-261. [PubMed 21361735</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016</li>
<li>Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32(12):1462-1467. [PubMed 15448116]</li>
<li>Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50(8):960-967. [PubMed 20498287</li>
<li>Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155-1162. [PubMed 30605231</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.</li>
<li>Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food and intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614-626. [PubMed 28430398</li>
<li>Ibrance (palbociclib) capsule [prescribing information]. New York, NY: Pfizer Inc; September 2019</li>
<li>Ibrance (palbociclib) tablet [prescribing information]. New York, NY: Pfizer Inc; November 2019</li>
<li>Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021;6(5):100231. [PubMed 34509802</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649</li>
<li>Del Re M, Omarini C, Diodati L, et al. Reply to comments on: drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2022;7(1):100381. [PubMed 35131649]</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PubMed 19075045</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; November 2013</li>
<li>Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839. [PubMed 19220151</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-5510[PubMed 22890761</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott (US), LLC; April 2015</li>
<li>Kinov P, Boyanov M. Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health. 2012;4L:167-174. [PubMed 22532780</li>
<li>Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114. [PubMed 30539272</li>
<li>Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998-1004. [PubMed 21321287</li>
<li>Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161-1168. [PubMed 22890365</li>
<li>Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016-1022. [PubMed 23307040</li>
<li>Prieto-Alhambra D, Pages-Castella A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268-274. [PubMed 23761350</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Yang SD, Chen Q, Wei HK, et alBone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysisInt J Clin Exp Med2015;8(4):4899-4910[PubMed 26131063</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782</li>
<li>Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC Jr, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63(10):2070-2073. [PubMed 26415604</li>
<li>Roux C, Goldstein JL, Zhou X, et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277-284. [PubMed 21365461</li>
<li>Asaoka D, Nagahara A, Hojo M, et al. Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomed Rep. 2016;5(2):165-170. [PubMed 27446535</li>
<li>Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31(2):206-211. [PubMed 23138352</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014:607145. [PubMed 25436170]</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin Inc; July 2017</li>
<li>Prilosec (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Nexim (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2016</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; October 2016</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2016</li>
<li>Protonix (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July 2017.</li>
<li>Retevmo (selpercatinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; May 2020.</li>
<li>Norouzi G, AsadZade A, Salimi Y, Khoshbakht S, Pirayesh E. Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi. J Nucl Cardiol. 2022;29(4):1552-1561. [PubMed 33527332</li>
<li>Rose DS, Robinson B, Kannan S, Lee JC. Interaction between the effects of proton pump inhibitors and aspirin on gastric wall sestamibi uptake on myocardial perfusion imaging. J Nucl Cardiol. 2021;28(5):1976-1985. [PubMed 31741323</li>
<li>Qutbi M. What is this image? 2019: Image 2 result : Reduction in interfering gastric wall uptake on myocardial perfusion SPECT following a 2-week period of omeprazole withdrawal. J Nucl Cardiol. 2019;26(5):1517-1519. [PubMed 31359363</li>
<li>Singh H, Mittal BR, Sood A, et al. Association of use of proton pump inhibitors and H2 antagonists with stomach wall uptake in 99m-Tc-methoxy-isobutyl-isonitrile (MIBI) myocardial perfusion imaging. J Nucl Cardiol. 2020;27(5):1611-1619. [PubMed 31087263</li>
<li>Javadi H, Jallalat S, Semnani S, et al. The association of increased stomach wall radiotracer uptake with prolonged use of omeprazole capsules on myocardial perfusion imaging (MPI) using 99mTc-sestamibi SPECT. Nucl Med Rev Cent East Eur. 2013;16(2):91-94. [PubMed 24068640</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974</li>
<li>Cardiolyte (technetium Tc 99m sestamibi) [prescribing information]. N. Billerica, Massachusetts: Lantheus Medical Imaging; December 2019</li>
<li>Technetium Tc 99m sestamibi [product monograph]. Laval, Quebec, Canada: Curium Canada Inc; November 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2020</li>
<li>Vosevir (sofosbuvir and velpatasvir and voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2019</li>
<li>Seyen MV, Colbers A, Abbink EJ, Drenth JPH, Burger DM. Concomitant intake of coca-cola to manage the drug-drug interaction between velpatasvir and omeprazole studied in healthy volunteers. Clin Pharmacol Ther. 2019;106(5):1093-1098. [PubMed 31313296]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270</li>
<li>Evekeo (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2013.</li>
<li>Czerwinski E. Atypical subtrochanteric fractures after long-term bisphosphonate therapy. Endokrynol Pol. 2011;62(1):84-87. [PubMed 21365585</li>
<li>Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169-180. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009;32(9):775-785. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-1998. [PubMed 19333676</li>
<li>Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-1218. [PubMed 21483462</li>
<li>Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768-776. [PubMed 21185417</li>
<li>Chiu HF, Huang YW, Chang CC, et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131-1136. [PubMed 20872906</li>
<li>Gray SL, LaCroix AZ, Larson J, et alProton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health InitiativeArch Intern Med2010;170(9):765-771[PubMed 20458083</li>
<li>Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93-101. [PubMed 20353792</li>
<li>Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326. [PubMed 18695179</li>
<li>Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. [PubMed 17190895</li>
<li>Bodmer M, Meier C, Kraenzlin ME, et al. Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf. 2010;33(10):843-852. [PubMed 20812769</li>
<li>Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(3):903-910. [PubMed 20585937</li>
<li>Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959. [PubMed 18657011</li>
<li>Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896-904. [PubMed 19931262</li>
<li>Tanaka M, Itoh S, Yoshioka T, Yamashita K. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014;2014:607145. [PubMed 25436170</li>
<li>Hyun JJ, Chun HJ, Keum B, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med. 2010;26(6):877-883. [PubMed 21042782]</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767-773. [PubMed 27737436</li>
<li>Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257-263. [PubMed 26803708</li>
<li>Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43(4):309-315. [PubMed 10071982</li>
<li>van Doorn L, Heersche N, de Man FM, et al. Effect of the proton pump inhibitor esomeprazole on the systemic exposure of capecitabine: results of a randomized crossover trial. Clin Pharmacol Ther. 2022;111(2):455-460. [PubMed 34656072]</li>
<li>Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23(1):37-39. [PubMed 11413862</li>
<li>Bertilsson L, Tybring G, Widen J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44(2):186-189. [PubMed 9278208]</li>
<li>Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2-receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183]</li>
<li>Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-353. [PubMed 22422635</li>
<li>Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23(3):317-321. [PubMed 3567046</li>
<li>Onfi (clobazam) [prescribing information]. Winchester, KY: Catalent Pharma Solutions, LLC; February 2021</li>
<li>Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999;21(6):604-608. [PubMed 10604819</li>
<li>Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589-592. [PubMed 22293514</li>
<li>Grigoleit HG, Hajdu P, Hundt HK, et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur J Clin Pharmacol. 1983;25(1):139-142. [PubMed 6617718]</li>
<li>Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2022.</li>
<li>Frick A, Kopitz J, and Bergemann N, “Omeprazole Reduces Clozapine Plasma Concentrations: A Case Report,” Pharmacopsychiatry, 2003, 36(3):121</li>
<li>[PubMed 12806570</li>
<li>Intensive Medicines Monitoring Programme accessed at http://www.medsafe.govt.nz/Profs/Puarticles/ClozOmep.htm May 14, 2013</li>
<li>Mookhoek EJ and Loonen AJ, “Retrospective Evaluation of the Effect of Omeprazole on Clozapine Metabolism,” Pharm World Sci, 2004, 26(3):180</li>
<li>[PubMed 15230368</li>
<li>Wagner S, Varet-Legros MG, Fabre C, et al, “Confounding Factors for Variation of Clozapine Plasma Levels: Drug Interactions With Proton Pump Inhibitor or Infectious Etiologies?” Eur J Clin Pharmacol, 2011, 67(5):533</li>
<li>[PubMed 21057941</li>
<li>Philipps RJ, Lee Demler T and Lee C, “Omeprazole-Induced Blood Dyscrasia in a Clozapine-Treated Patient,” Innov Clin Neurosci, 2012, 9(9):14</li>
<li>[PubMed 23074697]</li>
<li>Reichenspurner H, Meiser BM, Muschiol F. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transplant. 1993;12(6):987-992. [PubMed 8312324</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al. Changes of resorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc. 1994;26(5):2800-2801. [PubMed 7940881</li>
<li>Schouler L, Dumas F, Couzigou P. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86(8):1097. [PubMed 1858755</li>
<li>Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993;35(2):156-160. [PubMed 8443034</li>
<li>Castellote E, Bonet J, Lauzurica R. Does interaction between omeprazole and cyclosporin exist? Nephron. 1993;65(3):478. [PubMed 8290007</li>
<li>Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM. More about omeprazole-cyclosporine interaction. Am J Gastroenterol. 1993;88(1):154-155. [PubMed 8420264</li>
<li>Zegerid (omeprazole) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; November 2020.</li>
<li>Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057-1069. [PubMed 25929560</li>
<li>Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519. [PubMed 29105855</li>
<li>Kamiya C, Inui N, Hakamata A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361-366. [PubMed 30902567</li>
<li>Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487-494. [PubMed 15025747</li>
<li>Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141-152. [PubMed 11907488</li>
<li>Vlase L, Neag M, Popa A, Muntean D, Leucuta SE. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. Curr Ther Res Clin Exp. 2010;71(6):360-368. [PubMed 24688155</li>
<li>Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653-662. [PubMed 24569517</li>
<li>Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. [PubMed 34877801</li>
<li>Inrebic (fedratinib) [prescribing information]. Summit, NJ: Celgene Corporation; August 2019</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672</li>
<li>Vfend (voriconazole) [prescribing information]New York, NY: Pfizer; January 2019</li>
<li>Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021</li>
<li>Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23(2):77-81. [PubMed 11932962</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; January 2020</li>
<li>Armas D, Holt RJ, Confer NF, Checani GC, Obaidi M, Xie Y, Brannagan M. A phase I pharmacokinetic study of cysteamine bitartrate delayed-release capsules following oral administration with orange juice, water, or omeprazole in cystinosis. Adv Ther. 2018;35(2):199-209. [PubMed 29411268]</li>
<li>Prezista (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; June 2016</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicriob Agents Chemother. 2007;51(3):958-961. [PubMed 17210768]</li>
<li>Adderall XR (extended release mixed amphetamine salts) [prescribing information]. Lexington, MA: Shire US Inc.; July 2019</li>
<li>Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009;121(5):11-19. [PubMed 19820270]</li>
<li>Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.</li>
<li>Grahnen A, Olsson B, Johansson G, Eckernas SA. Doxycycline carrageenate-an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmcol 1994;46(2):143-146. [PubMed 8039533</li>
<li>Monodox (doxycycline monohydrate). Aqua Pharmaceuticals, LLC; Fort Lauderdale, FL: April 2017</li>
<li>Nexium (esomeprazole). AstraZeneca Pharmaceuticals LP; Wilmington DE: October 2016.</li>
<li>Grasela Jr TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615-617. [PubMed 2751276</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081</li>
<li>Misiak PM, Eldon MA, Toothaker RD, Sedman AJ. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin. J Clin Pharmacol. 1993;33(1):53-56. [PubMed 8429114]</li>
<li>Lozano R, Bibian C, Quilez RM, Gil J, Constante Y, Garcia-Arilla E. Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients. Br J Clin Pharmacol. 2014;77(6):1086-1087. [PubMed 23919252</li>
<li>Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391-1400. [PubMed 23928296</li>
<li>Lexapro (escitalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Courlet P, Guidi M, Glatard A, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019;85(9):2022-2032. [PubMed 31144347</li>
<li>Escitalopram [product monograph]. Kirkland, Quebec, Canada: Accord Healthcare Inc; September 2017.</li>
<li>Marti-Masso JF, Lopez de Munain A, Lopez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother. 1992;26(3):429-430. [PubMed 1554966]</li>
<li>Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-1241. [PubMed 3932118</li>
<li>Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24(4):543-545. [PubMed 3689634</li>
<li>Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935-46. [PubMed 22612290</li>
<li>Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6):563-568. [PubMed 10613611</li>
<li>Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215-220. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al. Reduction of phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol. 1983;25(1):135-137. [PubMed 6617717</li>
<li>Bartle WK, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther. 1983;33(5):649-655. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, Jordan JE. Effect of cimetidine on phenytoin serum levels. Epilepsia. 1983;24(3):284-288. [PubMed 6851961</li>
<li>Iteogu MO, Murphy JE, Shleifer N, Davis REffect of cimetidine on single-dose phenytoin kineticsClin Pharm1983;2(4):302-304[PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology. 1985;35(4):562-565. [PubMed 3982643</li>
<li>Sambol NC, Upton RA, Chremos AN, Lin ET, Williams RL. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. Br J Clin Pharmacol. 1989;27(1):83-87. [PubMed 2565119</li>
<li>Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effects of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 1989;30(2):225-229. [PubMed 2647472</li>
<li>Fuerst RH, Graves NM, Leppik IE, Brundage RC, Holmes GB, Remmel RP. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 1988;29(4):488-491. [PubMed 3391153</li>
<li>Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-544 (ADD 03055) in epileptic patients. Epilepsia. 1985;26(6):602-606. [PubMed 4076064</li>
<li>Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40(8):1122-1128. [PubMed 10448826</li>
<li>Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997;62(5):572-577. [PubMed 9390115</li>
<li>Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol. 1996;53(11):1191-1192. [PubMed 8912496</li>
<li>Rindone JP, Bryan G. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med. 1996;156(10):1113. [PubMed 8639000</li>
<li>Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology. 1996;46(4):1172-1173. [PubMed 8780118</li>
<li>Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother. 1998;32(12):1295-1298. [PubMed 9876809</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, Shearman DJ, Hann CS. Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed). 1981;282(6275):1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med. 1981;95(2):244-245. [PubMed 7258891</li>
<li>Phillips P, Hansky J. Phenytoin toxicity secondary to cimetidine administration. Med J Aust. 1984;141(9):602. [PubMed 6092884</li>
<li>Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12(4):329-333. [PubMed 2396305</li>
<li>Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36(4):380-382. [PubMed 12959321</li>
<li>Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol. 1992;34(1):75-78. [PubMed 1633070</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.</li>
<li>Dujic T, Cvijic S, Elezovic A, et al. Interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype. J Pers Med. [published online May 3 2021].doi:10.3390/jpm11050367] [PubMed 34063566]</li>
<li>Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474-484. [PubMed 34649118</li>
<li>Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487-5493. [PubMed 32933995</li>
<li>Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR tirals. Ann Oncol. 2020;31(4):535-531. [PubMed 32115349</li>
<li>Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016;26(9):609-615. [PubMed 27603551</li>
<li>Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacotherapy. 2022;56(4):377-386. [PubMed 34282636]</li>
<li>Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12(15):2080-2082. [PubMed 9814882</li>
<li>Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-428. [PubMed 18281734</li>
<li>Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122-129. [PubMed 27693678]</li>
<li>Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.</li>
<li>Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69(4):266-273. [PubMed 11309556</li>
<li>Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-397. [PubMed 11966672]</li>
<li>Sharma VR, Brannon MR, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. Southern Med J. 2004;97(9):887-889.[PubMed 15455980</li>
<li>Salovaara S, Sandberg A-S, Andlid T. Combined impact of pH and organic acids on iron uptake by caco-2 cells. J Agric Food Chem. 2003;51:7820-7824. [PubMed 14664552</li>
<li>Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Ann Rev Nutr. 2003;23:283-301. [PubMed 12626689]</li>
<li>Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42(10):4243-4246. [PubMed 21168674</li>
<li>Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061-2067. [PubMed 20671023</li>
<li>Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196-1201. [PubMed 19783713</li>
<li>Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009;9(7):1650-1656. [PubMed 19519820</li>
<li>Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605-611. [PubMed 19481022</li>
<li>Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Transplant Proc. 2014;46(5):1362-1365. [PubMed 24935300</li>
<li>David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit. 2012;34(3):331-336. [PubMed 22549498</li>
<li>Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30(1):46-51. [PubMed 18223462</li>
<li>Kato R, Ooi K, Ikura-Mori M, et alImpairment of mycophenolate mofetil absorption by calcium polycarbophilJ Clin Pharmacol2002;42(11):1275-1280[PubMed 12412828</li>
<li>Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518-524. [PubMed 24162246</li>
<li>Rissling O, Glander P, Hambach P, et al. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Br J Clin Pharmacol. 2015; Apr 24 (Epub ahead of print): doi: 10.1111/bcp.12664. [PubMed 25913040</li>
<li>Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265-1272. [PubMed 21903891</li>
<li>Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120-123. [PubMed 21192310</li>
<li>van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014;72(2):86-90. [PubMed 24659591</li>
<li>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; September 2013</li>
<li>Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565-571. [PubMed 21256049</li>
<li>Sakuludomakan W, Takuathung MN, Dukaew N, Koonrungsesomboon N. Drug-drug interactions between mycophenolic acid and proton pump inhibitors: a systematic review and meta-analysis. Ther Drug Monit. 2022;44(3):384-390. [PubMed 35239287</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.</li>
<li>Mycapssa (octreotide) delayed release capsules [prescribing information]. Scotland, UK: MW Encap Ltd; June 2020.</li>
<li>Prescribing information. Adempas (riociguat). Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., October 2013.</li>
<li>Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401-1406. [PubMed 16791014</li>
<li>Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914</li>
<li>Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83(6):867-872. [PubMed 17898705</li>
<li>Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genentech, Inc.; September 2020</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50:1081-1084. [PubMed 12461038</li>
<li>Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacother. 2006;26(8):1060-1068. [PubMed 16863482]</li>
<li>Nexavar (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2018</li>
<li>Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. J Cancer Res Clin Oncol. 2020;146(10):2693-2697. [PubMed 32449002</li>
<li>Lind JSW, Dingemans AMC, Groen HJM, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(11):3078-3087. [PubMed 20395213]</li>
<li>Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet. 2008;23:134-138. [PubMed 18445994</li>
<li>Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet. 2007;22:441-444. [PubMed 18159131</li>
<li>Moreau C, Debray D, Loriot MA, et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation. 2006;81:487-488. [PubMed 16477241</li>
<li>Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38:791-794. [PubMed 15010519</li>
<li>Homma M, Itagaki F, Yuzawa K, et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation. 2002, 73:303-304. [PubMed 11821750</li>
<li>Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821-826. [PubMed 19139162</li>
<li>Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos. 2007;28:167-175. [PubMed 17377957</li>
<li>Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56:1055-1059. [PubMed 15285851</li>
<li>Itagaki F, Homma M, Yuzawa K, et alDrug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutationTransplant Proc2002;34:2777-2778[PubMed 12431607</li>
<li>Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin a blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56:439-440. [PubMed 11009056</li>
<li>Mei T, Noguchi H, Suetsugu K, et al. Effects of concomitant administration of vonoprazan fumarate on the tacrolimus blood concentration in kidney transplant recipients. Biol Pharm Bull. 2020;43(10):1600-1603. [PubMed 32999170</li>
<li>Suzuki Y, Yoshihashi T, Takahashi K, Furuya K, Ohkohchi N, Oda T, Homma M. Drug-drug interaction between tacrolimus and vonoprazan in kidney transplant recipients. J Clin Med. 2021;10(17):3964. [PubMed 34501411</li>
<li>Pascual J, Marcen R, Orea OE, et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. Transplant Proc. 2005;37(9):3752-3753. [PubMed 16386527</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862. [PubMed 9224780</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A4 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143]</li>
<li>Mouden M, Rijkee KS, Schreuder N, Timmer JR, Jager PL. Influence of proton-pump inhibitors on stomach wall uptake of 99mTc-tetrofosmin in cadmium-zinc-telluride SPECT myocardial perfusion imaging. Nucl Med Commun. 2015;36(2):143-147. [PubMed 25356621</li>
<li>Goel S, Bommireddipalli S, DePuey EG. Effect of proton pump inhibitors and H2 antagonists on the stomach wall in 99mTc-sestamibi cardiac imaging. J Nucl Med Technol. 2009;37(4):240-243. [PubMed 19914974]</li>
<li>Ock M, Lee S, Kim H. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor coadministration in patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2022;47(7):1028-1035. [PubMed 35257383]</li>
<li>Aptivus (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 20202. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89. [PubMed 18193914]</li>
<li>Ahmad S. Omeprazole-warfarin interaction. South Med J. 1991;84(5):674-675. [PubMed 2035104</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [PubMed 1493083</li>
<li>Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-184. [PubMed 2718223</li>
<li>Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci. 2003;20(4-5):439-449. [PubMed 14659488</li>
<li>Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab. 2005;6(5):399-411. [PubMed 16248835</li>
<li>Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol. 1993;110(1):482-490. [PubMed 8220911</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit. 2008;30(3):276-281. [PubMed 18520598</li>
<li>Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011;153(3):379-385. [PubMed 21418179</li>
<li>de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LMNo effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamicsBr J Clin Pharmacol1997;44(4):399-401[PubMed 9354316</li>
<li>Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN. Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol. 1997;32(10):991-994. [PubMed 9361171</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827. [PubMed 15258107</li>
<li>Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780]</li>
<li>Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56 Suppl 1:56-61. [PubMed 14616415</li>
<li>Yan M, Wu ZF, Tang D, et al. The impact of PPIs on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018;108:60-64. [PubMed 30216801</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological disease. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211. [PubMed 18171251</li>
<li>Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses. 2012;55(6):483-492. [PubMed 22429709</li>
<li>Tian X, Zhang C, Qin Z, Wang D, Yang J, Zhang X. Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients. Antimicrob Agents Chemother. 2021;65(9):e0020721. [PubMed 34152823</li>
<li>Boyd NK, Zoellner CL, Swancutt MA, et al. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001-6002. [PubMed 22890768</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer; January 2019.</li>
<li>Veerman GDM, Hurkmans DP, Paats MS, et al. Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother. 2022;155:113695. [PubMed 36126454]</li>
<li>Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J Clin Pharmacol. 2004;44(6):640-645. [PubMed 15145972</li>
<li>Pylera (bismith subcitrate, metronidazole, tetracycline) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc.; September 2012.</li>
<li>Tabrecta (capmatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</li>
<li>Lau YY, Gu W, Lin T, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(6):1119-1128. [PubMed 28424965</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2016.</li>
<li>Clarithromycin [prescribing information]. Bedminster, NJ: Alembic Pharmaceuticals, Inc.; February 2022</li>
<li>Prilosec (omeprazole) [prescribing information]. Zug, Switzerland: Covis Pharma; March 2022.</li>
<li>Michaud V, Kreutz Y, Skaar T, et al. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 2014;14(2):151-159. [PubMed 23629159</li>
<li>Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475-482. [PubMed 22318618</li>
<li>Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharmacol Drug Dev. 2016;5(4):269-277. [PubMed 27310328</li>
<li>Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2015;60(1):105-114. [PubMed 26459906</li>
<li>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29. [PubMed 25646891</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. Doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. [PubMed 18076219</li>
<li>Nader A, Mostafa NM, Kim E, Shebley M. Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women. Clin Transl Sci. 2022;15(5):1269-1280. [PubMed 35137535</li>
<li>Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol. 2014;54(4):422-431. [PubMed 24165884</li>
<li>Vassiliou D, Sardh E, Harper P, et al. A drug-drug interaction study evaluating the effect of givosiran, a small interfering ribonucleic acid, on cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250-1260. [PubMed 34510420</li>
<li>Luzu (luliconazole) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; February 2017</li>
<li>Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509. [PubMed 29178272</li>
<li>Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465-472. [PubMed 28155129</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Tpoxx (tecovirimat) [prescribing information]Winchester, KY: Catalent Pharma Solutions; July 2018</li>
<li>Brukinsa (zanubrutinib) [prescribing information]. San Mateo, CA: BeiGene USA, Inc.; November 2019</li>
<li>Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999;47(4):454-457. [PubMed 10233213</li>
<li>Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Jaypirca (pirtobrutinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; January 2023.</li>
<li>Bolek T, Samos M, Stanciakova L, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2017;Apr 25 (Epub ahead of print). [PubMed 28452843</li>
<li>Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33(6):619-623. [PubMed 29255511</li>
<li>Stangier J, Eriksson BI, Dahl O, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555-563. [PubMed 15831779</li>
<li>Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59. [PubMed 18076218</li>
<li>Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175. [PubMed 21972820</li>
<li>Schnierer M, Samos M, Bolek T, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020;75(4):333-335. [PubMed 31895873</li>
<li>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. [PubMed 19717844</li>
<li>Ollier E, Hodin S, Basset T, et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29(6):604-614. [PubMed 26392328</li>
<li>O'Dea D, Whetteckey J, Ting NA prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatranCardiol Ther2016;5(2):187-201[PubMed 27709460</li>
<li>Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586-595. [PubMed 25960019</li>
<li>Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-1713, 1713a-1713b. [PubMed 23425521</li>
<li>Pradaxa (dabigatran) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; July 2020.</li>
<li>Tafinlar (dabrafenib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.</li>
<li>Drewelow B, Schaffler K, Reitmeir P, Bethke TD. Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittelforschung. 2010;60(8):483-491. [PubMed 20863004</li>
<li>Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-164. [PubMed 7648765</li>
<li>Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995;58(1):62-72. [PubMed 7628184</li>
<li>Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47(1):79-85. [PubMed 2104790</li>
<li>Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39(1):51-54. [PubMed 2276389</li>
<li>Lima DR, Santos RM, Werneck E, Andrade GN. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers. Eur J Drug Metab Pharmacokinet. 1991;16(3):161-170. [PubMed 1814733</li>
<li>Locniskar A, Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. J Clin Pharmacol. 1986;26(4):299-303. [PubMed 2871051]</li>
<li>Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569-572. [PubMed 1954072</li>
<li>Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1995;33(9):481-485. [PubMed 8520804</li>
<li>Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400-402. [PMID: 17458401</li>
<li>Le GH, Schaefer MG, Plowman BK, Morreale AP, Delattre M, Okino L, Felicio L. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors. Am J Health Syst Pharm. 2003;60(13):1343-1345. [PubMed 12901036</li>
<li>Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CBV. Omeprazole does not modulate pharmacokinetic effect of digoxin in patients with heart failure. Int J Cardiol. 2015;179:343-344. [PubMed 25464482]</li>
<li>Rozlytrek (entrectinib) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; August 2019.</li>
<li>Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508-516. [PubMed 18492125</li>
<li>Intelence (etravirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; July 2019.</li>
<li>Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose fedratinib in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(5):995-1001. [PubMed 32318809]</li>
<li>Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on the filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585-594. [PubMed 30768860</li>
<li>Jyseleca (filgotinib) [summary of product characteristics]. Mechelen, Belgium: Galapagos NV; January 2022.</li>
<li>Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;8:457-464. [PubMed 17760738</li>
<li>Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 2006;42:61-67. [PubMed 16639341</li>
<li>Kiser JJ, Lichtenstein KA, Anderson PL, et al. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26:511-514. [PubMed 16553510</li>
<li>Ford SL, Wire MB, Lou Y, et al. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49:467-469. [PubMed 15616339</li>
<li>Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48:791-798. [PubMed 14982766]</li>
<li>Yin O, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850. [PubMed 15608563</li>
<li>Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012;68(5):553-560. [PubMed 22189672</li>
<li>Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731. [PubMed 19299322</li>
<li>Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509. [PubMed 20186406]</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</li>
<li>Brexafemme (ibrexafungerp) [prescribing information]. Jersey City, NJ: Scynexis Inc; June 2021.</li>
<li>Actemra (tocilizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2021</li>
<li>Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386-1394. [PubMed 26054042]</li>
<li>Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185-189. [PubMed 21150767</li>
<li>Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821-829. [PubMed 27890768</li>
<li>Tran-Duy A, Connell NJ, Vanmolkot FH, et al. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J Intern Med. 2019;285(2):205-214. [PubMed 30141278</li>
<li>Imai R, Higuchi T, Moriomoto M, Koyamada R, Okada S. Iron deficiency anemia due to long-term use of a proton pump inhibitor. Inter Med. 2018;57(6):899-901. [PubMed 29151538</li>
<li>Mabuchi S, Suzuki R, Sasak M, et al. Case report of severe iron deficiency anemia caused by proton pump inhibitor in an elderly patient. Geriatr Gerontol Int. 2017;662-663. [PubMed 28405975</li>
<li>Hashimoto R, Matsuda T, Chonan A. Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med. 2014;53(20):2297-2299. [PubMed 25318791</li>
<li>Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97(9):887-889. [PubMed 15455980</li>
<li>Khatib MA, Rahim O, Kania R, Molloy P. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig Dis Sci. 2002;47(11):2596-2597. [PubMed 12452401</li>
<li>Eghbali A, Khalilpour A, Taherahmadi H, Bagheri BPantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled studyTherapie2019;74(5):507-512[PubMed 30704764</li>
<li>Shalev H, Quider AA, Harosh MB, Kapelushnik J. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia. Pediatr Hematol Oncol. 2016;33(7-8):457-461. [PubMed 27960647</li>
<li>Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291-1295. [PubMed 17344278</li>
<li>Tempel M, Chawla A, Messina C, Celiker MY. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol. 2013;30(3):307-310. [PubMed 24385811</li>
<li>Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-292. [PubMed 1607604</li>
<li>Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011;134(2):224-231. [PubMed 21911976</li>
<li>Sarker SA, Mahmud H, Davidsson L, et al. Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology. 2008;135(5):1534-1542. [PubMed 18775429]</li>
<li>Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34(5):317-325. [PubMed 24567279</li>
<li>Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; June 2019.</li>
<li>Koch KM, Im Y-H, Kim S-B, et al. Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients. Clin Pharmacol Drug Dev. 2013;2(4):336-341. [PubMed 27121938</li>
<li>Tyverb (lapatinib) [summary of product characteristics]. Camberley, United Kingdom: Novartis Europharm Limited; November 2015</li>
<li>Tykerb (lapatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.</li>
<li>Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</li>
<li>Adhansia XR (methylphenidate) extended-release capsules [prescribing information]. Wilson, NC: Purdue Pharmaceuticals LP; July 2019</li>
<li>Cotempla XR ODT (methylphenidate) extended-release orally disintegrating tablets [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands LLC; June 2017</li>
<li>Concerta (methylphenidate) extended-release tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2017</li>
<li>Ritalin LA (methylphenidate) extended-release capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019</li>
<li>Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Greenville, NC: Patheon Manufacturing Services LLC; June 2019</li>
<li>Jornay PM (methylphenidate) extended-release capsules [prescribing information]. Cherry Hill, NJ: Ironshore Pharmaceuticals Inc; April 2019</li>
<li>Metadate CD (methylphenidate) extended-release capsules [prescribing information]. Smyrna, GA: UCB Inc; June 2014</li>
<li>Quillichew ER (methylphenidate) extended-release chewable tablets [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; March 2017</li>
<li>Quillivant XR (methylphenidate) extended-release oral suspension [prescribing information]New York, NY: Pfizer Inc; January 2017</li>
<li>Ritalin SR (methylphenidate) extended-release tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.</li>
<li>Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120-2138. [PubMed 28808886</li>
<li>Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; February 2022.</li>
<li>Ji T, Rockich K, Epstein N, et al. Evaluation of drug-drug interactions of pemigatinib in healthy participants [published online July 19, 2021]. Eur J Clin Pharmacol. doi: 10.1007/s00228-021-03184-z. [PubMed 34282472</li>
<li>Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; February 2021.</li>
<li>Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. [PubMed 18303127</li>
<li>Seiler D, Doser K, Salem I. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. Arzneimittelforschung. 2011;61(4):247-251. [PubMed 21650084</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed 25012577</li>
<li>Kagami T, Yamade M, Suzuki T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype. Clin Pharmacol Ther. 2018;103(5):906-913. [PubMed 28875498</li>
<li>Effient (prasugrel) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; December 2020.</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Yang E, Ji SC, Jang I-J, Lee S. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet. 2023;62(4):599-608. [PubMed 36897544</li>
<li>Kolawole JA, Mustapha A, Abdul-Aguye I, Ochekpe N, Taylor RB. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal. 1999;20(5):737-743. [PubMed 10701981</li>
<li>Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole, and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol. 2019;85(7):1454-1463. [PubMed 30845361</li>
<li>Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. Eur J Clin Pharmacol. 1996;50(5):417-419. [PubMed 8839666]</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2020</li>
<li>Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-492. [PubMed 19143531]</li>
<li>Zhou J, Quinlan M, Glenn K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol. 2016;82(4):1022-1029. [PubMed 27277189</li>
<li>Odomzo (sonidegib) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2017.</li>
<li>Tazverik (tazemetostat) [prescribing information]. Cambridge, MA: Epizyme, Inc.; January 2020.</li>
<li>Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. [PubMed 16641395</li>
<li>Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. [PubMed 17669709</li>
<li>Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-59. [PubMed 16477543</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075</li>
<li>Abi-Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? Arq Bras Endocrinol Metabol. 2014;58(7):731-736. [PubMed 25372582</li>
<li>Ermeza (levothyroxine) solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022</li>
<li>Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. [PubMed 25259910]</li>
<li>Giri P, Gupta L, Naidu S, et al. In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, alicarb, methiocarb, motelukast and ziprasidone. Drug Metabo Lett. 2019;12(2):101-116. [PubMed 30117405</li>
<li>Egaten (triclabendazole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2019.</li>
<li>Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26-33. [PubMed 23110788]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. Doi: 10.1007/s40262-017-0591</li>
<li>[PubMed 28866861]</li>
<li>Verquvo (vericiguat) [prescribing information].Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2021.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2022</li>
<li>Calquence (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2022.</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al, “Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel after Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,” Pharmacotherapy, 2010, 30(8):787-96. [PubMed 20653354</li>
<li>Evanchan J, Donnally MR, Binkley P, et al, “Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor after Stent Placement for Acute Myocardial Infarction,” Clin Cardiol, 2010, 33(3):168-71. [PubMed 20235209</li>
<li>Stockl KM, Le L, Zakharyan A, et al, “Risk of Rehospitalization for Patients Using Clopidogrel with a Proton Pump Inhibitor,” Arch Intern Med, 2010, 170(8):704-10[PubMed 20421557</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2018.</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2021.</li>
<li>Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067]</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2019.</li>
<li>Becker ML, Franken WP, Karapinar F, Verzijl-Zeegers R, Schalekamp T, van der Hoeven RT. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. Eur J Clin Pharmacol. 2015;71(12):1461-1465. [PubMed 26400679</li>
<li>Bertram V, Yeo K, Anoopkumar-Dukie S, Bernaitis N. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract. 2019;73(11):e13382. [PMID 31250945</li>
<li>Nexium (esomeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2014.</li>
<li>Huang Q, Liu Q, Yin T, Hu L, Ding H, Liu S, Jiang Y. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol. 2020;76(6):833-842. [PubMed 32157329</li>
<li>Cojutti P, Candoni A, Forghieri, et al. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and/or with CYP inhibitors plus CYP inducers. Basic Clin Pharmacol Toxicol. 2016;118(6):474-479. [PubMed 26572687</li>
<li>Iwamoto T, Monma F, Fujieda A, et al. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Clin Ther. 2011;33(8):1077-1080. [PubMed 21802143</li>
<li>Scholler J, Nivoix Y, Herbrecht R, et al. Ventricular bigeminy associated with voriconazole, methadone and esomeprazole. Int J Clin Pharm. 2011;33(6):905-908. [PubMed 22108788</li>
<li>Tsubokura M, Miura Y, Itokawa T, et al. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol. 2011;51(10):1488-1490. [PubMed 21098688</li>
<li>Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262-3267. [PubMed 23629724</li>
<li>Dexilant (dexlansoprazole) [prescribing information]Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2018</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; October 2017</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc.; January 2019.</li>
<li>Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” Ann Pharmacother, 2003, 37(6):808-11. [PubMed 12773066</li>
<li>Jacobson TA, “Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors,” Am J Cardiol, 2004, 94:1140</li>
<li>[PubMed 15518608</li>
<li>Amsden GW, Kuye O,Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” J Clin Pharmacol, 2002, 42:444</li>
<li>[PubMed 11936570</li>
<li>Lee AJ,Maddix DS, “Rhabdomyolysis Secondary to a Drug Interaction between Simvastatin and Clarithromycin,” Ann Pharmacother, 2001, 35:26-31. [PubMed 11197581</li>
<li>Chen C, Lin J, Smolarek T, et al, “P-Glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in Mdr1a/B Knockout and Wild-Type Mice,” Drug Metab Dispos, 2007, 35:1725</li>
<li>[PubMed 17640956</li>
<li>Chen C, Mireles RJ, Campbell SD, et al, “Differential Interaction of 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitors with Abcb1, Abcc2, and Oatp1b1,” Drug Metab Dispos, 2005, 33:537-46. [PubMed 15616150</li>
<li>Hochman JH, Pudvah N, Qiu J, et al, “Interactions of Human P-Glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin,” Pharm Res, 2004, 21:1686-91. [PubMed 15497697</li>
<li>Wu X, Whitfield LR,Stewart BH, “Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter,” Pharm Res, 2000, 17:209-15. [PubMed 10751037</li>
<li>Pauli-Magnus C, Rekersbrink S, Klotz U, et al, “Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein,” Naunyn Schmiedebergs Arch Pharmacol, 2001, 364:551</li>
<li>[PubMed 11770010</li>
<li>Collett A, Tanianis-Hughes J, Carlson GL, et al, “Comparison of P-Glycoprotein-Mediated Drug-Digoxin Interactions in Caco-2 with Human and Rodent Intestine: Relevance to in Vivo Prediction,” Eur J Pharm Sci, 2005, 26:386-93. [PubMed 16153812]</li>
<li>Prevacid (lansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Prevacid (lansoprazole) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2020.</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed: 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review. J Am Heart Assoc. 2015;4(11). [PubMed: 26514161</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed: 22464478</li>
<li>Shamliyan TA, Middleton M, Borst C. Patient-centered outcomes with concomitant use of proton pump inhibitors and other drugs. Clin Ther. 2017;39(2):404-427. [PubMed: 28189362</li>
<li>Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823. [PubMed: 20102352</li>
<li>Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70(9):1049-1057. [PubMed: 25012577</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-36[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244</li>
<li>Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig. 2011;31(10):727-733. [PubMed 21877765</li>
<li>Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44(11):1223-1229. [PubMed 15496639</li>
<li>Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005;60(1):61-68. [PubMed 15963095</li>
<li>Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162-164. [PubMed 15546944]</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2014; July 28 (Epub ahead of print). [PubMed 25068772</li>
<li>Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-277. [PubMed 18615373</li>
<li>Uno T, Sugimoto K, Sugawara K, Tateishi TThe role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazoleTher Drug Monit2008;30(3):276-281[PubMed 18520598</li>
<li>Niu Q, Wang Z, Zhang Y, et al. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther. 2017;22(2):142-152. [PubMed 27512080</li>
<li>Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11). pii: e002245. [PubMed 26514161</li>
<li>Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43(3):212-224. [PubMed 22564422</li>
<li>Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35(2):127-139. [PubMed 22204719</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Lu M. Report: Impact of drug combination of clopidogrel and pantoprazole in the prognosis of patients with transient ischemic attack. Pak J Pharm Sci. 2017;30(1):217-221. [PubMed 28603135</li>
<li>Choi YJ, Kim N, Jang IJ, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-511. [PubMed 28395507</li>
<li>Gu RX, Wang XZ, Li J, Deng J, Li XX, Wang JEffects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrelMil Med Res2016;3</li>
<li>[PubMed 28018669</li>
<li>Bolek T, Samos M, Simonova R, et al. Does pantoprazole affect the on-treatment platelet reactivity in patients with acute STEMI treated with ADP receptor blockers?-a pilot prospective study. Am J Ther. 2017;24(2):e162-e166. [PubMed 27415979</li>
<li>Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacol Rep. 2012;64(2):360-368. [PubMed 22661187</li>
<li>Protonix IV (pantoprazole) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2020</li>
<li>Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012;33(5):278-283. [PubMed 22623337]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, Dammann G, Hiemke C, Grunder G, Paulzen M. The effects of co-prescription of pantoprazole on the clozapine metabolism. Pharmacopsychiatry. 2020;53(2):65-70. [PubMed 31614374]</li>
<li>Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metabol Dispos. 2014;42(7):1174-1179. [PubMed 24764147]</li>
<li>Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. Clin Pharmacokinet. doi: 10.1007/s40262-017-0591</li>
<li>Chandelia S, Dubey NK. Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole. Indian J Crit Care Med. 2016;20(2):127-128. [PubMed 27076718</li>
<li>Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39(6):700-703. [PubMed 7654493</li>
<li>Henriksen DP, Stage TB, Hansen MR, Rasmussen L, Damkier P, Pottegard A. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. 2015;24(12):1337-1340. [PubMed 26395871</li>
<li>Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-512. [Pubmed1493083</li>
<li>Li XQ, Andersson TB, Ahlstrom M, Weidolf LComparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activitiesDrug Metab Dispos2004;32(8):821-827[PubMed 15258107</li>
<li>Ko J, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25(7):853-862. [PubMed 9224780</li>
<li>Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71(9):1059-1066. [PubMed 26071277</li>
<li>Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. [PubMed 20844485]</li>
<li>El-Bohy D, Sharkawy M, Abo-Elazm S, et al. Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney transplantation: A randomized clinical trial. Ther Apher Dial. 2020;24(5):591-598. [PubMed 31856374</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-440. [PubMed 11009056</li>
<li>Lorf T, Ramadori G, Ringe B, Schworer H. Pantoprazole does not affect cyclosporin a blood concentration in kidney-transplant patients. Eur J Clin Pharmacol. 2000;55(10):733-735. [PubMed 10663451]</li>
<li>Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74(10):2187-2192. [PubMed 20736505</li>
<li>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70(3):383-392. [PubMed 20716239</li>
<li>Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. [PubMed 19108880</li>
<li>Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375. [PubMed 19106083</li>
<li>Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. [PubMed 19106084</li>
<li>Brandt JT, Close SL, Iturria SJ, et alCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007;5:2429-2436[PubMed 17900275</li>
<li>Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. [PubMed 16772608</li>
<li>Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735-741. [PubMed 17361128</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. [PubMed 15258107]</li>
<li>Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61(3):309-314. [PubMed 16487224</li>
<li>Aciphex (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2018.</li>
<li>Liu G, Wen J, Guo D, et al. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. J Pharmacol Sci. 2016;132(4):244-248. [PubMed 27245553]</li>
<li>Hata M, Hayasaka M, Sezai A, et al, “Proton Pump Inhibitors May Increase the Risk of Delayed Bleeding Complications after Open Heart Surgery If Used Concomitantly with Warfarin,” Thorac Cardiovasc Surg, 2008, 56:274-7</li>
<li>Ahmad S, “Omeprazole-Warfarin Interaction,” South Med J, 1991, 84:674-5</li>
<li>Unge P, Svedberg LE, Nordgren A, et al, “A Study of the Interaction of Omeprazole and Warfarin in Anticoagulated Patients,” Br J Clin Pharmacol, 1992, 34:509-12</li>
<li>Sutfin T, Balmer K, Bostrom H, et al, “Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men,” Ther Drug Monit, 1989, 11:176-84</li>
<li>Zhou Q, Chan E, “Effect of Omeprazole on the Anticoagulant Activity and the Pharmacokinetics of Warfarin Enantiomers in Rats,” Eur J Pharm Sci, 2003, 20:439-49</li>
<li>Zhou Q, Zhou S, Chan E, “Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and cDNA-Expressed Cytochrome P450 Isozymes,” Curr Drug Metab, 2005, 6:399-411</li>
<li>Hermans JJ, Thijssen HH, “Human Liver Microsomal Metabolism of the Enantiomers of Warfarin and Acenocoumarol: P450 Isozyme Diversity Determines the Differences in Their Pharmacokinetics,” Br J Pharmacol, 1993, 110:482-90</li>
<li>Uno T, Sugimoto K, Sugawara K, et al, “The Role of Cytochrome P2C19 in R-Warfarin Pharmacokinetics and Its Interaction with Omeprazole,” Ther Drug Monit, 2008, 30:276-81</li>
<li>Li XQ, Andersson TB, Ahlstrom M, et al, “Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,” Drug Metab Dispos, 2004, 32:821-7</li>
<li>Ko J, Sukhova N, Thacker D, et al, “Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms,” Drug Metab Dispos, 1997, 25:853-862.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2016.</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield IL, Takeda Pharmaceuticals America Inc; June 2018.</li>
<li>Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (Tak-390mr), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29:35-50. [PubMed 19067473</li>
<li>Hata M, Shiono M, Akiyama K, et al. Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese. Thorac Cardiovasc Surg. 2015;63(1):45-50. [PubMed 25068772</li>
<li>Dexilant (dexlansoprazole) [Prescribing Information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2017</li>
<li>Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, Shin JG. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos. 2005;33(2):209-213. [PubMed 15537834]</li>
<li>Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311. [PubMed 22464259</li>
<li>Przespolewski ER, Westphal ES, Rainka M, Smith NM, Bates V, Gengo FM. Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel. J Stroke Cerebrovasc Dis. 2018;27(6):1582-1589. [PubMed 29449127</li>
<li>Dexilant (dexlansoprazole) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; June 2018</li>
<li>Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2018</li>
<li>Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30(8):787-796. [PubMed 20653354</li>
<li>Stockl KM, Le L, Zakharyan A, et alRisk of rehospitalization for patients using clopidogrel with a proton pump inhibitorArch Intern Med2010;170(8):704-710[PubMed 20421557</li>
<li>Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168-171. [PubMed 20235209</li>
<li>Mahabaleshwarkar RK, Yang Y, Datar MV, et al. Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients. Curr Med Res Opin. 2013;29(4):315-323. [PubMed 23362935</li>
<li>Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012;32(9):809-818. [PubMed 22744772</li>
<li>Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors - a cohort study. Ann Intern Med. 2010;152(6):337-345. [PubMed 20231564</li>
<li>O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997. [PubMed 19726078</li>
<li>Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329. [PubMed 19933932</li>
<li>Juurlink DN, Gomes T, Ko DT, et al. A population based study of drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. [PubMed 19176635</li>
<li>Wei P, Zhang YG, Ling L, et al. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-2864. [PubMed 27882086</li>
<li>Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824-834. [PubMed 22364155</li>
<li>Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2CDrug Metab Dispos. 2012;40(9):1698-1711. [PubMed 22648560</li>
<li>Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965-974. [PubMed 22464478]</li>
<li>Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2018.</li>
<li>Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc; April 2006</li>
<li>Kayexalate (sodium polystyrene sulfonate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; December 2010</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a “nonsystemic” antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Fernandez PC, Kovnat PJ. Metabolic acidosis reversed by the combination of magnesium and a cation-exchange resin. N Engl J Med. 1972;286(1):23-24. [PubMed 5006921</li>
<li>Ziessman HA. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. South Med J. 1976;69(4):497-499. [PubMed 817399</li>
<li>Madias NE, Levey AS. Metabolic alkalosis due to absorption of “nonabsorbable” antacids. Am J Med. 1983;74(1):155-158. [PubMed 6849324]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36(6):1219-1224. [PubMed 1329615</li>
<li>Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother. 1996;37(Suppl A):41-55. [PubMed 8737124</li>
<li>Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989;46(6):700-705. [PubMed 2598571</li>
<li>Shiba K, Sakamoto M, Nakazawa Y, et al. Effects of antacid on absorption and excretion of new quinolones. Drugs. 1995;49(Suppl 2):360-361. [PubMed 8549362</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):39-48. [PubMed 11352441</li>
<li>Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830-832. [PubMed 1503446</li>
<li>Lehto PL, Kivisto KTDifferent effects of products containing metal ions on the absorption of lomefloxacinClin Pharmacol Ther1994;56(5):477-482[PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35(3):302-304. [PubMed 8471407</li>
<li>Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Emrok O (levonadifloxacin) tablet [product information]. Maharashtra, India: Wockhardt Limited; April 2022.</li>
<li>Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet. 2001;40(suppl 1):39-48. [PubMed 11352441</li>
<li>Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy. 1999;45(6):504-511. [PubMed 10567782</li>
<li>Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther. 1998;20(6):1149-1158. [PubMed 9916608</li>
<li>Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on the absorption of DR-3355 in humans. Antimicrobial Agents Chemother. 1992;36(10):2270-2274. [PubMed 1444308</li>
<li>Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother. 1990;34(12):2436-2438. [PubMed 2088202</li>
<li>Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34(3):432-435. [PubMed 2334155</li>
<li>Grasela TH Jr, Schentag JJ, Sedman AJ, et alInhibition of enoxacin absorption by antacids or ranitidineAntimicrob Agents Chemother1989;33(5):615-617[PubMed 2751276</li>
<li>Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):93-97. [PubMed 9222077</li>
<li>Hoffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4(3):345. [PubMed 3160584</li>
<li>Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol. 1992;33(1):115-116. [PubMed 1540482</li>
<li>Jaehde U, Sorgel F, Stephan U, Schunak W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother. 1994;38(5):1129-1133. [PubMed 8067750</li>
<li>Maesen FP, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids. J Antimicrob Chemother. 1987;19(6):848-850. [PubMed 3475268</li>
<li>Prescribing information. Cytotec (misoprostol). New York, NY: Pfizer Inc., September 2009.</li>
<li>Quinine [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; July 2015.</li>
<li>Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017</li>
<li>Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020-3026. [PubMed 22450971</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494</li>
<li>FDA Antiviral Drugs Advisory Committee Meeting. ISENTRESS™ (raltegravir) 400 mg For Treatment of HIV (NDA 22-145). Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf. Published September 5, 2007. Accessed online November 15, 2013.</li>
<li>Dimaval (DMPS) Hartkapseln (unithiol) [summary of product characteristics]. Berlin, Germany: Haupt Pharma Wulfing GmbH; June 2020.</li>
<li>Calquence (acalabrutinib) capsules [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc.; March 2010</li>
<li>Ruggiero M, Brunese M, Morelli S, et al. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-777. [PubMed 6895034</li>
<li>Karbach U, Ewe K. Calcium and magnesium transport and influence of 1,25-dihydroxyvitamin D3. In vivo perfusion study at the colon of the rat. Digestion. 1987;37(1):35-42. [PubMed 3609503</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: Modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;25(15):1093-1115</li>
<li>Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium. 1986;5(5-6):293-300. [PubMed 3807422</li>
<li>Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Thioctic acid tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200201478. Accessed September 1, 2014.</li>
<li>Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2013</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; August 2020.</li>
<li>Evaluation of Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis and Clinical Implications. Guidance for Industry [Draft]. Available at: https://www.fda.gov/media/144026/download. Accessed July 22, 2021.</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; June 2019.</li>
<li>HalfLytely and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) [prescribing information]. Braintree, MA: Braintree Laboratories Inc; May 2006.</li>
<li>De-Noltab (tripotassium bismuth dicitrate) [UK summary of product characteristics]. Chertsey, Surrey, United Kingdom: Astellas Pharma Ltd.; September 2012.</li>
<li>Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010</li>
<li>Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015</li>
<li>Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011</li>
<li>Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015</li>
<li>Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</li>
<li>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc.; April 2023.</li>
<li>Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; January 2021.</li>
<li>Calcijex (calcitriol) injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; March 2012</li>
<li>Ruggiero M, Brunese M, Morelli S, Salvia PF, Mangoni C, Stefano S. Plasma 1,25 hydroxycholecalciferol concentrations and net intestinal calcium, phosphate and magnesium absorption in man. Boll Soc Ital Biol Sper. 1981;57(7):791-797. [PubMed 6895034</li>
<li>Ritchie G, Kerstan D, Dai LJ, et al. 1,25(OH)(2)D(3) stimulates Mg2+ uptake into MDCT cells: modulation by extracellular Ca2+ and Mg2+. Am J Physiol Renal Physiol. 2001;280(5):F868-F878. [PubMed 11292630</li>
<li>Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;26(15):1093-1115. [PubMed 14640773</li>
<li>Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49(1):163-167. [PubMed 8770963]</li>
<li>Cefdinir [prescribing information]. Parsippany, NJ: Ascend Laboratories; January 2018.</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ, Collier PS. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine. J Trop Med Hyg. 1982;85(4):159-163. [PubMed 6292443</li>
<li>McElnay JC, Mukhtar HA, D'Arcy PF, Temple DJ. In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin. J Trop Med Hyg. 1982;85(4):153-158. [PubMed 7143531</li>
<li>Iwuagwu MA, Aloko KS. Adsorption of paracetamol and chloroquine phosphate by some antacids. J Pharm Pharmacol. 1992;44(8):655-658. [PubMed 1359089</li>
<li>Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: sanofi-aventis US LLC; October 2018.</li>
<li>Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology. 1981;80(4):661-665. [PubMed 7202937</li>
<li>Naggar VF, Khalil SA, Gouda MW. Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans. J Pharm Sci. 1978;67(7):1029-1030. [PubMed 207854</li>
<li>Lee DA, Taylor GM, Walker JG, et al. The effect of concurrent administration of antacids on prednisolone absorption. Br J Clin Pharmacol. 1979;8(1):92-94. [PubMed 552304</li>
<li>Tanner AR, Caffin JA, Halliday JW, et al. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. Br J Clin Pharmacol. 1979;7(4):397-400. [PubMed 444359</li>
<li>Albin H, Vincon G, Demotes-Mainard F, et al. Effects of aluminum phosphate on the bioavailability of cimetidine and prednisolone. Eur J Clin Pharmacol. 1984;26(2):271-273. [PubMed 6723769]</li>
<li>Product monograph. Pradaxa (dabigatran etexilate). Burlington, Ontario: Boehringer Ingelheim Canada Ltd., February 2019</li>
<li>Prescribing information. Pradax (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2012.</li>
<li>Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700-709. [PubMed 19395585</li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</li>
<li>Ferriprox (deferiprone) tablets [prescribing information]. Weston, FL: ApoPharma USA Inc; July 2019</li>
<li>Ferriprox (deferiprone) oral solution [prescribing information]. Weston, FL: ApoPharma USA Inc; April 2018.</li>
<li>Rescriptor (delavirdine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2019</li>
<li>Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol. 2003;43(2):171-179. [PubMed 12616670]</li>
<li>Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Hectoral (doxercalciferol) injection [prescribing information]. Cambridge, MA: Genzyme Corporation; June 2016</li>
<li>Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015</li>
<li>Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764-776. [PubMed 19446149]</li>
<li>Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64(1):45-50. [PubMed 23774876</li>
<li>Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2019</li>
<li>Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2019</li>
<li>Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug-drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:1</li>
<li>[PubMed 30798679]</li>
<li>Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products LP; April 2019.</li>
<li>Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals Inc; October 2016.</li>
<li>Allegra (fexofenadine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2010.</li>
<li>Fosinopril [prescribing information]. Princeton, NJ: Sandoz Inc; May 2013</li>
<li>Apo-fosinopril (fosinopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2008.</li>
<li>Yagi T, Naito Y, Mino Y, Umemura K, Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet. 2012;27(2):248-254. [PubMed 22240839</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008</li>
<li>Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009</li>
<li>Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490</li>
<li>Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581</li>
<li>Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976</li>
<li>McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345</li>
<li>Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282]</li>
<li>Prescribing information. Anaspaz (hyoscyamine). Lenexa, KS: B. F. Ascher &amp; Compant, Inc., 6/2010</li>
<li>Prescribing information. Hyosyne (hyoscyamine). Spring Valley, NY: Silarx Pharmaceuticals, Inc., 4/2007</li>
<li>Prescribing information. Levsin (hyoscyamine). Marietta, GA: Alaven Pharmaceutical LLC, 2/2008</li>
<li>Prescribing information. Symax SR (hyoscyamine). Ft. Worth, TX: Capellon Pharmaceuticals, LLC, 9/2012</li>
<li>Prescribing information. Oscimin-SR (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011</li>
<li>Prescribing information. Oscimin (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</li>
<li>Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr. 1991;53(1):106-111. [PubMed 1984334</li>
<li>Pruchnicki MC, Coyle JD, Hoshaw-Woodard S, Bay WH. Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol. 2002;42(10):1171-1176. [PubMed 12362933</li>
<li>Wallace KL, Curry SC, LoVecchio F, Raschke RA. Effect of magnesium hydroxide on iron absorption following simulated mild iron overdose in human subjects. Acad Emerg Med. 1998;5(10):961-965. [PubMed 9862585</li>
<li>Hall GJ, Davis AE. Inhibition of iron absorption by magnesium trisilicate. Med J Aust. 1969;2(2):95-96. [PubMed 5803866</li>
<li>Ekenved G, Halvorsen L, Solvell L. Influence of a liquid antacid on the absorption of different iron salts. Scand J Haematol Suppl. 1976;28:65-77. [PubMed 1064903</li>
<li>O'Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Rastogi SP, Padilla F, Boyd CM. Effect of aluminum hydroxide on iron absorption. J Ark Med Soc. 1976;73(3):133-134. [PubMed 134015</li>
<li>Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81(6):1068-1071. [PubMed 7286584</li>
<li>Benkhedda K, L'abbe MR, Cockel KAEffect of calcium on iron absorption in women with marginal iron statusBr J Nutr2010;103(5):742-748[PubMed 19860985</li>
<li>Minihane AM, Fairweather-Tait SJ. Effect of calcium supplementation on daily nonheme-iron absorption and long-term iron status. Am J Clin Nutr. 1998;68(1):96-102. [PubMed 9665102</li>
<li>Dawson-Hughes B, Seligson FH, Hughes VA. Effects of calcium carbonate and hydroxyapatite on zinc and iron retention in postmenopausal women. Am J Clin Nutr. 1986;44(1):83-88. [PubMed 3014855</li>
<li>Spencer BR, Guo Y, Cable RG, et al. Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. Transfusion. 2019;59(10):3146-3156. [PubMed 31318071</li>
<li>Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016;97(6):583-593. [PubMed 27155295</li>
<li>Al-Quaiz JM. Iron deficiency anemia. A study of risk factors. Saudi Med J. 2001;22(6):490-496. [PubMed 11426238</li>
<li>Potgieter MA, Potgieter JH, Venter C, Venter JL, Geisser P. Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia/a single-centre randomized controlled isotope study. Arzneimittelforschung. 2007;57(6A):392-400. [PubMed 17691589</li>
<li>Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med. 1999;33(4):400-405. [PubMed 10092717</li>
<li>Miranda M, Olivares M, Brito A, Pizarro F. Reducing iron deficiency anemia in Bolivian school children: calcium and iron combined versus iron supplementation alone. Nutrition. 2014;30(7-8):771-775. [PubMed 24984991]</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced Oral Itraconazole Bioavailability by Antacid Suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236</li>
<li>Sporanox (itraconazole) oral suspension [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2017.</li>
<li>Van der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, et al. Disposition of ketoconazole, an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Ketoconazole [prescribing information]. Hoschton, GA: Aavis Pharmaceuticals, LLC; September 2021.</li>
<li>Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc.; February 2016.</li>
<li>Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</li>
<li>Recorlev (levoketoconazole) [prescribing information]. Chicago, IL:Xeris Pharmaceuticals, Inc.; January 2022.</li>
<li>Synthroid (levothyroxine sodium) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2009</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669]</li>
<li>Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020</li>
<li>Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Lialda (mesalamine) delayed-release tablets [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; December 2020</li>
<li>Delzicol (mesalamine) delayed-release capsules [prescribing information]. Madison, NJ: Allergan USA Inc; October 2020</li>
<li>Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Shire USA Inc; October 2020</li>
<li>Hussain FN, Ajjan RA, Moustafa M, Weir NW, Riley SA. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Br J Clin Pharmacol. 1998;46(2):173-175. [PubMed 9723828</li>
<li>Bashiri H, Bozorgomid A. Protective effect of Asacol in combination with pantoprazole in ulcerative colitis patients who defecate Asacol tablets intactly: a clinical trial study. Clin Exp Gastroenterol. 2020;13:47-51. [PubMed 32158250</li>
<li>Urex (methenamine) [prescribing information]. Wytheville, VA: Vatring Pharmaceuticals, Inc.; December 2006.</li>
<li>Cerklewski FL, “Influence of Dietary Magnesium on Fluoride Bioavailability in the Rat,” J Nutr, 117(3):496-500. [PubMed 3572562</li>
<li>Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” Clin Pharmacol Ther, 1980, 28(4):529-35. [PubMed 7408412</li>
<li>Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002</li>
<li>Spencer H, Kramer L, Osis D, et al, “Effect of Calcium, Phosphorus, Magnesium, and Aluminum on Fluoride Metabolism in Man,” Ann N Y Acad Sci, 1980, 355:181-94. [PubMed 6940475]</li>
<li>O’Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA. 1986;255(11):1468-1470. [PubMed 3005669</li>
<li>Benjamin IB, Cortell S, Conrad ME. Bicarbonate-induced iron complexes and iron absorption. Gastroenterology. 1967;35:389</li>
<li>Coste JF, De Bari VA, Keil LB, et al. In vitro interactions of oral haematinics and antacid preparations. Curr Ther Res Clin Exp. 1977;22:205.</li>
<li>Cellcept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; December 2019</li>
<li>Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41(6):513-516. [PubMed 8799515</li>
<li>Myfortic (mycophenolic acid) [prescribing information]. Novartis Pharmaceuticals Corporation; April 2020.</li>
<li>Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemother Pharmacol. 2013;71(1):219-226. [PubMed 23070146</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013</li>
<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350. [PubMed 22623211]</li>
<li>Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulphate. Clin Pharmacol Ther. 1983;33(4):465-470. [PubMed 6831825</li>
<li>Lyle WH. Penicillamine and iron. Lancet. 1976;2(7982):420. [PubMed 73880</li>
<li>Harkness JA, Blake DR. Penicillamine nephropathy and iron. Lancet. 1982;2(8312):1368-1369. [PubMed 6129465]</li>
<li>Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr. 1993;12(1):26-30. [PubMed 8440814</li>
<li>Cuprimine (penicillamine) [prescribing information]. Bridgewater, NJ: Aton Pharma Inc; November 2015.</li>
<li>Phospha 250 Neutral (sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic and sodium phosphate, monobasic, monohydrate) [prescribing information]. Allendale, NJ: Rising Pharmaceuticals, Inc.; June 2012</li>
<li>K-Phos No. 2 (potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</li>
<li>K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; October 1998.</li>
<li>Levofloxacin [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; May 2022</li>
<li>Lomefloxacin [product labeling]. Kolon Pharmaceutical Co., Ltd.; March 2016</li>
<li>Norfloxacin [product monograph]. Vaughan, ON, Canada: AA Pharma Inc.; June 2019</li>
<li>Ofloxacin [summary of product characteristics]. Dublin, Ireland: Gerard Laboratories; June 2022</li>
<li>Pipemidic acid [Korean product labeling]. Aprogen Pharmaceutical Co., Ltd.; January 2014</li>
<li>Ciprofloxacin [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022</li>
<li>Baxdela (delafloxacin) [product labeling]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries; April 2022</li>
<li>Moxifloxacin [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited, May 2019</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Canada: Merus Labs International, Inc.; August 2018</li>
<li>Enoxacin [Korean product labeling]. Seoul, South Korea: Crystal Life Science Co. Ltd; June 2018</li>
<li>Prulifloxacin [summary of product characteristics]. Ancona, Italy: A.C.R.A.F. S.p.A.; February 2022.</li>
<li>Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2(8501):294. [PubMed 2874321</li>
<li>Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids. Lancet. 1986;2(8497)</li>
<li>[PubMed 2873348</li>
<li>Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med. 1988;109(2):168-169. [PubMed 3382110</li>
<li>Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005;27(2):81-82. [PubMed 15999916</li>
<li>Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. J Antimicrob Chemother. 1991;28(1):87-94. [PubMed 1663108</li>
<li>Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015</li>
<li>Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013</li>
<li>Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014</li>
<li>Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005</li>
<li>Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014</li>
<li>Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012</li>
<li>Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013</li>
<li>Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011</li>
<li>Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003</li>
<li>Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017</li>
<li>Pefloxacin tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199101448 Accessed October 26, 2017.</li>
<li>Edurant (rilpivirine) [prescribing information]. Raritan NJ: Tibotec Therapeutics; May 2011</li>
<li>Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</li>
<li>Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October 2013.</li>
<li>Groenendaal-van de Meent D, Kerbusch V, Barroso-Fernandez B, et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin Ther. 2021;43(6):1079-1091. [PubMed 33962762</li>
<li>Evrenzo (roxadustat) [summary of product characteristics]. Woking, United Kingdom: Astellas Pharma Ltd; September 2022.</li>
<li>Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol. 1997;43(3):269-272. [PubMed 9088581</li>
<li>Sotalol [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; March 2020</li>
<li>Kahela P, Anttila M, Sundgvist H. Antacids and sotalol absorption. Acta Pharmacol Toxicol (Copenh). 1981;49(3):181-183. [PubMed 7336975]</li>
<li>Summary of product characteristics. Protelos (strontium ranelate). Gidy, France: Les Laboratoires Servier Industrie, 7/2012.</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023</li>
<li>Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. Obes Surg. 2014;24(5):741-746. [PubMed 24347350</li>
<li>Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. Obes Surg. 2018;28(8):2252-2260. [PubMed 29556889]</li>
<li>Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013</li>
<li>Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013</li>
<li>Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</li>
<li>Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet. 1962;114:9-14. [PubMed 14498173</li>
<li>Albert KS, Welch RD, DeSante KA, et al. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J Pharm Sci. 1979;68(5):586-588. [PubMed 435335</li>
<li>Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247(16):2266-2267. [PubMed 7040708</li>
<li>Demeclocycline [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; March 2017</li>
<li>Rosenblatt JE, Barrett JE, Brodie JL, et al. Comparison on in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother. 1966;6:134-141. [PubMed 4964450</li>
<li>Garty M, Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976</li>
<li>Nguyen VX, Nix DE, Gillikin S, Schentag JJEffect of oral antacid administration on the pharmacokinetics of intravenous doxycyclineAntimicrob Agents Chemother1989;33(4):434-436[PubMed 2729939</li>
<li>Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther. 1971;12(5):779-784. [PubMed 4936141</li>
<li>Nuzyra (omadacycline) [prescribing information]. Boston, MA: Paratek Pharmaceuticals, Inc.; October 2020</li>
<li>Tetralysal (lymecycline) [summary of product characteristics]. Watford, Herts, UK: Galderma (UK) Limited; June 2020</li>
<li>Seysara (sarecycline) [prescribing information]. Exton, PA: Almirall, LLC; June 2002</li>
<li>Jaffe JM, Poust RI, Feld SL, et al. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974;63(8):1256-1260. [PubMed 4852448]</li>
<li>Garty M and Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther. 1980;28(2):203-207. [PubMed 7398187</li>
<li>Healy DP, Dansereau RJ, Dunn AB, et al. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother. 1997;31(12):1460-1464. [PubMed 9416381</li>
<li>Khalil SA, Daabis NA, Naggar VF, et al. Effect of magnesium trisilicate and citric acid on the bioavailability of tetracycline in man. Pharmazie. 1977;32(8-9):519-522. [PubMed 201941]</li>
<li>Syprine (trientine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; December 2016</li>
<li>Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1(8273):643-647. [PubMed 6121964</li>
<li>Cuvrior (trientine) [prescribing information]. Chicago, IL: Orphalan; April 2022.</li>
<li>Epclusa (sofosbuvir and velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; June 2016.</li>
<li>Fann WE, Davis JM, Janowsky DS, et al, “Chlorpromazine: Effects of Antacids on its Gastrointestinal Absorption,” J Clin Pharmacol, 1973, 13(10):388-90. [PubMed 4355737</li>
<li>Forrest FM, Forrest IS, and Serra MT, “Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients,” Biol Psychiatry, 1970, 2(1):53</li>
<li>[PubMed 5414905</li>
<li>Moustafa MA, Babhair SA, and Kouta HI, “Decreased Bioavailability of Some Antipsychotic Phenothiazines Due to Interactions With Absorbent Antacid and Antidiarrhoeal Mixtures,” Int J Pharm, 1987, 36:185-9.</li>
<li>Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017</li>
<li>Schroeder ET. Alkalosis resulting from combined administration of a 'nonsystemic' antacid and a cation-exchange resin. Gastroenterology. 1969;56(5):868-874. [PubMed 5782298</li>
<li>Dad T, Garimella PS, Strom JA. Quiz: An unusual case of metabolic alkalosis in a patient with CKD. Am J Kidney Dis. 2017;69(1):A13-A16. [PubMed 28007194</li>
<li>JAMP calcium polystyrene sulfonate [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2020.</li>
<li>Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol. 1984;22(11):626-629. [PubMed 6389377]</li>
<li>Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Hughes GS, Heald DS, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674-685. [PubMed 2557183</li>
<li>Cefpodoxime proxetil [prescribing information]. Allendale, NJ: Rising Pharmaceuticals Inc; May 2017</li>
<li>Food and Drug Administration Center for Drug Evaluation and Research (CDER). Evaluation of gastric pH dependent drug interactions with acid-reducing agents: Study design, data analysis, and clinical implications (November 2020). Available at: https://www.fda.gov/media/144026/download.</li>
<li>Fann WE, Davis JM, Janowsky DS, Sekerke HJ, Schmidt DM. Chlorpromazine: effects of antacids on its gastrointestinal absorption. J Clin Pharmacol. 1973;12(10):388-390. [PubMed 4355737</li>
<li>Chlorpromazine [prescribing information]. Columbus, OH: American Health Packaging; October 2018</li>
<li>Perphenazine [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; December 2016</li>
<li>Haldol (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2019</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2008.</li>
<li>Allard M, Legare N, Millaud F. A possible case of clozapine interaction with aluminum hydroxide. Schizophr Res. 2008;101(1-3):346. [PubMed 18272349</li>
<li>Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corp., March 2008</li>
<li>Prescribing information. Risperdal (risperidone). Titusville, NJ: Ortho-McNeil- Janssen Pharmaceuticals Inc., August 2008</li>
<li>Prescribing information. Seroquel (quetapine). Wilmington, DE: AstraZeneca Pharmaceuticals LP, January 2009</li>
<li>Prescribing information. Abilify (aripiprazole). Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd., August 2008.</li>
<li>Diacerein [prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198802489. Accessed October 1, 2014.</li>
<li>Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909]</li>
<li>Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Respir Dis. 1974;109(1):41-47. [PubMed 4588090</li>
<li>Lin M-Y, Lin S-J, Chan L-C, Lu Y-C. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(7):806-818. [PubMed 20550762</li>
<li>Peloquin CA, Namdar R, Dodge AA, Nix DEPharmacokinetics of isoniazid under fasting conditions, with food, and with antacidsInt J Tuberc Lung Dis1999;3(8):703-710[PubMed 10460103</li>
<li>Sun H, Jin T, Wu X, Yang L, Zuo Y, Liao R. Efficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis. J Int Med Res. 2021;49(7):3000605211027736. [PubMed 34311594</li>
<li>Weber V, Abbott TEF, Ackland GL. Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. Br J Anaesth. 2021;126(3):608-621. [PubMed 33218672</li>
<li>Dong J, Gao L, Wenqing L, Xu Z, Zheng J. Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis. PLoS One. 2014;9(12):e114231. [PubMed 25460931</li>
<li>Sinatra RS, Philip BK, Naulty JS, et al. Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulphate. Anesth Analg. 1985;64:1220-1222. [PubMed 2865911</li>
<li>Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular-blocking agents. Anesthesiology. 1970;32:23. [PubMed 5460601</li>
<li>Ip-Yam C, Allsop E. Abnormal response to suxamethonium in a patient receiving magnesium therapy. Anaesthesia. 1994;49:355-356. [PubMed 8179157</li>
<li>Baraka A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology. 1987;67(5):806-808. [PubMed 2890318</li>
<li>Gaiser RR, Seem EH. Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour. Br J Anaesth. 1996;77:669-671. [PubMed 8957990</li>
<li>Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth. 1996;76(4):565-556. [PubMed 8652332</li>
<li>Yoshida A, Itoh Y, Nagaya K, et alProlonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean sectionJ Anesth2006;20(1):33-35[PubMed 16421674</li>
<li>Kwan WF, Lee C, Chen BJ. A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. J Clin Anesth. 1996;8(5):392-397. [PubMed 8832451</li>
<li>Na HS, Lee JH, Hwang, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth. 2010;104(3):344-350. [PubMed 20042475</li>
<li>Telci L, Esen F, Akcora D, et al. Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements. Br J Anaesth. 2002;89(4):591-598. [PubMed 12393361</li>
<li>Aldrete JA, Zahler A, Aikawa JK. Prevention of succinylcholine-induced hyperkalaemia by magnesium sulfate. Can Anaesth Soc J. 1970;17(5):477-484. [PubMed 5506078</li>
<li>Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth. 1995;74(4):405-409.[PubMed 7734259</li>
<li>Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulphate. Br J Anaesth. 2003;91(3):435-438. [PubMed 12925489</li>
<li>De Vore JS, Asrani R. Magnesium sulfate prevents succinylcholine-induced fasciculations in toxemic parturients. Anesthesiology. 1980;52(1):76-77. [PubMed 7352649</li>
<li>Cizmeci P, Ozkose Z. Magnesium sulphate as an adjuvant to total intravenous anesthesia in septorhinoplasty: a randomized controlled study. Aesthetic Plast Surg. 2007;31(2):167-173. [PubMed 17437152</li>
<li>Olivieri L, Plourde G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery: report of two cases. Can J Anaesth. 2005;52(1):88-93. [PubMed 15625263</li>
<li>James MF, Cork RC, Dennett JE. Succinylcholine pretreatment with magnesium sulfate. Anesth Analg. 1986;65(4):373-376. [PubMed 3513667</li>
<li>Fei S, Xia H, Chen X, Pang D, Xu X. Magnesium sulfate reduces the rocuronium dose needed for satisfactory double lumen tube placement conditions in patients with myasthenia gravis. BMC Anesthesiol. 2019;19(1):170. [PubMed 31472669</li>
<li>Micuci AJQR, Vercosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2019;36(7):502-508. [PubMed 30985540</li>
<li>Ghodraty MR, Saif AA, Kholdebarin AR, et al. The effects of magnesium sulfate on neuromuscular blockade by cisatracurium during induction of anesthesia. J Anesth. 2012;26(6):858-863. [PubMed 22752440</li>
<li>Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: a randomised controlled trial. Eur J Anaesthesiol. 2012;29(2):95-55. [PubMed 22183158</li>
<li>Brown AF, Cobert J, Dierkes J, Kuhn CM, Grant SA. Delayed neuromuscular blockade reversal with sugammadex after vecuronium, desflurane, and magnesium administration: a case report. A A Pract. 2019;13(8):295-298. [PubMed 31283534</li>
<li>Unterbuchner C, Ziegleder R, Graf B, Metterlein T. Magnesium-induced recurarisation after reversal of rocuronium-induced neuromuscular block with sugammadex. Acta Anaesthesiol Scand. 2015;59(4):536-540. [PubMed 25582520</li>
<li>de Almeida CED, de Carvalho LR, Andrade CVC, do Nascimento Jr P, de Barros GAM, Modolo NSP. Effects of magnesium sulphate on the onset time of rocuronium at different doses: a randomized clinical trial. Braz J Anesthesiol. 2021;71(5):482-488. [PubMed 34403648</li>
<li>James MF, Schenk PA, van der Veen BW. Priming of pancuronium with magnesium. Br J Anaesth. 1991;66(2):247-249. [PubMed 1817630</li>
<li>Stacey MR, Barclay K, Asai T, et al. Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Anaesthesia. 1995;50(11):933-936. [PubMed 8678246</li>
<li>Nimbex (cisatracurium) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2018</li>
<li>Quelicin (succinylcholine) [prescribing information]. Lake Forest, IL: Hospira, Inc.; August 2021</li>
<li>Atracurium [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2018</li>
<li>Pancuronium [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2019</li>
<li>Rocuronium [prescribing information]. Lehi, UT: Civica, Inc.; July 2020.</li>
<li>Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminum hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231-1235. [PubMed 18355422</li>
<li>Crestor (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.</li>
<li>Foresti V. Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Sodium polystyrene sulfonate [prescribing information]. Rahway, NJ: Sunrise Pharmaceutical, Inc.; March 2020.</li>
<li>Prograf (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US, Inc.; August 2009</li>
<li>Envarsus XR (tacrolimus extended-release tablets) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med. 1994;97(4):363-365. [PubMed 7942938</li>
<li>Morini E, Catalano A, Lasco A, Morabito N, Benvenga S. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. [PubMed 30919287</li>
<li>Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-486. [PubMed 21595516</li>
<li>Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch Intern Med. 1992;152(1):183-184. [PubMed 1728914</li>
<li>Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol. 1999;84(3):107-109. [PubMed 10193669</li>
<li>Levothyroxine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; September 2022</li>
<li>Ermeza (levothyroxine) oral solution [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd.; April 2022.</li>
<li>Regardh CG, Lundborg P, Persson BA. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Biopharm Drug Dispos. 1981;2(1):79-87. [PubMed 7236872</li>
<li>Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E. Interaction of atenolol with furosemide and calcium and aluminum salts. Clin Pharmacol Ther. 1981;30(4):429-435. [PubMed 7285476]</li>
<li>Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 1991;31(2):164-167. [PubMed 1849152</li>
<li>Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 2003;17(3):563-577. [PubMed 14711077</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013</li>
<li>Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</li>
<li>Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; February 2011</li>
<li>Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998;4:941-948. [PubMed 9563888</li>
<li>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2016 [published October 13, 2016]. doi:10.1001/jamaoncol.2016.3358. [PubMed 27737436</li>
<li>Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104. [PubMed 11286326]</li>
<li>Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med. 1976;295(19):1034-1037. [PubMed 972657</li>
<li>Allen MD, Greenblatt DJ, Harmatz JS, Smith TW. Effect of magnesium-aluminum hydroxide and kaolin-pectin on absorption of digoxin from tablets and capsules. J Clin Pharmacol. 1981;21(1):26-30. [PubMed 7012189</li>
<li>Cooke J, Smith JA. Absence of interaction of digoxin with antacids under clinical conditions. Br Med J. 1978;2(6145):1166-1167. [PubMed 709293]</li>
<li>Radwanski E, Nomeir A, Cutler D, Affrime M, Lin CC. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double-strength liquid or with ranitidine. Am J Ther. 1998;5(2):67-72. [PubMed 10099040</li>
<li>Cedax (ceftibuten) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2015.</li>
<li>Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. Clin Pharmacol Ther. 1976;19(2):234-239. [PubMed 770046]</li>
<li>Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. Clin Pharmacol Ther. 1978;24(3):308-315. [PubMed 28870</li>
<li>Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS. Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. Clin Pharmacol Ther. 1982;31(2):180-183. [PubMed 6120059</li>
<li>Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD. Effect of antacids on absorption of clorazepate. Clin Pharmacol Ther. 1977;22(3):329-335. [PubMed 19188</li>
<li>Tranxene (clorazepate dipotassium) [prescribing information]. Barceloneta, PR: AbbVie LTD; September 2016.</li>
<li>Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI. Diazepam absorption: effect of antacids and food. Clin Pharmacol Ther. 1978;24(5):600-609. [PubMed 699484</li>
<li>Nair SG, Gamble JA, Dundee JW, Howard PJ. The influence of three antacids on the absorption and clinical action of oral diazepam. Br J Anaesth. 1976;48(12):1175-1180. [PubMed 1023953</li>
<li>Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI. Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. J Clin Pharmacol. 1984;24(5-6):255-263. [PubMed 6747022</li>
<li>Valium (diazepam) [prescribing information]. South San Francisco, CA: Hoffman-La Roche; December 2016.</li>
<li>Yamreudeewong W, Scavone JM, Paone RP, Lewis GP. Effect of antacid coadministration on the bioavailability of erythromycin stearate. Clin Pharm. 1989;8(5):352-354. [PubMed 2743731]</li>
<li>Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333-342. [PubMed 688726]</li>
<li>Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother. 2005;49(1):467-469. [PubMed 15616339</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2019.</li>
<li>Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. Eur J Pharm Biopharm. 1998;46(3):299-303. [PubMed 9885302]</li>
<li>Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. Drug Intell Clin Pharm. 1986;20(10):792-795. [PubMed 3769772</li>
<li>Burland WL, Darkin DW, Mills MW. Effect of antacids on absorption of cimetidine. Lancet. 1976;2(7992):965. [PubMed 62195</li>
<li>Bodemar G, Norlander B, Walan A. Diminished absorption of cimetidine caused by antacids. Lancet. 1979;1(8113):444-445. [PubMed 84296</li>
<li>Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. N Engl J Med. 1982;307(7):400-404. [PubMed 708843</li>
<li>Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. J Clin Pharmacol. 1989;29(7):670-672. [PubMed 2569486</li>
<li>Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol. 1987;24(4):551-553. [PubMed 2891370</li>
<li>Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces the bioavailability of ranitidine. Br Med J. 1982;285(6347):998-999. [PubMed 6289961</li>
<li>Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol. 1990;42(5):352-354. [PubMed 1976784</li>
<li>Donn KH, Eshelman FN, Plachetka JR, et alThe effects of antacid and propantheline on the absorption of oral ranitidinePharmacotherapy1984;4(2):89-92[PubMed 6326064</li>
<li>Sullivan TJ, Reese JH, Jauregui L, Miller K, Levine L, Bachmann KA. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. Aliment Pharmacol Ther. 1994;8(1):123-126. [PubMed 7910488]</li>
<li>Tanatril (imidapril) [summary of product characteristics]. London, UK: Mitsubishi Tanabe Pharma Europe Limited; December 2014.</li>
<li>Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663</li>
<li>Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029]</li>
<li>Kristalose (lactulose) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; July 2018</li>
<li>Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014</li>
<li>Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663]</li>
<li>Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</li>
<li>Livtencity (maribavir) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; November 2021.</li>
<li>Segre EJ, Sevelius H, Varady J. Letter: Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583. [PubMed 4852768</li>
<li>Weber SS, Bankhurst AD, Mroszczak E, Ding TL. Effect of Mylanta on naproxen bioavailability. Ther Drug Monit. 1981;3(1):75-83. [PubMed 7233492</li>
<li>Naprosyn (naproxen) [prescribing information]. Apharetta, GA: Canton Laboratories, LLC.; April 2021.</li>
<li>Ismail FA, Khalafallah N, Khalil SA. Absorption of ketoprofen and bumadizone calcium on aluminum-containing antacids and its effect on ketoprofen bioavailability in man. Int J Pharm. 1987;34:189-196</li>
<li>Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6 Pt 2):33S-39S (review). [PubMed 2082311</li>
<li>Holmes GI, et al. Effects of Maalox on the bioavailability of diflunisal. Clin Pharmacol Ther. 1979;25:229</li>
<li>Verbeeck R, Tjandramaga TB, Mullie A, et al. Effect of aluminum hydroxide on diflunisal absorption. Br J Clin Pharmacol. 1979;7(5):519-522. [PubMed 314299</li>
<li>Segre EJ, Sevelium H, Varady J. Effects of antacids on naproxen absorption. N Engl J Med. 1974;291(11):582-583 (letter). [PubMed 4852768</li>
<li>Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; January 2011</li>
<li>von Schrader HW, Buscher G, Dierdorf D, et al. Nabumetone - A novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Tox. 1983;21(6):311-321. [PubMed 6688407</li>
<li>Shaker MA, Akhtar N, Minhas MU, Khan KU, Zangi MI, Munir A. Effect of an Al-Mg hydroxide antacid and food on the pharmacokinetics of dexibuprofen. Drug Res (Stuttg). 2020;70(4):158-164. [PubMed 32110819]</li>
<li>Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.</li>
<li>Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. Br J Clin Pharmacol. 1978;6(2):177-179. [PubMed 678395</li>
<li>Garnett WR, Carter BL, Pellock JM. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1980;37(7):467. [PubMed 7387502</li>
<li>Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Ther Drug Monit. 1981;3(4):333-340. [PubMed 7336470</li>
<li>McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Br J Clin Pharmacol. 1982;13(4):501-505. [PubMed 7066165</li>
<li>Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC. Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol. 1979;36(7):436-438. [PubMed 454247</li>
<li>O'Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. Br J Clin Pharmacol. 1978;6(2):176-177. [PubMed 678394</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</li>
<li>Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115(1):12-18. [PMID 9925057</li>
<li>Gupta PR, Mehta YR, Gupta ML, Sharma TN, Jain D, Gupta RB. Rifampin-aluminium antacid interaction. J Assoc Physicians India. 1988;36(6):363-364. [PubMed 3182711</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifadin (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013</li>
<li>Rifamate (rifampin/isoniazid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2013</li>
<li>Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2010</li>
<li>Rifater (rifampin/isoniazid/pyrazinamide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2009.</li>
<li>Itthipanichpong C, Sirivongs P, Wittayalertpunya S, Chaiyos N. The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers. Drug Metabol Drug Interact. 1992;10(3):213-228. [PubMed 1424642</li>
<li>Gaspari F, Vigano G, Locatelli M, Remuzzi G. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis. 1988;11(4):338-342. [PubMed 3354570</li>
<li>Shastri RA. Effect of antacids on salicylate kinetics. Int J Clin Pharmacol Ther Toxicol. 1985;23(9):480-484. [PubMed 4055159</li>
<li>Levy G, Lampman T, Kamath BL, et al. Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid. N Engl J Med. 1975;293(7):323-325. [PubMed 239345</li>
<li>Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol. 1980;20(5-6 Pt 1):326-331. [PubMed 7400368</li>
<li>Macpherson CR, Milne MD, Evans BM. The excretion of salicylate. Br J Pharmacol Chemother. 1955;10(4):484-489. [PubMed 13276608</li>
<li>Elliot Cham B, Dykman JH, Bochner F. Urinary excretion of aspirin. Br J Clin Pharmacol. 1982;14(4):562-564. [PubMed 7138740</li>
<li>Feldman S, Carlstedt BC. Effect of antacid on absorption of enteric-coated aspirin. JAMA. 1974;227(6):660-661 (letter). [PubMed 4405837</li>
<li>Strickland-Hodge B, Thomas TR, Gould WA, et al. The effects of antacids on enteric-coated salicylate preparations. Rheumatol Rehabil. 1976;15(3):148-152. [PubMed 968338]</li>
<li>Kivisto KT, Neuvonen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1992;42(6):675-679. [PubMed 1623912</li>
<li>Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol. 1991;32(2):215-220. [PubMed 1931470</li>
<li>Zuccaro P, Pacifici R, Pichini S, et al. Influence of antacids on the bioavailability of glibenclamide. Drugs Exp Clin Res. 1989;15(4):165-169. [PubMed 2505996</li>
<li>Kivisto KT, Lehto P, Neuvonen PJ. The effects of different doses of sodium bicarbonate on the absorption and activity of nonmicronized glibenclamide. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):236-240. [PubMed 8390970</li>
<li>Kivisto KT, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminum hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol. 1991;40(4):383-386. [PubMed 1646724</li>
<li>Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther. 1991;49(1):39-43. [PubMed 1988239</li>
<li>Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839-1864. [PubMed 21942976]</li>
<li>Arnold LA, Spurbeck GH, Shelver WH, Henderson WM. Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm. 1979;36(8):1059-1062. [PubMed 484565</li>
<li>Reed RC, Schwartz HJ. Lack of influence of an intensive antacid regimen on theophylline bioavailability. J Pharmacokinet Biopharm. 1984;12(3):315-331. [PubMed 6502473</li>
<li>Darzentas LJ, Stewart RB, Curry SH, Yost RL. Effect of antacid on bioavailability of a sustained-release theophylline preparation. Drug Intell Clin Pharm. 1983;17(7-8):555-557. [PubMed 6872853</li>
<li>Muir JF, Peiffer G, Richard MO, et al. Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation. Eur J Clin Pharmacol. 1993;44(1):85-88. [PubMed 8436162</li>
<li>Ferrari M, Olivieri M, Romito D, Biasin C, Barozzi E, Bassetti S. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline. Riv Eur Sci Med Farmacol. 1991;13(5-6):269-274. [PubMed 1819857</li>
<li>Fernandes E, Melewicz FM. Antacids and theophylline-ranitidine interaction. Ann Intern Med. 1984;101(2):279. [PubMed 6331245</li>
<li>Myhre KI, Walstad RA. The influence of antacid on the absorption of two different sustained-release formulations of theophylline. Br J Clin Pharmacol. 1983;15(6):683-687. [PubMed 6871067</li>
<li>Shargel L, Stevens JA, Fuchs JE, Yu AB. Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. J Pharm Sci. 1981;70(6):599-602. [PubMed 7252799</li>
<li>Theophylline oral solution [prescribing information]. Congers, NY: Chartwell RX LLC; October 2022.</li>
<li>Rudzki P, Jarus-Dziedzic K, Filist M, et al. Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacol Rep. 2021;73(2):604-614 [PubMed 33686610]</li>
<li>Kroboth PD, Smith RB, Silver MR, et al. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol. 1985;19(6):839-842. [PubMed 2862896]</li>
<li>May CA, Garnett WR, Small RE, et al, “Effects of Three Antacids on the Bioavailability of Valproic Acid,” Clin Pharm, 1982, 1(3):244</li>
<li>[PubMed 6821035]</li>
<li>Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother. 1990;34(10):2032-2033. [PubMed 2291673</li>
<li>Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6(4):552-554. [PubMed 6253434</li>
<li>Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21(1):151-158. [PubMed 6282204</li>
<li>Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201-206. [PubMed 15896236]</li>
<li>Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother. 2004;48:804-808. [PubMed 14982768</li>
<li>Kraft WK, Chang PS, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020-4025. [PubMed 24798274</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2022.</li>
<li>Exjade (deferasirox) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2020.</li>
<li>Relyvrio (sodium phenylbutyrate and taurursodiol) [prescribing information]. Cambridge, MA: Amylyx Pharmaceuticals Inc; September 2022.</li>
<li>Weissman I, Krivoy N. Interaction of aluminum hydroxide and allopurinol in patients on chronic hemodialysis. Ann Intern Med. 1987;107(5):787. [PubMed 3662305]</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Effect of ascorbic acid on gastrointestinal aluminum absorption. Lancet. 1991;338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int. 1991;39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654</li>
<li>Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci. 1989;297(1):9-11. [PubMed 2913801</li>
<li>Main J, Ward MK. Potentiation of aluminum absorption by effervescent analgesic tablets in a haemodialysis patient. Br Med J. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol. 1989;31(1):40-44. [PubMed 2914409]</li>
<li>Foresti V. Intestinal obstruction due to Kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41(4):252. [PubMed 8026121</li>
<li>Garcia-Pardo G, Martinez-Vea A, Auguet T, et al. Intestinal obstruction complicating calcium polystyrene sulphonate therapy. Nephrol Dial Transplant. 1996;11(4):751. [PubMed 8671882</li>
<li>Hurley JK. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel. J Pediatr. 1978;92(4):592-593. [PubMed 633020</li>
<li>Calcium Resonium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec: Sanofi-Aventis Canada Inc., April 2006.</li>
<li>Cholbam (cholic acid) [prescribing information]. Baltimore, MD: Asklepion Pharmaceuticals LLC; March 2015.</li>
<li>Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</li>
<li>Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568-572. [PubMed 10049268</li>
<li>Myambutol (ethambutol) [prescribing information]. Langhorne, PA: STI Pharma LLC; April 2012</li>
<li>Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol. 1978;5(2):161-166. [PubMed 619949]</li>
<li>Prescribing information. Neurontin (gabapentin). New York, NY: Pfizer Inc; October 2017.</li>
<li>Mircol (mequitazine) [summary of product characteristics]. Madrid, Spain: ITF Medilab Farma, SA; July 2013.</li>
<li>Moxifloxacin [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; November 2022.</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” Lancet, 1991, 338(8780):1467. [PubMed 1683458</li>
<li>Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” Kidney Int, 1991, 39(4):598-601. [PubMed 2051716</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” Am J Kid Dis, 1991, 17(6):708-11. [PubMed 2042654</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ, 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” Clin Nephrol, 1989, 31(3):123</li>
<li>[PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” Clin Nephrol, 1986, 26(3):146</li>
<li>[PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” Proc Eur Dial Transplant Assoc Eur Ren Assoc, 1985, 21:390</li>
<li>[PubMed 3991529</li>
<li>Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” Am J Physiol, 1985, 249(2 Pt 1):G209-13. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205. [PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” J Lab Clin Med, 1986, 108(2):96-102. [PubMed 3755457]</li>
<li>Moon J, Davison A, Bandy B. Vitamin D and aluminum absorption. CMAJ. 1992;147(9):1308, 1313. [PubMed 1340782</li>
<li>Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol. 1989;31(3):123-127. [PubMed 2706809</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Clin Nephrol. 1986;26(3):146-149. [PubMed 3769230</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:390-394. [PubMed 3991529</li>
<li>Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol. 1985;249(2 Pt 1):G209-G213. [PubMed 4025548</li>
<li>Anthony J, Fadl S, Mason C, et alAbsorption, deposition and distribution of dietary aluminium in immature rats: effects of dietary vitamin D3 and food-borne chelating agentJ Environ Sci Health B1986;21(2):191-205[PubMed 3011882</li>
<li>Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al. 1,25-dihydroxyvitamin D3 increases serum and tissue accumulation of aluminum in rats. J Lab Clin Med. 1986;108(2):96-102. [PubMed 3755457]</li>
<li>Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kid Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Urso 250 / Urso Forte (ursodiol) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2021</li>
<li>Actigall (ursodiol) [prescribing information]. Corona, CA: Watson Pharmaceuticals, Inc.; September 2002</li>
<li>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. [PubMed 30070375]</li>
<li>Demontis R, Leflon A, Fournier A, et al. 1 Alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH</li>
<li>Fournier A, Demontis R, Tahiri Y, et al. 1 Alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH</li>
<li>Zemplar (paricalcitol) capsules [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Rocaltrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Zemplar (paricalcitol) injection [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>Dovonex (calcipotriene) cream [prescribing information]. Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]Greenville, NC: Mayne Pharma; May 2019</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018</li>
<li>Vitamin D (ergocalciferol) [prescribing information]. Laurelton, NY: Epic Pharma, LLC: October 2018.</li>
<li>Chenodol (chenodiol) [prescribing information]. San Diego, CA: Retrophin, Inc; June 2015.</li>
<li>Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ. 1992;304(6843):1686. [PubMed 1633526</li>
<li>Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J. 1994;87(9):894-898. [PubMed 8091252</li>
<li>Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr. 1994;48(1):71-73. [PubMed 8200332</li>
<li>Nestel AW, Meyers AM, Paiker J, Rollin HB. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients. Nephron. 1994;68(2):197-201. [PubMed 7830856</li>
<li>Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study. South Med J. 1993;86(12):1385-1388. [PubMed 8272917</li>
<li>Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs. 1991;14(10):625-629. [PubMed 1748529</li>
<li>Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-711. [PubMed 2042654]</li>
<li>Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; June 2019</li>
<li>Envarsus XR (tacrolimus extended-release) [prescribing information]. Cary, NC: Veloxis Pharmaceuticals, Inc.; September 2020.</li>
<li>Spencer H, Kramer L, Norris C, et al. Effect of aluminum hydroxide on fluoride metabolism. Clin Pharmacol Ther. 1980;28(4):529-535. [PubMed 7408412]</li>
<li>Hong CY, Hu SC, Lin SJ, Chiang BN. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Clin Pharmacol Ther Toxicol. 1985;23(5):244-246. [PubMed 4008113</li>
<li>Inderal (propranolol) tablets [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals LLC; March 2011.</li>
<li>PhosLo (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; March 2011.</li>
<li>Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985;4:345. [PubMed 3160584</li>
<li>Schentag JJ, Watson WA, Nix DE, et al. Time-dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther. 1988;43:135</li>
<li>Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992;36:1219-1234. [PubMed 1329615</li>
<li>Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulphate and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother. 1992;36:2270-2274. [PubMed 1444308</li>
<li>Sahai J, Healey DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302-304. [PubMed 8471407</li>
<li>Frost RW, Lettieri JT, Noe A, et al. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin Pharmacol Ther. 1989;45:165</li>
<li>Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990;34:432-435. [PubMed 2334155</li>
<li>Kays MB, Overholser BR, Mueller BA, et alEffects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacinAm J Kidney Dis2003;42(6):1253-1259[PubMed 14655198</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439</li>
<li>Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014</li>
<li>Federspiel J, Bukhari MJ, Hamill MM. Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. BMJ Case Rep. 2021;14(1):e236655. [PubMed 33408101</li>
<li>Gunnarsson PO, Davidson T, Andersson SB, et al. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189-193. [PubMed 2338118</li>
<li>Emcyt (estramustine) [prescribing information]. New York, NY: Pharmacia and Upjohn Company; June 2007.</li>
<li>Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” Am J Clin Nutr, 2007, 85(1):6-18. [PubMed 17209171</li>
<li>Peacock M, “Calcium Metabolism in Health and Disease,” Clin J Am Soc Nephrol, 2010, 5 Suppl 1:S23-30. [PubMed 20089499</li>
<li>Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” Cochrane Database Syst Rev, 2011, (7):CD007470. [PubMed 21735411]</li>
<li>Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr. 2002;21(3):239-244. [PubMed 12074251</li>
<li>Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19-22. [PubMed 9554821]</li>
<li>Staff H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):27-32. [PubMed 11352439]</li>
<li>HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2018. Available at https://aidsinfo.nih.gov. (Accessed 06/24/2019</li>
<li>HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. (Accessed 06/24/2019</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 22066494]</li>
<li>Tetracycline [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; June 2009</li>
<li>Minocin (minocycline) [prescribing information]. Cranford, NJ: Triax Pharmaceuticals, LLC; August 2010</li>
<li>Vibramycin (doxycycline) [prescribing information]. New York, NY: Pfizer Inc; April 2007</li>
<li>Jung H, Peregrina AA, Rodriguez JM, et al. The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Biopharm Drug Dispos. 1997;18(5):459-463. [PubMed 9210983]</li>
<li>Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822-2825. [PubMed 10838651</li>
<li>Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11:967-971. [PubMed 11716045</li>
<li>Mazokopakis EE, Giannakopoulos TG, Starakis IK. Interaction between levothyroxine and calcium carbonate. Can Fam Physician. 2008;54(1):39. [PubMed 18208953</li>
<li>Csako G, McGriff NJ, Rotman-Pikielny P, et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35(12):1578-1583. [PubMed 11793625</li>
<li>Butner LE, Fulco PP, Feldman G. Calcium carbonate-induced hypothyroidism. Ann Intern Med. 2000;132(7):595. [PubMed 10744606</li>
<li>Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA. 1998;279(10):750. [PubMed 9508149</li>
<li>A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82(1):136-141. [PubMed 25040647</li>
<li>Diskin CJ, Stokes TJ, Dansby LM, et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int Urol Nephrol. 2007;39(2):599-602. [PubMed 17216296]</li>
<li>Salerno DM, Anderson B, Sharkey PH, et al, “Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia With and Without Calcium Pretreatment,” Ann Intern Med, 1987, 107(5):623</li>
<li>[PubMed 3662276</li>
<li>Haft JI and Habbab MA, “Treatment of Atrial Arrhythmias. Effectiveness of Verapamil When Preceded by Calcium Infusion,” Arch Intern Med, 1986, 146(6):1085</li>
<li>[PubMed 3718093</li>
<li>Schoen MD, Parker RB, Hoon TJ, et al, “Evaluation of the Pharmacokinetics and Electrocardiographic Effects of Intravenous Verapamil With Intravenous Calcium Chloride Pretreatment in Normal Subjects,” Am J Cardiol, 1991, 67(4):300</li>
<li>[PubMed 1990794</li>
<li>O’Quinn SV, et al, “Influence of Calcium on the Hemodynamic and Anti-ischemic Effects of Nifedipine Observed During Treadmill Exercise Testing,” Pharmacotherapy, 1990, 10:247 (abstract)</li>
<li>Wohns DH, Patterson JH, Clarke S, et al, “Influence of Calcium Administration on the Short-term Hemodynamic and the Anti-ischemic Effects of Nifedipine,” J Am Coll Cardiol, 1991, 18(4):1070</li>
<li>[PubMed 1894852</li>
<li>Bar-Or D and Gasiel Y, “Calcium and Calciferol Antagonize Effect of Verapamil in Atrial Fibrillation,” Br Med J, 1981, 282(6276):1585</li>
<li>[PubMed 6786574]</li>
<li>Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999;75(887):554-556. [PubMed 10616693</li>
<li>Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. Anesth Analg. 1972;51(2):202-205. [PubMed 5062119</li>
<li>Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA. 1978;240(6):533-534. [PubMed 671662</li>
<li>Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. Br Med J. 1978;1(6108):279-280. [PubMed 620306</li>
<li>Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507. [PubMed 5418023]</li>
<li>Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. Chest. 1992;101(1):174-180. [PubMed 1729065]</li>
<li>Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriat Soc. 1984;32(5):405-407. [PubMed 6715769</li>
<li>Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R. Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy. Can Med Assoc J. 1979;121(5):591-594. [PubMed 497950</li>
<li>Gora ML, Seth SK, Bay WH, Visconti JA. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm. 1989;8(3):227-229. [PubMed 2706898</li>
<li>Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55-59. [PubMed 5305802</li>
<li>Rehan MA, Rashid A, Krell K, Gabutti C, Singh R. Calcium alkali thiazide syndrome: what we need to know. Cureus. 2020;12(10:e10856. [PubMed 33178509</li>
<li>Morini L, Doneli D, Santi R, et al. Severe milk-alkali syndrome in a patient with hypoparathyroidism associated with 1,25(OH)2D, hydrochlorothiazide and anthranoid laxative consumption. Eur J Case Rep Intern Med. 2017;4(10):000729. [PubMed 30755914</li>
<li>Singh A, Ashraf A. Hypercalcemic crisis induced by calcium carbonate. Clin Kidney J. 2012;5(4):288-291. [PubMed 25874082</li>
<li>Parvez B, Emuwa C, Faulkner ML, Murray JJ. Milk alkali and hydrochlorothiazide: a case report. Case Rep Med. 2011;2011:729862. [PubMed 21738535]</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; May 2021</li>
<li>Rayaldee (calcifediol) [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019</li>
<li>One-Alpha drops (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Dovonex (calcipotriene) [prescribing information]. Dublin, Ireland: LEO Laboratories Ltd.; March 2015</li>
<li>Rocalctrol (calcitriol) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Vectical (calcitriol) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2020</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019</li>
<li>Ergocalciferol [prescribing information]. Laurelton, NY: Epic Pharma, LLC; October 2018.</li>
<li>Flura-Drops (sodium fluoride) [prescribing information]. Lake Oswego, OR: Kirkman Laboratories Inc; September 2019.</li>
<li>Borel P, Desmarchelier C, Dumont U, et. al. Dietary calcium impairs tomato lycopene bioavailability in healthy humans. Br J Nutr. 2016;116(12):2091-2096. [PubMed 28069089]</li>
<li>Stass H, Wandel C, Delesen H, Moller JG. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet. 2001;40(suppl 1):27-32. [PubMed 11352439</li>
<li>Moxifloxacin [prescribing information]. Levittown, PA: Torrent Pharma Inc; January 2022.</li>
<li>Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118]</li>
<li>Meiact (cefditoren) [Saudi Arabian product labeling]. Riyadh, Saudi Arabia: Astra industrial group; May 2016.</li>
<li>Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351-352. [PubMed 22678358</li>
<li>Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Atelvia (risedronate sodium) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; August 2020.</li>
<li>Klein CE, Chiu YL, Cai Y, et al, “Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir,” J Clin Pharmacol, 2008, 48(5):553-62. [PubMed 18440920]</li>
<li>Wang X, Boffito M, Zhang J, et al, “Effects of the H2-Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir with or without Tenofovir in HIV-Infected Patients,” AIDS Patient Care STDS, 2011, 25(9):509-15. [PubMed 21770762</li>
<li>Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, February 2012.</li>
<li>Vizimpro (dacomitinib) [prescribing information]. New York, NY: Pfizer Inc; September 2018.</li>
<li>Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; October 2016</li>
<li>Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136-142. [PubMed 23910908]</li>
<li>Saito Y, Takekuma Y, Kobayashi M, et al. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(3):381-388. [PubMed 33029650</li>
<li>Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410</li>
<li>Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540. [PubMed 9208361</li>
<li>Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004;44(8):919-927. [PubMed 15286096</li>
<li>Sporanox (itraconazole) capsule [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 2018.</li>
<li>Mchavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347</li>
<li>Ketoconazole [prescribing information]. Mason, OH: Burel Pharmaceuticals, LLC; September 2021.</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017</li>
<li>Chiu Y-L, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV infected patients. AIDS Patient Cre STDS. 2007;21(4):247-251. [PubMed 17461719</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451</li>
<li>Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985;38(6):652-655. [PubMed 2933205</li>
<li>Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RMW. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958-966. [PubMed 17210768]</li>
<li>Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc.; February 2020</li>
<li>Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2017;83(3):554-561. [PubMed 27628584]</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013</li>
<li>Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis. 2008;46(10):1627; author reply 1627</li>
<li>[PubMed 18419503</li>
<li>Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207-12. [PubMed 19858252</li>
<li>Vehreschild JJ, Muller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987-95. [PubMed 22286158</li>
<li>Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJMulticenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentrationAntimicrob Agents Chemother2012;56(11):5503-10[PubMed 22890761]</li>
<li>Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics; March 2022.</li>
<li>Invirase (saquinavir) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; December 2003.</li>
<li>Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</li>
<li>Saathoff N, Lode H, Neider K, Kepperman KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992;36(4):796-800. [PubMed 1354432</li>
<li>Cefpodoxime [prescribing information]. Princeton, NJ: Sandoz GmbH for Sandoz Inc; February 2014.</li>
<li>Reichenspurner H, Meiser BM, Muschiol F, et al, “The Influence of Gastrointestinal Agents on Resorption and Metabolism of Cyclosporine After Heart Transplantation: Experimental and Clinical Results,” J Heart Lung Transplant, 1993, 12(6 Pt 1):987-92. [PubMed 8312324</li>
<li>D'Souza MJ, Pollock SH, Solomon HM, “Cyclosporine-Cimetidine Interaction,” Drug Metab Dispos, 1988, 16(1):57</li>
<li>[PubMed 2894956</li>
<li>Shaefer MS, Rossi SJ, McGuire TR, et al, “Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men,” Ann Pharmacother, 1995, 29(11):1088-91. [PubMed 8573949</li>
<li>Jadoul M and Hene RJ, “Ranitidine and the Cyclosporine Treated Recipient,” Transplantation, 1989, 48(2):359. [PubMed 2667215</li>
<li>Tsang VT, Johnston A, Heritier F, et al, “Cyclosporine Pharmacokinetics in Heart-Lung Transplant Recipients With Cystic Fibrosis Effects of Pancreatic Enzymes and Ranitidine,” Eur J Clin Pharmacol, 1994, 46(3):261</li>
<li>[PubMed 8070508</li>
<li>Jarowenko MV, Van Buren CT, Kramer WG, et al, “Ranitidine, Cimetidine, and the Cyclosporine-Treated Recipient,” Transplantation, 1986, 42(3):311</li>
<li>[PubMed 3529532]</li>
<li>Procysbi (cysteamine) delayed-release [prescribing information]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; February 2020</li>
<li>Doxofylline tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200101732. Accessed December 15, 2015.</li>
<li>Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2019</li>
<li>Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084. [PubMed 12461038]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413</li>
<li>Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2009.</li>
<li>Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med. 1987;107(2):261-262. [PubMed 3111324</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514</li>
<li>DiaBeta (glyburide) [prescribing information]. Bridgewater, NJ: Sanofi Aventis US; July 2016.</li>
<li>Viracept (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals Inc; September 2016.</li>
<li>Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol. 1984;18(2):175-181. [PubMed 6091709</li>
<li>Rocci ML Jr, Kosoglou T, Ferguson RK, Vlasses PH. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. J Pharmacol Exp Ther. 1989;248(3):923-928. [PubMed 2467982</li>
<li>Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. Ther Drug Monit. 1987;9(4):378-383. [PubMed 2447687</li>
<li>Ranitidine [prescribing information]. East Winsor, NJ: Novitium Pharma LLC; September 2018.</li>
<li>O'Conner-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther. 2001;70(2):126-31. [PubMed 11503006</li>
<li>Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm. 1991;10(7):539-43. [PubMed 1860302</li>
<li>Halcion (triazolam) [prescribing information]. New York, NY: Pfizer Inc,; October 2019.</li>
<li>Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med. 1990;112(1):76-77. [PubMed 2293824</li>
<li>Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin clearance after ranitidine and cimetidine. Clin Pharmacol Ther. 1984;35(3):338-341. [PubMed 6321081</li>
<li>O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144(5):989-991. [PubMed 6324710</li>
<li>Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32(2):165-172. [PubMed 3582481</li>
<li>Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12(6):791-794. [PubMed 6122462</li>
<li>Powell JR, Donn KH. The pharmacokinetic basis for h2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95-113. [PubMed 6140286]</li>
<li>Gertz BJ, Holland SD, Kline WF, et al, “Studies of the Oral Bioavailability of Alendronate,” Clin Pharmacol Ther, 1995, 58(3):288-98. [PubMed 7554702</li>
<li>Prescribing information. Fosamax (alendronate). Whitehouse Station, NJ: Merck &amp; Co., Inc., 04/2013</li>
<li>Prescribing information. Binosto (alendronate). San Antonio, TX: Mission Pharmacal, 4/2013</li>
<li>Abrahamsen B, Eiken P, Eastell R, “Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate,” Arch Intern Med, 2011, 171(11):998-1004. [PubMed 21321287</li>
<li>Czerwinski E, “Atypical Subtrochanteric Fractures After Long-Term Bisphosphonate Therapy,” Endokrynol Pol, 2011, 62(1):84</li>
<li>Giusti A, Hamdy NA, Papapoulos SE, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” Bone, 2010, 47(2):169-80. [PubMed 20493982</li>
<li>Ing-Lorenzini K, Desmeules J, Plachta O, et al, “Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates: A Case Series from a Swiss University Hospital,” Drug Saf, 2009, 32(9):775-85. [PubMed 19670917</li>
<li>de Vries F, Cooper AL, Cockle SM, et al, “Fracture Risk in Patients Receiving Acid-Suppressant Medication Alone and in Combination with Bisphosphonates,” Osteoporos Int, 2009, 20(12):1989-98. [PubMed 19333676</li>
<li>Roux C, Goldstein JL, Zhou X, et al, “Vertebral Fracture Efficacy During Risedronate Therapy in Patients Using Proton Pump Inhibitors,” Osteoporos Int, 2012, 23(1):277-84. [PubMed 21365461]</li>
<li>Piqray (alpelisib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; June 2022.</li>
<li>Perveen S, Gauhar S, Yousuf RI, Ali H, Zafar F, Sheikh AF. Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan. PLoS One. 2022;17(5):e0267791. [PubMed 35609024</li>
<li>Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33(11):1901-1907. [PubMed 2610502]</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360</li>
<li>Diacetylmorphine (diamorphine) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc.; February 2022</li>
<li>Diamorphine [summary of product characteristics]. Middlesex, United Kingdom: Accord Healthcare Limited; May 2020.</li>
<li>Esposito R. Cimetidine and iron-deficiency anaemia. Lancet. 1977;2(8048):1132. [PubMed 73039</li>
<li>Bianchi FM, Cavassini GB, Leo P. Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists. Int J Clin Pharmacol Ther Toxicol. 1993;31(5):209-217. [PubMed 8100220</li>
<li>Partlow ES, Campbell NR, Chan SC, Pap KM, Granberg K, Hasinoff BB. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. Clin Pharmacol Ther. 1996;59(4):389-393. [PubMed 8612382]</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055</li>
<li>Ueno T, Miyajima Y, Landry I, Lalovic B, Schuck E. Physiologically based pharmacokinetic modeling to predict drug interaction of lemborexant with CYP3A inhibitors. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):455-466. [PubMed 33704920</li>
<li>Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int. 2005;67(3):1152-1160. [PubMed 15698457</li>
<li>Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369-376. [PubMed 10223772</li>
<li>Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol. 1991;32(4):519-522. [PubMed 1958451]</li>
<li>U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).</li>
<li>Aasmundstad TA, Storset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17(6):347-352. [PubMed 9688360]</li>
<li>Mirapex ER (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014</li>
<li>Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33(4):495-499. [PubMed 15640376]</li>
<li>Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251-2257. [PubMed 18786302</li>
<li>Donn KH, Eshelman FN, Plachetka JR, Fabre L, Powell JR. The effects of antacid and propantheline on the absorption of oral ranitidine. Pharmacotherapy. 1984;4(2):89-92. [PubMed 6326064]</li>
<li>Machavaram KK, Gundu J, Yamsani MR. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 2006;22(1):47-65. [PubMed 17152347]</li>
<li>Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114(9):755-757. [PubMed 2012358</li>
<li>Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7(3):317-321. [PubMed 8117350</li>
<li>Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845</li>
<li>Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol. 1998;16(1):33-37. [PubMed 9821410]</li>
<li>Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;58:663-687. [PubMed 29309257</li>
<li>Li TT, An JX, Xu JY, Tuo BG. Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver. World J Clin Cases. 2019;7(23):3915-3933. [PubMed 31832394]</li>
<li>Poudel RR, Kafle NK. Tizanidine-induced acute severe cystitis in a female taking famotidine. Clin Pharmacol. 2015;7:83-85. [PubMed 26251632</li>
<li>Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013</li>
<li>Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 1993;24(3):255-258. [PubMed 8462230</li>
<li>Bachmannn K, Sullivan TJ, Reese JH, et al. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 1995;35(5):529-535. [PubMed 7657856</li>
<li>Verdiani P, Di Carlo S, Baronti AFamotidine effects on theophylline pharmacokinetics in subjects affected by COPDComparison with cimetidine and placeboChest1988;94(4):807-810[PubMed 3168576</li>
<li>Sunlenca (lenacapavir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; November 2022.</li>
<li>Nexterone (amiodarone) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; September 2021.</li>
<li>Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987;27(10):813-816. [PubMed 3323258</li>
<li>Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011;55(7):3091-3098. [PubMed 21518836]</li>
<li>Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; August 2019</li>
<li>Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol. 2000;49(1):64-71. [PubMed 10606839]</li>
<li>Ellence (epirubicin hydrochloride). New York, NY: Pfizer Inc.; July 2019</li>
<li>Murray LS, Jodrell DI, Morrison JG, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol). 1998;10(1):35-38. [PubMed 9543613]</li>
<li>Veozah (fezolinetant) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2023.</li>
<li>Plaquenil (hydroxychloroquine) [prescribing information]. Dublin, Ireland: Amdipharm Limited; May 2021</li>
<li>Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65(1):10-20. [PubMed 9951426</li>
<li>Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20(3):317-324. [PubMed 10831018</li>
<li>Orap (pimozide) [prescribing information]. Horsham, PA: Teva Pharmaceuticals USA; March 2014.</li>
<li>Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol. 1997;37(11):1056-1061. [PubMed 9505999</li>
<li>Serdolect (sertindole) [summary of product characteristics]. Valby, Denmark: Lundbeck AS; March 2021.</li>
<li>Volkin RL, Shadduck RK, Winkelstein A, Zeigler ZR, Selker RG. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine. Arch Intern Med. 1982;142(2):243-245. [PubMed 7059252</li>
<li>Selker RG, Moore P, LoDolce D. Bone-marrow depression with cimetidine plus carmustine. N Engl J Med. 1978;299(15):834. [PubMed 692572</li>
<li>BiCNU (carmustine) [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; November 2021</li>
<li>Dorr RT, Soble MJ. H2-antagonists and carmustine. J Cancer Res Clin Oncol. 1989;115(1):41-46. [PubMed 2564000]</li>
<li>Kirch W, Janisch HD, Ohnhaus EE, van Peer A. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit. 1989;11(4):411-414. [PubMed 2741189]</li>
<li>Priskorn M, Larsen F, Segonzac A, et al. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 1997;52:241-242. [PubMed 9218934</li>
<li>Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci. 2011;32(3):507-509. [PubMed 21491099</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA, Inc; January 2019.</li>
<li>Ampyra (dalfampridine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; December 2019</li>
<li>Fampyra (fampridine) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; January 2022.</li>
<li>Hetzel DJ, Bochner F, Hallpike JF, et al, “Cimetidine Interaction with Phenytoin,” Br Med J (Clin Res Ed), 1981, 282:1512. [PubMed 6786537</li>
<li>Algozzine GJ, Steward RB, and Springer PK, “Decreased Clearance of Phenytoin with Cimetidine,” Ann Intern Med, 1981, 95:244. [PubMed 7258891</li>
<li>Phillips P, Hansky J, “Phenytoin Toxicity Secondary to Cimetidine Administration,” Med J Aust, 1984, 141(9):602. [PubMed 6092884</li>
<li>Neuvonen PJ, Tokola RA, Kaste M, “Cimetidine-Phenytoin Interaction: Effect on Serum Phenytoin Concentration and Antipyrine Test,” Eur J Clin Pharmacol, 1981, 21(3):215-20. [PubMed 7318881</li>
<li>Frigo GM, Lecchini S, Caravaggi M, et al, “Reduction of Phenytoin Clearance Caused by Cimetidine,” Eur J Clin Pharmacol, 1983, 25(1):135</li>
<li>Bartle WK, Walker SE, and Shapero I, “Dose-Dependent Effect of Cimetidine on Phenytoin Kinetics,” Clin Pharmacol Ther, 1983, 33:649-55. [PubMed 6839635</li>
<li>Salem RB, Breland BD, Mishra SK, et al, “Effect of Cimetidine on Phenytoin Serum Levels,” Epilepsia, 1983, 24(3):284</li>
<li>Iteogu MO, Murphy JE, Shleifer N, et al, “Effect of Cimetidine on Single-Dose Phenytoin Kinetics,” Clin Pharm, 1983, 2:302, 304. [PubMed 6883958</li>
<li>Levine M, Jones MW, Sheppard I, “Differential Effect of Cimetidine on Serum Concentrations of Carbamazepine and Phenytoin,” Neurology, 1985, 35(4):562</li>
<li>Sambol NC, Upton RA, Chremos AN, et al, “A Comparison of the Influence of Famotidine and Cimetidine on Phenytoin Elimination and Hepatic Blood Flow,” Br J Clin Pharmacol, 1989, 27(1):83</li>
<li>Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2022</li>
<li>Landry I, Aluri J, Nakai K, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmcol Drug Dev. 2021;10(6):681-690. [PubMed 33455055]</li>
<li>Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017.</li>
<li>Zokinvy (lonafarnib) [prescribing information]. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; November 2020.</li>
<li>Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2018</li>
<li>Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545-551. [PubMed 3593625</li>
<li>Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637-645. [PubMed 18551044</li>
<li>Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471-2472. [PubMed 12882884</li>
<li>Boehm KM, Gunaga S. Cimetidine-induced lactic acidosis and acute pancreatitis. South Med J. 2010;103(8):849. [PubMed 20622719</li>
<li>Seo JH, Lee da Y, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. Intern Med. 2013;52(19):2245-2248. [PubMed 24088760</li>
<li>Umehara KI, Iwatsubo T, Noguchi K, Usui T, Kamimura H. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. Xenobiotica. 2008;38(9):1203-1218. [PubMed 18686197</li>
<li>Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185-191. [PubMed 19164462</li>
<li>Sultana N, Arayne MS, Ahmed N. In vitro availability of metformin in presence of h(2) receptor antagonists. Pak J Pharm Sci. 2006;19(1):28-34. [PubMed 16632449]</li>
<li>Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther. 1991;49(1):32-38. [PubMed 1988238</li>
<li>Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2015.</li>
<li>Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol. 1988;26(3):118-121. [PubMed 2457561</li>
<li>Christian CD Jr, Meredith CG, Speeg KV Jr. Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther. 1984;36(2):221-227. [PubMed 6204803</li>
<li>Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25(3):339-345. [PubMed 6194997</li>
<li>Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982;307(17):1080. [PubMed 6181402</li>
<li>Bauer LA, Black D, Gensler A. Procainamide-cimetidine interaction in elderly male patients. J Am Geriatr Soc. 1990;38(4):467-469. [PubMed 2329253</li>
<li>Higbee MD, Wood JS, Mead RA. Procainamide-cimetidine interaction: a potential toxic interaction in the elderly. J Am Geriatr Soc. 1984;32(2):162-164. [PubMed 6693705</li>
<li>Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol. 1985;28(6):671-675. [PubMed 2866097]</li>
<li>Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol. 1986;22(3):346-350. [PubMed 3768247</li>
<li>Qualaquin (quinine sulfate) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals Industry Inc; June 2019.</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019</li>
<li>El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther. 2016;9(4):157-161. [PubMed 26684920</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499</li>
<li>Fyarro (sirolimus) protein-bound [prescribing information]. Pacific Palisades, CA: Aadi Bioscience Inc; November 2021.</li>
<li>Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19(6):494-499. [PubMed 10587283</li>
<li>Preskorn SH. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract. 2005;11(3):192-196. [PubMed 15920392</li>
<li>Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 1997;25(1):24-32. [PubMed 9027670</li>
<li>Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2010</li>
<li>Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, Llerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59(1):45-50. [PubMed 12682803</li>
<li>Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther. 2007;82(5):555-565. [PubMed 17460606</li>
<li>Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60(5):543-553. [PubMed 8941027</li>
<li>Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002;16(4):361-364. [PubMed 12503836</li>
<li>Sunvepra (asunaprevir) [product monograph]Montreal, Canada: Bristol-Myers Squibb Canada; March 2016</li>
<li>Manerix (moclobemide) [product monograph]. Mississauga, Ontario: Hoffmann-LaRoche Limited, June 2011.</li>
<li>Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005;78(4):400-411. [PubMed 16198659</li>
<li>Villa-Zapata L, Gomez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disporportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022;45(8):863-871. [PubMed 35834155]</li>
<li>Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2019.</li>
<li>Flind AC. Cimetidine and oral anticoagulants. Br Med J. 1978;2(6148):1367. [PubMed 719395</li>
<li>Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2(8138):317-319. [PubMed 89387</li>
<li>Kerley B, Ali M. Cimetidine potentiation of warfarin action. Can Med Assoc J. 1982;126(2):116. [PubMed 7059881</li>
<li>Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med. 1979;90(3):348-349. [PubMed 426403</li>
<li>Hetzel D, Birkett D, Miners J. Cimetidine interaction with warfarin. Lancet. 1979;2(8143):639. [PubMed 90304</li>
<li>Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol. 1986;30(5):619-623. [PubMed 3758150</li>
<li>Harenberg J, Staiger CH, de Vries JX, et al. Cimetidine does not increase the anticoagulant effect of phenprocoumon. Br J Clin Pharmacol. 1982;14(2):292-293. [PubMed 7104184</li>
<li>O’Reilly RAComparative interaction of cimetidine and ranitidine with racemic warfarin in manArch Intern Med1984;144(5):989-991[PubMed 6324710</li>
<li>Unrecognized drug interactions ith famotidine and nizatidine. Arch Intern Med. 1991;151(4):810, 814, 815. [PubMed 1672811]</li>
<li>Sonata (zaleplon) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; November 2016.</li>
<li>Dixon R, French S, Kemp J, Sellers M, Yates R. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clin Drug Invest. 1998;15(6):515-522. [PubMed 18370509</li>
<li>Zomig (zolmitriptan) [prescribing information]. Hayward, CA: Impax Laboratories Inc; September 2012.</li>
<li>Alfenta (alfentanil) [prescribing information]. Lake Forest, IL: Akorn, Inc.; October 2019.</li>
<li>Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Abernathy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46(1):35-39. [PubMed 8005185</li>
<li>Suzuki Y, Shioiri T, Muratake T, et al. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur J Clin Pharmacol. 2003;58(12):829-833. [PubMed 12698310</li>
<li>Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol. 2009;65(7):699-704. [PubMed 19225771</li>
<li>Drabant S, Toth M, Bereczki A, Bajnogel J, Tomlo J, Klebovich I. Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug alprazolam. Eur J Clin Pharmacol. 2006;62(7):587-588. [PubMed 16791582</li>
<li>Xanax (alprazolam) [prescribing information]. New York, NY: Pfizer Inc; March 2021.</li>
<li>Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; November 2020</li>
<li>Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53(6):475-478. [PubMed 9551707]</li>
<li>Astelin (azelastine) nasal spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals Inc.; October 2014.</li>
<li>Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987;41(5):562-570. [PubMed 2882883</li>
<li>Apo-bromazepam (bromazepam) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2016.</li>
<li>Winship LC, McKenney JM, Wright JT, Wood JH, Goodman RP. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. Pharmacotherapy. 1985;5(1):16-19. [PubMed 3982974</li>
<li>Felodipine [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; December 2020</li>
<li>Kirch W, Ramsch K, Janisch HD, Ohnhaus EE. The influence of two histamine H2-receptor antagonists, cimetidine, and ranitidine on the plasma levels and clinical effect of nifedipine and metoprolol. Arch Toxicol Suppl. 1984;7:256-259. [PubMed 6151387</li>
<li>Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther. 1989;249(2):638-645. [PubMed 2724144</li>
<li>Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43(6):673-680. [PubMed 3378388</li>
<li>Smith SR, Kendall MJ, Lobo J, Beerahee A, Jack DB, Wilkins MR. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol. 1987;23(3):311-315. [PubMed 3567045</li>
<li>Renwick AG, Le Vie J, Challenor VF, Waller DG, Gruchy B, George CF. Factors affecting the pharmacokinetics of nifedipine. Eur J Clin Pharmacol. 1987;32(4):351-355. [PubMed 3609112</li>
<li>van Harten J, van Brummelen P, Lodewijks MT, Danhof M, Breimer DDPharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidineClin Pharmacol Ther1988;43(3):332-341[PubMed 3345623</li>
<li>Muck W, Wingender W, Seiberling M, Woelke E, Ramsch KD, Kuhlmann J. Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. Eur J Clin Pharmacol. 1992;42(3):325-328. [PubMed 1577052</li>
<li>Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50(4):394-403. [PubMed 1914375</li>
<li>Kirch W, Hutt HJ, Heidemann H, Ramsch K, Janisch HD, Ohnhaus EE. Drug interactions with nitrendipine. J Cardiovasc Pharmacol. 1984;6 Suppl 7:S982-S985. [PubMed 6085389</li>
<li>Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther. 1990;253(3):1042-1048. [PubMed 2359015</li>
<li>Abernethy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Loi CM, Rollins DE, Dukes GE, Peat MA. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther. 1985;37(6):654-657. [PubMed 4006365</li>
<li>Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition--effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol. 1985;19(3):385-391. [PubMed 3986090</li>
<li>Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984;36(4):551-554. [PubMed 6478741</li>
<li>Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer Inc; October 2017</li>
<li>Conjupri (levamlodipine) [prescribing information]. CSPC Ouyi Pharmaceutical Co., Ltd.; December 2019.</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J. Cimetidine and carbamazepine: a complex drug interaction. Epilepsia. 1986;27(5):553-558. [PubMed 3757941</li>
<li>Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol. 1984;27(3):341-343. [PubMed 6096154</li>
<li>Dalton MJ, Powell JR, Messenheimer JA Jr. The influence of cimetidine on single-dose carbamazepine pharmacokinetics. Epilepsia. 1985;26(2):127-130. [PubMed 3987645</li>
<li>Macphee GJ, Thompson GG, Scobie G, et al. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984;18(3):411-419. [PubMed 6487479</li>
<li>Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011;24(1):63-68. [PubMed 21190921</li>
<li>Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit. 1987;9(1):24-27. [PubMed 3107168</li>
<li>Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 1986;8(4):387-392. [PubMed 3824425</li>
<li>Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy volunteers. Phytother Res. 2015;29(5):701-706. [PubMed 25624269</li>
<li>Pisani F, Narbone MC, Fazio A, et alEffect of viloxazine on serum carbamazepine levels in epileptic patientsEpilepsia1984;25(4):482-485[PubMed 6745218</li>
<li>Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49(10):1142-1145. [PubMed 3783175</li>
<li>Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine. Ann Intern Med. 1981;94(4 pt 1):544. [PubMed 7212521</li>
<li>Garcia B, Zaborras E, Areas V, Obeso G, Jimenez I, de Juana P, Bermejo T. Interaction between isoniazid and carbamazepine potentiated by cimetidine. Ann Pharmacother. 1992;26(6):841-842. [PubMed 1611171</li>
<li>Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol. 1993:36(6):615-616. [PubMed 12959283</li>
<li>Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991:84(6):583-584. [PubMed 1792934</li>
<li>Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie. 1992:47(2):165. [PubMed 1412145</li>
<li>Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust. 1991;155(11-12):851. [PubMed 1745195</li>
<li>Sonne J, Luhdorf K, Larsen NE, Andreasen PB. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand. 1983;68(4):253-256. [PubMed 6659865</li>
<li>Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine of fluvoxamine. Ther Drug Monit. 1993:15(3):247-250. [PubMed 8333006</li>
<li>Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother. 1987;20(Suppl B):121-129. [PubMed 3429380</li>
<li>Leite SA, Leite PJ, Rocha GA, Routledge PA, Bittencourt PR. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq Neuropsiquiatr. 1994;52(2):210-215. [PubMed 7826249</li>
<li>Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018</li>
<li>Equetro (carbamazepine) extended-release capsules [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2016</li>
<li>Carbatrol (carbamazepine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc.; August 2018.</li>
<li>Desmond PV, Patwardhan RV, Schenker S, Speeg Jr KV. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med. 1980;93(2):266-268. [PubMed 7406377</li>
<li>Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg Jr KV. Lack of tolerance and rapid recovery of cimetidine - inhibited chlordiazepoxide (Librium) elimination. Gastroenterology. 1981;81(3):547-551. [PubMed 7250643</li>
<li>Nelson DC, Avant GR, Speeg Jr KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology. 1985;5(2):305-309. [PubMed 3979962</li>
<li>Cimetidine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2019.</li>
<li>Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. Eur J Clin Pharmacol. 1981;21(1):83-85. [PubMed 7333351]</li>
<li>Szymanski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52:21-22. [PubMed 1988413</li>
<li>Watras M, Taylor D. A therapeutic interaction between cimetidine and clozapine: case study and review of the literature. Ther Adv Psychopharmacol. 2013;3(5):294-297. [PubMed 24167705]</li>
<li>Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2000;49(1):49-63. [PubMed 10606838</li>
<li>Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18(4):311-316. [PubMed 9690697</li>
<li>Raaska K, Raitasuo V, Laitila J, Neuvonen P. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalized patients. Basic Clin Pharmacol Toxicol. 2004;94(1):13-18. [PubMed 14725610</li>
<li>Al Hadithy A, Leeffers E, Bruggeman R. Clozapine levels might be affected by excessive cola consumption. J Clin Psychopharmacol. 2012;32(5):717-719. [PubMed 22926611</li>
<li>Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol. 1994;14(4):284-285. [PubMed 7962690</li>
<li>Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry. 1991;52(1):21-22. [PubMed 1988413</li>
<li>Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. Psychosomatics. 2007;48(2):170-175. [PubMed 17329613</li>
<li>Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM. Clozapine and oral contraceptives: a possible drug interaction. J Clin Psychopharmacol. 2002;22(6):621-622. [PubMed 12454563</li>
<li>Schoretsanitis G, Kane JM, de Leon JAdding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature reviewJ Clin Psychopharmacol2020;40(3):308-310[PubMed 32332470</li>
<li>Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50-56. [PubMed 23104241</li>
<li>Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2017.</li>
<li>Bernard E, Goutelle S, Bertrand Y, Bleyzac N. Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. Ann Pharmacother. 2014;48(12):1580-1584. [PubMed 25280976</li>
<li>Cai J, Huang Z, Yang G, et al. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.  Am J Cardiovasc Drugs. 2011;11(6):401-409. [PubMed 22149319</li>
<li>Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clin Transplant. 2007;21(2):277-284. [PubMed 17425758</li>
<li>Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation. 2003;76(5):865-868. [PubMed 14501869</li>
<li>McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol. 1997;48(5):336. [PubMed 9403222</li>
<li>Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7(6):831-835. [PubMed 8793790</li>
<li>Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. [PubMed 16133554</li>
<li>Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28(1):25-29. [PubMed 16541194</li>
<li>Synercid (quinupristin/dalfopristin) [prescribing information]New York, NY: Pfizer Inc; March 2017</li>
<li>Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet. 1990;19(6):499-502. [PubMed 2292171</li>
<li>Momper JD, Yang J, Kerr J, Saunders I, Smith J, Shah MM. Interaction between cyclosporine and palbociclib in a renal transplant patient: case report and pharmacokinetic perspective. J Pharm Pract. 2020;33(6):912-914. [PubMed 31248333</li>
<li>Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24(3):297-300. [PubMed 8082935</li>
<li>Wang CH, Chou NK, Wu FL, et al. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients. Transplant Proc. 2006;38(7):2032-2034. [PubMed 16979990</li>
<li>Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol. 2005;45(7):781-791. [PubMed 15951468</li>
<li>Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</li>
<li>Lebsack ME, Nix D, Ryerson B, et al. Effect of gastric acidity on enoxacin absorption Clin Pharmacol Ther. 1992;52(3):252-256. [PubMed 1526081]</li>
<li>Mogford N, Pallett A, George C. Erythromycin deafness and cimetidine treatment. BMJ. 1994;309(6969):1620. [PubMed 7819942]</li>
<li>Mailing D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005;60(3):287-290. [PubMed 16120067</li>
<li>Kerendia (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2021.</li>
<li>Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</li>
<li>Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</li>
<li>Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984;18(3):421-430. [PubMed 6487480]</li>
<li>Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother. 1998;32(4):432-436. [PubMed 9562139</li>
<li>Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol. 1995;8(4):231-233. [PubMed 8561837]</li>
<li>Archambeaud-Moueroux F, Nouaille Y, Nadalon S, Treves R, Merle L. Interaction between gliclazide and cimetidine. Eur J Clin Pharmacol. 1987;31(5):631. [PubMed 3830250]</li>
<li>Feely J, Collins WC, Cullen M, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321-323. [PubMed 8471413]</li>
<li>Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022</li>
<li>Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008;14(9):2701-2709. [PubMed 18451235]</li>
<li>Kishikawa K, Namiki A, Miyashita K, Saitoh K. Effects of famotidine and cimetidine on plasma levels of epidurally administered lignocaine. Anaesthesia. 1990;45(9):719-721. [PubMed 2240530</li>
<li>Parish RC, Gotz VP, Lopez LM, Mehta JL, Curry SH. Serum lidocaine concentrations following application to the oropharynx: effects of cimetidine. Ther Drug Monit. 1987;9(3):292-297. [PubMed 3672572</li>
<li>Abernathy DR, Schwartz JB, Todd EL. Lack of interaction between verapamil and cimetidine. Clin Pharmacol Ther. 1985;38(3):342-349. [PubMed 4028631</li>
<li>Jackson JE, Bentley JB, Glass SJ, Fukui T, Gandolfi AJ, Plachetka JR. Effects of histamine-2 receptor blockade on lidocaine kinetics. Clin Pharmacol Ther. 1985;37(5):544-548. [PubMed 3987178</li>
<li>Bauer LA, Edwards WA, Randolph FP, Blouin RA. Cimetidine-induced decrease in lidocaine metabolism. Am Heart J. 1984;108(2):413-415. [PubMed 6464978</li>
<li>Wing LM, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S. Lidocaine disposition-sex differences and effects of cimetidine. Clin Pharmacol Ther. 1984;35(5):695-701. [PubMed 6713782</li>
<li>Feely J, Wilkinson GR, McAllister CB, Wood AJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med. 1982;96(5):592-594. [PubMed 7073151</li>
<li>Powell JR, Foster J, Patterson JH, Cross R, Wargin W. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics. Clin Pharm. 1986;5(12):993-998. [PubMed 3802729</li>
<li>Berk SI, Gal P, Bauman JL, Douglas JB, McCue JD, Powell JRThe effect of oral cimetidine on total and unbound serum lidocaine concentrations in patients with suspected myocardial infarctionInt J Cardiol1987;14(1):91-94[PubMed 3804509</li>
<li>Knapp AB, Maguire W, Keren G, et al. The cimetidine-lidocaine interaction. Ann Intern Med. 1983;98(2):174-177. [PubMed 6824249</li>
<li>Patterson JH, Foster J, Powell JR, Cross R, Wargin W, Clark JL. Influence of a continuous cimetidine infusion on lidocaine plasma concentrations in patients. J Clin Pharmacol. 1985;25(8):607-609. [PubMed 4078028</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Single dose oral H2-antagonists do not affect plasma lidocaine levels in the parturient. Acta Anaesthesiol Scan. 1989;33(7):593-596. [PubMed 2683547</li>
<li>Flynn RJ, Moore J, Collier PS, Howard PJ. Effect of intravenous cimetidine on lignocaine disposition during extradural caesarean section. Anaesthesia. 1989;44(9):739-741. [PubMed 2802120</li>
<li>Dailey PA, Hughes SC, Rosen MA, Healy K, Cheek DB, Shnider SM. Effect of cimetidine and ranitidine on lidocaine concentrations during epidural anesthesia for cesarean section. Anesthesiology. 1988;69(6):1013-1017. [PubMed 3195744</li>
<li>Lidocaine [prescribing information]. Lake Forest, IL: Hospira Inc; April 2013.</li>
<li>Co-Phenylcaine Forte (lidocaine and phenylephrine) [Singapore product labeling]. Singapore: Ziwell Medical (S) Pte Ltd.; October 2015.</li>
<li>Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR. Cimetidine alters pethidine disposition in man. Br J Clin Pharmacol. 1984;18(6):907-914. [PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062-1065. [PubMed 3605428</li>
<li>Guay DR, Meatherall RC, Chalmers JL, Grahame GR, Hudson RJ. Ranitidine does not alter pethidine disposition in man. Br J Clin Pharmacol. 1985;20(1):55-59. [PubMed 4027136]</li>
<li>Shord SS, Chan LN, Camp JR, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160-166. [PubMed 20233179</li>
<li>Urva S, Bouillaud E, Delaney R, Jappe A, Cheung W. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects. J Clin Pharmacol. 2013;53(4):444-450. [PubMed 23426978</li>
<li>Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol. 2011;51(12):1712-1720. [PubMed 21209230</li>
<li>Mavyret (glecaprevir and pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020</li>
<li>Kiang TKL. Clinical pharmacokinetics and drug-drug interactions of elbasvir/grazoprevir. Eur J Drug Metab Pharmacokinet. 2018;43(5):509-531. [PubMed 29557529</li>
<li>Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; February 2017</li>
<li>Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56-62. [PubMed 25103957</li>
<li>Koch KM, Dees EC, Coker SA, et alThe effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancerCancer Chemother Pharmacol2017;80(6):1141-1146[PubMed 29098381</li>
<li>Vitrakvi (larotrectinib) [prescribing information]. Stamford CT: Loxo Oncology Inc; November 2018</li>
<li>Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191-202. [PubMed 24825095</li>
<li>Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 plus 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652-659. [PubMed 20881954</li>
<li>Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos. 2005;33(12):1859-1866. [PubMed 16183781</li>
<li>Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol. 1994;46(6):551-555. [PubMed 7995324</li>
<li>Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65. [PubMed 30427584</li>
<li>Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics; November 2019</li>
<li>Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217. [PubMed 21870106</li>
<li>Qelbree (viloxazine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Tavneos (avacopan) [prescribing information]. Cincinnati, OH: ChemoCentryx, Inc.; October 2021</li>
<li>Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017</li>
<li>Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15(6):1406-1416. [PubMed 35293131</li>
<li>Vaprisol (conivaptan) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; October 2016</li>
<li>Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53(3):298-305. [PubMed 8453848</li>
<li>Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol. 1993;73(3):180</li>
<li>Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56(5):389-394. [PubMed 11009047</li>
<li>Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</li>
<li>Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126-132. [PubMed 9562227</li>
<li>Nymalize (nimodipine) oral solution [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; December 2020</li>
<li>Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; December 2015.</li>
<li>Tornizol (ornidazole) [South Korea prescribing information]. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199300808. Accessed June 3, 2022</li>
<li>Arrow ornidazole (ornidazole) [New Zealand data sheet]. Auckland, New Zealand: Teva Pharma (New Zealand) Limited; October 2018</li>
<li>Ramesh S, Kumar YS, Rao YM. Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77. [PubMed 17152348]</li>
<li>Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(Suppl 350):102-106. [PubMed 2530759]</li>
<li>Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol. 1988;28(7):649-654. [PubMed 3216031</li>
<li>Luke DR, Rocci ML Jr, Hoholick C. Inhibition of pentoxifylline clearance by cimetidine. J Pharm Sci. 1986;75(2):155-157. [PubMed 3958924]</li>
<li>Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther. 2000;67(3):222-228. [PubMed 10741624]</li>
<li>Yee T, Barakos JA, Knight RT. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med. 1999;170(2):112-115. [PubMed 10063399</li>
<li>Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis. 1994;169(3):689-691. [PubMed 8158054</li>
<li>Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother. 1997;41(6):1256-1259. [PubMed 9174180</li>
<li>Biltricide (praziquantel) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; January 2019.</li>
<li>Inderal (propranolol) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; March 2011</li>
<li>Kirch W, Spahn H, Kohler H, Ohnhaus EE, Mutschler E. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr. 1982;60(22):1401-1407. [PubMed 7176462</li>
<li>Kirch W, Spahn H, Kohler H, Mutschler E. Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine. Arch Toxicol Suppl. 1983;6:379-383. [PubMed 6578746</li>
<li>Kirch W, Kohler H, Spahn H, Mutschler E. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet. 1981;2(8245):531-532. [PubMed 6115283</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17(Suppl 1):51S-57S. [PubMed 6146340</li>
<li>Tateishi T, Ohashi K, Fujimura A, Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992;32(12):1099-1104. [PubMed 1487547</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Comparison of kinetic interactions of nadolol and propranolol with cimetidine. Am Heart J. 1984;108(4 Part 2):1084-1086. [PubMed 6148867</li>
<li>Duchin KL, Stern MA, Willard DA, McKinstry DN. Kinetic interactions of nadolol and propranolol with cimetidine. Br J Clin Pharmacol. 1984;17(4):486-487. [PubMed 6721996</li>
<li>Donn KH, Powell JR, Rogers JF, Eshelman FNThe influence of H2-receptor antagonists on steady-state concentrations of propranolol and 4-hydroxypropranololJ Clin Pharmacol1984;24(11-12):500-508[PubMed 6150946</li>
<li>Heagerty AM, Donovan MA, Castleden CM, Pohl JF, Patel L, Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J. 1981;282(6280)1917-1919. [PubMed 6786672</li>
<li>Reimann IW, Klotz U, Siems B, Frolich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981;12(6):785-790. [PubMed 7340880</li>
<li>Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzneimittelforschung. 1987;37(8):953-956. [PubMed 2890358</li>
<li>Asgharnejad M, Powell JR, Donn KH, Danis M. The effect of cimetidine dose timing on oral propranolol kinetics in adults. J Clin Pharmacol. 1988;28(4):339-343. [PubMed 3392231</li>
<li>Reimann IW, Klotz U, Frolich JC. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther. 1982;32(6):749-757. [PubMed 6291839</li>
<li>Donovan MA, Heagerty AM, Patel L, Castleden M, Pohl JE. Cimetidine and bioavailability of propranolol. Lancet. 1981;1(8212):164. [PubMed 6109849</li>
<li>MacKichan JJ, Boudoulas H, Schall SF. Effect of cimetidine on quinidine bioavailability. Biopharm Drug Dispos. 1989;10(1):121-125. [PubMed 2923957</li>
<li>Hardy BG, Zador IT, Golden L, Lalka D, Schentag JJ. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol. 1983;52(1):172-175. [PubMed 6858908</li>
<li>Kolb KW, Garnett WR, Small RE, Vetrovec GW, Kline BJ, Fox T. Effect of cimetidine on quinidine clearance. Ther Drug Monit. 1984;6(3):306-312. [PubMed 6506138</li>
<li>Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol. 1988;26(8):388-391. [PubMed 3220613</li>
<li>Farringer JA, McWay-Hess K, Clementi WA. Cimetidine-quinidine interaction. Clin Pharm. 1984;3(1):81-83. [PubMed 6697678</li>
<li>Polish LB, Branch RA, Fitzgerald GA. Digitoxin-quinidine interaction: potentiation during administration of cimetidine. South Med J. 1981;74(5):633-634. [PubMed 7244727</li>
<li>Quinidine sulfate [prescribing information]. Laurelton, NY: Epic Pharma LLC; July 2021.</li>
<li>Bohmer GM, Gleiter CH, Morike K, Nassr N, Walz A, Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol. 2011;51(4):594-602. [PubMed 20484614</li>
<li>Cui X, Huang J, Zheng X, Jiang J, Kuang Y, Hu P. Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: application for a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029-1030:60-67. [PubMed 27423044</li>
<li>Li Q, Wang Y, Liu L, Ma P, Ding L. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide in healthy Chinese subjects after single and multiple oral doses. Eur J Drug Metab Pharmacokinet. 2017;42(3):371-381. [PubMed 27306372</li>
<li>Zoryve (roflumilast) cream [prescribing information]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July 2022</li>
<li>Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</li>
<li>Kim J-R, Jung JA, Kim S, Huh W, Ghim J-L, Shin J-G, Ko J-W. Effect of cilostazol on the pharmacokinetics of simvastatin in healthy subjects. Biomed Res Int. 2019;1365180. [PubMed 30729119</li>
<li>Xu CF, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 23(9):2470-2471. [PubMed 22918879</li>
<li>Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19(1):247. [PubMed 31640597</li>
<li>Poumeaud F, Fontanier A, Dion J, et al. Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report. Front Oncol. 2022;12:1026434. [PubMed 36591506</li>
<li>Huynh T, Cordato D, Yang F. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32(9-10):486-490. [PubMed 12380704</li>
<li>Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; September 2020.</li>
<li>Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant. 2006;10(6):736-739. [PubMed 16911499]</li>
<li>Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001;15(2):95-99. [PubMed 11264634</li>
<li>Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit. 2005;27(5):587-591. [PubMed 16175131</li>
<li>Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc.; January 2016</li>
<li>Breslin NT, Salerno DM, Topkara VK, et al. Prior amiodarone exposure reduces tacrolimus dosing requirements in heart transplant recipients. Prog Transplant. 2019;29(2):129-134. [PubMed 30845890</li>
<li>Mavyret (glecaprevir/pibrentasvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2020</li>
<li>Shapiro R, Venkataramaan R, Warty VS, et al. FK 506 interaction with danazol. Lancet. 1993;341(8856):1344-1345. [PubMed 7684106</li>
<li>Seck S, Bellantoni M, Zoccali C, Enia G. Ranolazine can markedly increase tacrolimus blood levels. NDT Plus. 2011;4(1):44-45. [PubMed 25984101</li>
<li>Patni H, Gitman M, Hazzan A, Jhaveri KD. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. Ren Fail. 2012;34(2):251-253. [PubMed 22263871</li>
<li>Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain EPharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant childTransplantation 2012;93(7):e29-e30[PubMed 22450597</li>
<li>Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2013;69(10):1861-1862. [PubMed 23765408</li>
<li>Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2018</li>
<li>Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2020.</li>
<li>Maeda Y, Konishi T, Omoda K, et al. Inhibition of theophylline metabolism by aciclovir. Biol Pharm Bull. 1996;19(12):1591-1595. [PubMed 8996645</li>
<li>Sato J, Nakata H, Owda E, Kikuta T, Umetsu M, Ito K. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur J Clin Pharmacol. 1993;44(3):295-298. [PubMed 8491248</li>
<li>Vestal RE, Thummel KE, Musser B, Mercer GD. Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol. 1983;15(4):411-418. [PubMed 6849776</li>
<li>Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN. Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med. 1984;144(3):484-486. [PubMed 6322709</li>
<li>Cohen IA, Johnson CE, Berardi RR, Hyneck ML, Achem SR. Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit. 1985;7(4):426-434. [PubMed 4082242</li>
<li>Mulkey PM, Murphy JE, Shleifer NH. Steady-state theophylline pharmacokinetic during and after short-term cimetidine administration. Clin Pharm. 1983;2(5):439-441. [PubMed 6627870</li>
<li>Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 1989;45(5):476-486. [PubMed 2721103</li>
<li>Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol. 1982;23(2):129-134. [PubMed 7140802</li>
<li>Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski REffects of tobacco smoking and oral contraceptive use on theophylline dispositionBr J Clin Pharmacol1983;16(3):271-280[PubMed 6626419</li>
<li>Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;24(2):939-941. [PubMed 2444839</li>
<li>Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline. Pharm Weekbl Sci. 1987;11(9 suppl):S72-S75. [PubMed 3481439</li>
<li>Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986;22(6):677-683. [PubMed 3567014</li>
<li>Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest. 1987;92(4):663-669. [PubMed 3477409</li>
<li>Staib AH, Harder S, Fuhr U, Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. Int J Clin Pharmacol Ther Toxicol. 1989;27(6):289-293. [PubMed 2737798</li>
<li>Miners JO, Wing LM, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol. 1985;20(3):219-223. [PubMed 4041342</li>
<li>Lombardi TP, Bertino JS Jr, Goldberg A, Middleton E Jr, Slaughter RL. The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. J Clin Pharmacol. 1987;27(7):523-529. [PubMed 2888791</li>
<li>Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980;28(4):463-467. [PubMed 7408406</li>
<li>Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther. 1987;41(3):358-362. [PubMed 3816023</li>
<li>Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29(suppl 2):77-83. [PubMed 8620674</li>
<li>Spinler SA, Gammaitoni A, Charland SL, Hurwitz J. Propafenone-theophylline interaction. Pharmacotherapy. 1993;13(1):68-71. [PubMed 8437970</li>
<li>Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. Clin Pharmacol Ther. 1992;51(3):353-355. [PubMed 1544292</li>
<li>Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ. Cimetidine-theophylline interaction: report of four patients. Ann Allergy. 1982;48(2):100-102. [PubMed 6121526</li>
<li>Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR. Cimetidine decreases theophylline clearance. Ann Intern Med. 1981;95(1):68-69. [PubMed 7247131</li>
<li>Lofgren RP, Gilbertson RA. Cimetidine and theophylline. Ann Intern Med. 1982;96(3):378. [PubMed 6800293</li>
<li>Mojtahedzadeh M, Sadray S, Hadjibabaie M, Fasihi M, Rezaee S. Determination of theophylline clearance after cimetidine infusion in critically ill patients. J Infus Nurs. 2003;26(4):234-238. [PubMed 12869856</li>
<li>Koren G, Chin TF, Correia J, Tesoro A, MacLeod SM. Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. Clin Invest Med. 1985;8(3):222-2[PubMed 4042465</li>
<li>Theo-24 (theophylline anhydrous) [prescribing information]. Malvern, PA; Endo Pharmaceuticals Inc.; August 2017.</li>
<li>Cate EW, Rogers JF, Powell JR. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986;26(5):372-377. [PubMed 3700691</li>
<li>Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157-163. [PubMed 3383988</li>
<li>Adebayo GI, Coker HA. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. Eur J Clin Pharmacol. 1988;34(6):653-656. [PubMed 3169118</li>
<li>Stockley C, Keal J, Rolan P, Bochner F, Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur J Clin Pharmacol. 1986;31(2): 235-237. [PubMed 3803421</li>
<li>Dey NG, Castleden CM, Ward J, Cornhill J, McBurney A. The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol. 1983;16(4):438-440. [PubMed 6626438]</li>
<li>Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983;16(6):743-746. [PubMed 6140941</li>
<li>Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology (Berl). 1983;80(3):275-278. [PubMed 6137021</li>
<li>Friedman H, Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol. 1998;28(3):228-233. [PubMed 3360971</li>
<li>Pourbaix S. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447-451. [PubMed 2864320</li>
<li>Britton ML, Waller ES. Central nervous system toxicity associated with concurrent use of triazolam and cimetidine. Drug Intell Clin Pharm. 1985;19(9):666-668. [PubMed 40428607. Parker WA, MacLachlan RA. Prolonged hypnotic response to triazolam-cimetidine combination in an elderly patient. Drug Intell Clin Pharm. 1984;18(12):980-981. [PubMed 6150838]</li>
<li>Curry SH, De Vane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433. [PubMed 3912187</li>
<li>Amsterdam JD, Brunswick DJ, Potter L, et al. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology. 1984;83:373-375. [PubMed 6436867</li>
<li>Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. [PubMed 3950073</li>
<li>Sutherland DL, Remillard AJ, Haight KR, et al. The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. Eur J Clin Pharmacol. 1987;32:159-164. [PubMed 3582480</li>
<li>Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. [PubMed 379426</li>
<li>Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. [PubMed 6692646</li>
<li>Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229(3):702-705. [PubMed 6726654</li>
<li>Brown MA, Haight KR, McKay G. Cimetidine-doxepin interaction. J Clin Psychopharmacol. 1985;5:245-247. [PubMed 4019813</li>
<li>Shapiro PACimetidine-imipramine interaction: case report and commentsAm J Psychiatry1984;141:152[PubMed 6691449</li>
<li>Miller DD, Macklin M. Cimetidine-imipramine interaction: a case report. Am J Psychiatry. 1983;140:351. [PubMed 6829810</li>
<li>Miller DD, Sawyer JB, Duffy JP. Cimetidine’s effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm. 1983;17(12):904-905. [PubMed 6653407</li>
<li>Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther. 1987;42:278-282. [PubMed 3621787]</li>
<li>Urasap (urapidil) [Summary of Product Characteristics]. Frosinone, Italy: INCA-Pharm Srl; September 2012.</li>
<li>De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother. 2002;46(2):458-463. [PubMed 11796358</li>
<li>Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2010.</li>
<li>Desager JP, Harvengt C, Bianchetti G, Rosenzweig P. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. Int J Clin Pharmacol Ther Toxicol. 1993;31(11):568-571. [PubMed 7904983]</li>
<li>Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; November 2022</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Hendset M, Molden E, Enoksen TB, et al. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit. 2010;32(6):787-790. [PubMed 21068650</li>
<li>Abilify Maintena (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; January 2020</li>
<li>Abilify Asimtufii (aripiprazole) extended-release injectable suspension [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; April 2023.</li>
<li>Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20(1):55-64. [PubMed 15770075</li>
<li>Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37. [PubMed 21739267</li>
<li>Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44(11):1850-1854. [PubMed 20978219</li>
<li>Qulipta (atogepant) [prescribing information]. Dublin, Ireland: Forest Laboratories Ireland Ltd; September 2021.</li>
<li>Ortikos (budesonide) extended-release capsules [prescribing information]. Sun Pharmaceutical Industries, Inc.; June 2019.</li>
<li>Buspirone [prescribing information]. Laurelton, NY: Epic Pharma LLC; May 2020</li>
<li>Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ. Lack of interaction between cimetidine and buspirone. Pharmacotherapy. 1987;7(3):72-79. [PubMed 2888096]</li>
<li>Epidiolex (cannabidiol) oral solution [prescribing information]. Carlsbad, CA: Greenwich Biosciences Inc; October 2020</li>
<li>Thai C, Tayo B, Critchley D. A phase I open-label, fixed sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(11):1279-1289. [PubMed 33951339</li>
<li>Beach CA, Mays DC, Guiler RC, Jacober CH, Gerber N. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986;39(3):265-270. [PubMed 3948467</li>
<li>Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol. 1995;48(2):161-166. [PubMed 7589032</li>
<li>Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28(4):425-428. [PubMed 4029248</li>
<li>Kinzig-Schippers M, Fuhr U, Zaigler M, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther. 1999;65(3):262-274. [PubMed 10096258</li>
<li>Pegintron (peginterferon alfa-2b) [prescribing information]Whitehouse Station, NJ: Merck &amp; Co Inc; January 2019</li>
<li>Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988;35(6):651-656. [PubMed 2853056</li>
<li>Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45(3):234-240. [PubMed 2920498</li>
<li>Michaud V, Mouksassi MS, Labbe L, et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit. 2006;28(6):779-783. [PubMed 17164694</li>
<li>Bachmann F, Duthaler U, Meyer HE, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2 [published online December 17, 2020]. Clin Pharmacol Ther. doi: 10.1002/cpt.2141. [PubMed 33336382]</li>
<li>Coreg (carvedilol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</li>
<li>Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009;104(12):3116-3117. [PubMed 19956146]</li>
<li>Rize (clotiazepam) [KR prescribing information]. Available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198802970]. Accessed [January 30, 2023]</li>
<li>Ochs HR, Greenblatt DJ, Verburg-Ochs B, Harmatz JS, Grehl H. Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. Eur J Clin Pharmacol. 1984;26(1):55-59. [PubMed 6143670]</li>
<li>Mitigare (colchicine) capsule [prescribing information]. Memphis, TN: Hikma Americas, Inc.; September 2014.</li>
<li>Enablex (darifenacin) [prescribing information]. Rockaway, NJ: Warner Chilcott US LLC; March 2012.</li>
<li>Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15(1):18-24. [PubMed 8451775</li>
<li>Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997;62(2):145-156. [PubMed 9284850</li>
<li>Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008</li>
<li>Effexor (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017</li>
<li>Norvir (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2019</li>
<li>Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664-674. [PubMed 16338282</li>
<li>Orladeyo (berotralstat) [prescribing information]Durham, NC: BioCryst Pharmaceuticals Inc; December 2020</li>
<li>Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989;146(12):1611-1613. [PubMed 2486749</li>
<li>Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329-336. [PubMed 2288330</li>
<li>Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit. 1992;14(3):194-196. [PubMed 1412604</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res. 1993;13(3):167-171. [PubMed 8225700</li>
<li>Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15(3):243-246. [PubMed 8333005]</li>
<li>Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017</li>
<li>Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70(9):1115-1122. [PubMed 25028073</li>
<li>Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacol (Berl). 1998;135(1):22-26. [PubMed 9489930</li>
<li>Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(4):747-755. [PubMed 24013574</li>
<li>Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020</li>
<li>Qelbree (viloxazine) [prescribing information]Winchester, KY: Catalent Pharma Solutions LLC; April 2021</li>
<li>Saphris (asenapine) [prescribing information]. Irvine, CA: Allergan USA Inc; February 2017</li>
<li>Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64(3):257-268. [PubMed 9757149]</li>
<li>Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother Pharmacol. 1999;43(2):126-132. [PubMed 9923817]</li>
<li>Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer Inc.; June 2016</li>
<li>Cardura XL (doxazosin extended-release) [prescribing information]. New York, NY: Pfizer Inc.; February 2017.</li>
<li>Cerdelga (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2018</li>
<li>Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</li>
<li>Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14-23. [PubMed 11180034</li>
<li>Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol. 1996;50(3):203-208. [PubMed 8737760</li>
<li>Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther. 2002;72(3):247-255. [PubMed 12235445]</li>
<li>Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77(1):17-23. [PubMed 15637527]</li>
<li>Flecainide [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals Pvt. Ltd.; September 2017</li>
<li>Tjandra-Maga TB, van Hecken A, van Melle P, Verbesselt R, de Schepper PJAltered pharmacokinetics of oral flecainide by cimetidineBr J Clin Pharmacol1986;22(1):108-110[PubMed 3741720]</li>
<li>Sullivan KM, Small RE, Rock WL, Cox SR, Willis HE. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm. 1986;5(7):586-589. [PubMed 3742949</li>
<li>Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol. 1990;30(7):660-664. [PubMed 2391398]</li>
<li>Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507. [PubMed 20573085</li>
<li>Horizant (gabapentin enacarbil) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020</li>
<li>Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer Inc; December 2020.</li>
<li>Kubacka RT, Antal EJ, Juhl RP. The paradoxical effects of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1987;23(6):743-751. [PubMed 3111514]</li>
<li>Dumitras S, Sechaud R, Drollmann A, et al. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. Int J Clin Pharmacol Ther. 2013;51(10):771-779. [PubMed 24040847]</li>
<li>Zircol (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013</li>
<li>Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:31S-36S. [PubMed 11879257</li>
<li>Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-581. [PubMed 15365656]</li>
<li>Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</li>
<li>Luder PJ, Siffert B, Witassek F, et al. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31(4):443-448. [PubMed 3816925</li>
<li>Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24(3):390-392. [PubMed 3663452]</li>
<li>Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319-1321. [PubMed 15541258</li>
<li>Garimella T, Tao X, Sims K, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R D. 2018;18(1):55-65. [PubMed 29255971</li>
<li>Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130-137. [PubMed 12891223</li>
<li>Celexa (citalopram) [prescribing information]. Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67-70. [PubMed 2917591</li>
<li>Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466-477. [PubMed 10824625</li>
<li>Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113-123. [PubMed 14748763</li>
<li>Thibault N, Ibrahim J, Peterschmitt MJ, et al. Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. Mol Genet Metab. 2020;129(4):278-285. [PubMed 32029355</li>
<li>Lexapro (escitalopram) [prescribing information]Madison, NJ: Allergan USA Inc; January 2019</li>
<li>Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27(1):28-34. [PubMed 17224709</li>
<li>Ogasawara K, LoRusso PM, Olszanski AJ, et al. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol. 2020;86(1):87-95. [PubMed 32537715</li>
<li>Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol. 1987;31(5):575-578. [PubMed 3830242</li>
<li>Laurent-Kenesi MA, Brentano-Funck C, Poirier JM, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 1993;36(6):531-538. [PubMed 12959269</li>
<li>Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24(2):213-220. [PubMed 3620296</li>
<li>Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2019</li>
<li>Cho DY, Bae SH, Lee JK, et al. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. Xenobiotica. 2015;45(3):256-263. [PubMed 25268386</li>
<li>Ketek (telithromycin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2015</li>
<li>Effexor XR (venlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.</li>
<li>Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's Disease. Biopharmaceut Drug Dispos. 1988;9(2):219-227. [PubMed 2897213</li>
<li>Loft S, Dossing M, Sonne J, Dalhof K, Bjerrum K, Poulsen HE. Lack of effect of cimetidine on the pharmacokinetics of metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol. 1988;35(1):65-68. [PubMed 3220096</li>
<li>Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. Eur J Clin Pharmacol. 1987;32(1):35-41. [PubMed 3582467</li>
<li>Gugler R, Jensen JC. Interaction between cimetidine and metronidazole. N Eng J Med 1983;309(24):1518-1519. [PubMed 6646177</li>
<li>Viaflex Plus Container (metronidazole injection) [prescribing information]. Deefield, IL: Baxter Healthcare Corporation; December 2017</li>
<li>Pearce RE, Cohen-Wolkowiez M, Sampson MR,Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013;41(9):1686-1694. [PubMed 23813797</li>
<li>Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE . Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol. 1991;41(8):1127-1134. [PubMed 2009091]</li>
<li>Korlym (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; November 2019.</li>
<li>Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the h2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 1997;43(2):201-204. [PubMed 9131955]</li>
<li>Bendayan R, Sullivan JR, Shaw C, et al. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans. Eur J Clin Pharmacol. 1990;38:165-169. [PubMed 2338114</li>
<li>Bendayan R, Kennedy G, Frecker RC, Sellers EM. Lack of effect of cimetidine on cigarette smoking. Eur J Clin Pharmacol. 1993;44(1):51-55. [PubMed 8436155]</li>
<li>Ochs HR, Greenblatt DJ, Gugler R, Muntefering G, Locniskar A, Abernethy DR. Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther. 1983;34(2):227-230. [PubMed 6872417</li>
<li>Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; November 2013.</li>
<li>Fine A, Churchill DN, “Potentially Lethal Interaction of Cimetidine and Morphine,” Can Med Assoc J, 1981, 124(11):1434</li>
<li>[PubMed 7237324</li>
<li>Prescribing information. Opana (oxymorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010</li>
<li>Gogas KR, Hough LB, Eberle NB, et al, “A Role for Histamine and H2-Receptors in Opioid Antinociception,” J Pharmacol Exp Ther, 1989, 250(2):476-84. [PubMed 2547933</li>
<li>Bluhm R, Zsigmond EK, Winnie AP, “Potentiation of Opioid Analgesia by H1 and H2 Antagonists,” Life Sci, 1982, 31(12-13):1229-32. [PubMed 6128651</li>
<li>Robertson JA, Hough LB, Bodnar RJ, “Potentiation of Opioid and Nonopioid Forms of Swim Analgesia by Cimetidine,” Pharmacol Biochem Behav, 1988, 31(1):107-12. [PubMed 2855266</li>
<li>Lam AM, Clement JL, “Effect of Cimetidine Premedication on Morphine-Induced Ventilatory Depression,” Can Anaesth Soc J, 1984, 31(1):36-43. [PubMed 6420025</li>
<li>Mojaverian P, Fedder IL, Vlasses PH, et al, “Cimetidine Does Not Alter Morphine Disposition in Man,” Br J Clin Pharmacol, 1982, 14(6):809-13. [PubMed 7150459</li>
<li>Dawson GW, Vestal RE, “Cimetidine Inhibits the In Vitro N-Demethylation of Methadone,” Res Commun Chem Pathol Pharmacol, 1984, 46(2):301</li>
<li>[PubMed 6515123</li>
<li>Guay DR, Meatherall RC, Chalmers JL, et al, “Cimetidine Alters Pethidine Disposition in Man,” Br J Clin Pharmacol, 1984, 18(6):907-14[PubMed 6529532</li>
<li>Eisendrath SJ, Goldman B, Douglas J, et al, “Meperidine-Induced Delirium,” Am J Psychiatry, 1987, 144(8):1062</li>
<li>Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014</li>
<li>Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005;28(2):328-334. [PubMed 15684493</li>
<li>Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K. Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull. 2004;27(5):684-690. [PubMed 15133245]</li>
<li>Mutschler E, Spahn H, Kirch W. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol. 1984;17 Suppl 1:51S-57S. [PubMed 6146340</li>
<li>Spahn H, Kirch W, Mutschler E. The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol. Br J Clin Pharmacol. 1983;15(4):500-501. [PubMed 6849789</li>
<li>Visken (pindolol) [product monograph]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016</li>
<li>Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992;51(4):379-387. [PubMed 1563208]</li>
<li>Pritchett EL, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol. 1988;28(7):619-624. [PubMed 3063727]</li>
<li>Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; December 2017.</li>
<li>Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53(suppl 1):31S-36S. [PubMed 11879257</li>
<li>Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; February 2018.</li>
<li>Lamisil (terbinafine hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016</li>
<li>Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219. [PubMed 9382559]</li>
<li>Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol. 1993;45(1):41-46. [PubMed 8405028]</li>
<li>Jonderko G, Jonderko K, Marcisz C, Kotulska A. Effect of cimetidine and ranitidine on absorption of [125]levothyroxine administered orally. Zhongguo Yao Li Xue Bao. 1992;13(5):391-394. [PubMed 1300037</li>
<li>Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-498. [PubMed 18466075]</li>
<li>Gabitril (tiagabine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2015.</li>
<li>Spiriva (tiotropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2015.</li>
<li>Conzip (tramadol) extended-release capsules [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC; March 2021.</li>
<li>Chantix (varenicline) [prescribing information]. New York, NY: Pfizer Inc; February 2019.</li>
<li>Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(suppl 1):51-55. [PubMed 14616414</li>
<li>Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother. 2009;53(4):1712-1714. [PubMed 19171800</li>
<li>Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; April 2019.</li>
<li>Wang K, Yao X, Zhang M, et al. Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):441-454. [PubMed 33687157]</li>
<li>de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020;70:55-59. [PubMed 31865063</li>
<li>Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019;10:2042098619854007. doi: 10.1177/2042098619854007. [PubMed 31258887</li>
<li>Tsai SC, Sheu SY, Chien LN, Lee HC, Yuan EJ, Yuan RY. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000-2009. [PubMed 29745438</li>
<li>Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780-1782. [PubMed 7500509</li>
<li>Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med. 1986;146(10):2070-2071. [PubMed 3767555</li>
<li>Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J. 2010;103(2):178-180. [PubMed 20065895</li>
<li>Corsini GU, Zompo MD, Cianchetti C, et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacologia. 1976;47(2):169-173. [PubMed 1273213</li>
<li>Tarsy D, Parkes JD, Marsden CD. Metoclopramide in parkinsonism. Lancet. 1975;1(7918):1244-1245. [PubMed 48872</li>
<li>Tarsy D, Parkes JD, Marsden CDMetoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesiasJ Neurol Neurosurg Psychiatry1975;38(4):331-335[PubMed 1095689</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020</li>
<li>Migramax (aspirin and metoclopramide) [summary of product characteristics]. London, United Kingdom: Zentiva Pharma UK Limited; March 2022.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; August 2017</li>
<li>Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC. 2013;13:152. [PubMed 23714238</li>
<li>Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004;44(6):661-665. [PubMed 15637848</li>
<li>Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ. 1988;297(6654):964-965. [PubMed 3142568</li>
<li>Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J. 1991;84(5):626-628. [PubMed 2035085</li>
<li>Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolid-fluoxetine and olanzapine-metoclopramide interactions: a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission. Case Rep Med. 2016;2016:7128909. [PubMed 27433163]</li>
<li>Cabergoline [prescribing information]. Peapack, NJ: Greenstrone LLC; November 2019.</li>
<li>Barnes TR, Braude WM, Hill DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2(8288):48-49. [PubMed 6123780</li>
<li>Metoclopramide [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; July 2021</li>
<li>Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000;23(Suppl):S64-S70. [PubMed 11052222</li>
<li>Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. [PubMed 19886950</li>
<li>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446]</li>
<li>Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.</li>
<li>Patterson JF. Metoclopramide therapy of MAOI orthostatic hypotension. J Clin Psychopharmacol. 1987;7(2):112-113. [PubMed 3584514]</li>
<li>Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</li>
<li>Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009</li>
<li>Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” Trends Neurosci, 2000, 23(Suppl):S64-70. [PubMed 11052222</li>
<li>Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” Aliment Pharmacol Ther, 2010, 31(1):11</li>
<li>Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” Ann Pharmacother, 2008, 42(9):1290</li>
<li>Trelstar (triptorelin) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions, LLC; December 2018</li>
<li>Trelstar (triptorelin) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc.; September 2022.</li>
<li>Prescribing information. Malarone (atovaquone and proguanil). Research Triangle Park, NC: GlaxoSmithKline, 02/2013.</li>
<li>Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos. 2006;27(6):285-289. [PubMed 16770757</li>
<li>Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-2281. [PubMed 27621638</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932</li>
<li>Gimoti (metoclopramide) nasal spray [prescribing information]. Solana Beach, CA: Evoke Pharma, Inc.; June 2020.</li>
<li>Mehta D, Bradley EL Jr, Kissin I. Metoclopramide decreases thiopental hypnotic requirements. Anesth Analg. 1993;77(4):784-787. [PubMed 8214666</li>
<li>Thiopental sodium [Summary of Product Characteristics]. Berkshire, UK: Archimedes Pharma UK Limited; January 2014.</li>
<li>Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013</li>
<li>Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990;39(6):1045-1053. [PubMed 2322292]</li>
<li>Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011</li>
<li>Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015</li>
<li>Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015</li>
<li>Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.</li>
<li>Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: Ani Pharmaceuticals Inc; August 2017.</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation. 1987;43(2):211-213. [PubMed 3544377</li>
<li>Wadhwa NK, Schroeder TJ, O’Flaherty, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant patients. Transplant Proc. 1988;20(2 suppl 2):487-490. [PubMed 3284095</li>
<li>Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2017.</li>
<li>Johnson CD, Shynett B, Johnson CD, Maldonado BJ. Rapid onset of Parkinsonian-like symptoms in a geriatric dental patient: a case report. Compend Contin Educ Dent. 2006;27(11):622-625. [PubMed 17133932]</li>
<li>Aczone (dapsone) gel [prescribing information]. Irvine, CA: Allergan, Inc.; July 2015.</li>
<li>Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</li>
<li>Gamble JA, Gaston JH, Nair SG, Dundee JW. Some pharmacological factors influencing the absorption of diazepam following oral administration. Br J Anaesth. 1976;48(12):1181-1185. [PubMed 1023954</li>
<li>Chapman MH, Woolner DF, Begg EJ, Atkinson HC, Sharman JR. Coadministered oral metoclopramide does not enhance the rate of absorption of oral diazepam. Anaesth Intensive Care. 1988;16(2):202-205. [PubMed 3394914]</li>
<li>Kirch W, Janisch HD, Santos SR, Duhrsen U, Dylewicz P, Ohnhaus EE. Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinetic. 1986;11(4):249-250. [PubMed 3582418</li>
<li>Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984;36(6):724-730. [PubMed 6499354</li>
<li>Schwartz BG. Metoclopramide and digoxin cause 22 episodes of bradyarrhythmias. Am J Med. 2010;123(6):e5</li>
<li>[PubMed 20569744</li>
<li>Johnson BG, O'Grady J, Bye C. The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. Br J Clin Pharmacol. 1978;5(5):465-467. [PubMed 656287]</li>
<li>Monurol (fosfomycin) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2018.</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One. 2013;8(11):e81208. [PubMed 24278396</li>
<li>Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6(9):e23728. [PubMed 21961030</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015</li>
<li>Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488</li>
<li>Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662]</li>
<li>Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.</li>
<li>Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016</li>
<li>Synera (lidocaine and tetracaine) topical patch [prescribing information]. Souderton, PA: Galen US Inc; March 2014</li>
<li>Pliaglis (lidocaine and tetracaine) cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; November 2013</li>
<li>Citanest plain (prilocaine) [prescribing information]. York, PA: Dentsply Pharmaceutical; June 2010</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006</li>
<li>Marcaine Spinal (bupivacaine hydrochloride in dextrose injection, USP) [prescribing information]. Lake Forest, IL: Hospira, Inc.; November 2018</li>
<li>Lardieri AB, Crew PE, McCulley L, Kim IE, Waldron P, Diak IL. Cases of benzocaine-associated methemoglobinemia identified in the FDA adverse event reporting system and the literature [published online January 2, 2019]. Ann Pharmacother. doi: 10.1177/1060028018823532. [PubMed 30600685]</li>
<li>Tercan M, Efe EM, Turker G, et al. Do metoclopramide and ondansetrone alter mivacurium-induced neuromuscular blockade? - a randomised trial. Braz J Anesthesiol. 2014;64(1):35-39. [PubMed 24565386</li>
<li>El Ayass N, Hendrickx P. Decreased mivacurium infusion rate and delayed neuromuscular recovery after metoclopramide: a randomized double blind placebo-controlled study. Eur J Anaesthesiol. 2005;22(3):197-201. [PubMed 15852992</li>
<li>Motamed C, Kirov K, Combes X, Dhonneur G, Duvaldestin P. Effect of metoclopramide on mivacurium-induced neuromuscular block. Acta Anaesthesiol Scand. 2002;46(2):214-216. [PubMed 11942874</li>
<li>Skinner HJ, Girling KJ, Whitehurst A, Nathanson MH. Influence of metoclopramide on plasma cholinesterase and duration of action of mivacurium. Br J Anaesth. 1999;82(4):542-545. [PubMed 10472219</li>
<li>Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth. 1990;65(2):220-224. [PubMed 2223340</li>
<li>Kambam JR, Parris WC, Franks JJ, Sastry BV, Naukam R, Smith BE. The inhibitory effect of metoclopramide on plasma cholinesterase activity. Can J Anaesth. 1988;35(5):476-478. [PubMed 3273154]</li>
<li>Inomax (nitric oxide) [prescribing information]. Hampton, NJ: INO Therapeutics; March 2013</li>
<li>Genosyl (nitric oxide) [prescribing information]. Atlanta, GA: Vero Biotech; December 2019</li>
<li>Sinisterra S, Miravet E, Alfonso I, et al. Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic. J Pediatr. 2002;141(2):285-286. [PubMed 12183731</li>
<li>Lopez A, Bernardo B, Lopez-Herce J, et al. Methaemoglobinaemia secondary to treatment with trimethoprim and sulphamethoxazole associated with inhaled nitric oxide. Acta Paediatr. 1999;88(8):915-916. [PubMed 10503695</li>
<li>Emla (prilocaine/lidocaine) [prescribing information]. Wilmington, DE: AstraZeneca LP; April 2006.</li>
<li>Metozolv ODT (metoclopramide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2011.</li>
<li>Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011;67(6):591-599. [PubMed 21161196</li>
<li>PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</li>
<li>Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958-966. [PMID: 19075045</li>
<li>Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 11/2013.</li>
<li>Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006</li>
<li>Skold A, Cosco DL and Klein R, “Methemoglobinemia: Pathogenesis, Diagnosis, and Management,” South Med J, 2011, 104(11):757-61. [PubMed 22024786</li>
<li>Mansouri A and Lurie AA, “Concise Review: Methemoglobinemia,” Am J Hematol, 1993, 42(1):7-12. [PubMed 8416301]</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022</li>
<li>Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</li>
<li>Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced serotonin syndrome. Intern Med. 2017;56(6):737-739. [PubMed 28321081</li>
<li>Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002;36(1):67-71. [PubMed 11816261</li>
<li>Aussedat M, Lavoie A, Bussieres JF, Kleiber N. Suspected overlap between serotonin syndrome and neuroleptic malignant syndrome in a child treated with metoclopramide? J Pediatr Pharmacol Ther. 2020;25(6):552-558. [PubMed 32839660</li>
<li>Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664</li>
<li>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718</li>
<li>Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713</li>
<li>Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil. 2009;21(12):1235-1238. [PubMed 19906028]</li>
<li>Provenzani A, D'alessandro N, Polidori P. Toxic tacrolimus concentrations associated with intravenous use of metoclopramide in a lung transplant patient. Ann Pharmacother. 2019;53(5):548-549. [PubMed 30739475</li>
<li>Prescott WA Jr, Callahan PL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 2004;24(4):532-537. [PubMed 15098810</li>
<li>Wadhw NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879</li>
<li>Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019.</li>
<li>Prescribing information. Baltimore, MD: Cangene BioPharma, Inc., 2/2012</li>
<li>Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</li>
<li>Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology. 1989;70(6):905-908. [PubMed 2658689</li>
<li>Turner DR, Kao YJ, Bivona C. Neuromuscular block by suxamethonium following treatment with histamine type 2 antagonists or metoclopramide. Br J Anaesth. 1989;63(3):348-350. [PubMed 2572248</li>
<li>Dell-Kuster S, Levano S, Burkhart CS, et al. Predictors of the variability in neuromuscular block duration following succinylcholine: A prospective, observational study. Eur J Anaesthesiol. 2015;32(10):687-696. [PubMed 26213905</li>
<li>Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” Br Med J, 1973, 1:587. [PubMed 4694406</li>
<li>Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” Br J Clin Pharmacol, 1981, 11:430-1P</li>
<li>Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” J Pharm Pharmacol, 2001, 53(7):1041</li>
<li>[PubMed 11480539</li>
<li>van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” Methods Find Exp Clin Pharmacol, 1990, 12(4):291</li>
<li>[PubMed 2374477</li>
<li>van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” Methods Find Exp Clin Pharmacol, 1992, 14(5):379-82. [PubMed 1513194</li>
<li>Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” Br J Clin Pharmacol, 1983, 15(4):487</li>
<li>[PubMed 6849786</li>
<li>Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” Cephalalgia, 1988, 8(3):139-47. [PubMed 31970094</li>
<li>Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” Eur J Clin Pharmacol, 1992, 42(2):235</li>
<li>[PubMed 1618258]</li>
<li>Kaukab I, Shah SNH, Kharaba ZJ, Buabeid MA, Alfoteih YA, Murtaza G. Effect of clarithromycin pre-treatment on the pharmacokinetics of metoclopramide after their simultaneous oral intake. Expert Opin Metab Toxicol. 2020;16(8):735-740. [PubMed 32524862]</li>
<li>Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013;28(2):99-105. [PubMed 23221858</li>
<li>Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559</li>
<li>Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. [PubMed 18809731</li>
<li>Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018</li>
<li>Khedezla (desvenlafaxine) [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; August 2017.</li>
<li>Moffett PM, Cartwright L, Grossart EA, O’Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23(1):102-105. [PubMed 26720490</li>
<li>Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53-58. [PubMed 22046106</li>
<li>Tracz K, Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br J Clin Pharmacol. 2015;79(4):669-676. [PubMed 25293524</li>
<li>Obal D, Yang D, Sessler DI. Perioperative doses of ondansetron or dolasetron do not lengthen the QT interval. Mayo Clin Proc. 2014;89(1):69-80. [PubMed 24388024</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder TClinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort studyBr J Clin Pharmacol2009;67(3):347-354[PubMed 19523015</li>
<li>Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105(2):389-395. [PubMed 8306734</li>
<li>Kroll CR, Gettes LS. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol. 2002;13(9):936-938. [PubMed 12380935</li>
<li>Otsuka M, Kanamori H, Sasaki S, et al. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med. 1997;36(10):705-708. [PubMed 9372331</li>
<li>Farguhar Zanetti LA, Oliphant CM. Pentamidine-induced torsades de pointes. Ann Pharmacother. 1994;28(2):282-283. [PubMed 8173154</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</li>
<li>Matsuo J, Yamaori S. Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. [published online ahead of print] J Clin Pharm Ther. 2021. doi:10.1111/jcpt.13539. [PubMed 34664726</li>
<li>Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther. 1988;43(5):577-581. [PubMed 3365919</li>
<li>Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol. 2003;41(8):1199-1201. [PubMed 12842189</li>
<li>Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality. 1991;3(1):14-18. [PubMed 2039678</li>
<li>Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</li>
<li>Kaukab I, Shah SNH, Abrar MA, Anwer N, Murtaza G. Influence of rifampicin pre-treatment on the in vivo pharmacokinetics of metoclopramide in Pakistani healthy volunteers following concurrent oral administration. Curr Drug Metab. 2020;21(4):301-306. [PubMed 32407272]</li>
<li>Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013</li>
<li>Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003:31(5):631-636. [PubMed 12695352]</li>
<li>Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.</li>
<li>Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2016;37(1):15-27. [PubMed 26356245</li>
<li>Pham CP, de Feiter PW, van der Kuy PHM, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7-8):1456-1461. [PubMed 16849620</li>
<li>Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc.; March 2015.</li>
<li>Yoshizato T, Kotegawa T, Imai H, et al. Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol. 2012;68(9):1287-1294. [PubMed 22418831</li>
<li>Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411-421. [PubMed 21883386</li>
<li>Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63(6):656</li>
<li>[PubMed 18477279</li>
<li>Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179(3):172. [PubMed 12885276</li>
<li>Kotanko P, Kirisits W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron. 2002;90(2):234</li>
<li>[PubMed 11818715</li>
<li>Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009;2009. [PubMed 21931583</li>
<li>Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum Mal Osteoartic. 1992;59(4):281</li>
<li>(Article in French) [PubMed 1496277</li>
<li>Collidge TA, Razvi S, Nolan C, et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barre syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med. 2010;27(6):696-700. [PubMed 20546290</li>
<li>Kearney S, Carr AS, McConville J, McCarron MO, Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ. 2012;345:e6562. [PubMed 23047962</li>
<li>O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325</li>
<li>[PubMed 18644925</li>
<li>Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka EAcute rhabdomyolysis after atorvastatin and fusidic acid therapyAm J Med2000;109(1)</li>
<li>[PubMed 10991749</li>
<li>Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33</li>
<li>Xelenta (lefamulin) [prescribing information]. Ireland: Nabriva Therapeutics US, Inc.; August 2019.</li>
<li>Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213-1217. [PubMed 21732066</li>
<li>Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1989;46(8):722-730. [PubMed 2665687</li>
<li>Orap (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011</li>
<li>Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon VRisk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugsJ Clin Psychopharmacol2017;37(5):540-545[PubMed 28817488</li>
<li>Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2019</li>
<li>Panos G, Velissaris D, Karamouzos V, Matzaroglou C, Tylianakis M. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295-300. [PubMed 27125217</li>
<li>Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303-314. [PubMed 20297862</li>
<li>Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355-2358. [PubMed 28475803</li>
<li>Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301-311. [PubMed 19646076</li>
<li>Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726-1734. [PubMed 16705579]</li>
<li>van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-1014. [PubMed 20925438</li>
<li>Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421-424. [PubMed 25828198</li>
<li>Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888. [PubMed 20652862</li>
<li>Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663-666. [PubMed 18589449</li>
<li>Vieira MC, Miyague NI, Van Steen K, et al. Effects of domperidone on QTc interval in infants. Acta Paediatr. 2012;101(5):494-496. [PubMed 22226330</li>
<li>Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-723. [PubMed 15690231</li>
<li>Digby G, Machaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiol J. 2010;17(2):184-188. [PubMed 20544619</li>
<li>Fais P, Vermiglio E, Laposata C, et al. A case of sudden cardiac death following Domperidone self-medication. Forensic Sci Int. 2015;254:e1-e3. [PubMed 26119456</li>
<li>Domperidone [product monograph]Toronto, Ontario, Canada: Apotex Inc; March 2015</li>
<li>Xalkori (crizotinib) [prescribing information]. New York, NY: Pfizer Inc; March 2016</li>
<li>Kisqali (ribociclib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2017</li>
<li>Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2018</li>
<li>Tisdale JE, Jaynes HA, Kingery JR, et alDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes2013;6(4):479-487[PubMed 23716032</li>
<li>Rocha CM, Barbosa MMQT interval prolongation associated with the oral use of domperidone in an infantPediatr Cardiol2005;26(5):720-723[PubMed 15690231</li>
<li>Romero J, Baldinger SH, Goodman-Meza D, et al. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol. 2016;45(1):37-45. [PubMed 26589717</li>
<li>Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol. 2012;52(4):520-529. [PubMed 21558456</li>
<li>Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk AClarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reportsTher Adv Infect Dis2013;1(4):121-138[PubMed 25165548</li>
<li>Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2017</li>
<li>Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019</li>
<li>Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204. [PubMed 20673553</li>
<li>Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. [PubMed 16317317</li>
<li>Meyer-MassettiC, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, et alThe FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med2010;5(4):E8-16[PubMed 20394022</li>
<li>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketin analysis. Ann Emerg Med. 2014;64(1):19-25. [PubMed 24314899</li>
<li>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon VDevelopment of a risk score for QTc-prolongation: the RISQ-PATH studyInt J Clin Pharm2017;39(2):424-432[PubMed 28281228</li>
<li>Taylor AJ, Hull RW, Coyne PE, Woosley RL, Eliasson AH. Pentamidine-induced torsaes de pointes: safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther. 1991;49(6):698-700. [PubMed 2060258</li>
<li>Parlodel (bromocriptine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; July 2021</li>
<li>Bromocriptine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.</li>
<li>Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2019</li>
<li>Sangana R, Gu H, Chun DY, Einolf HJ. Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modeling approaches. Drug Metab Dispos. 2018;46(1):26-32. [PubMed 29038231]</li>
<li>Devandla A, Yamsani SK, Yamsani MR. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers. Drug Metab Pers Ther. 2015;30(4):257-261. [PubMed 26353177]</li>
<li>Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287</li>
<li>Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E16. [PubMed 20394022</li>
<li>Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262-268. [PubMed 15231861</li>
<li>Kitagawa K, Kawada K, Morita S, et al. Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 2012;23(3):743-747. [PubMed 21690231</li>
<li>Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16(11):3019-3027. [PubMed 20501625</li>
<li>Kim H-H, An SH, Cho YH, Kim S-Y, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013;52(6):1223-1224. [PubMed 23368679</li>
<li>Chung LW, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156-157. [PubMed 18618340</li>
<li>Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. [PubMed 20529041</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJThe FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med2010;5(4):E8-E16[PubMed 20394022</li>
<li>Product monograph. Dom-Domperidone (domperidone). Montreal, Quebec, Canada: Dominion Pharmaceutical, May 2012.</li>
<li>Min JJ, Lee J, Lee H-C, Ryu H-G, Shin M, Kim HJ. A comparison of the effects of sevoflurane and desflurane on corrected QT interval prolongation in patients undergoing living donor liver transplantation: a prospective observational study. Transplant Proc. 2016;48(1):96-101. [PubMed 26915850</li>
<li>Bestas A, Hanbeyoglu O, Keles E, Bayar MK. The effect of adrenaline on desflurane-induced prolonged QTc interval: a randomized double-blind trial. Eur Rev Med Pharmacol Sci. 2013;17(11):1523-1528. [PubMed 23771541</li>
<li>Liu Y, Fu X, Gao H, Ren Y, Li H, He Y, Wang G. Effects of different concentrations of desflurane on the index of cardiac electrophysiological balance in gynecologic surgery patients. Can J Physiol Pharmacol. 2020;98(5):332-335. [PubMed 31770012</li>
<li>Aypar E, Karagoz AH, Ozer S, Celiker A, Ocal T. The effects of sevoflurane and desflurane anesthesia on QTc interval and cardiac rhythm in children. Paediatr Anaesth. 2007;17(6):563-567. [PubMed 17498019</li>
<li>Owczuk R, Wujtewicz MA, Sawicka W,Lasek J, Wujtewicz M. The influence of desflurane on QTc interval. Anesth Analg. 2005;101(2):419-422. [PubMed 16037155</li>
<li>Lindgren L, Saarnivaara L. Cardiovascular responses to enflurane induction followed by suxamethonium in children. Br J Anaesth. 1983;55(4):269-273. [PubMed 6838741</li>
<li>Lindgren L. E.C.G. changes during halothane and enflurane anaesthesia for E.N.T. surgery in children. Br J Anaesth. 1981;53(6):653-662. [PubMed 7248128</li>
<li>Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol. 2001;67(9):637-640. [PubMed 11731753</li>
<li>Kuenszberg E, Loeckinger A, Kleinsasser A, Lindner KH, Peuhringer F, Hoermann CSevoflurane progressively prolongs the QT interval in unpremedicated female adultsEur J Anaesthesiol2000;17(11):662-664[PubMed 11029563</li>
<li>Kleinsasser A, Kuenszberg E, Loeckinger A, Keller C, Hoermann C, Lindner KH, Peuhringer F. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg. 2000;90(1):25-27. [PubMed 10624970</li>
<li>Silay E, Kati I, Tekin M, Guler N, Huseyinoglu UA, Coskuner I, Yagmur C. Comparison of the effects of desflurane and sevoflurane on the QTc interval and QT dispersion. Acta Cardiol. 2005;60(5):459-464. [PubMed 16261774</li>
<li>Thiruvenkatarajan V, Osborn KD, Van Wijk RMAW, Euler P, Sethi R, Moodie S, Biradar V. Torsade de pointes in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia. Anaesth Intensive Care. 2010;38(3):555-559. [PubMed 20514968</li>
<li>Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg. 1998;86(4):701-702. [PubMed 9539586</li>
<li>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: How should institutions respond? J Hosp Med. 2010;5(4):E8-E[PubMed 20394022</li>
<li>Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem. 2011;54(24):8407-8420. [PubMed 220664]</li>
<li>L’Hommedieu CS, Nicholas D, Armes DA, et al, “Potentiation of Magnesium Sulfate-Induced Neuromuscular Weakness by Gentamicin, Tobramycin, and Amikacin,” J Pediatr, 1983, 102(4):629-31. [PubMed 6834204]</li>
<li>Carver PL, Berardi RR, Knapp MJ, et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994;38(2):326-329. [PubMed 7910724</li>
<li>Nix DE, Watson WA, Handy L, et al. The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin. Pharmacotherapy. 1989;9(6):377-380. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum. Antimicrob Agents Chemother. 1990;34:931-933. [PubMed 2360833</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al. Combined Use of Ciprofloxacin and Sucralfate. DICP. 1991;25:578-582. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin Levels When Receiving Sucralfate. JAMA. 1989;262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al. Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin. Antimicrob Agents Chemother. 1989;33(1):99-102. [PubMed 2712548</li>
<li>Lehto PL, Kivisto KT. Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin. Antimicrob Agents Chemother. 1994;38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al. Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers. Antimicrob Agents Chemother. 1992;36:2785-2760. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al. The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers. Eur J Clin Pharmacol. 1994;47(1):67-69. [PubMed 7988627</li>
<li>Zix JAPharmacokinetics of Sparfloxacin and Interaction With Cisapride and SucralfateAntimicrob Agents Chemother1997;41:1668-1672[PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al. The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin. Br J Clin Pharmacol. 2000;49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al. The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers. Int J Antimicrob Agents. 2000;15(4):283-289. [PubMed 10929878</li>
<li>Stass H, Schuhly U, Moller JG, et al. Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, A Novel 8-methoxyfluoroquinolone, in Healthy Volunteers. Clin Pharmacokinet. 2001;40(Suppl 1):49-55. [PubMed 11352442</li>
<li>Lehto PL, Kivisto KT. Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin. Clin Pharmacol Ther. 1994;56:477-482. [PubMed 7955811</li>
<li>Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate absorption. DICP. 1991;25(7-8):745-746. [PubMed 1949932</li>
<li>Carafate (sucralfate) [prescribing information]. Madison, NJ: Allergan USA Inc; June 2018.</li>
<li>Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</li>
<li>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed [March 6, 2020].</li>
<li>Furosemide tablets [prescribing information]. Somerset, NJ: Solco Healthcare US, LLC: April 2020.</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011</li>
<li>Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” CMAJ., 1992, 147(9):1308, 1313. [PubMed 1340782</li>
<li>Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” J Environ Sci Health B, 1986, 21(2):191-205[PubMed 3011882</li>
<li>Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed). 1983;286(6375):1379-1381. [PubMed 6404468</li>
<li>Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis. 1989;13(3):194-199. [PubMed 2919600</li>
<li>Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int. 1990;47(5):291-295. [PubMed 2257522</li>
<li>Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. Nutr Clin Pract. 1991;6(5):199-201. [PubMed 1775116</li>
<li>Spivey JM, Cummings DM, Pierson NR, “Failure of Prostatitis Treatment Secondary to Probable Ciprofloxacin-Sucralfate Drug Interaction,” Pharmacotherapy, 1996, 16(2):314</li>
<li>[PubMed 8820479</li>
<li>Nix DE, Watson WA, Handy L, et al, “The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin,” Pharmacotherapy, 1989, 9(6):377-80. [PubMed 2616352</li>
<li>Garrelts JC, Godley PJ, Peterie JD, et al, “Sucralfate Significantly Reduces Ciprofloxacin Concentrations in Serum,” Antimicrob Agents Chemother, 1990, 34:931</li>
<li>Van Slooten AD, Nix DE, Wilton JH, et al, “Combined Use of Ciprofloxacin and Sucralfate,” DICP, 1991, 25:578-82. [PubMed 1877263</li>
<li>Yuk JH, Nightingale CN, and Quintiliani R, “Ciprofloxacin Levels When Receiving Sucralfate,” JAMA, 1989, 262:901. [PubMed 2754785</li>
<li>Parpia SH, Nix DE, Hejmanowski LG, et al, “Sucralfate Reduces the Gastrointestinal Absorption of Norfloxacin,” Antimicrob Agents Chemother, 1989, 33(1):99-102. [PubMed 2712548</li>
<li>Lehto P and Kivisto KT, “Effect of Sucralfate on Absorption of Norfloxacin and Ofloxacin,” Antimicrob Agents Chemother, 1994, 38:248-51. [PubMed 8192452</li>
<li>Lubowski TJ, Nightingale CH, Sweeney K, et al, “Effect of Sucralfate on Pharmacokinetics of Fleroxacin in Healthy Volunteers,” Antimicrob Agents Chemother, 1992, 36:2785-60. [PubMed 14824145</li>
<li>Kawakami J, Matsuse T, Kotaki H, et al, “The Effect of Food on the Interaction of Ofloxacin with Sucralfate in Healthy Volunteers,” Eur J Clin Pharmacol, 1994, 47(1):67</li>
<li>Zix JA, “Pharmacokinetics of Sparfloxacin and Interaction With Cisapride and Sucralfate,” Antimicrob Agents Chemother, 1997, 41:1668-72. [PubMed 9257738</li>
<li>Kamberi M, Nakashima H, Ogawa K, et al, “The Effect of Staggered Dosing of Sucralfate on Oral Bioavailability of Sparfloxacin,” Br J Clin Pharmacol, 2000, 49(2):98-103. [PubMed 10671902</li>
<li>Allen A, Bygate E, Faessel H, et al, “The Effect of Ferrous Sulphate and Sucralfate on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers,” Int J Antimicrob Agents, 2000, 15(4):283</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. Slow release of tetracycline from a mucoadhesive complex with sucralfate for eradication of helicobacter pylori. Chem Pharm Bull (Tokyo). 2008;56(10):1412-1416. [PubMed 18827380</li>
<li>Higo S, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. The acidic complexation of tetracycline with sucralfate for its mucoadhesive preparation. Drug Dev Ind Pharm. 2004;30(7):715-724. [PubMed 15491049</li>
<li>Slomiany BL, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Scand J Gastroenterol Suppl. 1995;210:82-844. [PubMed 8578215]</li>
<li>Urso Forte (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; June 2013</li>
<li>Sucralfate [prescribing information]. Largo, FL: VistaPharm, Inc.; February 2020</li>
<li>Dovonex (calcipotriene) cream [prescribing information]Parsippany, NJ: LEO Pharma Inc.; March 2015</li>
<li>Sorilux (calcipotriene) foam [prescribing information]. Greenville, NC: Mayne Pharma; May 2019</li>
<li>Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35(9):1765-1771. [PubMed 1952845]</li>
<li>Havrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med. 1992;117(5):445-446. [PubMed 1503346</li>
<li>Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994;96(6):531-535. [PubMed 8017451</li>
<li>Khan F, Jeanniton E, Renedo M. Does sucralfate impede levothyroxine therapy? Ann Intern Med. 1993;118(4):317. [PubMed 8481187</li>
<li>Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. Ann Intern Med. 1994;121(2):152. [PubMed 8017736</li>
<li>Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2020.</li>
<li>Smart HL, Somerville KW, Williams J, Richens A, Langman MJ. The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol. 1985;20(3):238-240. [PubMed 3840029</li>
<li>Hall TG, Cuddy PG, Glass CJ, Melethil S. Effect of sucralfate on phenytoin bioavailability. Drug Intell Clin Pharm. 1986;20(7-8):607-611. [PubMed 3755676</li>
<li>Malli R, Jones WN, Rindone JP, Labadie EL. The effect of sucralfate on the steady-state serum concentrations of phenytoin. Drug Metabol Drug Interact. 1989;7(4):287-293. [PubMed 2489199</li>
<li>Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2022.</li>
<li>Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin. Ann Intern Med. 1983;98(4):557. [PubMed 6687662</li>
<li>Braverman SE, Marino MT. Sucralfate-warfarin interaction. Drug Intell Clin Pharm. 1988;22:913. [PubMed 3234259</li>
<li>Parrish RH, Waller B, Gondalia BG. Sucralfate-warfarin interaction. Ann Pharmacother. 1992;26:1015-1016. [PubMed 1504385</li>
<li>Neuvonen PJ, Jaakkola A, Totterman J, Penttila O. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol. 1985;20(2):178-179. [PubMed 3840028</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med. 1989;86(6A):38-44. [PubMed 2735334</li>
<li>Caille G, du Souich P, Besner JG, Gervais P, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med. 1987;83(3B):67-73. [PubMed 3661612</li>
<li>Caille G, du Souich P, Gervais P, Besner JG. Single dose pharmacokinetics of ketoprofen, indomethacin, and naproxen taken alone or with sucralfate. Biopharm Drug Dispos. 1987;8(2):173-183. [PubMed 3593897</li>
<li>Lafontaine D, Mailhot C, Vermeulen M, Bissonnette B, Lambert C. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm. 1990;9(10):773-777. [PubMed 2242657</li>
<li>Crysvita (burosumab-twza) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; September 2019.</li>
<li>Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009</li>
<li>Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010</li>
<li>Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004</li>
<li>Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010</li>
<li>Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007</li>
<li>Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010</li>
<li>Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</li>
<li>One-Alpha (alfacalcidol) oral drops [summary of product characteristics]. Berkshire, United Kingdom: Leo Laboratories Limited; September 2020</li>
<li>Vectical (calcitriol) ointment [prescribing information]. Fort Worth, TX: Galderma Laboratories; July 2020</li>
<li>Rocaltrol (calcitriol) oral solution [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; November 1998</li>
<li>Rayaldee (calcifediol) extended-release capsules [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC: December 2019.</li>
<li>Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2(1):10-32. [PubMed 3547004</li>
<li>West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975;16(2):93-98. [PubMed 1168607</li>
<li>Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut. 1969;10(9):717-722. [PubMed 4318526</li>
<li>Zemplar (paricalcitol) [prescribing information]. North Chicago, IL: AbbVie Inc.; October 2016</li>
<li>Welchol (colesevelam) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; June 2013</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2010</li>
<li>Rocaltrol (calcitriol) [prescribing information. Parisppany, NJ: Validus Pharmaceuticals LLC; July 2009</li>
<li>Rayaldee (calcifediol) [prescribing information]Miami, FL: OPKO Pharmaceuticals LLC; June 2016</li>
<li>Heaton KW, Lever JV, Barnard D. Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea. Gastroenterology. 1972;62(4):642-646. [PubMed 5020877</li>
<li>Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology. 1978;74(5 pt 1):900-902. [PubMed 640344</li>
<li>Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. Dig Dis Sci. 1985;30(5):477-482. [PubMed 3987479</li>
<li>Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427-430. [PubMed 2125243</li>
<li>Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med. 1992;119(4):407-411. [PubMed 1583392</li>
<li>Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980;65(2):243-250. [PubMed 7354970]</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; February 2011</li>
<li>Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2007</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario:LEO Pharma Inc.; March 2010.</li>
<li>Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015</li>
<li>Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36(7):647-653. [PubMed 8844448</li>
<li>Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306-313. [PubMed 10757623</li>
<li>McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-822. [PubMed 12126214]</li>
<li>Vella A, Gerber TC, Hayes DL, et al. Digoxin, hypercalcemia, and cardiac conduction. Postgrad Med J. 1999;75:554-556. [PubMed 10616693</li>
<li>Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. [PubMed 22998989</li>
<li>Hectorol (doxercalciferol) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2018.</li>
<li>Formosa N, Torpiano J, Allgrove J, Dattani MT. Anticonvulsant treatment associated with intractable hypocalcaemia in a female child with hypoparathyroidism. Horm Res Paediatr. 2015;83(1):62-66. [PubMed 25227206</li>
<li>Rubinger D, Korn-Lubetzki I, Feldman S, Popovtzer MM. Delayed response to a alpha-hydroxycholecalciferol therapy in a case of hypoparathyroidism during anticonvulsant therapy. Isr J Med Sci. 1980;16(11);772-774. [PubMed 7440128</li>
<li>One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario: LEO Pharma Inc; August 2017.</li>
<li>Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011</li>
<li>Hepburn NC, Abdul-Aziz LA and Whiteoak R, “Danazol-Induced Hypercalcaemia in Alphacalcidol-Treated Hypoparathyroidism,” Postgrad Med J, 1989, 65(769):849-50. [PubMed 2616424]</li>
<li>Lemann J, Jr., Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28:951-958. [PubMed 3003445</li>
<li>Santos F, Smith MJ,Chan JC. Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide. Am J Dis Child. 1986;140:139-142. [PubMed 3753816</li>
<li>Brickman AS, Massry SG,Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms. J Clin Invest. 1972;51:945-954. [PubMed 4552338</li>
<li>Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res. 2006;38:821-826. [PubMed 17163358</li>
<li>Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12:531-535. [PubMed 2592738</li>
<li>Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250:144-153. [PubMed 11489064</li>
<li>Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34:421-424. [PubMed 3887100</li>
<li>Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33:1140-1146. [PubMed 3404813</li>
<li>Nowack R, Hofner MC, Reichel H, et alSubacute effects of thiazide administration on renal hemodynamics and calcium metabolismClin Investig1992;70:686-691[PubMed 1392446</li>
<li>Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50. [PubMed 12492451</li>
<li>Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2019.</li>
<li>Ивашкин В.Т., Трухманов А.С., Годжелло Э.А., Маев И.В., Евсютина Ю.В., Лапина Т.Л., Сторонова О.А. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению ахалазии кардии и кардиоспазма. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):36-54</li>
<li>Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders [published online ahead of print, 2016 Feb 15]. Gastroenterology. 2016;S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012</li>
<li>Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013 May;66(3):201-2. doi: 10.4212/cjhp.v66i3.1261. PMID: 23814291; PMCID: PMC3694945.Ы</li>
                </ol>
              </div>
            </div>
          </div>
        </div>
      </section>
    </div>
                    </main>
    
 
<div class="container">
<div class="event-info__bottom tab__bottom">

RUS2283099-3
</div>
</div>


<?require($_SERVER["DOCUMENT_ROOT"]."/bitrix/footer.php");?>


